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Summary 
There exists the concept of a valley of death that prevents the progress of science from the 
laboratory bench to the point where it provides the basis of a commercially successful 
business or product. The future success of the UK economy has been linked to the success 
of translating a world class science base to generate new businesses with the consequent 
generation of UK jobs and wealth. For decades Governments have sought to promote 
technological innovation and ensure that the UK benefits from its world class science base. 
The current Government has made several changes to the innovation landscape and 
therefore we considered this an opportune moment to consider whether government 
policy was moving in a positive direction. 
A troubling feature of technology companies in the UK is how many are acquired by 
foreign owners where the subsequent jobs and wealth are generated outside the UK. 
Evidence to the Committee indicated that there are several reasons for this. These 
businesses take time to develop and to become profitable in an environment where 
financing is focussing more on quick returns and on less risky investments. We consider it 
key that the Government ensure that sufficient capital is available and recommend that the 
proposed bank for business, possibly in partnership with the Business Growth Fund, be 
used to promote a bond market for medium sized businesses, thus providing growing 
small businesses with an additional source of funding. We also recommend that the 
Government investigate the potential to require funds to have a proportion of European 
SME equities. 
We consider it important that investors have a better understanding about technology 
investments and that the Government ensure that investors have ready access to 
information that would encourage their interest in technology based investments. The 
amount of information available would, in our view, be improved by the restoration of 
both the R&D Scoreboard and Bank of England monitoring on the availability of finance to 
SMEs. 
The broader fiscal context is extremely important, especially for smaller companies. We 
considered that there needs to be a mechanism to support SME's who do 
disproportionately badly from the current R&D tax credit scheme. Indeed the Government 
needs to distinguish in its innovation policy between small and medium enterprises: a 
single SME category is too broad. We had some concerns that VAT might in some cases 
hinder commercialisation activity and urge the Government to iron out any such issues. 
The Technology Strategy Board is becoming the focus for government innovation policy 
and we considered the portfolio of funding mechanisms and facilities available for them to 
support innovation and growth. We were concerned about the access of small firms to 
large scale test and experimental production facilities. We considered that the Technology 
Strategy Board and other commercialisation activities needed to ensure projects were 
properly supported in issues of manufacturing capability. We recommended that 
Government consider how they can resource the TSB to provide local level advice to 
technology businesses. The Small Business Research Initiative (SBRI) and the SMART 
Award scheme would appear to be successful initiatives but lack sufficient funds to meet 
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the demand from companies. We consider it vital that the Catapults are made to work but 
have concerns that they may be pushed to become self-financing too quickly. 
We recommend that that TSB produce a review of regulatory burdens on technological 
innovation in the UK that includes a roadmap of how that regulatory reform might be used 
to drive innovation and which institutions should take the lead. 
While our academic research is the jewel in the crown of UK innovation activity, we have 
some concerns about how universities interact with the commercialisation of research. We 
would like to see how well changes to the Higher Education Innovation Fund improve 
commercialisation activity; whether there is a need for greater amounts of proof of concept 
funding in the sector; and challenge the institutions to become more accommodating to 
non-traditional backgrounds among their academic staff. We have concerns that driving 
an innovation agenda too aggressively through universities may have diminishing returns 
with regard to commercialisation and risk damaging the academic research that is working 
well. It is crucial that the Government has a coherent plan on how to engage the research 
base (people, facilities and intellectual property) with the innovation agenda. The 
Government’s objective should be to create a commercial demand for university 
engagement to which they are already primed to respond. 
The Government’s ambition to increase innovation activity will depend on its willingness 
to engage and speculate in that activity. A key feature of that speculation should be leading 
the way by investing in small technology businesses through its procurement policy. The 
Government will need to upskill its staff on how to better exploit government procurement 
for this purpose; better utilise the NHS in driving biomedical advances and ensure centres 
of excellence, such as the Crick Institute, proactively engage with business. We also 
recommend a Minister in HM Treasury be given responsibility for the delivery of 
procurement-driven benefits identified by the Department for Business, Innovation and 
Skills. 
Finally there is a need for a clear vision from the Government to provide businesses 
confidence to make R&D investments. Without a definite commitment from Government 
about which sectors it intends to fund, business is more reticent about making its own 
financial commitment. A clear strategy for the future should aid the higher levels of 
business related research and development from businesses in the UK. 
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1 Introduction 
Background 
1. Victorian England has been portrayed as a golden age of science and engineering.1 The 
nineteenth century saw huge leaps in the application of science and resulted in science-
driven industrial and agrarian revolutions. Major cities grew on the back of industrial 
clusters which traded throughout the British Empire: Glasgow (steam locomotives); 
Manchester (cotton); Bradford (wool); and Newcastle (ship building).2 
2. But it was not all smooth sailing. The financially innovative discount house, Overend 
and Gurney, collapsed in 1866, triggering a wave of company insolvencies.3 A decade later 
Lewis Carroll’s ‘Snark’ had its life threatened by a railway share.4 Ultimately, the heavily 
skewed distribution of wealth and the extension of the franchise (the second Reform Act 
was introduced in 1867) made the system unsustainable.5 
3. The material destruction and social turmoil of the first World War was followed by the 
financial destruction of the 1929 stock market crash and the Committee on Finance and 
Industry (chaired by Hugh Macmillan but reportedly dominated by John Maynard 
Keynes) was formed by the government to examine what could be done.6 Its report noted 
the problems faced by small companies seeking investment and in 1945, at the end of the 
second World War, the Industrial and Commercial Finance Corporation (ICFC) was 
established to finance small businesses. 
4. Since 1945 and the formation of the ICFC, there have been various efforts by 
Government to build on the UK science base. In the early 1990’s renewed attention was 
paid to the potential use of the research base for economic and social development. The 
research councils7 were reorganised and the national technology foresight initiative 
established, under the aegis of an Office of Science and Technology. This began an on-
going dialogue between public and private research establishments and end-users to 
promote wealth creation and technology transfer. Later in that decade the Regional 
Development Agencies (RDAs) were created; a key part of their role being to further 
economic development. The RDAs introduced a variety of programmes and incentives to 
encourage research commercialisation and dialogue between industry and the research 
 
1 For example, “Age of Wonder”, Richard Holmes, HarperPress, September 2009 
2 For example, “The First Industrial Nation: The Economic History of Britain 1700-1914”, Peter Mathias, October 2001 
3 “The Mystery of Overend & Gurney: A Financial Scandal in Victorian London”, Geoffrey Elliott, Methuen Publishing Ltd, 
June 2007  
4 http://etext.virginia.edu/etcbin/toccer-
new2?id=CarSnar.sgm&images=images/modeng&data=/texts/english/modeng/parsed&tag=public&part=all p64 
5 For example, “The Penguin Social History of Britain: English Society in the Eighteenth Century”, Roy Porter, Penguin, 
April 1990 
6 http://www.nationalarchives.gov.uk/cabinetpapers/themes/policy-protectionism-imperial-preference.htm and “John 
Maynard Keynes 1883-1946 by Robert Skidelsky 2003 ISBN 0333903129 – pp 419-427 
7 The first research council, the Medical Research Council, was established in 1920 following a recommendation of the 
1918 Haldane Report. This was followed by the establishment of the Agricultural Research Council in 1931 and the 
Science Research Council, the Natural Environment Research Council and the Social Science Research Council in 1965.  
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base. More recently we have seen the advent of the TSB and the Innovation centres 
(Catapults) being established with cross party agreement. 
5. In this report we describe how, in the early years of the 21st century major fiscal 
incentives were introduced to encourage businesses to increase their expenditure on 
research and development.8 We focus particularly on the role of the current Government 
in maintaining and developing these and other policies intended to encourage the 
commercialisation of innovation.  
6. The UK has a world class science base but there remains a need to attach world class 
exploitation mechanisms to leverage that research to gain economic benefits. This report 
considers the issue of the exploitation of research by looking first at the overall framework 
for innovation in the UK and some of the broad issues that affect the development of 
policies in this area, then at how government might further encourage the engagement of 
business with research activity and finally at how general government spending might be 
used to deliver wider innovation policy objectives. 
The inquiry 
7. We announced our inquiry into Bridging the “valley of death”, improving the 
commercialisation of research on 14 December 2011 and issued a call for evidence based on 
the following terms of reference:  
i. What are the difficulties of funding the commercialisation of research, and how can 
they be overcome? 
ii. Are there specific science and engineering sectors where it is particularly difficult to 
commercialise research? Are there common difficulties and common solutions 
across sectors? 
iii. What, if any, examples are there of UK-based research having to be transferred 
outside the UK for commercialisation? Why did this occur? 
iv. What evidence is there that Government and Technology Strategy Board initiatives 
to date have improved the commercialisation of research? 
v. What impact will the Government’s innovation, research and growth strategies 
have on bridging the valley of death?  
vi. Should the UK seek to encourage more private equity investment (including 
venture capital and angel investment) into science and engineering sectors and if 
so, how can this be achieved? 
vii. What other types of investment or support should the Government develop? 
8. We received 94 written submissions and took oral evidence from a range of witnesses 
and organisations; we are grateful to all those who contributed. In the course of our 
inquiry, we met a range of academics and industrialists engaged in the business of 
 
8 These we describe in the report 
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commercialising research. We visited both the Warwick Manufacturing Group within 
Warwick University and the Advanced Manufacturing Research Centre in Sheffield where 
we were able to speak with those involved in meeting business needs and tackling 
fundamental research challenges. We are extremely grateful to both of these institutions for 
hosting us and providing an invaluable insight into the business of bringing commercial 
success from academic research. 
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2 Innovation and the “valley of death” 
9. The valley of death describes the point where a business, often a technology based 
business, has a working prototype for a product or service that has not yet been developed 
enough to earn money through commercial sales. The company needs to find sufficient 
money to develop the prototype until it can generate sufficient cash, through sales to 
customers, that would allow it to be self sufficient and grow. Growing companies will 
generate both jobs and wealth, a key objective for any government. 
10. The Government recently published an Innovation and Research Strategy for Growth, 
which sets out how it plans to work with business and the knowledge base to underpin 
private sector led growth.9 In the same week, the Government published its strategy for the 
life sciences, outlining how the Government will take action to make the UK a world-
leading place for life sciences investment.10 
11. Our predecessor Committee’s 2010 The impact of spending cuts on science and scientific 
research concluded that the UK had an excellent research base but was still failing to 
maximise its potential by translating research into wealth and health. It recommended that 
the Government should consider increasing funding for the translation process to at least 
the same order of magnitude as that provided for basic research.11 The 2009 inquiry 
Engineering: turning ideas into reality concluded that the UK was likely to miss out on the 
economic return associated with translating the findings of research into commercialised 
technologies, and called for a serious revision of the structures used to support the growth 
of fledgling industries.12 
12. This Committee’s 2011 inquiry into the Technology and Innovation Centres (now 
known as Catapults) cautioned that the limited funds available for innovation should not 
be monopolised by the TICs and noted that there was a lack of knowledge in the business 
world regarding existing UK research and development capabilities. The report 
recommended that the Technology Strategy Board (TSB) maintain a public list in the form 
of an online catalogue of centres that are ready and willing to work with business, in 
particular SMEs (small and medium enterprises), in specific technology areas.13 A key 
feature of these centres was to follow the example of the Fraunhofer institutes in Germany 
in delivering long-term capital in an institution bringing together university expertise with 
private capital to produce industrial demand driven research and development.14 
 
9 BIS, “Innovation and Research Strategy for Growth”, December 2011, Cm 8239 
http://www.bis.gov.uk/assets/biscore/innovation/docs/i/11-1387-innovation-and-research-strategy-for-growth 
10 BIS, “Strategy for UK Life Sciences”, December 2011 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/32457/11-1429-strategy-for-uk-life-
sciences.pdf 
11 Science and Technology Select Committee, “The impact of spending cuts on science and scientific research”, Sixth 
report of 2009-10, HC 335, 23 March 2010  
12 Innovation, Universities, Science and Skills Select Committee, “Engineering: turning ideas into reality”,  Fourth Report 
of 2008-09, HC 50, 27 March 2009  
13 Science and Technology Select Committee, “Technology and Innovation Centres”, 2nd Report of 2010-2012, HC 619, 17 
February 2011  http://www.publications.parliament.uk/pa/cm201011/cmselect/cmsctech/619/61902.htm 
14    Science and Technology Select Committee, “Technology and Innovation Centres”, 2nd Report of 2010-2012, HC 619, 
17 February 2011 , Chapter 3 http://www.publications.parliament.uk/pa/cm201011/cmselect/cmsctech/619/61902.htm 
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13. Evidence submitted by the Department for Business, Innovation and Skills (BIS) 
outlined the portfolio of policies that have been developed for the practical support for 
innovation which includes: 
• Initiatives managed by the Technology Strategy Board (TSB), including the 
Catapult centres, the Small Business Research Initiative (SBRI), Smart awards, 
and Knowledge Transfer Partnerships (KTPs)  
• R&D tax credits - provide tax relief for technological R&D 
• UK Innovation Investment Fund (UKIIF) - funding for venture capital 
• Patent Box – reduced tax on patents from 2013  
• Higher Education Innovation Fund – funding available to universities for 
knowledge transfer, provided through the Higher Education Funding Council 
for England (HEFCE).15 
The Linear Model of Innovation 
14. The Science and Technology Policy Research Unit (SPRU) at the University of Sussex, 
and Exeter Business School (EBS) expressed concern that the Government’s strategy for 
growth16 “still retains an implicit discredited linear model in many places” mentioning 
specifically the Knowledge Transfer Partnerships (KTPs).17 Others who criticised the idea 
that there was a single ‘valley of death’ tended to argue that the concept encouraged people 
to think that innovation was linear, and that financial obstacles were only found in one 
place.18 
15. The linear idea of innovation may be described in the following way: 
 
16. The Higher Education Funding Council for England (HEFCE) highlighted to us that 
the role of universities may be less instrumental in the commercialisation process than is 
assumed: 
 
15 Ev 101-102, paras 41–58 
16 BIS, “Innovation and Research Strategy for Growth”, December 2011, Cm 8239 
17 Ev143, paragraphs 19, 27 
18 For example, Ev 174, para 4; Ev 122, para 5; Ev w108; Ev 145; and Ev w42-43, paras 1.1, 4.1; 5.1 
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The vast majority of new technologies in the world that become commercially 
adopted will be devised and developed in the business world, by entrepreneurs, 
technology consultants, large and small businesses and in supply chains (albeit, we 
believe, infused and informed by university ideas and human capital development). 
[...]we estimate that only 19% of patent application filings from [the] UK [originate 
in] universities19 
17. SPRU & EBS20 expanded on the contribution of the linear model to high technology 
manufacturing: 
Much thinking about the commercialisation of research adopts an inappropriate and 
misleading ‘linear model of innovation’ in which university research generates 
innovations, that are then transferred and commercialised. Only 3% of the economy 
is in high tech manufacturing that draws on research in this way21  
18. Written evidence from the Government noted that relatively little innovation was 
commercialised in this manner. Rather, the main route by which knowledge generated by 
the research base is commercialised is through “collaborative and contract research, 
consultancy, and the provision of professional training”.2223 
19. The University of Manchester also criticised the linear model: 
We have some discomfort with the phrase “valley of death” which implies that it is 
only necessary to get through this particular stage. In fact successful innovation is an 
interactive process in which commercialisation plans have to be effective in all stages 
and sometimes simultaneously.24  
The Innovation ecosystem 
20. The four resources essential for economic activity are knowledge, finance, services and 
people. The challenge for government policy is to define how it provides an environment 
where those four resources can be accessed effectively by businesses that already exist and 
those that may start up and grow. This is as true of technology sectors as of the wider 
economy but the way in which the resources are made available and the particular kinds of 
knowledge, capital and people required (or the balance between them) may differ from the 
business community as a whole. 
21. The organisations, relationships and flows of money and knowledge by which 
innovation can be translated into jobs and wealth, often termed the innovation ecosystem, 
is a complex one. Professor Georghiou of the University of Manchester provided us with a 
diagram that we reproduce below: 
 
19 Ev 140, para 27 
20 Science Policy Research Unit at the University of Sussex and the Exeter Business School 
21 Ev w130, para 7 
22 Ev 95, para 5 
23 Ev 98, para 24 
24 Ev 122, paragraph 5. 
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22. The context for the whole ecosystem is determined by the regulations, standards and 
the fiscal environment set by Government. Universities and Public Sector Research 
Establishments attract finance and produce trained people, knowledge and intellectual 
property.  Research and Technology Organisations (RTOs) perform a similar but more 
commercially oriented function.  Finance flows from Government, larger firms, seed and 
venture capital organisations, banks and public markets. Ultimately the innovations that 
generate jobs and wealth are developed by businesses large and small and depend on a 
complex web of finance and knowledge transfer between these public and private 
organisations. The purpose of innovation policy is to ensure that both knowledge and 
finance flow efficiently to support the commercialisation of innovative products and 
services. 
23. Insurance companies and pension funds have been major investors in this area but, in 
recent years, have become more cautious in their investment portfolio.25 It was with some 
concern that we heard that a venture capitalist who made an investment in ARM26 in the 
1990s gauged that ARM would not, in today’s financial environment, have received that 
funding27 without which it might have failed to become one of the world’s leading 
computer chip manufacturers. The issue of institutional investment will be considered in 
more depth later in the report. 
24. Rolls Royce pointed out in their evidence that a common misconception was that 
innovation happened in smaller companies when a significant amount of innovation came 
from within large companies.28 They highlighted their participation in networks alongside 
universities and small and medium sized businesses.29 In October 2011, the Confederation 
of British Industry (CBI) published the Future Champions report which highlighted the 
 
25 Q 56 
26 ARM Holdings plc is a British multinational semiconductor and software design company headquartered in Cambridge. 
It is a key player in the field of mobile phone chips based on the ARM architecture and possibly the most widely 
known of the 'Silicon Fen' companies. 
27 Q 53 [Katie Potts] 
28 Ev 186, para 5.5.1 
29 Q 209 
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relative value of medium sized businesses to the economy. The report pointed out that 
firms with a turnover of between £10 million and £100 million represent less than 1% of 
businesses but generated 22% of economic revenue and 16% of all jobs, suggesting that 
growing this size of company would have a disproportionately beneficial impact on wealth 
and jobs creation. 30 
25. Having outlined the innovation system in the UK we next consider where that system 
may not be functioning and how it might be improved. 
Access to money and equipment 
26. For a business to be successful it must, over time, generate more money than it spends. 
However, the timescale for achieving a positive cash position can be lengthy; Amazon 
famously operated successfully, for seven years, spending more money than it was 
making.31 Technology companies are similar in that they often need to invest heavily 
before they can demonstrate the potential to be profitable.32 If they cannot find patient 
investors, then they may go out of business or be forced to sell out cheaply before they 
realise their potential.33 
Picking winners 
The challenge is to ensure that appropriate types of finance are available at all stages of a 
company’s development and, as resources are always limited, that they go to the companies 
that will use them to best effect. It is widely accepted that Government is unable to “pick 
winners” (though we learned that resources available to the TSB means that it has to do so 
in allocating grants such as SMART awards). Recent reports on patents relating to 
graphene suggest that despite the £50m commitment from the government, China is 
taking a lead in this field. The University of Oxford had “concerns about strategies that rely 
on predicting technology futures and ‘winners’”.34 The SME Innovation Alliance also 
warned against the Government “picking winners” or allowing “the ‘Great and Good’ to 
judge or select winners: such panels will always pick the well presented, apparently ‘safe’, 
project and miss the exciting and good”.35 However, we were told that Government does 
need to make choices in terms of which sectors to prioritise when assisting R&D 
investment and may, on occasion, need to go further.36 
27. Sir Peter Williams, Vice President of the Royal Society and Chairman of the National 
Physical Laboratory, told us that there might be times when the Government needed to be 
brave and back good companies but that when it does, such as in the case of graphene,37 
 
30 “Future Champions”, CBI, October 2011 
31 Amazon was incorporated in 1994 and reported its first profitable quarter in 2001. 
32 For example, Ev 132, intro & Ev 153, para 6 
33 Ev 165, para 1.2 
34 Ev w139, para 21 
35 Ev 128, para 33 
36 Q 9 
37 On 3 October 2011, the Chancellor of the Exchequer pledged a £50m investment to create a graphene global research 
and technology hub and build a national capability to support the commercialisation of applications for graphene 
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“you are going to have to try to pick two or three winners and give them not sub-critical 
but super-critical financing, so that you do enable them to be a leader in the facilitation and 
deployment of this remarkable substance in new applications”.38 
Finding the cash to do business 
Equity capital and public market finance 
28. A traditional route for start-up companies is to seek capital from personal sources then 
look for business angels and venture capitalists. Capital of this nature is usually acquired by 
exchanging part ownership of the company (equity) meaning that the original 
entrepreneurs see their interest in the company diminish over time: 
The key point is that, if you are an entrepreneur and you have to go and get money, 
you virtually sell 95% of your idea very quickly either to venture capital, AIM39 or 
whatever. You are left with 5%. That literally leaves the vast majority of people 
emotionally drained of the energy to take their idea forward.40 
The SME Innovation Alliance were also concerned about how the need to seek venture 
capital increases the chance of control of the company and its technology moving overseas: 
The VC funding model is also a systematic means to export UK technology. The vast 
majority of funds come from overseas. If a company has three funding rounds, and if 
80% of funds are non-UK, then mathematically the chances of control remaining in 
the UK after three rounds is 0.8%41 
29. Anne Glover, co-founder and Chief Executive of Amadeus Capital Partners Ltd, 
explained one reason for the short term nature of equity investment: 
The reason that our time scales are short is that at the moment, historically, until [the 
Business Growth Fund] came along, the availability of the next stage of capital was 
too weak. Basically, we had to assume that we could work only with our own and 
that made us much more risk averse. If there was a ladder of financing that worked, 
we would take the long-term risks and be happy about it.42 
We heard that the short timescales of venture capital investment means that small 
companies are often developed for the sole purpose of being sold43 and that, as most buyers 
are overseas, many of these companies and their technology end up being developed 
                                                                                                                                                              
and ensure the UK remains at the forefront of graphene work.  BIS Press Release, “£50 million hub to commercialise 
Nobel Prize winning material”, 3 October 2011 
38 Q 116 [Sir Peter Williams] 
39 AIM is the London Stock Exchange’s international market for smaller growing companies. A wide range of businesses 
including early stage, venture capital backed as well as more established companies join AIM seeking access to 
growth capital.  http://www.londonstockexchange.com/companies-and-advisors/aim/aim/aim.htm 
40 Q 95 [Dr Francis] 
41 Ev 129, para 27 
42 Q 53 
43 Q 53 [Stephen Welton] 
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overseas.44 An example of this is referred to in our previous report on Technology 
Innovation Centres, see paragraph 5. 
30. We have been told that the UK needs to change the financial environment to 
incentivise more smaller companies to grow further independently rather than sell out to a 
larger, and probably foreign, competitor.45 
31. The issue of long term capital has been the subject of a recent report to the Department 
of Business Innovation and Skills. That report noted a failure in the marketplace to provide 
significant sums of patient capital to enable companies to develop and grow.46 We were 
also told that many UK institutional investors had withdrawn from the UK stock markets, 
Katie Potts of Herald Investment Management Ltd, stated: 
pension fund and insurance companies at their peak in 1994 owned about 60% of the 
UK stock market. They have now withered to less than 20%, and they have been 
replaced by overseas investors, who do not look at smaller companies and do not 
care about early stage companies. That degree of shrinkage means cash outflow. [...] 
It makes me weep having gone through the risk phase and then finding that foreign 
companies buy them too cheaply.47 
32. In her written evidence she had explained the reasons for this change: 
These institutions were professional long-term stable investors, with good corporate 
governance skills who controlled executive remuneration etc. It is a tragic and 
devastating unintended consequence of the abolition of ACT relief, combined with 
the rising liabilities for defined benefit pension schemes as life expectancy has grown, 
and investment returns have diminished. The accounting requirement to disclose 
these liabilities with valuation methodologies which discourages equity investing has 
been the final death knell, which has led to the disappearance of institutional 
investors on the registers of our investee companies.48 
33. The CBI, Future Champions, report highlighted the difficulty of medium sized 
companies in the UK accessing a functioning bond market such as those found in 
Germany and the US, which further accentuates the lack of capital to technology 
companies. The report stated: 
Many large firms have found that issuing debt either through a private placement or 
through public bond markets, has a number of advantages; they can make a return 
on investment over long time periods and choose investors that share in their 
objectives, all without reducing the equity stake of existing shareholders.49 
 
44 Q 56 [Katie Potts] 
45 Q 218 [Tim Crocker] 
46 BIS, “The Kay review of UK equity markets and long-term decision making”, July 2012 
http://www.bis.gov.uk/assets/biscore/business-law/docs/k/12-917-kay-review-of-equity-markets-final-report.pdf 
47 Q 56 [Katie Potts] 
48 Ev 201, para 1(i) 
49 “Future Champions”, CBI, October 2011 
Bridging the valley of death: improving the commercialisation of research    15 
 
34. Stephen Welton of the Business Growth Fund also highlighted the importance of 
medium sized businesses: 
I think the fact you can raise money for businesses that are more mature in and of 
itself is not a bad thing. What we want to do is expand the number of growing 
medium-size companies. Based on the research we have done, there are 5,000 
companies currently in the UK turning over between 2.5 million and 100 million, 
growing in excess of 10% per annum.50  
They are not growing at 50% compound per annum, but they have grown well. 
These are the businesses which can go from 2.5 million, 5 million, 10 million to 20 
million. The economic effects of that are dramatic in terms of employment, tax 
revenues and everything else, but that market needs funding from investors and 
banks.51 
Non-equity based capital 
35. Not least because of the concerns over ownership which are noted above, public sector 
grant funding (UK and EU), which does not require any loss of equity, is an enticing 
prospect for small technology companies. Its disadvantage is that it is often highly 
bureaucratic to apply for52 and, in some cases, highly competitive and only enough to “get 
an idea off the ground”.53 
36. Another non-equity option could be a loan from a bank. The Government has schemes 
to encourage bank lending to business, for example the ‘Enterprise Finance Guarantee’ 
scheme54  and, under the Merlin agreement,55 banks have pledged to proactively support, 
and invest in, small businesses.  Early in 2012 Government provided banks with £20 billion 
at low rates of interest for the National Loan Guarantee Scheme56 so that they could 
provide small businesses with loans up to one percent cheaper57 than they might otherwise 
be offered.58 However we heard that banks were requiring entrepreneurs to provide 
security to obtain these loans. For example Dr Worswick, Chairman, Cobalt Light Systems, 
stated that: 
 
50 The witness later stated that there are 4,000 companies currently in the UK turning over between 2.5 million and 100 
million, growing in excess of 10% per annum. 
51 Q 59 [Stephen Welton] 
52 Qq 81-2 
53 Ev 173, para 37 
54 A bank loan where the government guarantees 75% to the bank.  http://www.bis.gov.uk/efg 
55 An accord between the UK Government and the major UK banks – specifically Barclays, HSBC, LBG and RBS, and 
Santander – in which the banks explicitly recognised their responsibility to support economic recovery, not least in 
providing finance to small and medium sized enterprises through the creation of the Business Growth Fund and 
other direct lending.  
http://www.hm-treasury.gov.uk/d/bank_agreement_090211.pdf 
56 HM Treasury website, “National Loan Guarantee Scheme”, http://www.hm-treasury.gov.uk/nlgs 
57 The delivery of the 1 percentage point discount may also vary between banks as some offer a reduced interest rate 
over a number of years, whereas others may offer the discount as an up-front cash payment. 
58 “Chancellor launches scheme to boost small business lending” HM Treasury press notice, 19 March 2012 
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We approached HSBC, with whom I had had a very long and excellent relationship, 
under the Government loan guarantee scheme. We wanted to borrow £400,000 for 
working capital on a specific project. It took a fair amount of time but that is okay; 
they had due diligence and so on. Remember that 75% of that—£300,000—was 
covered by Government guarantees. They then turned round and said, “Well, the 
directors of the company will have to warrant the other £100,000.”59  
In some cases, the only security available may be a family home. The Minister recognised 
that banks had become bad at lending where there were no assets such as a house to 
guarantee a loan. He did point out however that under the Enterprise Finance Guarantee 
Scheme conditions “lenders must not take a charge on the principal private property”.60 
37. Matthew Bullock was head of Barclay’s technology financing team in Cambridge for 
ten years. He told us it was possible for banks to fund technology innovation: 
We provided bank finance in Barclays for the kind of venture I am talking about, not 
the one that was running very quickly towards product development and going 
down through the negative loop. We lent very consistently. We had a loss rate of one 
sixth of the bank’s average over a 10-year period, and basically it was a very good 
business. We rotated our finance because basically we were providing working 
capital finance against contract payments from creditworthy customers who we were 
satisfied would be very sound debtors. We had to monitor things very closely, which 
we did, but it was basically quite good business for banking.61 
38. We were encouraged that there might be a remedy for some of these problems in the 
near future. While we were inquiring into this issue, Rt Hon Vince Cable MP, the Secretary 
of State for Business, Innovation and Skills, announced that a bank for business will be 
established within the next 18 months. This was confirmed by the Chancellor of the 
Exchequer in the Autumn Statement62 but details of how this bank will be constituted or 
operate are not expected until spring 2013. 
39. We are concerned that our small companies are too often bought up by larger 
overseas companies before they can develop into the medium sized enterprises that 
would produce substantial jobs and wealth in the UK. We are convinced that while 
equity investments have a place, too many companies are forced into over-reliance on 
this route because other types of funding are unavailable. We recommend that the 
proposed bank for business, possibly in partnership with the Business Growth Fund, be 
used to promote a bond market for medium sized businesses, thus providing growing 
small businesses with an additional source of funding. 
40. We have concerns that regulation to de-risk pension and insurance funds has had 
the effect of starving technology companies of a source of long term patient capital. 
There is a need to deploy these funds more usefully. We recommend that the 
 
59 Q 84 [Dr Worswick] 
60 Q 308 
61 Q 53 [Matthew Bullock] 
62 HC Deb, 5 December 2012, c880 
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Government investigate the potential to require funds to have a proportion of European 
SME equities. 
41. Lloyds Banking Group run a scheme where senior staff attend a Warwick based 
engineering course designed to help them make better decisions on financial risk by giving 
them a better understanding of some emerging technologies.63 We recommend that the 
bank for business adopts such an approach for its staff from the outset. 
42. The bank for business announced by the Government may provide a useful go-
between for institutional investors and technology businesses. We urge the Government 
proactively to seek to develop not only the market in technology equities but to ensure that 
the market has ready access to information that may change the perception of these 
equities and their relative risk and create mechanisms, such as the Lloyds scheme, to help 
fund managers understand evolving technologies. However, reporting requirements and 
other costly regulatory burdens on UK-based listed companies, especially in the AIM 
market, should be kept to a ‘fit for purpose’ minimum. 
43. The development of companies may not be linear but it is important that, at whatever 
stage a company finds itself, there is an obvious next investment step to take. If the 
investment ladder is not complete then companies may take development steps at 
inappropriate times. For example, Birmingham University pointed out that without access 
to proof of concept funds, universities may establish companies too early in order to 
qualify for SMART.64 
44. The Wellcome Trust was concerned that  
the Government’s ambition for university knowledge exchange income from 
external sources to grow by 10 per cent over the next three years [...] will encourage 
universities to see their interactions with businesses within a context of short-term 
revenue generation, rather than sharing knowledge for longer-term public benefit. It 
may dissuade them from seeking out local partnerships that will create jobs and see 
intellectual property retained within the UK, if greater profit can be made from 
licensing technology internationally. 
45. We recommend that the Government re-examine their portfolio of interventions to 
determine where gaps may lie and to ensure there is a consistent spread of funding across 
the spectrum of business need. It is important that government funding fits the needs of 
growing companies rather than company growth having to adapt to gain government 
funding. It is also important to ensure that the incentives from Government tend towards 
greater growth and retention of jobs and wealth creation in the UK. 
Getting access to the necessary technology 
46. The successful commercialisation of research requires parallel efforts to develop 
manufacturing technologies. Professor Bill O’Neill, University of Cambridge, stated: 
 
63 Personal communication, Head Office, Lloyds Baking Group. 
64 Ev w49, para 1.4 
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Translational research and development has been widely recognised as of vital 
importance to ensuring that the UK gains a wealth creation dividend from 
investment in science. However, the importance of parallel research and 
development in the supportive manufacturing sphere has, until recently, received 
less attention. 
[...] 
For some inventions, for instance in the material sciences, manufacturability has 
remained a constraining challenge for years after the invention’s market potential 
has been recognised. These, wasteful, fallow years could have been foreshortened if 
the manufacturing research and development effort had been mobilised sooner.65 
47. Rolls Royce identified a need for national manufacturing infrastructure that could 
support pre-production R&D: 
Our overseas competitors benefit significantly from access to rigs and facilities in 
National research centres which are funded and maintained at the state-of-the art 
out of the public purse (e.g. NASA in the USA, DLR in Germany, ONERA in 
France). In the UK, such facilities have largely been privatised. It is no surprise then 
that many of these facilities have been, or are being closed as they cannot be 
maintained as a commercial operation, or else face under-investment so that they 
become uncompetitive. Such facilities are essential to take technology through the 
TRLs 4, 5 and 6. 66 
As example, Rolls Royce pointed to the lack of a UK engine altitude test facility, the 
repeated threat of closure of the Noise Research Centre in QinetiQ and the difficulty the 
Aircraft Research Centre in Bedford has faced in seeking to modernise facilities. 67 
48. Dr Eoin Sullivan of the Centre for Science, Technology and Innovation Policy at the 
University of Cambridge wrote of the importance of manufacturing requirements: 
Public science and engineering research programmes typically focus on building one 
technology artefact to demonstrate innovation/technology; but lack resources to 
address risks in maturing manufacturing processes. 68 
The following graphic was produced, by Dr O’Sullivan,69 to demonstrate the close 
relationship required between a developing technology and the manufacturing capability 
necessary for its eventual commercial production. 
 
65 Professor William O’Neill 
66 Ev 184, para 1.11 
67 Ibid. 
68 E.O'Sullivan, “Manufacturing Uncertainty and the Valley of Death”, CSTI Briefing Note, 2012 
69 E.O'Sullivan, “Manufacturing Uncertainty and the Valley of Death”, CSTI Briefing Note, 2012 
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49. Engineering the Future hoped that the Catapult centres70 and Local Enterprise 
Partnerships could “effectively reduce investment capital requirements for companies 
entering certain markets by offering open access prototyping, scale-up and demonstration 
facilities”.71 The University of Birmingham believed the key to the catapults contributing in 
this way lay in “how “open access” these facilities will actually be and/or what funding 
streams will be available to enable such access”.72 The Royal Society for Chemistry wrote: 
Access to facilities could be improved by providing funding to small and medium 
enterprises (SMEs) to use the new facilities. A good model was the funding offered 
for the Industrial Biotechnology pilot plant facilities at the Centre for Process 
Innovation and this should be replicated for other centres part of the HVM 
Catapult73 
50. Dr Ruth Mallors, Director of the Aerospace, Aviation and Defence Knowledge Transfer 
Network, told us that “there are lots of facilities in [the university sector], but there is not 
an overarching understanding of what bits we need nationally to create a national 
capability”.74 She added that an “overarching strategy and facility approach is not there, 
particularly for industries where physical and virtual testing is so important because of 
safety and the regulatory environments. It is becoming an increasingly big issue for those 
sectors”.75 We heard of other examples of facilities that could provide the basis of a national 
infrastructure. Examples include the Open Innovation campus in Stevenage in the 
biosciences,76 the National Physical Laboratory in Teddington and the Rutherford 
Appleton Laboratory in Didcot. 
 
70 Catapults centres are government funded networks of academics and businesses focussed on technological innovation 
in particular technology sectors.  
71 Ev 165, para 1.3 
72 Ev w52, para 5.4 
73 Ev w82, para 26 
74 Q 203 
75 Ibid. 
76 Ev 194, para 4.3 
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51. We share the concerns of our witnesses that the UK small business sector lacks access 
to large scale test and experimental production facilities. We recommend the Government 
to find a way to ensure that those facilities that do exist can be more readily accessed by 
business, that gaps in requirements are identified and a fund established to subsidise 
those facilities that cannot afford to remain at the leading edge in a purely commercial 
environment. 
52. We urge the Government, when looking at the issue of production facilities, to ensure 
that the Technology Strategy Board and other commercialisation activities address 
whether projects are properly supported in issues of manufacturing capability. 
Creating the right environment 
Incentivising R&D activity 
53. The key government support for companies investing in research and development is 
the R&D tax credit which provided “over £1 billion of support [...] through the Small and 
Large Companies schemes in 2009–10”.77 
54. Research carried out by HM Revenue and Customs in November 2010 showed that 
between 2003 and 2008 the tax credit successfully encouraged business expenditure in 
research and development (BERD) to grow from £11.33 billion to £14.99 billion while the 
amount of that spending used to claim tax credits grew from 50% to 72% of R&D 
expenditure.78 Interesting features of the analysis within the report were that the main 
sectors claiming the credit were Real estate, Renting and Business activities (36% in 2007–
08, 40% in 2008–09) and Manufacturing (31% in 2007–08, 40% in 2008–09);79 and that 
over the period 2004–05 to 2008–09 ‘high tech’ accounts for “two thirds of SME claims 
accounting for over 90% of the tax cost” (the corresponding figures for large company 
'high tech' claims are 42% and 74%).80 A key feature was that 80% of the tax credit was 
claimed by large rather than small and medium sized businesses: 
For 2008–09, the most recent year for which figures are complete, 6,600 SMEs made 
claims averaging £40k each, whereas 2,190 large companies made average claims of 
£328k.81 
55. Prior to the 2010 General Election, the Conservative Party commissioned James Dyson 
to develop proposals to make Britain the leader in Europe for hi-tech exports. He 
recommended that the tax credit be refocused on “high tech companies, small businesses 
and new start-ups in order to stimulate a new wave of technology”.82 Greater support for 
 
77 Ev 96, para 13 
78 HMRC, “HMRC Research Report 107 - An Evaluation of Research and Development Tax Credits”, November 2010, 
Table 4 
79 HMRC, “HMRC Research Report 107 - An Evaluation of Research and Development Tax Credits”, November 2010, 
Figures 5 and 6 
80 HMRC, “HMRC Research Report 107 - An Evaluation of Research and Development Tax Credits”, November 2010, p6 
81 HMRC, “HMRC Research Report 107 - An Evaluation of Research and Development Tax Credits”, November 2010, p5 
82 “Ingenious Britain: Making the UK the leading high tech exporter in Europe”, James Dyson, March 2010 
http://www.dodsmonitoring.com/downloads/Misc_Files/Ingenious_Britain_Support.pdf 
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SMEs was a feature of many responses to this inquiry particularly from industry and trade 
associations.83 
56. In oral evidence, Sir Peter Williams and Sir David Cooksey, both of whom participated 
in the working group that first recommended the tax credit to the Treasury,84 advocated a 
greater refocusing of the credit to SMEs: 
I have to say that, reflecting today, 10 or more years on, that scheme has been highly 
effective with SMEs. Can we have some more, please? It probably has not 
conditioned behaviour in R and D of larger companies. They willingly bank the 
cheques.  It is always good news. I sat on the boards of two major plcs who received 
considerable R and D tax credits during my time as an [non-executive director]. I do 
not think you are moving the needle with big companies, but, boy, are you moving 
the needle with smaller companies.85 
Both Sir Peter and Sir David appeared before our predecessor Committee in 1998 
subsequent to the publication of their report to the Treasury. At that time they spoke of the 
measure as a way of encouraging the growth of smaller businesses by helping them stretch 
the value of their capital: 
in most of these companies, anything up to 70 or 80 per cent of their total 
expenditure in the early phase is on research and development in one form or 
another. If you are able to offset this expenditure as a tax credit which could accrue 
within the company against taxable income paid elsewhere, then that would be 
extremely helpful because it would just make that investment last that much longer86 
Sir Peter was certain that the tax credits could do more to help emerging technology based 
companies if they were better focussed on smaller companies, possibly with some 
reallocation from larger companies.87 
  
 
83 Ev w110, para 18 
84 HM Treasury, “Financing of High Technology Businesses”, November 1998  
http://archive.treasury.gov.uk/pub/html/docs/fhtb.pdf 
85 Q 98 
86 Q 631, House of Commons Science and Technology Committee, Second Report of 1999-2000, HC 195, “Engineering and 
physical sciences based innovation”, 9 February 2000  
87 Q 100 [Sir Peter Williams] 
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57. HMRC published an assessment in November 2010 which showed the various impacts 
of the tax depending on the nature of the company. Data from Table 2 in the document, 
Effect of tax credits and grants for R&D,88 is reproduced below. It demonstrates very 
different responses to the R&D tax credit between a range of firm sizes: 
 R&D tax credits
One person, one product May not claim 
Small research-based business Useful bonus may increase amount of R&D conducted 
Established SME, suite of products Regular claims good for cashflow 
 
May increase amount of R&D conducted  
High tech, high ambition  Nice to have, but not factored in to decisions  
Large company, separate R&D 
function 
Political statement of support for R&D in UK  
 
Little direct impact on amount of R&D  
 
58. During 2011 the Government consulted twice on R&D tax credits. In response to the 
first consultation the Government indicated that it did not intend to refocus the tax to high 
technology firms along the lines of the Dyson report but it did introduce a range of 
measures to increase the benefits to SMEs.89 
59. The Government indicated that it would not follow the James Dyson report 
recommendations that the tax credit should be refocused on high technology sectors or 
on small and start-up companies. The R&D tax credit has been successful in increasing 
spend by business on research and development but this has, mostly, been within larger 
companies. We recommend that the Government identify the reasons why R&D spend 
still appears to be drifting away from the UK despite the benefits enjoyed by larger 
companies. We also believe that there needs to be a mechanism to support SME's who do 
disproportionately badly from the current scheme. 
60. A number of submissions highlighted the need to develop more medium sized 
companies. The SET Squared partnership indicated that “One of the biggest problems 
facing the UK economy is its relative inability to develop and retain mid-sized high growth 
companies”.90 Cambridge Enterprise Ltd stated that “if retaining and developing such 
companies in the UK are objectives, they would be assisted by a consistent national strategy 
to develop companies beyond the early stage”.91 Mark A Phillips, first Chairman of 
BRITEST Ltd and a visiting professor at Leeds University Business School, highlighted a 
potential problem that a lack of medium sized companies might cause: 
In fields like high precision engineering and robotics the UK appears to lack 
companies of sufficient scale to engage in major manufacturing development 
 
88 HMRC, “Qualitative research into businesses’ Research and Development (R&D) decision-making processes”, 
November 2010  http://www.hmrc.gov.uk/research/report101.pdf   
89 HM Treasury, “Research and Development tax credits: response and further consultation”, June 2011 
http://www.hm-treasury.gov.uk/d/consult_r_d_tax_credits.pdf 
90 Ev w174, para 3.6 
91 Ev w19, para 5 
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programmes and we have had to look to Europe and the Far East to provide partners 
with the required capability.92 
61. We conclude that the Government needs to distinguish in its innovation policy 
between small and medium enterprises: a single SME category is too broad. 
62. Engineering the Future and the University College of London both welcomed the 
Government’s action to exempt universities from VAT on shared services and that such 
action was “a strong signal of support from government”. However the Wellcome Trust 
raised an issue in relation to the Francis Crick Institute: 93  
zero rating for new charitable buildings can only be retained if the building is used 
95% for non-business charitable purposes. In the case of the Francis Crick Institute, 
this will restrict the ability to conduct on-site technology transfer and 
commercialisation activities.94 
This was expanded upon on our visit to the Advanced Manufacturing Research Centre in 
Sheffield and subsequently detailed in writing. 95 A recent change in VAT rules meant that 
it imposed an additional cost on the “construction, equipment and running costs” of their 
Knowledge Transfer Centre and AMI Training Centre that can only be recouped by 
increasing the cost of apprenticeship fees to those companies seeking to train their future 
staff. 
63. We recommend that the Government address the issue of VAT and how it might 
ensure that VAT rules allow academic teaching and research to sit alongside commercial 
and incubation activities within public or charitably funded laboratories and research 
centres without creating a financial burden for the institute. 
Regulation 
64. On its website the Department for Business, Innovation and Skills says: 
Cutting red tape and improving our regulation and policies is a key priority for BIS. 
We aim where appropriate, for a light-touch regulatory environment, with less red 
tape and burdens on business, whilst protecting the public, consumers and 
employees.96 
65. We were provided with several examples of regulation in the bio-pharma sector 
impeding product innovation. David Cooksey told us that, even in the USA, it was simpler 
and cheaper to conduct in-human trials: 
 
92 Ev w21, para 3 
93 The Francis Crick Institute is a partnership between the Medical Research Council (MRC), Cancer Research UK, the 
Wellcome Trust, UCL (University College London), Imperial College London and King's College London.  It is 
envisaged that the Institute will combine the specialist knowledge, expertise and resources from each of these 
organisations to encourage ground-breaking research, help make sure that laboratory discoveries are turned into 
treatments as quickly as possible, keeping the UK at the forefront of innovation in medical research, attracting high-
value investment and strengthening the economy. 
94 Ev 135, para 16 
95 VAT Officer, AMRC 
96 http://www.bis.gov.uk/policies/better-regulation-at-bis 
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The sheer cost, bureaucracy and difficulty of getting that done in this country means 
that, of the portfolio of companies that I have been involved with, probably more 
than 75% of them have given up in this country and have gone to do their trials in 
Philadelphia, Boston or North Carolina, because they can get it done quicker and 
cheaper and with a system that delivers more coherent results.97 
This was supported by evidence from Action on Hearing Loss: 
Hearing research that does take place in the UK can be undermined by an overly 
complex regulatory and governance environment. An Action on Hearing Loss-
funded project, investigating genetic predisposition to hearing loss caused by a 
specific class of antibiotic often used to treat life threatening infections in premature 
babies, has been held up for over two years due to the complicated bureaucracy 
involved in conducting clinical research at multiple sites in the UK and the lack of 
support to help researchers navigate the regulatory process.98 
Action on Hearing Loss already sent the majority of their research overseas, mostly due to 
a lack of appropriate research capacity; a trend that is not likely to be reversed in the face of 
a difficult regulatory system.99 
66. The British Society of Plant Breeders were concerned that regulation surrounding GM 
was so difficult that procedures that might be classed as GM were avoided.100 The 
Aerospace, Aviation & Defence Knowledge Transfer Network highlighted the difficulties of 
innovating in a highly regulated environment such as aerospace when the regulations are 
complex and fragmented,101 LGC102pointed to regulation as a barrier to the introduction of 
innovative procedures.103 Rees Ward, Chief Executive Officer, ADS,104 indicated that better 
information from Government could help industries working in highly regulated sectors: 
Different sectors require slightly different approaches here, but the broad picture is 
that we need to understand in highly regulated and government dominated sectors 
where the government wants to go in the long term105 
67. Tim Crocker of the SME Innovation Alliance believed that not only did the regulatory 
burden fall more heavily on smaller businesses, it also added to the liabilities of doing 
business: 
If I want goods signed off for sale in this country, I end up signing the certificate of 
compliance. If I go to a German test house, the test engineer, who is an employee of 
the German state, signs it off. That is a massive liability difference. 
 
97 Q 115 
98 Ev w73, para 24 
99 Ev w73, para 23 
100 Ev 132, para 6 
101 Ev 131, para 2.1 
102 Formally the Laboratory for Government Chemist now a private forensics company 
103 Ev w106, para 5.1 
104 ADS is the trade organisation advancing the UK Aerospace, Defence, Security and Space industries.  
105 Q 179 [Rees Ward] 
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68. The CBI also raised the issue of regulation, noting that intelligent regulation could 
drive innovation as long as companies were provided with certainty. This could be 
accomplished if the Government was able to: 
• Inform businesses of future planned changes in the regulatory environment, 
allowing time to plan and comply with new rules 
• Provide a degree of flexibility in how regulations could be met 
• Provide clarity in requirements and ensure new rules were not open to 
misinterpretation 
• Ensure poor regulations were dealt with effectively and that additional burdens or 
conflicts were not placed on business by overlapping or multiple layers of 
regulation.106 
69. Iain Gray, Chief Executive, TSB, maintained that, in Germany, standards were used to 
drive innovation rather than being an inhibitory factor and that, “There are a lot of non-
financial ways in which [the TSB] can help business”.107 The Minister indicated that he was 
open to exploring options that might reduce burdens on small businesses: 
We have flagged an issue that we should do more work on to try to understand this 
German system, though as I say, we are not necessarily sure that the earlier evidence 
absolutely matches our understanding of how it works. But we will undertake to look 
into it further.108 
The Government, in 2011, published an independent review on how the impact of health 
and safety regulation might on business might be reduced “maintaining the progress that 
has been made in health and safety outcomes”.109 
70. Poor regulation adds to the risk burden of entrepreneurs. We welcome the proactive 
response of the Minister on the issue raised in evidence to us and recommend the TSB to 
undertake a review of regulatory burdens on technological innovation in the UK. This 
review should be consistent with the advice to Government by Professor Ragnar Lofstedt 
on Health & Safety matters but should not include just a list of regulatory burdens in 
need of reform but a roadmap of how that reform might be used to drive innovation and 
which institutions should take the lead. 
Intellectual property 
71. Innovators often have an unrealistic expectation of the worth of their IP; the 
BioIndustry Association identified a problem with university technology transfer offices 
and businesses having different perceptions of the value of intellectual property: 
 
106 Ev 151, para 13 
107 Q 265 [Iain Gray] 
108 Q 286 
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Research conducted by the Advanced Institute of Management Research (AIMR) 
and Imperial College Business School showed that between 2004 and 2008 an 
increasing number of firms reported a range of problems that they consider barriers 
to greater collaboration with [Technology Transfer Offices] including a perceived 
lack of realistic expectations.110 
The Royal Society of Edinburgh underlined the problem: 
There is a common perception among industry and investors that universities can be 
unrealistic in negotiating terms on the transfer of IP, often expecting large 
percentage returns even where IP is not assigned but exclusive licence granted. In a 
company’s early years, when cash flow is often a make-or-break issue, heavy 
repayments to the university in the form of licence payments or wage costs for 
academics involved, can be a significant factor in the success or failure of 
commercialisation.111 
The Minister was aware of this issue: 
One thing that does concern me is that perhaps in the past there was a kind of target 
culture when notching up patents was the priority, especially as universities and 
researchers do sometimes exaggerate the starting value of their discovery and 
underestimate the value added by the commercial development of the discovery. 
Sometimes you can have a dialogue of the deaf in a negotiation where the university 
sits and thinks it has high value for the IP they have, whereas the commercial 
entrepreneur thinks that is exaggerated. There are areas where we can improve 
here.112 
72. Patent laws were introduced to encourage inventors to put their ideas into the public 
domain by providing them with a period in which they would have a monopoly on benefits 
from the use of that technology. It is commonly believed that patents prevent others from 
using the technology but in fact it only provides an inventor with a right to take legal action 
against a third party whom they believe has used the technology. The onus is on the patent 
holder to prove the breach: a patent holder must be aware that a breach has occurred and 
have sufficient funds to take the matter to court.  Small technology companies can find it 
difficult to protect their IP. Tim Crocker, SME Innovation Alliance, stated that: 
you cannot exercise the rights of those patents unless maybe you have got a fighting 
fund of half a million quid; and that would be a minimum sort of fighting fund, as 
lawyers would advise you.  [...] if you are a £20 million-worth company [you] can’t 
continually fight half-a-million quid battles to enforce your commercial rights.113 
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73. The result is that the easiest way for a small technology company to realise the value of 
a patent is probably to sell the patent, or the company, to a larger competitor rather than 
attempt to exploit a technology they could not afford to protect.114 
74. The Minister acknowledged that a problem existed for smaller companies. He was not 
aware of any Government initiative to address it,115 though he did indicate actions taken to 
alleviate some aspects of the current system: 
There has been some improvement in the Patents County Court. In terms of 
companies getting protection through law, we have tried to lower the costs for them 
of protecting their patents through the legal system. We have also tried to help 
provide alternatives to court action, including hearings before the [Intellectual 
Property Office] tribunal or using the [Intellectual Property Office’s] mediation and 
patent opinion services.116 
The Intellectual Property Office (IPO) offers a mediation service “to help companies and 
individuals involved in intellectual property (IP) disputes” covering all intellectual 
property, “unregistered copyright and design rights, as well as registered rights such as 
patents, trademarks and registered designs”.117 There is however no requirement for 
companies to use mediation nor a compulsion to abide by any ruling of a mediator. 
75. We note that the Business, Innovation and Skills Committee in its report The 
Hargreaves Review of Intellectual Property: Where next? stated that the needs of SMEs in 
the area of intellectual property was 
an important area to address to support growth in the economy and we recommend 
that in its Response to this Report the Government set out in detail its commitment 
to this service in terms of money and resources.118 
While the Government did not set out any detail in its response it said that “Ensuring that 
these businesses, which make up 99% of UK enterprises and nearly 60% of UK 
employment, can maximise the value of their intellectual property assets is key to 
economic growth”.119 
76. We judge that the IPO mediation service could be more heavily used to arbitrate in 
matters of intellectual property. We recommend that the Government require the use of 
mediation before any legal action can be taken in a UK court, both speeding up the 
resolution of disputes and reducing the costs of protecting intellectual property. We also 
recommend that refusal to engage in mediation be taken into account in awarding costs. 
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77. It is unsurprising that universities generate intellectual property. Academic research is 
ideally placed to discover or stumble across innovative materials or behaviour that may 
prove commercially viable. HEFCE estimated that 19% of patent filings in the UK came 
from university sources.120 The Government has encouraged universities to exploit this 
resource and several sources of funding have been developed to facilitate exploitation of 
university IP.121  The Higher Education Innovation Fund (HEIF), provided by HEFCE122 
for the purposes of knowledge exchange, was popular among those universities that wrote 
to us as was the recent Government move to focus the HEIF more closely on universities 
where there has been greater success in translating IP into business opportunities.123 
78. We heard of cases where universities had been reluctant to patent innovations 
discovered by academics. Dr Peter Dean, Founder and Chairman, Cambio Ltd, gave us an 
example of university technology failing to translate into UK wealth creation due to patent 
issues: 
We produced a patent [to do with diabetic management], which the university did 
not support financially in any way. The company involved, which was Canadian, 
suggested that they take all the patent costs and run the patent for us, which was fine. 
At the end of six months they pulled out; they said they had changed their objectives 
and were doing something else. As a result, the University of Liverpool was asked to 
support the patent through its foreign filings and whatever. It refused to do that, and 
the patent was sold to the USA for a pittance. The USA completed the patent. There 
are 283 million diabetics in the world. That University of Liverpool test is used pretty 
much throughout the world, but there is no royalty coming to this country because 
of the failure to strategise the patent process.124 
79. Patents are only useful if they are exploited. We were told by Trevor Francis, Technical 
Director, Byotrol Technology Ltd, that universities, due to the expense of maintaining IP, 
may allow their patents to lapse with the consequence that the intellectual property “simply 
passes into the public domain instead of potentially passing to companies that could 
equally use that patent for knowledge and exploit it”.125 
80. Professor Nick Wright told us that some universities have, as a result begun an 
experiment in easy access IP: 
 several members of the Russell Group universities banded together into what is 
called the Easy Access IP consortium. That is quite an innovative arrangement 
created by Steve Beaumont, a very forward-thinking guy, at the University of 
Glasgow. It is a system whereby UK companies can access IP from member 
universities for free, provided it is to the benefit of the UK. That is an excellent 
scheme. There are other schemes. In the north-east, we have a similar scheme, 
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allowing collaborative working between Newcastle and Durham universities, for 
example.126 
Rolls Royce warned of broader access to open data that might also have relevance to easy 
access IP: 
Proposals [...] for increasingly ’Open Data’ must be implemented with great care. If 
such proposals help all companies access the mass of data in the public domain more 
effectively and free up Government-owned data for easier access, they are to be 
welcomed. However, if they make it easier for our overseas competitors to access and 
exploit the research base in the UK, especially those elements where UK companies, 
like our own, have made a significant contributions, then, far from promoting 
growth in the UK, they could be severely damaging our competiveness.127 
81. We recommend that the Government assess the benefits of the Easy Access IP 
experiment and whether it improves the flow of IP not just between universities but into 
wealth creation activities within the UK. 
82. We understand the intent behind changes to HEIF that further reward institutions 
that have already benefitted from successfully commercialising their IP. We have 
concerns that IP transfer from universities that have been less successful in 
commercialising their IP may decrease further. We recommend that the Government 
review the situation after three years and publish a report on how the changes have 
contributed to increased IP transfer, job creation and related social benefits. 
Evidence based policy 
83. It is important that Government policy, where possible, should be based on robust 
evidence and where that evidence may not exist that processes are in place to gather 
evidence of how any policy is performing. Dr David Connell, University of Cambridge, 
criticised the nature of information produced by government on innovation spending and 
policy: 
If we look across Government organisations involved in technology, rather than 
providing annual reports in the format that you would see from a public company, 
they tend to produce brochures with examples of what they are doing at the time. It 
would be really good to know where the money went, actually, and to see some 
proper reporting to the kind of standards that we should demand.128   
84. Dr Paul Nightingale, University of Sussex, made a similar point: 
In terms of commercialisation, the UK is very good compared with the rest of 
Europe, with the possible exception of Scandinavia. There is an issue about relative 
amounts of GDP that we spend on university research. [...] The key issue is that we 
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need proper evaluation of these schemes. We really don’t know what works. It is very 
complicated right now and this has been a problem.129 
Matthew Bullock highlighted the absence of information on activity by soft start 
companies: 
An important point to make is that the development of technology products and 
equipment on contract—what the great, soft majority of smaller technology 
companies do—does not appear anywhere in the R&D statistics: the activity does not 
conform to the Frascati definition used by BIS/ONS to measure R&D activity; for the 
small supplier the activity is recorded as sales; and in their large customer’s accounts 
it may appear as capital expenditure or revenue expense. The Frascati definition 
requires the activity to be speculative, without a firm sale in prospect130 
85. The R&D Scoreboard was an information resource produced annually by the 
Department for Business Innovation and Skills. The Scoreboard provided an overview of 
spending on research and development by private companies. In 2010, the foreword to the 
Scoreboard indicated that, due to financial considerations, it was to be discontinued. 
Engineering the Future told us: 
It is regrettable that BIS chose to withdraw funding from the well respected and 
widely used R&D Scoreboard in 2010. As a measurement of innovation, knowing the 
amounts of funding is of limited use, but without the Scoreboard there is no way of 
comparing R&D spend across the full range of industry sectors.131 
The UK Deans of Science were concerned about evaluation and stated: 
[Government] has also decided to stop funding the excellent R&D Investment 
Scoreboard so will have almost no robust way of judging the success or failure of any 
of its policies.132 
86. We also heard that, between 1991 and 2004, the Bank of England monitored the 
availability of finance to small and medium sized enterprises (SMEs).133 Their role was to 
identify any areas where access to appropriate finance seemed problematic, to investigate 
and highlight those issues with key stakeholders and to encourage them to find solutions, if 
any were needed. This work led to the publication of a series of reports and articles 
including a regular annual report on finance for small firms. 
87. We consider that the R&D Scoreboard was a useful and widely respected source of 
information for technology businesses and we recommend that the Government should 
reinstate it. We also recommend that the Bank of England should resume their 
monitoring activity on the availability of finance to SMEs. 
 
129 Q 18 [Dr Nightingale] 
130 Ev196 
131 Ev 167, para 5.3 
132 Ev 125, para 20 
133 Ev w58, para 23 
Bridging the valley of death: improving the commercialisation of research    31 
 
3 Connecting science with industry 
88. The importance of the university sector in attracting inward investment by business 
was made clear to us on several occasions.134 BP, in its evidence to us, highlighted the value 
of academic research and development to where they site their own research and 
development activity: 
BP spends 40% of its total research & development funds in the UK and has three 
major research centres in Sunbury, Pangbourne and Hull. The excellence of UK 
academic research is a key factor in determining why companies like BP choose to 
site their R&D activities in the UK.135 
A fundamental ambition of UK innovation policy is to connect the science base and 
industry. In this chapter we explore the Government’s innovation agency, the Technology 
Strategy Board (TSB) and how the university sector is encouraged to facilitate and advance 
innovation policy. 
Technology Strategy Board 
89. “The TSB is the Government's prime channel of support for business-led technology 
innovation”.136 The TSB describes its work and role on its website: 
Our role is to stimulate technology-enabled innovation in the areas which offer the 
greatest scope for boosting UK growth and productivity. We promote, support and 
invest in technology research, development and commercialisation. We spread 
knowledge, bringing people together to solve problems or make new advances.  
We advise Government on how to remove barriers to innovation and accelerate the 
exploitation of new technologies. And we work in areas where there is a clear 
potential business benefit, helping today's emerging technologies become the growth 
sectors of tomorrow.137 
Funding 
90. Sir Peter Williams, Treasurer of the Royal Society and Chair of the National Physical 
Laboratory, was concerned the TSB would not have sufficient funding to achieve what was 
expected of it, stating, “you can never have too much money in this sector. [The TSB] is 
small by comparison with, if you like, the private equity players in this space, and, 
therefore, being brutal about it, its impact will be commensurately small if we are not 
careful”.138 
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91. Rolls Royce also questioned whether the TSB was adequately resourced even to operate 
its core remit of funding collaborative research: 
The TSB has developed efficient mechanisms for supporting collaborative research. 
Their funding, at just over £300m p.a. is, however, inadequate for the task in hand.  
The Government is spending over £3.5bn on low TRL research, and cannot hope to 
adequately capture the benefits from this investment when spending so little on 
support through the valley of death. 139 
92. Iain Gray, Chief Executive of the TSB, did not think that the balance was correct.140 
Sir John Savill representing Research Councils UK was sympathetic to that view, though he 
was clear that any increase in the budget to commercialise should not be funded through a 
cut to the Science Budget.141 
93. Evidence on the TSB uncovered a number of criticisms on small issues but, 
overwhelmingly, there was an appreciation for their work and their funding programmes 
and a consistent call for funding to be increased.142 The key programmes are SMART 
Awards143 and the SBRI.144 Dr David Connell recommended a huge increase in SBRI 
funding145 and Sir Peter Williams told us that the Government need to pick some winners 
and give them generous funding. He considered the SBRI a decent vehicle through which 
to do this but it would need more extensive funds than those envisaged by the 
Government.146 
94. We examine the role of SBRI in relation to Government procurement in more detail 
later in this report. 
95. SMART Awards are a key funding initiative for proof of concept work147 and have been 
subject to strong competition; Rolls Royce told us that the competition for those awards 
indicated the strength of the technology marketplace. The University of Birmingham was 
concerned that the inability of universities to gain access to SMART Awards would push 
university spin-offs into commercialisation too early just to become eligible.148 Although 
there are other sources of funding for proof of concept work,149 the University of 
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Bournemouth150 and others151 argued that the total amount was insufficient. The 
University of Edinburgh stated: 
The valley of death can be encountered at various stages of the commercialisation 
process, but is most often acutely felt in pre and early stage company formations 
where there are gaps between the early stage/proof of concept nature of the 
technology and the beginning of increased production and generation of significant 
revenues152 
The Association of Independent Research and Technology Organisations (AIRTO) (V45) 
suggested that better proof of concept funding would encourage more equity funding by 
effectively reducing the risk of investment.153  
96. We recommend the Technology Strategy Board examine the current provision of 
proof of concept funding to universities and small companies and report to Government a 
coherent view of the amounts of funding available along with a recommendation on 
whether there exists a shortfall of provision of these funds and whether a consolidation of 
provision into a single programme would be helpful. 
Effectiveness 
97. We sought views on the Technology Strategy Board (TSB) and how effective its 
intervention was in stimulating innovation and helping companies across the valley of 
death.  Many responses indicated that it was still too early to make that assessment. 
98. Others, however, were critical. We received evidence suggesting that TSB funding 
might not suit small businesses,154 public sector research organisations or research and 
technology organisations.155 The SME Innovation Alliance recommended that the TSB 
stop “playing at ‘Dragon’s Den’, themed competitions, timed ‘calls’ and [...] stick to funding 
projects quickly and simply on pure merit”.156  Plant Bioscience Ltd told us that “TSB funds 
are slow to obtain and involve far too much bureaucracy”.157 Sir Peter Williams was more 
challenging. He was supportive but had some concerns: 
I am a fan of the TSB in concept. In fact, in my SET and the City report, I single them 
out as being worthy of receiving more Government funding and having more clout 
and influence. I always fear in this country when things become centralised [...] that 
they become risk-averse at the same time. [...] if we are here criticising Government 
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for becoming timid and the City for being risk-averse, we have got to show by what 
the TSB does that it is bold, brave and is not risk-averse. That is my only fear.158 
99. His main criticism was that the “central executive did not have enough absolute power 
to just get on with the job”. 159 Imperial Innovations told us that “within our company 
portfolio we have many examples where the TSB programs have been a great catalyst and 
shared risk method of facilitating small growing companies to collaborate on 
commercialisation with larger companies without having to give up early rights”.160 
100. There is an evident need for an innovation agency in the UK and it makes greater 
sense to ensure the TSB and its schemes evolve to meet this need than create a new 
organisation. It also makes sense to concentrate the innovation function within a single 
agency to ensure there is coherence and consistency within the system. We support the 
current Government’s approach to its innovation policy. 
101. One of the determinants of whether the TSB is effective will be the success of the 
Catapult system, a key policy intended to bring together SMEs with university based 
research and one we commended in our report Technology Innovation Centres in 2011. 
One measure of this success may be how involved smaller companies are with the 
Catapults and how regularly companies of that size, which have serious growth potential, 
access catapult facilities. 161  
102. However both Rolls Royce and ADS162 warned us that pressure from Government for 
the Catapults to start earning revenue too quickly could potentially lead to a distortion of 
their priorities163 and stifle the growth of their capabilities.164 
103. We consider it vital that the Catapults are made to work. We ask the Government 
to confirm to us that they will not seek to push the Catapults to generate revenue but 
instead allow them to grow slowly and organically with a focus on developing the 
necessary capabilities to support innovation. 
The need for local knowledge 
104. We received mixed commentary on the loss of the Regional Development Agencies. 
While there was no general desire to see them reinstated and some definite criticisms of 
their work, we did see some instances where particular agencies played a significant role in 
connecting local business and research organisations. While we found Sir Peter Williams 
compelling in his evidence about the potential overplay of regional policy, we have 
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concerns that the TSB are properly resourced to facilitate the necessary local components 
of innovation activity that was once the remit of the RDAs. 
105. Douglas Robertson, UnicoPraxis, highlighted the value of advice in addition to 
funding: 
The KTP scheme in terms of evolutionary technology developments, is a very good 
co-funding scheme. It has been running for over 30 years. One of the reasons why it 
works is because it has advisers who work with the company to help them figure out 
how to get through the process. It means it is more costly because you have to 
provide advisers165 
106. This was supported by small technology businesses we spoke to. Dr Francis, Technical 
Director, Byotrol Technology Ltd, told us:  
our relationship with the North West Development Agency and through some of the 
business contacts was very good. It was local; they were quite often in Daresbury. 
You could meet them and have a coffee and talk to them about what you were trying 
to do, and they would help to guide you as advisers. 166 
107. Dr Worswick, Chairman, Cobalt Light Systems, added: 
The regional support was pretty well organised. Whether one is in favour of regions 
having their own budgets and so on is another matter, but the network they created 
was very helpful when you applied to them.167 
108. Another source of local advice that has been lost to business was outlined by 
Stephen Welton, Chief Executive Officer, Business Growth Fund: 
If the banking industry have a challenge, it is that they have centralised their model 
so much that the credit committees are all-powerful, and a lot of the local credit 
officers in the regions do not necessarily know what the outcome of the credit 
committee is going to be. That is not empowering the people on the ground, who 
have to make decisions that are pretty fundamental. Do you trust the people you are 
backing? The judgment of people, understanding how they sit within their local 
community—all these very old-fashioned business principles—are critically 
important, and we need to do more to invest in that.168  
109. We have concerns about the ability of the TSB to provide real local information 
unless they have the funding and resources to develop regional points of contact that can 
talk knowledgeably to local businesses. We recommend that the Government consider 
how they can resource the TSB to provide local level advice to technology businesses. 
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Leveraging our research establishments 
110. The Government, in its evidence to us, pointed out that the Higher Education 
Institutions generated external income of over £3 billion in 2011/12. What may be 
surprising is that only 2–4% of that money was due income from licensing and sales of 
shares in spin-outs. The greater part, in cash terms, was the conduct of collaborative and 
contract research, consultancy and the provision of professional training.169 
The value of universities 
111. The university sector as it contributes to academic research and development is a 
global success. A report, produced by the Department for Business Innovation and Skills, 
looking at the competitiveness of UK said: 
While the UK has far fewer researchers than larger countries such as the US and 
China, as a country, it is far more efficient in terms of output per researcher: of the 
top five research nations (based on article output in 2010: US, China, UK, Japan, 
Germany), UK researchers generate more articles per researcher, more citations per 
researcher, and more usage per article authored as measured by global downloads of 
UK articles.170 
112. The challenge for Government is how that world class academic research can be 
translated into commercial activity. Despite the problems outlined throughout this report, 
there are many instances of fruitful collaboration between business and universities. In its 
written evidence the Government provided examples of how universities have been 
involved in the development of new businesses, participated in the improvement of 
existing business, improved public policy and services and attracted foreign investment.171 
113. David Connell, of Cambridge University, described the myth of the role of academic 
research: 
Besides being intuitively attractive, the myth surrounding university spin-outs has 
been perpetuated as a result of premature celebration by government and media of 
high profile, VC-backed spin-outs when they are still at a pre-revenue stage, together 
with a tendency to incorrectly ascribe university research origins to successful 
Cambridge companies such as ARM and CSR. 
There is no doubt that policies could be put in place to improve the 
commercialisation of academic science. However, the reality is that at Cambridge, 
just as at MIT, it is entrepreneurial university alumni rather than research results 
which play the key role in building successful new S&T companies. This distinction 
is important as it has profound implications for policy.172   
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114. The UK Deans of Science questioned how far universities should be expected to 
commercialise their research activity: 
In addition to the financial risks and the challenges of finding commercial partners 
there is a question as to how far a university should extend its traditional role of 
teaching and research to encompass commercial activities that others are better 
placed to do. Thus many reports have suggested that universities and public research 
bodies should regard the IP they create as supporting wider societal and economic 
benefit rather than expecting commercialisation to deliver a significant income 
stream173 
115. The Wellcome Trust was concerned that pressure from Government to increase the 
monetary value of knowledge exchange with business misunderstood the broader nature of 
the relationship with business and the longer term public benefits: 
Universities should be recognised for the broader value they add to the economy, for 
example through tacit knowledge and the provision of skilled graduates, rather than 
just the external revenue they generate.174 
116. Plant Bioscience Ltd argued that universities’ genuine need to pursue world class 
scientific progress was often fundamentally incompatible with business need and that the 
incentives for academics to do excellent science made them less inclined to pursue business 
related work and added: 
We find it often quite challenging to find public sector researchers interested and 
able to conduct some of the applied proof of concept work that is needed even if 
funding can be found.175 
Cambridge Environmental Research Consultants Ltd agreed that universities may not be 
capable of the kind of development that innovative small companies need: 
Academic Research Council grants or short period DTI, TSB etc. research projects 
do not take the place of long standing applied research laboratories, which also play a 
role in the development of small companies. Indeed where they have existed in the 
UK some have been closed down such as the NE wind energy centre. The policies of 
the present UK Government for technology centres announced by the present 
government may provide some stimulus to commercialisation of research, but they 
do not have the same focus or continuity or labs based on a specific industrial 
objective.176 
117. UK universities collectively constitute a world class research base which is, 
consequently, attractive to foreign businesses. Even if they are not focussed on 
commercial considerations, they will inevitably generate ideas and discoveries that are 
of commercial value. 
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118. They are an important facet of the UK innovation ecosystem but a resource to be 
drawn on rather than a primary driver of commercialisation. 
119. The value of universities also lies in the people they produce: not only the academics 
who will engage with the cutting edge research that is so vital to innovation177 but also 
those who will provide the technical backbone to the knowledge economy. Highly skilled 
technicians have a valuable role in academic and private sector companies. Sir Peter 
Williams, Treasurer of the Royal Society and Chair of the National Physical Laboratory, 
told us that “the technician class is a forgotten, underrated and undervalued one in this 
country and has been endemically”.178 
Realising the benefits of universities 
Knowledge exchange 
120. Tim Crocker, of the SME Innovation Alliance, told us that the current models for 
knowledge exchange were predicated on universities pushing information into businesses 
but, he argued, the flow of information should be two way. He thought there could be a 
more effective sharing of knowledge if there was more mobility of people from business 
into universities and back again: 
in the UK we have the KTP finance system—knowledge transfer—which assumes 
transfer of knowledge from the university outwards. If you are on a peer-to-peer 
basis—in lots of cases our companies are more advanced than universities—there is 
no funding mechanism at all by which we can engage with the universities and our 
time and theirs can be paid for. All we can ever do is use TSB money to subcontract 
to them, and that is a very unsatisfactory relationship. [...] Visiting professors [in 
Germany] spend half a day a week teaching, and the integration between universities 
and industry is entirely on a peer-to-peer basis.179 
121. This perspective was endorsed by Tim Bradshaw of the CBI who thought that the two 
way flow of information between universities and business was essential.180 Plymouth 
University wrote that they would like to see “national schemes such as ‘senior internships’ 
or ‘industry-academia secondments’ where the exchange of senior personnel can create 
productive and strategic relationships”.181 The UK Deans of Science suggested “initiatives 
to encourage secondments to university departments”.182 
122. However, the Campaign for Science and Engineering suggested that the Research 
Excellence Framework (REF) might discourage “universities from hiring staff with 
backgrounds from industry due to gaps in (or absence of) publication records”.183 Sir Tim 
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Wilson’s review of collaboration between universities and business also looked at the topic 
of knowledge transfer through secondment of people but followed the model of 
transferring knowledge from universities to business, making no mention of secondments 
in the opposite direction.184 
123. We are sympathetic to the demand that universities become more accommodating 
to non-traditional backgrounds among their academic staff. We regard it as axiomatic 
that the extended presence of people with an industrial background within university 
faculties would facilitate a greater understanding of commercial imperatives and the 
most effective ways to engage university resources within businesses. 
Technology Transfer 
124. David Connell argued that innovation policy should encourage businesses to draw 
upon university resources rather than pushing academics into becoming businessmen.185 
125. An important facet of commercialisation of university based research is achieved 
through technology transfer offices (TTOs) in universities. However the Scottish 
Lifesciences Association wrote that “each university having its own TTO can become a 
significant barrier to larger companies seeking commercialisation agreements with a 
number of institutions”.186 In response the Scottish Government plans to streamline the 
technology transfer functions of all Scottish Higher Education Institutions through a single 
office that will have representatives within each institution.187 HEFCE wrote that English 
universities are also consolidating their commercialisation activities.188 
126. The Society of Biology suggested that there needed to be recognition of academics 
who engage in commercialisation activity: 
The excellence of a University or academic has until now been judged at review on 
the basis of scientific achievement, publications and achievement of grant-funding, 
with less focus on translation and impact. Thus the former have remained academic 
priorities. Greater recognition for achievements such as filing IP and forming 
industry collaborations (at a realistic value) could address this deficit and it may be 
redressed by the [Research Excellence Framework] ‘economic impact score’. 
Knowledge transfer should be recognised as a contribution worthy of academic 
recognition and reward.189 
In 2003, the Lambert Review of the collaboration between business and universities 
indicated that: 
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The main challenge for the UK is not about how to increase the supply of 
commercial ideas from the universities into business. Instead, the question is about 
how to raise the overall level of demand by business for research from all sources.190 
127. We are concerned that driving an innovation agenda too aggressively through 
universities may have diminishing returns with regard to commercialisation and risk 
damaging the academic research that is working well. We recommend that the 
Government’s objective should be to create a commercial demand for university 
engagement to which they are already primed to respond. This echoes and reinforces the 
point made almost 10 years ago in the Lambert Review. 
Engagement with businesses 
128. We received suggestions on how universities could be encouraged or incentivised to 
engage more closely with business requirements. 
129. The Electronics Technology Network stated that their members felt that services 
tendered through universities were too expensive and that universities needed to have 
incentives to engage with their local businesses: 
Future funding for Universities should be based upon their past record of 
commercialisation. Incentives should be given to Universities to adapt research to 
reflect the skills and interests of their local business community, thereby 
strengthening the region’s cluster.191 
130. The University of Plymouth supported the establishment of fellowships for 
universities to engage in research, embedded within industrial partners.192 Bournemouth 
University suggested the creation of “a list of ‘industry/university brokers’ who could assist 
linking industry to universities and assessing the relevance of university research to an 
industry”.193 
Public Sector Research Establishments 
131. Universities are not the only publicly funded research organisations. There are also 
the Public Sector Research Establishments, The Department for Business, Innovation and 
Skills explained: 
Public Sector Research Establishments (PSREs) are a diverse collection of public 
bodies carrying out research. This research supports a wide range of Government 
objectives, including informing Government policy making, statutory and regulatory 
functions and providing a national strategic resource in key areas of scientific 
research. Many of these bodies are involved in commercialising research.194 
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132. The Association of Independent Research and Technology Organisations (AIRTO) 
told us that these laboratories cannot access the funds available to universities to replace 
the loss of Regional Development Agency funds towards commercialisation activity. 
AIRTO suggested that funds from the Research Councils should be extended to PSREs and 
even to commercial organisations to make that funding more effective.195 This stance was 
supported by Midven, a venture capital fund manager. AIRTO also pointed out that the 
structure of funding from the TSB means that PSREs may find they cannot participate in 
TSB related innovation activity without losing money.196 
133. The National Physical Laboratory (NPL) pointed out that while the Government’s 
recently published Innovation and Research Strategy for Growth197 “recognises the 
importance of PSREs like NPL for translational research, it does not include any 
recommendations to enhance their role”.198 NPL explained the benefits that they provide to 
small businesses seeking to innovate technologically: 
Public Sector Research Establishments (PSREs) like NPL maintain significant 
scientific and technological capability to fulfil their core government function, in the 
case of NPL to provide the UK national measurement system infrastructure. NPL 
makes spare capacity on this capability available to business and government 
customers through R&D services at commercial rates. NPL often receives inquiries 
from SMEs with a need to de-risk a technology through the application of our 
specialist facilities and knowledge which they cannot afford to access, putting the 
commercialisation of their research at risk.199 
In paragraphs 47–53, we addressed the lack of access to test facilities and the fragmented 
approach to capital equipment. Engineering the Future stated: 
Among the developed European nations, the UK is unusual in that it has not 
historically supported ‘intermediate institutes’ of any significance and certainly not 
on the scale of the Fraunhofer Institutes (Germany), TNO (Netherlands) or VTT 
(Finland). Instead, the UK placed greater emphasis on university research with 
mixed results for the nation’s innovation performance. The creation of the TSB 
Catapult centres, following the announcement of a £200m innovation programme in 
2010, was a welcome development. The TSB could also coordinate a strategic 
programme to support and strengthen the supply networks.200 
134. The Council for Science and Technology (CST) in its report “A Vision for UK 
Research” recommended that the Government consider the establishment of Large 
Technology Platforms: 
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New technologies often need to be further developed by substantial teams for a 
number of years before they are commercial. These teams need to be larger than the 
research teams which first made the discovery. They often need expensive 
production equipment to make the research industrially useful. This requires a 
dedicated environment with a clear focus for a period of 5 to 10 years. 
[...] 
To make a difference in a global context we suspect that each of these platform 
technologies will need between £50 to £100m over a 5 to 10 year period to become 
the basis of numerous start-ups and licensed projects to large companies. This will 
lead to clusters of expertise in these sectors that feed off each other in a virtuous 
circle enabling the UK to retain global leadership in large markets.201 
The CST recommended that funding should come from various public sources (TSB, 
EPSRC, European Framework Programme, RDAs, Universities etc) but should have a 
substantial industrial component that would require some incentive from Government. 
135. Public Sector Research Establishments were identified in Lord Sainsbury’s “Race to 
the Top” review of government’s science and innovation202 as key players in innovation 
and commercialisation activity. However, the review made no reference to the role PSREs 
might play in hosting technology that could be made available to commercial exploitation. 
136. It is crucial that the Government has a coherent plan on how to engage the 
research base (people, facilities and intellectual property) with the innovation agenda. 
However, the current situation is fragmented and confusing and, as such, extremely 
difficult for small businesses to engage with. 
137. We ask the Government to provide, in their response to this report, its perspective 
on the adequacy of the national infrastructure for innovation, benchmarked against 
nations with which we compete and how it intends to remedy structural short-comings, 
possibly along the lines recently recommended by the Council for Science and 
Technology. We recommend that Public Sector Research Establishments play a key role 
in this infrastructure and we plan, in future, to examine their role within the research 
and innovation ecosystem in more detail. 
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4 Government as a lead customer 
138. Until now we have been looking at money the Government spends as a patron of 
research spending. However, that is very small compared to the amounts that the 
Government spends every year in purchasing goods and services from businesses. The 
Royal Society of Chemistry stated that “In 2010–2011 the UK's public sector spent 
approximately £236 billion on goods and services, which is significantly higher than the 
annual investment in all aspects of research and innovation of £11 billion”.203 This chapter 
looks at the role of Government as a customer of innovative companies and in the direct 
development of such companies. Procurement is important. The  small companies we 
spoke to told us that customers were more important than grants.204 
139. Matthew Bullock, previously head of technology at Barclays and recent holder of the 
Chair of the Centre for Business Research and the UK Innovation Research Centre, told us 
about the need for the Government to leverage its spending: 
My experience is getting people to the base where they have got a business, got the 
experience and know their markets, which is very important. In this country’s 
approach, as Government, you are the biggest customer in Government; you have 
the most technical demands; you have an enormous range of things that you would 
like to see developed. We absolutely do not use it as an engine of growth; it is 
absolutely absurd.205 
140. Sir Peter Williams, Treasurer of the Royal Society and Chair of the National Physical 
Laboratory, stressed the advantages of Government procurement: 
There is no doubt whatsoever that schemes like Merlin have been well intended to 
push capital down to businesses. If intelligent procurement and Government 
contracts pushed real orders resulting in real revenues and real cash flows into 
emerging businesses, that is the one thing that would persuade investors to buy their 
shares and back those companies. So procurement has a double whammy: it helps 
the company directly, and it conditions the market perception of this whole sector.206 
This was further developed by Dr Tim Bradshaw of the CBI: 
If you look at it from the pull side—the Government procurement side—yes, 
absolutely, that is what can really make a difference. Despite what I have just said 
about grants, aid and things, most companies would bite your arm off for a contract 
rather than a grant. The more the Government can do to encourage innovation 
through their procurement lines the better, be it through SBRI or maybe making sure 
that all the public procurement space is also looking at innovation so that we 
transform it. We look at things like outcome-based procurement and whole-life 
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value; we encourage those involved in procurement to look for innovative new ideas 
that might save them money long term, rather than short-term upfront costs.207 
141. Fergus Harradence, Deputy Director, Innovation Policy, Department for Business, 
Innovation and Skills outlined the major challenges to a better system of procurement: 
The first is to simplify and streamline the procurement process and free up more 
time within procurement functions to enable them to go out and engage with the 
marketplace and businesses in a strategic way, combined with better signalling of 
Government demand in particular areas. The work that has been done on future 
capability needs in areas like tunnelling would be an example of that. We published 
quite a lot of information earlier this year about future Government needs. 
Secondly, there is a big challenge in upgrading the skills and knowledge of people in 
the procurement profession. The difficulty in doing that is that procurement is not in 
most public sector organisations a centralised function; [...] The culture, structures 
and the way procurement is managed in the UK are fundamentally different, and 
that makes it hard for us to procure in the same strategic way that you see the US 
doing. I would not say that these problems are insuperable; they could all be tackled 
over time, but, being realistic about it, it will be a process of long-term improvement 
and cultural change. 
Training disparate groups of staff to achieve a common understanding is not a new 
concern, especially not in the arena of innovation and commercialisation of research. 
Praxis originated in 2002 from a government-backed collaboration between Cambridge 
and the MIT to address the shortage of skilled knowledge and technology transfer 
personnel. Praxis merged with Unico (the representative body of professionals that worked 
to commercialise UK university and public sector research) in October 2009 to form 
PraxisUnico “an educational not-for-profit organisation set up to support innovation and 
commercialisation of public sector and charity research for social and economic impact”.208 
142. PraxisUnico provides training programmes and networking events to improve 
technology transfer skills across the whole of the university sector. It is a good example 
of a government sponsored programme that delivered necessary skills across a 
disparate sector. We recommend that the Government should consider it as a model 
for the delivery of a coherent set of skills across the whole of Government procurement. 
143. Sir David Cooksey, Chair of the Francis Crick Institute, pointed to a fundamental 
problem for SMEs seeking to gain Government contracts: 
The situation on procurement is that, if you look at the requirements Government 
place on their Departments for making procurement, the qualifications required in 
terms of the financial size and stability of the companies are such that they positively 
exclude the sort of companies we are talking about from supplying Government, and 
that is completely wrong. What we should be looking at is Government being 
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prepared to pay for the prototypes from these companies to get them off the ground 
and make them work.209 
Small Business Research Initiative 
144. SBRI is the Government’s key policy to support the establishment of innovative 
companies and provide a gateway for small technology firms to gain government contracts 
procuring goods and services. The Government told us that it understood the principle of 
procurement as a tool to drive innovation: 
Innovation procurement initiatives reduce risk, guarantee sales, encourage market 
entry, provide early testing ground and manufacturing experience, create demand 
and make latent demand manifest, and diffuse technology.210 
145. Dr David Connell recommended a huge increase in SBRI funding: 
i. Increasing the UK SBRI programme in steps from around £20m per annum 
currently to £250m per annum. [...] 
ii. Adding an equivalent sized budget for larger scale demonstration projects (above 
the £1m SBIR Phase 2 ceiling) 
iii. Establishing a similar programme to encourage more private sector organisations 
to act as lead customers for new technologies developed by SMEs. [...]After piloting 
this programme, the aim should be to increase funding projects to £100m a year.211 
146. We welcome the Government’s ambition to grow SBRI: 
Since 2009, when we relaunched the programme, we have been able to build it to a 
level of about £20 million a year of expenditure, [...] In an ideal world, I would like to 
see it more than double, and we should be aiming to grow this to a level of about £50 
million a year, which I think is feasible and achievable in a relatively short space of 
time.212 
147. However, improving the funding of SBRI will only be fully exploited if that investment 
is not followed up by intelligent government procurement providing commercial 
opportunities for the companies involved. Mr Harradence, BIS, stated: 
We have been doing some work on better supply chain management and how 
Government can engage more effectively to support the development of new 
products and services over the longer term through our Forward Commitment 
Procurement programme. We have used that to procure zero-waste mattresses for 
the Prison Service, which are more environmentally friendly and cost less, and to 
develop a new type of ward environment, this time for the National Health Service. 
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We have got to the point where it has been demonstrated. It is in the Building 
Research Establishment in Watford.213 
148. While we were pleased to hear of successes, Iain Gray, CEO of the TSB highlighted 
how companies that the TSB has nurtured through to commercialisation often fail to 
achieve sales to the Government. For example, 
Eykona won an SBRI contract. It has taken it to the next stage. The managing 
director of Eykona would say, “We would not exist as a company were it not for 
SBRI”, but he has now reached the critical point John describes, which is: how does 
he move that on now into a procurement-type contract in the NHS? Ironically, the 
market he is now chasing to procure the technology that has been developed under 
an SBRI contract is overseas. He is chasing overseas contracts because, when it comes 
to the critical point of the next stage in the procurement contract, there is a risk-
averse approach in the UK. 
We have got great science and technology; we have got the SBRI in place, which is 
helping small businesses get their technology to the point where they can take it to 
market; and we need that pull at the next stage to act from a procurement point of 
view to move the technology into the NHS.214 
149. Midven, a for-profit venture capital manager, thought that the SBRI was still managed 
like a government grant scheme which might be one reason it did not function as a 
intended as “a route to early, sustainable sales for SMEs”.215 The Academy of Medical 
Sciences argued that the scheme needed to be properly embedded itself across all 
government departments “particularly the larger spending departments such as the 
Ministry of Defence”.216 The University of Birmingham pointed out that in the USA 
government departments were required to spend a defined percentage of their budget 
supporting small businesses.217 In contrast, the Science Policy Research Unit unconvinced 
of the evidence in support of the SBRI scheme, highlighting the lack of clarity on the costs 
of the scheme218 and Engineering the Future suggested that time should be taken to 
properly evaluate it.219 
150. We were concerned that the SBRI scheme fails to assist companies to gain 
Government commercial contracts. We recommend that the Government ensure that its 
procurement officers, and those of other public sector agencies, are properly trained to 
take into consideration the wider public benefits of procuring services from small 
technology companies that have been developed through the SBRI. 
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National Health Service  
151. We were interested to discover what advantage the existence of National Health 
Service would deliver in enabling innovation in health technologies. Andy Richards gave us 
an investor’s perspective: 
This is not just a statement about drug discovery; it is a much broader comment. [...] 
Customer traction is one of the most attractive things for any investor. There has 
been a situation where any business plan, business model or business idea that comes 
up that says, “By the way, the first thing we are going to do is sell into the NHS,” just 
makes it uninvestable, because the NHS does not take up, let alone new drugs, new 
technologies, new software systems, new anything. It is notoriously hard to sell 
anything new into the NHS. That is partly a cultural thing. Partly, there are some 
elements within the NHS that, for one reason or another, have a “they shall not pass” 
mentality. It does make it incredibly hard to innovate in the medical field—medtech, 
health care, IT—in an environment where your local market, who are the easiest 
people you have to reach to talk to as customers, are hard to access.220 
152. Novartis stated: 
The key point here is that pharmaceutical R&D investment in the UK is, to some 
extent, dependent on the willingness of the NHS to support and adopt the 
innovations that are developed as a result of R&D activity. Without adequate uptake, 
medicines commercialisation will decline.221 
153. The Association for Medical Charities was concerned that the NHS did not provide 
any market certainty for innovative drugs: 
To attract investment into commercialisation of research there needs to be an end 
market. Our members have expressed frustration with the products of their research 
both failing to receive NICE approval or receiving NICE approval and subsequently 
not being adopted throughout the NHS. Strict commissioning guidelines are needed 
to ensure approved innovations are rapidly taken up across the NHS.222 
154. ISIS Innovation, the technology transfer office for the University of Oxford, 
confirmed this view: 
In Healthcare there is an urgent need for the NHS to present itself as a willing 
customer of innovative products from UK technology companies. The NHS needs to 
become a first port of call. At present UK healthcare technology companies actively 
avoid engaging with the NHS because it is such a poor customer (slow decision 
making, late adoption), turning instead to overseas markets.223 
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155. Dr Bianco, Director of Technology Transfer at the Wellcome Trust, explained that a 
fundamental problem in driving innovation in the NHS would appear to be that people 
that took risks in innovating rarely experienced any financial benefit. 
One of the disincentives, which is a real problem, is that if you produce, for example, 
an invention that reduces bed stay because the surgical procedure is less invasive, it is 
the cost centre for the beds that gets the advantage and the risk is taken by surgery. 
[...] Adoption has become a problem because the reward system is not necessarily 
linked.224 
156. Research hospitals should be the innovation pioneers within the NHS, a source of data 
and expertise but Dr Goodier of the Shelford Group indicated that they were poor partners 
for the biopharma industry and technology: 
We are very concerned at the Shelford Group because so many of the prices set for 
treating patients are set on averages. If you suffer from asthma, you can have three 
nebulisers and go home, or you can have a week in intensive care and two weeks on a 
ward. The price is set at an average, and that suits more the smaller district general 
hospitals, whereas the academic hospitals tend to get the more complex patients and, 
therefore, are chronically underfunded.225 
157. Despite these difficulties, witnesses believed that the NHS represented considerable 
potential as an encourager for future innovation, especially in the area of stratified (or 
personalised) medicine. Dr Tapolczay, Chief Executive of Medical Research Council 
Technology, stated: 
[] While I agree with everything that has been said, I also see it as an opportunity. If 
the problem is there but it could be fixed, we are still the only country in the world 
with an NHS. If we can find a way to allow engagement between the biomedical 
community in the private sector and the NHS more effectively, then it has to be a 
very positive step forward for both the NHS and the biomedical companies in the 
UK.226  
Dr Richards, entrepreneur and business angel investor, stated 
[] It is deeply frustrating that we are the best situated country to do personalised 
medicine because of the NHS. If we can gather the information from well collated 
records and use that—we have everything in place—and if we could do it, it would be 
the big game change.227 
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158. We recently inquired into the UKCMRI, later renamed the Francis Crick Institute.228 
This facility has the potential to be the flagship of innovation in the UK healthcare system 
and to doctors trained in deploying innovation and new technology throughout the NHS. 
159. We recommend the Government examine the critical role of research hospitals in 
addressing the most challenging of conditions and explore ways of ensuring that funding 
encourages the development of innovative solutions. 
160. We consider it critical for the future of the bioscience sector in the UK that the 
Government ensures that a significant proportion of the NHS procurement budget is 
accessible by small innovative companies. The Government should incentivise NHS 
Trusts to engage with SME companies for innovative technology solutions. A similar 
approach should also be adopted across other agencies including local government, police 
etc. 
Support for sectors of industry 
161. The UK has traditionally had a strong presence in the life sciences, confirmed by the 
attention the Government pays to this sector. The Strategy for UK Life Sciences announced 
it would provide £180 million targeted at the ‘valley of death’ to ‘de-risk’ investment in life 
science innovation, half of which will be funnelled through the TSB to support SMEs.229 
162. There are a number of policy instruments focussed on the life sciences sector:  
Strategy for UK Life Sciences230 contained recommendations to improve the uptake 
on innovations within the NHS, Innovation, Health and Wealth: Accelerating 
adoption and diffusion in the NHS231 and outlined further steps to support the 
commercialisation of health research in the UK. 
Biomedical catalyst scheme232 to support the development of promising early-stage 
drugs into new treatments by universities and small or medium enterprises (SMEs). 
Early Access Scheme consultation233 to identify where new treatments could 
potentially be given conditional authorisation, have their assessment accelerated or 
be licensed early to speed commercialisation. 
The strategy announced the establishment of a new Life Sciences Advisory Board 
comprising of representatives from industry, academia, government departments 
and agencies and the appointment of an MP to advise David Willetts on life sciences. 
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Steps have been announced to develop a safe and secure system which opens up 
patient data for research234 and ensures patients are offered opportunities to be 
involved in research relevant to them are valuable.  
Plan for Growth,235 though not life science focussed, heralded work to streamline the 
regulation of health research and establish a Health Research Authority. 
163. The Association for Medical Charities, like other organisations related to the life 
sciences,236 welcomed government initiatives in the life sciences but considered that some 
additional detail was still needed.237 The framework of policies provide a big picture within 
which the life sciences industry can see where they might fit in the future and inform their 
investment.238 The Government has developed policies to enable the sector to carry out its 
activities and, in partnership with charity and industry, has invested in infrastructure in the 
Francis Crick Institute239 and Stevenage Open Innovation campus.240 
164. However, Professors Anthony G M Barrett and R Charles Coombes of Imperial 
College, London, outlined concerns about a challenge in the bio-pharmaceutical sector 
where the big companies were leaving the field of drug discovery and universities were not 
able to fill the resulting research gap: 
Globally drug discovery is rapidly changing. The big pharma companies such as 
Pfizer, GlaxoSmithKline, AstraZeneca and others are leaving drug discovery rapidly 
and their exit will be complete in the next 5 to 10 years, perhaps sooner. The recent 
closure of Pfizer Sandwich and downsizing of AstraZeneca are not unusual events 
but are part of the inevitable global process. The trillion-dollar question is whatever 
next and where will the medicines of the future come from? Will pharmaceutical 
innovation be totally lost to the UK and the UK pharmaceutical industry, worth 
many billions to the UK economy, become another smokestack memorial.241 
165. Dr Ian Tomlinson further explained that early drug discovery was not an area in 
which large biotechnology firms were able to effectively operate: 
Big pharma needs to take some responsibility. The costs are going up and the 
regulatory hurdles are going up, but we did have a culture of trying to industrialise 
drug discovery and development—and it did not work. [...] Innovation comes from 
one person having an idea, or a small group having an idea, and prosecuting that 
idea to some kind of milestone. That is why we have changed dramatically over the 
last five years. We used to have thousands of people working in R & D. We would 
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throw a load of people at the problem and we would hope to solve it in that way. 
Now, we have 50-people groups, with a leader fully empowered to prosecute a very 
specific area of science.242 
166. Both the Crick institute and the Stevenage Open Innovation campus demonstrate 
that the Government is working actively with the industry to ensure that bioscience 
retains a strong presence in UK research and development. Government support for 
life sciences has been excellent and there is real innovation taking place in how that 
sector might be supported. 
167. Despite these successes, we heard that there was some disappointment that the 
particular requirements of the agriculture related sectors were not included in the 
strategy.243 The Agricultural Biotechnology Council told us:  
Research from the Rothamsted Institute found that the UK is losing its expertise in 
applied sciences, with those employed in applied R&D work increasingly getting 
older and fewer in number. There have been three significant closures of public 
research institutes associated with agriculture in the past decade. The closures of 
Long Ashton Research Station in 2003, Silsoe Research Institute in 2006 and the 
Hannah Research Institute in 2007, have all contributed to a decline in our public 
agricultural research base.244 
168. PraxisUnico considered that the “commitment shown to the bioscience sector needs 
to diversified into engineering and the physical sciences if the UK is to reshape its 
industrial base”.245 
169. Another sector of government procurement that would appear open to active 
encouragement for innovation is that of Defence, the UK Innovation Research Centre and 
the Centre for Business Research stated that the USA effectively utilises its military budget 
to drive innovation.246 The Rt hon David Willetts MP told us how the Ministry of Defence 
was using procurement to drive innovation. Fergus Harradence of the Department for 
Business, Innovation and Skills pointed out that the Ministry of Defence was a keen 
contributor to the SBRI scheme. However the Ministry would appear to be outsourcing its 
procurement which may limit its potential to utilise the budget in this fashion. In a 
statement in July 2012 the Defence Minister, Philip Hammond MP, said: 
Earlier this year, I therefore asked my officials to focus their efforts on considering 
the comparative benefits which could be derived from changing DE&S into either an 
executive non-departmental public body with a strategic partner from the private 
sector (ENDPB/SP), or a Government-owned, contractor-operated (GOCO) entity. 
The work done to date, suggests that the strategic case for the GOCO option is 
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stronger than the ENDPB option. Further value-for-money work is under way to 
confirm this assessment.247 
170. Evidence sent by the UK Innovation Research Centre and the Centre for Business 
Research pointed out that other governments were active supporters of innovation in their 
own industries: 
Many governments outside the UK support technology through specific R&D 
programs aimed at pre-commercial support in technology and market development 
around a group of applications. These provide R&D support and subsidies for 
specific technological areas; access to specialized equipment; forums for the 
establishment of standards; direct financial support for establishing new industries; 
public procurement by military and health departments especially of R&D services; 
acting as deep-pocketed first customers and procuring first quantities of 
technologies.248 
171. Professor Nick Wright, of the Russell Group of universities, was particularly scathing 
about the way various UK governments had approached the commercialisation of 
research: 
We seem to be the only major economy that thinks we can make this work on fairy 
dust and good intentions. [...] It does not have to be heavily prescribed; it can be an 
informal system, but [most large economies have] a national innovation system of 
some kind, and we desperately need that in the UK.249 
172. We have not been persuaded that the Department for Business, Innovation and 
Skills has a strong enough voice across Government policy to effect the necessary 
radical change in procurement practices. Procurement by Government departments 
needs to focus on issues other than simply cost. We recommend a Minister in HM 
Treasury be given responsibility for the delivery of procurement-driven benefits identified 
by the Department for Business, Innovation and Skills. 
173. Dr Tim Bradshaw, Confederation of British Industry, explained the demonstration 
effect of British companies gaining Government contracts: 
The more the Government can do to encourage innovation through their 
procurement lines the better, be it through SBRI or maybe making sure that all the 
public procurement space is also looking at innovation so that we transform it. 
[...]When you have some really good things in the public estate, showcase them. If 
you have got them in, show them off to the rest of the world and show what can be 
done. Make sure you are demonstrating to overseas buyers that we have done this in 
the UK250 
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The Minister indicated that the Government was aware of the need to ensure better 
information of public spending needs among businesses251 but was not convinced that 
more action needed to be taken to ensure broader benefits to UK industry through public 
procurement: 
We have to be very careful of protectionism.  
As I say, that is why our approach has been information in advance and sharing our 
future plans. [...] In the long run British businesses need the competitive challenge of 
winning in a competitive environment.252  
174. We recommend that the Government, in two years, publish a breakdown of 
companies successful in tendering for Government contracts and compare whether 
greater openness in procurement has resulted in increased contracts among small and 
developing British technology companies. 
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252 Q 293 
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5 Conclusions 
175. During our inquiry we have become aware of the multitude of issues and problems 
that are faced by businesses in a variety of innovation sectors. Each of these companies 
find issues in funding that innovation but their concerns and needs vary from sector to 
sector and are often predicated on the size of the business. We conclude there is no 
single valley of death that all businesses, or even all small businesses, must cross. 
176. What is consistent across business is the need for a clear vision from the 
Government to provide confidence into the future. Without a definite commitment 
from Government, business is more reticent about making its own financial 
commitment to the levels of risk that innovation requires. 
177. The evidence that we have seen shows that there is no coherent innovation policy. 
The Government has begun to consolidate its innovation policy by bringing more 
schemes and responsibilities within the Technology Strategy Board. We judge that this 
consolidation needs to go further and that the TSB should be given more funds 
including monies designed to better finance existing programmes such as SMART and 
SBRI but not at the expense of the Research Councils. 
178. We have seen a desperate need for government procurement to do heavier lifting 
than in providing encouragement to the growth of small technology companies. There 
is possibly a greater and more sustainable benefits to be gained by growing and 
developing small companies into successful medium sized ones than in attracting large 
companies. 
179. There needs to be a coherent strategy across the whole of UK industry to provide UK 
business with confidence in where they might expect Government support for the medium 
and long term—whether through procurement, R&D focus or fiscal policies. 
180. Finally we would urge the Government to seriously consider the financial markets 
and the inadvertent negative impacts that changes to policy there might have on 
innovation policy, for example how the regulation of pension funds has effectively 
starved technology firms of growth capital. Where it is not possible to foresee such 
impacts Government should be alert to the need to detect and to rectify them in a 
speedy fashion. 
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Conclusions and recommendations 
Investment in technology companies 
1. We are concerned that our small companies are too often bought up by larger 
overseas companies before they can develop into the medium sized enterprises that 
would produce substantial jobs and wealth in the UK. We are convinced that while 
equity investments have a place, too many companies are forced into over-reliance 
on this route because other types of funding are unavailable. We recommend that the 
proposed bank for business, possibly in partnership with the Business Growth Fund, be 
used to promote a bond market for medium sized businesses, thus providing growing 
small businesses with an additional source of funding. (Paragraph 39) 
2. We have concerns that regulation to de-risk pension and insurance funds has had 
the effect of starving technology companies of a source of long term patient capital. 
There is a need to deploy these funds more usefully. We recommend that the 
Government investigate the potential to require funds to have a proportion of 
European SME equities. (Paragraph 40) 
3. Lloyds Banking Group run a scheme where senior staff attend a Warwick based 
engineering course designed to help them make better decisions on financial risk by 
giving them a better understanding of some emerging technologies. We recommend 
that the bank for business adopts such an approach for its staff from the outset. 
(Paragraph 41) 
4. The bank for business announced by the Government may provide a useful go-
between for institutional investors and technology businesses. We urge the 
Government proactively to seek to develop not only the market in technology equities 
but to ensure that the market has ready access to information that may change the 
perception of these equities and their relative risk and create mechanisms, such as the 
Lloyds scheme, to help fund managers understand evolving technologies. However, 
reporting requirements and other costly regulatory burdens on UK-based listed 
companies, especially in the AIM market, should be kept to a ‘fit for purpose’ 
minimum. (Paragraph 42) 
5. We recommend that the Government re-examine their portfolio of interventions to 
determine where gaps may lie and to ensure there is a consistent spread of funding 
across the spectrum of business need. It is important that government funding fits the 
needs of growing companies rather than company growth having to adapt to gain 
government funding. It is also important to ensure that the incentives from 
Government tend towards greater growth and retention of jobs and wealth creation in 
the UK. (Paragraph 45) 
6. We consider that the R&D Scoreboard was a useful and widely respected source of 
information for technology businesses and we recommend that the Government should 
reinstate it. We also recommend that the Bank of England should resume their 
monitoring activity on the availability of finance to SMEs. (Paragraph 87) 
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The need for physical infrastructure 
7. We share the concerns of our witnesses that the UK small business sector lacks access to 
large scale test and experimental production facilities. We recommend the Government 
to find a way to ensure that those facilities that do exist can be more readily accessed by 
business, that gaps in requirements are identified and a fund established to subsidise 
those facilities that cannot afford to remain at the leading edge in a purely commercial 
environment. (Paragraph 51) 
8. We urge the Government, when looking at the issue of production facilities, to ensure 
that the Technology Strategy Board and other commercialisation activities address 
whether projects are properly supported in issues of manufacturing capability. 
(Paragraph 52) 
Small companies 
9. The Government indicated that it would not follow the James Dyson report 
recommendations that the tax credit should be refocused on high technology sectors 
or on small and start-up companies. The R&D tax credit has been successful in 
increasing spend by business on research and development but this has, mostly, been 
within larger companies. We recommend that the Government identify the reasons 
why R&D spend still appears to be drifting away from the UK despite the benefits 
enjoyed by larger companies. We also believe that there needs to be a mechanism to 
support SME's who do disproportionately badly from the current scheme. 
(Paragraph 59) 
10. We conclude that the Government needs to distinguish in its innovation policy 
between small and medium enterprises: a single SME category is too broad. 
(Paragraph 61) 
Taxation and regulation 
11. We recommend that the Government address the issue of VAT and how it might 
ensure that VAT rules allow academic teaching and research to sit alongside 
commercial and incubation activities within public or charitably funded laboratories 
and research centres without creating a financial burden for the institute. 
(Paragraph 63) 
12. Poor regulation adds to the risk burden of entrepreneurs. We welcome the proactive 
response of the Minister on the issue raised in evidence to us and recommend the TSB 
to undertake a review of regulatory burdens on technological innovation in the UK. 
This review should be consistent with the advice to Government by Professor Ragnar 
Lofstedt on Health & Safety matters but should not include just a list of regulatory 
burdens in need of reform but a roadmap of how that reform might be used to drive 
innovation and which institutions should take the lead. (Paragraph 70) 
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Intellectual property and technology transfer 
13. We judge that the IPO mediation service could be more heavily used to arbitrate in 
matters of intellectual property. We recommend that the Government require the use 
of mediation before any legal action can be taken in a UK court, both speeding up the 
resolution of disputes and reducing the costs of protecting intellectual property. We also 
recommend that refusal to engage in mediation be taken into account in awarding 
costs. (Paragraph 76) 
14. We recommend that the Government assess the benefits of the Easy Access IP 
experiment and whether it improves the flow of IP not just between universities but 
into wealth creation activities within the UK. (Paragraph 81) 
15. We understand the intent behind changes to HEIF that further reward institutions 
that have already benefitted from successfully commercialising their IP. We have 
concerns that IP transfer from universities that have been less successful in 
commercialising their IP may decrease further. We recommend that the Government 
review the situation after three years and publish a report on how the changes have 
contributed to increased IP transfer, job creation and related social benefits. 
(Paragraph 82) 
16. We recommend the Technology Strategy Board examine the current provision of proof 
of concept funding to universities and small companies and report to Government a 
coherent view of the amounts of funding available along with a recommendation on 
whether there exists a shortfall of provision of these funds and whether a consolidation 
of provision into a single programme would be helpful. (Paragraph 96) 
The UK innovation ecosystem  
17. There is an evident need for an innovation agency in the UK and it makes greater 
sense to ensure the TSB and its schemes evolve to meet this need than create a new 
organisation. It also makes sense to concentrate the innovation function within a 
single agency to ensure there is coherence and consistency within the system. We 
support the current Government’s approach to its innovation policy. 
(Paragraph 100) 
18. We consider it vital that the Catapults are made to work. We ask the Government to 
confirm to us that they will not seek to push the Catapults to generate revenue but 
instead allow them to grow slowly and organically with a focus on developing the 
necessary capabilities to support innovation. (Paragraph 103) 
19. We have concerns about the ability of the TSB to provide real local information unless 
they have the funding and resources to develop regional points of contact that can talk 
knowledgeably to local businesses. We recommend that the Government consider how 
they can resource the TSB to provide local level advice to technology businesses. 
(Paragraph 109) 
20. UK universities collectively constitute a world class research base which is, 
consequently, attractive to foreign businesses. Even if they are not focussed on 
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commercial considerations, they will inevitably generate ideas and discoveries that 
are of commercial value. (Paragraph 117) 
21. They are an important facet of the UK innovation ecosystem but a resource to be 
drawn on rather than a primary driver of commercialisation. (Paragraph 118) 
The role of universities 
22. We are sympathetic to the demand that universities become more accommodating 
to non-traditional backgrounds among their academic staff. We regard it as 
axiomatic that the extended presence of people with an industrial background within 
university faculties would facilitate a greater understanding of commercial 
imperatives and the most effective ways to engage university resources within 
businesses. (Paragraph 123) 
23. We are concerned that driving an innovation agenda too aggressively through 
universities may have diminishing returns with regard to commercialisation and risk 
damaging the academic research that is working well. We recommend that the 
Government’s objective should be to create a commercial demand for university 
engagement to which they are already primed to respond. This echoes and reinforces 
the point made almost 10 years ago in the Lambert Review. (Paragraph 127) 
24. It is crucial that the Government has a coherent plan on how to engage the research 
base (people, facilities and intellectual property) with the innovation agenda. 
However, the current situation is fragmented and confusing and, as such, extremely 
difficult for small businesses to engage with. (Paragraph 136) 
25. We ask the Government to provide, in their response to this report, its perspective 
on the adequacy of the national infrastructure for innovation, benchmarked against 
nations with which we compete and how it intends to remedy structural short-
comings, possibly along the lines recently recommended by the Council for Science 
and Technology. We recommend that Public Sector Research Establishments play a 
key role in this infrastructure and we plan, in future, to examine their role within the 
research and innovation ecosystem in more detail. (Paragraph 137) 
Government procurement 
26. PraxisUnico provides training programmes and networking events to improve 
technology transfer skills across the whole of the university sector. It is a good 
example of a government sponsored programme that delivered necessary skills 
across a disparate sector. We recommend that the Government should consider it as 
a model for the delivery of a coherent set of skills across the whole of Government 
procurement. (Paragraph 142) 
27. We were concerned that the SBRI scheme fails to assist companies to gain Government 
commercial contracts. We recommend that the Government ensure that its 
procurement officers, and those of other public sector agencies, are properly trained to 
take into consideration the wider public benefits of procuring services from small 
technology companies that have been developed through the SBRI. (Paragraph 150) 
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28. We recommend the Government examine the critical role of research hospitals in 
addressing the most challenging of conditions and explore ways of ensuring that 
funding encourages the development of innovative solutions. (Paragraph 159) 
29. We consider it critical for the future of the bioscience sector in the UK that the 
Government ensures that a significant proportion of the NHS procurement budget is 
accessible by small innovative companies. The Government should incentivise NHS 
Trusts to engage with SME companies for innovative technology solutions. A similar 
approach should also be adopted across other agencies including local government, 
police etc. (Paragraph 160) 
30. Both the Crick institute and the Stevenage Open Innovation campus demonstrate 
that the Government is working actively with the industry to ensure that bioscience 
retains a strong presence in UK research and development. Government support for 
life sciences has been excellent and there is real innovation taking place in how that 
sector might be supported. (Paragraph 166) 
31. We have not been persuaded that the Department for Business, Innovation and Skills 
has a strong enough voice across Government policy to effect the necessary radical 
change in procurement practices. Procurement by Government departments needs 
to focus on issues other than simply cost. We recommend a Minister in HM Treasury 
be given responsibility for the delivery of procurement-driven benefits identified by the 
Department for Business, Innovation and Skills. (Paragraph 172) 
32. We recommend that the Government, in two years, publish a breakdown of companies 
successful in tendering for Government contracts and compare whether greater 
openness in procurement has resulted in increased contracts among small and 
developing British technology companies. (Paragraph 174) 
33. During our inquiry we have become aware of the multitude of issues and problems 
that are faced by businesses in a variety of innovation sectors. Each of these 
companies find issues in funding that innovation but their concerns and needs vary 
from sector to sector and are often predicated on the size of the business. We 
conclude there is no single valley of death that all businesses, or even all small 
businesses, must cross. (Paragraph 175) 
Final conclusions 
34. What is consistent across business is the need for a clear vision from the 
Government to provide confidence into the future. Without a definite commitment 
from Government, business is more reticent about making its own financial 
commitment to the levels of risk that innovation requires. (Paragraph 176) 
35. The evidence that we have seen shows that there is no coherent innovation policy. 
The Government has begun to consolidate its innovation policy by bringing more 
schemes and responsibilities within the Technology Strategy Board. We judge that 
this consolidation needs to go further and that the TSB should be given more funds 
including monies designed to better finance existing programmes such as SMART 
and SBRI but not at the expense of the Research Councils. (Paragraph 177) 
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36. We have seen a desperate need for government procurement to do heavier lifting 
than in providing encouragement to the growth of small technology companies. 
There is possibly a greater and more sustainable benefits to be gained by growing and 
developing small companies into successful medium sized ones than in attracting 
large companies. (Paragraph 178) 
37. There needs to be a coherent strategy across the whole of UK industry to provide UK 
business with confidence in where they might expect Government support for the 
medium and long term—whether through procurement, R&D focus or fiscal policies. 
(Paragraph 179) 
38. Finally we would urge the Government to seriously consider the financial markets 
and the inadvertent negative impacts that changes to policy there might have on 
innovation policy, for example how the regulation of pension funds has effectively 
starved technology firms of growth capital. Where it is not possible to foresee such 
impacts Government should be alert to the need to detect and to rectify them in a 
speedy fashion. (Paragraph 180) 
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Q1 Chair: Gentlemen, thank you for coming in this
morning. It would be helpful for the record if you
would be kind enough to introduce yourselves.
Dr Robertson: I am Douglas Robertson, Chair of
PraxisUnico, and Director of Research and Enterprise
Services, Newcastle University.
Dr Nightingale: I am Paul Nightingale, Deputy
Director of the Science and Technology Policy
Research Unit, University of Sussex.
David Connell: I am David Connell. I am a Senior
Research Fellow at the UK Innovation Research
Centre at Cambridge University, but my background
is in the technology community, including as co-
founder and chief executive for many years of an
early-stage venture fund in Cambridge.
Professor Georghiou: I am Luke Georghiou, Vice-
President for Research and Innovation at the
University of Manchester, and also a professor in
innovation studies.
Q2 Chair: We have a lot of ground to cover this
morning. If one of you is asked a question and others
want to supplement it, please feel free, but if there is
a repeat answer just say so, if you are agreeing with
each other. First of all, can I start off with some
definitional issues? Does innovation begin with the
intellectual property or the entrepreneur? What is the
beginning of the process?
Dr Nightingale: Most innovation takes place in firms
rather than with individuals. Most innovation takes
place in large firms rather than in small firms, and
most innovation does not involve intellectual property.
There are other ways in which you can protect
innovation: secrecy, complexity, degrees of scale and
being first to market. When we are talking about
innovation and IP we are talking about a subset of
innovation, but it is particularly important in high-tech
areas where lots of economic growth is driven from.
In terms of entrepreneurship, the areas of innovation
where entrepreneurship in small firms is important are
Sarah Newton
Graham Stringer
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Roger Williams
biomedical, innovation, software and so on, but in
general the focus for innovation policy should be on
firms—and large firms—rather than start-ups.
Dr Robertson: When you look at the IP landscape,
it is important to recognise that tacit knowledge is
incredibly important, not just formal intellectual
property; it is ideas that matter. Very often when a
piece of technology is patented and starts to be
worked up commercially, it is not that protected
technology that gets to market. It is a second or third-
generation technology that gets to market, alongside
the tacit knowledge that comes through people.
David Connell: The answer is that it can be both,
together or separately. There are important differences
that have led to some confusion in innovation policy.
If you look at, for example, Cambridge’s most
successful science and technology companies, there is
a general assumption among many people, including
policy makers that the innovation in those companies
is based on university IP. The reality is that the
overwhelming majority of the most successful, in
terms of job generation and sustained profitability, are
based on solving customer problems in a business
environment.
The second part of the answer is that policy is often
influenced by looking at the experience of some very
high-profile, internet companies—for example,
Facebook and Google—where it is the entrepreneurial
drive that is the key rather than the university IP.
Therefore, it is easier to demonstrate a working
product with real users, the time to market can be
much quicker and the risk is much lower. I take it that
the focus of this Committee is on deep-research-based
IP and innovation.
Q3 Chair: I want to turn, specifically, to universities.
In terms of universities hanging on to IP, is there a
rule of thumb about how long that should be or is it
on a case-by-case basis?
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Professor Georghiou: There is no rule of thumb. We
do not find IP ready in our labs. What we find are
researchers with good ideas. It often takes assistance
and some work on proof of concept, both
technologically and with commercial advice, to
generate IP. We see our job as holding on to it long
enough so that it is stable in a way that we can
successfully hand it on, either in a licensing or spin-
off mode. So we are custodians of it. It is not our
intention to keep it forever.
Dr Robertson: It is important to recognise that one of
the challenges with intellectual property protection is
that it is a right to stop people doing things. Therefore,
if it leaves the university and goes into the hands of
somebody who does not wish to use it, it becomes a
mechanism for stopping innovation rather than
advancing it. The answer, as Luke indicates, is holding
on to the intellectual property for sufficient time that
it can then move on to someone who will make good
use of it. The rule of thumb is don’t hold on to it if
someone else can make good use of it and start paying
the fairly heavy protection costs that are involved, but
don’t let go of it until you know that you have a
reliable partner.
Dr Nightingale: I would agree with this point. There
are two issues. There is how long universities should
hold on to it for the good of universities and how long
universities should hold on to it for the good of UK
plc. These two issues can be in conflict. For the good
of universities, they will want to hold on to it for,
perhaps, longer than they should and try to
commercialise it, but it may be better for UK plc to
distribute it much more freely. The most successful
model of this would be the University of California.
Their IP model is to disperse discoveries and IP as
broadly as possible for the benefit for the State of
California, because it is publicly funded, not for the
benefit of the University of California, and that seems
to be a very successful model.
Dr Robertson: I have one further thing to add. The
Universities of Glasgow and Bristol and King’s
College are running a pilot scheme on something
called “Easy Access IP”, where, basically, they look
at their intellectual property portfolio and divide it
into two components—one that they feel they can do
something with and one that they feel they cannot do
anything further with and it is better to be in the hands
of others. They make that available on non-exclusive
licence terms without necessarily the requirement for
payment. That scheme is starting to generate some
interesting results. It has only been running for just
over 12 months.
Q4 Chair: Stemming from that, should universities
extend their traditional role of teaching and research
to encompass commercial activities?
Professor Georghiou: I think we should. We should
not let it dominate our activities. Clearly, research and
teaching are at the core of what we do. We also have
a third mission—a mission of social and economic
responsibility. It also provides a focus for teaching our
students entrepreneurship. If we are not doing it
ourselves and we do not have the mechanisms, it is
difficult to engage them. A very important area
highlighted in the Wilson inquiry now is the idea that
you start engaging students with entrepreneurship at
the earliest possible stage in their careers.
Dr Robertson: One of the challenges for the UK is
this tension between the university direction of travel
and the benefits for UK plc. One of the real challenges
universities face is the absorptive capacity of UK
industry. We only have two of the top 50 companies
in the world in terms of investment in R & D as a
percentage of a country’s GDP. They are AstraZeneca
and GSK. Therefore, it is finding a UK partner that
the university can work with in order to trap the
benefits for UK plc. To some extent that is why some
universities pursue the venturing route because that
attempts to trap the value in the UK as the company
is formed in the UK, and, hopefully, the investment
and employment flow into the UK.
David Connell: Clearly, universities are already
embracing that objective significantly. My colleague
made a very important point—if we want to create
jobs in the UK we have to look to spin-outs and
exploitation by medium-sized companies of university
IP as the key mechanism, not necessarily partnering
with big companies, which will almost certainly be
based overseas.
The problem that we have faced in the UK is that
some policy makers have tended to assume that
universities can take the development and exploitation
of some research further along the process than is
actually possible within a university environment.
Universities are about teaching and publishing papers.
Academics do not work full time on development.
Staff are predominantly PhDs and post-docs, who tend
to move on quickly, making it difficult to build spin-
out teams. It is difficult to manage IP produced over
the course of a project or succession of projects.
University academics rarely have the technical means
to produce demonstrators, which is what is required
to engage with the commercial community. That
means that there is an intermediate stage in the
innovation process, which I call the exploratory
development phase, which cannot usually be
undertaken in a university, but has to be done in a
more or less commercial environment before an
innovation is sufficiently advanced to be funded by
venture-backed capital.
There are two policy solutions to this problem, in my
view. One is creating new and specialised institutions,
such as the Fraunhofer Institutes in Germany, to
undertake that role. The other solution is to put
substantial Government money into very early stage
companies, at the point before they are ready for
venture capital investment, which is, essentially, the
US approach through procurement-based policies,
such as SBIR. We have, collectively, assumed that
universities can go too far in the direction of
commercialisation and we need to recognise that there
is an intermediate stage that needs to be filled.
Dr Nightingale: If the taxpayer is going to pay money
to universities, then universities have an obligation to
contribute towards economic development activities,
and that is widely accepted. The key issue would be
the diversity of the university system. The UK has
universities like UCL, Imperial, Cambridge and
Oxford, which are world class at moving technology
into the economy, and it has other institutions that do
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not have that capability. Overall, that capability is,
probably, pretty low. If you asked the venture capital
community what they thought of technology transfer
offices, you would get a fairly negative response. One
comment that I heard was that there are three things
wrong with universities: they are ignorant, greedy and
risk averse. Not all universities are like the University
of California, and we have to accept that diversity,
but there is nothing wrong with universities not being
world-class technology transfer institutions. It is
perfectly fine for them to be teaching institutions.
Professor Georghiou: Can I disagree with my two
colleagues? Our leading universities I would hope we
are within that group, but also Imperial College,
Cambridge, Oxford and Newcastle are, in my view, as
good as US universities in fostering technology. We
normally work through subsidiary companies in
partnership with venture capitalists, who exercise a
commercial discipline on every decision that is taken.
We have a number of companies that have been
capitalised in the hundreds of millions, exporting the
highest of technology around the world. The challenge
is more to spread that expertise rather than to try and
replace it with what sound to me like bureaucratic
structures—not commercial ones. We always have a
challenge in situating a different kind of activity in
the university model. The way to do it is to put it at
arm’s length and make sure that commercial people
are driving it.
Q5 Chair: Would you like the last word before we
move on?
Dr Robertson: I have to react to the comment that
Paul made with regard to the venture capitalists’ view
of universities and technology transfer offices. The
amount of true venture capital funding under
management by BVCA members is 4% of the BVCA
funds under management. It comes to £313 million a
year from the early stage, through seed to the next
round of funding. That is a very small amount of
money to invest to try and support venturing out of a
science base that is the second best and, in some cases,
the best in the world.
Q6 Stephen Mosley: We have heard evidence that
the traditional “linear” model of innovation—
basically, in which a university generates research that
moves forward, is then transferred and
commercialised—has been discredited, to quote.
Would you agree with that analysis?
Dr Nightingale: Yes. The point made by David that
the majority of innovations and high-growth firms in
the Cambridge area are spinning out of firms, not
universities, is supported by a large amount of
research. High-tech innovation is only 3% of the
economy. Universities do play a role, but their main
role is generating well-trained people.
Professor Georghiou: I agree with that. I don’t think
it is discredited; rather, it is a special case that happens
only in a limited amount of circumstances. The worry
is that it often is given more weight in policy making
than it should be, and we lack the kind of things that
David Connell was talking about—the importance of
interacting with users, with the demand side, and
therefore using instruments like public procurement.
Q7 Stephen Mosley: You have come on to my next
question, which is, do you think that Government and
organisations like the TSB put too much emphasis on
the linear progression, and are those organisations
flexible enough to cope with how it really works?
Dr Robertson: The challenge is that, if you try to
institutionalise something, the linear model suits a
process that is easy to manage and to challenge. The
challenge for technology development is that it is full
of failure. You don’t just succeed. If you fail, you then
figure out why you failed and you go back into an
iterative process, sometimes having to go back quite
a long way to go through the next stage in
development. That is a very difficult model for public
sector investment because it is about investing enough
to succeed but being aware that you will invest and
fail. That is a tough job for people like the TSB, who
are looked at as the major innovation agency in the
UK. It is a real challenge for them, but that is why
the venturing model is one that I, personally, favour,
because venturing is about investment and not grant
funding. It takes you into a quasi-commercial
environment in order to pursue a technology that you
have to have enough money to fail once or twice. You
have some other people giving evidence later this
morning who will give you ample evidence on the
demise of the linear model.
David Connell: Can I comment on your question also
and an earlier remark about venture capital? An
interesting question is, if it is not the linear model,
what is it? Clearly, there are a whole variety of
different ways through which technology is turned
into commercial products. It can take a lot of time
over many different actors and organisations, based
all over the world sometimes. Again, there are useful
lessons from looking at Cambridge, which is probably
our best example of a science and technology cluster.
There is a particular model that is really prevalent
there, and that is is sometimes called the soft start-up
model, whereby companies quite often start not by
developing standard products for a wide market,
probably with venture capital as backing, but by
undertaking development contracts for individual
customers, perhaps based around a piece of IP or
based around their technolgical expertise and skills.
Over time they might build a contract R&D
business—that is a service business—or they might
move out of that model into developing a product
business on the back of that as a result of stumbling
across a generic opportunity or building a piece of IP.
The soft start-up model is the dominant model in
Cambridge amongst the most successful companies.
In fact, the key source of jobs in product companies
in Cambridge is four technology consultancies—
really contract R & D houses—which have their
origins 50 years ago in three young engineering
graduates who left the University of Cambridge to
offer consulting services to industry. Through spin-
offs this has lead over the last 50 years to a sub-cluster
of companies that make a living by developing
products and technology for individual customers.
Over the last 30 years, they have together also created
more jobs in sponsored spin-out companies making
and selling standard products than the entire
university.
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You can see this model replicated in other areas. For
example, there is a very successful CAD software
company called Aveva—a product company,
employing 500 people—whose origins were in what
was effectively a predecessor of the TSB’s new
Catalyst institutes, actually set up by a Labour
Government in the ’70s, and called the CAD Centre.
The point I want to make is that it is really helpful
to look at the process of creating employment out of
research and innovation as being a two-stage process.
The first stage is to create expertise-based
organisations that do R & D for money, through
commercial contracts for individual companies. The
second stage is then to move into products, which is
when you begin to get the more substantial
employment gain. With different nuances, you can see
this model being applied across a whole variety of
different sectors. This is not just in Cambridge, by the
way, but also elsewhere. Microsoft was a soft start-
up. Vodafone is a spin-out from Racal, which was a
classic soft start up. Wilson Microelectronics in
Edinburgh, which is probably Scotland’s most
successful new technology business, was a soft start-
up. It moved into developing and selling products as
a second stage, after just providing semiconductor
contract design and development contracts for many
years.
Dr Robertson: The important aspect of innovation and
developing research is to think of it as at least two
different categories. There is revolutionary change and
there is evolutionary change. For the most part,
existing companies are very good at evolutionary
change. That is about the next increment on their
product range. It is in a comfort zone in a market
that they are fully aware of. The challenge for modern
economies is how you tackle revolutionary change.
You would not manage to sell a new model of light
bulb taken by a candle manufacturer because it would
undermine their entire market. Therefore, it is how
you tackle revolutionary ideas. The stuff that comes
out of universities, out of basic science and basic
engineering, and the stuff that we want to trap in the
UK, are the revolutionary ideas—the ones that will
create completely new industries as well as assisting
the continuous process of evolutionary development
through existing businesses.
Professor Georghiou: If I could just come back on
the soft start-up, hearing about Vodafone, I spent most
of the 1980s evaluating the country’s probably last
very large public technology programme—the Alvey
Programme for Advanced Information Technology.
That company had its origin in this public technology
programme, and many others do as well. We do not
have the same level of input going in now, although
the TSB is the natural successor, but we should not
neglect the fact that private success is often founded
in a public activity.
Q8 Stephen Mosley: Finally, what role, with the
model you have just outlined, have the Government
and organisations like the TSB got to play in that?
David Connell: The key to making this model work,
and it is something that venture capitalists look for as
well in the companies that they back, is lead
customers. What does a lead customer do? What a
lead customer does is, essentially, to react to the
technology and opportunities being presented by a
technology company and commit to paying for
feasibility studies and demonstrator developments, or
maybe buying anearly prototype for that technology
to be applied to the customer’s particular needs,
sometimes even with a view, if it is successful, for
that product to be sold to its competitors.
Again, in Cambridge and elsewhere—all over the
world, actually—you see the private sector playing
this role. Pharmaceutical companies like GSK have
played a terrific role in funding the development of
drug discovery research tools, for example. However,
you do not see the lead customer role applied in all
sectors. The issue is, what can Government do?
Government, as a very substantial part of the
purchasing economy through procurement, can play a
similar role to the private sector by specifying
problems that officials in its departments and agencies
believe need to be solved and technologies they
believe they need developed either as users or as
specifiers, or for policy reasons, and then funding, as
a customer, the development of those technologies
within small companies.
In the US there is a very effective programme which
does this called the Small Business Innovation
Research Program, which is worth about $2.5 billion
a year. There is about as much money again, or more,
coming through other programmes, which fund this
kind of development. It is about as unbureaucratic as
you can get in a public sector programme, because it
is competitive and because it tries to link company
developments to customer needs. . I would argue that
what the UK should do, and this applies also to the
European Commission, is to switch a substantial part
of its innovation budgets—and in the case of the UK
I am talking about TSB money and also R & D tax
credits—into private and public sector programmes of
this kind.
Dr Robertson: What Government can do, and it is a
tough call in a recession, is to invest. There is hardly
a country in the developing world that is not investing
substantially. The US, which is lauded as a private
sector-led economy, invests far more in co-investment
with business through the SBIR scheme than any
other country in the world. The public sector
intervention is a real challenge in the early stages of
technology development, but for the UK I do not think
there is much alternative. In a scheme that was run a
few years ago, which was called “University
Challenge”, the Government put £65 million in two
rounds into a consortia of universities to establish
their own venture funding. Some of those funds are
now evergreen, like the Lachesis Fund in the
Midlands. The University Challenge funds had £65
million of public sector investment and generated
£430 million of private sector investment. That 1:7
leverage is exactly the kind of initiative we now need
alongside our procurement strategy, which, as has just
been indicated, needs to be innovation oriented, and
alongside an SBIR scheme that creates an
environment where winners can emerge, rather than
endeavouring to pick winners.
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Q9 Hywel Williams: Taking on the point that Dr
Robertson was making about failure leading to
success, the phrase “picking winners” is used quite a
lot. Do the Government strike the right balance as
between being too selective or not selective enough?
How do you avoid wasting money on prolonging the
lifetime of weak ventures of weak companies?
Dr Nightingale: How do you stop prolonging the
support for weak firms? Don’t support weak firms.
There is very little evidence that supporting weak
firms has any economic benefit. There is a debate
going on in economics that it might be harmful for
the economy to have too much rubbish messing things
up. That was rather brutally put.
The key issue from economics literature on this point
is that it is not the case that there are good firms that
continue to grow over time. Even firms that have
grown very well for 10 years may have a bad period.
The growth of firms is very close to a random walk.
It is very close to tossing a coin. The ability of anyone
to pick winners is almost non-existent. I have a large
research team and fantastic data; I can explain about
2% of the variants. This is the reason why it is very
difficult to make money from technology investing. I
would not advise the Government to try and pick
winners. I would advise Government policy makers,
if someone says that they can pick winners, to accept
that they can’t and that they should put their own
money in before the taxpayer puts money in. The
issue, as has been mentioned before, is to create an
environment where you can have growth, job creation
and innovation. It is not necessarily by picking firms,
but by creating that environment where some firms
may grow one year and a whole group of different
firms may grow the next year, and it does not matter
to the economy that they are different.
Dr Robertson: The challenge for the TSB is fairly
large, but there is a danger of coming up with too
many schemes targeting too little money in too-
narrow areas. I understand the rationale that says, “We
need some activity in this area,” so it then leads to a
move. It is a real challenge for them to get the balance
right, but they need to have a sufficient portion of
their funds that are responding to bright people with
bright ideas that nobody has thought of apart from
those bright people, and focus not on that project and
evaluating that project, but on evaluating the team, the
partnership and the people. That is the way
universities work fairly effectively with businesses.
When it works, it works swimmingly well. Actually,
it is a real challenge for a university that finds a
company it wishes to work with to then find a scheme
that will bring in public sector intervention to support
that partnership if it does not fit something that
somebody else has already thought of. I would see a
more responsive portion of the TSB funding being in
SBIR and being in collaborative grants for research
and development without pre-determining the area of
activity.
Professor Georghiou: We should not confuse picking
winners in companies—I fully agree with everything
that has been said—with picking markets or, in some
cases, technologies. We have to have some benefits of
concentration and focus. A country this size simply
cannot afford to cover everything. If we spread out
the money evenly, we would be behind everybody.
David Connell: I agree with that. Who, 20 or 30 years
ago, would have picked vacuum cleaners as an area
in which the UK would have built one of its most
successful new companies? One of the ways though
that we can focus innovation support is through an
SBIR programme. We have had a broadly similar
“SBRI” programme in the UK, as you will probably
be aware, for the past three years. It is quite small,
about £20 million per annum. It would need to be
worth about £250 million per annum if it was going
to be equivalent to the US programme, bearing in
mind the relative sizes of the economies. The way that
it works is by using potential public sector customers
and users to define the problems that need to be solved
and then running the programme competitively at
different stages. So companies, if they are successful,
initially win a £100,000 Phase 1 contract to do
undertake a feasibility study, and then companies
reapply and roughly half go on to win a Phase 2
contract, typically worth £500k to £1m based on
progress during Phase 1. There is therefore a natural
process of progressively focusing funding on the best
projects, unlike the kind of grant programmes that we
have tended to operate in the past, frankly.
Q10 Gareth Johnson: You highlighted the problem
of picking out winners and trying to identify those
companies that are likely to be successful. Would you
say that that applies to situations where we have
previously had match funding and, therefore, also had
problems in doing that? Mention was made about
vacuum cleaners. Dyson is probably the best example
of disruptive technology. It is pushing out an existing
technology. If we went down the route of having more
match funding, do you think it would have a
disruptive effect on those companies that are trying to
muscle in on technology that already exists?
Dr Nightingale: We have done an evaluation of the
match funding scheme run by BIS. Our conclusion is
that they are effective, cheap and generate jobs. The
problem of being able to go better than 2% in
predicting growth is so difficult that you need to have
professional investors, but professional investors—
because it is difficult to make money out of
innovation—find it difficult to raise money in the
markets. Match funding is an effective piece of
Government policy. The UK has been running high-
risk schemes for a long period of time. BIS have
learned well and they have schemes that work. This
is a piece of public policy that I would support. There
seems to be a lot of support among my colleagues
here for the SBIR initiative in the United States.
I did some work for your colleagues on the House of
Lords Select Committee, and I reviewed the literature
on this. Two types of evaluations are done. One is
evaluations where you ask people whether they think
it is a good idea that they got money for free, and they
generally come out with the answer, “Yes.” There are
other evaluations where they look at controls and do
proper econometric analysis. As far as I am aware,
there have only been two proper evaluations of that
scheme, and both of them found that it did not
produce major improvements in job creation. One of
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them found that it produced no improvements in job
creation. However, it does play a very important role
in providing accreditation for the value of technology,
so it provides due diligence for free. It plays an
important role that way, but it is not going to solve
the Government’s problems.
Dr Robertson: I certainly favour match funding
schemes. I don’t favour the Government pre-
determining the areas in which that match funding
should take place. Government officials should be
judging proposals that are put forward by partnerships
between universities and companies and companies
with other companies, rather than trying to pre-
determine the outcome and deciding if that is a good
investment of public money, because that decision has
to be made. Too often it takes too long for a company
to come through some of these systems and they just
don’t think that it is worth the effort. What that means
is that they do not work with that university to take
on that high-risk idea. They will stick to the knitting,
and they will do what they do very well, but without
taking their company, maybe, into a new technology
sector or a new challenging field.
The KTP scheme, in terms of evolutionary technology
developments, is a very good co-funding scheme. It
has been running for over 30 years. One of the reasons
why it works is because it has advisers who work with
the company to help them figure out how to get
through the process. It means it is more costly because
you have to provide advisers, but, when you have the
investment in business R & D that we have in the UK,
we have to create more businesses investing in R &
D. I see co-funding and not tax credits as the way to
get people to do something that they had not
previously thought of doing as their company tries to
come out of recession. A recession, to some extent,
forces companies to think of new developments, so it
is a good time to further develop co-funding schemes.
Q11 Graham Stringer: This is fascinating. To take
a real recent example, £30 million to £40 million is
the next stage of development of graphene at the
University of Manchester. I would be interested in
Professor Georghiou’s view about whether that is a
good decision in the light of what you have just said.
David Connell: I will go first while you are thinking.
It is very hard to say whether or not this was a knee-
jerk reaction to the scientific breakthrough.
Q12 Graham Stringer: You take my point. What
you are saying indicates that it is a bad decision.
David Connell: No, I am not indicating that it is a
bad decision. What is really important is that we have
research excellence in the UK. Really high-quality
research universities are critical to any economic
activity and to any cluster, as much as anything
because of the people that they train. I do not know
enough about how that particular research centre is
being structured, but the question is—if it is,
essentially, for the time being, a university-style
managed research environment—whether that will
enable the technology to be taken far enough to be
turned into products. I suspect it is a 15 or 20-year
journey, in which case it is probably the right decision.
But we will probably need some further decisions to
ensure that we get to the end point that we need, in
terms of economic impact.
Professor Georghiou: Graphene is the kind of
opportunity that, probably, only comes along once
every 20 years. It is different and it has to be treated
differently. We have a strong world scientific lead. We
absolutely dominate the science in this field, although
almost every other major country is investing far more
than we are. Our £50 million does not look large on
the international scale at all.
The National Graphene Institute is partly there to
secure the leading science, but it was formed also to
support commercialisation in two ways. It has a built-
in incubator for start-up companies, which we already
have, and it is also there to attract business into and
from the UK to work with a number of companies in
developing the technology. Some aspects of it, as
David said, will take 20 years to realise. Others,
already with people like Samsung, will be appearing
in next year’s or the year after’s products. It is a little
bit different from lasers, let’s say, where there was a
very long time to market. We are doing everything we
can to support that economic benefit being realised.
I talked earlier about student entrepreneurship. We
have 50 PhDs in the graphene area, all of whom are
having entrepreneurship training, not just from
academics but with leading venture capitalists and
others coming in. They have been hugely enthused by
this. Several of them are already thinking about
forming their own companies or going to work in an
entrepreneurial environment using their own science.
So we have a huge opportunity here.
Dr Robertson: Graphene is an interesting example. It
is certainly an exciting technology. Anything less than
£50 million probably would not have scratched the
surface. One of the challenges sometimes is not the
amount of money, but the flexibility that comes with
that money and whether it can be used for capital or
capital and recurrent. We are quite good at the starting
investment in those areas, and quite often it is highly
capitally focused. The question then is that you have
to create an environment that would allow graphene to
be truly captured in the UK, which will take recurrent
funding on a regular basis with a rounded approach,
as Luke indicates, looking at enterprise, developing
the staff and the students in the graphene area to be
true hybrids between science and enabling
commercialisation on the back of that science.
Q13 Stephen Metcalfe: I would like to pick up on
some of the issues around funding and particularly the
way it is allocated. We have a number of submissions
about how the Government allocate funding across the
entire science and technology spectrum. Bearing in
mind that the Government have a limited amount of
resources at the moment—it is a tough economic
climate—have they got the balance right between
basic research, the Higher Education Innovation Fund
and the TSB? Is where they are putting the money
correct and are they supporting commercialising
innovation?
Dr Robertson: That is a good question.
David Connell: I will attempt to answer the question.
I will also comment on an earlier question that is
related to this matter, which is about match funding.
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Let me pick up match funding first. Match funding
can take place in two ways: first, by the Government
giving a company a grant on condition the company
puts money alongside that. That is fine for large
companies. For small companies that is really
difficult. Most small companies do not have venture
capital. Only a tiny minority have venture capital,
cash assets or the profitability to sustain those
investments. The way small companies succeed, in the
main, is through fully paid contracts from customers.
The Government would do well to emulate that.
The other kind of match funding is through the way
in which Government has sought to encourage private
sector institutional investment in venture capital funds
by acting as lead investor—on the same terms as
private sector investors—in specialised “fund of fund”
vehicles which will invest in this kind of asset.. The
problem with that is that the average return on venture
capital, especially at the early stage, in the UK is
round about zero. This is true across Europe. And it
is a long-term issue. This is not a temporary problem.
For a long, long period you would not have wanted
any portion of your personal pension funds invested
in a basket of early-stage UK funds. The lack of
venture capital in the UK is not market failure. This
is rational behaviour on behalf of our pension funds.
So, if we want a viable venture capital industry,
government either needs to provide significant, non-
equity, financial support to start ups and small
technology firms directly or it needs to have some
kind of two-tier structure for its investment in VC
funds in which Government takes on more of the
financial risk, thereby making it more attractive—for
the private sector to play its role.
Coming back to your broader question about
funding—if we put aside the funding that goes into
universities for the time being—if you look at the
funding that goes into companies, there are, broadly,
three or four elements to that. There is the TSB
collaborative R & D programme, of which, I guess,
probably about £150 million, maybe, goes into
companies. Historically, the majority of that has gone
into big companies, although the situation is changing
a bit now. There are some small schemes that probably
bring in a bit more. Then you have R & D tax credits
that cost the Government a billion pounds a year, three
quarters of that going into large companies.
If you just look at that portfolio, the companies that
benefit most are large businesses. Large businesses
have very strong lobbies, as of course does the
university system. The part of the economy that does
not have a strong lobby is small businesses,
particularly small technology businesses. Basically,
their directors are too busy to lobby, frankly. That is
where money needs to be shifted. It needs to be
shifted, first of all, more towards small businesses,
and, secondly, it needs to be focused on the higher risk
investments in R & D that those companies undertake.
Important beneficiaries of the R & D tax credit
scheme appear to be the banks, for example.
According to the 2009 BIS R & D scoreboard, HSBC
and RBS came above BAe Systems and Rolls-Royce
in terms of expenditure on R & D, despite the fact
that five years previously they had not admitted to
spending more than a million pounds each. Who
knows what the background to that is? What it
suggests to me is that the R & D tax credit programme
has grown to the extent where it is supporting a lot of
routine R & D, which, basically, companies ought to
be able to fund themselves. We should be trying to
find a way of focusing that substantial part of the
spend on the higher risk, longer- term, more difficult
area of R & D, which is where companies really
need help.
Dr Nightingale: There are really two issues. In terms
of research, the big issue for the UK, compared with
the United States, is that we spend about half as much
as a percentage of GDP on research as they do. That
has a big impact on our economy and a big impact on
high-level skills. The big issue in terms of research is
that we are an also ran. We are not playing in the
premier league of international investment in
university research.
When it comes to commercialisation, the issue is not
so much how much money do you put in, because
such a small number of innovations actually generate
high returns—it is very skewed—but it is whether or
not you are putting money into programmes and
institutions that will generate that innovation. We have
put a large amount of money into the Regional
Venture Capital Funds, and that was, effectively, a
waste of time. However, in the United States they
have a VC scheme where they make very small
investments in a tiny number of companies. VC in the
US invests in about 600 to 800 early-stage companies
a year. For an economy the size of the US, they have
generated over a third of their stock market
capitalisation. So it is a tiny proportion of firms that
make all the difference, and you need professional
investors to do that. People like me who work in
universities are unable to make those decisions. Match
funding to build up a professional investor system is
very important, but it is not so much the amount of
money; it is whether it is going to the right institutions
that counts.
Q14 Chair: Can I just hold fire at the moment, both
colleagues and witnesses? I am conscious of the fact
that one of our next witnesses is on a very difficult
time schedule. Can we speed up the responses? If
there are additional pieces of information, I would be
grateful if the witnesses would formally write to us.
Dr Robertson: We are heading in the right direction.
If we wish to retain the quality of British science, it
will be difficult if we move funding away from the
basic science budget and stay in that position given
the comments that have already been made. I would
make a plea from my sector’s perspective. The
University Challenge Seed Fund Scheme was a very
powerful scheme generating partnerships with venture
capital and, potentially, now partnerships with
corporate venture capital, which is becoming
incredibly important. It is part of the “valley of death”.
If we want to capitalise on our higher education base,
we need to make those kind of investment decisions
alongside the things that Paul has just mentioned.
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Q15 Stephen Metcalfe: Very briefly, because I am
conscious of what the Chairman has just said, does
the TSB have enough money allocated to it to make a
difference to UK plc?
Dr Nightingale: I return to my earlier point. It is not
the amount of money, but whether it is going in the
right place.
Professor Georghiou: First of all, it should not be a
trade-off with RCUK and HEIF because those are
both underfunded as well. We should think of the
overall investment in the growth of the economy.
Bearing that in mind, it is probably still sub-critical in
the amount of money it has by international standards.
If we look at successful public technology investors,
like Germany or Finland, they, relatively, have
considerably more.
Q16 Stephen Metcalfe: You are not suggesting
moving money from the research budget.
Professor Georghiou: No; absolutely not.
Dr Nightingale: Certainly not.
David Connell: My view is that substantially more
funding is needed of the kind that the TSB deploys. I
would like to see more of it deployed through
spending Departments as customers—not from the
research budget, but from maximising the innovation
budget for business.
As our time is coming to an end, can I make an
invitation? I would like to invite the Committee
members to come to Cambridge—we have a compact
cluster of companies—and visit some of the
businesses of different shapes and sizes that illustrate
some of the points that we have all been talking about.
Perhaps you could come up for half a day or a day. I
would be delighted to help you with that.
Chair: I will take you up on that, thank you.
Q17 Pamela Nash: I will put all my questions into
one, considering we are very short on time. In your
opinion, compared with our main competitor
countries, what are the barriers in the UK to the
commercialisation of science? I would, in particular,
like to know what your opinion is, David, of the
Government’s recent policies in trying to bridge those
barriers, and particularly will the new Catapults help
to bridge the gap at the moment between universities
and companies? Also, is the Technology Strategy
Board taking the right approach at the moment?
David Connell: Catapults are part of the right
solution. We do need those kinds of organisations for
long lead time technologies. We are virtually the only
advanced country that has not been investing
significantly in that kind of organisation. There is still
a question mark over whether they are being designed
in the way that many of us would like to see. Seeing
them spread over different geographical organisations
is not the right solution, in my view. They need to be
focused, well funded and managed in a very
commercial way. More generally, a lot of what both
this Government and the previous Government have
been doing has been moving very much in the right
direction. The same is true of the EU, by the way. The
new EU Horizon 2020 proposals include very
significant changes in terms of supporting small
technology businesses.
But there is still more to be done. The devil is in the
detail, very often, in getting the policies right.
Q18 Pamela Nash: Who do you think the
Government should be speaking to in that case, in
order to improve the Catapults?
David Connell: That is very easy. The best role model
for the Catapult centres, actually, is the four
Cambridge so-called technology consultancies.
Catapult centres are, basically, broadly based on the
Fraunhofer Institutes in Germany, which employ
16,000 people in 60 different institutes. They are
about partial Government funding of commercially
orientated R & D organisations, which will then spin
off companies and exploit technology commercially.
The best people at doing that are the Cambridge
consultancies, but they do it without Government
support. The Government would do well to draw on
the expertise of those consultancies.
Dr Robertson: As to major barriers, one is the early-
stage venture environment. It is a real challenge in the
UK. The second major barrier is the absorptive
capacity of UK industry, primarily because business
investment in R & D is among the lowest in the
OECD countries. That is why schemes like co-
investment and co-funding have to be used to catalyse
the business community. In terms of who we need to
be speaking to we need to be getting more of our
bright technology entrepreneurs, chief execs and
chairs into the room, rather than relying on people
who are working with large companies that do not
have a significant UK footprint. It is a real challenge
for the UK, but we have some very bright technology
entrepreneurs and those are the people who should be
being consulted and talked to.
Dr Nightingale: In terms of commercialisation, the
UK is very good compared with the rest of Europe,
with the possible exception of Scandinavia. There is
an issue about relative amounts of GDP that we spend
on university research. One of the problems we face
is unrealistic expectations about things like spin-outs,
SMEs and whether or not they are going to produce
that much, because there is not much evidence that
they do. The key issue is that we need proper
evaluation of these schemes. We really don’t know
what works. It is very complicated right now and this
has been a problem. I would make the suggestion that,
if we wanted to reallocate some money, we shut down
the Patent Box scheme. Take that billion and put it
into whatever schemes that you suggest. That is
probably one of the worst pieces of public policy that
I have ever seen in my career.
Q19 Caroline Dinenage: I am going to take a leaf
out of Pamela’s book and formulate my questions into
one big one. The Wilson review highlighted the lack
of data on the innovation ecosystem. In your view, is
there a sufficient evidence base to inform the
Government’s decisions in this area? It also said that
there was no single overriding voice across the whole
innovation landscape. I would like to hear your
thoughts on that. Finally, was the University of
Oxford right to say that the innovation ecosystem
suffers from initiative-itis?
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Professor Georghiou: First of all, on initiative-itis, it
is a problem that has been with us for, probably, 15
years. It is not something new. We tend to have a lot
of clever schemes that are too small, are recycled, re-
announced and, therefore, confuse the client
communities—particularly the small business client
communities. So larger, more flexible and more long-
running schemes would certainly be better. On
evidence, yes, we need better evaluation. We have
probably gone a little backwards on that, having been,
maybe, the leading country in the area a few years
ago.
I should call attention to the fact that my colleagues
in Manchester are working with Nesta to provide a
compendium of evidence on innovation policy
initiatives, trying to pull together what has been
learned about these around the world. This will be a
useful resource that is coming through now.
If I could, very briefly, wind back to the previous
question that relates to main barriers, one more thing
should come into the evidence, which is that we keep
looking inside the research and innovation system, but
our biggest barrier is probably an insufficient
entrepreneurial culture outside it, whereby we can get
our bright students wanting to work in small and high-
technology companies.
David Connell: I have a very brief comment. It is not
so much on evaluation but on reporting the basics. If
we look across Government organisations involved in
technology, rather than providing annual reports in the
format that you would see from a public company,
they tend to produce brochures with examples of what
they are doing at the time. It would be really good to
know where the money went, actually, and to see
some proper reporting to the kind of standards that we
should demand.
Dr Robertson: I would echo that. Case studies and
lessons learned are very valuable ways to evaluate
these schemes. You have to be careful. Many people
around the world have been studying innovation, and
if everybody cracked it we would not be where we
are. There is plenty of evidence. It is the boldness of
decision making that is the next key step.
Dr Nightingale: On initiative-itis, they should be
flexible and larger. They should be integrated. On
evaluation, there are far too many poor-quality
evaluation reports where they ask people whether it is
a good idea that they receive free money. They are a
waste of time. If you look at a country like Finland,
they build proper evaluation into every single public
policy scheme. We should be doing that, but we do
not.
Q20 Sarah Newton: Thinking about some of the new
technologies that the Government have prioritised,
such as offshore renewables, to what extent do you
think we should be looking at the geographical
locations of research institutes to support these new
emerging industries and technologies?
Professor Georghiou: Geography is really important.
David was talking about the Cambridge cluster. We
have a number of other clusters. We also have a huge
potential in our cities. Cities are probably the most
important regional unit that we have. The kind of
interactions that take place there bring technology into
contact with the cultural sector, with investors and
others. There are huge opportunities which we can use
the LEPs to capitalise on. We also have a problem in
this country that the vast bulk of public technology
investment is concentrated in the south-east. We have
enormous potential in other parts of the country. In the
north of England where I come from, the N8 Group of
research-intensive universities has been working
together successfully to engage with large companies
collectively. We have had some very good results.
Chair: You know how to please the Chairman, don’t
you?
Sarah Newton: Certainly the Combined Universities
in Cornwall, I would say, are working very well.
Gareth Johnson: Live in the south-east!
Dr Nightingale: I would agree with that point. There
is too much concentration in the south-east. There is
some fantastic research going on in universities
outside the south-east. Should geography matter?
Geography should not matter. We should be relying
purely on quality. That will have an effect in that
people who are innovative, highly educated and
entrepreneurial want to live in certain places and not
in others, and they will move to those places. They
may move to the south-east. There is a public policy
issue as to what we should do about that, but in terms
of innovation we should rely entirely on quality.
Dr Robertson: Geography does matter. You have to
invest in excellence but money talks. If you invest
money, then excellence will quite often aggregate
around the resource, so I am sure there will be more
people in graphene heading to Manchester and co-
locating and working with Manchester as a
consequence of that investment than would have been
the case in the absence of the cash. We do have a
relatively small country, but we seem to be able to
create it as if it is the size of the United States of
America. We are incredibly privileged. You can get
from Newcastle to London in two and a half hours by
train. It is not the end of the world. It is a really good
place for people to invest, and I would commend it to
any organisation.
Q21 Sarah Newton: We have had a very good
advertisement for universities around the country.
Finally, do you think there is going to be any impact
at all on the commercialisation of research as a result
of the loss of the Regional Development Agencies?
Dr Nightingale: No.
Q22 Chair: Are there other views on that?
Professor Georghiou: The one in our region was
doing a number of good things. It was well engaged
with the science and innovation community, so it is
more a matter of preserving those functions than the
particular channel by which those are delivered.
Dr Robertson: I would agree with that again. In the
north-east we had a good Regional Development
Agency. It did some very good work. The best thing
it did was that it talked to people about what it was
doing and engaged them in the process.
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Chair: Gentlemen, thank you very much indeed. I am
sorry that we had to push you a little because of time.
There may be some further thoughts when you have
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Witnesses: Dr Ted Bianco, Director of Technology Transfer, Wellcome Trust, Dr Ian Tomlinson, Senior Vice-
President, Head of Worldwide Business Development and Biopharmaceuticals R&D, GlaxoSmithKline, Dr
David Tapolczay, Chief Executive Officer, Medical Research Council Technology, Dr Gareth Goodier, Chair,
Shelford Group, and Chief Executive, Cambridge University Hospitals NHS Foundation Trust, and Dr Andy
Richards, serial biotechnology entrepreneur and business angel, gave evidence.
Q23 Chair: I am conscious that this is going to be
harder than it was with the previous panel as we have
an extra person. I would be grateful if the five of you
introduced yourselves for the record.
Dr Tomlinson: I am Ian Tomlinson. I am Head of
Biopharmaceutical R&D and Worldwide Business
Development for GlaxoSmithKline. In a previous
existence I founded a biotech company called
Domantis that GSK bought. For 11 years before that
I was an academic at the MRC.
Dr Tapolczay: My name is David Tapolczay. I am the
Chief Executive of Medical Research Council
Technology, which is, in essence, a tech transfer office
managing the intellectual property of the Medical
Research Council in the UK. I have worked for Glaxo,
GlaxoWellcome, GlaxoSmithKline, Zeneca and ICI
Pharma, and also I started up seven biotech
companies.
Dr Goodier: I am Gareth Goodier. I am Chief
Executive of Cambridge University Hospitals and the
Chair of the Shelford Group, which represents 10
academic medical centres in this country. As a CO, I
have been responsible for four academic centres
myself in north-west London, which at the time had
23% of the health R & D budget.
Dr Richards: My name is Andy Richards. I am an
entrepreneur and business angel investor, specialising
in the life sciences area. While I am a director of nine
companies and chairman of four, and involved with
important organisations like BBSRC, Babraham
Bioscience Technology and Cancer Research
Technology, I am here very much in my own personal
capacity as an entrepreneur, founder and investor in
more than 20 companies over the last 20 years.
Dr Bianco: I am Ted Bianco. I am the Director of
Technology Transfer at the Wellcome Trust and a
member of the Executive Board. We initiated a new
funding division in 2003 called Technology Transfer
that does translational funding to bridge the gap. This
has now spent in the order of £350 million, having
ramped this figure up from £8 million in the first year
of operation. We have seen a leverage of something
like £685 million of third-party funding on the back
of these projects. This is my key job.
Q24 Chair: Thank you very much. First of all,
bioscience is often quoted in the press as an area
where Britain has got it right and the Government life
sciences strategy has been praised. What has made
biosciences so much more successful than some other
sectors? Is it the right skill base, the right companies
read the transcript. I would be grateful if you provided
any additional comments. Thank you very much for
what was an extremely informative session.
or being more in tune with the Government’s financial
support? What are the key things?
Dr Tapolczay: From my observations, if you look at
the most successful bioscience clusters around the
world, they share a certain commonality in their
heritage. To a large degree that is founded by the
presence of major pharmaceutical R & D
establishments in their locations. Germany is
successful in biotech. The UK is successful in biotech,
as are the east and west coasts of the US. All those
are homes to major biopharmaceutical companies—
R & D establishments. A lot of the young spin-out
start-up companies actually take their work force out
of those big companies. They are trained in our
universities and they get an excellent education in our
universities, but they do not get a knowledge of the
industry or how to do drug discovery and
development in life sciences until they join the likes
of GSK. It is people who spend time on those big
industries and then leave and join a biotech
organisation that lead to the success of that cluster.
Dr Richards: There is no doubt that the quality of the
research base here is one of those things that has done
that. I agree with a lot of what David has said.
Historically, it is interesting that one of the reasons
we have a biotech cluster that set up rather early on
was because various companies shut down. You can
end up with tracing a lot of it back to the G D Searle
plant shutting down and that spawning British Biotech
and a lot of the people into Celltech, and Amersham
downsizing, resulting in a lot of people coming into
the Cambridge cluster. That is one of the interesting
phenomena. It is the movement and fluidity of people
across those sectors, across from large companies to
small companies and back again, which is very
important to the growth of clusters. You can see that
that has happened in the more dynamic and longer-
lived clusters in America.
Dr Bianco: Within a few square kilometres in the
region around MIT, on the Cambridge side of the river
in the Boston area, most of the pharmaceutical
companies have R & D headquarters alongside
institutions like the Broad Institute, the Koch Institute,
MIT, and Massachusetts General Hospital. This is a
powerhouse of innovation where there is a very strong
culture of entrepreneurship. There is a huge
distinction between the level of entrepreneurship in
the University of Harvard in comparison with many
other players in that culture. The Wellcome Board
visited recently to try and get some learning as to what
created the magic at MIT. A great deal of it is cultural.
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Dr Goodier: I support what has been said, but I would
add that communities grow up where there is a sense
of innovation. It takes, sometimes, decades to create
that community. Cambridge, as in Cambridgeshire, is
a very small community, yet in terms of Nobel prizes
it is one of the most successful in the world as
compared with, say, the Boston Cambridge. It is not a
size issue, necessarily, but more the bringing together
and, indeed, intimacy of different scientists working
on similar problems from different angles.
Dr Tomlinson: I would agree. It is a diversity of
critical mass in one place. Clusters are terribly
important. Bringing together science, innovation, the
entrepreneurs and the funding is clearly an important
part. Again, it is all about creating those critical
masses of entrepreneurs and innovation.
Dr Richards: Just to add an aspect on that cluster—it
goes back to some of the discussion that occurred in
the first group—geography and concentration matter.
I agree with the comments on quality of funding, but
concentration is about the ease of meeting and mixing
of individuals, and about individual risk. A cluster is
a low-risk environment for an individual to jump out
of somewhere like GSK or the MRC and join a start-
up, knowing that it will probably fail, but when it fails
they will be able to dial up and go into something
else. You can only do that within the concentration,
risk environment and culture that occur as, for
example, in Cambridge and in elements of London,
Oxford and Manchester.
Q25 Chair: That is very helpful. Can I ask a specific
question to Dr Bianco? Wellcome introduced the New
Venture Fund. What has it added to Wellcome’s
toolkit for exploiting bioscience research?
Dr Bianco: Wellcome has three shots on goal here.
The first is that we have an investment group that
works for financial return to ensure that we have an
income to pursue our charitable purpose. They invest
across all sectors irrespective of our health care
interest, because they are generating the resource with
which we deliver our mission. We have my division,
which is mission related. We fund projects both in
companies through programme-related investment and
in the public sector. There is no financial return
expectation. This is around mission. In fact, we don’t
believe in double bottom lines. Sigma is an attempt to
say that we will have a financial return proposition,
£200 million in financial return motive, but it will take
advantage of the particular knowledge we have of the
health care sector. As an organisation we have a fairly
deep knowledge of health care, yet our investment
team pursues, on a financial return, many different
areas that any investment house might use. Sigma is,
if you like, a niche to exploit what we believe should
be a competitive advantage to a financial return
investor working for an organisation that lives and
breathes health care.
Q26 Stephen Metcalfe: We are particularly
interested in the Stevenage open innovation park. Can
you explain how that model differs from what would
be considered the more traditional research and
development model?
Dr Tomlinson: Maybe I should start and Ted can chip
in. I am GSK’s representative on the board of the
Stevenage Bioscience Catalyst. It is multifactorial.
Location is important; it is in Stevenage. What is
different about that park is that it is, obviously,
adjacent to a 3,500 person R & D facility owned by
GSK. There is an opportunity there for information,
expertise and guidance to be shared between GSK and
the people who occupy that site. I think a lot of that
is osmotic. It is in the coffee room. It is like the
canteen at the MRC Laboratory of Molecular Biology,
where a lot of these Nobel prizes came from in
Cambridge. It is those informal discussions that
people have that spark a lot of the ideas and
innovation that we are trying to create there. The key
difference of that park is that it is co-located with a
big pharmaceutical company.
Dr Bianco: I would like to add that there are very
many different views on the advantages of open
innovation where it has worked. For me, an absolutely
key one is that the quality of British science in the life
sciences is very high indeed, as we have heard. How
the industry views that is governed by the level of
access. Is there an interplay between public research,
the insights it generates and what can be used by an
industry that has to be profitable? Open innovation,
which we are trying to exemplify there, will be a win
for this country if what happens is that pharmaceutical
companies believe that Britain is a place where you
can have an ongoing, interesting and important debate
about what is emerging in life sciences, so they want
to be here. It is not about the IP per se and it is not
about the profitability of any one small business. The
big win is that this is an interesting place with a
culture of sharing the learning so that everyone can
try and get on and produce the products that society
needs.
Q27 Pamela Nash: A BioCity has just opened in my
constituency following the success of BioCity in
Nottingham. My understanding is that it is a similar
model but not situated next to an existing
pharmaceutical or bioscience company. Just to be
clear, do you think that is key to the success of
Stevenage, and what is the difference, in your
experience, with the success of Nottingham?
Dr Richards: With all of these it is very early to tell.
That is the first point. The second point is that open
innovation, this model and clusters are about people,
not about buildings. So you have to think about the
people. If you want to ask, “Is Biocity going to be
important?”, ask the question as to how you are
reducing the risk for the individual to take the risk and
do something to get involved in those clusters. The
point that Ian made is that Stevenage will be a
success, not as a building but as a place, culturally,
where small companies, large companies, scientists
and investors mix. If you can get them together in the
coffee room, mixing in an environment where they
feel they are not taking a high risk to be there, then it
will work.
Dr Tapolczay: Just to pick up two points, one from
Ian and one from Andy, and tie the two together, the
Stevenage Bioscience Catalyst park is a very exciting
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and interesting new proposition. It is the only park
in the UK of its kind where a major pharmaceutical
customer—and supplier, for that matter—is co-located
alongside young start-up entrepreneurial companies. I
think it will be a great success. I certainly hope it
will be a great success, and we are working closely
with them.
You mentioned BioCity. BioCity, although not having
a major pharma company next to it, started by the
demise, as Andy pointed out earlier, of a major
pharma company. It was Boots Pharmaceuticals
originally. Then it was bought by BASF, and BASF’s
decision to close their campus there gave BioCity the
opportunity to start. The model has proved very
successful in Nottingham. Again, picking up Ian’s
point, it is about concentration of talent and getting
people to mix together. The fact that you suddenly
have all these people, all in the same boat, many of
whom decided to start companies with people they
knew and with people they work with, led to the
creation of a very successful culture in BioCity.
Exactly the same is happening in Newhouse. You have
the closure of a major pharmaceutical R & D facility,
and BioCity have shown that they can make it work
in Nottingham. Let us hope that they can also make
it work in Scotland. The key, again, comes down to
availability of funding, to make things like that give
it the opportunity to grow. It is like a young seed that
has been planted. It needs watering, otherwise it is not
going to work.
Q28 Stephen Metcalfe: With regard to the
interactions between the large anchor organisation and
all the smaller firms and researchers that are around
the place, does someone facilitate those interactions
or do you just hope that it happens by itself, or is it
just, “There’s the coffee. Get on with it.”?
Dr Bianco: I am going to pick up the Nottingham
question to answer this. We have a couple of groups
in Nottingham, one of which has its roots back to MIT
and is using very MIT principles in trying to find a
way to prevent biofilms on devices. That international
link is massively important. It is because of that
international link that we think they are more likely
to succeed. It might well be in the US that they obtain,
the first traction on the adoption of technology. The
linkages that people want to make should not be seen
parochially. In basic science people have collaborators
all over the world, and so it is in any other branch of
scientific endeavour.
The second example is that we are funding an NHS
based group to develop a device to deal with cataracts.
We are going to send them along with the other
ophthalmology teams to India to the Prasad Eye
Institute where they have a catchment of 20 million
patients. That is not something that is easy to scale in
Britain, but they believe they are just getting going
with a catchment of 20 million patients. That provides
another form of traction. I would say that the
important thing in getting people together is that you
can’t do forced marriage but you can give invitations
to embrace an opportunity. That might lie down the
corridor and they will find each other in the coffee
shop, so you don’t need to do much about it. If they
happen to lie in another continent, you had better just
let them know, “Hey, there’s a chance.” Wellcome
believes that the best we can do is facilitate but using
a light touch.
Dr Tomlinson: Facilitating can come in many forms.
Some is going to be formal interactions and
contractual interactions between the parties. GSK is
an arm’s length party here to the SBC, and it is all
about stimulating the UK biosciences economy. We
put, currently, about £2 billion a year into R & D in
the UK. We have 15,000 people in GSK in the UK.
We are looking at other ways that we can stimulate
the biosciences economy more broadly, whether that
is through our investment in the Stevenage Bioscience
Catalyst, whether it is through our VC fund, SR One,
our commitment for the £50 million going into the
UK via this VC fund, or other initiatives that we have.
It is all about what we can do. It is all about specific
and concrete action that we can take to stimulate the
UK biosciences situation, because it is quite delicate.
A company like GSK can invest in the UK and we
can invest elsewhere. I totally disagree with the Patent
Box comment made in the previous session. These
pieces of legislation are extremely important in order
to focus our investment—a global company’s
investment—in the UK. You will know that we have
recently announced a £500 million investment,
including something that is close to my heart as Head
of Biopharmaceuticals, which is a new manufacturing
plant in Ulverston that we will be building. It will
employ 1,000 people and cost £250 million to build.
We would not have made these investments in the
absence of the Patent Box legislation.1
Q29 Stephen Metcalfe: That is interesting. Thank
you for that. You did ask this question, but what is or
was the single biggest driver behind the opening of
the Stevenage open innovation park and campus?
Dr Tomlinson: What was the single biggest driver for
us getting into it in the first place? It was a matter
of looking at ways that we can stimulate the biotech
community in general and different models to
stimulate those interactions. There are lots of different
ways to skin a cat. We felt that having a park in close
proximity to one of the largest pharma R & D
facilities in the UK would be a good way to do it. It
is an experiment and a model. We think it is going to
be successful. Of course it is a concrete step to try and
stimulate innovation, and that is what it is all about.
Q30 Stephen Metcalfe: But there must be a
commercial aspect to that as well for GSK.
Dr Tomlinson: For GSK, yes, because if there are
more biotech companies in the UK, we can,
potentially, do more deals with those biotech
companies. Half our pipeline of drugs comes from or
is partnered with biotech or other pharmaceutical
companies. Partnership is a massive part of what we
do. Without collaborations with biotech companies
1 The witness later clarified that the new manufacturing plant
at the GlaxoSmithKline Ulverston site in Cumbria will cost
approximately £350 million to build, and combined with
other investments GlaxoSmithKline announced at the same
time, would create up to 1,000 new jobs.
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and other strong pharmaceutical companies, our
pipeline would be a fraction of what it is today. It is
absolutely critical to have lots of successful biotech
companies. Even if we are not involved in them
financially, there is an opportunity in the future to
become involved in them through business
development.
Dr Richards: You have to look at the Stevenage
development in the context of global moves in
pharmaceutical R & D. The pharmaceutical industry
has been moving away from doing the majority of its
own R & D towards an open innovation model and
getting more from elsewhere. When you do that, these
big single centres of R & D, such as those we saw at
Sandwich, as we have at Stevenage, and we have had
in Scotland, Nottingham and Alderley, start looking
like an old model and do not really work. It is part of
a move to get a diverse ecosystem on that site. One
of the sad things about Sandwich was that it was
sitting out there on its own without its ability to create
a diverse and dynamic ecosystem. What GSK is trying
to do is to create a diverse ecosystem around
Stevenage. It happens to be easier in Stevenage
because you can live in Cambridge and work in
Stevenage. Your partner can live in Cambridge and
work in Stevenage. You can work in a biotech in
London and not move house. If the company moves
to Stevenage, you can be there. In an environment
where companies are very fluid—it is that great
fluidity of small companies at the moment that is
key—that geographical closeness and the low risk to
make those moves is an important factor.
Dr Tomlinson: While we are on the issue of
invitations, there is an absolute open invitation for you
guys to come to see the Stevenage Bioscience
Catalyst. We will take you round it and also show you
GSK’s operations there at any time.
Dr Bianco: A key principle when Wellcome entered
this as a joint venture park with GSK is that this is
not a proprietary relationship. It really builds on what
Andy is saying. The whole industry is hungry to learn
from outside its R & D walls as well as within. We,
as the Wellcome Trust, provided a level of neutrality
in the way that the culture of the park would be
perceived externally. It is really important that there
is a sense that this is a place for all- comers. GSK,
clearly by being locals, will have the advantage of
being locals, and they are putting in the value, which
is really what a big company can do, and shared
learning with the small companies. The principle is
that the governance arrangements provided a welcome
to all. Everyone does well out of that because they
browse off the system. They do not want to gobble
the whole thing up. It is quite selective.
Q31 Stephen Metcalfe: I have one final question. Do
you think that this model could work for other sectors
outside biosciences and, if so, which particular
sectors?
Dr Bianco: It has.
Dr Richards: It already does.
Q32 Stephen Metcalfe: Give me an example.
Dr Bianco: Aerospace. When they build a wing, there
is collaboration among many companies. Aerospace
has a very strong tradition of integrating intellectual
property to produce things like wings.
Dr Richards: Obviously, some of the software and
tech. I would even point you to Formula 1. That is an
example of that sort of cluster in this country.
Q33 Graham Stringer: How does the Francis Crick
Institute fit into this new ecology and new business
model within the pharmaceutical industry? Will it be
a big game change?
Dr Tapolczay: I certainly hope it will be a big game
change, looking at the amount of money that is being
poured into it. It is a commitment to invest in the basic
research of the UK in biomedicine. That is one of the
key selling points that attracts investment from the
likes of major pharmaceutical companies into the UK.
As Ian said, GSK’s business model is evolving and
changing. GSK spends a lot of money in this country
and wants to continue to spend money in this country,
but it will only do so if the quality of the science in
this country is world class and world beating in the
area that GSK is particularly interested in. That is true
of any major pharmaceutical company. The
investment in Francis Crick to bring together key
research groups, such as the National Institute for
Medical Research—NIMR—at Mill Hill, the CRUK
and the sponsorship by MRC and the Wellcome Trust,
and other partners, is an excellent opportunity to focus
expertise in biomedicine in one world-leading, world-
class laboratory. The success of that kind of approach
has been proven by the MRC time and time again at
the LMB—the Laboratory of Molecular Biology—in
Cambridge, which Ian referred to and, indeed, studied
at. Looking at the success that LMB has enjoyed with
MRC’s funding, and saying, “Look, we are going to
try and build the same kind of model again,” has to
be in the interests of British science and, therefore, in
British business in life sciences.
Dr Bianco: Paul Nurse came back from being
President of the Rockefeller because this was a big
carrot. If Nurse is the Aaron Klug of the LMB, we
will be well placed.
Dr Goodier: The model has been established before,
and most of the major academic centres medically
have this aggregation of Wellcome and some
biopharma. We have the Wellcome Trust, MRC, GSK,
Cancer Research UK all on the same campus with the
hospital. It is that integration of patient care with these
research facilities that really adds weight to the
bioscience research agenda.
Dr Tomlinson: It is great for big pharma as well. The
more science there is in the UK, the better for GSK.
There is not necessarily going to be an immediate
benefit for GSK from the setting up of the Crick, but
the whole thing about creating a talent pool of great
scientists, great innovation and the entrepreneurs
means that we have got to accelerate the growth of
these capabilities. If we do, it is to everyone’s benefit.
It really is a win-win situation. GSK is terribly
supportive of it.
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Q34 Graham Stringer: Sticking with the new
business model within the pharmaceutical industry,
the Drug Discovery Centre at Imperial College do not
see it as a win-win situation. They worry and fear that
there is going to be a funding gap when it comes to
commercialisation in the future. Do you agree with
that? Do you think that a technology strategy board
will fill that funding gap, if indeed it will exist?
Dr Tomlinson: The answer is not totally
straightforward. There is, clearly, investment and
more investment required in that gap between
academic research, early-stage target discovery and
validation, and then making a drug. How you fund
that area is not entirely straightforward. It could be by
biotech. It could be by initiatives such as the
Biomedical Catalyst fund. I have just agreed to be on
the major awards committee of that, so, hopefully, I
can help in terms of that investment vehicle. It is
multifactorial. TSB, for sure, hopefully, will help.
There are the seed VC groups that are being set up.
The Wellcome Group has just created a large early
stage investment fund and GSK has invested $50M in
Index’s sixth lifesciences fund. I do not pretend to
have all the answers. We need to do everything we
can to support that kind of translational research. That
is why the Crick seems to be a great vehicle for
building a core cluster of capabilities in translational
research.
Q35 Graham Stringer: Is what is at the bottom of
this change in the business model major multinational
drug companies saying, “It is too expensive now to
develop the next generation of drugs and we need
public sector funding.”? Is that what we are saying,
simply?
Dr Tapolczay: I certainly do not think that that is the
case. It is very expensive. It is probably too expensive
for one single organisation to do everything it has to
do in its own house. If then it does it in partnership
with other organisations, whether those organisations
are publicly funded or privately funded, is not of
relevance to the big pharmaceutical companies. What
has changed is that big pharmaceutical companies
have to show a return on their investment to their
shareholders. That is one of the reasons why they are
in business. Obviously, they want to produce new
medicines as well. One of the reasons why the CEOs
get paid is to show a return on investments to their
shareholders. It has become increasingly difficult to
do that in pharmaceuticals. The costs of doing R & D
and the costs of registering new products have
spiralled over the last 10 years, so it has become very
expensive to do everything. The response of the
model, in terms of evolutionary response, is, “Okay,
so we won’t do everything ourselves in-house and we
will partner with other groups that do it.” At present
there are plenty of other groups out there for the big
pharma companies to partner with. If we don’t keep
funding basic research that leads to these new
companies and we don’t keep funding start-up
businesses that allow those businesses to develop,
then those partners will not be present in the future,
and then GSK may look outside Britain to find its
innovations.
Dr Tomlinson: Big pharma needs to take some
responsibility. The costs are going up and the
regulatory hurdles are going up, but we did have a
culture of trying to industrialise drug discovery and
development—and it did not work. At that point, I
guess we were quite arrogant in some respects. We
thought we could do it all ourselves and we thought
we could do it by industrialising science. All scientists
will know that science is not something that should be
and can be industrialised. As soon as you industrialise
science, the innovation goes away. Innovation comes
from one person having an idea, or a small group
having an idea, and prosecuting that idea to some kind
of milestone. That is why we have changed
dramatically over the last five years. We used to have
thousands of people working in R & D. We would
throw a load of people at the problem and we would
hope to solve it in that way. Now, we have 50-people
groups, with a leader fully empowered to prosecute a
very specific area of science. If they work, great. If it
does not work, that is Darwinian evolution. You have
a model where people are accountable for prosecuting
a specific area of science. It is very different from the
way all big pharma used to do it 10 years ago. There
is a big change in the way that we are going about it.
Q36 Chair: In a way, Dr Tomlinson, you are saying
that the pharmaceutical industry was a bit slow on the
uptake, because industries like Formula 1, aerospace
and telecoms did all this years ago.
Dr Tomlinson: Yes.
Dr Richards: There is a difference. The time scales
between an initiative and the output are much longer
than in Formula 1. In Formula 1 you make the
initiative and you find out within a few weeks whether
it is working. In pharmaceuticals, you do not. One of
the problems in the industry—Ian is absolutely right
to point it out—is that the industrialisation of the drug
discovery process was a mistake and a problem. The
biggest problem was that everyone did it. The
industry, as a whole, tends to do this, because within
a large company the career path of an individual is
shorter than finding out whether something has
worked. There is an incentive. As an individual—I
come back to individuals—people have been very
successful at jumping on the latest fashion and
bandwagon, rising up in their career from it well
before they have discovered whether it works or not.
One of the things I am most encouraged about at the
moment is that there is a greater diversity of approach
and fashion in the sector as a whole, which is really
healthy. There was a problem when everyone
followed the same fashion. Everyone got into
molecular biology and got out of pharmacology.
Everyone got into combinatorial chemistry and got out
of the whole industry, not just in the UK but
worldwide. That has been a very unhealthy
phenomenon, and that has changed.
Dr Tomlinson: In our defence, big pharma did get it
wrong, but GSK, in particular, was one of the earliest
to realise that they had got it wrong and fixed the
problem, which is why GSK is in a pretty good
position, particularly in terms of its UK investment
base today, whereas others are not necessarily in as
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good a position. We have been early adopters of this
small, focused research model, which is very akin to
the way that biotechs work in the UK.
Dr Bianco: We have run an experiment for the last
five years called Seeding Drug Discovery. The board
agreed £91 million to specifically address small
molecule discovery of what is called “the lead
optimisation stage”, which is one of the gaps that is
famously difficult for public labs to address. What has
turned out is that transaction size is critical. We have
this general translation scheme. We did not have £3
million to £5 million per transaction available. That is
what it takes to do that step. That lead optimisation
step, if modestly done, costs in the ballpark of £3
million, £4 million or £5 million. One of the things
with all of these schemes is that one needs to be
cognisant of what the transaction size is that really
matters. If you have a scheme that dishes out money
at one level, which is only at £35 million, it is going
to be a poor fit for some people’s needs. If it only puts
out £35,000, it is going to be a poor fit. You have to
ensure that the rules of engagement do not prevent
you from addressing a need. We created this scheme
because we knew it was going to be in the order of
£3 million to £5 million per go. So £91 million bought
us 30 projects. The board has just agreed another £210
million for a second five-year period.2 Is it a
success? We can’t answer that yet, but we know that
about a third of the projects are still standing on their
legs at the end of our funding—only a third. That is
why this is tough stuff to do. Our board has to take
that on the chin. And they are willing to do it.
Q37 Stephen Mosley: You have talked about the
problems with the big pharma model. Of course in the
UK we have a big customer model as well. We have
the NHS, which is the major purchaser of medical and
pharmaceutical products. How much influence does
the NHS have on the bioscience market in the UK?
Dr Richards: Let me just put this as an investor in
early-stage companies. I work in angel groups, and
angel groups are full of people from the technology
sector as well. This is not just a statement about drug
discovery; it is a much broader comment. I come back
to some of the points that David Connell made in the
earlier session. Customer traction is one of the most
attractive things for any investor. There has been a
situation where any business plan, business model or
business idea that comes up that says, “By the way,
the first thing we are going to do is sell into the NHS,”
just makes it uninvestable, because the NHS does not
take up, let alone new drugs, new technologies, new
software systems, new anything. It is notoriously hard
to sell anything new into the NHS. That is partly a
cultural thing. Partly, there are some elements within
the NHS that, for one reason or another, have a “they
shall not pass” mentality. It does make it incredibly
hard to innovate in the medical field—medtech, health
care, IT—in an environment where your local market,
who are the easiest people you have to reach to talk
to as customers, are hard to access.
2 The witness later clarified that the board has just agreed
another £110 million for a second five-year period
I hope and I think that is changing. For my sins, over
the last couple of years, I have made some
investments with other people in companies that do
intend to access the NHS as their first market—in fact
some of them as their primary market. I hope that that
works but the jury is out. It is really important.
Dr Goodier: That is something I hear a lot. The NHS
does tend to run as a top-down command-and-control
massive organisation, so, when it does IT, it does it as
one massive contract and, inevitably, fails. We do not
seem to be able to find the middle ground. The
foundation trust movement is a very good movement
for encouraging innovation and encouraging academic
centres to find their own place in the sun. At the
moment, the tariff structure is such that the Shelford
Group, for example, which is, probably, the 10 most
prestigious academic medical centres, in 2010–11 had
a turnover of £7.3 billion. If you take away the under-
the-table supplements because of potential deficits, the
group made a loss of £3 million. Therefore, there is
not, in a business sense, the capacity to be able to
invest in IT. As I reflect upon it, we are falling behind
as a health system compared with our international
comparators because what we all want is to have good
electronic records, an e-hospital, with databases that
can be interrogated for research purposes as well as
for individual patient care. We are way behind the
American equivalents there, some of the Dutch and so
on, because there is no spare cash at the hospital level.
The spare cash is at the SHA level.
Q38 Chair: Presumably, if we do not get the data
structure correct, innovations like stratified medicine
will be damaged inexorably in the UK as a research
activity.
Dr Goodier: We are very concerned at the Shelford
Group because so many of the prices set for treating
patients are set on averages. If you suffer from
asthma, you can have three nebulisers and go home,
or you can have a week in intensive care and two
weeks on a ward. The price is set at an average, and
that suits more the smaller district general hospitals,
whereas the academic hospitals tend to get the more
complex patients and, therefore, are chronically
underfunded. This is a serious threat in terms of the
future of the biopharma industry in this country. If
the core—not just the Shelford Group—20 academic
medical centres in this country are not, as in other
countries, given supplements because of the
complexities of their patients, because they are seen
as centres of excellence where they need to be the
leaders in IT and so on, necessarily they are poor
partners for the biopharma industry and technology.
Dr Tapolczay: While I agree with everything that has
been said, I also see it as an opportunity. If the
problem is there but it could be fixed, we are still the
only country in the world with an NHS. If we can find
a way to allow engagement between the biomedical
community in the private sector and the NHS more
effectively, then it has to be a very positive step
forward for both the NHS and the biomedical
companies in the UK.
Dr Richards: It is deeply frustrating that we are the
best situated country to do personalised medicine
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because of the NHS. If we can gather the information
from well collated records and use that—we have
everything in place—and if we could do it, it would
be the big game change.
Dr Bianco: The motive when we launched the Health
Innovation Challenge Fund in partnership between
Wellcome and the Department of Health was exactly
how to drive innovation. The areas that we called for
proposals are agreed with the Department of Health.
That is an attempt to say, “What do they want? We
will try and build what is needed.” One of the
disincentives, which is a real problem, is that if you
produce, for example, an invention that reduces bed
stay because the surgical procedure is less invasive, it
is the cost centre for the beds that gets the advantage
and the risk is taken by surgery. Who should take the
big decision? The next layer up. It is a well-
established problem, but you can get unintended
consequences. Adoption has become a problem
because the reward system is not necessarily linked.
Dr Goodier: To bring a more positive note to it, the
work of Professor Dame Sally Davies has really
improved biomedical research in this country
tremendously over the last three years, and a number
of initiatives have just started but are too early to
assess, which Sally has been the author of, which are
very promising. What we are all trying to do is to
get comprehensive electronic records with genomics
attached to them, because, as I understand it, what the
biopharma industry wants is not to do everything but
to have very specialised interests of care. Once the
research is conducted, we offer personalised care to
the patients who are engaged in this. Particularly,
Imperial, University College, Oxford and Cambridge
are very focused on that, but all of the academic
centres are striving in that direction.
Dr Tomlinson: We support the reforms of the NHS.
Obviously, it is early days. The key here is to come
up with a system. It is this win-win situation, where,
“You can help us to help you and support the uptake
of innovative medicines.” We believe that the
medicines we are going to be able to create can make
a big difference to the patients in the UK. There is
definitely a partnership here to be established and
worked on. It is all about supporting innovation
because without the support for the innovation there
will be no innovation, and without innovation there
will be no advance in medicines for patients. It is a
partnership.
Q39 Pamela Nash: Which countries do you think are
our main competitors in bioscience?
Dr Tomlinson: Obviously, the US. We have a big R &
D presence in the US as GSK. Talking about clusters
again, if you look at the investment in SMEs in the
Boston biosciences cluster, it is bigger than the whole
of the UK put together. Why is that? Again, they have
been at it longer, there are more entrepreneurs and
more large companies have sited and invested there.
In fact, they have attracted companies from outside
Boston into Boston. I am talking about the likes of
Amgen and others, which now have large research
facilities in Boston. Again, if you have that critical
mass of talented scientists who, as Andy said, are not
fearing for their jobs as there is always somewhere
else for them to go, it is incredibly empowering. From
these groups, you can spark up little biotechs all over
the place. Entrepreneurs are going from one company
and making it successful. Maybe the next entrepreneur
is not successful, but they are moving on to the next
thing all the time. We have that a little bit in the UK,
but it is nothing like the way it is in Boston. We can
build upon that if we make these specific and concrete
investments in the biosciences opportunity in the UK.
Dr Richards: Just to add to that and go on the US
model, the US has a number of things, including a
health care system that uptakes innovation somewhat
earlier. One of the other reasons why you look at
Boston is not just its longevity, but this is about the
valley of death, as this hearing is. There is no doubt
that in the US the financing continuum is more
complete or there are fewer discontinuities than there
are at any one time. Those discontinuities change and
move. It is one of the things that is very hard to assess.
At the moment there are specific ones. It means, as an
investor, you invest in things and you are most
worried about the financing risk. That is less of an
issue in the US. It has allowed companies to grow
bigger.
The Cambridge Phenomenon Conference last year
was a conference about tech as well as life sciences
and biotech. A leading US venture capitalist said,
“You guys have created the most effective corporate
veal factory in the world.” He was talking about
Cambridge. What he meant by that was that we were
creating beautifully formed high science—great little
companies, which were then being sold very early,
rather than financing them up to the next stage. While
there is a gap early, the moment one of those gaps is
on the public market, no one IPOs the company. So
ventures, angels, high net worths and corporate
venture are investing in companies to get to a certain
stage, stay virtual, get sold on, rather than grow. In
Boston, you will find that there are those companies
that have made that jump to the next stage and become
$1 billion, $5 billion or $10 billion companies.
Dr Tapolczay: I agree with everything that has been
said, but I think your specific question was where our
main competitors are in bioscience. They are
Germany, for sure; Scandinavia, for sure; in Europe;
obviously, the US. Then I do not think we can—or we
do at our own risk—ignore China. There is a
phenomenal amount of investment, the kind of
investment that this panel would dream of having at
its own disposal, being pumped into basic academic
research in Chinese institutes doing medicine. The
number of high-quality publications coming out in
China now is overtaking us. We are becoming third in
the world. Historically, for the last 50-odd years, we
were second in the world to the US. China is now
starting to overtake us. Is that a real threat or can we
do something with them? Because Germany has a
long and well-established history in biotech, much
like ourselves, and many of the big pharmas started
life in Germany, they could be seeing us as a
competitor. Scandinavia, potentially, similarly. The
US, clearly, will see us as a competitor. With China,
we have an opportunity to become a partner rather
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than a straight competitor because the one thing that
China has in spades is plenty of cash, but the one
thing they don’t have is knowledge of this industry in
the translational space between lead optimisation and
pre-clinical to clinical development.
In terms of manufacturing, they can outperform us any
day of the week on scale, but it is that knowledge-
based bit in the middle where we can strive to create
a really strong partnership with China that, potentially,
can bring economic benefit here in the UK. It is not
just teaching them what we know. It is becoming a
true partnership so that economic gain in China is
mirrored with economic gain and growth in the UK.
Dr Goodier: It depends on what aspect of research
you are talking about. In experimental medicine and
early-phase research we are still regarded as very high
quality. By the time you get to phase 3 clinical trials,
frankly, Novartis would just put that where they could
do the trial the cheapest and get the easiest return. So
all of the BRIC countries and quite a few others are
competitors for that sort of research. I would agree
that China is amazing in the way they are making
progress. We have a lot of contact with China, and the
partnership model is, frankly, the only way to go.
Dr Bianco: It depends on which bit of the valley of
death you are talking about as to where our main
competitor lies. This conversation illustrates that. The
US, definitely, if you are talking about the interface
between basic science in the public sector and
business, which is why the cluster in Boston is the
way it is. Why is that? I believe that is because it is
underpinned by clarity of motive. MIT gave us some
statistics when the board visited. In 2009 figures, they
had $2.3 billion coming in as revenues across US
academic institutions, but set against an outlay of $54
billion. The research base is $54 billion and it brings
back $2.3 billion. That is 4.8%. This is no way to
make money, but it creates 500,000 high-end jobs.
Where is the win? The win is in the richness of your
entire sector, not the individual companies.
MIT has a policy that it will not allow its investigators
to roll into the company. You can be a consultant but
you stay in the academic department. You might be a
serial entrepreneur, so you do what you are good at.
You advise to ensure the success of the enterprise you
have spawned. These are very important principles.
They do it because they believe it is their mission as
an educational establishment and as an establishment
endeavouring to put out societal good. They get
enough return that they can reward the founders and
others to create the entrepreneurial instinct. Six
institutions across the US bring in the vast majority of
that $2.3 billion of revenue receipts, but if they have
a profitable business it is probably selling T-shirts.
That is the local joke. They know what their margin
will be on selling T-shirts, but they do not know what
their margin is on intellectual property.
Pamela Nash: You have covered most of the points
that I wanted to raise. Thank you very much.
Q40 Caroline Dinenage: I have a quick question. I
know you are here to talk about the bioscience sector,
and it clearly is a great British success story. I
wondered what other sectors could learn from the
experience of building this success, the pitfalls and
the quick wins.
Dr Richards: It could be smart about ensuring that a
financing continuum of investors who understand the
space grows up. When the financing continuum is too
diffuse and too spread apart, it does not work. It is a
challenge at the moment in areas like food and
agriculture, elements of bioenergy, energy and
renewables. Bringing that financing continuum and
investors together, with the academic and
entrepreneurial base, is really important. I don’t quite
know why it happened early on in the life sciences
area, but it did, and it has been growing. We have the
City of London, so we have a heritage in investment
and investors. They get, periodically, interested in
areas and build on that. They ensure that in areas that
we are going to focus on we can have a concentrated
investor base and a connected investor base as an
important thing.
Dr Tapolczay: The point Andy makes is really
important, but we also need to consider that there may
be different types of investor that will be interested in
a particular investment during its evolution. Clearly,
the venture capital community and most of the
professional investment community are interested in a
return on whatever cash they are putting in. There is
a second potential investor, which was discussed in
the earlier session, which is the state itself—public
cash going in. For publish cash, I do not believe that
the return should solely be how much cash we have
generated in return on the investment. We should
consider, and I am sure we do consider, other societal
benefits associated with funding that particular
project. They may be unmet medical needs in patient
populations where, commercially, you are never going
to make much money because there are too few
patients in the UK. The medical charities in the UK
invest very heavily in the area of unmet medical need
in areas that major pharma companies would not want
to go into because the return on investment does not
make sense, and certainly venture capital firms will
not want to go into them because they cannot see an
exit.
There is a much stronger need in the UK for a greater
integration between public and private funding. With
many fantastic pieces of scientific discovery, at the
point at which they are discovered, it is not obvious
how you are going to make any money out of them.
They need funding in order to be developed to a point
at which, suddenly, somebody goes, “That’s it. That’s
how we are going to make money out of this.” When
you get to that point, there is plenty of VC money
floating around or professional investor money. It is
how you get from the stage of, “Well, it looks really
interesting, but we really don’t understand how
anybody is ever going to make any money out of it,”
to the point where suddenly the investment
community is willing to take it on. In many cases, it
is a bit of a relay race. You need different runners for
each leg of the relay race.
Dr Tomlinson: I do not think you can overestimate
the importance of the critical mass of talent. In the
end, the reason that Cambridge is the way it is, and
the reason why it was so easy, relatively speaking, to
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set up a biotech company in Cambridge and to hire
scientists in Cambridge, is because there are loads of
scientists in Cambridge. In a way, it is as simple as
that. Yes, you hire people from overseas and you hire
people from outside Cambridge, but half the people
who worked for Domantis were from a 2-mile radius
around our facility in Cambridge and came from the
LMB, the university and the other biotech companies
in Cambridge. That is why clusters and focusing
investment in the clusters are so important, because
they grow and you get that snowball effect. That is
what we need to ensure when we are considering how
we are going to treat London, Cambridge, Oxford and
Stevenage, the triangle, and all that stuff, going
forward. We need to create the critical mass. If we do
not have it, we will fail. If we do have it, we can be
much more successful than we have been to date. I
agree that we have been pretty successful in the
biosciences sector, but it is nothing compared with
some of the US cities. If we can just keep the ball
rolling, keep the momentum and make the investment,
be very specific about what we are going to do and
make concrete moves, we can be more successful.
Clusters, for me, is the way to go.
Chair: I think this follows on very neatly because it
is challenging the other side of the coin as our final
question.
Q41 Roger Williams: Just to follow on from Dr
Tomlinson’s comments, we understand about the
golden triangle, the critical mass and the concentration
of scientific expertise and scientists. Is it important to
be near London as well in order to be near financial
institutions that will invest in these opportunities, or
will the investors go where the expertise is?
Dr Goodier: I would suggest, from Cambridge’s point
of view, that this is a community and they feed off
each other. The scientists are there, as you have heard
described, and the money men follow the scientists
because they know that the deals are to be had there,
the start-up companies and so on. It creates a
community that feeds off itself.
Dr Bianco: We had an interesting debate with Merck,
who came over to talk about what the industry was
looking for. They gave a great anecdote about their
in-licensing groups. They had no in-licensing group
in Europe. Consequently, they picked up no projects.
Then they set one up here in London with tentacles
reaching into continental Europe and they started
hoovering them up. They noticed they were hoovering
them up at a greater rate than on the west coast of the
US. Why was that? Because they had not put an in-
licensing team in there. It is massively parochial. Stuff
under their nose was getting hoovered. That is because
it does not happen in a moment in time. They don’t
have a group come in, do a show and tell, and say,
“We are buying today.” It is a dance. There is stuff
that goes on; there are tos and fros: “This is interesting
but...” Unless there is a feeding frenzy around that
particular product, and you are lucky, there is going
to be a dance. That means that proximity matters.
They found out that it completely mattered, even to
the point that they were not getting from the Bay area
what would seem fairly obvious that they could have
got; they just did not have a team there.
Q42 Roger Williams: I asked that question because
one of the more outspoken members of the other panel
did suggest that some of the more peripheral
universities ought to concentrate on teaching rather
than research that could be spun out into
commercialisation. I come from one of those more
peripheral areas and would like to see our universities
involved in that high-quality work as well. We are
told, for instance, that good teachers are always up to
their elbows in research and commercialisation. From
my point of view, teaching and research go together.
Dr Bianco: The University of Dundee is an absolutely
fantastic example. There is no reason, geographically,
why it is well placed, but it has a fabulous tradition
in drug discovery, in the way that the kinase group
has become a magnet for many industries. It has just
been deliberate.
Dr Tomlinson: They have just done it. That is the
thing about Dundee—they have done it. They were
sending out flyers many years ago. They were just
doing it and that is what it is all about. You can’t just
talk about it. You have got to do something to make
these things happen. While it is true that a lot of the
biosciences R & D is centred around the south-east, if
you look at manufacturing, there is a lot of that in
Scotland and in mainland Ireland. There is
manufacturing all over the place. We are going to put
a biopharm plant at our facility in Ulverston, Cumbria
because there is talent there—talent that knows how
to do manufacturing. There are people on the site
already. There are people round and about who you
can bring in to do that kind of work. It is horses for
courses. There are certain places where there is a
critical mass of certain expertise. If a university has
an expertise in a particular area, then good for it. It
should focus on that and make the most of it. It should
not just focus on teaching. If it has a critical mass of
expertise in a particular area, there is no good reason
why that university should not exploit it.
Dr Tapolczay: I would agree. In one sense, geography
or location is not particularly important. What is
important is that you have the right team in order to
do it. Dundee, clearly, had the right team. When they
started in drug discovery, they realised that they did
not have the right team so they imported the right
team. They brought the right team to them. They hired
people who were ex-GSK, who knew what drug
discovery was about, and they put them there. The
industry does not care. AstraZeneca does not care
whether they are collaborating with Dundee,
Aberdeen, Manchester or London. What they care
about is the quality of the team that they are
collaborating with and the quality of the science. To
your point, is it a waste of money to try and do this
activity at your university? Absolutely, if you do not
have the right team. If you have the right team, it will
not be. Dundee is a perfectly good example of that.
Q43 Roger Williams: I visited Syngenta recently to
look at the work that they are doing. They were telling
me that in identifying agrochemicals they are very
Science and Technology Committee: Evidence Ev 19
18 April 2012 Dr Ted Bianco, Dr Ian Tomlinson, Dr David Tapolczay, Dr Gareth Goodier
and Dr Andy Richards
much curtailed by EU regulations in terms of
percolations of water and these sorts of issue. Do EU
regulations hamper your type of science and
investments?
Dr Tapolczay: That is probably one for you guys.
Dr Tomlinson: No. Obviously, companies like GSK
have a responsibility to become more green. We have
investments in green chemistry. We are in discussions
with Nottingham University about the possibility of
setting up a new laboratory there in this field. It is our
obligation to become more green, to have less waste,
to use less water and all that kind of stuff. We have
quite a big programme in place to make ourselves
more green and to exceed all the regulations that exist.
It is important that we make those moves. It is simply
a corporate responsibility to do that as a company
like GSK.
Q44 Roger Williams: The point they were making
was that they are a worldwide organisation and it was
much easier to produce new chemicals and new
reagents in other countries than it was in the
European Community.
Dr Tomlinson: We have a considerable manufacturing
base in Europe and especially in the UK. So I don’t
see it as an issue for us.
Dr Bianco: The European regulation that has been
brought to my attention that is most problematic for a
small company is employment law. You have to take
on people with a longer-term commitment than you
have cash flow. That can create very extreme
problems. For the very small companies it is
employment law issues.
Q45 Roger Williams: With the Regional
Development Agencies not existing—we never had
one in Wales—as I understand it, and talking to some
people involved in your sector, they were very useful
in producing capital in order to set up fairly large
research organisations. Did you find that to be the case
or will they be missed when they are not there?
Dr Tomlinson: The East of England Development
Agency did contribute to the Stevenage Bioscience
Catalyst, as did the TSB. I guess that most of the focus
is now going to shift on to TSB being the main vehicle
to pick up the slack that has been created by getting
rid of the RDAs. Again, we need to focus on what
that is going to be, how it is going to work and how
those investments are made to make sure that they are
as effective as possible. That is my understanding.
Dr Richards: The RDAs did some useful things. Was
it the most efficient mechanism? Probably not. You
ended up so often with discussions about the north-
west versus the north-east, when it should have been
the UK versus Boston, Shanghai, Palo Alto or San
Diego. That is one of the problems in a global industry
like ours.
Dr Tapolczay: I would 100% agree with that. Having
funding available has to be a good thing. Whether it
is managed properly, administered properly and
whether the rules of engagement with the fund were
too complex in the RDAs, those are all debatable
points. Having funds available has to be a good thing.
My experience of the RDAs was that it took an
incredibly long time to get to a decision point.
Frequently, I could get money from other sources
faster than going through the RDAs. It cost
businesses, because if I went to the venture
community I was frequently giving large chunks of
equity away to the venture community. Therefore, it
was more attractive to try and get RDA funding, but,
bureaucratically, it was difficult to handle.
Chair: Gentlemen, thank you very much for your
evidence this morning. It has been extremely helpful.
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Q46 Chair: Good morning and welcome to our
witnesses. We are extremely grateful that you have
given up time to come and speak to us. It would be
helpful for the record if you would be kind enough to
introduce yourselves.
Anne Glover: I am Anne Glover, chief executive of
Amadeus Capital Partners. We are a technology
venture capital group that has been in existence since
1997 with £500 million under management. I have
been in the industry in the UK since 1989.
Katie Potts: I am Katie Potts from Herald Investment
Management. I started my working life at GKN,
which, somewhat eccentrically, educated me as a
welding engineer. I then went to the City. In 1994 I
set up Herald Investment Management. It was born of
my frustrations at Warburgs because I thought large
companies were boring. Investors were not going to
make money and you had to invest in smaller
companies, but there were too many risks and there
was too little liquidity. So I said, “Why not have a
collective vehicle that invests in lots of them to spread
the risk?”
Matthew Bullock: My name is Matthew Bullock. I
have been involved in financing technology
companies since the late ’70s. I spent 10 years as
Barclays head of technology financing team and 12
years as chairman of a life sciences company that
grew out of the Cambridge phenomenon. I am also
chairman of the Centre for Business Research and the
UK Innovation Research Centre, which is a joint
venture between Cambridge and Imperial. I am a
director of Addenbrooke’s where I take an interest in
the commercialisation of medical services and
devices.
Stephen Welton: I am Stephen Welton. I am chief
executive of the Business Growth Fund. We were set
up last year by five of the major UK banks to provide
growth capital to SMEs across the UK. We have £2.5
billion worth of capital. We are investing in a range
of companies, which include technology-related
businesses, and we provide growth rather than start-
up capital. I have spent my career in the investment
industry, and also for a couple of years I ran a media
and technology company. So I have seen businesses
from both sides of the fence.
Q47 Chair: We have got rather a lot to get through
in a very short time, so we will try to make things
reasonably succinct. If you have any additional
Graham Stringer
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information to feed to us afterwards because we don’t
have time to squeeze it in, we would be grateful if
you would follow up with letters. We all accept that
cash flow is the lifeblood of small companies. What
is your impression of where small high-tech
companies get their money to maintain cash flow?
Anne Glover: At the beginning, it is their own capital
as entrepreneurs and angels. Later on, they can get it
from venture capitalists but also corporations who do
licensing agreements with them. For small high-tech
loss-making businesses debt is not an option, so the
grants that are also offered by various Government
bodies like the Technology Strategy Board are an
important component.
Matthew Bullock: There is a different model from
that, which is a respectable one. The one that is more
commonly adopted is that people get into business
basically by selling their competencies as a service.
This produces quite early cash flow. It requires large
lead customers, usually large companies, but they can
be research institutes or could possibly be
Government—which is perhaps an issue for us to
come back to—where they sell their services, usually
on a term basis, delivering a particular technical
service, and that gives them cash flow very early on.
This is the soft model as opposed to what Anne is
talking about, which is the hard start-up model, and it
is in fact the dominant model. Although the hard
company model is the classically understood one, it is
very much the exception.
Q48 Chair: Is there in the different models an ideal
balance or is it horses for courses?
Matthew Bullock: I think the answer is that if you
can get venture capital it is the first best solution, but
the truth is that it is not very readily available and
most companies get into businesses by selling their
services and moving up the scale gradually to create
a product. It is possible to get into that business with
personal equity, maybe with some angel support, but
it is also a business that we in the bank, when I ran
the group, were able to finance from a fairly early
stage on debt.
Anne Glover: I agree that it is horses for courses, and
it depends on the competitive framework. If you need
to move very fast because of competition globally, the
softer model cannot respond quickly enough.
Stephen Welton: A related point to all of this is
investment readiness and the quality of financial
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controls and planning, which one often finds lacking
in very small companies and is an area in which they
invest last. Clearly, cash flow is the lifeblood of any
business no matter how big, so the better prepared
they are in being able to present themselves to outside
investors, be they corporate or financial investors, the
greater the likelihood of achieving success.
Q49 Chair: We have been told that heavy reliance
on equity finance is not always welcome due to its
dilution effects. What are the barriers to preventing
better availability of non-equity loan finances to small
firms with genuine growth potential to become
medium-size companies?
Matthew Bullock: If I was to compare this with
America, which is often cited as the home of multiple
venture capital, the real difference is Government’s
attitude to procurement. Since the 1940s the US has
had a consistent policy of using small firm
procurement as a way of developing technologies,
from both a policy and industrial point of view. In the
second world war they adopted a series of what were
called “V for Victory” contracts where Government
Departments that wanted to stimulate the production
of key bits of sensitive technology would place R and
D contracts for delivery with small companies where
they knew they had the competencies technically but
not necessarily the business competencies.
Q50 Chair: How does that explain the success of,
say, biotech companies these days?
Matthew Bullock: If you look at many biotech
companies, they are actually tool companies and not
necessarily people who are going for a silver bullet
drug. One has to say that in America there are very
large programmes of support. My own company had
a major contract with DARPA for the production of
blood. As a simple voir dire, soldiers die on
battlefields because they lose blood. They wanted to
produce sacks of fresh pluripotential blood in the
battlefield. To do that, they needed to have equipment
that could produce such things. There is nobody in the
world who does that.
They came to us and said, “You are part of a
consortium. We would like you to bid for this, and we
will give you milestone payments for the achievement
of different steps in the production process.” It was an
extremely well-run process by a rather experienced
postdoc. This was a Government Department
bureaucrat in the DOD. At the end of the period, he
changed consortia members to make sure he got the
best bid. He said to us, “When you come to your
second stage, here is our market forecast for the world
market for blood. When you put forward your next
proposal we want you to come with a plan of how
you will deliver us blood for $10 a sack.”
That is driven by a very clear and long-experienced
group of people in DARPA, ARPA, the Office of
Naval Research and other Government Departments,
who use procurement creatively to stimulate the
growth of companies. On the back of that many
venture capitalists then come into these companies
and put their money in when they have got a product
defined from the result of such contracts.
Stephen Welton: Often it is incredibly difficult for
small companies to deal with government because
they do not have a lot of resources in terms of
management capability. It is often the tender process
or finding the right way to deal with government in
public contracting that is too difficult, and yet that is
a natural way to support these smaller businesses who
are trying to innovate. The companies we talk to
bemoan the rhetoric in terms of being able to work
with the public sector. The reality of landing contracts
and the cost of tendering puts them off even from
starting in the first place. They find it too big and
amorphous a body to work with.
Anne Glover: I would agree that Government
procurement can add tremendously early on, but,
frankly, the bigger reason for the success of high-tech
growth companies—very specifically growth
companies in the US—is the financing chain that
exists all the way up the ladder. Therefore, it is the
presence of the exit markets and capital exit that
encourages middle and early stage investors to
continue to finance the company through its losses. I
think we will come back to that later. For the 10 years
when Sarbanes-Oxley was dominant, US venture
returns were very low. The House has just passed the
JOBS Act, which is removing and rolling back five
years of regulation and is going to transform the
venture industry in the US again. We will,
unfortunately, be left behind by that or have to go to
those markets.
Q51 Chair: It is a slightly different explanation. To
try to bring the two together, is there any evidence
that your additional points would not exist if there
was not in the first place that different approach to
Government procurement?
Anne Glover: I think they are complementary.
Matthew Bullock: Historically, small and SME
American technology businesses grew from the 1940s
through to about the 1980s before venture capital
became freely available. What happened was that the
entrepreneurs who went through those first phases
sold their companies typically to large corporations.
They did not go to IPOs but they gained the skills, and
many of those people were the first venture capitalists.
Katie Potts: There has been far more angel investing
in the States because there have been more successful
companies. Look how many household names there
are of first generation billionaires who have deep
pockets to recycle. One area in which we have
invested in start-up straight into the quoted market,
even in the last year or two, is where individuals have
come to me and said, “Look, we sold out our business;
it was a takeover. We’re starting again. Will you put
some money in?” It is backing people. They can raise
worthwhile amounts of money.
Matthew Bullock: Kleiner Perkins—both of them ran
businesses before they started the financing operation.
Q52 Sarah Newton: We have been told that venture
capital is not very well placed to support innovative
science and technology start-ups or indeed to enable
organisations to grow. If you look at the enterprise
capital funds, so far they have tended to invest in
things with a shorter return and quicker gain, like the
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next generation mobile, rather than graphene and new
sorts of renewable energy where perhaps it is harder
to understand how they can be commercialised. Do
you see that as a problem given the time scales
required for venture capitalists compared with the
need to invest in that sort of science and technology-
led innovation?
Katie Potts: Every fund manager has a pot of money
and the choice whether to buy this or that. It depends
on where the value is. One of the problems is that
equity valuations are so low that you think, “Why take
the risk that something may or may not succeed when
I can buy something that is already profitable?” I
consider that a real bottleneck. The problem is that the
UK equity market has been shrinking month by
month. If people do not have positive cash flows, they
do not have new money to put into new companies. I
think that is why there is such a logjam, which then
makes it too risky to invest early stage because you
do not know if you will get the follow-on funding to
take it to the next stage. I am quite exercised about it
because it is something I have done all my life and I
am worried that people do not realise that the situation
is so much worse than it has been.
Q53 Sarah Newton: To focus on that logjam, is that
driven by the need to get a return back into the fund
within a particular time scale or just lack of
preparedness to take on extra risk, because, as you
say, it is something that might take longer or is less
known to be able to be scaled up commercially within
a reasonable period?
Anne Glover: I agree with Katie. The difference is
that when I was doing early stage investing in the
mid-1990s there was a large number of growth capital
players who would continue to finance the company,
and there was the prospect of a public market after
that. Two of our companies are now public. For 16
years we were investors in Optos, which is in the Best
of British Manufacturing exhibition for the Olympics.
The reason that our time scales are short is that at the
moment, historically, until Stephen’s fund came along,
the availability of the next stage of capital was too
weak. Basically, we had to assume that we could work
only with our own and that made us much more risk
averse. If there was a ladder of financing that worked,
we would take the long-term risks and be happy
about it.
Katie Potts: I remember in 1996 and 1997 ARM, or
Acorn as it was then, coming to me desperate for
money. I put in £1 million when they needed it. I
doubt that ARM would get funded in the current
environment.
Anne Glover: It wouldn’t.
Matthew Bullock: I think there is a distinction
between the two examples you gave. If one were to
look at something like the energy market you talked
about, that is really an issue of distribution. How do
you break into the distribution in a way that enables
you to overcome the inherent conservatism of some
of the big utility companies or people like that? That
is where I would argue that procurement, pushing
some of the utility companies to procure new
technologies, would be a very good way of opening
their eyes to it. Graphene is different. Graphene is at
a state of development that is quite common in
technologies, which is what I would call really quite
inchoate. We do not know what we can use graphene
for. To pump equity into a graphene venture at this
stage when we do not know what we are going to sell
would be quite risky.
There is a company in Cambridge called Teradata,
which has been working with a range of spectrum that
people do not understand; it is kind of new. You spend
your time going out with soft contracts trying to
develop areas of the market without betting the whole
company on it. I refer to people like Government
Departments. I would cite the Ministry of Defence as
the largest single buyer of anything in the country, and
it has resolutely refused to deal with small companies;
it loves being locked in with the large suppliers, for
the reason that no doubt they will be arraigned by
the Public Accounts Committee if they do anything as
wasteful as spend money with small companies. But
go off with them and try to work out what you can
use the technology for. Take small bets until you are
clear what product you can do with it. I use the
philosophical expression “We rush to reify”; we try to
turn it into a product too soon before we know what
it will be used for. Sometimes you just have to get
into the market in this soft way and find where you
can get the applications.
To come back to Stephen’s point about skills, the two
gentlemen who discovered graphene are not the kind
of people who could take an investment of, say,
£5 million, invest it gently over a period and go
through a loss-making phase where, as the losses get
greater, the pressures on you as an entrepreneur get
bigger and bigger each month. You have to turn it
round, successfully market it and get it exactly into
the market at the right price against all your
competitors from a standing start. The whole point
about the soft contract is that it also educates the
entrepreneurs to become business people before they
start to take in equity finance from venture capitalists,
which, when it comes, is always very welcome.
Stephen Welton: I have perhaps a slightly different
perspective on it structurally. One of the reasons that
capital is provided over the short term is the way it is
raised. If you look at a classic venture capital fund or
a private equity fund, for that matter, it is normally
raised as a limited liability partnership with a 10-year
life, and it has a five to six-year investment period.
Then you have to liquidate the investments to give
them back to investors, so there is a structural way in
which capital is raised, which drives a need to achieve
an exit.
One of the things we are capitalising on is that we are
investing off our balance sheet. We can take whatever
time frame we think is appropriate, subject, clearly, to
our shareholders being supportive of the company.
That flexibility is incredibly useful because it enables
us to evaluate a business and what its cash flow is
going to be, going back to the initial question. It may
well be that in the short term you will be very cash
negative because you are expanding overseas or
investing in R and D. For many small companies, the
need to get a return quickly is a disincentive because
they do not feel confident enough in doing that. Often
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that leads to a deferral of investment, or they limit
their ambition or they sell the company.
Matthew Bullock: Can I make a point on bank
finance? We provided bank finance in Barclays for the
kind of venture I am talking about, not the one that
was running very quickly towards product
development and going down through the negative
loop. We lent very consistently. We had a loss rate of
one sixth of the bank’s average over a 10-year period,
and basically it was a very good business. We rotated
our finance because basically we were providing
working capital finance against contract payments
from creditworthy customers who we were satisfied
would be very sound debtors. We had to monitor
things very closely, which we did, but it was basically
quite good business for banking.
Katie Potts: On the comment you made about a lot of
companies that are started by people getting revenues
from services, that has been very prevalent in, say,
computer software where people provide services that
have generated cash for them to do other products that
they can then scale, but that is not so for deep
technology because you need product development;
you need to file patents and get designed into a
product. That takes much deeper capital, and that is
why there is a funding shortage.
Matthew Bullock: I beg to differ. The company I chair
now turns over 20 million and is the leading company
in cell culturing automation in the world. We started
off selling some contracts to Merck and Pfizer for a
particular system. We got paid by them, and we have
been self-financed throughout. That was a very big
product; they were sometimes $2 million to
$3 million sales.
Q54 Hywel Williams: The situation that you
describe seems to favour structurally the safe and the
status quo. Do you think this provides a further
problem for people enterprising in unlikely locations?
I should say that I am a Member of Parliament for
north-west Wales where we have some high-
technology companies, but I think there is a
substantial geographical problem there as well.
Anne Glover: There is but not as much as you think.
For example, I know a very interesting start-up in St
Asaph that came out of Daresbury. Their challenge is
in the medical technology field. They have been
funded by angels and venture capitalists because they
are so world leading in what they do. The challenge
is not location but getting profile and being willing to
travel to meet the investors sometimes, because the
investors are not in St Asaph, sadly. This particular
company attracted a chairman from Chicago in the
field because it is so high profile. However, they are
struggling with the next phase of fund raising, having
developed a product and just getting it ready for
FDA trial.
Q55 Hywel Williams: I should say I have a company
located in my constituency that was based in Los
Angeles, New Jersey and Llanberis.
Matthew Bullock: I think the whole issue of clusters
is that they are basically risk management systems;
they are ecosystems that help people to manage risks,
and that is why people go there.
Katie Potts: I do not agree. I have done exercises
going out to Stanford and MIT. Why have there been
such successful clusters in California and in the
Boston area? I think the simple reason is that there is
a whole generation of management who have been
trained and watched companies scale. It is not the
deep technology but the management and sales skills.
They feed on themselves.
Matthew Bullock: I wrote a history of the
development of technology financing in America,
which interviewed the original people who were
involved in the 1940s. They did start, I am afraid, with
very deep technology but typically came out and sold
services, and it was over a period of time. This is one
of the difficulties you have. If you go to California
and just visit, you get a snapshot of where they are
now; you do not see how they develop.
Katie Potts: I go five times a year.
Matthew Bullock: You have to go backwards, not
just currently.
Anne Glover: I agree, Matthew, but I think the world
has accelerated. This is the challenge. I know the
history rather well myself having lived it. It is very
informed and helpful, but the reality today is that
development activity is much faster than it was even
then. I do not necessarily mean in just mobile where
Instagram goes in nine weeks to $1 billion. In the life
sciences and deep technology the pace of change is
just phenomenal. The good news is that we can be
connected through the internet and by travel, and we
can create these distributed organisations. It has never
been so good to be an entrepreneur in a wonderful
place to live, as opposed to where you do not want to
live, as long as you have a global attitude and build
an organisation globally and travel for the needs,
whether it is customer contracts or finance. I am not
as worried about the regional problem. Clusters are
very helpful, and I agree with Katie that it is the
experience you get from clusters that matters, but it is
how we get the people connected to the growth
prospects that exist in the world today, which are well
beyond America, frankly.
Stephen Welton: I think that raises a very interesting
opportunity for all these small companies, which is to
harness the experience of very capable people who are
keen to work with smaller businesses, and that has no
boundaries. There are a lot of very talented people
who have made money; they become angel investors,
or they have experience in particular areas of
technology and science. If you can harness that
expertise with somebody who has got something very
innovative and the passion and ambition to grow, that
truly has a lot of potential. They should be thinking
globally. We are a small market. In Wales, Scotland
or anywhere else in the UK there is no lack of
innovation and entrepreneurship. I do not think that is
a nationalistic thing. If you have a good idea, you
should be able to attract capital and get people who
will in a way endorse that idea because they are
prepared to put their time and effort into it, which
in turn helps to bring capital. Capital will follow the
experience. If somebody has a brilliant idea but not
the proven track record to commercialise it and build
the sales network internationally, it is very difficult to
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convince somebody who will be more dispassionate
in looking at an opportunity that it is going to work.
Q56 Stephen Metcalfe: I want to explore a little
further the soft start-up model. One of you said that
ARM would not get funded in the current climate.
Would ARM have been able to start up using the soft
start model?
Matthew Bullock: To go back, ARM was founded out
of Acorn; Acorn was funded by bank finance against
the contract from the BBC. Its original contract was
from Bally, a slot machine manufacturer, for whom
they did some small electronic cards. It was a
development contract of exactly the sort I am talking
about. They then shot forward. As you know, the BBC
contract put them into a position where they did an
IPO, and some of that is history. ARM was project
no. 96 in their R and D portfolio. They had to go down
because they were bumped out into the real world by
the collapse of Acorn. They had to go off and get
licensing contracts to get themselves going.
Katie Potts: They raised money from other
investors—from public market shareholders.
Matthew Bullock: Did they?
Anne Glover: Yes, absolutely. There was substantial
funding. The IP licensing model is a difficult one to
get up and running. Interestingly, there is a small
listed company on the AIM market on the same
business model based in Los Angeles. They came into
the UK market because the market did understand the
licensing model and were able to get public capital.
They were not able to get private capital at that
particular time. It is a very difficult business model to
get off the ground because it relies so heavily on the
belief that these large companies will deal with a
small company, but it can be done. I do not think a
venture capitalist would finance it today.
Katie Potts: I flatter myself that I have been
significant on a global basis in investing in the IP
licensing model. I have invested in Ceva in Israel, in
ARM and in Imagination. I invested in a company
called Virage Logic in the States. That is a material
proportion. It has been a good model that I flatter
myself I spotted early. You have to invest in advance
of revenues, and it is a classic example of why it is a
capital-intensive business. What happened with
something like Imagination is that they sold a $2
million licence to Intel and a $2 million licence to
Texas Instruments. They had to design their
technology into their products, and then Texas
Instruments had to sell it to Apple, Nokia and so on.
There is another 18-month design cycle, so from
signing the licence to having products on the shelves
is a three-year period. That needs a lot of funding. It
is a classic of development costs occurring in advance
of revenues. It is absurd to think you can fund it out
of—
Anne Glover: Correct me if I am wrong, but you have
done it as a public market investor.
Katie Potts: We have done it as a public market
investor.
Anne Glover: That is the point.
Katie Potts: My concern is that in days gone by we
could do it with nine other people and there are not
nine other people to do it with any more, because
pension fund and insurance companies at their peak
in 1994 owned about 60% of the UK stock market.
They have now withered to less than 20%, and they
have been replaced by overseas investors, who do not
look at smaller companies and do not care about early
stage companies. That degree of shrinkage means cash
outflow. That is why people have also been too ready
to accept takeover bids. If you have redemptions, you
have to give some money back. They say, “Oh, great;
there’s a takeover bid. We can take some money out.”
It makes me weep having gone through the risk phase
and then finding that foreign companies buy them
too cheaply.
Matthew Bullock: The licence is not the soft model.
If you are going to do licensing, you have to produce
a product, so you are into all the heavy capital
expenditure. You do not have the marketing so much
because you have dealt with that issue, but you have
all the production expenditure, which is high risk.
That is not bankable.
Q57 Stephen Metcalfe: I suppose what I am trying
to get at is: what are the limitations of the soft model?
Matthew Bullock: It is slow.
Q58 Stephen Metcalfe: But is that the only
limitation? There is no technology that could not
develop under it. What I am concerned about is
whether there are particular sectors of technology that
will slip through the gaps because they do not fall into
either of the two main models.
Matthew Bullock: Pharmaceutical development is
very hard to do. You are doing something very
specific. It is possible to develop pharmaceutical tools
companies that get into areas and develop ideas that
you can then sell in the soft model. It is impossible to
do a drug development as a soft company. My view
about biotech is that a lot of people rushed to set up
silver bullet companies because the money was there.
They spent the money and often produced very little.
Mine is a more gradual approach—perhaps more a
farmer’s than hunter’s approach. I would come back
to the Cambridge area. Cambridge is predominantly
filled with soft, not hard, companies. When the money
is there it is great, but the money does come and it
does go.
One point on clusters, which I do think are important,
is that they are social systems. If the system suddenly
withers because there is no money, the skills go. When
Acorn and Sinclair both collapsed, we as a bank
worked very hard to try to make sure we did not have
a cataclysmic collapse. We allowed them to subside
so we did not fracture the social network that meant
everybody said, “Oh, gosh, British technology
companies are a mess. Don’t go near them.” We
sustained the Cambridge network across that period
so that people stayed in the game. It is very important
that people do not adopt strategies that tip them over
the edge. It is the valley of death. The reason it is
called that is that most people do not get across it.
Q59 Stephen Metcalfe: But was that out of the
goodness of your heart or because there was a
commercial imperative?
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Matthew Bullock: Commercial value. We were
making money as a bank out of doing lending of this
sort and we thought it was worthwhile trying to
sustain the system.
Anne Glover: You asked whether there were
businesses being missed by either of these approaches.
I think there are. I would argue that it is not so much
businesses as opportunities that get missed; in other
words, we are rather good at starting companies, or
even rather good at getting them up to a certain small
scale, but the financial ecosystem as it is currently—I
am not talking about what it was—does not
necessarily encourage those companies to stay as the
global leader in their space. There is a combination of
factors happening here, which is a little bit of the
public market point that Katie is bringing in, which is
that, even if you do get listed, you are not able to
scale because there is not the support, the price is not
as competitive, and you cannot make acquisitions.
That means it is rather difficult for us to maintain a
leadership position. So it is not just the valley of
death; it is taking those opportunities and creating
heroes out of our entrepreneurs. I was saddened when
Mike Lynch sold his company to HP. It was 8.6
billion. That was a venture-backed start-up in the mid-
1990s. It required venture capital because he was a
very ambitious leader who went on an acquisition
spree.
Katie Potts: We put money in before there was
profitability in the public market.
Anne Glover: That happened in the mid-1990s; it is
not happening today. We can look back on our laurels.
I am worried about right now.
Stephen Welton: That is an excellent point. For the
start-up and innovation phases to work you have to
have the next stage on the next rung of the ladder,
because it provides the liquidity and returns to the
early investors and entrepreneurs can fund more start-
ups. When people talk about equity gaps, there is
more than one; there are multiple equity gaps. It will
always be hardest to start up a company from scratch.
A lot of companies fail because they do not have
commercial viability, but a lot of companies are then
getting to the first phase where they have a
commercial product and sales; they have gone through
proof of concept funding, and they then need to scale
up. It is a completely different set of challenges.
Then there are challenges of management as well as
product commercialisation, and the amounts of money
are considerably greater. They are going to go beyond
the realms of what either individuals or venture
capitalists can fund. That is where you need growth
capital. The returns for growth capital are clearly
lower because you are not looking for a home run;
you are looking to try to build something that has
already got a degree of substance. The more you can
make that part of the market work, the more it will
reinforce the financing for start-ups. As businesses get
bigger, it becomes easier to raise capital.
Katie Potts: I have raised two venture capital limited
partnerships without any tax subsidising from
institutional investors. Regularly I say at my venture
meeting that I just do not get why we should take the
risk of investing in an early stage company that needs
10 million to get to revenues when we can buy things
cheaply in the quoted market that are already
profitable. Looking investors in the face, I say it is
better for them to put money into the quoted market.
Stephen Welton: Maybe that shows there are
opportunities in the quoted market, so for the 10
million venture start-up you have got to find
something more compelling to do that. I think the fact
you can raise money for businesses that are more
mature in and of itself is not a bad thing. What we
want to do is expand the number of growing medium-
size companies. Based on the research we have done,
there are 5,000 companies currently in the UK turning
over between 2.5 million and 100 million, growing in
excess of 10% per annum.1
They are not growing at 50% compound per annum,
but they have grown well. These are the businesses
which can go from 2.5 million, 5 million, 10 million
to 20 million. The economic effects of that are
dramatic in terms of employment, tax revenues and
everything else, but that market needs funding from
investors and banks. If that market works well, it does
not necessarily mean that the start-up end of the
market is working well, but it will clearly be a healthy
part of the ecosystem, because the more this
continuum of finance is proving to be successful the
more it will help all companies.
Anne Glover: I think we are hearing a theme here,
which is public growth and venture. We are all
suffering from a lack of local capital interested in
taking risk. All three of us are trying to raise capital
in today’s market. Stephen, you have already done it,
but through rather unusual means. It is the lack of
appetite for risk at any of these stages that is present
in today’s financial markets that we have to address.
Q60 Hywel Williams: Do the Government do
enough to encourage serial entrepreneurship? We have
heard, for example, that failure is less stigmatised in
the United States than, say, in the UK. Is initial failure
too stigmatised in this country to promote serial
entrepreneurship?
Stephen Welton: I would pick up the point that Anne
made. I think the entrepreneurs who create successful
businesses really are heroes, and they are local heroes
because they start in all different parts of the country.
We do need to have Government as well as the media
promoting entrepreneurial activity. We want to get
behind entrepreneurs. These are the people who have
the ideas, courage and ambition to set up businesses.
We should focus more on what it is that makes an
entrepreneur successful. Often failure may be that you
are just not realising your potential. Sometimes the
best advice to an entrepreneur is, “This particular idea
isn’t going to work. You’ve got a lot of potential as
an individual, but try something different.”
Maybe there is an element of serendipity in doing that,
but, focusing right now on where the economy is,
there is quite clearly a lack of investment. That goes
right across the cycle, and that will be true of the
largest as well as the smallest companies in the
country and is reflected by the fact that companies are
hoarding cash. If you look at the SME sector now,
1 The witness later stated that there are 4,000 companies
currently in the UK turning over between 2.5 million and
100 million, growing in excess of 10% per annum.
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they are net depositors with the banking system,
which is absurd. You have small companies
effectively lending money to the banks because they
are not investing. I think it reflects a culture now that
there is an unwillingness to invest, and partly that is
to do with confidence, but it partly reflects the need to
promote entrepreneurship. Government can definitely
play a part there.
Katie Potts: At a higher level it is completely
bewildering to me that pension funds are happy to buy
Government bonds that yield negative returns in real
terms rather than own equities that can yield 3% or
4%. The stock market is incredibly cheap relative to
bonds. I do not understand actuaries driving
allocation.
Anne Glover: I would like to give you a piece of good
news. I think that problem is solved and you do not
need to worry about serial entrepreneurs any more. In
our latest fund 70% of the people we back are serial
entrepreneurs, not all of whom have been successful.
I would not say that the cultural challenge that I
encountered when I came back has gone completely
from every pocket, but it has largely gone.
Entrepreneurs’ relief has been very helpful in
attracting people back into that risk-taking mode. It is
not the people that we are missing.
Matthew Bullock: I would say it depends on how you
fail. There are good and bad failures, and people
watch that. If you fail honourably, by and large people
say, “Okay; you’ve tried your hardest and it didn’t
work out. That’s fine.” If you commit fraud and burn
people, they remember it.
Q61 Chair: That has always been the clear case in
the US. There is an absolute distinction between the
person who takes somebody for a ride and the person
who goes down honourably. Do you think that is more
the case here now?
Matthew Bullock: I do. I agree with Anne that we
have come on a long way, and people can have
honourable failures and start again with a different
idea. To be clear, the truth is that we have had an
economy that has been pumped up on debt steroids
for a long time, and, as we withdraw from that, it is
going to be enormously painful for a very long time.
There is going to be very little cash. In the case of the
Biosystems company that I chair we have managed to
raise a bank loan. It took us a long time when we
thought we were a pretty successful company, and we
just went through a great moil with the banks. They
are all going to suffer while the banks go through their
own de-gearing nightmares.
Q62 Hywel Williams: This is a comment rather than
a question, but I think it is counter-intuitive. It was
picking winners but is picking losers, and there is
some mileage in that.
Matthew Bullock: To be clear, if an entrepreneur can
get venture and equity capital, it is by far the best
route, but it is not very frequently available. Is it 4%
of businesses who go for venture capital actually get
finance, so 96% do not get equity finance of one sort
or another? Are we going to say to them that they
cannot get into the business? As a banker I was very
happy to deal with the 96%. I was very happy for the
4%; it was terrific, but let’s keep those percentages in
mind. There are 96% of people who do not get venture
capital who could still be in the business, and those
are the ones who could grow slower businesses but
build up their skills. To come back to Stephen’s point,
growth capital is more frequently available than start-
up capital. My experience is getting people to the base
where they have got a business, got the experience
and know their markets, which is very important. In
this country’s approach, as Government, you are the
biggest customer in Government; you have the most
technical demands; you have an enormous range of
things that you would like to see developed. We
absolutely do not use it as an engine of growth; it is
absolutely absurd.
Q63 Roger Williams: I have just had a message to
say we are back in recession, or a technical recession,
so perhaps the Government will focus on these things
a little more. Banks are not really held in very high
esteem in this country at the moment. Do you think
there is a lever there that Government could use in
some way to encourage banks to be a bit more
generous—that is the wrong word—or to invest with
greater passion in some of the businesses we are
talking about?
Stephen Welton: We have to remember that banks are
there to lend money and therefore they have to be
repaid. It is a pretty old-fashioned idea. To pick up
Matthew’s idea, we have gone through the last 20 or
30 years with an explosion of debt finance, whether
that is for companies, individuals or countries. One
can see the consequences of that now. What we
absolutely need is a banking system that is working
very well but is prudent, because to lend too much
money especially to small companies too early, to go
back to the point about cash flow, will lead to
inevitable consequences and the business will fail.
What is important is to make sure businesses are
soundly capitalised and they raise the right type of
finance. If they are a small growing company, they
can raise invoice discounting on the back of their
debtors. There is a continuous debate about whether
banks are not lending or companies are not borrowing.
There is probably an element of both. There is a need
to get the banks to lend, but companies need to be
prepared to borrow and be happy with the terms on
which they are raising that debt.
Part of the answer here is to look at the whole picture.
From our standpoint, when we invest in companies
we put capital on to the balance sheet; we strengthen
the management by putting people on to the board;
we review the financial and strategic plans; we
challenge the management. All of those things are a
good thing. We turn round to the banks and say,
“Given all of that, this must be more creditworthy.
Therefore, you should lend more because it is a
stronger capital base.” In my mind that is a much
more practical way of trying to address this. We need
the banks to be lending but to make sure that
borrowers understand how to borrow. How do you
approach a bank? What is a bank looking for? I do
not think that in terms of what we are talking about
here for start-ups you will get banks lending large
sums of money to businesses that have no proven cash
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flow, because then it is not a loan they are making; it
is an investment, and they need to recognise it as such.
Katie Potts: Primarily, the banks should fund the
growth in working capital for a growing business, i.e.
to fund stocks and debtors, whereas equity is needed
to fund development costs.
Matthew Bullock: If you go down the cash flow
profile of a start-up, you will start up with
development expenditure, which is people’s
equipment, laboratory space and so forth. Then, if you
stabilise the product, you will start to invest in
machinery to produce the product, and you will have
to start to invest in marketing and distribution. To go
back to what I said in my evidence, IBM’s rule was
that it was one, three, 10: one to stabilise the product;
three to get it ready and manufactured; and 10 to
market it. For some technologies it would be bigger
than 10. If you are a small company, you will have to
find 13 units, as it were, before you even start to get
a sale.
You do not know whether you are going to get a buyer
if you go down the speculative route, which is the
hard company route. It is very hard for a bank to say,
“I’m going to invest all that money in the hope that
you have judged this brand new market correctly.” We
turned it round the other way, which was to say, “Do
you have a sale? Do you have somebody who will
actually buy something from you?” Typically, they
were large lead customers. Then we would say, “Get
a contract from that person and we will then finance
it.” He did not have any of the major manufacturing
expenditure because typically it was a softer start; he
did not have the marketing expenditure; and he was
therefore able to start the business at a much lower
figure. That is bankable. The kind of company that
goes off down product development and then takes
the product to market has to have equity finance.
Banks cannot touch that and deal with that.
Katie Potts: Why can we not require pension funds to
have an allocation in their portfolios to equities or UK
or European smaller company equities? It would not
cost anything.
Anne Glover: As to our portfolio, those who are
qualifying for bank loans can find them. It is the
equity capital that is missing in today’s environment;
it is the follow-on equity capital and the exit equity
capital in the capital markets.
Q64 Roger Williams: It is unrealistic to expect that
banks would change their criteria against which they
would lend to these companies.
Matthew Bullock: Although it is tighter because
basically there is less money around, period, banks are
continuing to lend in this way. I have now left
Barclays, and I do not think they have the same focus
team they had when I was there. As a way of doing
the business, it is still possible to get that kind of
finance, but it is against many other priorities where
people are clamouring for finance. As a bank it
requires quite a commitment to do it, and I do not see
that at the present time.
Q65 Roger Williams: Over the years many
organisations have been charged by Government to
lend in to SMEs. In hindsight, some of those have
seemed to be quite successful. I think 3i was set up in
1994 or something like that.
Matthew Bullock: In 1946, after the Macmillan gap.
Q66 Roger Williams: So in a way we are not dealing
with a new issue.
Anne Glover: They called it loans but it was actually
equity that they provided.
Matthew Bullock: They used to provide convertible
mortgages, so if they gave you a long-term loan and
took the freeholds of your property they would take
equity in your company. When I was starting in
finance in Cambridge that was what 3i offered. From
a bank shareholder point of view, it did not make a
very good return for a long time; I think it made below
10% return. In the end, banks were quite happy to get
rid of you.
Stephen Welton: I think that is too much of a
simplification. If you look at the creation of ICFC
after the second world war, that was created on the
back of the Macmillan report, which he worked on
with Keynes to look at small companies. This is a
long-standing problem, and it will be here in another
70 years. Small companies will always find it harder
to raise capital. ICFC was very innovative for its time;
it effectively created the venture capital industry in
this country. A lot of people who worked at ICFC,
which went on to become 3i, now populate the private
equity industry and that model was replicated across
the world, so it clearly worked. What happened over
time is that the very gap ICFC was set up to address,
which was small amounts of capital, maybe by way
of loan capital, preference shares or ordinary shares,
moved away from its roots, so it became a private
equity firm operating on a global basis doing what
other private equity firms are doing. I am not saying
that is wrong; it is just a natural progression that it
made as a company. In doing that it moved away from
providing small amounts of capital to lots of
companies.
Matthew is right in the sense that the return from
investing in lots of small companies is not as great as
investing tens of millions in a few companies and
having some good successes. I suppose the capitalist
system works on the basis that capital will always go
to the highest returning asset classes, and buy-outs and
private equity have performed very well. They are not
performing as well now because the leverage in the
system is reducing. If I look at what we are trying to
do, essentially it is to go back to where ICFC started.
We are providing between £2 million and £10 million
worth of growth capital to small companies. It is
harder to do that because we need to have a lot of
people right across the country to talk to lots of
companies, but our own experience in a few months
shows that there are lots of companies who are
interested to talk to us because we are providing
something they cannot get anywhere else. There is
definitely a structural gap here and the challenge is to
fill it, recognising that it is only part of the solution.
That goes back to the point we are all making that
there is a continuous range of issues here.
Q67 Roger Williams: You would say that the
business growth fund that you operate at the moment
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is the current institution that takes the place of ICFC
or 3i.
Stephen Welton: We have some similar historical
origins in terms of how we have come about out of a
recession with the support of the banks encouraged by
the Government. There are direct parallels there, but
it would be naive to think that one institution alone
can plug a gap. We can certainly make a big impact
on that. The much bigger effect will be how we work
with the banks generally and the banking system
generally, because, if banks are lending more to SMEs
and SMEs are borrowing more, the economy will be
healthier. One of the things we are tracking now is the
population of companies that are growing at 10% per
annum. It was 7,000 companies three years ago; it is
now 4,000 companies. A very simple litmus test for
us is that on a quarter-by-quarter basis, if those 4,000
become 5,000 or 6,000, the economy must be
healthier. It is no more scientific than that, and I do
not think it needs to be. It is a reflection of the fact
that there is growth at the bottom of the economy.
Q68 Stephen Mosley: On the business loan fund,
what sort of metrics are you using to determine
whether or not you are successful?
Stephen Welton: Following on from the previous
comment, this is a structural gap. If we are here in 10
years I think we have been successful. To be here in
10 years we have got a commercially viable business,
because we have shareholders, who are not running a
charity and expect to get a return on their capital. In
order for us to be commercially successful, we have
to back businesses that are in turn going to grow and
be very successful. We are very confident that there
are a lot of companies in this environment, even if we
are back in recession, that are growing.
Maybe entrepreneurs are by nature schizophrenic
individuals. The companies we talk to are almost
bashful about telling us they are growing. It is almost
as if they think they are tempting fate by saying,
“We’re growing; maybe we’ll stop growing, or maybe
somebody will come and clobber us.” There is a lot
of enterprise and innovation. These are businesses that
will be able to capitalise on the weak environment we
are in. A lot of the successful companies you are
going to see in five and 10 years will be growing right
now. They will be the ones that are taking advantage
of what is a different view of the world. When the
economy is growing and every company is growing,
it looks easy to make a business successful. It is not.
The really good quality companies of the next five to
10 years are being created now, so we are very
positive, frankly. In a way it is self-selecting, because
the companies that come to us are by definition more
ambitious because they are talking to us about raising
capital, but we have not seen anything to suggest that
it is a very small segment and that companies are not
prepared to sell a stake in their business if they think
they get something for that. It has to be about more
than just money, because I think you will hear a
consistent theme that for small companies to succeed
they need a range of different things. Expertise and
help are as important as the money, because money
invested in the wrong area will clearly not make a
return.
Katie Potts: On a brighter note, I have about 120
investments in UK tech companies and there is not a
recession. I am old enough to have dealt with
recessions in the past. In 2002 every conversation
was, “What’s the burn rate? How many people are
you making redundant?” It is not that environment at
all. Now we hear, “We cannot get the right skills; it is
hard to recruit.”
Anne Glover: It is not a global recession in tech; I
agree with that.
Katie Potts: It isn’t a global recession in tech.
Anne Glover: No; it is not a global recession in tech;
tech is doing very well.
Katie Potts: But there is a shortage of capital for new
start-ups.
Matthew Bullock: We have come quite a long way;
we are not back to the 1940s, as it were. The
management community—people who have been
involved with companies and have that expertise—
and the simple density of angels is much greater than
it was. Companies are growing, and I would echo the
comment that it is not in a recession there. It is clear
that the banks are more difficult to deal with than they
were. If I look at the 1990s when the Centre for
Business Research did continuous studies of the
availability of finance, there is no question that finance
became more freely available to small companies. It
dropped down as a barrier to growth versus
availability of skills. It has come up again. Is it going
to be insuperable? No; it is just difficult. On both the
bank and equity side it is more difficult. Because of
our experience in the last 30 years we have built a
much more robust entrepreneurial community that can
cope with that, but it is important we do not think
there is only one way to start a company. There are
many ways to start a company, and we have an active
start-up community that is continuing to form
companies, and when the equity comes back
undoubtedly they will be there to take advantage of it.
Q69 Stephen Mosley: One issue that has cropped up
several times in the discussion has been the
availability of pension fund money. The regulators are
encouraging pension funds to invest in things like
bonds, which are well understood; there is plenty of
information about them; they can make predictions as
to their future earnings, growth and so on. When it
comes to small equities, you do not have that
information. What sort of information is needed? Is
there any way that we can improve the information
that you get on companies in AIM or before that?
Anne Glover: That is the fallacy; it is about taking
risk and allocating a small proportion of a very large
capital base to long-term risk equities. You could do
a statistical analysis on history, but even that would
not tell you very much because it is about the future.
Katie Potts: The frustration is that the long-term
records show that small companies have out-
performed. One of the problems of the abolition of
defined benefit pension schemes to defined
contribution is that corporates do not then have a
vested interest in maximising the return; they just
want not to get into trouble.
Matthew Bullock: I think that is true. The
environment for trustees coming on to pension fund
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trustee boards is to minimise risk. Companies
themselves have to put in large amounts of capital so
they do not want to make any mistakes, and the
trustees are told in the regulatory environment, “Your
duty is to make sure that you take no risk.”
Anne Glover: It is a real problem. Only yesterday I
was sent through the data on what is happening in
venture. I found it fascinating that Katie came up with
exactly the same figure for public markets. Less than
20% of the capital provided to venture now comes
from major financial institutions: pension funds,
insurance companies and banks. All of them have
withdrawn from this risk category because of
regulation. Much of it is at the European level; you
have Solvency II for the insurance companies, Basel
III for the banks, and now you have the EU Pension
Funds Directive coming through as well. Then you
compound it with the asset allocators basically saying,
“Go for bonds instead of equities”, and our savings
industry—this group of equity providers who are
managed institutionally—do not support the equity
culture that is required to build high-growth
companies. We have to completely reinvent where we
go to raise our capital—from family offices and
individuals.
Katie Potts: We used to hide behind the pension funds
and insurance companies because they were
responsible investors with good corporate governance
and kept pay under control. Why has pay gone out of
control in the private sector? It is because pension
funds are not there.
Anne Glover: We need to figure out how to address
that issue for the whole chain to work.
Matthew Bullock: And the love of trading. To take
the banks, I have to say that the big shift in the
financial sector is from “invest and hold” to trading.
Q70 Stephen Mosley: As MPs we get constituents
coming to us with good business ideas. Sometimes
they are running their own businesses and they are
looking for finance. We also get people who have
either sold a business or, in many cases, have very
substantial sums of money they want to invest. They
say, “Do you know how we can get more funding or
how we can invest some money we have got?” In both
those situations what would you advise? Can people
with money come to guys like you and say, “I’ve got
x million to invest”?
Anne Glover: Yes, they can.
Stephen Welton: I tell you how we address that. We
are fortunate that we have a substantial capital base,
so we do not need capital. What we definitely value,
though, is expertise. We have private investors; they
could be angel investors or exactly the sort of
individuals you are talking to. They have sold a
business and have a lot of capital to invest. We are
very keen to work alongside them. If a company needs
£3 million and we have a private investor who wants
to put in £1 million, we will invest £2 million. We do
not mind how much we are investing. We would
prefer the latter because we get the benefit of
somebody who, in the great phrase, has got skin in
the game. They have money in the company and take
it more seriously; they commit more time to it. That
is a very positive thing.
How you get pension funds to invest is a different
issue. As to how you get private individuals with
money to invest, I do not think that is a problem. In
my experience, most individuals who have made a lot
of capital are quite keen to reinvest it. They like
working with small companies because they
understand it; they think it is quite fun and enjoyable,
and clearly tax policy is trying to encourage that as
well. I do not think that is a problem area. As Anne
said, there are enough serial entrepreneurs out there,
so if there are issues they are focused more on the
institution than the individual.
Katie Potts: I would say they should go to the British
Venture Capital Association for the list of people who
invest in various companies.
Q71 Graham Stringer: In answer to previous
questions you defined a number of issues that are
important to successful companies, but when you look
at where the UK Innovation Investment Fund has
invested, approximately half of its investments have
gone overseas. Why is that? What are we not doing
as well as the Germans, who take half of that half for
their investment? What are they doing better than us?
Why are we not getting more?
Katie Potts: From my perspective, Germany is not
innovative. Germany has been fantastic at making its
big companies even bigger, but there is not innovation
in Germany. The start-ups are in Israel and America.
Anne Glover: I do not know the answer to that. The
decision making on some of them has been
extraordinary. I agree with Katie that it is not
particularly because Germany is more innovative.
Katie Potts: There are successful first generation
businesses in Germany.
Stephen Welton: As to where the Germans have
clearly been successful, they have coined this phrase
that everybody trots out about “Mittelstadt”.
Everybody talks in hallowed terms about the
“Mittelstadt”, which is the backbone of the German
economy—that is, medium-size and small companies
up to companies like Bosch and huge global
engineering companies. What the Germans have
shown they can do very well is build a business for
generation to generation, so there are more examples
of family companies going through generations than
in this country or the US, where there is perhaps a
tendency to sell and capitalise on the gain you have
got. I think they are very good at harnessing
Government and exporting very well. They use their
commercial power as a country to support their small
and medium-size businesses. That is something we
definitely should be doing, going back to what
Government can do here. Trade missions focused on
small companies, technology and innovation are
clearly a very good thing. The likes of Rolls-Royce
are fantastic businesses, but look at all the suppliers
to Rolls-Royce or all our automotive companies. The
Germans are very good at getting behind those sorts
of small businesses.
Matthew Bullock: The German model is a real puzzle.
Even though we have done a lot of research on
different industrial policies, we do not understand
clearly how the German economy works in the
Mittelstadt. One thing that I think is clear from the
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research we have done is that the role of the trade
associations has turned out to be more important.
They create, if you like, communities in sectors
whereby the large companies tend to have a clearer
relationship with their small suppliers and place
contracts with them. I would say that is very non-
existent here. When I was in the bank I used to deal
with GEC, Racal and people like that. The bank had
a 40% market share. We knew all these small
technology companies. I used to say to them, “Are
you interested in seeing these small technology
companies? You might find something of interest.”
One finance director said to me, “Why should I pay
any interest? I’ll just wait until the banks put them
into receivership and then pick them up cheap.”
Anne Glover: The German venture industry is
suffering in exactly the same way as the UK and a
number of countries, so it is not isolated at all, but
one thing it does have which we do not is a big private
wealth management industry. There are lots of
German doctors and dentists who will add capital to
funds. This is entirely speculation. I know that the
innovation fund has always required matching
investment, which it should do, so it is entirely
appropriate; but the German VCs I know have been
able to raise money from those domestic sources more
easily than the equivalent domestic sources available
in the UK.
Q72 Graham Stringer: I have diverted my own
question on to Germany, whereas I was interested, if
not more so, in what this country and the regions,
which again do not do as well as the south-east, could
do better to attract funds. What we are interested in
as a Committee at the end of the day is what
recommendations we can make to Government to help
small businesses in this country do better. What is
missing?
Matthew Bullock: One of the things that we have
done in the eastern region is set up an SBIR
programme in the health sector. This was done when
we had EEDA, and obviously such entities no longer
exist. It has been quite interesting. I met a company
that had got one of these contracts. It is producing an
innovative product that has some legs on it; it is a
device. That was done at a regional level. It was
capable of being done at a regional level, and it is
producing a number of companies that have got into
business as a result.
To go back to Germany, Germans are very regionally
as well as sectorially oriented. They find it easier to
put together their thinking at regional level than we
do in this country, where everything is very
metropolitan and goes straight up to London.
Stephen Welton: As a very recent experience, we set
up in May of last year. One thing that is absolutely
critical is not to be a London-centric organisation,
dealing with the UK from London. Obviously, the
south-east is an important part of the economy, but it
is a part of the economy. The thing we were adamant
to do right from the beginning was to be regional. You
need to be local to the companies that you are talking
to. There is a lot of expertise around the country,
which was why we set up six offices around the
country very rapidly. The thing we found hardest to
do, which was a surprise to me, was that, when we
started to open offices and expand, the professional
services communities in some of the regional cities in
the country—that could be in Bristol or Manchester—
had diverted their own resources away from helping
small companies to raise capital because it was not
very profitable. We need to be reinvesting in the
professional services communities around the country
because they are important. The accountants and
lawyers who deal with small companies are often the
source of advice and mentoring to get them to a bank
or investor. That will definitely help in promoting
things regionally and making sure you have
expertise—and, critically, that you have real
accountability and decision making locally.
If the banking industry have a challenge, it is that they
have centralised their model so much that the credit
committees are all-powerful, and a lot of the local
credit officers in the regions do not necessarily know
what the outcome of the credit committee is going to
be. That is not empowering the people on the ground,
who have to make decisions that are pretty
fundamental. Do you trust the people you are
backing? The judgment of people, understanding how
they sit within their local community—all these very
old-fashioned business principles—are critically
important, and we need to do more to invest in that. I
think the banks are taking that on board just in terms
of the qualifications of the people working within
them to make sure their regional centres have more
power than they used to, so it is going to regional
credit committees rather than national credit
committees. Things like that, which are perhaps
unseen, will start to make a difference.
Anne Glover: To dovetail a couple of ideas that have
come up in this conversation, local authority pension
funds could become a major player in the provision
of equity capital for SMEs across the UK. They
probably need to be co-ordinated through a fund-of-
fund programme and incentivised to do it as opposed
to being told to do it. It would be possible to create a
win-win situation if you created a fund-of-fund type
of activity, with the local authority pension funds
getting a benefit from being asked to participate in
some way if the Government could figure it out or
perhaps create that on the fly. That would be a way of
involving local authorities.
Chair: Thank you very much for a very informative
session. I have let it overrun a few minutes because it
was a very useful session and we are extremely
grateful for your time. I know there will be some
follow-up questions. I have had to stop colleagues
pushing harder. Thank you very much for the session.
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Examination of Witnesses
Witnesses: Dr Richard Worswick, Chairman, Colbalt Light Systems Ltd, Dr Peter Dean, founder and
Chairman, Cambio Ltd, and independent consultant, inventor and entrepreneur, and Dr Trevor Francis,
Technical Director, Byotrol Technology Ltd, gave evidence.
Q73 Chair: Good morning, gentlemen. Thank you
very much for coming. I know you were listening to
the previous session. Would you kindly introduce
yourselves for the record?
Dr Dean: I am Peter Dean from Cambridge.
Dr Worswick: I am Richard Worswick. I am currently
non-executive chairman of a small company called
Cobalt Light Systems Ltd, which has developed
sophisticated instruments mainly for use in the
pharmaceutical industry and for airport security, using
novel Raman spectroscopy, which arose from work at
the Rutherford Appleton Laboratory, part of the
STFC. I was previously the Government Chemist and
chief executive of the Laboratory of the Government
Chemist. In 1996 I led a management buy-out to
purchase the laboratory as part of a competitive
privatisation. As chief executive of the company I
formed, I developed LGC into an international
company with laboratories and offices in more than
20 countries. In recognition of LGC’s achievement I
was awarded Entrepreneur of the Year in 2003. I
should emphasise that I finally ended my involvement
with LGC a couple of years ago when the company
was sold to Bridgepoint. During my career I have had
experience of both the private and public sectors and
small and large companies.
Dr Francis: I am Trevor Francis. I am director of
technology for an SME called Byotrol based in
Daresbury. We are an AIM-listed company employing
27 people. Our technology is an anti-microbial
technology that is applicable for hygiene disinfection.
We also have a consumer division where our products
are currently found in Boots, Tesco and other
locations.
Q74 Chair: I can see Daresbury from my garden.
Welcome to all three of you. You are here to tell us
about your experience, if you have had it, of the valley
of death. Have you been there? When did you realise
you were there?
Dr Worswick: In my career financing has never been
straightforward, but I have to confess that I have been
very fortunate in not having experienced the valley of
death. It was a term with which I was not particularly
familiar until your inquiry. I should emphasise that my
experience at LGC was quite different from my
current experience with a very small company, Cobalt
Light Systems. LGC is a science-based service
company and grew from a turnover of about £14
million when I took it over to well over 100 million
in less than 10 years. It now employs well over 1,000
people in many countries.
I think the toughest part was the initial growth. There
are certain barriers when a company grows. Getting
to £50 million for us was a huge achievement. During
that period most of the expansion was funded from
revenue. To pick up a point made at an earlier session,
early sales—particularly of services—enabled us to
generate a good cash flow, even though we were not
particularly profitable. We used that cash flow to
invest in new ventures. We also got bank loans,
particularly for some acquisitions, both in the UK and
Europe, but the 1990s was a period when it was
relatively easy to get such loans. We also received
some modest regional development funding when we
wanted to expand in the north-west, which was
psychologically quite important.
Q75 Chair: Was that from the RDA?
Dr Worswick: That was from the RDA, yes. In
Germany we received some generous capital
allowances from the federal state of Brandenburg
because we had a company just south of Berlin that
was very innovative. Their allowances and the
relationship with the local government there was one
of the reasons we decided to invest more in that area
in Germany.
Q76 Chair: Before I ask the others to respond, in
both the UK and Germany the availability of funds
through a regional government structure made a
difference to you.
Dr Worswick: It made a small difference. I do not
think it would have changed our decision, but in the
north-west it enabled us to take on more people more
quickly than we would have been able to do. In
Brandenburg we decided to invest quite heavily in
equipment. We got very good grants. I think it was
50% of capital on instruments and so on. That was
very attractive at a time when we were not flush for
cash. That reinforced our decision about that area.
There were other reasons why we wanted to expand
in Germany, but that was one of the factors.
Coming to equity finance, for LGC our initial investor
was 3i, but their cash input was relatively small. Once
we got to £50 million we could afford much more in
the way of infrastructure, business development and
so on, and in 2004 we brought in a new investor,
Legal & General Ventures, and got a lot of capital and
bank finance which we could use for a further phase
of growth.
Just to finish, and I don’t want to hog the
conversation, Cobalt is very different. Cobalt Light
Systems is a small company making a liquid bottle
scanner that can be used at airports. It scans a bottle
in four seconds and tells you whether there is an
explosive, or something like it, inside it. It got going
as a company only three years ago. I joined as
chairman in March 2009, and the chief executive, Paul
Loeffen, was appointed shortly after. Current sales are
only about £1 million per annum, although we have
plans for a very rapid expansion over the next
18 months. The initial investment of £700,000 came
from Oxford Technology Enterprise Capital Fund, a
Government-backed seed fund, Rainbow Seed Fund,
a few private individuals, and the Research Council,
STFC, put in money. We have since borrowed money
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from HSBC for working capital, which I can talk
about.
Dr Francis: We are in the valley of death. As a small
technology company. We went a different route. The
founder of Byotrol is Stephen Falder. His family
owned a paint company in Manchester. They put
family money into it initially and got some additional
seed money. In 2005 they went to AIM and got AIM-
listed on the basis that there was no alternative source
of income for them. That has taken them down a route
where they need to commit to sales targets and
delivery against sales revenue at a time when the
company is looking to try and expand its technology
base and build its capability. As we speak, we are
trying to balance our cash flow against our sales
commitments, identify new markets in which to sell
and, equally, to try to find sources of revenue to fund
new technology programmes that we would dearly
like to run.
Q77 Chair: Are you seeing light at the end of the
tunnel?
Dr Francis: We are in a joint development agreement
with a Fortune 150 company. That joint development
agreement has had an extension of six months to this
summer while it carries out some market concept
work. If that comes through, we will see light at the
end of the tunnel; if it does not come through, then
we will see a longer tunnel, I suspect.
Dr Dean: One of the biggest problems I have seen
over the years, which is a stumbling block within the
valley, is the appalling attitude in our universities
towards patenting. In the UK we suffer from having a
patent system that is not a level playing field with the
rest of the world. In a paper which I have prepared
for you I make the point that Japan, USA and Canada
all have grace periods that we do not have. I know the
European collective system is improving and is up for
further improvement, but in the British university
context one of the difficulties is that there is no patent
strategy to guide the inventor through the process.
I think one of the reasons why your colleagues picked
me out was the invention to do with diabetic
management. I was happy enough to get asked to
solve the problem in the ’80s. We produced a patent,
which the university did not support financially in any
way. The company involved, which was Canadian,
suggested that they take all the patent costs and run
the patent for us, which was fine. At the end of six
months they pulled out; they said they had changed
their objectives and were doing something else. As a
result, the university of Liverpool was asked to
support the patent through its foreign filings and
whatever. It refused to do that, and the patent was sold
to the USA for a pittance. The USA completed the
patent. There are 283 million diabetics in the world.
That university of Liverpool test is used pretty much
throughout the world, but there is no royalty coming
to this country because of the failure to strategise the
patent process. To me, that is one of the stumbling
blocks within the valley.
I have had seven companies start up with me. The one
I am in currently has much more serious problems
within the valley. We are getting in enormous
revenues from the States with crucifixion on the time
it takes to clear cheques, would you believe? It can
take three or four months, and we are expected to fund
that cash flow differential, in an outrageous manner in
my opinion. This is because the international banking
community insists on protection against money-
laundering, blah, blah. It is all perfectly valid, but,
believe me, when you are in the valley, it is hell and
I wish that we could do something about it. If
Government wish to do something about the situation
immediately to create a level playing field, it would
be to improve our patent system so that we enjoy the
same grace periods or at least a level playing field.
Dr Francis: To comment on Peter’s view on patents,
I recently sat as a panel member at the R and D
Society, which reviewed Sir Tim Wilson’s business-
university collaboration paper. The vice-chancellor of
Cambridge, Professor Borysiewicz, made a very
similar statement about the ownership of patents
within universities. The patent process definitely
needs looking at for the particular reason that
universities may well come up with technical know-
how; they identify it and file it as a patent. The
complication is that to maintain patents becomes very
expensive. We spend in the region of £500,000 every
two years simply protecting our patents around the
world. When you are a small £2 million or £3 million
business, that is an incredible amount of cash flow that
you need to manage. However, we are a technology
company and we thrive on new technology and
patents.
The difficulty is that, if a university, having filed a
patent, decides after two years that it does not want to
continue to fund it because it is no longer of interest,
it simply lets it lapse. That puts it into the public
domain. Companies like us do not even know about
the patent because there is no national database you
can search to identify patents of relevance to you as a
business. That simply passes into the public domain
instead of potentially passing to companies that could
equally use that patent for knowledge and exploit it.
Q78 Stephen Metcalfe: We have heard conflicting
reports or different views on the best way to support
a company in its early days, whether that is access to
some early major clients or finance. Which of those
two do you think is more important? Please do not
say “both”. We want you to decide which route you
think works best.
Dr Worswick: If I could speak for Cobalt Light
Systems Ltd, this was technology that came out of the
Research Council, STFC, and the Rutherford
Appleton Laboratory. It was very fortunate that that
laboratory had an innovation unit, which incidentally
handled the patents. We have not had the same
problems because they were quite savvy about the
things that needed to be patented. We obviously pay
for them now, but the work had been done very well.
It is important to remember that the time taken to go
from proof of concept to a product that is marketable
is quite long. Before our company was even formed,
they supported quite a lot of work—£5,000 here,
£10,000 there—showing that this technology had
applications.
That led to the forming of a company. Again, that
innovation unit, of which I have had good experience,
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was very instrumental in finding investors–and so on.
Clearly, in getting things going, the initial capital is
absolutely vital. Having said that—I am not going to
say both are important—early sales are incredibly
important, because not only do they bring in cash flow
but they give you experience of the market and an
understanding of how you manufacture or provide a
service.
Taking up a point from the earlier session,
Government can be incredibly helpful, particularly in
novel technologies like Raman spectroscopy. We were
fortunate in getting an early contract from a
Government Department, which involved a certain
amount of development, and making some early sales
to the pharmaceutical industry. Investment is very
important, but I would say that getting going and
pulling yourselves up gradually through sales and
processes is perhaps more important.
Q79 Stephen Metcalfe: But you started off with
finance.
Dr Worswick: A little bit of finance to get the thing
going and then early work and you gear up, but it
takes time, and it has taken a long period of time even
to reach the point we are at now.
Dr Francis: I would definitely say that customers are
more important than capital. We have been fortunate
in a couple of our directors. I had a long career with
Unilever, so it gave us real influence, action and entry
to a number of senior people not only in that
organisation but other people you can network. I think
it is the selling of innovation that is one of the most
difficult parts of the total process. I know that the
Committee has spent a lot of time looking at the
finance, venture capital and access to funding, but, if
you look at the complete process of commercialisation
of research and understanding what the customer
needs, selling a technology that is looking for a
solution is incredibly difficult. If somebody has a
problem and you can solve it, it is incredibly easy.
In Unilever there were scientists who had worked in
research for maybe 25 years and had never seen one
single piece of the research on to the consumer
market. On the other side, there are all these
orphans—i.e. technical ideas, sitting in research that
never got commercialised. First and foremost, I think
it is the customer.
That takes me on to Richard’s previous point about
Government. We at Byotrol try to sell into the
healthcare sector. Healthcare in the UK is dominated
by the NHS. I know you have heard it before, but
when I was at Liverpool at an innovation conference
about nine months ago, the lady chairing it was a BBC
presenter who had been on “Tomorrow’s World” and
so on. She said she was doing a documentary to be
called “Seventeen”. When asked why, she said that it
had taken 17 years for a small technology company
to get innovation into the NHS. As you can imagine,
most small companies do not have that period of time.
Q80 Chair: You must relate to that.
Dr Dean: I agree with the other two. Customers have
always been first. We have been asked, for example,
by FSS to provide support in various things, all
funded by ourselves but they were the customer. I
think it is a pointless comparison, because Richard’s
point was that you needed to get proof of concept
before you get anywhere near a customer. Of course,
that does cost money, but I would say, as a small
business in biotech, that customers come first and
always have done.
Q81 Stephen Metcalfe: As we have already
discussed, one of the biggest potential customers is
Government. It operates, via the TSB, the Small
Business Research Initiative. Do you rate that as a
way of stimulating innovation and supporting
businesses in this sector?
Dr Francis: We had one entry into SBRI;
interestingly, it was for a hand hygiene system for the
NHS. We thought we were pretty well placed for it.
We did not get it; a new and more novel technology
did. I do not know how that technology got on. My
view about SBRI is that there are probably better
schemes that are more relevant for us as a company.
We were fortunate to receive from the North West
Development Agency what was called a GRAND—
now a SMART award—and we recently put in a
European WP7 application. We are also looking at
KTPs. It may well suit other companies, but for us
there are other more interesting opportunities.
Dr Worswick: Coming back to the point about the
NHS, at LGC I spent the best part of a year of my life
trying to sell genetic services to the NHS. I went
round lots of hospitals and met lots of people in the
Department of Health and so on. After a year we
decided we could not waste any more effort; it was
terribly difficult.
Leaving that aside, I come back to your point about
other support and TSB in particular. Cobalt has been
fortunate. We got a grant from the South East England
Development Agency—SEEDA—which is now of
course closed. That was quite important. It was
£100,000 to develop a particular instrument. We have
just recently been awarded £180,000 from the TSB—
the Technology Strategy Board. The procedures there
have not been very helpful. We applied last September
under an open round and got a huge amount of support
from people who said this technology was incredibly
important. We did hear very quickly. Within a month
we heard informally that our proposal was likely to
be accepted. It then went into a black hole.
I have seen it from both sides. I have worked for large
organisations. Perhaps a four-month delay for a large
organisation is not very long, but last September
Cobalt had cash to last it a few months. You have to
pay your staff and so on. Knowing that we were
getting this would have made a lot of difference.
There was a helpline at TSB, which was never
answered, and we had unhelpful exchanges of e-mail.
They are probably doing the right thing overall, but
as a small company interacting with them we found it
quite difficult. We have been awarded this grant, for
which I am eternally grateful because it is very
important to us. The £180,000 will contribute to this
airport scanner, which is potentially a huge market
and is very exciting.
Dr Dean: One of the problems is that many of the
rules for application are rather unclear and
complicated. My own view, and that of several people
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I have talked to, is that the Government are not doing
their job if there are too many consultants to help you
through this morass of technology information, how
to apply and all those sorts of things. Several
companies I have been in have applied for various
bits of support. One TSB support was very successful:
Medesign. It went on to become a substantial
company, but for Cambio in Cambridge we have not
failed; we just have not got the time to apply, and that
is awful.
Dr Worswick: The time to apply is quite important.
There is a comparison with the US system, because
we are also applying to be on the qualified products
list. There you have quite a good system. You just fill
in five pages, submit it and very quickly you get a
yes/no answer as to whether it is of interest. If it is of
interest it is followed up, but you have a filter system,
which means that, if you know you have no hope in
the first place, you do not waste a huge amount of
time filling in very long forms. The way in which you
interact with Government Departments is incredibly
important.
Dr Francis: To be fair to SBRI, they have that
scheme; it is two pages for the very first application
phase, and it takes more detail afterwards. When you
look at some of the European schemes, they are even
more complicated. We put in an application last week
and we would not expect to hear anything until July.
That is for about £1 million, which would be a
significant piece of research activity for us.
Q82 Stephen Mosley: We have heard evidence that
people find it difficult to navigate the complicated and
ever-changing Government funding initiatives. I guess
from your previous responses your answer to that
would be yes.
Dr Dean: There is an additional complication, which
is the business of full economic costings that go on.
You put in for a grant or make a case for some money,
to whomsoever, and you find that the institute you
want to work with has a very expensive loading,
which in a way is paying for something we have
already paid for. The business taxing system allows
for the fixed costs of universities. Many of the
industrial people I have talked to feel that the industry
already pays for that. The difference is small and not
necessarily a problem; it is the fact that you have to
pay twice that comes over hard. There are 135%
costings for a typical NHS laboratory for a trial, when
we are already paying taxes to support that. That does
not seem fair.
Dr Worswick: Coming back to Government support,
the one thing that is very simple is R and D tax
credits, of which I am a strong supporter. When they
were introduced in the mid-1990s by Gordon Brown,
it took a little while before tax inspectors and
companies learned how to use the system, but it is
now well established. It has been extended a bit, but
from the point of view of small companies it has not
changed a lot. It is completely non-bureaucratic, and
it has been a real help to us. I cannot remember the
sums exactly, but it is of the order of £60,000 or
£70,000. That helps our cash flow enormously at
Cobalt Light Systems. It did at LGC; it encouraged us
to invest more in R and D. I strongly support that
system as being very simple and clear cut, and I would
happily see it extended.
Dr Francis: My experience has been on two levels.
Going back to the Regional Development Fund, at that
time our relationship with the North West
Development Agency and through some of the
business contacts was very good. It was local; they
were quite often in Daresbury. You could meet them
and have a coffee and talk to them about what you
were trying to do, and they would help to guide you
as advisers. Within the KTP there are business
advisers. The difficulty of being a small company is
that you just do not have the time and resources, so
you have many people trying to keep a lot of different
plates in the air at the same time and running from
one thing to the next, never really sitting down and
spending a lot of real focused time on saying, “What
am I going to do? How am I going to use the TSB?
How am I going to get the innovation awards?”
The other point I wanted to make is that companies
need to decide almost strategically that they are going
to be very focused on going after awards as part of
their financing system. You can then spend a lot more
time looking at virtually every single award, but that
takes a strategic direction, which I do not think many
companies take. You have an entrepreneur who has an
idea that he wants to get to market, but he has
problems with finance and cash flow, and the whole
thing becomes a mêlée. More Government advice
about what his strategy is, how he will get to market,
how he will get funding and whether he has looked at
the TSB could be provided for many of these small
companies.
Dr Dean: This is all about communication, if the
Government were prepared to advertise in places
where inventors read stuff—for example, the fashion
magazine Nature, which is regarded very highly by
most scientists as a good place to read things. Very
infrequently do I see adverts that promote
Government activity in particular areas. I think it is
all about simplifying the system and communicating.
Dr Worswick: I would agree with that. The regional
support was pretty well organised. Whether one is in
favour of regions having their own budgets and so on
is another matter, but the network they created was
very helpful when you applied to them.
Q83 Chair: I take it that for all three of you the
simple answer to this question is that you do not
know. With the demise of the RDAs, where do you
go to find the parallel information and support?
Dr Worswick: I suppose it is the TSB, which is getting
going, but I agree with Trevor. If you are very small,
you have to make a decision. Are you going to spend
a lot of time understanding these schemes and
tailoring your application to them, or are you just
going to go ahead and do what you can without them?
Q84 Sarah Newton: We have heard a lot of
discussion about the different sorts of finance that
businesses can access or would like to access. What
has been your experience of the ease with which you
can access them versus your preference? Are you
driven to what is easily accessible rather than your
preference?
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Dr Worswick: For a bigger company, in LGC we had
substantial equity finance. I was keen that all the staff
should have shares. We had schemes so they would
have some ownership of the finance, but we went for
bank loans as well. Starting up a smaller company
is different. Obviously, you have to start with equity
finance. We got that from an enterprise capital fund
(Oxford Technology ECF) and other investors. About
a year ago we felt that we were getting in orders and
we could do with some support with working capital.
We approached HSBC, with whom I had had a very
long and excellent relationship, under the Government
loan guarantee scheme. We wanted to borrow
£400,000 for working capital on a specific project. It
took a fair amount of time but that is okay; they had
due diligence and so on. Remember that 75% of
that—£300,000—was covered by Government
guarantees. They then turned round and said, “Well,
the directors of the company will have to warrant the
other £100,000.” I did warrant for my part; I was in a
position where I could afford to lose that amount of
money if push came to shove. Another director was
able to do that; another director did so for a very small
amount. But there was a bank saying, “We’ll lend you
money, but you’ve got to cover it all so there’s no risk
to us at all”, and for that you pay a premium interest
rate. I think 2% is added on for the Government risk
premium and so on, so it is about 7% on all of it.
At the end, they said, “Moreover, we’ll lend you
£400,000, but we will give it to you in two tranches.
We’ll give you £200,000 and then another £200,000
when you’ve met certain milestones.” Six months
later we thought we had met the milestones. We went
before the bank’s credit committee and were turned
down and another milestone was produced. In the end,
we made lots of protests and got the £400,000.
According to my contacts, we were one of rather few
companies in the area who got that far, so we have
done jolly well in getting that loan.
I make this point not to knock HSBC because other
banks—not so much HSBC—have got into terrible
trouble with dodgy loans to all sorts of people. They
have now reacted and said, “Why should we put
£400,000, albeit for working capital, into a small
company with a relatively small turnover? The risks
are quite high.” They probably are. I can see their
point of view, but I have to say it was deeply
frustrating from our point of view.
Having said that, a month ago we finished another
funding round. We have raised £2 million, largely
from existing investors, to fund manufacturing. We
are optimistic that we are going into a very steep
growth phase. Because it was from existing investors
who knew us it was relatively straightforward, so we
did not experience a valley of death there.
Dr Francis: We went AIM in 2005, for the reason
that, as a technology company that is not involved in
manufacturing, the heart of the business is the
technical know-how that we develop. Venture
capitalists really do not want to touch us with a
bargepole. We have not got assets. Therefore, we are
incredibly high risk. After getting through the early
family and seed money, AIM was really the only place
to go. I would not knock AIM too heavily. We have
been back five times and over that period of time we
have raised about £15 million. On at least one
occasion we were offered an awful lot more than we
were asking for, which we declined, perhaps rightly,
because the founder would have found himself
incredibly rich. What you then do is squander the
money instead of using it wisely.
The difficulty of AIM is twofold. First, at the very
early stage as an entrepreneur you go along and then
list. You are desperate for money. There is no other
choice; you have to get the money or the company
will literally fold. You tend to be over-optimistic and
commit to sales targets that are probably far too early.
It is all about managing the expectations of the AIM
market and what you as a business are likely to
achieve. Had we gone along and said, “Look, we’re
going to take four years to develop our technical base;
we’re not going to be delivering any sales”, life would
have been so much easier. However, in order to get
the money, we committed to a sales revenue over a
period of time. You are then committed to delivering
against that, which then becomes the management
focus instead of doing what you really should be
doing, which is developing the technology.
Dr Dean: In the 1980s we tried to raise 20 million-
odd for agricultural genetics. I was one of the
directors. We were very successful. Most of it came
through Rothschild and other venture capitalists.
Venture capitalists imposed an IRR of 33%, which
was punitive but very nice for them, if we could get
it. I think that was the demise of that particular
technology transfer exercise, and I hope that it never
gets done again that particular way. If anybody wants
to consult me afterwards, I am happy to tell them
about it.
Q85 Sarah Newton: Some of the types of finance
that are available come with so-called expertise and
advice. How important do you think it is to have that
type of support perhaps for the start-ups or people
who have reached a particular stage and need to get
up to the next one?
Dr Dean: It is absolutely vital. If you are lucky
enough to be on a science park, of which there are, I
think, 17 around Cambridge, you have blessings of
communal activity and communal patenting. You have
lots of technology around lots of people who are
looking to move and so forth. I think that is a lovely
place to start. I have done it several times, and I
recommend it to anybody.
Dr Worswick: I would echo that it is not just the
investment; it is getting advice from your investors. 3i
were fairly hands off in that they had a minority stake
in LGC, but when we had Legal & General Ventures
we had very helpful advice from them, particularly
initially. Banks—as I have said, I have had a long
relationship with HSBC—have provided some
extremely good advice. When you are trying to
expand internationally, you desperately need help in
different countries. You may have to raise finance in
different countries. A small company does not have
the expertise to do that, so you have to be able to
draw on their expertise. It is a very important part
of investment.
In the case of Cobalt Light Systems, at the beginning,
Oxford Technology Management, which invested in
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us, were very hands on. One of their partners spent
time with the company. They are quite experienced in
the pitfalls of getting small start-ups going, and they
have given some very useful advice. At Cobalt we
have an excellent board with our investors represented
on it as well as other senior management.
Dr Francis: I agree it is absolutely vital. If I go to
our experience of AIM, the AIM investors did not
impose the disciplines that some of the venture
capitalists would have done. There is nobody on the
board. Yes, it appoints non-execs, and, yes, AIM is
expensive as well, but you do not get people coming
in and telling you how to run your business. However,
people who would have worked with the management
at the time would have said, “What is your strategy?
What is your business model? Who are you trying to
sell to? Are you trying to sell to people who will really
appreciate the technology?” That in itself would have
been a very useful exercise.
Q86 Stephen Metcalfe: I think we are all aware that
clustering or supported networks have a role to play
in helping to nurture this. How important do you think
that is in helping to convert early technology?
Dr Worswick: It is quite important. Cobalt is on the
same site as the Rutherford Appleton Laboratory in a
building that was built for start-up companies. Right
from the beginning, the innovation unit there was able
to provide us with some space. The scientist Pavel
Matousek, who invented this clever technology, is just
across the road. Particularly at the beginning he spent
quite a lot of time with the company sorting out
problems that arose, so there was close proximity to
and association with a larger organisation. In
enforcing patents and so on a small company has very
little muscle, but if you say you are a spin-off from
the STFC Rutherford Appleton Laboratory you hope
someone will take notice. That is incredibly useful.
LGC was at Teddington, which is a very bad place to
be for a technology company. I much preferred being
in the north-west and the proximity to Manchester
university, where there was a pool of excellent young
staff to join you and so on. Location is important.
Although I have never been on a science park, I like
the idea; it has distinct advantages.
Dr Dean: You need a critical mass around the
inventor. If you have an enterprise club, science park
or that sort of thing, it is so much easier and
networking there is absolutely vital. You can pick it up
so much more easily that way. I think the Government
should be prepared to fund things opportunistically.
For example, in Manchester the discovery of graphene
was very well brought out. There was a sudden
realisation that if we did not do it now we would lose
it. I am hoping to start something up with the John
Innes Institute in Norwich on exactly the same lines.
They have a good attitude in that area. They have a
sort of science park, but it could be much improved.
Dr Francis: It is utterly vital. The reason we are based
in Daresbury is that I was looking for a laboratory for
Byotrol at the time and was part of the Daresbury
business network meetings that happen once a month
on a Friday. From my career in Unilever, there are
two things. First, innovation happens at the interface;
it does not happen internally; it happens when you
interact with others. Creating networks and contacts
between similar types of businesses, universities and
all the other players is critical just for innovation
itself. Second, innovation is chaotic, so you try to
make sure you have got the interactions wherever
you can.
Daresbury has been a great place for us to be located.
We are close to Manchester, Liverpool, Lancaster and
so on. I just wish we could get more interaction in
Daresbury with the universities. There is still a belief
that universities expect people to come to them as
opposed to going to the customer. I think that getting
greater interaction between universities—
Q87 Chair: It used not to be the case, did it? I
remember that one of your colleagues from Unilever
was a visiting professor from Manchester working in
Daresbury.
Dr Francis: It depends on which area you are talking
about. Where there is a big research programme in
Daresbury relating to physics or whatever, that is more
likely to be the case. If you are an SME based in
Daresbury, that is much less likely to happen.
Sir Tim Wilson’s review of business-university
collaboration spent a lot of time looking at big
business and universities. I am not necessarily just
critical of universities, but they really do not know
how to interact with very small technology
companies, and it is quite a struggle.
Dr Worswick: I think it is quite a good model. I do
not know whether your Committee will be visiting
science parks or companies, but you will be very
welcome to visit Cobalt Light Systems, which is an
example of a very small but interesting company, and
see how it interacts with the Research Council
laboratory on the same site. It is not too far from
London.
Dr Dean: Innovation is not taught in our universities.
It is a fundamental process, which follows invention.
I go round the country giving talks on this and I am
appalled at how few people have heard half the points
I want to make.
Q88 Stephen Metcalfe: The Government have a
focus on investing in science and technology
commercialisation. Do they have their balance right
in funding capital projects and putting money into that
side of things, or should they be investing more in the
support structures and networks to try to encourage
self-development?
Dr Worswick: That is an incredibly difficult and
complicated question. The fact that the science budget
has to a degree been protected is hugely beneficial.
From a rather parochial view of someone who is
helping a company to supply scientific instruments,
there were cutbacks in the capital budgets of
universities, which affected us terribly because what
we are selling is a capital purchase. You buy an
instrument to analyse something very quickly. That
has slowed down the market, because a lot of the
market is in universities, Government establishments
and so on. I would like to see investment in science
continuing. I do not think it is an either/or. It has to
improve some of the linkages. Clearly, for the NHS,
for example, the linkages are appalling, but I would
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hate to see that being at the expense of capital
schemes.
Dr Dean: I regard that question as extremely
complicated. I do not know how to answer you most
accurately. If you read the paper that I have written
for your colleagues, at the back of it you will find
a bit about Cambridge university’s failure to keep a
business going even though they were getting a good
revenue stream from it, basically because they were
not prepared to support the technology—the
machines—with simple contracts for maintenance.
Dr Francis: I am probably not best placed to answer
that question because we are not really that heavily
involved in capitalisation. The bigger question is not
an either/or, but the total amount of money that is
available for the commercialisation of research is the
biggest challenge.
Q89 Hywel Williams: I am a Welsh MP. First, how
important is it to be close to London in order to
commercialise research? Secondly, how aware are you
of the efforts of Governments in Cardiff, Edinburgh
and perhaps Belfast in this field? Are they salient at
all in your thinking, or is the relationship here and
with Government here?
Dr Worswick: From our point of view, being close to
London is not hugely important; being close to some
centres and having good transport links is important.
But you must remember that even small companies
are acting internationally on the supply side in buying
in pieces of equipment. We buy equipment that is
manufactured by a company in Northern Ireland; we
buy in equipment manufactured in Denmark and the
US. We are selling into markets that are international,
too. It is really being networked rather than where you
are actually sitting. I would love Cobalt to move to
Cornwall, but quite seriously, there are some transport
problems. Our instrument is quite big and we need to
get it around Europe and internationally, even to
Wales.
Dr Francis: For us, other than the links with the
financial investors, it does not matter at all. In fact,
for us, it is more about identifying the right university.
I am in Cardiff on Monday and Tuesday of next week
looking at the university. It really does not matter at
all.
Q90 Hywel Williams: I am just wondering whether
the Welsh Government have any salience at all in your
thinking, or is it just the university?
Dr Francis: We have a sister company through one
of our investors that is based in Flint in Wales. We
know that they probably have good access to
alternative types of funding, which we look at with a
degree of jealousy, but it is not such a critical aspect
of it.
Dr Dean: Cardiff pulled off a spectacular one when
they got Martin Evans from Cambridge to join them.
He is obviously doing very well.
Q91 Chair: I think the mention of Cornwall has
pricked up Sarah’s ears.
Dr Worswick: It is only because I like Cornwall.
Q92 Sarah Newton: As a Cornish MP I would like
to do everything I can to overcome those barriers that
would enable you to move to Cornwall and join the
other vibrant and innovative manufacturing
companies that we have there.
Dr Worswick: More seriously, at the next stage, if we
are to set up manufacturing facilities for this
instrument, there are some quite difficult choices, to
be frank whether you put it in the UK or somewhere
else.
Q93 Chair: I was going to come to that.
Dr Worswick: We are not in that league yet.
Q94 Chair: Given the three of you have very broad
and somewhat different experiences—I do not invite
you to look outside at the weather before you answer
this question—if you were starting again now, where
would you locate both as a start-up and subsequently
developing into a manufacturing operation?
Dr Worswick: For LGC, it would not have been in
Teddington. Would you be in the UK? There was a
little discussion about Germany. Our experience in
Germany was very positive. When we were expanding
in the Brandenburg district we were visited by
Ministers from the area. They made you feel really
good about it. There is something about the culture in
the UK that means we do not link politics with
industry terribly well. You have pictures of politicians
in hard hats visiting engineering firms and it looks as
if it is the first time in their lives they have ever been
inside. I have taken Ministers round LGC and it is the
first time in their lives that they have been in a
laboratory.
Chair: Yes?
Dr Worswick: I don’t know; maybe I am being unfair.
This is all very anecdotal and I am not critical of
politicians in any way, but in Germany you have a
network among the finance sector, politicians,
industrialists and so on. This does affect the growth;
it is the climate.
Q95 Chair: You have moved around a bit.
Dr Dean: I have started three companies in Liverpool.
Michael Heseltine was appointed by her Ladyship to
visit as the Minister. I am afraid that not even he was
able to make much of an impression. Much as I love
Liverpool, the critical mass does not exist. As to the
networks you can create, albeit Manchester is
excellent, they are too far away for Liverpool.
Abingdon or Cambridge in my experience have been
the easiest places because of the points I have made.
Dr Francis: As to the UK, there has been a lot of
discussion in previous panels about the soft innovation
model. Where you have a couple of very large
companies that have real needs, small technology
companies can feed off them, be close to them and
interact with them. Creating a hub of innovation with
universities and small technology companies is
absolutely the ideal place to be in many ways. In the
north-west we have AstraZeneca; in Macclesfield we
have Unilever and Port Sunlight; but the ability to
interact with either of those companies is difficult.
There is no hub, for example, in the north-west of a
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soft innovation model. As a result, we are very much
in a hard innovation model.
I did my postdoc in Germany. What amazed me
continually was the ability of the prof at the time to
be able to go to companies like Volkswagen and
simply say, “I’ve got a visiting professor coming from
Japan. I need you to give me 200,000 DM.” He got it
without any difficulty. Subsequently, when I left
Unilever and was running an innovation consultancy, I
looked very much to the German model. The German
family model is absolutely critical. The key point is
that, if you are an entrepreneur and you have to go
and get money, you virtually sell 95% of your idea
very quickly either to venture capital, AIM or
whatever. You are left with 5%. That literally leaves
the vast majority of people emotionally drained of the
energy to take their idea forward. In Germany you
have a family business model that is willing to put
more money into it. It does not necessarily take
complete ownership away from the individual—from
the entrepreneur—and that allows greater ownership
of the idea, the technology and the company within
the hands of the individual instead of investment
houses.
Chair: Gentlemen, thank you very much for your
time this morning. It has been a very interesting
session. I hope you found it valuable, too.
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Q96 Chair: Gentlemen, can I welcome you to this
morning’s session? We are extremely grateful to you
for coming in. Just for the record, I would be grateful
if you would identify yourselves.
Sir David Cooksey: I am David Cooksey, chairman of
the Francis Crick Institute. I have been involved in
the venture capital business since starting the first UK
venture capital fund back in 1981—so quite a long
history.
Sir Peter Williams: I am Peter Williams. In my semi-
retirement, I am treasurer of the Royal Society. I sit
on one or two boards. I am chairman of the National
Physical Laboratory and have walked through the
valley of death with one or two small companies in
the past. So far I have survived.
Q97 Chair: Gentlemen, we recognise that you are
both involved in very important institutions, but we
have invited you here today as two wise men in the
field in your personal capacity. We would be grateful
if you could just share information with us from your
own point of view and experience. You have both
written important works in this area. Had you been
doing it today in the current financial climate, would
you have made any different recommendations?
Sir Peter Williams: Shall I go into bat first? That is
always a difficult question. If you perceive wisdom in
the two of us, that is your judgment. You have also
got age and distance from past events, so the rose-
tinted spectacles come out. On the environment today,
the first thing I would like to say is that the reason we
are even able to have this conversation today is that
the science base in the UK is clearly as strong as it
ever was. You can benchmark it internationally
against the best of breed anywhere on the planet, and
we still backed IAP. We Brits tend to disparage
ourselves—witness the hysteria over England’s 1-nil
win against Ukraine last night—and we do so at our
peril in the world of science. Science is in great shape.
Q98 Chair: The Committee is not doing an inquiry
on goal-line technology.
Sir Peter Williams: No; perhaps you should. In terms
of whether we would say anything different today
from the various reports, I suspect among your
catalogue of reports you may not have seen the one
David commissioned and I chaired to the Treasury in
1998 on the financing of high technology businesses,
which is very much the question that is intimately
linked with what you are talking about today.
Stephen Mosley
Pamela Nash
Sarah Newton
Graham Stringer
Were I talking today about the things that we put in
this report in 1998 to a committee of Members of
Parliament, I would be drawn immediately to that
which Government can and cannot do to optimise the
chances of traversing the valley of death. You would
look immediately at the taxation environment. In
1998, we raised issues of capital gains tax, which, by
the way, led to the business assets taper. We had a
10% CGT, so that entrepreneurs were incentivised on
exit, not that we want them to exit too quickly; that is
a British disease that we need to get away from. I have
to say that the CGT environment, while the current
Administration are trying hard with things like the
Patent Box, probably still ignores some of the basic
facts we put before Government in 1998, which are
that you must have the most competitive taxation
environment in order to attract entrepreneurs to take
the undeniable risks in traversing the valley of death.
The other thing we put forward then was what we
called emerging growth rebates, which became R and
D tax credits. That has run and run very successfully
for a decade. If I look at the detail, however, I have
dug out the recent BIS independent evaluation of R
and D tax credits conducted in 2010: £980 million
was committed to the tax credits in that year, split
between our original scheme, which was to be focused
entirely on SMEs in technology, and larger
companies. Larger companies were introduced in
2002. I have to say that, reflecting today, 10 or more
years on, that scheme has been highly effective with
SMEs. Can we have some more, please? It probably
has not conditioned behaviour in R and D of larger
companies. They willingly bank the cheques. It is
always good news. I sat on the boards of two major
plcs who received considerable R and D tax credits
during my time as an NED. I do not think you are
moving the needle with big companies, but, boy, are
you moving the needle with smaller companies. That,
I would reflect, has moved positively.
The elephant in the room in all this is not
Government; it is the City of London financial
services that provide the working capital for all these
businesses. There I would say the environment is in
current circumstances, inevitably so, less propitious
than it was, but, leaving aside current challenges and
difficulties, I think there is more risk aversion today
vis-à-vis technology-based businesses than there was
when David and I started down this track many a
decade ago. In your case, David, it was probably in
1980. Those would be my opening reflections,
Chairman.
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Q99 Chair: Sir David, is there anything you want
to add?
Sir David Cooksey: I very much endorse what Peter
has said. There are a number of issues I would like to
raise. One is that in order to make the valley of death
crossable you need to have finance to do it in the first
place. If you look at what has happened to the venture
capital industry, it has not made the returns (over the
30 years I have been involved in it) that are needed in
order to persuade the City, with their risk-averse
nature, to invest in venture capital, which is a very
long-term investment they cannot get out of once they
are in it. If you look today at the successful venture
capital firms, they are the ones that are investing at
the later stages of the process, as the company comes
up the other side of the valley of death, and the real
problem is getting from the early stage to where you
see the growth beginning to take place.
What we have got is an unfinanceable situation, and
we have got to look at ways to improve on that. As
you know, I have spent quite a lot of time looking at
the life sciences industries in particular. What became
very obvious to me when I was asked to write the
Cooksey review of 2006 on the financing of health
research—but I ventured into the whole business of
authorisation of drugs at that time as well—was that
the model the pharmaceutical industry had been using
was broken. The costs of developing a new drug were
rising and rising, and the pressure on the price that
would be paid for that drug was going in the opposite
direction and there was a big squeeze coming. While
not many of the pharmaceutical companies have yet
admitted it, what they have got is a broken model,
which we have got to do a lot to rectify.
I think it was an absolute classic in 2006. That report
was commissioned by Gordon Brown at the Treasury,
rather than the Department of Health or BIS. When
it was published, after a lot of negotiation with the
Department of Health, all of the recommendations
were accepted on day one. If I look back, six years
later, at what has happened, there has been an awful
lot of huffing and puffing, but, in getting to the end
points that I wanted to acheive, in truth we have made
almost no progress whatsoever. There has been a lot
of political good will. People in the Department of
Health, universities and so on have all wanted to go
in the right direction. The MRC and NIHR benefited
from hugely increased funding as a result of that
report, but it has not got the critical support to make
it work.
Q100 Chair: That leads me very neatly to the next
question. Very simply, apart from more tax credits and
a better tax system that Sir Peter described, give us a
shopping list of actions that Government can take to
improve the environment.
Sir Peter Williams: Let’s look at tax. One has to keep
a watchful mind on the concept that there is no new
money around. We are talking about shuffling the
deck. The point I made about R and D tax credits is
that the singular omission in the 2010 evaluation was
the apportionment between large and small
companies. Were that data to be available, I believe it
would show that disproportionately the £980 million
is going to large companies where, as I asserted
earlier, one does not move the needle. Quite readily,
the Treasury could redirect getting on for £1 billion
much more heavily towards the emerging company
sector. While the scheme is reasonably generous as
currently embodied, it is not quite as generous as
David and I and colleagues envisaged back in 1998. I
think a simple resharpening of the pencil on R and D
tax credits—my plc colleagues will kill me for saying
this, of course—would assist with what you are
engaged in today, which is traversing the valley of
death.
I doubt you can do much about CGT rates. As to the
entrepreneurs that I know, my next door neighbour is
Jan Hruska in Oxford, who founded Sophos, an anti-
virus software company. Many of you will not have
heard of it; it does not sell to the retail user; it sells
only to corporates. That is hugely, massively
successful. It was founded in Oxford just 20 years
ago. Jan has never been motivated since the very
earliest days by the exit rates on his CGT bill, but his
investors undoubtedly keep a watchful eye on this
parameter.
The Patent Box, which is a wonderful concept, is
immensely complex and busy entrepreneurs will
shove it to the side of their packed desk and not focus
on it, so it is not having an incentive. I think in that
arena—those two areas we talked about in 1998—
there are things, neutral in overall cash terms, that can
be done to sharpen the pencil.
In terms of TSB activities, schemes that go directly to
the heart of SMEs and trying to incentivise them,
frankly, pale into insignificance with the one big item
on my wish list, which is that, somehow or other, you
can bring pressure to bear on Government to become
an intelligent procurer of goods and services with set-
aside for emerging SMEs, which has been the norm
in the United States for decades. It works. If anything,
over the last 15 to 20 years, we have gone in the
opposite direction: the perceived flight to safety of a
large company rather than risking it on a small
supplier. If you think large companies are a flight to
safety, try building aircraft carriers for a living. It is
time the Government woke up and started pushing a
set-aside-style procurement scheme on the US model
slap bang into the middle of this sector of emerging
companies having recently crossed, or about to cross,
the valley of death.
Q101 Chair: Sir David, your report was, as you say,
well received by Government—by BIS and the
Department of Health as well—but, apart from
reminding them that they needed to take some actions
to implement your well-received report, is there
anything else that you would add?
Sir David Cooksey: Yes. Just picking up that
procurement point, procurement is absolutely vital to
small companies in the life sciences area. They tend
to have longer gestation periods than IT and telecoms
companies. The situation on procurement is that, if
you look at the requirements Government place on
their Departments for making procurement, the
qualifications required in terms of the financial size
and stability of the companies are such that they
positively exclude the sort of companies we are
talking about from supplying Government, and that is
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completely wrong. What we should be looking at is
Government being prepared to pay for the prototypes
from these companies to get them off the ground and
make them work. There is no question about that.
Peter mentioned state aid. If I speak to my colleagues
in the venture capital industry in France, Germany, the
Benelux countries or Italy, they will laugh at me when
I talk about having to wait for state aid approval. They
just get on and do it and worry about state aid when
Brussels reprimands them. Here, we spend months
and months. Look at the Catalyst Fund scheme
proposed by the MRC and TSB to get TSB into the
business of supporting life sciences companies. It is
only very recently that the TSB has paid any attention
to life sciences at all. We waited for, what, six or nine
months for approval from Brussels? We should have
got on with it. It is ridiculous.
There is another area that I find very inhibiting. The
Francis Crick Institute is a good example of this. We
are building a building: the building will cost about
£540 million to complete, and there are lots of other
expenses on top of that. We are going to have to pay
VAT on those buildings if we have more than 5%
commercial activity within them. I might say that
includes the canteens if you get a subcontractor to
come and run your canteen for you. But the point is
that what we are trying to do with the Crick is have a
much more open relationship with the pharmaceutical
and medical devices industries and so on. What we
would like to do is invite people who are, yes,
commercial in origin but who can contribute to what
is going on in the Crick and enable the translation of
scientific discoveries into good commercial products
that will benefit patients. Very often, the way you
collaborate best is to bring in some of the people from
the commercial sector, but we are faced with the fact
that, if we do that, we will probably be charged VAT
on the entire building, which adds another
£100 million. When you see this going out of one
pocket of Government and into the other, it is even
more ridiculous that they should insist on it, but those
are the sorts of problems we are up against.
I mentioned earlier the whole business of bringing
forward the licensing process. What I called
“conditional licensing” has now become “adaptive
licensing” for new drugs. Everybody welcomed it in
2006 as a concept. There have been lots of
discussions, conferences ectetera about it; but,
somehow, because it requires bureaucrats to take more
risk and use new techniques, which are not necessarily
proven to the last i dottted and t crossed, you have a
situation where that whole process of trying to shorten
the approval cycle for drugs has run into a snowdrift
because bureaucracy is standing in the way.
Sir Peter Williams: To add just one more comment
on my procurement wish list, which is, I think, a fairly
obvious one but I would like to draw to your attention
nevertheless, Governments of all shades find it
extremely difficult to move the elephant in the room
in any given direction. The financial sector is its own
creature and soul. There is no doubt whatsoever that
schemes like Merlin have been well intended to push
capital down to businesses. If intelligent procurement
and Government contracts pushed real orders resulting
in real revenues and real cash flows into emerging
businesses, that is the one thing that would persuade
investors to buy their shares and back those
companies. So procurement has a double whammy: it
helps the company directly, and it conditions the
market perception of this whole sector.
Q102 Stephen Mosley: Sir Peter, I was very
interested in what you were saying about the R and D
tax credits. You have outlined that you believe most
of those tax credits go to large rather than small
companies and we need some sort of rebalancing. But
does the particular sector of those R and D tax credits
matter? We have seen evidence that some of the
biggest beneficiaries of the R and D tax credit
schemes are the banks. The 2009 BIS R and D
scoreboard shows that HSBC and RBS spent more on
research than BAE Systems and Rolls-Royce. Would
you consider refocusing which sector or areas of
research are funded by tax credits, or would you just
talk about entirely shifting all of it from large to
small companies?
Sir Peter Williams: There are a couple of questions
intertwined there. The first thing is that the 2010
report was interesting and revealing, but it was
important in what it did not say and the absence of
data. The first thing I would do is put in a pitch to
reinstate the R and D scoreboard. That is a general,
publicly available database, which tells you exactly
the nature of the R and D expenditures of all these
various companies and brings out for anybody with
an interest in the field exactly what you have just
observed—that banks nominally conduct more
research than BAE Systems. Let’s get the facts on the
table and bring transparency and openness and make
rich databases available to everybody.
With that in mind, it is probably true that the nature
of the marketplaces that the credits finally find their
way to inevitably is very difficult for legislation to
condition. You can never anticipate the inventiveness
of the organisations you are dealing with, which is
why banks have prevailed so successfully in that
sector. When we originally suggested what is termed
in this report the emerging growth rebate, it was aimed
fairly and squarely, and unambiguously, at emerging
technology-based businesses. We went as far as to
define an SME in financial terms and to give a
definition of technology-based businesses. You are
building on Frascati and all the various other pieces
of history you can dig up for yourselves.
It is genuinely difficult to ring-fence a sector like that
effectively, as we have always found. Legislation
always finds that the money leaks out somewhere
unanticipated, but I believe that you could make a
stride forward by re-emphasising SMEs. Already you
have a concession from Brussels—dare I say it?—to
define an SME as employing not 250 employees but
500, which is quite a significant size business, so you
have plenty of scope to push in that sector. Just get
the absolute facts on the table, because if, as I believe
to be the case, the great majority of the £980 million
goes to big businesses, frankly, they do not need it as
much as these emerging companies we are talking
about. If you can work out a way of legislating to put
it into technology sectors, which I believe you can
define accurately enough, that will be even better.
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Q103 Stephen Mosley: There are some clear actions
there, which is always nice for us on the Committee.
One of the problems we hear not just with R and D
tax credits but funding in general for SMEs is that, if
you are an SME, they are entrepreneurs who are
putting all their effort into developing their ideas and
growing their business, rather than filling in forms or
lobbying to get funding, whereas universities and big
companies have got the resources to lobby and to play
the system, basically. How would you alter the system
to try to ensure that SMEs have a more level playing
field when it comes to lobbying, filling in the forms,
meeting the right people and finding out about these
grants?
Sir Peter Williams: That is a difficult one, because
you have accurately hand-sketched a typical
entrepreneur, who is busy, unpredictable, somewhat
idiosyncratic and off the wall in style and so on. They
do not really have any time, philosophically speaking,
for red tape; it annoys them. By the way, that also
brings in a broader question of regulation and red tape
in this country, which, contrary to myth and rumour,
has not been reduced in recent decades; if anything, I
think it has increased. These are people who do not
want to spend much of their day on that.
Equally, if you have a clear, well-drafted scheme, as I
believe the business assets taper CGT was prior to
Alistair Darling’s last budget, it is pretty simple for a
busy entrepreneur to see, when they are contemplating
an exit of their business, the nature of the advantages
of the scheme in front of them. It is pretty easy for
them to see in a SMART award what is in it for them.
So make it simple and straightforward. Frankly, an
entrepreneur establishing a 20-person company in
technology, looking at the Patent Box definition, will
just stick it to one side. It is far too complicated; it is
too wrapped up. It may look wonderful to a legislator
in the Palace of Westminster, but, as you say, it does
not cut it on the desk of a busy entrepreneur, if indeed
they do have a desk. Keep it simple; make sure the
financial incentives are abundantly clear and razor
sharp; and, above all, make sure there is liquidity. The
great thing about R and D tax credits for small
companies is that they get real folding money out of
it and it keeps them alive for a period.
Q104 Stephen Mosley: That ties in nicely with
something Sir David said about the 2006 report. It
came up with all these recommendations, but then
nothing was done. We have seen evidence from
people saying that Governments tend to believe that
things must be done, so they keep coming up with
these new schemes. All these schemes are being
announced. There is a feeling that you have to
announce things to be seen to be doing things; but of
course it leads to a much more complicated
environment and it is a lot more difficult to handle.
You said, “Keep it simple.” Sir David, do you think
that a few good clear and simple schemes are better
than having a situation whereby Governments keep
announcing things but nothing seems to improve?
Sir David Cooksey: When I say nothing is done, very
often the organisation is put in place to make it
happen, but the whole system does not allow it to
happen. I agree with Peter entirely; keep it as simple
as possible. An area I would draw your attention to is
the fact that venture capitalists are really only
prepared, with very few exceptions, to invest on the
upward curve from the valley of death. There is one
area where you can get money at the moment, but it
is like sucking blood from a stone. Some rich private
individuals are still prepared to back really interesting
new investments. Quite frankly, whatever can be done
to incentivise angels of that type to invest early in
companies and to provide that really high-risk capital
is, I think, absolutely vital, but, again, they do not
want to be tied up with incredibly complicated rules
and regulations; it has got to be simple.
It is interesting that Peter was saying earlier that we
had agreed with the Inland Revenue back in 1998 on
a definition of a Small High-Technology Company.
They agreed they would put a wrap around those
companies and enable them to identify them. The truth
of the matter is that the Inland Revenue, or HMRC,
as it is now, have pushed that back and back because
they do not like incentives being provided to one
particular sector of the economy.
Q105 Stephen Metcalfe: Sir David, I think it was
you who said that venture capitalists had not made the
returns they had hoped. Is that because they were
trying to pick winners too early? Is it because they
did not necessarily understand what it was they were
looking at? That brings me to the second part of the
question, which is: is it important that entrepreneurs
understand science? Does science need to understand
entrepreneurs, or is it just another business?
Sir David Cooksey: So often, it is the scientist who is
the entrepreneur who starts these businesses. There is
a certain degree of arrogance about academic
scientists who think the business bit is easy. If you
look at what happens out there in the real world,
scientists often hang on to running companies far too
long beyond their capability. Where we have found
the greatest success is where we have been able to
bring in really good seasoned businessmen to come
and work alongside the scientists. They have got to
understand the science and so on. It is those two
forces working together with good marketing and so
on that really make a difference to the performance of
the companies.
I think a lot of people going into the venture capital
industry have been too willing to put on rose-tinted
spectacles and think these companies are going to
have a wonderful run into the future and beat Google
at their own game, or whatever it is, but the truth of
the matter is that penetrating the market, and very
often establishing a market for a new product, is a
tough business. That is the problem.
Sir Peter Williams: Could I add a comment? I have
some data that I dug out for another purpose the other
day. Lest you feel that this problem about the returns
on venture capital that David has alluded to is solely
a British problem, it is not. In the US and EC industry
until the end of the 1990s, the upper quartile
managers—the best of breed—were getting four or
five times money out. The best of breed today are
getting 1.1 to 1.4 times money out, so the whole
marketplace has got tougher since the turn of the
millennium.
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Against that background environment, the Royal
Society has established a philanthropically-funded
enterprise fund, which is basically venture capital but
is solely into the science space that our Fellows
inhabit. Whenever we talk to the fledgling companies
we are about to invest in—some are very tiny
companies still at the university lab bench—the two
issues that always come up are the inability to raise
finance and, as David has pointed out, the inability to
find an enlightened manager, who is both
technologically savvy and business-wise. These
people are in great demand. The reason the business
angels have such huge value in this space is not just
the investments they make and the private money they
put in, but they are the exemplars; they are typically
people who have walked through the valley of death.
They have done it and built their reputation, often
several times over. They are a role model, but it is
still extremely tough.
Q106 Stephen Metcalfe: You said that the latest data
says 1.1 as the return.
Sir Peter Williams: David knows these figures better
than I.
Q107 Stephen Metcalfe: I do not need it exactly but
the spread.
Sir Peter Williams: When I dug them out the other
day, the spread of returns is currently from 0.7 to 1.4
times money. That sounds like a good return to you
and me, but to a venture capitalist that is nothing. It
used to be five times in the 1990s.
Q108 Stephen Metcalfe: How does that compare
with other sectors that venture capitalists might
invest in?
Sir Peter Williams: That is the whole of venture
capital.
Q109 Stephen Metcalfe: But is investing in science
and technology companies at the bottom end or top
end of that?
Sir Peter Williams: In the US, I think you would not
readily distinguish between technology businesses and
others, for the simple reason that they are the home
of all the great success stories, particularly in the new
economy—Google, Twitter, Facebook and so on.
Q110 Stephen Metcalfe: The other thing that I think
is required other than ideas and money is a supply of
good, well trained staff—employees, people—which
is a really important resource. Are we creating enough
of those people and in the right mix with the right
skills to be able to support these companies as they
emerge?
Sir Peter Williams: I speak as a former chancellor
of Leicester university. Having inhabited a few other
universities in the golden triangle, it has got better.
Let’s be optimistic about a few things. It has
improved. When the challenge seed fund-type
schemes came in 10 or 15 years ago, universities
started realising that their business schools were not
just an adjunct to make money down the road from
their main campus but had a value within the
university to bring undergraduates into familiarity
with business, entrepreneurship and so on. We have
made steps forward. In that sense, what can you in
Government do? All you can hope to do is create an
environment. You cannot be responsible for the fact
that there is a deficiency of mechanical engineers who
happen to want to found businesses, but you can
create an environment, and the environment has
improved in the last 20 years.
Q111 Stephen Metcalfe: From the sound of that,
there is still some way to go.
Sir Peter Williams: From a low base, yes.
Sir David Cooksey: I certainly agree with that.
Universities have taken on the business of business
education much more seriously, which I think is
positive. I also think that there is increasing mobility
in employment. Recently, a company that I chair,
which is halfway through the valley of death at the
moment, managed to recruit a very senior executive
from Thomson Reuters to head it. The fact is that, if
you get the right combination of financing and quality
of product, you can attract the right people these days
much more easily than you could 20 years ago.
Q112 Stephen Metcalfe: As that company grows and
you require a range of people to support it, are we
educating at the right levels? We have a fantastic pure
science base—I think we all accept that—but are we
creating the right environment that is encouraging
people to take on technical subjects—STEM
subjects—where they can act as middle technicians
and skilled people who will allow a business to grow?
Are we creating that framework?
Sir David Cooksey: I think that is always a problem.
We do not train enough of those people; I agree.
Sir Peter Williams: If David Sainsbury were with us
today, he would undoubtedly point out that the
technician class is a forgotten, underrated and
undervalued one in this country and has been
endemically. I agree with him entirely that in the
1990s we had this obsession with turning everybody
in the country into a university graduate without any
thought whether the market and demand was there for
such people, and at the same time and in the same
process, we therefore implicitly devalued what the
Germans might term the product of the
Fachhochschule, rather than the university. The net
result is that you sow what you reap—sorry, you reap
what you sow and vice versa. We could get into deep
philosophy here. We miss this at our peril. It does not
necessarily relate to the value. The people in these
small companies are polymaths—they all do three or
four jobs—but the technician class for big and
growing businesses is sorely in need of more
technicians.
Sir David Cooksey: On top of that, if you look at the
science base, yes, it is very good; the research base is
very good, but we are bad at translating that science
base into good business. This is the crucial factor. It
is the people who can take the thing forward; it is
taking the bench discovery in the university laboratory
through the clinic to producing a drug that is valuable
to patients and the economy. It is the same thing
through the engineering base as well. It is the people
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who can translate good science into good business that
is the crucial missing factor.
Chair: The chip is still on my shoulder about the
denigration of the technician class, but I am in the
chair now.
Q113 Gareth Johnson: Sir Peter, at the beginning of
your evidence you said that the British science sector
was very praiseworthy. I know it is a big question, but
what more can we do to ensure that we retain some
of the benefits from the UK science sector? It is all
very well investing in British companies and so on,
but surely we need to ensure that more of the benefits
from that remain in the UK and do not go abroad. Do
you have any suggestions as to how we can make
that happen?
Sir Peter Williams: I have a comment on whether it
is either likely or desirable for it to happen. Higher
education, like technology business, is basically a
global industry today. Undergraduate teaching and
taking our young from their school days and
transitioning them into more useful and well trained
human beings is a vital part of our national needs,
and will remain thus. When you look at an average
university today, however, particularly the Russell
Group, that which dominates their planning and
horizon, financially and intellectually, is postgraduate
training and research, and that is where their efforts
are going.
As soon as you look at postgraduate training and
research, you are in an international and totally global
industry. An average research lab in Cambridge will
be full of Americans, Chinese, Danes, Dutch, South
Africans, Australians and Brits, of course. The same
is true in the National University of Singapore or
Tsinghua in Beijing. That is something I would urge
you not to try to roll back, because it is good for
humanity and for the planet that that is the case. It is
a great way of mixing the future leaders of all nations
together, and the benefits accrue to everybody. Putting
it more bluntly and financially, the way Margaret
Thatcher summarised it is that we do 5% of the
world’s research and we need access to the other 95%.
The same is true for every other nation, including
America, Germany and China. I am not sure that you
can easily capture for Britain the research fruits and
outpourings of our British research universities, but
what you can ensure, if you get more candidates
across the valley of death and grow more businesses
domiciled in Britain, with their employment base in
Britain, is that we capture the benefits of everybody’s
science base globally.
Q114 Gareth Johnson: How do we do that? You say
that we need to ensure we keep British companies
based here. We are told that there are lots of instances
of foreign companies taking over British industries
because it seems more attractive on occasions, but
what is it that you think is encouraging businesses to
go abroad? What more can be done to ensure that they
flourish in the UK?
Sir Peter Williams: I will comment on that briefly. I
am sure David wants to come in on this one. It is
questionable whether they “go abroad”. Let’s take
Autonomy and Mike Lynch, which is a brilliant
success story. He comes straight out of Cambridge,
grows to stardom and FTSE 100 status and so on, and
sells off to an American parent. Autonomy has not
been packed into containers and shipped to California;
it remains British. Moreover, Mike Lynch, if I make
a top-of-my-head guess, is going to become a serial
entrepreneur; he is going to do it all again several
times over in the next few years, with Hewlett-
Packard money in this case. This is not a bad thing; it
is a good thing for the British economy and for life in
this country. I am pushing back on the fundamental
precept behind your question.
Sir David Cooksey: I want to take a slightly different
line. Going back to the life sciences, you get a
company that has gone through in vitro testing. It has
picked up a discovery from a university laboratory,
formed a company, gone through in vitro and probably
animal model testing in this country. It then wants to
do in-human trials. The sheer cost, bureaucracy and
difficulty of getting that done in this country means
that, of the portfolio of companies that I have been
involved with, probably more than 75% of them have
given up in this country and have gone to do their
trials in Philadelphia, Boston or North Carolina,
because they can get it done quicker and cheaper and
with a system that delivers more coherent results. It is
quite difficult to get everybody to work to the same
protocol in this country for various reasons.
Q115 Gareth Johnson: Can you give any examples
of that bureaucracy? Is there a particular bureaucratic
element we have here that you do not have abroad?
Sir David Cooksey: It is because, if you want a multi-
centre trial, at each centre you have to go through,
first, a separate acceptance that they will do the trial.
Then it has to go to the R and D committee to decide
whether or not they are going to accept it. Then it
goes to the ethics committee at each of those centres.
I know Sally Davies and NIHR are trying to get this
right, but we are still in a position where it is very
bureaucratic, and each of those committees wants to
tweak the protocol. This is why I am talking about
different protocols and so on. At the end of the day,
you can find that the trials are not valid because they
have not all been carried out to the same protocol. If
you have a single portal to go through, once you have
persuaded a senior group of reviewers that this is the
appropriate thing to do, means you can get out to five
or six centres and not go through the same process
time and time again, with huge wodges of paperwork
involved in every one, which small companies just
cannot manage. It is just beyond them.
Q116 Graham Stringer: I think there is a consensus
that Government cannot pick winners; it can create a
financial, tax and cultural environment to encourage
innovation and business success. There is an
exception at the moment with graphene, inasmuch as
Government have decided that they are going to put
large sums of money into it. Are they right? Are there
particular lessons that can be drawn from that? Is it a
one-off? I would just be interested to hear your
opinions, because it does stick out as a very different
approach by Government from the general approach
to other companies.
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Sir Peter Williams: To answer that, I take you back
to the 1980s and something which I guess you might
have heard of but probably will not have encountered.
I refer to the Alvey report and the Government money
that resulted from it, which coincidentally was also
£50 million of the day; it was the same in nominal
terms. As to whether it is desirable, I will come back
to that. Let me talk about process and mechanics. In
the typically British style of risk aversion, because it
was then a large sum of money, Alvey was scattered
in small pieces so that nobody could blow a large sum
of money on something that was high risk. The net
result is that I suspect for many in this room the name
Alvey is entirely new. I commend that you go back
and look at the evaluation reports on Alvey. You will
see that it made no difference whatsoever to the
electronics and IT industries in the United Kingdom
in the subsequent decades. If you like, it is a warning
signal to Government on graphene.
Should graphene be singled out in this manner? It is
a remarkable substance. I used to do research on two-
dimensional structures for about five to 10 years of
my academic career, so there is no doubt whatsoever
that it has the potential to do a lot in everything from
biomedical devices, unique catalysts and possibly
even ultra-fast electronics. The danger is that, because
nobody quite knows what it is going to do and we are
risk-averse, we will chop it into quarter-million-pound
pieces and scatter one piece per university across the
whole of the United Kingdom, and it will vanish
without trace. While you are correct in your assertion
that Governments can create a taxation, financial and
cultural environment and should not pick winners, if
you are to do a £50 million graphene programme, I
am sorry, Government, you are going to have to try to
pick two or three winners and give them not
sub-critical but super-critical financing, so that you do
enable them to be a leader in the facilitation and
deployment of this remarkable substance in new
applications. You will not get there if you scatter it to
the four winds.
Q117 Graham Stringer: Sir David, did you want to
add anything?
Sir David Cooksey: No. I totally endorse that.
Q118 Jim Dowd: One reflection on one of the things
you said is that in Germany, for example, it is much
more likely that you would have engineers rising to
the uppermost level, even becoming CEOs, and to the
higher levels of management of very large companies
certainly in the technological field. That just does not
happen in this country. In Germany there is not a
separate discipline of accountancy, for example. That
is something a manager has to acquire anyway, but,
here, companies are run almost entirely by
accountants, CEOs, company secretaries and so on.
First, do you think that is true as a generalisation?
Secondly, do you think that accounts for the fact that
R and D in Germany is so much more advanced than
it is here?
Sir Peter Williams: Answering your first point purely
factually, when I chaired the Engineering Technology
Board we ran an annual survey of the FTSE 100
boards. You will be surprised to learn—I have not
refreshed this exercise since 2006—that at that time
in 20 to 25 of the FTSE 100 boards, the leading
executive, sometimes chairman and CEO, sometimes
CEO and executive chairman, trained originally in
science or engineering. That contrasted with lawyers
and MBAs in small single figures and accountants in
the low teens. So, as a professional class, scientists
and engineers in the FTSE 100 as the leading
executives do rather well. It is something that, again,
somebody could very simply do the research on and
you might be pleasantly surprised. It is a moot point.
Somebody doing a first degree in engineering does not
make them an engineer, as we all know, but it is a
good start.
On the German point, I had the great pleasure a month
ago to entertain Hans-Jörg Bullinger, president and
CEO of the Fraunhofer-Gesellschaft. He was invited
to a seminar at the Royal Society. We had an
interesting audience. People from BIS and Hermann
Hauser, with his TICs, catapults, or whatever you now
call them, came along. It was very revealing to listen
to the fount of all wisdom in this whole sector, Hans-
Jörg, how the Fraunhofer came about in the first place
and how it operates. I will not bore you or detain you
today with the details of the story, but I commend
it to you. Down the decades everybody, from John
Fairclough onwards, has said to Government, “Look
at the Fraunhofer-Gesellschaft; there are lessons to be
learned.” It is a fact that they do not have to debate
the issues that we are debating today because they
have been through the valley of death as a nation,
as it were, and they prosper by valuing and backing
engineering with their Länder, federal government,
financial institutions, Mittelstand families, scientists,
engineers and business folk playing like a team, which
is why they are going to win the European
championship as well. They are a model, but please,
please, check, before we go away reflecting negatively
about it, the constituency of FTSE 100 and you will
be surprised pleasantly.
Q119 Jim Dowd: So we could have all these benefits
as well if all we did was change every single piece of
our social structure.
Sir Peter Williams: We might win the Euro as well.
Q120 Jim Dowd: I might win the lottery on
Saturday; sure.
Sir Peter Williams: We are different. Let’s play to
our strengths.
Q121 Jim Dowd: We have listened to much of what
you said earlier about the difficulties in this area in
this country. Are there any specific advantages of
commercialising research in the United Kingdom?
Sir David Cooksey: What should be an advantage is
the City of London, which is a big financial centre,
but the problem with the City of London is that it is
too short term. Again, that is a big difference between
the Germans and the Brits. Quite frankly, the City of
London reacts to financial incentives. The problem
with it is that it also tends to take financial incentives
and apply them to applications for which they were
not intended, and then we lose the incentives because
of abuse. I think we have to work out a way of
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incentivising much longer-term attitudes in the City
for getting money into these companies.
Q122 Jim Dowd: What about the potential of the
Government as a lead customer promoting it?
Sir David Cooksey: That is where we fall down very
badly compared with all our European partners and
particularly the United States. The United States
requires 25% of all Government spending, direct or
indirect, to go to SMEs. You see with the Department
of Defense, Department of Energy and various other
activities in the United States a huge amount of
commissioning of prototypes from these valley of
death-type companies. If one looks at, say, the
National Health Service, these companies have to wait
until they have grown by exporting their products
until they qualify to supply the NHS. If you turn that
on its head and require procurement from these
smaller companies, it would make a huge difference
to the economy of this country and to the success rate
of these companies in shallowing the valley of death.
It would make a massive contribution.
Sir Peter Williams: I talked about the science base
right at the opening. Within that, the stereotypical
image of the engineer as the lab-coated scientist or
mathematician could not be further from the truth. We
Brits are an idiosyncratic bunch; we are rebellious by
nature. I think that among the scientific community
there are literally tens of thousands of bright scientists
and engineers who have this kind of off-the-wall
characteristic that would lead them to take this leap
into the unknown if there was just some additional
carrot, and to me procurement is the low-hanging fruit
that this Government can seize and do something
about.
Q123 Jim Dowd: On universities generally, should
they all attempt to commercialise R and D, or should
we be looking to concentrate on a few centres of
excellence that specialise solely in that?
Sir David Cooksey: If you go back to pre-1985, the
old National Research and Development
Corporation—NRDC—had a complete monopoly on
any output from Government-funded science, and the
universities depended on it. Quite frankly, it suffered
from being part of Government and non-
entrepreneurial. Yes, it did foster certain things, like
magnetic resonance imaging and so on, but so much
got lost through the cracks of bureaucracy in the
whole thing. I do not think that every university in the
country has enough exploitable technology coming
from it to justify having a technology transfer
department of its own. Some of the big ones do.
Oxford, Cambridge, Kings, Imperial and UCL all
have plenty to exploit. I think you should see that
syndicates of the intermediate universities are coming
through and using expertise across a broader horizon
of universities to get the best of both worlds.
Sir Peter Williams: To add a comment, you will
doubtless have heard the words “academic freedom”
from others in this Committee. I think you should
encourage the pursuit of excellence in science, and
that is not uniform and egalitarian across the United
Kingdom; it cannot be. There will be what some
would term an elite. I just simply term them
universities who have a different function. There are
other honourable functions of a university than
becoming a world leader in some research field. So
focus on the research but then try to inculcate in those
leading research universities an ethos that says to any
individual academic that he or she may indeed focus
solely on the lofty intellectual heights of their
discipline, if that is what they so wish—that is what I
mean by “academic freedom”—but each and every
one of them should nevertheless be conscious of the
way in which society might benefit from the fruits of
their research and scholarship. Do not press it upon
them but create an environment where demand pull-
through is always better than push. If you attempt to
designate universities as technology-rich, research-
rich or teaching-rich, you are trying to force artificial
distinctions that the natural evolution of excellence in
research will take care of for you. What you need is
to get ingrained in the psyche of the young that
research is not only inspiring and fun, but it can be
damned useful and wealth-creating as well, and then
let nature take its course.
Q124 Chair: Letting nature take its course means
that that list of universities will not be a static one.
Sir Peter Williams: No; it fluctuates with time. We
have seen it in our own lifetime.
Chair: Two weeks ago we spent some time in
Warwick, for example; 25 years ago you would not
have thought that would have been possible. There are
some extraordinary achievements there.
Q125 Pamela Nash: Gentlemen, do you think that
the abolition of the regional development agencies
was the right decision at the time?
Sir David Cooksey: If we are talking about the valley
of death, it probably was. The truth of the matter is
that the regional development agencies started by
helping young technology companies, but their
performance in that area was woeful. As a result one
could say it did not work. What we have got to do is
replace that with something that is more effective and
not just forget it. What they were trying to do initially
was fine. Most of them walked away from it to a great
extent. What we need to do is use those same
resources much more effectively.
Sir Peter Williams: Declaring an interest, as it were,
I had a Scottish mother, Welsh father and I was born
in England. There is one thing that I think could
benefit from regionalisation. I admire a number of the
things the Scottish Government are doing in fostering
a climate, which we have ascribed to Government as
one of their main roles. Likewise, the Welsh in the
past have done something similar. The issue of the
RDAs and their abolition is, if you like, an English
question. As David has just said—I agree with him
entirely—there was little evidence that the RDAs were
prospering in terms of this agenda of the valley of
death, which we have been going on about for two or
three decades. We need something better.
I also remind people that Britain is about the size of
the state of Texas. Why is it that we feel we have to
have something different? I was brought up in
Yorkshire. For Yorkshire, the south-west and London
are so radically different. Can we not work out
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sensible, adult mechanisms that do not inevitably
focus on that which takes place inside the M25 and
deploy to strengths, where they are manifest and
evident, without erecting structures, committees,
regulations and red tape—I am sure there is a better
way of doing it—and encourage the Scots, Welsh and
Northern Irish to get on with doing their own thing,
which by and large they do pretty well?
Q126 Pamela Nash: Do you think that the new LEPs
are going to be able to provide a valuable
contribution?
Sir Peter Williams: I do not feel competent to
comment on that.
Q127 Pamela Nash: Okay; I will let you off. To
move on to the Technology Strategy Board, the
Government’s support for innovation is now
centralised in the TSB. Do you think that is the right
approach from the Government?
Sir Peter Williams: I am a fan of the TSB in concept.
In fact, in my SET and the City report, I single them
out as being worthy of receiving more Government
funding and having more clout and influence. I always
fear in this country when things become centralised—
this goes back to your regional question—that they
become risk-averse at the same time. I do not want to
trot out anecdote here. The last thing that you want to
hear as a committee is anecdote, but I have just a tinge
of a fear that they could be doing with—dare I say
it?—a touch bolder. It goes back to the picking-
winners question. There is such an aversion to picking
winners in this country. I say to myself that we are
being disingenuous because at the end of the day we
want a load of winners. Are we just going to wait until
they emerge? The TSB should, surely, be given the
luxury and responsibility of placing its best bets
wisely, and, if we are here criticising Government for
becoming timid and the City for being risk-averse, we
have got to show by what the TSB does that it is bold,
brave and is not risk-averse. That is my only fear.
Q128 Pamela Nash: What is preventing the TSB
from being more bold and taking those risks at the
moment?
Sir Peter Williams: It is structured like a plc, which
is fine; I have sat on plc boards for four decades. In a
sense, it is the right role model. I do not feel the
central executive have enough absolute power to just
get on with the job. What you want is a CEO and
team, backed by directors who both challenge them
and support them, who will take these bold moves that
all of us, viewing it from the outside, want them to
take. They have to be brave and risk failure.
Sir David Cooksey: To my mind, the TSB has been
very slow off the mark in the life sciences area. It is
only in the last few months that it has put together a
team of people to address the life sciences area; so
one huge part of the responsibility it had was not
being tackled.
Q129 Pamela Nash: Do you think that is just about
the rules and set-up of the TSB?
Sir David Cooksey: It is the way it has evolved. It did
start with a physical sciences responsibility. Having
been given the broader responsibility, it should have
got on with it a lot quicker.
Q130 Pamela Nash: Is it your impression that the
TSB is adequately resourced to do the work it is doing
at the moment in terms of both human and financial
resources?
Sir Peter Williams: You can never have too much
money in this sector. It is small by comparison with,
if you like, the private equity players in this space,
and, therefore, being brutal about it, its impact will be
commensurately small if we are not careful. So, being
risk-averse, which is a potential hazard for TSB itself,
and certainly a hazard for Government, will not get us
through the valley of death. Government have got to
be braver, and that might equate with redirecting more
money into the TSB from somewhere else with a zero
sum game, TSB has to be braver and bolder and
particularly take care of David’s life sciences point.
David is not alone in being critical of their slowness
off the mark in the life sciences.
Q131 Pamela Nash: Finally, we received various
pieces of evidence that praised the return of the
SMART awards under the TSB. Is this something that
each of you supports? Do you think it would be
beneficial if we expanded this programme?
Sir David Cooksey: The great success of the SMART
awards is the fact that they were simple and easy to
apply for. You knew what you had got and what was
expected of you, which is exactly what a small
emerging company wants. I thoroughly commend
bringing them back for that reason, as long as they
stay that way and do not get wrapped in more
bureaucracy.
Sir Peter Williams: Make a bit more razzmatazz when
you are giving them away; have a big flash do at the
Dorchester with lots of media and the press, the great
and the good, and Members of Parliament of course.
Q132 Pamela Nash: Are we not part of the great and
the good then? We are separate.
Sir Peter Williams: You don’t know us two.
Chair: Gentlemen, thank you for a very frank
exchange this morning. It has been incredibly helpful.
When you see the transcript, if you feel there are
additional pieces of information you would like to
feed in, we would be extremely grateful. Thank you
very much for your attendance.
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Q133 Chair: Gentlemen, thank you for joining us
this morning. I would be grateful if you would
introduce yourselves for the record.
David Sweeney: I am David Sweeney. I am director
of research, innovation and skills with the Higher
Education Funding Council for England—HEFCE.
Professor Haines: I am Ian Haines. Among other
things, for what is supposed to be one day a week, I
am the executive secretary of the UK Deans of
Science.
Professor Wright: I am Nick Wright. I am the pro-
vice chancellor for research and innovation at
Newcastle university. I am here to represent the
Russell Group universities.
Q134 Chair: With introductions like that, my next
comment is: your starter for 10. All the university
charters I have seen have some sort of reference to
the role of the university in terms of the local
economy. How does that work? Is there a conscious
effort within the university structures to work with
local entrepreneurs and businesses and try to create
centres of excellence that work within the regions they
are located in?
David Sweeney: Every university, of course, is firmly
located in a place. It is typically the second largest
employer in the area. Many of its graduates look for
jobs in the local area, and engagement with local
companies is just part of the scene. Different
universities have different missions. Cambridge is
quoted as saying, “Research excellence and return to
the UK economy should be a common goal.” I think
that, generally, for Cambridge that involves
interaction with large companies and many
multinationals, but still with a concern for the local
area. So I think we have a diversity of institutions.
Some are more focused on the local area than others,
but all of them have demonstrated a keen enthusiasm
for the benefit of the university and the economy in
engaging with business.
Professor Wright: I would support David’s statement.
What the Committee should really understand is that
over the last 15 to 20 years there has been a
considerable transformation in UK universities in
respect of the commercialisation of research. The
landscape now is very different from what it was 20
years ago. Most research universities, like the Russell
Group, have invested significantly in infrastructure to
support entrepreneurial things. For example, almost
all the universities have incubator suites for staff and
students who want to start their own companies. I
think most of the big universities have specialised
staff whose job it is to go round talking to local
companies, to understand their needs and to try to
address their needs either through research or more
applied work. It is a very diverse landscape, as David
alluded to, but huge progress has been made.
Professor Haines: To add a little to that—I think you
have covered a lot of the points—it is quite difficult
for an international research group necessarily to
relate to the local unless they have particular kinds of
companies close by. Most universities attempt to have
local people on their governing bodies. I would go
down to the undergraduate and postgraduate level as
well. Part-time students, who are always coming from
the local area, tend to give a huge amount of contact
between universities and the local companies.
I can think of examples. I have been round
universities doing all kinds of jobs in the past. In one
materials technology department, I saw a part-time
class being run. All these people were working in
companies in the polymer materials sector. The
tutorials were being run where students were able to
bring problems that they had into the tutorial class. I
remember that in one particular case an inspector was
wandering around the class. At the end of it, he said,
“That student got more consultancy value out of it
than they could possibly have been charged as a
university for what the member of staff told them
about how to solve the particular problem they had
raised.”
Professional doctorates are beginning to grow in the
science area; they have certainly grown significantly
in the health and psychology area. There is another
area where local people can go, at a higher level than
the usual undergraduate programmes, and begin to use
the interest and knowledge they have gained inside
their companies and other organisations and do a
doctorate, and finally realise how much further some
of their ideas can be developed, commercially as well
as academically.
Professor Wright: That is an extremely good point
and one that we do not often think enough about in
the UK. A lot of the big international success stories
of which one is conscious where technology firms
have come out of universities—Microsoft,
Facebook—came from students, not staff. It is
important that people realise the productive role that
students have in these sorts of things. I think all
universities now offer entrepreneurial modules that
students can do as part of their degree courses, for
example. That is encouraging a whole wave of student
entrepreneurs. In my own university, students form
about 40 to 50 companies per year. All of those are
in the local economy—in my case, the north-east of
England—but this is happening across the whole of
the UK and is very important. We have tended in this
country to ignore the contribution that students make.
Q135 Jim Dowd: Is it really that surprising, given
the fact that the staff are invariably by definition
academics? It is not the first thing they look at. The
student body is replenished certainly every year, if not
more; God knows how often the academic staff are
replenished. So it is a dynamic of the organisation, is
it not?
Professor Wright: You are absolutely spot on. It is
completely obvious, and you can do the maths on it.
My university has 5,000 new students a year. We are
a medium-size university, but we have a few hundred
new staff a year. It is likely that you will get much
greater churn. You also have a group of individuals
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who are at a stage of life when they can afford to take
risks, particularly immediately after graduation. They
tend to have very little in the way of family
encumbrances and so on. So they are in a position in
life; they have often got an attitude that encourages
risk as well. Actually they are a very productive group
of people. But the whole debate in the UK—the frame
of much of the evidence you have received—has been
about staff-led entrepreneurship and spin-out
companies. It is a shame we do not do more in the
UK to support students starting companies.
Q136 Chair: I think you were sitting at the back
when we were talking to the previous panel. You may
have heard us refer to our informal session at Warwick
a couple of weeks ago. The relationship that has
developed there between the Warwick Manufacturing
Group and regional business has obviously been
incredibly important, not just to the university but the
regional and, indeed, the national economy. Is there
not a responsibility on the university sector to look for
synergies like that?
Professor Wright: I think there is, but that is already
widely understood. Of course, different parts of the
UK have different types of industrial clusters, don’t
they? I am sorry to talk about my own area, but it is
the one I know best. In the north-east of England there
are two predominant industrial clusters. One of them
is the chemical industry, where I believe that, as in
the north-west, we have a very significant proportion
of the GDP of the chemical industry in the country.
Our university, Durham, Teesside and Sunderland
work a lot with local chemical companies. There is a
lot of stuff going on.
The other big sector in our area is the marine and
offshore sector. Again, our university has a big
department in marine engineering. We support the
local economy very deeply. It is the same in the south-
west. Bristol university set up the National Composite
Centre to support the aerospace industry in the south-
west. You will see different clusters, but now that
every major university is involved in some kind of
activity of that ilk, and that is a tremendous thing to
happen over the last 20 years.
David Sweeney: I would absolutely take it for granted
that in the mission of every university is a
commitment to work not just with business and
industry but the social and cultural sector. We also
have a stream of funding that is hypothecated to
support that in the higher education innovation fund.
On measures of success, the income to universities
has shown a tremendous, 50% increase over the last
six years. I think it is absolutely embedded in
universities that there is a commitment to society. That
has been reaffirmed in the contribution to society of
research being taken as part of the method of
assessment. It is part of the commitment to students
on employability. Student enterprise is very attractive.
We have funded NACUE, a charity that supports
student enterprise societies and young entrepreneurs,
to provide infrastructure, so that universities and
students with their enthusiasm can have that harnessed
and channelled to a profitable end. I think the
incentives for universities are there to do what you
describe, and I think universities are enthusiastic
about it.
Q137 Sarah Newton: I would like to come back to
what Professor Wright said. I represent Cornwall. The
University of Exeter has just become a member of
the Russell Group. In my lifetime, the community in
Cornwall has been transformed by having a university.
There was no university when I grew up there. I
would very much endorse what you say about the
importance of working with renewable energy
companies and deep geothermal in the marine
environment. It has been enormously beneficial both
to the university and the students but also those
businesses, because they say that the university is their
R and D department and they could not develop
without that. So, I can see, even in a very remote part
of the UK, away from the golden triangle, world-class
Russell Group research going on. That is quite an
unusual situation in Cornwall. The Russell Group
does attract the vast majority of research funding. To
what extent do you think that those institutions have
a responsibility in their wider regional economies to
enable different sorts of organisations to work in
partnership with the Russell Group and benefit from
some of that research funding?
Professor Wright: There is a responsibility, and that
responsibility is now quite openly acknowledged.
Most Russell Group universities have modified, for
example, their mission statements and corporate
documents. If you read those documents, you will find
embedded in the corporate thinking of the university
an acknowledgement of that responsibility, which is
taken quite seriously. I would like to speak about
universities now rather than in the past. In the past,
perhaps that was not the case, but my experience now
is that that is very much acknowledged. It is good for
the universities as well. While it is very important that
universities are part of the global research game that
you heard an earlier witness speak about, you can
float, a bit disconnected, on that global market, if you
are not careful. Some degree of regional rooting is
quite healthy for the universities as well, so a local
connection based on pursuing interesting and
excellent ideas, like the ones you talk about, is very
helpful as a balancing force with the global push that
you also see at big universities. I think it is good for
us, but I hope it is also good for the local economies.
David Sweeney: The Russell Group does a
tremendous job and it works in partnership, but I
would not see that as the focus of the work in
Cornwall, for example. The University of Plymouth,
with its very strong enterprise offering, is the right
university to lead. Exeter is part of that. University
College Falmouth, as well as combined university
colleges, is involved. You have to be alert to the
particular regional needs, rather than trying to craft
the regional needs to fit what the Russell Group might
offer, and that is exactly what is happening. Plymouth
is active in co-ordinating work that no longer happens
because the regional development agency is not there.
It is active in Brussels looking at opportunities for
structural funds in Cornwall. The university has taken
on a tremendous role, led by Plymouth but in
collaboration with others.
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Professor Haines: I agree with both responses. If I
can throw in one negative point about regional issues,
I think that London, or the M25 area, is a problem in
relation to universities of all kinds working together.
The regions have got some reason to do it. In London,
there is a tendency for the largest universities to
plough their own furrow and not do the same sorts of
things as both these—
Q138 Chair: To whose disadvantage?
Professor Haines: I think to the disadvantage of all,
including UK plc.
Q139 Jim Dowd: What about the economic health
sciences outside the initiatives of Imperial and King’s?
Surely, that is a local thing, particularly in an area
where, as we heard from earlier speakers, we are
lagging seriously behind, largely because of the
monolithic nature of the NHS?
Professor Haines: I would agree.
Professor Wright: You are right. In life sciences and
wider health sciences, the economic benefits of
medical research are not just drugs; they often come
out in other ways. The NHS is both an enormous boon
to the UK in that respect but also, to a degree,
something which inhibits innovation. The NHS itself
has got better. There are many initiatives within the
NHS to try to encourage innovation, ideas brought
both from universities but also from within their own
staff, but it is a very big organisation and is very slow
to move. I did not hear all the evidence given by the
previous witnesses, but I would echo the point made
about procurement in the NHS. It is quite bizarre in
the modern age that we do not use both NHS and
MOD procurement, for example, as an effective tool
to encourage innovation.
Q140 Sarah Newton: Going back to the theme of
my questions: you are absolutely right that there is a
unique partnership in Cornwall between Plymouth and
University College Falmouth. I am glad you have
reminded the Committee of that. They are in my
constituency, so I know them all very well. It is a
partnership effort. That is a very good model for us,
but it has been suggested to us by other witnesses that
it would be better if universities in particular areas
were designated with responsibility for the
commercialisation of science into companies. You
would not have every single university trying to do
the same thing, but lead universities in particular areas
would be doing that. What do you think about that
idea?
David Sweeney: I do not think we do have every
university trying to do its own thing. Although all of
them have a commitment to supporting business and
the economy, they do it in different ways. We already
see collaborations happening: Aston, with Oxford’s
Isis Innovation and Cranfield with Imperial. We
already see universities keen to cut their costs by
sharing activity. We have funded collaborations
through our higher education innovation fund. Some
of them prosper where the universities see mutual
benefit, but some of the structural collaborations we
have encouraged founder because the objectives of the
universities are different. I am all for universities
sharing services; we do a lot to support that, but we
have to let those grow organically where universities
see benefit to themselves and business coming from
shared activity.
Professor Haines: Incidentally, that is not to say—
this was one of the points made by the earlier
witnesses—that having technology development
centres that work across universities is not a good
idea. To think of every university, especially those that
are not terribly active, having a complete office to
look after its commercialisation seems to me to be
quite a good idea.
Professor Wright: There is an obvious problem as
well, which is that universities do research across a
broad spectrum. We might one day have an idea in
life science and on another day in aerospace, but we
have only a very small number of technology transfer
staff, so we cannot really maintain the expertise across
that broad spectrum. Some kind of collaborative
working helps a great deal, and a lot of universities
are doing it either formally, through the partnerships
that perhaps feature with HEFCE, but also informally.
You will find that the universities in your constituency
are meeting regularly and sharing information and
best practice among themselves in a way that is
probably quite surprising to people.
Sarah Newton: Oh, indeed.
Professor Wright: That helps them maintain a breadth
of expertise, which I am sure they find very helpful.
Q141 Sarah Newton: Following on from that, it has
been suggested to us that the caps on funding by
HEFCE for those institutions that are fostering this
collaboration should be lifted. I am just wondering
what you feel about that.
David Sweeney: I have absolutely no doubt that the
cap we have on the higher education innovation fund
would, if lifted, lead to more activity, but we have a
fixed pot. We gave great consideration to how we
allocated the funding. We did withdraw funding from
about 30 universities which we did not feel were
demonstrating sufficient performance to justify
funding, although I have to say that was performance
in terms of income; they were doing some great things
that were not represented in income. If we want to
support the breadth of the UK economy, we want to
support the kind of thing that happens in Plymouth
and Cornwall and we want to support work with small
and medium-sized enterprises, we have to have some
kind of cap, given there is a limited budget, to ensure
money flows across the breadth of universities. At the
moment, on the evidence we have, we have got that
right, but we review it every three to four years. If
only we could have more money and release that cap,
we could stimulate more activity. We know there is a
return of roughly £6 for every pound invested in
Higher Education Innovation Funding. The highest
performers return about £14 for every pound invested
in HEIF. We would love to invest more, but times
are tough.
Professor Haines: You are talking about the cap at
the top and bottom of the funding. Looking at the list
of amounts of money awarded to different
universities, it would be very unfortunate if an
increase in the cap at the top end were to reduce the
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amount of money going to some universities. Just
once, I shall be parochial. My ex-university, the
London Met, where I was director of the graduate
school—I admit it is not a research-intensive
university—was receiving something like £1.5 million
from the HEIF, and a university like Coventry
receiving something like £2.5 million. It would be a
great shame if universities falling into that part of the
sector were to lose a significant amount of the money
they get to deliver what they are doing, in different
ways from those that are at the £2.85 million cap.
Professor Wright: In general, most of the sector
believes that HEFCE has shown quite good judgment
in HEIF over the years. The important thing is
continuity. We cannot recruit technology transfer
officers if we have to make them redundant three
years later, so continuity is very good and helps
everybody. I am not going to embarrass David, but
HEFCE has done a very good job with HEIF.
Q142 Caroline Dinenage: Professor Wright, I would
like to pick up what you said one question ago about
the fact that a lot of ideas are coming up, and there is
a lot of potential research fodder there for your
students to get involved in. Is there pressure on them
to focus their research on the things that are going to
be more commercially viable and financially
profitable, rather than the things that might purely
increase the UK’s research standing?
Professor Wright: Pressure on the individual research
students or young researchers or academics?
Q143 Caroline Dinenage: Yes, and the academics.
Professor Wright: I do not think so at individual level,
and that is probably right as well. It is entirely
reasonable to expect a research university that has a
substantial grant income to be regularly producing
good commercial outcomes, either spin-out companies
themselves or, more importantly in many ways,
transferring technology to existing UK companies. If
you put that pressure on individuals, I am sure that is
not right. If you compare international best practice, I
do not think that is an approach followed by any of
the competitors we hear favourably spoken of. The
system is balanced at the moment. Individuals have
the freedom to pursue their research, but universities
have the responsibility to find the golden examples
among that portfolio and make the very best of them.
That is probably the best approach.
David Sweeney: In terms of the incentives behind the
science budget, the research councils, funding
councils and indeed the TSB talk frequently about the
balance of incentives that we are providing. We are
all agreed that excellence in research, delivering the
seed corn for the future, is the priority. However, it is
not the only objective. It is clear from the research
councils’ policy and ours on research assessment that
the highest quality world-leading work, much of
which is theoretical and will lead to a contribution to
society well down the line, is the priority for
universities and funders, but that is backed up by
recognition that more applied and immediate work is
often good and will be rewarded.
Q144 Caroline Dinenage: Do you think there is an
imbalance between the investment that goes in at a
low level of technological readiness stage, or the
research stage, and almost a lack of available funding
when it comes to the bridging of the valley of death
later on? Would that be an issue?
David Sweeney: The way that our dual support system
works, with roughly half the money being spent by
the research councils on projects and programmes,
where it has considered what the grand challenges are,
and roughly half the money going to universities as
a un-hypothecated block grant, is intended to deliver
flexibility to universities in chasing what they think in
their engagement with research users—business,
industry and the cultural sector—is the most sensible
way forward. No one person is taking a decision about
the balance. This is a devolved decision between the
research councils taking disciplinary views and
universities taking views which we insist are informed
by the engagement with research users. There are
mechanisms in place to achieve a reasonable balance,
and I do not think anybody has produced any evidence
that our balance is significantly awry. We continue to
perform exceedingly well in world-leading research,
as measured in citations, and we see multinational
companies repeatedly rolling up to this country
because of the strength of the research base and
wanting to work with us. Although one must always
question what we are doing, at the moment there is
quite strong evidence that we are in the right area.
Q145 Caroline Dinenage: We seem to hit above our
weight in terms of basic research internationally but
not necessarily always in commercialisation activity.
You do not think that the balance of funding is in
some way awry.
David Sweeney: We have to tease out that oft-quoted
view. We have done a lot of research. We have had
the Centre for Business Research at Cambridge,
PACEC—the Public and Corporate Economic
Consultants—Library House, as was, and also the
OECD working on this. In terms of incentives to
universities, the UK ranks alongside the US. We have
more spin-out companies per pound of investment in
the UK than in the US. Certainly, the US is ahead on
licensing; the UK is ahead of the States on building
recognition for business engagement into promotion
procedures, and both of us wrestle with very similar
problems with technology transfer offices. The US
complains about inflexible technology transfer offices,
as crops up in this country. In terms of the incentives
to universities, we are competing with the US. Taking
work through to commercialisation is certainly not
just about universities and public funding. You have
to look, as indeed you are, much more broadly at the
environment for taking ideas, as the TSB puts it, from
concept through to commercialisation. I am not sure
that at my end, the university end, we have an
imbalance.
Professor Wright: I agree largely with what David has
said. You have to see it in a much broader context. I
have spent part of my career in industry—I am an
engineer by background—and part of my life in
university, so I have seen the problem from both ends.
When I was working in industry, the technologies
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were much more developed than the kind of ideas that
typically come out of a university research lab. If I
was investing my own money or my company’s
money, I would look pretty sceptically at some of the
propositions put to me by university research teams,
because they are at too early a stage, too preliminary.
Most large economies have understood this problem
quite well and put in place what you might call a
national innovation system of some description. It
varies between different countries. In Germany, it
works differently from the way that it does in the US.
We seem to be the only major economy that thinks
we can make this work on fairy dust and good
intentions. It is quite perverse. Most countries have
put in place a proper system. It does not have to be
heavily prescribed; it can be an informal system, but
there is a national innovation system of some kind,
and we desperately need that in the UK.
Q146 Caroline Dinenage: What form does that take
elsewhere?
Professor Wright: It can vary. The Fraunhofer system
in Germany is well acknowledged; the US system
works quite well. We have to think very carefully
about our national characteristics and the way that we
work in the UK and tailor that to our needs. I think
the previous set of witnesses said much the same
thing. This is desperately needed in the UK. We must
first understand the necessity for this first of all. It is
not an impossible problem to solve; we can easily do
it. The Russell Group universities have a pretty strong
view about what we would like to see as part of a
national innovation system, but unless we put in place
a system, we will suffer these problems. The
components you would expect to see in that system
are definitely support at the early stages from public
finance, as David has alluded to, from HEFCE and
research councils, but you also need to bring into play
things like government procurement and, for example,
military procurement, which is what happens in the
US. Most small US technology companies receive an
enormous amount of money from the American
military through various programmes. That is their
support mechanism and national innovation system.
Q147 Stephen Metcalfe: You have been talking
about a national innovation system. You mention the
Fraunhofers. The Government have taken steps
towards creating the catapult centres, under the
guidance of the TSB.
Chair: We know about the catapult centres. We do
not like the name.
Stephen Metcalfe: Yes. It is supposed to be based on
the Fraunhofer model, but do I take it from what you
said that it is not going to fulfil that role?
Professor Wright: The comparison between the
catapult centres and the Fraunhofers is a big topic.
There are many more Fraunhofers in Germany than
the catapult centres. One observation that Russell
Group universities would make is that there is a much
closer interaction between Fraunhofers and German
universities than between catapults and UK
universities, for example, so that is an open question.
Q148 Stephen Metcalfe: But are not catapult centres
that have been established so far all established
around universities?
Professor Wright: A small number of them have been.
David Sweeney: I do not think the objective is to
establish them around universities. These are
business-focused organisations, where universities
will be stakeholders and will contribute. We have got
half a dozen catapults in development. We have
different models for the different catapults that reflect
the different structure of the industries involved. Good
progress is being made in setting them up, but until
they have had an opportunity to deliver, it is difficult
to say whether they are a significant or small part of
the answer.
Q149 Stephen Metcalfe: The jury is out.
Professor Wright: I would disagree with that. I do
not think good progress has been made. They are too
disconnected from universities. The Technology
Strategy Board is not talking to universities about the
alignment of strategies. For example, every year we
invest in new staff and researchers. That is not being
done in a co-ordinated way with the TSB.
Q150 Chair: But if you went down the route of the
German Fraunhofer model, you would redirect
resource from the research councils directly to the
Fraunhofers and not to the universities.
Professor Wright: I do not think we should go for the
German model. The German model works fine for
them, but they have a very different system. The way
that they have designed their national system puts
different functions in different parts of it.
Q151 Chair: You want to bolt both bits together. I
am all in favour of more money going into research,
but you want it to go through the research councils to
universities and a separate sum of money to go
through the TSB into the catapults. You are inviting a
still larger sum.
Professor Wright: Of course. It would clearly be a
mistake for the nation to cut off its future by shutting
down research funding. That would be a calamitous
mistake. At the same time, we need to make much
better use of the very large sums of public money that
are going through procurement in things like the
MOD and NHS, for example. If you are looking for
an extra source of revenue, it is staring you in the face.
Q152 Jim Dowd: You were talking about the
national approach to innovation. I just want to look at
a national approach to providing the correct balance
of courses across the higher education sector. Whose
responsibility is it—this is a question for anyone who
wants to answer it—to ensure that the balance across
the nation as a whole in the different disciplines,
particularly engineering, science and technology, is
provided by the higher education sector?
Professor Haines: Can I start by reminding the
Committee that it is demand-led, and the demand is
student demand?
Q153 Jim Dowd: So, your answer is nobody.
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Professor Haines: It is students who create the
demand. There have been a small number of
initiatives to support STEM degrees. Amounts of
money have been given to professional bodies to press
the case and to advertise the opportunities in science
and engineering. But we do have an issue, because
students are loaned money by the Government to go to
a university and apply for a programme. Every science
department and faculty I know works incredibly hard
going to schools and other places to try to convert
people to study science, but, frankly, it is led by
student demand. It is very unfortunate at the
postgraduate end because such a significant amount of
student demand is international, rather than home-
based.
Q154 Jim Dowd: This is chicken and egg, is it not?
Professor Haines: Absolutely.
Q155 Jim Dowd: They apply for the courses that
are there.
Professor Haines: No, absolutely not. Universities are
putting on courses for which there is a demand.
Universities are continually closing down courses for
which there is not a demand.
Q156 Jim Dowd: So this is not a strategic question;
it is just a market question.
David Sweeney: It is a strategic question as well. We
have always had student choice as the key element in
the courses that universities run. However, we are
putting a good bit of effort at the moment into
informing students about employment opportunities,
wage outcomes and success in getting jobs, in all
disciplines, so they can make wise choices. We have
had a campaign running for six or seven years
working with STEM people in schools, working with
universities and professional bodies to try to stimulate
students to choose science and engineering subjects at
school, and supporting capacity in universities, where
perhaps in the short term there is a drop off-in
numbers, so they can maintain that capacity until
numbers flow again. We have seen some significant
successes notably in maths and some areas of
engineering, although not in others. There is a
strategic approach to encourage universities, who are
working with us—I speak very highly of them—to
provide opportunities for students. There is a strategic
approach, with schools, to persuade students to do
STEM subjects, but it is up to students to choose that.
We have had some success in this over the last five
years, and we need to keep at it for the next 25 years
if we are going to produce the skilled graduates in the
number and disciplines that the nation needs.
Q157 Jim Dowd: That is exactly what I was aiming
at. Individual higher education institutions just work
with the funding council on the general strategy of
producing students who can make the choice. There
is no guarantee that, even if they have got the
qualifications to move into science and engineering
when they go to university, they will actually do it.
David Sweeney: Nor is there any guarantee if they
achieve good science degrees, as many do, that they
will go into employment in that area. Indeed, our
business scene is considerably enriched by people
with numerate skills who go into management
positions. We are absolutely determined to stick at
encouraging universities to offer a broad range of
courses and students to choose to do that, but you
cannot keep running courses if repeatedly nobody
chooses to do them. There is absolutely a national
strategy on this, but it is not directive of individual
students.
Q158 Jim Dowd: How much can you factor in the
vagaries of one year’s intake compared with the next?
Just because in one year there is a fall in the numbers,
so there is a financial question for the institution, you
cannot simply say that you are going to close down a
department simply because you have not got enough
students this year.
David Sweeney: There is a shared responsibility with
universities. It is in their interests to support things
over the medium term, as Nick has pointed out,
because stability in research goes alongside teaching.
Teaching and research are inexplicably linked. I do
not think there is any danger from very short-term
fluctuations. There is a danger from medium-term
fluctuations. That is what we had, for example, in
maths and we set about doing something about it. In
computer science, we had a big bubble, and now we
are in the rather tricky position that there are poor
employment outcomes for computer science
graduates. The key question is: do you make this
information visible to prospective students in a way
that they can understand, and also visible to schools so
that careers advisers in schools can help prospective
students? In publishing our key information set, which
we hope will be available and accessible to those
groups as a way to help, we think we are going to
help students come to wise decisions.
Q159 Jim Dowd: Is it your estimation that we do
have enough science, engineering and technology
graduates at the moment, or is it a reflection of the
job market, in that it is the market that determines
what courses students sign up to? If there are
unemployed science and engineering graduates, are
we producing too many?
David Sweeney: Science and engineering graduates
offer a wide range of skills beyond the particular
knowledge in their discipline. I think we need more
of them, but it is quite difficult to analyse at the
moment, given the state of the economy, what the
continued need will be. We talk a lot to the CBI and
businesses generally. We have the Council for
Industry and Higher Education, where vice-
chancellors and captains of industry meet, and we are
getting a consistent view from business that they want
more STEM graduates. Although there are limits to
what we can do to achieve that, that is our intention,
recognising that arts, humanities and social science
graduates also have fantastic skills and many end up
in very senior positions.
Professor Wright: Perhaps I might add one thing. One
of the issues is that sometimes it is quite difficult for
universities to respond quickly to changes in the
demand for graduates. Sarah Newton talked earlier
about work in her area around renewable energy.
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There is a big global boom in renewable energy.
Almost all of that renewable stuff is connected with
electricity at some time, so there is a big demand for
electrical engineers. If you talk to any major
infrastructure company, they will tell you that they are
desperate for electrical engineers. It takes more or less
five years to go through a degree to come into that.
You then have to have professional training, and there
are not enough people coming through the system
quickly enough. It may be that particular industrial
sectors industry can make a coherent case to
somebody, perhaps David, to encourage a faster
response in terms of training more people more
quickly. The big danger is that if the companies cannot
get the people they need, they are forced to move
operations overseas because they simply cannot find
enough electrical engineers.
Professor Haines: I realise that the Chair wants to
move on, but let me add: I think we have answered
this question on the basis of thinking of graduates
doing their standard bachelor degrees and further up
the scale. There is a major issue about the training of
technical staff for a whole range of careers, which we
have not touched on.
Q160 Caroline Dinenage: Sorry to jump in, but this
is one of my pet subjects. How much are universities
doing to communicate with the schools at an early
stage to educate kids as to what GCSEs they should
take to pursue STEM subjects, for example? In my
constituency, we have an issue, where schools are
encouraging kids to take a combined science GCSE
and that prevents them from taking any of the STEM
subjects further up the food chain. At the age of 13
they are almost writing themselves off from some of
the careers that you have mentioned, because of a lack
of good advice from teachers and other staff around
them. At that age, potentially, they are not going to
think about their future and what kind of career they
may want to go into, but it cuts off a whole lot of
other careers.
David Sweeney: Every university I know is
substantially involved in schools outreach, and some
of that we have funded directly where we have
thought—for example, in physics—that there are
limits and we need to encourage more. This week,
we have seen potential developments with university
involvement in A-level curriculums. These things are
there. I suspect we could do more of it.
Q161 Caroline Dinenage: It has to be earlier, I think.
David Sweeney: Yes. It is really great to get into
primary schools. There is some wonderful work
funded by foundations, but it is just an issue of scale.
Q162 Chair: Absolutely. I am going to really push
you on this. There is undoubtedly a weakness in our
primary schools. We have some fantastic, well-
motivated primary schools but a massive shortage of
primary school teachers with any science or
engineering experience. Last year, I did some work
with the Royal Society of Chemistry and the Chemical
Industries Association to produce a DVD for primary
school teachers to help them explain basic scientific
concepts to children. Why not are the universities
doing it when they are training our teachers? It is
their responsibility.
Professor Wright: I am not sure I understand your
point.
Q163 Chair: We have a lot of very inspired young
teachers who have no qualifications and training in
science and engineering, but the university sector
trained them. Why do they not do that work with
young teachers to help them manage and inspire
people about things around them?
Professor Haines: Part of the reason—it is a rather
trite answer—is that there are too many things in
teacher training courses that need not be there and
need to be removed to make space for this sort of
thing. It is a very difficult thing to do. I would not
fancy trying to do it, with my experience of teaching
science in all kinds of different ways, but that is one
of the major issues. Let me throw in one more thing.
As well as many more primary school teachers
understanding science better and how to teach their
pupils, we need much better training of careers
advisers in schools, most of whom have an idea that
if you are going to do an A-level in chemistry the only
thing you can do is be a chemist or use it to get into
medical school and become a doctor or get into a
veterinary college.
Q164 Stephen Mosley: Changing the subject a bit,
we have heard of some blockages that stop academics
interacting with business. One is the Research
Excellence Framework. Do you think the REF
encourages academics to be involved with business,
or does it prove a hindrance and, if so, what would
you do to change it?
David Sweeney: I am responsible for the Research
Excellence Framework. We have incorporated, for the
first time, an explicit recognition of the contribution
that research makes to society, although there always
been recognition. We have pitched the level at which
we do that to reflect the importance of basic research
alongside work that makes a contribution to society. I
look round the university sector now, as people are in
the middle stages of preparing their submissions, and
I think universities have been galvanised by this, not
to alter their research programmes, but to dig out the
work that they have done and celebrate it, and to
stimulate greater engagement with business and
industry, so that research programmes are better
informed. I see a more positive attitude, which was
the intention, but we have to do the exercise. We have
to see what the outcome is and get feedback from the
universities on how they felt it was helpful to this
agenda, and whether there are issues that we need to
resolve. I think we have considerably adjusted
universities’ attitudes to research.
Professor Wright: I think that there are some side
effects from the REF, but I do not think that is one of
them. The REF in itself does not create any obstacles
for academics interacting with companies. Generally,
successful academics generally see themselves as
having a portfolio of work. Some of that work will
be fundamental and produce pure blue-skies research
papers, which they might submit to the REF, and often
they will have a portfolio of more applied work. The
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important thing is that people need to understand that
most successful academics are doing all of these
things at the same time; they are both doing pure
research but also working with companies. What we
really need to do is free up as much time as possible
for those people to do productive work, but I do not
think the REF in itself is an obstacle to any of that.
Q165 Stephen Mosley: There was quite a discussion
with the previous panel about intellectual property. In
some ways there is criticism of the universities in not
fully using their IP potential. What responsibility do
you think universities should have for assessing the
value of their IP and making sure that it is out there
for use?
Professor Wright: There certainly should be a very
strong moral obligation on universities to do so. That
situation is one of the things that has improved a lot
over recent years. For example, several members of
the Russell Group universities banded together into
what is called the Easy Access IP consortium. That
is quite an innovative arrangement created by Steve
Beaumont, a very forward-thinking guy, at the
University of Glasgow. It is a system whereby UK
companies can access IP from member universities for
free, provided it is to the benefit of the UK. That is
an excellent scheme. There are other schemes. In the
north-east, we have a similar scheme, allowing
collaborative working between Newcastle and
Durham universities, for example. That has probably
been one of the biggest changes in the last five years,
but we need more of those kinds of initiatives.
David Sweeney: It is an incredibly strong
responsibility, because most of the research is publicly
funded, so the intellectual property ought to be
deployed for taxpayers’ benefit. We have established
over many years, and internationally too, that there is
no single model for managing IP that provides an
optimal solution. We are very interested in, and
support, the Easy Access IP option. You triage the IP
at the start and treat that which you think has very
high potential differently from the bulk of IP. It
depends on the industries you are working with and
the way they want to manage their IP. We see
universities that work with commercial partners to
manage their IP; we see universities that do it
themselves. If we could identify an optimal model, we
would be further ahead, but nobody internationally
has done that. I am pleased that universities are
choosing different ways of doing it, so that we can
learn from each other.
Q166 Graham Stringer: Professor Wright, if I may,
I shall go back to the answer you gave earlier about
academics spending half their time with industry and
half the time on academic activities. When I have
talked to vice-chancellors, they have often said that
one of the problems of getting a transfer of good ideas
into business and technology is that there is a conflict.
Academics want to get their research out and publish
it, and you need to be quite secretive if you want to
make bags of money out of a new idea. We have not
heard that said once in this inquiry. Has the culture
changed, or is it just something we are not bringing
forward because it is too difficult?
Professor Wright: Those kinds of issues do occur at
the level of the individual academic who may have a
strong collaboration with a company and the company
wants to be more secretive about the work than the
academic does. I have been involved in discussions
trying to look for a negotiated agreement between the
academic and the company. I do not know whether it
is a systematic problem. It is a problem that occurs on
individual projects.
Q167 Graham Stringer: If you are an academic, you
are going to get your reward by citations and lots of
papers showing that you are the first in that particular
field, aren’t you?
Professor Wright: Earlier you or someone else
brought up the example of graphene, which is very
interesting. If you look at many of the latest results
now coming out where the technology is being
applied and people are publishing papers in the top
journals in the world—Science and Nature—you will
find that a lot of them are being published by
industrial companies. Very few of them are UK
industrial companies; they are mostly Korean and
American. It is clear that many companies consider it
to be to their advantage also to publish their results.
It is good for the company. Investors in the company
want to see that, and it is a form of public relations,
if you like. Many companies also want to publish. I
know that Rolls-Royce, with which I have worked a
lot, is keen to publish papers on its work, and many
other big UK companies are as well, so the idea that
companies want to hide everything is not really true.
A lot of companies want to publish, but what you get
are occasional difficulties, which usually can be
solved by discussion, and an agreement can be
reached. I do not think it is a widespread, systematic
problem.
David Sweeney: Nor would I like to stereotype all
academics as getting their reward through citations.
One of our successes over the last 10 years has been
to unlock entrepreneurial instincts in many academics.
Where we have academics who want to behave like
that, surely we want to encourage it, and they ought
to see some of the fruits of success going to them. It
is a shared responsibility between the academic, the
university that has employed them and, of course,
business. We have got to have vehicles for that to
happen. I do not think we have a systematic problem.
I agree with Nick that occasionally there are tricky
issues where we need legal help to find the best way
forward.
Q168 Chair: Should that not be reflected in the way
academics are assessed?
David Sweeney: It is.
Professor Wright: For example, the promotion criteria
in my university are about research and teaching but
also about engagement with either companies or the
local community in some way.
Q169 Chair: Is that sufficiently reflected in the way
the research councils operate, for example?
David Sweeney: I think it is. The research councils
are very enthusiastic about academics behaving
entrepreneurially.
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Q170 Graham Stringer: Researchers are
increasingly being asked to justify their work by
impact. We have had academics here who say that
is particularly difficult to do. Do you think that that
emphasis on impact, which nobody can really know—
because you do not know what is going to happen
in one, two or three years’ time—is in conflict with
excellence in research and a focus on absolute
academic excellence?
David Sweeney: I do not think individual academics
are generally asked to demonstrate their success
through impact.
Q171 Graham Stringer: But they are when they
apply for research grants.
David Sweeney: No, not at all. The research grants
are awarded primarily on the basis of excellence. The
research councils have been very clear on that. You
will have an opportunity to ask David Delpy.
Q172 Graham Stringer: That is not the evidence we
have had here. We have had evidence that people have
been asked when applying for research grants to
assess the impact. We have had very different
evidence about how that is evaluated.
Professor Wright: If you apply to the EPSRC, you
provide details of your scientific vision, but you are
also asked to fill in an accompanying document which
describes the pathway to impact, in the sense of how
you are going to help any impact that may be there to
flourish. That is probably a reasonable approach. It is
not asking the academic to prove there will be impact,
it is just saying, “What will you do to encourage it,
if anything is there?” That puts an obligation on the
academic to disseminate the information and
encourage local industries to come and learn about it,
for example. This has gone on in the US for a long
time. In the US, you will see quite commonly an
academic group will have an open day one day a year
to which they invite local companies. They will write
to 100 local companies and those companies will
come and tour the labs for an afternoon. One
afternoon a year is not a big burden on a research
group. That is the sort of mechanism the EPSRC is
asking for. There has been a change, and there are
some academics who are choosing to see that in the
way that you describe, but what the EPSRC is asking
for is something different; it is asking for people to
provide an explanation of how they are going to
encourage that kind of thing.
Q173 Graham Stringer: This is a real problem, and
I not think you can dismiss it. I have heard organic
chemists, physicists and all sorts of people
complaining about it, so it is a real issue in the
academic world. What I was trying to get at is whether
that is distorting the work that is being done.
Professor Wright: It probably plays out differently in
different disciplines. Some disciplines are more
naturally aligned to it than others, aren’t they? There
are strong opinions among discipline groups. In
particular, organic chemists are well known for their
view; other groups are less worried.
Q174 Graham Stringer: Let me finish my point and
Jim’s point, which you may want to consider. The
largest impact I have seen in encouraging people to
get into physics is by having a sexy professor who
presents good programmes.
Professor Wright: Absolutely: it works.
Graham Stringer: The demand for physics in
Manchester at the moment, particularly from women,
is through the roof, so maybe you should think about
that.
Professor Haines: From the perspective of UK deans,
when I was preparing our response to your
consultation exercise, I was quite heartened by the fact
that everybody who responded to the particular issue
of impact and commercialisation indicated that they
would be only too happy if any of their staff said to
them, “Look, I have an idea but I need two years to
work through it. If it works it will be worth umpteen
millions to the university, but it may be that in that
time I will not be able to publish in the same way as is
important to the REF and the research councils more
generally.” I do not think there is any discouragement;
in fact, there is quite a lot of encouragement to people
to look into the commercialisation of their work.
Personally, I do not think the impact agenda is going
to have a serious effect on research excellence, but
only time can tell. There is no doubt that the last 10
years have seen changes in attitude and in what
happens in universities, which right now we would
say is all to the good in terms of IP and
commercialisation. If you had asked academics 10
years ago if they would have been comfortable with
where we are now, quite a few would probably have
said no.
If I may make just one plea—we put it in our
response, but I make it publicly here—I ask you to
ensure that whatever you suggest makes allowance for
mathematicians who, however they do their work and
however they try to commercialise it in the short term,
quite often have a great deal of difficulty and
commercialisation is way into the future. I say that as
somebody who is not a mathematician.
Chair: The Chairman has a vested interest in
mathematicians. We are extremely grateful for your
evidence, gentlemen. Thank you very much for
attending.
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Q175 Chair: First, may I thank you for coming to
see us today and thank those responsible for inviting
us to your superb facilities here? It would be helpful
if, for the record, the five witnesses would introduce
themselves. We have quite a few questions that will
overlap, and we are trying to get opinions from all of
you. It is going to be quite difficult to do it in the
allocated time, so if you get squeezed out and have
got something to say, it would be really helpful if you
could pass us a note afterwards—send us a note of
your thoughts. If anyone violently disagrees with
something somebody else says, please indicate to me
that you want to speak.
Sir John Chisholm: I am John Chisholm, and I am
representing Engineering the Future today. I have
been asked by my colleagues to do a little bit of
coordinating in case we run out of time.
Dr Mallors: Good morning. My name is Ruth Mallors
and I am the Director of the Aerospace, Aviation and
Defence Knowledge Transfer Network, which is a
programme of the Technology Strategy Board.
Henner Wapenhans: Good morning, my name is
Henner Wapenhans. I am the Head of Technology
Strategy for Rolls-Royce.
Professor Hayward: I am Keith Hayward, Head of
Research for the Royal Aeronautical Society, which is
the learned society representing aerospace and
aviation professionals.
Rees Ward: I am Rees Ward; I am the Chief Executive
of ADS, a trade organisation representing aerospace,
defence, security and space.
Q176 Chair: This goes for all of us around the room:
if your mobile is on, it would be helpful if you
switched it off, as it interferes with the system.
We have been provided with examples of why big
firms are important—that is fairly obvious—and small
firms. A recent letter in The Times pleaded the case
for people in the middle, and I was privileged last
weekend to be at a brainstorming session on precisely
this subject in Ditchley Park, where there was quite a
wide-ranging discussion about the people in the
middle. What is the truth, in your sectors, and where
is the UK failing to create wealth and jobs?
Sir John Chisholm: Perhaps I can start with that,
Chairman. Obviously all parts—big, small and
middle—are important, but in different industries they
play different roles. You had the pharmaceutical
industry here quite recently. In the pharmaceutical
sector, science is hugely important and SMEs play a
Hywel Williams
key role. The pharmaceutical companies then buy
them up. In engineering, on the other hand, systems
are enormously important. Having the big systems
integrators—who can pull through what comes out
initially in science, often through SMEs, into bigger
companies and into the systems integrator—is
enormously important. If we had more companies like
Rolls-Royce, you would see that happening more
often in the economy. Perhaps I can ask Henner to say
a word.
Henner Wapenhans: Quite simply, innovation is the
process of taking a new bright idea to the market.
The bright idea might come from anywhere, but it is
important to have a structured approach so its chance
of success is maximised. That structured approach has
three elements to it: basic research, technology
demonstration and advanced manufacturing. In
particular, the latter two require a large amount of
investment. This is where we see that large companies
have the ability through the complex systems to drive
the innovation, to bring SMEs and their innovation on
to the vehicle—on to the systems we create—so that
they can come to market through our products and
services.
Q177 Chair: So you would see it as your
responsibility to pull through medium-sized
companies in the area?
Henner Wapenhans: We see that on technology
demonstrations or in advanced manufacturing, as on
this site here, that is the prime place to bring suppliers
in to pull them through, yes.
Professor Hayward: It is a very valid point Sir John
has made about the notion that aerospace is, par
excellence, a system of systems. I could also describe
it as a system of supply chains, where you have a
whole nexus of companies which contribute, often at
a very high level, to the scientific and technological
component of a system or a subsystem. One of the
particular places where—I would call it—the big/
small or the small/large companies can be found is the
avionics industry, where you have considerable
amounts of research and development devoted to
creating a significant part of a subsystem. For
example, some of the engine control systems that, if
you like, help drive the Rolls-Royce engine require a
huge technology input. It also requires a company of
sufficient size and research intensity to support
independent research to provide that product.
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Dr Mallors: The only point I would add to that is that
aerospace and space are very highly regulated
environments. The barrier to getting into that is quite
high. One of the key aspects the KTN assists with is
the brokering of an engineer-to-engineer-type
conversation at the right part of the development
chain. The reason a small company like
CPI Technologies is now engaged in three business
interactions and three potential business interactions
is because, through the KTN, they were introduced to
the head of engineering design or the head of
technology in the primes and tier ones at the right part
of the development cycle, not at the end when they
are just trying to procure a product and capability.
Q178 Chair: Is there any policy gap that you would
like to see filled to help the task of pulling through
those bright ideas from the small and medium-sized
companies?
Sir John Chisholm: The first thing to do is have a
clear strategy.
Q179 Chair: Is that a broad plea for an industrial
strategy, full stop?
Sir John Chisholm: Yes, but particularly in particular
sectors—to have a clear strategy in that sector, and
getting coherence in-country so that people investing
understand what the game plan is and have the
connections with the big, medium and small
companies, so that the technology can flow through
and you do not end up with a great pile of technology
that goes nowhere.
Rees Ward: Certainly on the aerospace side, the
dialogue that is going on between Government and
industry at the moment is very good. It is developing
extremely well through the Aerospace Growth
Partnership. Those are discussions that are in part
developing those supply chains, which are so
important to ultimately delivering the full product. In
defence, the issue is one of understanding where the
Government and the Ministry of Defence want to go
in 10 and 15 years’ time. As Sir John says, it is clarity
in where that direction is going. Once you have that
clarity and that position, you can work your way back
to the kinds of technologies that are required. That is
when you can start bringing SMEs in as well as the
whole supply chain. Different sectors require slightly
different approaches here, but the broad picture is that
we need to understand, in highly regulated and
Government-dominated sectors, where the
Government wants to go in the long term.
Q180 Chair: If we take, for example, the biosciences
sector, there are several interesting partnerships, but
let us take the one that is being built at St Pancras, the
Francis Crick Institute: publicly funded science and
money from Wellcome Trust and others are coming
together to create a centre of excellence that will, I
think, have a significant impact on our success in that
sector. Is there any parallel that ought to be looked at
in terms of the aerospace sector and, indeed, defence?
Sir John Chisholm: Perhaps I can make a point on
that. I go back to what I said earlier about the
difference with the biotechnology sector. In that
sector, the science is hugely important. The problem
is having an efficacious molecule that does the job,
and the understanding of that and making that work is
enormously important. The pharma companies tried to
industrialise that process and it did not work. That is
why everyone is going back to investing in the
fundamental science and working up from that to
individual products that work.
In the engineering sphere, although the science is
important, it is only a contributor to the overall
system. It is bringing that together in the total system
that makes the difference. That ecosystem—which has
science and SMEs in it, and medium-scale integrators
and the total system integrator working together—
makes the difference in the engineering sector.
Professor Hayward: There is also a fundamentally
different approach to the whole notion of the
innovation cycle. It is true to say that bioscience—
particularly pharmaceuticals—tends to be a linear
process, where you can put a lot of time and effort
into understanding the basic science of a molecule
that, after a long period of testing and proving,
eventually might be turned into a drug that can be
taken safely by a human being. In aerospace, as a high
value engineering sector, the process is much more
iterative. It is a generational exchange of ideas and
concepts that are subject to a period of evolution—
even, perhaps, passing out of aerospace into another
sector for development, and then coming back into the
aerospace sector some years later. The history of
carbon fibre composites in the UK is a classic
example: having been kicked off by research at the
old Royal Aircraft Establishment, it went into Rolls-
Royce, had perhaps something of a blind alley for a
while, went out into autosport, and has eventually
come back into complex aerospace structures. That, in
a nutshell, is the way innovation works in aerospace
and other related engineering sectors.
Henner Wapenhans: We, of course, have long-range
investments we have to make. In order to compete
effectively, we have to work with partnerships: with
suppliers, academia and the Government. An effective
model we see in that is the advance manufacturing
research centres, the AxRCs, that have now been
formed together into the High Value Manufacturing
Catapult. We see this as a very encouraging
opportunity to scale and increase the pace of drawing
technology as innovation through to the product. We
are very encouraged by the Catapult and would like
to see increased investment and the long-range
stability and understanding that one has access to
funding over a consistent period of time through this
type of catapult.
Dr Mallors: I would add that, for the space
community, what you are now starting to see is not
necessarily a bespoke centre but a clustering of
capabilities in centres around Harwell. You have
Diamond Light Source; ISIC; ESA has committed to
an agency in Harwell; it is attracting the primes like
Astrium to set up offices there; it is clustering SMEs
together. Again, it is the fruits of a long-term strategy
committed to by the industry and the Government,
with its Space Innovation and Growth Strategy. That
is now spawning a clustering and an evolution of
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capabilities for engineering system-of-systems-type
sectors, which is space, aerospace and very much
defence.
Q181 Chair: In this fantastic facility, the role of the
big prime contractors is fairly obvious; I see several
famous logos around us. How do you engage, in terms
of the organisation of an institute like this, with the
smaller players? How do they get brought in to the
decision-making process?
Henner Wapenhans: This is a very good question. If
we look at the evolution of the AMRC, the first one
took quite a long time to get off the ground. The
second one after that was three years from that. What
that has shown is large companies like Rolls-Royce
need to take a leadership role and be there in the early
part of creating these large centres. When they
become more effective and larger, that is when the
smaller companies are prepared to invest themselves,
because they can see the certainty that, if they come
into a centre here and have co-funding as well, they
can get a return on their investment. It is a question
of their risk profile; the risk profile goes down when
one has a larger system integrator involved with it.
We are seeing that we can attract more and more
suppliers at this time. We obviously bring them
together into proposals for research work; it can be
done either individually by the SMEs or through
larger programmes. We are quite pleased that recently
we had the approval of the SAMULET continuation
programme, which does include SMEs and also
universities that are partnering. Jointly we came up
with a proposal for that funding.
Q182 Hywel Williams: Can I ask a couple of broad
questions? Firstly, it is a truism that we live in hard
times. What I would like to ask you is, is the balance
between curiosity-driven research and
commercialisation activity right?
Sir John Chisholm: Can I start with that? Of course,
both are crucially important, but you need to have a
balance. You need to have processes to draw the
results from the curiosity-driven research into the real
world. An element of curiosity-driven research is
crucially important. I will put on my hat as Chairman
of the MRC for the moment: all our evidence is you
get the best value output from research by giving the
responsibility to researchers themselves to find the
researchable problems and apply their minds to them.
Having said that, you can direct the funding into areas
that are most fruitful in output terms; that is possible,
provided you allow the researchers their head to apply
what they know to researchable problems. That is
crucially important. Having said that, you then need
to make sure you do not just pile up a load of IP that
goes nowhere. You need to have avenues to draw that
out into the real world. I guess what would be
common amongst the people in front of you today
would be the thought that that is something we should
do more of in the United Kingdom.
Rees Ward: If I could just take that one on, the
balance is between the Research Councils’ budget, in
terms of the £2.6 billion, and the TSB’s budget, which
is variously £317 (2011–12) million plus £200 million
for Catapult. A recent £24 million call from the TSB
on manufacturing was 10 times oversubscribed. That
seems to indicate that there are a lot of companies out
there eager to get in this pull-through mechanism. The
TSB, on that particular data point, would appear to be
somewhat underfunded in the broad balance. If I
judged your question to be where the balance is
between all of this, I would suggest—certainly from
this kind of evidence—we need more pull through.
If it is a zero-sum game, that has to come from the
other portion.
Henner Wapenhans: I would endorse that view for
the low-level technology readiness—the kind of work
that happens with the early scientific investigation.
There is a warranted balance there between curiosity-
driven and impact-driven research, but as soon as one
gets closer to demonstration in advanced
manufacturing, it must be more heavily focused on
actual commercialisation. This is where we believe
the TSB is not properly funded. It is making the right
decisions, it is effective in how it is going about
making the decisions, but it needs to be more focused
on the higher level technology readiness to pull
through those innovations.
Dr Mallors: I would concur. I have to be careful
because, being funded by the Government, I am not
allowed to lobby the Government, but on the flip of it
being a scientist and being very logical—
Chair: You can be very logical in front of us.
Dr Mallors: Very, very logical.
Hywel Williams: We are not the Government.
Dr Mallors:—there is another slug there in terms of
the imbalance. You have the research base, over £3
billion, over £300 million around the TSB, and then
round about £1 billion in the regional growth fund,
which is about the growth agenda. It is another aspect
of the innovation landscape and pulling it through. It
just does not feel right that there is this funding dip at
a time when it should be lifted up.
A couple of other points I would say are that the
mechanisms are phenomenal, they are really good, but
KTP, SBRI, collaborative R and D, Smart, RGF, FP7
and Horizon 2020 are really confusing. The metrics
between those mechanisms do not join up. In terms of
a CASE award from academia, a measure of its
success should be becoming a knowledge transfer
partnership. That should be deemed successful by
becoming collaborative R and D. It is not that
innovation there is not linear, but the mechanisms
could be seen to be a bit more linear. My final thing
about this is there is a lot of corporate knowledge
within the Technology Strategy Board. That creates an
opportunity for other sectors, not necessarily
aerospace, defence and space but those sectors that
have much shorter term timescales, to attract venture
capitalists: creative industries, some of the CENSA
capabilities, the IT communities. That corporate
knowledge is not necessarily being leveraged from
within the TSB out, which would take some pressure
off the TSB to invest in longer term industries, such
as aerospace and space.
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Q183 Chair: Is it not a bit optimistic at the present
time to expect any real response from the venture
capitalists?
Dr Mallors: I do not know whether it is optimistic; I
just do not think they are being given an opportunity
to see the opportunity of pull through at the moment.
It is a very interesting market, and it depends on
whom you talk to as to whether it is up or down, but
the reality is that I might suggest that venture
capitalists are a bit like head-hunters—possibly a bit
lazy. If they were given the insight as to where
something may well be available for them to invest
in, they would look at it. There are companies out
there that do corral that kind of content and then
present it as pitch material: companies like Omni do
that. The TSB house a phenomenal amount of
knowledge and insight, and yet it is not made
available.
Sir John Chisholm: As someone responsible for a
venture capital fund, I would not say they are terribly
lazy; they work incredibly hard at looking at
investment opportunities. There are things that, from
a policy point of view, one can do to encourage more
investment into this Valley of Death arena. One of the
key things that the Government can do is create good
markets, which you can do through regulation, but of
course the Government is a huge procurer in the
market. One thing that all start-up businesses know is
a customer’s pound is worth 10 times an investor’s
pound. It is crucially important to have a market that
start-up companies can sell into. It is the big
advantage you get in the United States, and it is
something Government can really help through its
procurement.
Q184 Chair: Would, for example, the Israeli model
incentivise the VC industry to be a bit more proactive,
where you have the confidence of at least some
matched funding coming from some sort of
Government source?
Sir John Chisholm: There are such sources already in
the UK. The Government has put money into various
venture arms—the Innovation Investment Fund and
things like that—which are enormously helpful. The
Israelis have shown that is a very fruitful way of
developing and fast-tracking new companies into the
market. The Israeli companies have done extremely
well by having markets—particularly in the United
States—that they can sell their product into. I make
the point again: the markets are even more important
than capital.
Q185 Hywel Williams: Can I just ask you another
broad one? At what point should public funding stop
being about excellence and move on to what might be
commercially successful?
Sir John Chisholm: Do you want to take that up?
Professor Hayward: To some extent, there has been a
long, well-established track record in the aerospace
sector of repayable launch investment, which is a
classic instance of Government assuming a
shareholder role in the development of a new
programme, primarily an airframe or an aero-engine
programme in the United Kingdom. This has taken
great ideas, such as an airbus wing or the technologies
that Rolls has developed through the triple spool
engine, into producing families of aircraft and families
of engines. That has been a classic example. However,
there are certain issues related to that form of direct
investment. It is now potentially outlawed by the
WTO, and thus the importance of supporting generic
research that can apply to a sector or to a raft of
companies, as opposed to one or two individual
companies or projects, is becoming even more
essential. In principle, that sort of partnership—and it
has lasted now nearly 30 to 40 years in its current
form—has been an extraordinary success in rebuilding
and creating a world-class UK-based civil aerospace
industry.
Rees Ward: If I may, the new manifestation in terms
of the Aerospace Growth Partnership, which has been
worked on jointly between Government and industry
over the last year or so, is going down a very good
path in terms of sustaining a civil aviation industry
that has captured some 17% of the global market. That
market is increasing at something like 5% to 6% per
annum, and for value to the UK economy, that joint
partnership is focused absolutely on the right kinds
of things.
Henner Wapenhans: If I may add, there is also a very
big importance in terms of infrastructure for tests,
large-scale test rigs and things like that, which are not
project specific but very important. If we were doing
international comparison with other countries that are
very largely aerospace driven, we have competitors
that have access directly to Government facilities.
That is something that is not the case here in the UK.
Q186 Chair: I was asking your colleague Paul Stein
about this sort of thing at the weekend; he was at the
same event I was at. He was specifically asked how
the testing facility just outside Berlin was funded.
Henner Wapenhans: That was with German
government funding support.
Q187 Chair: Directly or through the Länder?
Henner Wapenhans: I would have to go back and
check that. I do not have the accurate data.
Chair: I would be interested to know.
Q188 Hywel Williams: Just one specific question, if
I may, Chair: what does the Energy Technologies
Institute do that the TSB and the catapults cannot?
Sir John Chisholm: Well, they all occupy the same
space.
Henner Wapenhans: Could I take that one, please?
We see a big advantage to having a construct like the
Energy Technologies Institute, in the sense that there
is a large commitment—10 years—to have a
programme to develop technologies in renewables,
where there is a commitment from industry to pledge
a certain amount, £5 million per annum, which is
matched by the Government, and gives within that
horizon flexibility to operate and also predictability in
terms of projects to fund. To an earlier point I made,
it is very important to our long-range technology
development to have those kinds of constructs. We are
very supportive of these joint technology initiatives,
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JTIs, or public-private partnerships. The Catapult can
act in that same way. We are hopeful that it will do
so through a combination of Government support and
industry support.
Sir John Chisholm: It is an good example of
coordination on the strategy and bringing together the
various elements in the whole value chain so that they
can work together. There are different funding sources
that come together to achieve something that could
not have been done separately.
Q189 Stephen Metcalfe: I particularly want to pick
up on the role of the customer in all this. We have had
some evidence that says customers are more important
than funding. First of all, do you agree with that
statement? Secondly, there is also the role of lead
customer. As I see it, there are lead customers
throughout the supply chain, starting with the very
smallest company and feeding up to the next layer.
Could you just tell us a little bit about your experience
around those, and whom you see as your lead
customer?
Sir John Chisholm: Can I just start by repeating what
I said before? I absolutely agree that customers are
hugely important. Going back to my experience in the
venture industry, a company coming forward asking
for money that has customers lined up is far more
likely to attract a good slice of funding than somebody
who is just coming forward with a great idea. Having
customers is hugely important. Of course, if you are
a small company, you are not actually addressing the
end customer. There is a supply chain you are part of.
Getting that chain working and having a lead
customer—particularly in the United Sates, the
Government plays a hugely important role as the lead
customer for advanced technologies—then pulls
through at various levels in the supply chain, and
enables the funding of that to be drawn in from the
private sector.
Q190 Stephen Metcalfe: So in the American model,
it is pulling the technology through. If the American
Government will identify a need and then look for
someone to provide that need, that is driving
innovation, is it?
Sir John Chisholm: Exactly so, exactly so.
Professor Hayward: Rees and I also arm-wrestle for
this one. In that sense, it is clear at least half the
business of the United Kingdom aerospace industry
is, in some respects, directly related to a Government
procurement exercise. Although a significant
proportion of that these days is somebody else’s
government doing the buying—either directly or
indirectly—nonetheless the UK MOD is still one of
the paramount customers for a large element of the
UK aerospace sector. We certainly have some
concerns about the default position of the MOD to
compete globally and to treat value for money in a
particularly narrow way that certainly excludes any
real, meaningful inclusion of externalities for national
welfare or technological benefit. That is explicitly an
element that American procurement policy, where
there is a clear determination: A) to buy national; B)
only to buy foreign if there is absolutely no
alternative; and certainly C) to encourage a whole raft
of research and development activity through a whole
plethora of dedicated research establishments. The
simple answer is Government is important to this
industry.
Q191 Chair: Can I just tie together the point that
Stephen has made and Hywel’s earlier point? What
then is the difference between launch aid and the US
Government operating as a lead customer?
Professor Hayward: A huge philosophical difference
on which the whole of the WTO dispute over the last
15 years has hung is—
Q192 Chair: In terms of the impact on the industry;
I am not being legalistic.
Professor Hayward: As an observer and historian of
the launch investment process, I would say the
repayable launch investment system is a much more
efficient and effective way of drawing technology into
commercial use. The United States has historically
used high levels of defence budget and defence
spending indirectly to support civil aeronautical
activity, either by encouraging people just by putting
money into a Boeing or a General Electric through a
large domestic defence budget, or of course enabling
some specific research, either through NASA or
through the DOD.
Q193 Stephen Metcalfe: I think I understand from
what you have said that the Government as a lead
customer in its own right has a slightly narrow view.
If you were able to write one of our recommendations
that would come off the back of this inquiry—I do not
want to put words in your mouth—what
recommendation would you like to make to
Government in how it may change its view and its
role as lead customer?
Professor Hayward: This is one for the trade
association. Writing a recommendation for a
Committee: life does not get any better than this,
does it?
Rees Ward: In the way that the MOD views its
procurement policy and its recent, if you will, focus
on buying off the shelf, it really does play to a very
narrow value-for-money proposition, i.e. for the
department itself in terms of performance, cost and
time. But from a trade association’s point of view,
because this is Government money, taxpayers’ money,
that is too narrowly defined. I would suggest that the
definition should be much broader on a national basis,
taking into account jobs, high-value employment,
taxes that are being paid, Jobseeker’s Allowances that
are not being claimed, and, and, and. There is a much
broader view here for UK plc that should be taken
into account.
Q194 Stephen Metcalfe: Thank you. Is defence
looked after as an industry rather than as a product for
support? Is the balance between MOD and BIS
interest correct, or do you think you need more BIS
input to view you as a business that can help support
UK plc, and then hopefully support some of those
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small and medium-sized companies to come up
through the supply chain?
Rees Ward: Yes, I would agree with that. The MOD
is voted money from Parliament to equip and train
Her Majesty’s armed forces. Those forces then do the
bidding of the Government of the day. In terms of
defence, the industry has felt itself kept at arm’s
length, because that is the way the MOD wishes to
have that relationship. As I said to a previous
question, I do believe that the industry must have
some view of the long-term nature of where the MOD
and indeed the Government want to go. The
investments that are made in defence matériel are
long-term investments; it is very difficult for an
industry to make those investments if they have no
idea where they are going.
Having said that, the MOD has taken up that notion
of the long-term view very recently. You have seen
their commitment to publish the 10-year programme,
and what detail comes out is anybody’s guess; we all
look forward to the NAO report sometime in the
autumn. There is also an agreement to work jointly
with industry to review what capabilities Her
Majesty’s armed forces require in the 10- to 15-year
period and work our way back down roadmaps to
identify the kinds of technologies and, therefore, the
kinds of investments that are required. At that point,
when we have more clarity and visibility, then
industry and Government can have a much more
informed debate about who does what and where.
Sir John Chisholm: Can I make a general point about
this, about the innovation process, which is hugely
important to this? I do not think that anybody will
dispute that, for the UK to survive in the 21st century,
we have to be innovators. We have to be lead
innovators, because that is one of the things that will
keep us competitive in the world. Innovation is clearly
good for the UK as a whole.
The problem with individual innovators is the
question of who gets the benefit of it. The benefit of
the innovation will be captured somewhere in the
economy; it is not at all obvious that the financing of
an individual innovation will itself pay off, if you see
what I mean, because the benefit spreads out through
the economy. This particularly relates to Government-
funded projects. There was a Government-funded
project that I remember well because I was around at
the time, in the 1980s, called Inmos, which was going
to revolutionise the microprocessor industry. It did not
and it failed. Therefore, it is a failed project, is it not?
However, if you look around Bristol now, which is
where it was, you find a plethora—a whole
architecture—of companies that spun out of it. The
project itself might not have achieved its end, but the
innovation that was created there spread out into the
economy.
Therefore, going to the issue of major projects: a
major project may well be castigated by the NAO for
not doing exactly what it was supposed to do.
However, that happens in major technology projects.
If it is going to be a genuine step forward, you are
going to launch it not knowing all the things you are
going to discover. You may, therefore, look in
retrospect and say, “We thought it was going to cost
£2 billion; in fact it cost £4 billion.” But in doing that
you will have created value that will have spun out
elsewhere in the economy.
Q195 Stephen Metcalfe: Well, you hope it will have
created value; that is what you have to be able to
measure, isn’t it?
Sir John Chisholm: You can measure in retrospect;
you can go round and look at the infrastructure that
has spun out of it. If you are going to do anything
serious in technology, you are going to discover things
you did not know to start off with. You could call that
a failure, but typically it is not a failure; it is a
discovery. It is skills that go out into the economy that
enable you to solve other problems further down the
line. Taking too narrow a view of the outcome of
technology projects can lead you into too risk adverse
a strategy.
Q196 Stephen Metcalfe: Do you think where the
Government as lead customer is located at the
moment is taking that too risk-averse view?
Sir John Chisholm: I defer to my trade association
there.
Q197 Stephen Metcalfe: Finally I suggested BIS as
perhaps a better location for the Government as lead
customer; someone suggested the Cabinet Office.
Does anyone have a view perhaps where as a buyer
the Government should sit?
Professor Hayward: In fairness to the Government
and the MOD, it seems probable—if not
inconceivable—to put the responsibility of the
customer for the UK armed services anywhere other
than the MOD. What Rees and I have in common is
a belief that the MOD’s view of how it selects
programmes and brings forward UK-based technology
needs to have a broader understanding of the impact
this has on national welfare.
Dr Mallors: The only thing I was going to say was
the role of the Department of Business, Innovation
and Skills—to repeat the message yet again—is of
long-term strategy that enables a whole stack of
Government departments to be intelligent and lead
customers, whether it is the Department of Health, the
Department for Education, the Department for
Transport or the MOD. We are seeing some of this
confusion going on at the moment with the
announcement made in March around UK
aerodynamics. It has been a product of the successful
Aerospace Growth Partnership, the early success
strategy of that, and it has a sort of civil aviation
focus, and the MOD is going, “Well, what about us?
Where are we on that? What about our requirements
and how are we trying to filter those in?” It pops up
as, “We have not been asked.” BIS being able to be a
strong leader on those long-term strategies on behalf
of multiple Government Departments would be
valuable.
Henner Wapenhans: I would echo the comments on
the MOD, but also we operate in many sectors. We
do not see the Government as being a lead buyer for
the civil sector. The Government does not buy civil
aircraft, power generation or nuclear power plants. For
Science and Technology Committee: Evidence Ev 63
2 July 2012 Rees Ward CB, Professor Keith Hayward, Henner Wapenhans, Dr Ruth Mallors and
Sir John Chisholm
those large technology-driven areas, the Government
can assist by providing the frameworks to enable the
technology to be pulled through into the product.
Q198 Chair: In the small business sector in the US,
for example, the Department of Defense still have to
engage through the SBRI schemes.
Professor Hayward: I think you are right; it has been
a while since I have looked at the specific detail, but
I think both NASA and the DOD are enjoined to let a
certain proportion of contract to what they define as
the small-business sector. My brain is scratching
around for citation, but I also think the United
States—parallel to the size of American dinners—
tends to have a larger view of what a small and
medium-sized enterprise should be. To some extent
they have a more liberal interpretation of what
constitutes a small company.
Dr Mallors: The SBRI project is alive and well
through the TSB here. It is in economies of scale,
and it is also about the certainty. In a lot of the US
programmes—and again, I have seen it a lot in
Canada recently—there is certainty. It is just a given
that year on year that programme will be in place, so
businesses can plan and shape around it.
Q199 Chair: The evidence here suggests that neither
the Ministry of Defence nor the Department of Health
have exactly switched on to the scheme here.
Dr Mallors: Not in scale.
Henner Wapenhans: We also see the difficulty here
in the UK of the Small Business Research Initiative
being applied to larger projects. If you look at the US,
they encourage sponsorship to be sought with a large
company, which has two benefits: it creates strong
relationships, and it creates the route to market. We
think there is definitely something that can be learnt
from the US system.
Q200 Pamela Nash: In the written evidence that
several of you have provided, we have examples of
technology that is not being manufactured in the UK
due to an inhospitable environment here. I wonder if
any of you can expand a bit on the issues that
companies are facing. Two of the problems raised
were prohibitive taxation and inability to scale up. I
would appreciate a bit more detail on those problems.
Also, to what extent do you think new Government
policy is going to be able to look at these problems
and fix the issues that we are seeing here?
Sir John Chisholm: I think each of us covered some
of this in our evidence. I know you did Henner. You
mentioned the taxation issue. That was to do with
Raspberry Pi, which in turn was in our evidence from
Engineering the Future. That was simply an issue
where Raspberry Pi had to pay tax on the import of
components, which put them at a disadvantage in
manufacturing in the UK as opposed to manufacturing
elsewhere. Henner, you made some comments from
Rolls-Royce’s point of view in terms of where you
put your plants.
Henner Wapenhans: One of the examples we gave
we touched on earlier, which was the test facility that
has been established in Brandenburg in Germany,
which is one of those examples of infrastructure
where the company that operates globally has to see
where it can compete globally. When other
governments provide frameworks that are attractive,
then it is something that we cannot not do. Another
example that we have is about our fuel cells business,
which is still in the pre-production phase, where we
managed to attract Department of Energy funding in
the US, which led us to transfer the activities into the
US for that business. These are all examples of
creating a level playing field between what other
industrialised nations are doing to attract R and D and
what the UK is doing to attract R and D.
The strength here in the UK is if we can build on the
starting coherency of making sure that all those three
elements that I mentioned, going through technology
demonstration to advanced manufacturing, are all
looked at as one whole. That then creates the delivery
mechanism for the technology. Again, I would raise
the subject of infrastructure. Another subject that has
been brought up by the Government is e-infrastructure
and giving companies and academia access to
computer power, which is a very important enabler for
technology development.
Professor Hayward: It is important to always
appreciate in this that the UK does not have a national
aerospace industry. We have the UK cluster of a
global aerospace industry, and the point that Henner
has made about having a supportive government for
national industry is really about ensuring that the UK
elements of this global industry are no worse off than
other parts of that global industry. I have particularly
in mind here, in a sense, that the destiny and future of
Airbus UK is decided by investment policies made in
Toulouse and elsewhere. Thus, when a multi-national
board is looking at where they are going to place the
next manufacturing infrastructure, they will look
around all of the options available and say, “That is a
much more favourable place for us there,” say North
Germany, “than the South West of the United
Kingdom.” It is essential for any Government to
appreciate the global context of this national industry
and to review and continually analyse our standing,
our regulatory position, our financially supportive
position, not in absolute terms but vis-à-vis our major
competitors and what they are offering our share of
the globally operating companies located within the
United Kingdom.
Q201 Pamela Nash: How would you rate the current
Government’s capability to respond to that?
Professor Hayward: It has as good a record as past
Governments. It has not yet been tested by a large
repayable launch investment request, although it has
supported Westland’s attempt to civilianise some of
its military helicopters, a very important part of
ensuring the survival of rotary craft development in
the United Kingdom. The support for technology
partnerships reflects several decades of support for
generic technology in aerospace and aerospace-related
industries. It falls, as past governments have fallen, on
the defence side. It fails to recognise that it does have
an active responsibility to support UK-based defence
industrial enterprise. In a sense, you could say there
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has been a whole series of curate’s eggs of
governments over the last 20 or 30 years. What is nice
about this is the recognition that the industry does
have a value, but one more push and Government
would become a sophisticated 21st century partner.
Q202 Pamela Nash: Throughout the evidence we
have taken so far, it has not been a great surprise to
anybody that we are constantly told that the
Government has to put more money into R and D, but
there is also an issue in the UK with private
investment and research and development. Do you
think there is anything more the Government should
be doing to encourage companies to invest in their
own R and D?
Sir John Chisholm: If I can start that again, it comes
back to having good markets. Companies are not
reluctant to invest because they want to give the
money back to shareholders. They will invest if the
circumstances are right. It is true to say that in the last
four or five years there has been a retreat in innovation
investment in the UK. Putting my Nesta hat on, it
looks to us like there has been something like a 20%
retreat in innovation investment since 2008, which is
a lot. It looks like it is probably worse here than it is
elsewhere, but these are very preliminary figures.
There is something to address here. On the other hand
the Government has begun to do things, like the
Innovation Investment Fund, where it is putting
money up on the basis of matched funding coming
from elsewhere, which will encourage more
investment. If you get the right markets, which is what
we have been saying here, that is the most important
thing that you can do.
On the general subject of money, there are other
potential sources that you might like to look at in your
committee, particularly the 4G auction monies, which
are coming along. Our view would be that innovation
in the UK would be an extraordinarily useful recipient
for those monies and would pay off handsomely for
the nation.
Henner Wapenhans: It is not just the amount of
money that is being invested by the Government; we
could see an improvement by speeding up the decision
process for making capital investment available. We
do see that there are other countries around the world
where that can happen very rapidly. We invest quite a
bit. Last year we invested £900 million of R and D,
and it has been consistently that high. The TSB has
been very effective in being timely, but further
improvement is possible by making quick decisions
possible when opportunities come up.
Rees Ward: To finally cap that, the aerospace and
defence industry figures indicate that they put back
about 8% of their turnover, which is high when you
look at the industry sectors here in the United
Kingdom. That is at the top end, probably in the top
two or three. I would like to re-emphasise the point
that an awful lot of the industries in the United
Kingdom are global, i.e. they have footprints in a large
number of markets and a large number of countries.
Therefore, their boards will be looking at where to
invest to get the best return. If the Government is not
providing the right conditions here in the United
Kingdom then, inevitably, that investment will go
elsewhere. To your original question about industries’
private investment in the United Kingdom, part of that
decision-making process is how attractive it is to do
business in the United Kingdom. Of course the
Government’s reduction in corporation tax is
excellent. The R and D pilot scheme, which is going
in the right direction, is also excellent, but the broader
piece about making the UK open and attractive for
business is absolutely essential if we are going to
attract inward investment.
Q203 Hywel Williams: Going on from this—you
have answered my question to some extent—looking
at the national innovation system, we have been told
that the UK wants commercialisation of research work
to be on the basis of fairy dust and good intentions,
putting it very succinctly. What gaps do you see in the
national innovation system, and does the engineering
base sector of the economy suffer specifically from a
lack of coherent funding, as well as facilities and also
with respect to regulation?
Sir John Chisholm: I think the point has been made
before that it is a bit bitty at the moment. There are
lots of virtuous elements of it, but it lacks a coherent
strategy that everyone can relate to. That is our
principal point here. There is a lot of argument in the
press about the national economy, about Plan A or
Plan B. We are quite keen on a Plan I, which is instead
an investment programme in relation to innovation as
the key driver for the economy of the future.
Dr Mallors: I would agree there is a fragmentation
issue. Some work carried out by City University a
couple of years ago looked at the academic
aeronautical-related facilities and showed their quite
substantial degradation. The really worrying thing
about some of those facilities is that a decision is
made at the local level—the university level—and not
against the national agenda. There are lots of facilities
in there, but there is not an overarching understanding
of which bits we need nationally to create a national
capability. Adding to that is that there is the need to
be able to take that academic research in a very small
wind tunnel and put it in a really big industrial-type
facility and see how it works, and then to be able to
take that kind of data into those high-level TRL stages
with academia to test it. That overarching strategy and
facility approach is not there, particularly for
industries where physical and virtual testing is so
important because of safety and the regulatory
environments. It is becoming an increasingly big issue
for those sectors.
Q204 Hywel Williams: Can I ask you a broad
question about defence innovation? Is it more
restricted by a lack of cash or a lack of strategic
direction?
Rees Ward: I think that we have to understand the
position the Ministry of Defence has been in up to this
point. It is heavily over programmed. The armed
forces need a lot of equipment and systems, and there
is a very constrained cash profile. When you are in
that sort of constraint, then I suspect—I cannot speak
for the Ministry of Defence, but one observes from
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outside—a rational set of choices would be, “I will
not do any research and development. I will buy it off
the shelf, put it in the hands of the Armed Forces
straight away and I will have achieved my remit,
which is equipping and training Her Majesty’s Armed
Forces to do the Government’s bidding.” I would
suggest, and I would say this as a trade organisation,
that is a very short-sighted view. The whole business
of research and development is continuity and
sustained investment. A lot of it is contained in
people’s heads and it is investment in people and
skills. If you start turning the tap off, those people will
go and you will never get them back. That will be a
complete waste of the investment. Well, it will not be
a complete waste, but it will go somewhere else in
another sector.
The Ministry of Defence is getting itself out of that
particular trap of too much in terms of programme
and not enough in terms of cash, but I still detect a
downward trend. For example, in R and D the
numbers have come down over the last decade, or just
under that, from about £2 billion down to £1 billion.
In S&T, which is much more clearly defined, it has
come down over the last 10 years from £800 million
to £400 million. You will not see the effects of those
reductions over the last few years. You will probably
see the effects of those reductions as we go forward.
The fact that the MOD has put a floor in at 1.2% of
the defence programme for S&T is very welcome, but
is that sufficient to sustain the kinds of technologies
that the Ministry of Defence will require in future?
That question is still open.
Professor Hayward: I would agree with everything
that Rees has said and make the basic observation
that, whilst there has been, over the years, a shift away
from the classic spin-off from advanced defence
technology into the commercial sector, there is now
much more evidence of spin-in—the way that streams
of commercial technology are now incorporated into
complex weapons systems and other military
equipment. But there are still areas of specific defence
research that do have, or could have, significant
commercial value to the aerospace sector. I am not
talking here about stealth airliners as a solution to
getting into Heathrow early, but it would certainly
apply to certain aspects of gallium nitride display
technology, which will, conceivably, create much
thinner, much lighter civil avionic equipment. There
are also the integrated power systems, which I suspect
is Henner’s area of expertise, that are being developed
for unmanned systems—because you need a lot of
power in a small space to fly the aeroplane but also to
power the sensors and all the rest of the equipment—
which will have significant value in generating power
for commercial airliners.
Dr Mallors: To supplement what Keith was saying, a
lot of the documentation out of the White Paper will
talk about the MOD reaching into non-defence supply
chains and pulling that capability back in. There are
two issues there; one is that they do not know where
to go, because they are used to working with a defence
industry or supply chain. The second thing is they talk
in a very strange and unusual language that is
fundamentally difficult to understand for the non-
defence supply chain. The KTN is leading what we
believe to be quite a unique programme, which is co-
funded by Dstl and the Technology Strategy Board,
which is aiming to start that process of facilitating
introductions of Dstl-type capability requirements and
where their research programmes are going, and
articulating that into the Knowledge Transfer Network
networks. I run one of 15 KTNs, but plugging them
into people like energy generation and supply KTN,
because they were not plugged in and they were not
plugged in to those supply chains. It is that
connectivity. They just do not know how to do it,
because they have not had to do it before.
Q205 Chair: Sir John, going back to your Plan I, was
that a subtle way of calling for the re-invention of the
original purpose of 3i?
Sir John Chisholm: Well, no.
Chair: Not as it is structured now.
Sir John Chisholm: It was specifically a venture
capital operation and, by the way, a very successful
one originally. However, my notion of Plan I is that it
is possible to construct, I believe, a comprehensive
plan from the UK perspective, which would have
immense advantage to industry in general, and
particularly to the engineering industry.
Q206 Chair: So this is a sector-specific industrial
strategy?
Sir John Chisholm: I would say it is a strategy for the
economy, which would help this sector enormously.
Q207 Chair: The second part of that is that,
increasingly, there are massive crossovers between
disciplines that used to be wildly disparate—the
overlap between work going on on this campus and,
for example, in medicine. There are massive overlaps
these days. How do you ensure that in that great
encompassing strategy, you make those things
continue to work together so that the spill over to
other disciplines can work effectively? You are in
charge of Plan I now, Sir John.
Sir John Chisholm: Plan I would inevitably have
maybe 15 components to it, things like the innovative
procurement we discussed before. It would indeed
have exactly those sorts of spin-offs in it, because it
would encompass a lot more than the Ministry of
Defence. It would encompass the NHS, the
Department of Energy and others. Within that, it
would encourage sector strategies to emerge. Through
various stimulant measures, it would encourage a
greater flow of private capital into the innovation
space. All of these things are important stimulants for
exactly that sort of broadly based, technological
response.
You are exactly right that a lot of the most important
breakthroughs in technology come at the intersection
between sciences. If you look at the way that
academia now organises itself, it goes out of its way
to try to encourage that. The kind of thing that you
see here, of bringing together parties, is exactly in the
same space. All of that should be part of a
comprehensive Plan I, which is not just one
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component but brings together a number of initiatives
into a coherent picture.
Dr Mallors: I would concur. One of those elements
would be this translation issue, so we know what is
appropriate for aerospace and how to translate that,
whether it is into Formula 1 or into the automotive
sector or outside. Bizarrely, you do not know where
that translation is going to come from. You may well
recall the BBC’s How To Build… A Nuclear
Submarine or How To Build… A Satellite. Astrium is
now having conversations with GSK; even though
they are in buildings next door to each other, they did
not have an understanding of the clean-tech facilities
that were bring deployed in Astrium to use their
satellites. The key aspect of the KTN is translating
those competitions and the funding that is available
or where the sectoral opportunities are, in and out of
the sectors.
Q208 Chair: That was also a weakness not just
between industries but within the Government
machinery. How do you ensure, using the networks
that we have through the research councils and
through TSB, that there is some feedback upstream,
so that bits of the Government machinery understand
the potential of exploiting technologies that come
from another sector?
Sir John Chisholm: It is a good point. We are making
progress, exactly as Ruth suggested, through
programmes such as the Catalyst Programme, which
the MRC and the TSB have together, which draws in
the biotech industry, in order to bring together funding
streams that were previously entirely separate. That is
definitely a direction of travel. As we have all
suggested, it can be better integrated, and I certainly
hope that would form one of your recommendations.
Q209 Chair: Now, the final question: the last time I
was on this site was a rather long time ago, when a
rather significant political event was occurring just
over there in the early 1980s. Things have transformed
out of all recognition here. There must have been
some catalyst that brought together this fantastic
cluster of world-class industry, small and medium-
sized companies and academia. What was the big
driver?
Sir John Chisholm: Do you know that—do you have
the history, Henner?
Henner Wapenhans: I can have a go at the history.
The big driver was a realisation that we had to do
more in manufacturing. We have always been a
technology company, and scaling in terms of size—
and we have grown quite significantly over the last
10–20 years—made us realise that a lot of attention
needs to be given to manufacturing. We are quite
proud of being one of the early partners in creating
this new model. It has been a good model to show
how, between industry, government and academia, it
has managed to work. It has created a critical mass so
that we now see a lot of international interest in what
is going on here and people are looking to the UK
and this advanced manufacturing park to see how they
might emulate it. It is a fantastic example.
Q210 Chair: At the time, what role did the Regional
Development Agency play?
Henner Wapenhans: I do not know that specifically,
but I think that they played quite a considerable role.
If I look at the kind of funding that has come through
and the kinds of activities we have had over the last
few years, the RDA has been a source of funding. A
big concern of ours is how that source can be replaced
and by what mechanism. Will it be through the TSB
or by which mechanism?
Q211 Chair: I want to push you on that, because we
are a relatively small country geographically—the size
of some individual states of the United States.
Henner Wapenhans: Texas.
Q212 Chair: Do we really need a regional policy to
make this work or can the centre do all of this?
Professor Hayward: I detect a certain political
undertone here. I will comment having seen, when I
was working for the trade association, the emergence
of the RDA process and also, as an academic,
observing the development and evolution of aerospace
clusters in Europe and elsewhere, there was indeed a
significant input of the appropriate regional-level
funding. The Midi-Pyrénées, for example, is a mixture
of the prefecture and the region. The City of Toulouse
also contributes investment and various forms of
infrastructure. All of this has helped to create a very
impressive, generalised, aerospace/high-technology
cluster in the Toulouse, Midi-Pyrénées region. You
will probably find the same input in the Länder in
Germany, who will contribute. Historically, Bremen
owned part of their local aerospace company. That has
now become a contribution to infrastructure and local
research and development activity, whether it be
funded through the local universities or some other
intermediary body. There is still a role and a function
for a regional organisation or agency of some
description.
Sir John Chisholm: It is clear from all of the
academic work that clusters are hugely important as a
stimulant for innovation. If you have been to
Aberdeen, there is a magnificent example of a cluster
that has sprung out of nothing, because the people in
Aberdeen clustered around the university have looked
at the problems that they were facing and created
entirely new industries. It can be done. Clusters are
highly important, and therefore there is a local
element that is very important in terms of
encouraging innovation.
Dr Mallors: The stuff that we could see with the RDA
model, and the point that you made, was that it was
creating an internal competition across the regions on
some of these things. The supply chains may well be
clustering, but they are global. It is about the
mechanism and how the mechanism is deployed to
foster national growth and international growth, rather
than creating an internal debate about which region is
better than the other region and who is winning on
funding and who is doing all those things. It is about
what is best for UK Plc and driving that. The shaping
and clustering is really important. We are seeing it in
Aberdeen, partly with oil and gas, and then
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recognising that we are on a bit of a dead duck here
if we are not careful. There is space stuff going on in
Harwell, the South West and North West. Aerospace
and defence clustering is very important.
Chair: It has been an extremely interesting session.
Dr Mallors, gentlemen, thank you very much indeed
for appearing before us this morning.
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Q213 Chair: Welcome to you, gentlemen. You are
familiar with the terms of reference of this inquiry.
We are going to be asking you a few questions in a
moment. It would be helpful if for the record you
would introduce yourselves.
Dr Bradshaw: I am Tim Bradshaw and I am here
representing the CBI.
Tim Crocker: I am Tim Crocker. I am here
representing the SME Innovation Alliance. Maybe I
ought to add that I am a committee member, but we
don’t have any salaried people, so in my day job I am
an R and D engineer.
Q214 Chair: Thank you very much. You will
probably be aware that later on this morning we are
hearing from some of the folk who spend Government
money. I notice that one or two are in the room. Do
you think they have got the balance about right so far
as big and small S and T-based businesses are
concerned?
Dr Bradshaw: Yes, by and large. We have to
remember that the majority of the R and D activity
that happens in the business community happens with
large companies. They are the anchors for R and D
activity, not just within their own companies but
within the value and supply chains that support them.
There is probably a two-thirds/one-third split, in terms
of where the money from Government goes,
particularly if you look at things like the R and D tax
credit, so supporting those large companies is
absolutely essential. It anchors R and D here and then
allows that to filter down through the supply chains to
other smaller companies. On top of that, we have very
good support for SMEs through their higher rate R
and D tax credit and with things like SBRI, which the
Government supports through the TSB. Roughly the
balance is probably okay, but whether the quantum is
right is perhaps another debate.
I know the inquiry is about the valley of death. I
suppose it is a difficult question, because there will
always be a valley of death no matter what you do.
There will be more R and D ideas than you could
possibly ever commercialise, and it is a case of trying
to flatten out, perhaps, that valley of death so that most
of the really promising ones get their chance of getting
further through to commercialisation, be it with small
or larger companies.
Tim Crocker: We could always say that we need more
money, but we are aware that that is not the game on
the table. I would take issue with some of the points
Sarah Newton
Hywel Williams
Roger Williams
that have been made. Where the money goes in and
where it is spent are slightly different things because
of the way the supply chain works. Quite a lot of
small companies are doing work on behalf of bigger
companies and the numbers will turn up in statistically
different places. The main problem that the SME
community has, which is different from that of the
large companies, is that traditionally most of the
funding support from Government has been on a
matched funding basis: a 60% grant with 40% being
found elsewhere. The assumption has been that the
40% comes from venture capitalists and private
investors—that is where the problem lies. It does not.
The investors who are available have very short-term
aims and want to sell the companies out faster than
the design cycle practically allows.
Q215 Chair: Does that apply to particular
technologies, or are you talking generally?
Tim Crocker: There are sectoral differences. We are
aware that the biotech and pharma sector works far
more like the Government model or, rather, the
Government model seems to apply to biotech and
pharma very well, but in what I would call the hard
industries—computing, mechanical engineering and
electromechanics—it is entirely different. There is a
quantum difference between SBRI funding, which is
basically 110% funding, and 60% funding. If we could
move all the TSB funding to SBRI, it would be
transformational; it would be a night-and-day job
because of the way the investment community
behaves.
Dr Bradshaw: We like SBRI. We have said a number
of times in the past that it is not as large as it should
be. If you compared it with the US equivalent and
scaled our economies, the UK system would still be
six times smaller than the US one. Yes, we would
agree SBRI is a very good vehicle. It is underfunded
and could be expanded. We would take issue with
moving all of the TSB’s funding into SBRI, though,
because it does an awful lot of very good work in
other areas, but, if Government money was available,
increasing the overall budget for the TSB so things
like SBRI could be increased would be good.
Q216 Chair: So that I have got this right, the two of
you are basically agreeing that there aren’t any major
gaps in the Government intervention mechanisms, but
there is a slight difference between you in how it is
managed and targeted. Is that right?
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Tim Crocker: I would say the fact that 60% to 75%
funding, depending on the scheme, has persisted for
20 years shows that there is a gap. I have spoken to
senior officials in DTI and BIS about this; it is
recognised. The other matched funding is not
available. The major reason why SME projects that
have merit crash is that you do the technical work and
maybe spend a few hundred thousand pounds, and the
follow-on funding that would match the Government
funding simply is not available. To us, the mechanism
of funding is one whereby SBRI procurement funding
pays the whole bill. You do the job and your company
is no worse off at the end of that, and you can move
on to the next phase. That is probably a difference that
won’t appear in the large company sector, where they
largely have ongoing product income and revenues
from other sources that can bridge those gaps.
Dr Bradshaw: That is one of the reasons why we have
been very supportive of things like the Enterprise
Investment Scheme being expanded, in terms of the
rates and limits, as well as venture capital trusts and
the ECF, which was given another £200 million in the
last spending review. There are other mechanisms for
getting money into that space.
Q217 Stephen Mosley: Technology businesses tend
to be very mobile and are able to move technology
around the globe. What makes one decide to invest in
a new technology in a particular location? I guess it
will be different as between big companies and small
ones, but why would someone start investing in a
certain technology in one particular place?
Dr Bradshaw: Most companies would say that the
most important factor would be the knowledge—the
people—and that can often override some of the other
costs involved. If you have an established community
of academics, other researchers or businesses making
a cluster where you can build and develop that idea
and take it further, that is probably the primary reason,
and then you look at other things. Have you got the
building space where you can set up a lab? Have you
got the other support infrastructure you might need to
be able to take things further? Have you got business
partners who can come in and help you?
Tim Crocker: One of the important things about our
membership is that they are largely people who have
come out of R and D in a big organisation, a
university, and set up in the private sector previously.
Where those people who have particular expertise end
up tends to be driven partly by family circumstances
but also by a lot of previous schemes where you could
get rent-free space in the peripheries of a country. A
lot of businesses were attracted to the west country
because they would be given a factory. The Welsh
Development Agency ran a lot of things like that. The
policy of the 1990s and the early part of this century
probably dispersed the small companies around the
country.
On the question about investment, probably most of
our member companies start with a technology idea,
but they are in the commercial world so they are not
starting this in vacuo. They are thinking, “This is an
idea that can take off but it is bigger than our scale of
business. Therefore, if we can get some Government
support, we will take it forward.” Then the matched
funding element drops in. You then have to find the
investors, so the proposition to the investors is, “You
guys are investors. There are angel networks and so
forth around with a lot of family and friends. This
looks like a good idea. I can get £100,000 from the
Government. Will you find us the other £60,000?” It
is very organic in that sense and driven by the match
of a new idea with a potential market.
Q218 Stephen Mosley: Assume that someone has set
up and come up with a good idea. They are becoming
successful and beginning to prove that the idea will
work. How do we make sure that that new idea stays
in the UK and doesn’t get taken elsewhere?
Dr Bradshaw: That is why it is nice to have things
like the proof of concept funding and the return of
Smart awards within the TSB. That is something that
can help anchor the next bit of research and
development to keep it in the UK. Beyond that, there
are all sorts of other good things we can do. We can
link them up with the universities, maybe to get more
people that they require and the skills to develop
things further, or access other R and D that might be
needed to add to what they have got to make a
commercially viable product. Then you scale it up at
the other end where you might have initiatives to
support corporate venturing. Some of the larger
companies are looking at these innovative new
technologies and might want to be able to help them
advance further. In the past, we have had schemes that
would support corporate venturing activity. I think
that shut down in 2010 or 2011—I forget exactly
when it was—and maybe it is time to have a look at
some of those things again.
Tim Crocker: This is where divergence really opens
up. Most companies manage to get to the proof of
concept stage. If they are successful in getting large-
scale venture capital backing, there is really only one
business model in town. In the last year I have been
to a number of investment events and have seen this.
The standard business model is to get a few million
pounds in Government grant, out of the TSB mainly,
and a few million pounds out of the venture capital
community. Then, because of the needs of the venture
capital community—the angels behave almost exactly
like venture capitalists now, the organised networks—
the company is sold on. The business model is: three
from the TSB; three from investors; sell for 20. You
can sit in an investment network and see that business
model churn, and the numbers change a little bit. The
effect of it is that these companies, at the point where
proof of concept has been passed, go into the hands
of large corporations. The IPO in the public market is
almost discredited now. I can’t find anybody who has
done it recently, and I can’t find a single business
adviser who will tell you it is a good idea. There are
companies languishing in the junior markets that can’t
get funds, so a sell-out for 20 million quid is the
business school model, and most of those buyers will
not be UK buyers. That is where the rub is.
Dr Bradshaw: I take issue with the emphasis put on
“sell-out”. Business life is like that. There will always
be times when companies will want to develop that
next stage further. They can’t afford to do it
themselves, and maybe the best way of doing it is
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with a larger company helping them take things
forward. There will be those who do grow themselves
and do it organically; there will be others where the
best route for them may well be to have different
management brought in, to have funding from another
source, or maybe to be taken over by a large company.
That is just the way business works. They are
commercial organisations. If you have a technology
which is really good but to make a difference you
have to get a market scale, which means global
penetration pretty much straight away, it is very
difficult if you are a small company to do that on your
own. Quite often, the best solution may well be to do
it with large company back-up.
Q219 Stephen Mosley: But the key thing for us here
in the UK is to make sure that the skills, jobs and
technology stay in the UK, even if the company is
sold on elsewhere. How would you try to ensure that
happens?
Tim Crocker: I disagree fundamentally with what you
said. I just have to register that that is completely not
the way we see it. I can promise you that there is only
one business model in town for small companies: to
get to £20 million and sell out. There has been a lot
of research on building what has now become
recognised as the equivalent of the German
Mittelstand and how we grow medium-size companies
from a sell-out value of £20 million to something with
a revenue of maybe £100 million, which we are really
short of in this country. To do that, you have to have
longer-term finance that will buy out the VCs and
keep the companies in this country. It may be in
partnership with a UK company, but the statistics
show that most of these companies are sold overseas
because the Americans, Indians and Chinese all have
their chequebooks open. We have pretty much stopped
visiting members of the CBI to sell things out,
because the first thing is that we haven’t got any
money and we don’t do that.
Dr Bradshaw: Last year we produced our “Future
Champions” report about mid-size businesses. One
thing we looked at in there was the lack of a bond
market in the UK for smaller bonds.
Tim Crocker: I absolutely agree with that.
Dr Bradshaw: Excellent. Finally, we agree.
Tim Crocker: If we had a bond market and other
financial instruments, this disagreement between
ourselves would disappear, but it is the absence of that
medium and long-term money in the UK market that
controls all this.
I have to add one other thing that is relevant here. In
this “only one business model in town” there is also
weakness in the patent system. When a small
company in the UK files a patent you can get very
good quality patent work done, if you can afford it,
and the TSB is supportive, but you cannot exercise
the rights of those patents unless maybe you have got
a fighting fund of half a million quid; and that would
be a minimum sort of fighting fund, as lawyers would
advise you. Therefore, when you sell out a company
to a large corporation and you have good patents,
those patents have value. If you try to hang on to
them, you cannot exercise the commercial rights of
those patents if you are a £20 million-worth company.
You can’t continually fight half-a-million quid battles
to enforce your commercial rights.
Q220 Hywel Williams: This is a matter of curiosity
on my part. For as long as I can remember, there has
been concern about the brain drain. A moment ago
Stephen Mosley made a point about companies
migrating overseas. I wince at the term, but is there a
brain pump? Do we attract in good and interesting
small companies, or take advantage of those sorts of
ideas from abroad? Are we as good as other countries
in doing that?
Dr Bradshaw: That is a good question. I am sure we
do attract them; just look at the “brain drain” bit as
well. Don’t forget that we have a lot of good UK
companies that are winning market share in places
like the US. Okay, they are bigger companies, but the
likes of QinetiQ and BAE Systems are doing very
well overseas at the moment. Do we attract other good
companies to the UK? I think so, and, yes, we have
smaller companies that are managing to win big
business with large overseas corporates. A good
example recently would be ECO Plastics, which is
working with Coca-Cola. They got private equity
funding to develop a system for turning post-
consumer plastic waste into food-grade plastic bottles
again for Coca-Cola. That is now going to be rolled
out much more widely than just in the UK. There are
some really good success stories of what you can do.
We would like to have more of them.
Tim Crocker: I cannot answer your question
directly—I don’t know the answer—but there are
some asymmetries built in, which we are not very
happy about, on the same lines. For instance, UKTI
has a budget to get overseas companies to invest here
and set up their own company, but it can’t help you
get investment into a UK company, which seems to
be an own goal. It could be 100% Indian, but it can’t
be 50%. On the other side, an awful lot of people look
at the greener grass on the other side—Germany and
America—and weigh the fact that they have family
and lifestyle issues here. There are lots of pluses for
the UK, so they stay out of a fairly solid allegiance.
They would simply like some structural change made
so that it is easier to do what Government want us to
do. These are structural changes that I do not think
have Exchequer cost. We can simply change some
rules and do better.
Q221 Hywel Williams: I should say that I have a
Siemens plant in my constituency of Arfon. One of
the reasons the previous company moved there from
the United States was lifestyle issues, because, as Mr
Crocker said, it is a very nice place to set up, and it
is free.
Tim Crocker: Yes. We view the world for medium
and large companies in the UK as being quite benign,
so a lot of the points made here by Tim I would not
disagree with at all. That community is good. It is just
the funding issue for SMEs which causes the
difficulty.
Q222 Hywel Williams: I would like to get on to that
point. It is said that the UK is very poor at growing
small companies to medium-size companies, and
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medium-size companies to large companies. Tim
Crocker has already referred to the finance provision.
Is it just a matter of finance, or is it a matter of
providing customers, and perhaps the Government as
customer as well? Is it an either/or, or is it both?
Tim Crocker: In my view it is definitely both. SBRI,
as we have it, is not quite the same as the American
SBIR. The American instrument is probably quite
crude, but it is the one that works best. That is what
most of the survey information says. The reason we
have matched funding is that Government wanted the
investment community to make the business judgment
and then come in alongside it with Government
money. The fact that the investment community don’t
want to engage and be in that early means that that
judgment is not being made. If you then move to
100% or 105% funding, which is what would drive it
on, you generate a very difficult decision, which is:
who gets the money? Panels of what we call the great
and the good, for perfectly natural reasons of human
nature, always put the money in the safe and well
presented, and not in the ones that retrospectively
would have been the successes.
What they say in the States is that they get round that
because they are not afraid to fail. If you have blanket
SBIR funding, the exciting projects, which may have
been hidden, will still come out. If we moved to 100%
funding, it is better that it is procurement funding,
because then it is at least decision making around
Departments of Government, each of which has some
expertise in the subject, is statistically more likely to
put the money in the right places and, more
importantly, is less likely to get stuck in a big
institutional handout system that always winds up on
itself and ends up looking expensive. I think the
Regional Development Agency story tells you what
can go wrong if you go down that path.
Dr Bradshaw: There is a two-sided story to this: the
push side, where Government is helping to do things
through the Technology Strategy Board or supporting
skills development etc, and the pull side from the
Government procurement line. Looking at the push
side and what is available in terms of Government
grants and aid that makes a difference, it is useful to
look back to a piece of work the Centre for Business
Research at Cambridge university did probably five or
six years ago, but it is still valid. They did a matched
sample of high-tech small companies in the UK and
the US, so they were very comparable, and looked at
whether they received Government funding, how
much money and whether it made a difference. The
UK came out quite well in terms of whether they
received Government funding; it was about two to one
in favour of the UK. But those companies that
received funding in the US got five times as much as
the UK ones. The story was that the money in the US
was transformational. It wasn’t just a little bit of
money for skills or a little bit of money for a project
on R and D; it was money that could make a
difference in building up their innovation skills and
perhaps leadership and management skills, and
helping them to access finance and do some R and D
activities. It was everything they needed in one place.
That is the difference, often, with the picture in the
US versus the UK. We do a lot of little things all over
the place, but we don’t bring it together to make a
real, critical difference.
Q223 Hywel Williams: How do they pick the
winners, then?
Dr Bradshaw: I don’t know. We will have to go back
to the story and look in a bit more detail at which
ones got that money. They are setting the bar a bit
higher, perhaps, in terms of what their market and
technology potential is to get that money to start off
with. In straitened financial times maybe you do have
to set the bar a little higher, but, if you do that, make
sure you give a critical mass of support that will make
a difference.
If you look at it from the pull side—the Government
procurement side—yes, absolutely, that is what can
really make a difference. Despite what I have just said
about grants, aid and things, most companies would
bite your arm off for a contract rather than a grant.
The more the Government can do to encourage
innovation through their procurement lines the better,
be it through SBRI or maybe making sure that all the
public procurement space is also looking at innovation
so that we transform it. We look at things like
outcome-based procurement and whole-life value; we
encourage those involved in procurement to look for
innovative new ideas that might save them money
long term, rather than short-term upfront costs. When
you have some really good things in the public estate,
showcase them. If you have got them in, show them
off to the rest of the world and show what can be
done. Make sure you are demonstrating to overseas
buyers that we have done this in the UK: “They’ve
got a fantastic contract with the UK Government, and
now they can go and supply Australia, Canada or
whoever else might need it.”
Q224 Hywel Williams: It is said that Germany is
better than us. We have compared ourselves with the
US already. I do not know whether you are familiar
with the model in Germany, but, if they are better,
what are they doing better than we are? How do they
do it more successfully?
Dr Bradshaw: The KfW bank is one of the things we
have looked at, and we think that is very good, in
terms of being an industry support structure. There is
perhaps a little difference in culture, in terms of
growing companies more organically for a longer
period of time. It would be worth looking at that in
more detail to see what the cultural difference is.
Tim Crocker: I would agree with that. The thing that
I noticed in doing business in Germany is that the
universities and businesses are integrated in a two-
way flow system. Implicit in Government policy
now—you see it in all sorts of policy documents—is
that the game is to get the technology out of the
universities and into the commercial companies. In the
bio and pharma sector I think that is the way it works,
but in other sectors it doesn’t. To me, it is bizarre that
I have closer bilateral relations with German
universities than I can have in the UK.
The signal of that is that in the UK we have the KTP
finance system—knowledge transfer—which assumes
transfer of knowledge from the university outwards.
If you are on a peer-to-peer basis—in lots of cases
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our companies are more advanced than universities—
there is no funding mechanism at all by which we can
engage with the universities and our time and theirs
can be paid for. All we can ever do is use TSB money
to subcontract to them, and that is a very
unsatisfactory relationship. There is very little walk-
back of Government scientists, or research scientists,
from the big corporations back into the universities
after an industrial career. If I speak to people in
Germany, these guys are in and out of the
universities—five years here and five years there.
Visiting professors spend half a day a week teaching,
and the integration between universities and industry
is entirely on a peer-to-peer basis.
Dr Bradshaw: We recognise that. This is a hands-on,
people-based activity. A two-way flow of information
back from industry into the universities and vice versa
is essential. The more we can do to support that, the
better, definitely. The KTPs do work quite well. One
of the issues is the speed at which these things can be
set up, and that is a particular issue for SMEs. It is a
relatively bureaucratic process. Later, Iain Gray will
probably tell you that it is not bureaucratic and it is
all lovely, but we know there are smaller companies
in particular who would like a shorter KTP activity
and to be able to set things up straight away. I think
there could be mechanisms to give money to the
universities that we know have a good record on KTP,
and say, “Look, we’ll trust you to set things up
quickly”, and then do the bureaucracy after they have
been set up, rather than the current system, which
means you have to go through all that process before
you can do anything. The speed of delivery of some
of these mechanisms would make a difference.
Tim Crocker: I would agree with that wholeheartedly.
My point is not that KTP is bad, but that it is
intrinsically one-way. If KTP were a bilateral deal and
faster, it would solve an awful lot of problems inside
the same funding.
Q225 Chair: Mr Crocker, earlier on you used a
phrase I did not fully understand. You said that if we
looked at the RDA story we would understand that. I
think that was the phrase you used. What story do
you tell?
Tim Crocker: I am based in the south-west. I do not
think there is any favourable press for the south-west
RDA, so I have probably the most jaundiced view. I
know that the one in the north-east did fantastic work,
but what we observed, which I think is the median
story of the RDAs, is that they spent an awful lot of
Government money on what I would call current
account spending. It built up an infrastructure that was
supposed to support the whole of industry, particularly
the SME community, but it spent it on its own
activities. I have been to a lot of events that are
completely useless.
Q226 Chair: In the south of England.
Tim Crocker: Yes, except that I have met some useful
people. What we would advocate in all this is to take
one lesson from the past, which is that, whenever you
set up a big bureaucracy, it tends to consume a lot of
current account money; it is just spent that year, and
no benefit is coming to our members. That is what
everybody says.
Q227 Chair: This is the curious thing I find. Dr
Bradshaw, when making a comparison with the
Germans, used the phrase, “It’s cultural.” I personally
don’t accept that it’s cultural. There is actually a
bureaucracy there, but it is a bureaucracy that works.
Tim Crocker: Yes. We have not managed to make our
support bureaucracies work, and that is because we do
different things.
Q228 Chair: Your criticism was not of the principle,
but the mechanics.
Tim Crocker: I am holding up a red flag: be very wary
about setting up another institution that on the current
account spends a lot of public money supposedly
supporting businesses. I would give you this germ of
an idea. One thing that frustrates a lot of people in the
small sector is the way that we have set up some of
the technical standards. We are more private—this is
done by private companies according to pro forma
standards—whereas these things are done in Germany
by the federal states at local government level. I
would be greatly in support of spending public money
to bring back into the public sector some of these
regulatory activities at a detailed level, which then
implicitly give support, because there is somebody to
talk to who knows the answer to a particular
technical problem.
What the RDAs did was to put in a vast senior
management of people who were good at putting on
events, shows and so forth, but if you asked them,
“How do I pass regulation such-and-such?, the answer
would be, “I will find you a consultant.” We suffered
deeply from that, whereas in Germany it would be,
“You will go to TÜV and talk to Dr So-and-So, and
he will tell you the answer.” The state would charge
you a fee for that, but it will be the definitive answer.
Q229 Caroline Dinenage: As I understand it, in
Germany it is compulsory for a business to be a
member of its local chamber of commerce. I have
been a business owner since I was 19 years old and
have never engaged much with a chamber of
commerce because it was too large to feel that it was
very good for me to grow my business. Is there any
mileage in businesses getting support from others,
particularly at the intellectual level?
Tim Crocker: I do think there is, but the approach of
the last 30 years, during which we have progressively
privatised this, is backfiring in an unintentional way.
What you want are definitive answers to questions, so
that you can say, “This person told me that”, and that
answer stands for the purposes of law, rather like the
relationship we have with the Inland Revenue where,
if you get a tax inspector to say, “That is how it is; I
agree it”, it is done and dusted. I cannot get that for
technical regulations, which for us are real barriers to
entry for products. If chambers of commerce became
more and more semi-official, with true partnerships
between businesses and local government, as they are
in Germany, I would think it a very good idea. If they
were the local government kissing off that form of
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responsibility so that it was only an opinion, it would
work entirely the other way.
Dr Bradshaw: I very much support businesses
learning from other businesses, and there are lots of
ways of doing that. I don’t necessarily support
compulsory membership of chambers; that is probably
not the way to do it, but there are lots of mechanisms
out there. The CBI does a couple of things. For
example, we set up some clubs for medium size
businesses around the country so that they can share
ideas and learn from experts on innovation, access to
finance, exporting and things like that. We have run a
business-university collaboration group at the CBI for
well over 20 years, in which we bring predominantly
large but quite a few small high-tech companies into
the room to discuss and share ideas and best practice
about working with universities, and the best way of
tapping into knowledge and expertise in the UK and
overseas. That sort of thing is probably better; it is
more of a technical thing that companies might need
and that might make a difference, rather than some of
the very general things you might get from just the
chambers perhaps.
Q230 Caroline Dinenage: That is interesting. You
have talked a lot about the lack of long-term risk-
taking by equity investors. Do you see that as
something the Government can influence? Do you
think the banks could have more involvement? Do
you see that the banks understand the needs of
growing small and medium-sized technological
businesses?
Dr Bradshaw: There is always a knowledge gap. The
companies themselves are the ones that probably
know best where their technology is going. Do the
banks have all the expertise? Maybe not. There may
well be a need for better expertise in certain areas.
That is why it is very useful to have things like the
Green Investment Bank, where there is a focus on a
particular sort of technology or technology area.
Should the Government be doing more to support
equity investment? We have lobbied for a long time
for the cost of raising equity to be normalised with
the cost of raising debt. At the moment there is a
difference between those two. We would far rather
that businesses were taking investment decisions
based on what they need to grow their companies,
rather than on their tax position and their profit and
loss account.
Tim Crocker: There are lots of elements to that
question. The question sometimes gets simplified to:
should the banks be involved in financing R and D? I
don’t think there is any way you can use debt finance
to finance R and D. There is an implicit risk there; if
the R and D activity fails, who repays the bank?
Therefore, you need some of the funding to do
R and D.
One thing that is fundamental and unavoidable is that
the UK is in the equivalent of an arms race on R and
D funding. All the competitor nations that we aspire
to be as good as are spending lots of public money on
R and D. There is an EU study by Professor
Mazzucato, who is now at Sussex university, which
spells this out in total detail. It is the most recent study
I am aware of, and it fits with all the facts that I have
ever observed about this. If we pose the question of
whether, to get more R and D done in the UK and
make it stick longer, we should do something to raise
more equity or put in more Government funding, the
only rational answer is to say that you have to put in
more Government funding, because nobody has ever
done it any other way. Our competitors are doing it
by Government funding in the here and now, so we
would be taking an enormous risk, even if we could
do it.
If you are going to move to putting in Government
funding, the question becomes: how do the taxpayers
get back their funds? If you look at the way the VC
community works in the United States, it pays an
awful lot of corporation tax back to the Government.
When the US Government do their accounting on
SBIR, as it is there, they find that it is a virtuous
circle. They can afford to spend this money because
the finance community is paying back the taxes, the
profits are appearing on the stock markets and so
forth. I am very doubtful that technically you can do
anything about equity funding more than the
initiatives that are going on with organisations like
Crowdcube and so forth, which are pushing it along.
I think Government have to bite the bullet and say
that getting R and D through to commercialisation is,
in our competitor nations, basically a state-funded
activity, and then set up the tax system to make sure
that it comes back in.
Dr Bradshaw: Don’t forget the pull side of that
equation. I go back to that again. That is the thing that
makes a real difference—getting a contract. If you are
using the public procurement system, not just through
SBIR but more widely, to try to bring through
innovation, and you have a better market where there
is an open dialogue between potential suppliers and
Government procurers about what is possible for the
future, looking at new capabilities and new
technologies coming on line, you will get a better
environment for those technologies and ideas to be
developed further, because there is then a potential
route to a customer.
Q231 Caroline Dinenage: If I may ask you about the
business community, is there sufficient support and
encouragement among the larger businesses for
smaller businesses within their supply chain? Is there
anything that the Government can do to encourage
that?
Tim Crocker: Our supply chain is very discontinuous.
Many of our members will have contracts with big
companies, and that is their best way forward, but it
is very binary. You might or might not, but it is very
hard to get the first one.
To add something on the issue of banking, I think the
Committee, BIS and the Treasury need to look at the
conditionality of banking in the high street, rather than
the rates that they see. One of the things that comes
up time and again is, “We applied for this Government
grant and then we are asked for personal guarantees”,
with people being wheeled in to sign off on £100,000
worth of Government support—soft funding—for
clean tech or one of these things, and then the
directors are asked for personal guarantees. The
problem with personal guarantees is that they limit
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the scale of ambition of the company to the financial
resources of the directors, if they are brave enough,
and turn it off if they are not.
I know we had an answer from the DTI 10 or 15
years ago that, with the Government-backed guarantee
schemes, 75% of the loan was guaranteed by the
Government and the bank had to pick up the other
25%. The banks made the borrowers pick up the other
25%. Nobody from the Government side is looking at
that conditionality. If you walk into the boardrooms
of the banks, they know nothing. Mystery shopping
and inspecting deals is the only way it is going to
happen. When I started my business, I was paying
2.5% over base; on very small short-term loans, I am
now paying 9.5%, and I know some people who are
paying 20% over base. There is no point in the Bank
of England setting the rate at 0.5% if the banks are
still lending as they were in the mid-1990s. This is
just running on and on.
Q232 Roger Williams: We have had written
evidence that the UK needs a clear national innovation
system, but what do businesses need most of all? Is it
the right people, access to equipment or access to
cash?
Dr Bradshaw: I don’t want to sound like a broken
record, but it is a push-and-pull thing. It is the
innovation system, industrial policy, which you can
wrap up into the same package, and public
procurement. I think the No.1 ask from business is
long-term strategic focus from Government. If you are
looking at an R and D investment and the time it takes
to bring that through to commercialisation, obviously
it is different for different sectors, but for the
aerospace industry it could take 20 to 40 years to
realise a return on your investment. So having
confidence that the Government will still be interested
in the aerospace industry and will support the
activities you are doing over that time frame with the
R and D that is required to bring that through to
market is essential—making sure that the overall
environment is good, in terms of universities, R and
D tax credit etc. These things take a long time to pay
off. Consisitency is what companies are looking for:
is it going to be stable in the UK? Do we have a good
environment for the long-term future that will get
those projects through, get the money and get a
potential market?
There are all sorts of other things beyond that. On the
people side, yes, definitely, we know there are
particular shortages in engineers. The Institution of
Mechanical Engineers looked at that and said we
needed to treble the output of university graduates that
are coming out at the moment with engineering
degrees to be able to meet the demand we know we
will have. That is an issue.
In terms of equipment and facilities, the universities
themselves have a lot of that on offer. There are more
schemes that we can use to encourage companies to
have a look at that and see what is available. The
innovation vouchers are being brought back in again
to encourage the first contact between SMEs and
universities to see what facilities are available to them.
I think the catapult centres, as they are now called, fill
that same slot. Last time I called them the “Andrew
Miller centres”, didn’t I? We were debating the name
then.
Chair: We preferred “Alan Turing”.
Dr Bradshaw: That is right. There are lots of
mechanisms out there now that have facilities,
expertise and equipment. Can we make sure that the
community is aware of those, and that you can best
match up what the companies need and what is
available in the UK? That is something we still need
to work on. It is an ongoing problem. We are getting
there, but we are not there yet. More emphasis needs
to be put on that.
Q233 Roger Williams: Mr Crocker, you did say
right at the beginning that more cash would be a good
thing but it is not an option at the moment. A senior
member of the Government said that he was going to
give 110% to growth. I don’t know whether you can
understand that, but what I understood by what he
was saying was that, if there was some Government
spending that isn’t delivering growth, it could be taken
to another sector where growth could be better
achieved. The case has been made that investment in
science and technology is a real element of growth in
the national economy. Is it that politicians are not
making the case for more investment in science and
technology, or is it business or the universities, or is
it just the Government who are resistant to that
argument?
Tim Crocker: I think our membership has been
invisible to Government for a long time. The
universities sometimes do come across as if they are
the only source of innovation. That is simply not the
case; the statistics say otherwise. When I said we
understand that cash is short, I absolutely agree that
the factor 6 figure is the ballpark of the per capita
increase in Government funding that we need if we
are to compete with the United States. I take it that it
is a decision for politicians where you are going to
get that factor 6 from. My plea is not to spend it on
salaries of advisers, because this becomes wishy-
washy money. That is not a plea for not spending it
in the public sector. I would like to see EMC
inspectors, or whatever the equivalent is in
biomedicine, so I can get decent, instantaneous
answers to questions.
Is it money or any of the other things? It is all the
things that have been said, but for our sector, it is the
length of the money that is the absolute big thing.
Four or five-year horizon money does not allow you
to do anything other than sell the company. People
say there are no medium-sizes companies because
they have all been sold to big companies, and it is just
an inalienable truth.
The point made earlier about us needing to package
the money in bigger slices is absolutely true. If you
receive £200,000 of R and D money it seems a lot,
but the lawyers who do the deal will want £100,000
of that. So we need bigger packages; we need to think
bigger. One idea arose earlier that we have been
looking at. The bond market is the only route forward
where, as far as I can see, the Government have to
stand by some sort of growth bond. That growth bond
has to go predominantly into some sort of
procurement funding.
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Q234 Roger Williams: Often, the universities have
provision for high-technology machinery and
equipment. Is that always available to the companies
that really need it and would make best use of it?
Tim Crocker: No. There is no lack of willingness;
these things are done with good intention. The
mechanisms at the detailed level are not there.
Dr Bradshaw: The facilities are there, but often it is
the matching of the need with the facility, and finding
routes to do that is difficult.
Q235 Roger Williams: Can you give us a view on
the catapult system and whether it is going to be a
good one for smaller to medium size companies?
Dr Bradshaw: I think it is still too early to say. These
things are only just being set up properly now. A few
of them—the advanced manufacturing ones—have
been going a little longer. We need to see how they
evolve with time. If you pull the roots up now to try
to examine them, you will do them no favours. We
would like to see them settle down a little, and let’s
ask that question again in a year or two and see what
success they can show. We always said, when they
were set up to try to emulate the Fraunhofers, that the
Fraunhofers had been there for many years and had
built up that brand equity by having a long-term
relationship and being able to demonstrate success
over time. Let’s give them a little bit of time to settle
down and show they can do something useful before
we start to try to pull them up.
Q236 Chair: When you undertake your review of the
catapults and how they are performing, I would
recommend that you look at the Fraunhofers. One of
the reasons I picked you up on the word “cultural” is
that, when I asked a senior German civil servant
whether it was the triangulation involving the
Fraunhofers that created the longer money that Tim
Crocker is looking for, his response was, “Mr Miller,
I used to be a banker. The answer is yes.” I think
the argument that it is cultural needs challenging, and
organisations like the CBI need to ask themselves
whether it is structural. If the answer is yes, I think
you would agree there is a case for going further with
the catapults. Is that fair?
Dr Bradshaw: Do you mean expanding the catapults
and doing more sectors and giving them more money?
Chair: Despite their name.
Dr Bradshaw: Despite their name. I don’t think they
have been there long enough to be able to see whether
they are the right mechanism. There is a lot of good
value in them, but they need to establish themselves.
Let’s not forget that they are also competing with
some very good university centres and research and
technology organisations, but they are fitting
themselves into the innovation ecosystem in the UK
and they have to find their space. If we find that they
are just duplicating effort elsewhere, then yes, we will
be vocal about that, but if we find they are doing a
really good thing in bringing bits together and making
a difference that is good, but it is a bit too early to say
at the moment.
Q237 Sarah Newton: I am very fortunate to have
the last question. This is your last opportunity to say
anything you have not said before. You have given us
an immense amount of useful information and food
for thought. It has ranged across the medium and
longer term and some short term. We have got
complete focus now, with the reshuffle, on growth, so
if you had the Ministers responsible here today, what
would you want the Government to do right now or
within the next 12 months to address the issues that
you have shared with us today?
Tim Crocker: I think the need for long-term strategy
is the absolute core of this, and the long-term strategy
will then pick up the points we have been making in
detail about money, patents and so forth. When you
make the distinction between “cultural” and
“structural”, a culture develops from the structure that
is there; it is an institutional process. I would say that
at the moment we have the wrong culture and
institutions that are probably not performing as well
as they should. It is possible to fine-tune the
institutions, but the trend that seems to have been
continuous since the last war is that we do not find
the means of doing technocratic governance very well.
Other countries that we admire for their technology
have state-run railways that run perfectly well.
I do not want to get into the politics of this, but our
solution is different. My absolute gut instinct—I am a
commercial person through and through—is that it is
the interface between private industry and the state
where the boundary has gone wrong. The state has
shed a lot of low-level activities that are absolutely
necessary and thrown them into the private sector, and
that forces the divide between us and the large
companies, because the large companies benefit from
this; they can soak it up. They have accounts
departments that can cope with 30-odd different
national insurance rates and so on and so forth. The
little companies are systematically disadvantaged by
this. It is not just tax rates; it is every little rule and
regulation. If I want goods signed off for sale in this
country, I end up signing the certificate of compliance.
If I go to a German test house, the test engineer, who
is an employee of the German state, signs it off. That
is a massive liability difference.
I know Mr Harradence is here later. I think it needs
to be absolutely inside BIS. Government have to view
BIS not as a spending Department but an earning
Department, and they have to have the absolute lean
and mean crack team that is going to work with
industry, not on its own, to get this structure sorted,
and then everything else will fall out. I would hope
that out of that we will see a means of getting longer-
term money, and moving grant support from
Government away from matched funding, which is the
real and immediate bugbear. Also—I have not said
this sufficiently strongly—the patent system needs
fixing for the small companies. The big companies
love it the way it is; we don’t. It is a Mandy Rice-
Davies thing: they would say that, wouldn’t they,
because it’s good for them, but it’s really bad for us.
Q238 Sarah Newton: Could you expand on how it
could be improved for small and medium-sized
businesses?
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Tim Crocker: At present, if my car is stolen I call the
police, who try to get it back; if my patents are stolen,
I have to go to a civil court, front up a few hundred
thousand pounds and have a fight with a multinational.
That means that my investors have absolutely no
security over the patents we hold. In more than half
of EU countries, patent infringement is now part of
criminal law to fix this. In the United States they have
triple punitive damages. In this country we have
absolutely nothing. In the hands of a big company,
those patents are perfectly powerful. As a bargaining
tool for small companies, they are worthless; they
have no value. We can only exercise that value by sale
to a big company. That is the other pillar by which
we do not have medium-scale technology companies.
Dyson broke the mould, but his success should not be
seen as the normal path. He did brilliantly well to
break that mould.
Dr Bradshaw: I will limit myself to three things,
although some of them are quite big. The No.1 would
be to have a new approach to industrial strategy that
is focused on our competitive advantage sectors and
helps to make sure that they are being encouraged and
supported to export and develop for the future. A lot
of that could well be around developing their value
chains in the UK. For example, there is a supply chain
initiative at the moment that BIS runs. It is only for
one year and it is for about £125 million, but what
about the next 10 years? Could we repeat that again
and again each year for the next 10 years to build the
facilities, skills, and innovation investments required
for the supply chains in the future? The first is an
industrial strategy.
The second would be the changes I mentioned around
public procurement. That is the big pull factor. I
suppose there are three big areas around that. One is
creating a better market environment, which is an
open dialogue between suppliers and buyers about
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Q240 Chair: Gentlemen, welcome to this morning’s
session. You are all familiar with the terms of
reference of this inquiry. I notice that you also listened
in to a significant part of the previous session. For the
record, would the three of you kindly introduce
yourselves?
Sir John Savill: I am John Savill, currently serving
as chief executive of the Medical Research Council,
but today I represent Research Councils UK, which is
the collaborative organisation of the seven research
councils.
Iain Gray: I am Iain Gray. I am the chief executive
of the Technology Strategy Board.
Fergus Harradence: I am Fergus Harradence, and I
am the deputy director for innovation policy in the
Department for Business, Innovation and Skills.
Q241 Chair: Welcome to the three of you. The
Government have told us that science is core to the
what is potentially possible. It is about capability
reviews, like the tunnelling capability review
produced recently for procurement pipelines. Those
are all very good because they help to give companies
confidence about what is needed for the future, but
those need to look a little further out, because at the
moment they are more about capacity than developing
new capabilities for the long term. If we looked ahead
up to 10 years rather than just five years, which is
what the current plans look for, that would really help.
Then there are wider changes within the outcome-
based procurement, looking for whole-life value and
being able to transfer money between revenue and
capital budgets in procurement to help bring through
some of those changes. Those would be very good.
The third and final thing would be around the funding
for the Technology Strategy Board. We have always
argued that it should have funding on a par with
something like the EPSRC. That will effectively
double its budget at the moment, but it has to work
with business and focus on the things business wants.
At the moment it does an awful lot of good things,
but its money is spread very thinly. If we could bring
a little more focus to and effort around some of the
core competitive advantage sectors, we could make
more of a difference.
Q239 Sarah Newton: If that budget was doubled,
would you keep the ratio of expenditure about the
same, or do you think it should be changed?
Dr Bradshaw: Within the TSB?
Sarah Newton: Yes.
Dr Bradshaw: Whether the budget is doubled is the
biggest question. If we achieved that, we would be
delighted, and then let’s have a look at how we
spend it.
Chair: Gentlemen, thank you very much indeed.
growth of the UK economy. In your opinion, have the
Government got the balance right between the funding
of basic science and stimulating and supporting
commercialisation?
Iain Gray: I think the answer is no. If you look at the
responses we heard earlier, there were some clues to
that as a direction of travel. The balance is wrong.
The key question is how we address that balance, and
too often the wrong ideas come forward as to how to
redress that balance. To look at things in a total cross-
governmental way is one of the ways forward to
address the balance, but, fundamentally, I think the
balance is wrong.
Sir John Savill: Can I qualify that view from the
perspective of the research councils, though I would
not disagree with it? The first thing to remember is
that without fundamental research and discovery there
is no translation. If changing the balance results in
reducing the funding to fundamental research, there
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will be less to translate for the nation and that has to
be borne in mind.
The second point—I won’t bore you with the detail
but will happily go into it if you are interested—is
that the research councils commit an awful lot of
resource to the translational pathway. In my own area
of biomedicine, where the valley of death is a very
real phenomenon, we have changed our way of
working over the last four or five years.
Thirdly, I would agree with Iain that the balance might
appear to be wrong. It is interesting to compare the
devolved nations of the UK. I live and work in
Scotland some of the time. The balance there between
Government funding through Scottish Enterprise to
the research council funds that reach Scotland through
competition is different.
Finally, all research councils enthusiastically engage
with TSB. For example, in developing the cell therapy
catapult, EPSRC, MRC and BBSRC have invested
£25 million in a regenerative medicine platform to
speed the transfer of fundamental research to the
catapult.
Personally, I have been involved in thinking
developed at the Office for Strategic Co-ordination of
Health Research, chaired by John Bell, where we
recognised a real shortage of funding available to
TSB. We were able to press the case with Government
for additional funding for TSB to partner MRC in the
biomedical catalyst. I would agree that the balance
might appear to be wrong. I think the most obvious
imbalance is in the budget of the TSB to the
research councils.
Q242 Chair: “Is wrong”; “appears wrong”. Mr
Harradence, I guess we are going to hear a slightly
different version from you.
Fergus Harradence: I would try to agree with both
points of view. I agree with Iain that, if you compare
the budget of the Technology Strategy Board relative
to the budget of the Research Councils, you would
draw the conclusion that there is a need for more
funding to go to the Technology Strategy Board to
support innovation, technology development in
business and the commercialisation of research, but I
don’t think the solution to that problem would be to
say that we should crudely aggregate those budgets
and decide to take some money away from funding
basic research, which performs a tremendously
valuable role, and not only in building intellectual
capital in the country and supporting the early stage
research that leads to translational research and
technology development in business; it also trains the
cadre of skilled people that we desperately need in the
economy, who will become the innovators of the
future.
Part of the solution is to seek additional funding from
outside for the Technology Strategy Board to try and
get a better balance. I also agree with Iain’s point that
there is a big need for us to become more joined-up
across Government. A lot of additional funding for
science, technology and innovation is held by various
Departments and other public bodies, and that is not
part of the simple TSB Research Councils’ calculation
when you look at the total budget for science and
innovation. There is more that we could do to link up
with Departments like Transport, Defence and Health
to achieve a better and more co-ordinated approach to
support for innovation that will draw on the
investments we make in the research base.
Sir John Savill: I agree with the last point. I have
lived in a space where over the last six years we have
tried to co-ordinate the public sector research budgets
involved in health research. They are not held just by
the Medical Research Council but also by four
national health service research and development
systems. OSCHR is a model that has worked to
co-ordinate spend across Government Departments
quite effectively; indeed, as such it has attracted
international visibility. In my travels within the
European health research community I am often asked
about OSCHR. It is an example of how you can
achieve what Fergus has highlighted in other domains.
Q243 Chair: This could take us down the lines of an
entirely different inquiry if we start focusing too much
on the structure of Governments, but there is some
common ground between you. Are there other budgets
that could be refocused that would help release
resources for commercialisation purposes?
Iain Gray: To give my perspective, first I reinforce
what John said. The working relationships among the
Technology Strategy Board, the research councils,
universities and science bases are very good. While I
gave a very blunt and straightforward answer, I would
reinforce that it is not about redressing the balance by
reducing investment in science and technology.
If you look at the overall investment in R and D across
the big spending Departments of Government, we
heard earlier this morning about SBRI. The
procurement of research across different Government
Departments needs to be drawn into this debate. If you
look at the overall public sector expenditure across
Government Departments, it is an order of magnitude
sum of money greater than that invested through BIS
in the Technology Strategy Board. I believe it is how
we can tap the large R and D expenditures and public
sector expenditures, particularly in pre-commercial
procurement, to help assist in the innovation agenda,
bridging the valley of death that we are talking about
this morning. To my mind, that is where there is some
untapped resource.
Q244 Chair: Is it your view that some other
countries do that better? The obvious part of your
answer is to look at the procurement side. For
example, you would not see too many non-French
police cars on the French roads, whereas in the north-
west of England we have police forces buying Kias.
Iain Gray: There are examples. Probably, the most
visible public sector example in the US is related to
defence, SBIR and the DARPA type of scheme.
Equally, you could look at other big spending
Departments. You could look at health and how we
do things in energy, but, from a US perspective, I
would cite the way that the defence budget is used to
stimulate innovation and growth through SBIR and
DARPA as a prime example.
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Q245 Chair: Mr Harradence, are there any projects
under way that we ought to be made aware of where
some of these issues would be addressed?
Fergus Harradence: Yes. I think we have made quite
a lot of progress over the last five years in becoming
a more intelligent lead customer in Government and
putting in place some procurement mechanisms and
processes that can help us use the power of public
procurement to pull through products and services.
One of the great successes of the Technology Strategy
Board has been the implementation of the Small
Business Research Initiative in the UK. We had two
previous goes at this in the early part of the last
decade. Both times the programme failed because it
lacked focus, resource and active management.
Since 2009, when we relaunched the programme, we
have been able to build it to a level of about
£20 million a year of expenditure, which compares
favourably with a lot of our other business support
programmes that are focused on technology-based
SMEs. So far under the programme we have awarded
over 900 contracts worth £78 million, of which 55%
have gone to either small or micro-businesses
employing fewer than 50 people in total, which
typically is the cadre of companies that the
Government and the public sector more widely find it
most difficult to contract with. There have been some
successes, but the scale of the programme is still too
small. In an ideal world, I would like to see it more
than double, and we should be aiming to grow this to
a level of about £50 million a year, which I think
is feasible and achievable in a relatively short space
of time.
I would highlight a couple of other initiatives. We
have been doing some work on better supply chain
management and how Government can engage more
effectively to support the development of new
products and services over the longer term through
our Forward Commitment Procurement programme.
We have used that to procure zero-waste mattresses
for the Prison Service, which are more
environmentally friendly and cost less, and to develop
a new type of ward environment, this time for the
National Health Service. We have got to the point
where it has been demonstrated. It is in the Building
Research Establishment in Watford. Most recently, in
May of this year we launched our Public-Private
Procurement Compacts. This is genuinely new and
innovative. I am not aware of anyone else in the world
that has done it. For the first time, the public and
private sectors in the UK are coming together in areas
where they have a shared interest in stimulating
demand for new products and services. We are
running them in low-carbon vehicles, biogas and zero-
carbon catering.
Q246 Pamela Nash: Is that a UK-wide initiative or
just in England?
Fergus Harradence: All the initiatives we run are
UK-wide, but we work with specific local partners.
In the case of the Forward Commitment Procurement
programme, we are working with hospitals in
England, but there is certainly no reason why hospitals
anywhere else in the UK cannot participate.
Q247 Pamela Nash: Has there been an approach to
NHS Scotland and Wales?
Fergus Harradence: They are aware of what we do,
and the Technology Strategy Board works very
closely with the NHS and Health Department in
Scotland. They co-fund a number of TSB
programmes, so, overall, Scotland is one of our bigger
partners on the innovation side.
Sir John Savill: Perhaps I may reiterate that the
OSCHR structure involves Iain and me, but the R and
D systems are from all the four nations. Andrew
Morris, the chief health scientist in Scotland, is a
member of OSCHR, so in the health area there is very
good communication. We have had many discussions,
as Iain knows, about the importance of innovative
procurement. We think we have seen movement in
England in the Nicholson report. I was a non-
executive director of Lothian Health Board for eight
years, and I know this is an issue on the agenda in
various health systems. The MRC recently made a
visit to Wales; indeed, we are going to Northern
Ireland in October. Again, I encountered interest in
this innovative procurement agenda in Wales and hope
to do so in Northern Ireland.
Q248 Pamela Nash: I appreciate that. From the
evidence that we have received from the Shelford
Group, which I appreciate is concentrated in England,
I was pretty shocked by one of the quotes we have
been given: “Currently the NHS invests more than
£1 billion each year into primary research, but as an
organisation it lacks an agreed structure to capture the
value of that investment in intellectual property.” Is
there any evidence at all that this expenditure is
benefiting life science companies and medical
technology companies within the United Kingdom?
Sir John Savill: I am sorry. Any evidence of?
Pamela Nash: Is there any evidence that the money
the NHS spends in England on R and D is being
translated into business success within the UK?
Sir John Savill: It is important to explain that a lot of
the research and development done in the NHS is late
stage and does not involve the development of new
intellectual property. I can refer to my Scottish
experience with Scottish Health Innovations Ltd—
SHIL—where there is a real effort by the Government
to mine intellectual property that derives from NHS
innovation. A good example of that is Touch Bionics,
a company that makes artificial limbs, which came out
of a Scottish NHS innovator.
I would like to move on and recount some anecdotal
evidence. I went to an event that Iain organised for
innovators. In this case they were from the English
NHS. They had developed really interesting new
approaches to improving health care. They had
formed companies to try to develop that, but had
found it impossible to penetrate the NHS in the shape
of a lead customer. This is an issue in the English
report. If the NHS were to be required to spend a very
small part of its procurement budget exclusively in
small innovative companies, that would help these
innovators to penetrate the market and demonstrate
worldwide that they can sell into health care.
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Q249 Pamela Nash: Would you be able to share with
us what the particular difficulties were in penetrating
that market?
Sir John Savill: The particular difficulty is that the
procurement system exists to drive down price, and
therefore it favours the high-volume trader. The small
company does not trade at high volume but gets
enormous benefit from selling 20 bits of kit to a small
part of the NHS. Iain will probably want to expand
on that.
Iain Gray: To give you an example, the bottom line
is that there is a huge opportunity. Some of the
restructuring, with the commissioning board looking
at things in a more central way around innovation,
presents big opportunities.
Coming back to SBRI, Tim Bradshaw in the previous
evidence stressed push and pull. It is the NHS
providing that pull that is the key ingredient in this. If
you take SBRI, I will quote just one company:
Eykona, which is a company which essentially has
been developed. It uses a 3D imaging type scheme to
assess wounds remotely in the home and avoids
regular trips to hospitals and things like that. It is a
terrific piece of technology. It came out of defence
and 3D imaging technology; it is a great spin-out from
other sectors.
Coming back to previous evidence from Tim, Eykona
won an SBRI contract. It has taken it to the next stage.
The managing director of Eykona would say, “We
would not exist as a company were it not for SBRI”,
but he has now reached the critical point John
describes, which is: how does he move that on now
into a procurement-type contract in the NHS?
Ironically, the market he is now chasing to procure the
technology that has been developed under an SBRI
contract is overseas. He is chasing overseas contracts
because, when it comes to the critical point of the next
stage in the procurement contract, there is a risk-
averse approach in the UK.
We have got great science and technology; we have
got the SBRI in place, which is helping small
businesses get their technology to the point where
they can take it to market; and we need that pull at
the next stage to act from a procurement point of view
to move the technology into the NHS. I believe that
has to be looked at in a much more holistic way.
Fergus Harradence: One of the problems across the
Department of Health and the NHS is the lack of an
obvious front door for small innovative companies
that would be parallel to, say, the Centre for Defence
Enterprise of the Ministry of Defence. As a small
company you are dependent, in most cases, on finding
an individual hospital that is willing to procure your
innovative product or service. While there are
certainly some hospitals in the NHS that have done
that and been helpful in bringing products to market,
you still lack that piece of central infrastructure that
is able to brigade demand, prioritise, signal and
market where the big strategic needs are in terms of
health procurement. That is probably something that
is lacking at the moment.
Q250 Pamela Nash: You mentioned the MOD. Is
there evidence that the MOD is much better at this?
Can I ask you to compare that with other Departments
in Whitehall? Are they better at spending the money?
Iain Gray: We have just signed a charter with Dstl,
which is part of the MOD. The chief executive,
Jonathan Lyle, and I have signed a charter to work
closer together particularly focused on SBRI, and the
MOD is committing money to that. It is the same
analogy. That is a small part of MOD expenditure. It
is looking at how you connect that development side
of things to the bigger operations side of MOD. How
do you create the pull and demand from the big MOD
spending budget? For me, that is where the connection
needs to be made, but we are making good
connections at departmental level on the R and D side.
It is the pull that is the key to making this successful
now.
Q251 Pamela Nash: Obviously, my experience is
based on my constituency in Scotland. Visiting
businesses over the recess, the main problems I found
were for medium size businesses to go into any sort
of public sector contract. They were going up against
companies from the rest of the EU when it got to
contracts that they might be going for, which is often
unfair because those companies may have additional
Government support in their own countries and lower
wage bills and poorer conditions for their workers.
For smaller companies, there still seems to be a lot of
red tape in trying to get Government contracts. One
company, without giving too much away, has a
product that could help prevent hospital-acquired
infections in Scotland, yet they have been told that it
would be difficult for them to sell to the NHS because
there is no one else in the UK with this product;
therefore, there is no competition. I would like to
know more about what the Government and their
agencies are doing to try to cut through this and help
British companies get these contracts.
Fergus Harradence: The Cabinet Office through the
Efficiency and Reform Group has been leading a
programme of work to try to tackle two of our big
problems. The first is to simplify and streamline the
procurement process and free up more time within
procurement functions to enable them to go out and
engage with the marketplace and businesses in a
strategic way, combined with better signalling of
Government demand in particular areas. The work
that has been done on future capability needs in areas
like tunnelling would be an example of that. We
published quite a lot of information earlier this year
about future Government needs.
Secondly, there is a big challenge in upgrading the
skills and knowledge of people in the procurement
profession. The difficulty in doing that is that
procurement is not in most public sector organisations
a centralised function; it is often devolved to a number
of agencies or individual public sector organisations
like local authorities and individual hospital trusts.
Fundamentally, it is their job to pay and manage their
staff and decide what they want to do. When you try
to encourage people to go out and engage in the
marketplace, it is very difficult to have the kind of
strategic approach adopted in the US where
procurement is much more centralised within major
departments like the Department of Defense, and it is
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a fundamental part of their operations. The culture,
structures and the way procurement is managed in the
UK are fundamentally different, and that makes it
hard for us to procure in the same strategic way that
you see the US doing. I would not say that these
problems are insuperable; they could all be tackled
over time, but, being realistic about it, it will be a
process of long-term improvement and cultural
change.
Iain Gray: To give a short answer to Pamela, I would
be very interested in talking to you about that specific
example. We were talking about hospital infections
with the First Minister in Scotland and how SBRI
could be a tool to help small businesses like that. It is
a generic issue.
In a broader sense, I tend not to talk about
procurement but the role of Government as a lead
customer. Procurement is, “I want something and I
want something now”, and inevitably you have a
value system that tends to focus on very specific
criteria when you are going to procure something. You
do that as an individual; Government Departments
would do that. The role of a Government as a lead
customer is to help to try to identify the needs much
earlier on so you can help work with businesses to see
what the potential solutions are.
We heard about standards and regulations and how
they can help, not hinder, UK businesses win
contracts. It is a matter of getting in much earlier to
identify the challenges and problems that hospitals
and public sector bodies face and using that need to
engage with business and understand what the
potential solutions and challenges are, and then have
the mechanisms by which the R and D they develop to
support those challenges can move into procurement
contracts. It is not just about a one-stop procurement
decision; it is about the role of Government as a lead
customer early on in the process that I think is
important.
Q252 Chair: Mr Harradence, I think that just before
you came into the room Tim Crocker said that UKTI
helps companies from abroad set up in the UK but
doesn’t help UK companies. Given your background,
is there more UKTI could do to help in this space?
Fergus Harradence: You have to look at the role of
UKTI. Its role is really twofold. First, it supports UK
companies to do business overseas, including the
public sector overseas. For example, when you have
something like the Olympic Games in Rio and the
Commonwealth Games in Delhi, UKTI will make an
awful lot of effort to help ensure that British
companies have access to those contracting
opportunities. Secondly, it has a role in inward
investment and bringing companies into the UK. One
of the things companies look for when deciding
whether to come to the UK as opposed to another
location is their access to a customer base, whether
that is in the public or private sector. It is not really
the role of UKTI to provide support to UK businesses
seeking to do business with the public sector in the
UK. That is something that the Department for
Business, Innovation and Skills would do working
with the Cabinet Office, because we have a
responsibility for procurement and innovation
procurement respectively.
Q253 Chair: There is this concept of joined-up
government that we were trying to encourage you to
think about at BIS. Is there not a case for creating
a parallel mechanism to make sure that indigenous
companies are not disadvantaged in that process?
Fergus Harradence: I am not sure there is any
evidence to show that British companies are
disadvantaged in public procurement decisions. I
agree there is some anecdotal evidence, but ERG has
had a look at the award of contracts to businesses.
Broadly, the level of awards of public sector contracts
in the UK to British businesses compares with the
situation that you would see in France, Germany and
other countries.
Chair: I will leave Mr Crocker to bend your ear after
the hearing.
Q254 Stephen Mosley: A couple of questions ago
the Chairman was asking about the balance of funding
between research councils and wider industrial
incentives. Looking specifically at research council
funding, what is the balance between the funding of
blue sky research through to the proof of concept side
of it? How do you decide where that balance of
funding lies?
Sir John Savill: First, it is a difficult question to
answer, but there is a feeling in the community that,
very roughly, two thirds of the research is what you
might call blue skies and one third right across the
seven research councils is more directed research.
Each research community has different opportunities
to translate and different challenges. In informatics
research might move very quickly into the market.
The Committee will know that in biomedicine it is a
very long haul, over at least a couple of decades. So
the approach you take as a research community
depends on the particular problem you face.
All the research councils have identified translation as
a priority. I guess you could identify that at least 10%,
or towards 20%, of the research funding is directed
specifically at translation. If there is time, I would
happily run you through a list of things that the
research councils broadly share in the way they try to
promote translation. We are definitely not ivory towers
that just do discovery blue skies research. We want to
see that research improve society and benefit the
nation’s wealth, and there are various strategies to do
that. I will happily go through them if you would like
me to.
Q255 Chair: It would be helpful if you could provide
a note covering that. I would also be interested to
know where that process overlaps and engages with
the TSB.
Sir John Savill: I will happily do that and also cover
in the note to you the relationship with the TSB.
Iain Gray: In the relationship between the Technology
Strategy Board and research councils, both in a
collective sense and on an individual research council
basis, in our delivery plan we have agreed objectives
and where we do work together. As John has said,
different councils have different objectives. It is not
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just about science in a blue skies commercialisation
sense. There is a very strong emphasis on the role of
social sciences and things like design and the
behavioural side of things, which engage very closely
with the commercialisation side of the agenda as well.
For each of the research councils there is, as part of
our joint delivery plans, a statement of those areas,
projects and activities where we will work together.
At the very beginning, we heard John talk about the
good work we have been doing with MRC,
particularly around the biomedical catalyst and the
cell therapy catapult area.
Sir John Savill: One of the strongest arguments for
seven research councils rather than one is that each
looks to a pretty different but fairly well defined set
of industries where the translational pathway has
different barriers and requirements. It is definitely not
one size fits all, but, as you will see, there are some
approaches—collaborative PhD studentships and joint
research centres—that really work for campuses and
a number of research councils. So I will happily write
in about that.
Q256 Stephen Mosley: That would be helpful. Have
there been any changes in the balance of that funding
in recent years, and what are the drivers for that? Are
they economic or political, or is there something else?
Sir John Savill: There definitely have been. In the
Medical Research Council’s domain, a key stimulus
was the report of Sir David Cooksey, who has given
evidence to you. That highlighted that we needed to
behave differently if we were to promote the
translation of biomedical research. There have also
been some very interesting differences from industry.
If you look back 20 years, industries like Rolls-Royce
had a monolithic discovery and development model,
not unlike pharma. Rolls-Royce realised that it
couldn’t lead the world if it had a monolithic R and
D model, and discussed with EPSRC the idea of joint
technology centres in universities. So a push has come
from industry to get into universities with
collaborative funding of research councils. EPSRC
has over 20 large companies involved in joint
technology centres. We are beginning to see that in
my domain in biomedicine as well.
You might say that some of the push is political—
David Cooksey’s report; some of it comes from
industry; and some of it just comes from the stage
which research brings you to. An example of that is
graphene, which is a brilliant breakthrough. That is a
new material that might revolutionise lots of
industries. It is a great opportunity. It has been
recognised, and the approach has been a collaborative
one with public sector funding through research
councils, universities and industry.
Q257 Stephen Mosley: I was interested that you
mentioned the EPSRC. As a committee we have been
lobbied quite hard on their shaping capabilities
programme. Has there been much reaction? A lot of
the research community out there tends to believe that
funding should purely follow research excellence. Has
there been some sort of push back, saying that perhaps
you should not be changing the way funding takes
place?
Sir John Savill: Different communities behave
differently. What I have seen in biomedicine is that
there is a grass-roots response to things like the
Cooksey report, where the applicants themselves
realise that they want to see the translation of their
research, so it is different strokes for different folks.
EPSRC has chosen to undertake the experiment of
shaping from above. In the case of the Medical
Research Council, much of it has been shaping from
below—from the grass roots. Every community
behaves differently. I don’t think there is one
particular method that works best across the piece,
which is another argument for seven research
councils, and any change always brings criticism. As
we all know, there has been criticism of EPSRC’s
push to do this. There was very strong criticism three
or four years ago of the Medical Research Council
supposedly abandoning basic research. That is not the
case. Any change brings criticism.
Q258 Stephen Mosley: On a different issue, last year
we did a report into peer review. How many scientists
do you have with an industrial background and
experience working for the research councils doing
peer review? Is it focused purely on academic
subjects?
Sir John Savill: No. It is a very important part of the
peer review process, but scientists in industry have a
day job and it can be difficult to find scientists whose
companies are prepared to release them to give time
to public sector peer review. Again, I can speak about
my own back yard. Every one of our standing boards
has industry involvement and folk who are based in
industry. We try to have as many of those as possible
and find it very useful, but for small companies in
particular it is difficult for scientists to give up the
time to do peer review.
Q259 Stephen Metcalfe: The TSB seems to be given
ever-increasing numbers of programmes and
initiatives to deal with. I have a simple question. Do
you have the resources, financial and human, to be
able to deliver on those?
Iain Gray: The simple answer is that as an
organisation we are growing and expanding to meet
the needs. We talked earlier about a confused
innovation landscape. The Technology Strategy Board
does help to draw together these different initiatives.
There are some things people are talking about that,
frankly, are scaling up what we do already; there are
some things that people talk about that are new
initiatives and mechanisms that require additional
finance and resource to do them. So the bandwidth of
the organisation has to adapt to the needs that are
placed on us in slightly differing ways. One issue is
not so much the resources and bandwidth to do what
we are asked to do but the bandwidth and resources
to do what the community out there expects us to do.
For example, post the world of RDAs, there was a
lot of anecdotal stories about the Technology Strategy
Board doing this or picking up that. What we do not
have the resources and finance to do is to meet all the
expectations that some of the outside world would
place on us.
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Q260 Stephen Metcalfe: How are you managing
those expectations and communicating back to the
outside world that these things are not your
responsibility?
Iain Gray: We are in close engagement with the
business community. One of the things we have tried
to work at quite hard is how we build the links with
local communities. In the north of England, for
example, with the N8 universities we have established
what is called the N8 Innovation Forum, which is a
mechanism that allows us to talk with the universities
and business clusters around those universities in a
constructive way about how we can engage for the
things that we do and things that we don’t do. We
can’t engage with every single business, LEP or
regional office of different professional or trade
associations. We have to try to find the right
mechanisms to talk to local communities and the
devolved Administrations, to come back to an earlier
point, making sure that we are regularly talking in
Northern Ireland, Wales and Scotland as well.
Q261 Stephen Metcalfe: Is it right you said you
were not talking to each individual LEP?
Iain Gray: I said we cannot talk to each individual
LEP on a structured basis. How many LEPs are there?
Fergus Harradence: There are 38 or 39.
Q262 Stephen Metcalfe: That doesn’t seem to be
that big a number to be communicating with—at least
to have a communication.
Iain Gray: If you add to that the 140 universities,
100,000 businesses, the trade associations and
professional bodies that all want to talk to us, you
could spend your entire life talking to people. What
we have to try to do is find a structured way of
engaging with business—large businesses, SME
communities and small businesses. We have some
good one-to-one relationships with large businesses;
we have the leadership councils that have been
established, which are business and Government
working together. That helps us engage with the
supply chain development. If you look at the SME
community, quite often we have to find more local
geographic cluster-based ways of talking to
communities. We are trying to find the appropriate
way to talk to communities. To have a structured
relationship which says that on a detailed management
basis you are going to build relationships with every
one of those bodies is just not a practical thing to do.
Q263 Stephen Metcalfe: You don’t think that the
work you are doing at the moment is stretching you
too thin? You have the resource to do that?
Iain Gray: I think we have the appropriate resource
to do the work we have been asked to do. The scale
of the Technology Strategy Board to meet the needs
of innovation is at the very heart of the economic
agenda. We have talked a lot about budget. We do not
have the resources to meet what I think the country
needs in terms of economic development, and there is
quite considerable scope to increase the influence and
mechanisms that have been put in place for overall
UK benefit, but to match the budget and initiatives we
have got there is an appropriate level of resource.
Q264 Stephen Metcalfe: Bearing in mind that
budgets are under pressure at the moment—they will
not be heading north any time soon in large
numbers—you have to use the resource you have in
the best possible way. There has been some criticism
that perhaps the TSB has been a bit timid in the way
it is using its resources. How would you react to that?
Do you have a strategy to be able to be bold and
innovative in trying to find areas to invest in, and how
is that arrived at?
Iain Gray: I have not heard the use of the word
“timid”.
Q265 Stephen Metcalfe: I use the word “timid”. I
think Sir Peter Williams tentatively said that you
could be a touch bolder.
Iain Gray: Maybe that is a separate conversation I
need to have with Peter. What I do recognise and hear
is that, in reality, with the resource available to us,
a lot more businesses are unsuccessful in their grant
applications to the Technology Strategy Board than
are successful. With the budget we have got, we have
to find better ways of making sure that businesses that
are unsuccessful feel they have got something positive
out of the engagement and that it is not just about
money. We have talked a lot this morning about some
of the other levers of Government: regulation and
standards. There was a question in the earlier session
about Germany and what Germany does. Germany
uses standards at the very heart of its innovation
agenda. There are a lot of non-financial ways in which
we can help business so that the businesses that have
been unsuccessful in applying for money can still be
very successful in the kinds of things we can do in a
non-financial sense.
I don’t recognise “timid”. I do recognise that there are
some tough choices to be made. We have made
choices. The reality is that everybody says they are
happy that you make choices, but when you make
them, sometimes those on the wrong side of that
decision are less happy.
Fergus Harradence: If you are to make a reasonable
assessment of whether or not you think the TSB is
timid, you have to compare it with the situation prior
to the TSB’s existence, when support for R and D and
innovation was run out of what was then the DTI. If
you compare what the TSB is doing now with what
the DTI was doing five or six years ago, you will see
that the TSB has moved to make substantial
commitments in new sectors or market areas of
activity in innovation and technology that the DTI
simply was not engaged in at all. It had a much
narrower focus in its programmes. The TSB has
developed new mechanisms specifically focused on
small businesses, which are intrinsically higher risk
than those focused on large companies or consortia.
We have more of those programmes, and a higher
proportion of the TSB’s budget is allocated to SME-
facing activities. We are doing work on emerging
technologies. Again, this is intrinsically high risk.
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Q266 Chair: Does putting those roles at arm’s length
from the civil service machine mean that the “Yes,
Minister” syndrome and risk-averse nature of the
traditional civil service mechanism is removed to the
advantage of business?
Fergus Harradence: Officially, I couldn’t possibly
comment.
Chair: Exactly.
Fergus Harradence: The answer is almost certainly
yes.
Chair: Thank you very much for being honest.
Q267 Stephen Metcalfe: You would refute that; you
are taking risks in some areas, so some of the
companies that are successful are exploring new areas.
Iain Gray: I am not sure what Peter was referring
to if he used the word “timid”. One thing we have
deliberately not gone out of our way to do in the first
five years of our existence is actively to promote the
Technology Strategy Board having done this or that,
because for us, what is much more important is what
is achieved in business. Five years on, the story of
what the Technology Strategy Board has done to
support business needs to be told louder and more
strongly, and, as we move into what I described as
chapter two of the TSB, that is something we will do,
but I don’t believe we have been timid in the sense of
making some difficult decisions.
Q268 Stephen Metcalfe: “Timid” was my word, not
Sir Peter’s, but it does mean that because of limited
resources you have to prioritise; you have to make
decisions and choices. As a final point, would making
those decisions and choices be easier if there was an
industrial strategy for the UK?
Iain Gray: I think the industrial strategy would help
provide a framework. What you heard this morning in
the first session were two quite contrary views
representing different membership organisations. The
industrial strategy would very much support the CBI
and the large corporates, picking the races that we are
in from a UK point of view. I think we have been
doing that, working very successfully with the
leadership councils of various communities,
Government and business working together, but it will
help in that framework. How we support smaller
businesses is a different dimension from what we are
about, particularly in a responsive mode sense. We
have to find good ways of supporting the type of
community that was talked about this morning, but
you heard that we support that in a slightly different
way. The answer is, yes, the industrial strategy will
provide a clear framework to help us in some of our
decision making. It might not help in other ways. We
have to use it sensibly.
Q269 Caroline Dinenage: The feedback we have
gathered on this Committee seems to show that a big
problem is the low level of business expenditure on
research and development in the UK. Is there any
evidence you have collected that current policies have
begun to address this?
Fergus Harradence: The existence of that problem is
unarguable; the evidence is very clear. If you look at
patterns of business expenditure on R and D in the
UK, businesses in this country invest 1.1% of GDP in
R and D and the OECD average is 1.6%. Even when
you add in public sector investment into R and D
activities, it pushes the total investment in R and D in
the UK only up to 1.8% of GDP. If you add
comparable public sector investment in other
countries, it tends to push it up to about 2%. So, yes,
there is a relatively low level of investment in R and
D in this country, which is explicable through a range
of factors, including our industrial structure but also a
culture of risk aversion when it comes to investment
in innovation and technology development.
As to what we have done to try to address that, over
the last 10 and 15 years a wide range of different
incentives has been put in place to encourage higher
business investment in R and D, as well as increased
expenditure in science, research, innovation, HE and
skills. We have also introduced things like the
Research and Development Tax Credit. There is some
evidence that that has influenced decisions within
businesses and made them more willing to invest in
this area and to build their capability to conduct R and
D, or their willingness to engage with universities or
other research-based institutions that can conduct R
and D for them. The fact remains that we have been
increasing levels of business investment in R and D
slowly and steadily, but only by degrees. What you
have seen is that in competitor countries the same
pattern has occurred, so the gap has not significantly
narrowed despite 10 to 15 years of sustained
investment in this area.
Sir John Savill: From my area, perhaps I may support
that with some evidence that Government are taking
measures to try to address this issue that are bringing
benefit. In the publicity around the decision by
GlaxoSmithKline to invest £700 million in Cumbria
and two sites in Scotland in biopharmaceutical
manufacture, specific reference was made to the
Patent Box that the Government have brought in as
one of the reasons that the GSK board decided to
invest in Britain rather than Singapore, India or the
USA. In my area that is one good piece of evidence
that benefit is ensuing.
Q270 Chair: To press you on that, is that partly
because business sees those developments as
transcending political change in Government?
Sir John Savill: I think it sees them as advantageous
to the UK.
Q271 Chair: Because they have a life that extends
beyond the lifetime of Governments.
Sir John Savill: Indeed, the coalition Government
have continued and developed policies that the
previous Government put in, so it is really about the
UK rather than each particular Government.
Iain Gray: Just picking the example of low-carbon
vehicles and the automotive sector, five years ago it
was generally believed that we had hollowed out the
supply chain in the UK. We were doing a lot of
assembly but not very much research. With the advent
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of some of the new opportunities arising out of low-
carbon vehicles, companies from overseas are now
looking to invest their R and D capability in the UK
and not just manufacturing or assembly; it is the total
chain. I think that gives the stickiness that we are
looking for in five, 10 or 15 years out. For me, there
is evidence. It is a long-term game, and you have to
get the right leading indicators to know whether or
not you are being successful in that game, but I would
cite that as a good example of where I see a
quantum change.
Q272 Caroline Dinenage: To go back to the subject
of the R and D Tax Credits, the Committee has had
varied feedback on the stimulus provoked by these.
One school of thought is that potentially the bigger
companies just use that money to invest in the whole
of their business expenditure, which is anything from
dividends to marketing. Is there any evidence to
suggest that if those tax credits were more focused on
SMEs it would have greater benefit?
Fergus Harradence: The eligibility criteria mean that
large companies cannot claim the R and D Tax Credit
against anything other than the eligible elements of
their expenditure. There is certainly a higher level of
dead weight in the large company scheme—that is,
expenditure on R and D that would have taken place
anyway, regardless of the public subsidy. However,
you have to take into account the fact that, now,
almost every country that the UK is competing with
economically has some form of tax relief on R and D.
It might not be an exact parallel to our own. For
example, in France they provide relief on employment
taxes relating to people with PhDs, but there is some
form of tax relief that relates to expenditure on R and
D and aims to reduce that for companies. If we scrap
this programme, it would have an impact on our
competitive position and ability to attract high-value
inward investment and retain high value-added
business activities in this country. Given that 20%—
or, to be specific, 21%—of all R and D in the UK is
funded from overseas, we have to be very sensitive to
anything that would worsen the UK’s competitive
position.
Q273 Caroline Dinenage: Some members of the
Committee went to Warwick university, and they
raised the issue that, while businesses can shop around
for academic expertise, there is not really a facility for
academic establishments to shop around for
interesting industrial problems to solve. Is there any
mechanism by which the TSB can communicate
industrial research interests to the academic
community?
Iain Gray: That is an interesting observation. In some
regard I would link it back to the earlier remark about
knowledge transfer partnerships and one-way
communication. How do we get good two-way
communication? I am seeing good evidence of that. I
talked earlier about the N8 Innovation Forum, which
is about universities and businesses coming together,
with businesses defining the challenges that they are
looking to resolve and the universities being able to
participate in the potential solutions that exist. We do
not have a one-size-fits-all-type mechanism, but there
are pockets of very good practice being developed. It
is something we need to continue to work at, but I
wouldn’t say it’s not happening; it’s something we
need to build on.
Q274 Roger Williams: We have heard quite a bit this
morning about the Small Business Research Initiative.
Do you think it is the right model for the UK, and
does it enable small businesses to become sustainable
and grow?
Iain Gray: From my perspective, in the last two years
we have demonstrated that it is a mechanism that can
work and provide demonstrable benefit. It needs to
scale up. We heard a couple of times today about the
importance of a contract versus a grant. SBRI is a
contract and therefore from a business perspective is
worth something very significant.
Two things need to happen: one is a scale-up of SBRI
itself across Government Departments; the second,
going back to the earlier discussion, is about providing
a market. SBRI is only the pre-commercial
procurement element of procurement. There has to be
the next stage. We have to get that right as well for
SBRI to be really successful. My answer is, yes, we
have a mechanism and it works. Let’s now use it and
make it work and find a way of scaling it up, but let’s
also find a way of providing that link into the end
procurement market.
Q275 Roger Williams: Does it work best when it
involves Government buying directly from small
companies or putting a requirement on larger
companies to use smaller companies in contracts with
Government Departments?
Fergus Harradence: They are really different
procurement issues. The aim of the Small Business
Research Initiative was always to increase the level of
direct contracting done between public sector
organisations and technology-based SMEs, and to
give those companies the opportunity to win a
contract that would help them develop a product or
service and take it to a point at which it was ready for
market. With a programme like that it is very
important that you have that direct customer/supplier
relationship. I do not think SBRI would function
effectively if you put in an intermediary layer, a large
prime contractor, and got it to manage the programme.
Interestingly, the evidence from the US with their
SBIR programme shows that, where they have tried
to use large prime contractors as part of the process
and SMEs as a means of developing small parts of
much larger projects for which primes are responsible,
in general it has not worked very well. You find that
these companies are not always attuned to the needs
of the prime contractor; they don’t see the bigger
picture in terms of the scale of the project. I would
not want to experiment with SBRI in that way.
However, more generally there is a question to be
asked in procurement about whether or not we are
effective in managing our relationships with large
prime contractors and whether or not we do enough
to encourage them to source innovative products and
services from UK SMEs that are developing
interesting new technologies. That is something we
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need to look at through our contracting frameworks
and policies.
Q276 Roger Williams: SBRI has not been used in
terms of a large main contractor or subcontractor.
Fergus Harradence: No.
Iain Gray: From my perspective, there is real merit in
looking at how we build supply chains through large
contractors, but it is a different mechanism. Some of
the things we are doing are already addressing that,
but I would take Fergus’s point. SBRI is specifically
trying to address the challenges of Government on the
one hand but providing the opportunities for direct
contractual relationships with smaller businesses that
have good innovative ideas but currently do not have
a route to market to do it.
The other thing about SBRI is that 900 companies
won SBRI contracts. That should be the first port of
call for venture capitalists looking at the kind of
businesses they should be investing in. That is what
happens with SBIR in the States. We need to talk
positively about it and about the companies that have
been successful in it. We need to scale it up and
provide the end market opportunities.
Q277 Chair: If I may give you an example of an
event that occurred, can you tell me that because of
SBRI it would not happen today? A company
developed a GPS-based safety device for health
workers working alone in the field. It was a relatively
small company, and it was an innovation for them.
When the final bit was flagged up on television by the
then Secretary of State, Frank Dobson, it was a
brilliant little device. When it came to the contracting
process, Richmond House knocked back this company
as a bidder and insisted that it go to bed with one of
the large telecom companies because it did not believe
that the company had sufficient financial security to
manage. Are you saying that is now something in the
past or will those events still occur?
Iain Gray: I said we have a mechanism and that SBRI
really works, but we need to find the next stage—
those routes to market. Even in SBRI terms, one is
moving companies from what was a phase one SBRI
contract into what we call a larger phase two SBRI
contract and then into a commercial contract with a
large spending department. Very few companies have
gone that complete route. For me, we need a
recognition that SBRI in phase one is all very well.
Companies would stand up and say—I quoted
Eykona—they would not exist today were it not for
SBRI. The number we have taken right the way
through that process is still very small, and we need
to keep working on that. The outcome is the endgame.
Q278 Sarah Newton: We have been talking a lot
about small and medium size businesses. There is a
huge amount of effort to try to support them, and there
are matters to do with regulation and all sorts of
things. To what extent do you think Government is
capable of distinguishing between the needs of small
technology-based businesses and small businesses
generally?
Fergus Harradence: Technology-based businesses
have specific needs that they share with other small
businesses. Obviously, you want efficient systems for
things like managing tax, ensuring you comply with
regulations and the provision of basic business
information about the legal requirements of running a
company and so on. But technology-based SMEs have
specific needs related to their ability to access the
support available through the innovation system,
whether it is specialist advice on issues like design or
measurement, intellectual property, or the ability to
access funding streams through the Technology
Strategy Board, Research Councils, Devolved
Administrations or whatever.
We have a pretty good grasp of the needs of
technology-based businesses. There are active trade
associations; they are engaged in things like the TSB’s
Knowledge Transfer Networks. We have a fair amount
of direct contact with businesses and their
representative organisations. There are lots of service
delivery organisations. It is not just the Technology
Strategy Board but Capital for Enterprise, which
supports venture capital investments, the Intellectual
Property Office, which deals with IP registration, and
bodies like the National Physical Laboratory. All of
these have SME-facing outreach programmes of one
sort or another.
Iain Gray: Sometimes we try to generalise things by
referring to small companies and large companies.
Life is more complicated than that. If we are talking
about life sciences, cell therapy or aerospace, it is a
10, 15 or maybe even a 40-year game, whereas, when
you talk about developing an app for a tourist
application, if you have not resolved it in three months
and got it to market you are dead, and yet small
businesses are involved in both of those extreme
sectors. To try to distinguish it by referring to “large”
and “small” is to oversimplify the problem.
Government has good links in with trade associations
and leadership councils on various big picture items,
but it is important that we don’t try to generalise it as
just large and small companies. There are different
time clocks for different sectors. Even in the
technology area there are different time clocks. We
need to be responsive in different ways to those
different needs.
Q279 Sarah Newton: From the work that you do, is
there a perception in Government that the special
needs you have talked about of technology companies,
which undoubtedly are there, are properly recognised
and valued? Is there a perception that the companies
are worth giving this much support because they have
a special place in the economy, or do they just have to
compete alongside all the other types of companies?
Fergus Harradence: We have a lot of forms of
support that are accessible only to technology-based
SMEs. All of the grant support programmes of the
TSB are not a generic tool for giving money to small
companies. Only a relatively small proportion of the
small company base—the ones engaged in R and D
activities—can access them. Similarly, a lot of the
investment funds that Capital for Enterprise puts
money into are focused on supporting technology-
based businesses. For university spin-outs, you have
the Research Council funds, the universities’ funds
and the Higher Education Innovation Fund. These are
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all targeted on technology-based businesses. We are
expecting new initiatives like the Growth Accelerator,
which is a mechanism BIS has put in place to deliver
support to companies with high growth potential. One
of the target groups for that will be technology-based
SMEs as well as SMEs in other sectors that have
growth potential. Yes, we do recognise and value the
fact that these companies are an important part of the
UK economy.
Chair: Gentlemen, thank you very much for your
contribution this morning. That has been extremely
helpful.
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Q280 Chair: Minister, thank you very much for
coming this morning. I know you have another
engagement shortly and other Members here are keen
to be in the Chamber on time, not just for Scottish
questions but for the Hillsborough statement and so
on. It is very important business.
You know the terms of reference of this inquiry. We
have taken some fascinating evidence over the last
couple of months on this. Of course the Department is
continuing to evolve the story, including with Vince’s
statement to the House following the Urgent Question
on Monday and his speech yesterday.
I want to start with the statement that he made on
Monday. There was considerable reference by several
Members of the House to the role of the Technology
Strategy Board, a body that has the wholehearted
support of this Committee. Can you confirm that it is
the policy of the Department for Business to allow the
Technology Strategy Board to expand in the future so
that greater support can be given to the kind of
businesses that we have been talking about, either
through the Catapults or the other mechanisms that
Iain Gray and his team are responsible for?
Mr Willetts: First of all, thank you very much for the
opportunity to answer your questions on this very
important subject. You are right that the Technology
Strategy Board is absolutely crucial in bridging the
so-called valley of death. We of course inherited it
from the previous Government and have been very
happy to support and sustain it.
Q281 Chair: That is the Technology Strategy Board,
not the valley.
Mr Willetts: Yes; the Technology Strategy Board.
BIS’s policy is to deliver our objectives within the
framework of agreed public spending totals, but we
recognise that many TSB programmes are
oversubscribed. I get complaints from individual
constituency MPs, when they have some horror story
of a small business that has applied for funding, which
has looked eligible for funding under Smart awards or
something. TSB’s problem has been that, although the
small business has a great case, there just are limits
on the amount of money it has to spend. Any
organisation, but certainly the TSB, could always
spend more money. What we are trying to do is to get
absolutely the maximum bang for the bucks it has at
the moment.
Q282 Chair: Do you agree with the point that I made
to Vince Cable on Monday that, whilst it would be
Stephen Mosley
Pamela Nash
Roger Williams
desirable to see the TSB expand, it should not be at
the expense of the Research Councils?
Mr Willetts: Absolutely. The science ring-fenced
protected budget is there as a protected budget. We
made a cast-iron commitment on that and that has to
be protected.
Q283 Pamela Nash: Minister, over the summer
recess I spent a lot of time meeting with my local
small businesses. One of the main issues that came up
was that they have to risk a lot of their own finances
when trying to bring new products to market. Even
when they did get public funding, that was often
matched funding and therefore they were still putting
themselves at a lot of risk. Is reducing the risk of
investors and small companies something that is
considered in your Department when policy is being
made?
Mr Willetts: Yes. If we can help small companies in
that way, we will. A lot of small companies say to us,
“Please will Government get out of the way?”, and
they are perfectly entitled to take that view. We are
not trying to encumber them unnecessarily, but where
we can work with them, both through advice and
perhaps financial support—my right hon. Friend the
Secretary of State is particularly good at this—and
cajoling the banks into lending again, we are up for
that, yes.
Q284 Pamela Nash: In terms of Government
funding to small companies when grants are being
given, is how you can reduce the risk for the company
something that is being looked at in the future?
Mr Willetts: Yes. The kinds of schemes that I am
particularly a great admirer of are the Smart awards,
which we have brought back under their original
name. They are start-up grants for companies that
have a great new high-tech idea. Michael Heseltine
originally set them up. Then they became one of the
RDAs’ responsibilities, and it is true to say that some
RDAs were better at that than others. We brought
them back as a national brand administered by the
TSB. They are a great way of helping small
companies.
Indirectly, we have also tried to get more flows of
venture capital funding into small businesses. There is
a question about how the venture capital business
model develops in the future. We put in co-funding
but the venture capital fund makes the decision. There
is £300 million or £400 million of extra public money
that has gone in to ensure extra funding for venture
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capital, which they in turn can invest in small
businesses.
Q285 Pamela Nash: We heard evidence that clusters
are a way that companies help to reduce and spread
the risk for them. Do you feel that the Government
have a role in encouraging and supporting clusters,
and how might you do that?
Mr Willetts: Clustering is a very fruitful way of
thinking of all this. The economist’s definition that I
find most helpful is to say that clusters are a low-risk
environment for high-risk activities. If there are lots
of different companies in the same business sector, if
you lose your job with one you have a greater chance
of being able to pick up a job with another one
without having to uproot your family and all that. We
are trying to support them. There are some identifiable
clusters around Harwell, Norwich and Daresbury,
where there is a clear pattern of investment by us.
That is one thing we can do.
A second thing that I have been very keen on and
where we have seen the rules improved is that
Research Council funding rules used to be pretty
restrictive. An individual institution got the funding.
We have tried to liberalise the rules a bit. If there is a
network that has come together, and it could be a
network of universities like N8 in the north or a shared
project like the Imanova project out in west London
in which UCL, King’s and Imperial have come
together, I think I have succeeded in getting the rules
liberalised so that they will fund those types of shared
projects and not just an individual institution.
Q286 Pamela Nash: Finally, as you mentioned, red
tape is something that small businesses in particular
usually struggle with, especially when it comes to
regulations on health and safety, though they are often
necessary. We heard evidence about the German
model, where the Government take responsibility for
issues for small companies such as electrical safety.
That has been found to be very helpful. Are the
Government looking at perhaps having certain
regulations relaxed for a small company?
Mr Willetts: Yes. It is true to say that, in BIS, we were
intrigued by this point made in an earlier evidence
session. We didn’t quite recognise the description of
the German regime. Of course, the trouble is because
it is such a federal system it may even differ from
Land to Land. We weren’t clear that the Länder were
all quite willing to take on as much of the liability
risk as was implied in your evidence, but I would
undertake already something useful that has come out
of your earlier inquiries. We have flagged an issue that
we should do more work on to try to understand this
German system, though as I say, we are not
necessarily sure that the earlier evidence absolutely
matches our understanding of how it works. But we
will undertake to look into it further.
Q287 Chair: But it is the Government’s position—
correct me if I am wrong—that changes in health and
safety, for example, are not intended to be at the risk
to people? It is about process rather than removing
necessary safeguards.
Mr Willetts: Yes. Sometimes some of the regulations
have been cumbersome and perhaps excessive for
people running an operation single-handedly out of
the front room of their house. The German issue was
particularly about measurement and assessment run by
these regional centres that they have. We think that
ultimately in Britain companies have to take
responsibility for that. But, if there is something that
they are doing better in Germany than we are here
that we can learn from, I am absolutely up for learning
from them.
Chair: We can move on to the Government as a lead
purchaser—the customer.
Q288 Roger Williams: Because of the sheer scale of
the Government purchase in the economy, both in
terms of goods and services, by default that has an
effect. The message that the Secretary of State has
been trying to put out over the last few days is that, if
that was better focused and structured, it could be a
greater force for good in the economy than it is at the
moment. BIS apparently will be the lead Department
in trying to get that better focus into other
Departments in terms of their procurement and
purchasing. Do you think that BIS, you and the
Secretary of State will have that effect in Cabinet to
alter the purchasing decisions of other Departments?
Mr Willetts: I think we can. Obviously we will work
with other Departments. One of the main messages in
the industrial strategy, which is a point that Michael
Heseltine has made in public and in private advising
us, is that a lot of these industrial strategy issues can
only be delivered by the Government as a whole and
not by BIS on its own, but working with other
Departments. In terms of procurement we work
particularly closely with the Cabinet Office, which has
important responsibilities here.
In my own area, life sciences is working very closely
with the Department of Health on trying to ensure
that the NHS becomes much more innovative in its
approach to procurement. Of course the Innovation,
Heath and Wealth report was published as part of the
life sciences strategy last year. That is an example.
So, yes, we are committed to using procurement to
drive innovation.
Q289 Roger Williams: Perhaps you could expand on
that a little bit in terms of the NHS and biomedical
science in the UK. How does that actually work in
practice?
Mr Willetts: One of the criticisms you sometimes hear
from companies is that they have gone through an
elaborate NICE assessment procedure and have
passed all the hurdles—they may have a new drug or
a new piece of equipment—but then they find they
can’t sell it into the NHS.
One of the proposals now as part of our life sciences
strategy is that, in future, if identifiable and excellent
innovations are not being purchased and used in
individual healthcare trusts, there should be a
budgetary penalty; and we have identified a first list,
which includes everything from getting someone who
has serious disabilities a wheelchair in a day through
to a new heart monitor via the oesophagus, which has
scored very highly as a cost-effective way of
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monitoring people’s heartbeat during operations.
Some of their budgets through the CQIN procedure
will be deducted unless they can show they are
adopting these innovations. It is an attempt to push
innovation through the health care system.
Q290 Roger Williams: One of the biggest
Government Departments that has had criticism about
its procurement is the MOD. How is BIS working
with the Ministry of Defence? They have already said
it is their intention to improve.
Mr Willetts: The MOD, for example, have been a
significant user of the SBRI programme and have run
47 of these competitions in SBRI. That is an excellent
way of driving innovation; so they are trying to play
their part.
Q291 Roger Williams: In terms of the SBRI, one of
the criticisms is that it helps small companies to bring
products or services to a certain stage, but the carry-
through or taking that on has been lacking. Does BIS
have any ideas of how that could be improved on?
The SBRI is seen as a good programme, but it just
needs that extra in order to make the most of the
investment.
Mr Willetts: Yes; that is a very interesting thought. I
am not directly involved with that particular
programme but I will certainly pass that comment
back if there is something there we can learn from.
I will be frank with the Committee. We have talked
about Health and Defence. The whole Bombardier
episode was a bit of a wake-up call. I have to say that
Bombardier was conducted within the framework that
we had inherited and we all have to comply with EU
rules. Post-Bombardier there has been a major
exercise across Government as to how we run
procurement. One of the lessons we have learned is to
improve transparency on procurement, to be more
open and to publish more evidence of what we are
planning to do in the future. Indeed, in April, Vince
Cable and Francis Maude published £70 billion of
potential future contracts over the next five years to
help people get sighted on what was likely to be
procured in the future.
Q292 Roger Williams: It is two and a half years into
this Parliament. Can you point to really significant
changes that BIS have been responsible for in
procurement across Government?
Mr Willetts: As I said, I would notch up as
achievements a much more explicit sharing with
industry of our plans for the future procurement
pipeline. It is work in progress but we are already
doing a lot. Secondly, there is a shift in the attitude of
the NHS driven by the life sciences strategy. I would
count those as two successes.
Q293 Chair: Can I just push you a little further on
the framework for procurement? I don’t know where
you took your holidays, Minister, but had you gone to
France you wouldn’t have seen a police car that
wasn’t built in France. The four north-west police
authorities here have now procured Kias, entirely built
outside the EU. We are not accusing the French of
being in breach of the procurement rules; they have
just used them more smartly than we have. Why don’t
we? Don’t you feel frustrated that major public
procurement doesn’t use the rules that are available in
a wise fashion to protect British interests?
Mr Willetts: I do believe in free trade and BIS
believes in free trade. All of us, especially Stephen
Green, but Vince and me as well, spend a lot of time
on trade missions. We go to other countries and try to
persuade them to procure products that we have made
here. We have to be very careful of protectionism.
As I say, that is why our approach has been
information in advance and sharing our future plans.
A police force is entitled to procure the equipment
that will best enable it to discharge its public function.
In the long run British businesses need the
competitive challenge of winning in a competitive
environment. If we can be smart, as you rightly say,
about indicating where we are heading so they don’t
suddenly have a bolt from the blue of procuring a new
type of police vehicle, whereas if only they had
known a couple of years in advance they could have
retooled and been ready, we can do that. Ultimately,
open procurement is in our own national interest.
Q294 Pamela Nash: Minister, I also believe in free
trade, but some of the companies in my constituency
have told me that they are competing with companies
in the rest of Europe that have Government subsidies
in their sector or countries that might have much
lower salaries or rights for their workers. Is it fair that
companies in Britain have to compete with companies
that are not looking after their staff and have ways
and means of getting the bottom line down that we
might not find acceptable?
Mr Willetts: These are deep questions now about trade
policy. Again, as a free trader, I think it is in our
national interest to be free trading, even if we are in
competition with countries that aren’t as free trading
as we are. In the long run it is in our own interests.
Going back to the original example, I would argue
that the British automotive industry is a great success
story. As you know, this year, after all, we are net
exporting for the first time for over 30 years. I just
wonder, Mr Miller, if it is just possible that some of
those cars that you describe as being French cars
might not have been made, at least to a significant
extent, in a British factory and had a French badge
put on them before they arrived on the French market.
I don’t know; it’s just possible.
Chair: I will test this. I think you will find that, in
both France and Germany, my example will hold out
pretty well and none of them will have cars from that
far afield. Anyway, we will move on.
Q295 Stephen Metcalfe: I am sure you are aware of
the Stevenage centre, which is a collaboration among
academia, the biotech industries and pharma. It is
based around one large company but to support lots
of innovative small ones. Do you and the Department
see that as a particularly pharma-based experiment, or
do you see it as a template that could be rolled out for
other sectors across the economy?
Mr Willetts: I have been there and it is a very exciting
initiative. It reflects a big change in the culture of the
life sciences industry away from just having great big
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in-house research facilities and moving to what they
call more open innovation, collaborating with external
companies, creating an environment for SMEs to flow.
It is very exciting. That industry can go a lot further
in that direction.
Perhaps one of the themes that may emerge from your
inquiry, as several witnesses have already said, is that
these issues do vary sector by sector. It is hard to pick
up a model from one sector and apply it elsewhere.
The reason why the Stevenage experiment is so
interesting is because it is novel for the life sciences
sector. I don’t feel confident enough to say whether
that exact model could be deployed elsewhere, but one
would hope so.
Q296 Stephen Metcalfe: I take it from your answer
then that the Department is not encouraging any other
large companies to establish similar sorts of set-ups in
different sectors?
Mr Willetts: We are, in general, believers in the model
of open innovation. Where we have a direct policy
role, I say to universities, for example, that there are
many ways they can raise their performance on
innovation rather than simply counting the number of
patents and thinking through IP. Open innovation is
certainly something I want to encourage in
universities. Initiatives such as those at Glasgow
University are very welcome. If the Committee has
observations on areas where you think legitimate
public policy can do things, without intruding into
genuine commercial decisions, we will look at that
with great interest.
Q297 Stephen Metcalfe: You have said before to this
Committee that the UK economy lacks mid-sized
companies that have the ability to leverage up our
research base. What are the Government doing to try
and resolve that problem and help smaller companies
grow into the medium-sized companies that our
economy seems to benefit from?
Mr Willetts: There are medium-sized companies, and
we have launched a Growth Accelerator scheme that
is aimed precisely at helping those companies. A lot
of it is essentially extra advice and assistance. It is to
help them, for example, plug into the services of
UKTI as they first get into exporting. Not enough of
our medium-sized companies are big players in export
markets. We can help them there and provide them
with assistance. That is one area.
Another area, to be frank, is whether they need help in
improving levels of management training. A company
may need a bit of help upskilling their managers for
the wider responsibilities they have. That is what our
Growth Accelerator programme is all about.
Q298 Stephen Metcalfe: Is that based on you
identifying companies and contacting them to say,
“Are there things that we can do to help you?”, or do
they have to come and search for this particular
advice?
Mr Willetts: We are publicly advertising this
programme, but we are particularly working through
chambers of commerce, LEPs, the IoD and CBI. We
encourage them by saying, “If you know of a
company, perhaps already heading from small to
medium size and growing quite fast, that you think
could benefit from the Growth Accelerator, do put us
in touch.”
Q299 Stephen Metcalfe: How much do you think
finance is a barrier to growing a business at that point?
Do you still see that as an issue—that banks are not
willing to take that step-change risk of a small
successful company trying to upscale to a mid
category?
Mr Willetts: Sadly it is a constraint. I know all the
problems that banks say they have. My right hon.
Friend, the Secretary of State, has this as his special
subject on “Mastermind”. He is really the person who
has been heavily involved in all this. Yes, there is a
real problem with bank lending. It comes in lots of
forms. One of the forms that particularly worry us is
the collapse of local banking and the withdrawal of
discretionary expertise at the local bank level.
If you are a large company, you can negotiate a major
facility for hundreds of millions of pounds with
people at head office. If you are an SME that wants
to call at your local branch to have a grown-up
conversation about finance for working capital as you
have a new set of export orders, it is a real problem
whether there are local staff who have local
knowledge and discretion to lend you the funding in
those circumstances. That is a real problem and it is
why one of the coalition’s priorities is to break down
the barriers to new entrants into banking. We hope
some of these new entrants—the Co-op or whatever—
will revive those traditions of local relationship
banking.
Q300 Chair: I wouldn’t call the Co-op a new entrant.
They have been around a year or two. Just on that,
Lloyds Bank told a seminar organised by Dods
recently that they have developed a programme in
partnership with Warwick University to get their
managers at least up to some speed in terms of
knowledge of engineering. Do you think that
programmes like that need to be encouraged in the
banking sector?
Mr Willetts: Yes, definitely. I wasn’t aware of that
particular initiative but that sounds excellent.
Q301 Gareth Johnson: Minister, I want to take you
back to the EU State Aid rules. Sir David Cooksey,
when he gave evidence to us, said that in this country
we often wait for State Aid approval before promoting
UK technology abroad, whereas in other countries
they got on with the job and then worried about it
if Brussels contacted them and said they were doing
something wrong. Do you think that is an accurate
depiction of the current situation?
Mr Willetts: We are certainly aware of State Aid rules.
There are lots of meetings where you think you are
making great progress until someone says, “Ah, but
remember EU State Aid rules,” and we do have to
comply with them. You say these other countries just
get on with it and wait to be challenged. Of course,
they can find that down the track they could face a
pretty hefty fine and have to repay large amounts of
money. Going ahead and then waiting to see if anyone
challenges you is itself quite a risky approach. But we
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are aware of the rules. We do work within them and
then try and move as fast as we can.
Q302 Gareth Johnson: Have we had any pretty
notable successes in promoting British technology
firms abroad by taking that approach?
Mr Willetts: Perhaps it is because of David Cooksey’s
particular expertise in life sciences. I think one of the
suggestions was that the Biomedical Catalyst
arrangement linking MRC and the TSB had been held
up by State Aid rules. I checked this when I read that
this was one of his concerns. All I can say is that we
believe we moved as fast as we could. We were aware
of state aid rules, but the rule of thumb is that
upstream Research Council science spend is exempt
from State Aid rules, and with a lot of the TSB
intermediate funding you can’t go above 50% support.
That is the sort of State Aid framework, and we try to
work within that so we can act as quickly as possible.
The framework of State Aid rules is basically a good
thing. It is to ensure that the single market is a genuine
market for competition. It is not an upward auction of
subsidies being offered by different EU countries.
That is something that we think is a good part of the
framework of the single market, so we do try to
comply with the State Aid rules.
Q303 Gareth Johnson: Do you think there is
anything that we should be doing better within that
framework in this current situation, or do you think
we have to break out of the framework to do better?
Mr Willetts: Again, I would be interested in the
Committee’s advice. One of the areas where we have
got smarter is that sectoral support is much easier to
do than individual business support. It goes back to
the point that Mr Miller, the Chairman, was making
at the beginning. If you look at something as a
broadly-based initiative—and I would welcome that
because I think it is the right approach to industrial
strategy, not trying to pick particular businesses—you
can get much further if you back a technology or
research programme of a range of applications that
can be drawn on by a range of companies. That is
much less likely to hit State Aid constraints than if
you want to write a cheque to an individual firm. We
do try to comply with that and it probably pushes us
in the right direction.
Q304 Caroline Dinenage: As you know, we have
taken evidence from quite a number of people over
the last months. The strong message coming through
from entrepreneurs is that, while there isn’t a
recession in technology, it is increasingly difficult to
get funding for technology companies. I know that the
Business Secretary in his announcements this week
said he would look at what the press are calling a
business bank—the idea of lending to businesses.
One of the things that we have been told by
entrepreneurs is that recent regulations have led to
pension funds and insurance companies greatly
reducing their investments in the UK equity markets
and that then drying up funding exchange for
businesses. Will the Government address that problem
alongside their efforts to increase bank lending?
Mr Willetts: Yes. This is something that John Kay’s
report touched on as well. If there are ways in which
regulations have impeded that kind of long-term
investment, we would be willing to look at it. John
Kay’s report did not come up with a list of detailed
public policy interventions. He was really after the
City to have a cultural shift and think more
imaginatively about the case of long-term investment,
but if there are things we can do there we would
happily look at it. As I said earlier, we have tried to
put in extra funding of over £200 million to reinforce
venture capital investment, which is a really practical
way we can help. We have maintained several venture
capital programmes that way.
We have also put another £50 million into an angel
investor co-fund. If you look at America, one of their
great advantages in getting those kinds of investments
is the angel investor community. For the first time we
have now said we will co-invest alongside angel
investors.
Q305 Caroline Dinenage: I want to ask you about R
and D tax credits, because that is something we have
spent a lot of time talking about. The feeling of the
witnesses we have spoken to was very much that they
tend to have a disproportionately positive effect on
smaller and medium-sized businesses than they do on
the large ones, where they get swallowed up in their
finances. We have been told that banks have received
more from R and D tax credits than even
GlaxoSmithKline and Rolls-Royce. Do you believe
the banks need an R and D tax incentive, and do you
think that in some way maybe there is a possibility
that R and D tax credits have been used as an
incentive, or even a bribe, to businesses to stay in
the UK?
Mr Willetts: I wasn’t aware of the banks being such
beneficiaries of the R and D tax credit. You are
tempting me to engage in a bit of banker bashing. If
they have a legitimate claim for R and D tax credit I
wouldn’t stop them, but we have tried to improve the
R and D tax credit regime both by increasing the total
amount of the relief and making it available above the
line. Now, the value of the R and D tax credit for
small companies is very substantial indeed. I should
have mentioned it earlier but it is a very important
part of the offer. The above-the-line treatment will
help them enjoy the benefits of it even if they have
not yet moved into profit.
Q306 Caroline Dinenage: Given that the
Government have provided banks with money to lend,
one of the things I have very much come across when
I have visited banks and asked them where the
difficulty is in lending to businesses is that they have
said that directors of small companies need to be
prepared to put their houses on the line and they need
to be able to put as much sacrifice into their own
companies as they are expecting from the banks. What
are your thoughts on that? What are the percentages
that should go into supporting businesses, particularly
technology companies, who might be investing in R
and D for something which may take a long time to
come to fruition?
Ev 92 Science and Technology Committee: Evidence
12 September 2012 Rt Hon Mr David Willetts MP
Mr Willetts: We do hear these types of concerns and
you do hear horror stories where the bank is making
a relatively small investment and then immediately
wants to take the first claim on someone’s house. The
purpose of our initiatives is to get banks to lend more
at lower cost without making their requests for
security any more onerous. Their requests for security
should not become more onerous. If anything, they
should maintain whatever they would have done
anyway or be less onerous. That is the whole purpose
of trying to lower the cost of banks’ access to
wholesale funding and other initiatives. If people
show that the banks’ terms have become more
demanding, we would certainly take that up with the
banks. That is not intended to be the way that our
schemes work.
Q307 Caroline Dinenage: Do you think there should
be a percentage breakdown between how much banks
are prepared to invest and how much small company
directors are prepared to put up as guarantees as well?
Mr Willetts: I am a bit wary of the Government
setting a rule on that. It is part of this breakdown of
the corporate lending relationship. Banks have got
very bad at project lending. If there is an asset,
including your owner-occupied house, that is all right,
but assessing and lending on the basis of a project is
a skill that, as I say, the banks on the west coast of
America have because they are used to that type of
lending. I think our banks have lost that capability
unless it is a very large project indeed. Your
underlying point is correct that the banks need to get
back to exercising judgment of lending on a project.
That requires a bit more judgment than sending round
a valuer to assess the value of someone’s house, but
the revival of that form of bank lending is very
important.
Q308 Jim Dowd: I want to follow up on that point.
You say banks have lost that. Are you sure that British
banks ever had it? The reason you say that on the west
coast they have this skill is because it is assessing
intellectual property rather than physical goods. I
don’t think British banks have ever been particularly
good at that. If you can’t count it or scratch glass
with it, they are not really interested. It is a lack of
imagination and a lack of understanding.
Mr Willetts: Thank you very much for that, because I
want to clarify one point. Let me read out a particular
point I should have made when answering the
previous question. These are the rules particularly for
the Enterprise Finance Guarantee Scheme. That is
where we are engaged ourselves directly in the
lending. “Lenders are allowed to take a personal
guarantee from borrowers under EFG, as they would
under commercial loan schemes. However, lenders
must not take a charge on the principal private
property.” That is one of our rules for the EFG. It then
goes on: “As EFG loans are for businesses lacking
sufficient track record or collateral, and the rate of
defaults is much higher than normal loans, we have a
cap on claims at 20%, which is 10 times larger than
on normal loan portfolios.” I am grateful for the
opportunity to clarify that. We have that specific rule
for that loan guarantee scheme.
On your wider point, yes, the experts tell me about the
so-called “Macmillan gap”. I don’t know how many
reports there have been in the course of the twentieth
century about problems of getting bank lending going.
As I said, if anything, the loss of local discretionary
bank managers has made things worse, not better.
Q309 Jim Dowd: I have a couple of brief questions
on the relationship between universities and business.
We have received evidence from the SME Innovation
Alliance that they feel this relationship is too heavily
skewed in favour of the priorities of universities rather
than the interests of innovative business. Given that
all human relations and activities can be improved in
any circumstance, how do you view the relationships
between business and universities?
Mr Willetts: I think it is getting closer. Indeed, the
most recent World Economic Forum competitiveness
report showed university and business collaboration
on R and D as one of our strengths compared with
our competitors. So we are making progress. We have
a programme—again it goes back to the previous
Government—of Knowledge Transfer Partnerships.
You mentioned human relationships. You get the time
of a post-graduate student helping a company tackle a
problem. I am encouraging Technology Transfer
Offices to think of their role more broadly than just
counting up patents and selling IP. I want them to have
a broader sense of their relationship.
One thing that does concern me is that perhaps in the
past there was a kind of target culture when notching
up patents was the priority, especially as universities
and researchers do sometimes exaggerate the starting
value of their discovery and underestimate the value
added by the commercial development of the
discovery. Sometimes you can have a dialogue of the
deaf in a negotiation where the university sits and
thinks it has high value for the IP they have, whereas
the commercial entrepreneur thinks that is
exaggerated. There are areas where we can improve
here.
Q310 Jim Dowd: The thrust of the evidence we have
received is that universities tend to see business
activity almost wholly through the spectrum of their
own spin-offs rather than augmenting and adding
value to current commercial activity. Do you see that?
Mr Willetts: As I say, the idea of Technology Transfer
Offices and universities having some IP was a good
idea. We probably ended up with that getting
exaggerated attention compared with these wider
relationships. We are trying to broaden those
connections through maintaining knowledge transfer
partnerships, through the innovation voucher
programme, which encourages SMEs to turn to a local
university to help solve a particular problem, and
through doctoral training centres where more and
more people getting a doctorate have business
experience as part of their doctoral programme.
Q311 Jim Dowd: On that point, do you think
practical business experience ought to count for
something in the way that published documentation
does when assessing lectureships or professorships or
whatever it might be?
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Mr Willetts: I respect the autonomy of universities.
One thing I do accept is that, when it comes to people
making an academic career, sometimes they say, “If
we go into an R and D lab of a company for five years
and we research for the company, and in that time we
are bound by commercial confidentiality and they
don’t want us to publish articles in learned journals
about what we are doing, that looks like a dark age in
our CV.” It looks like you have not generated anything
for five years. I have had this discussion with some of
our leading companies, who have realised that if they
want to get academics over to work for them they
have to provide vehicles in which the academics can
show their research activity during that time. We can
probably do better at valuing that as part of an
academic career.
Q312 Jim Dowd: What about the other way round
and getting business people into academia?
Mr Willetts: Yes, I am up for that. One area where I
think we could do a lot more particularly is in business
schools with business studies. There is a review of
business schools under way now. I am hoping to do a
serious speech setting out the issues on this next
month. I do think that business schools are an obvious
way in, but I have anecdotal evidence as a minimum
of people with a business background who want to
join a business school then being told, “The policy of
this university is that all our staff doing any teaching
should have a PhD. You have joined our business
school at age 45, having built up a business for 20
years, and now you need to get a PhD for us to accept
you as a member of staff of this university.”
To me, that does seem to rather miss the point of
businesses. There may be obstacles like that. Again, I
don’t want to send out an instruction; it is not how I
like to approach our universities. We do need
flexibility so that people with a business background
can be respected in academia without necessarily
meeting those types of requirements.
Q313 Jim Dowd: Finally, there is a general
presumption that knowledge transfer takes place
automatically from universities to business. Are you
satisfied that that really does happen consistently?
Mr Willetts: I think we can do more. Often a large
local university is the biggest single R and D resource
in an area. You know that in that university there are
staff in the IT department or in a range of departments
who should be seen as a resource for the local
business community and are up for being the local
business community. If there was an SME that needs
the use of a piece of equipment that it could never
afford to buy and operate 100% itself or needs some
expertise to solve a particular problem around a
particular new material or something, the university is
probably the best place for them to turn to. They don’t
turn to the university as much as they should, and that
is one of the reasons we commissioned Tim Wilson to
produce his report. Innovation Vouchers are a great
way of breaking down those barriers and things like a
single point of contact with the university. There are
still too many SMEs within 10 or 20 miles of a
university who may not have set foot in that university
and thought about how it can help them grow their
business. Yes, there are still barriers to break down on
both sides.
Q314 Chair: I want to press you further on your
comments about business schools. Would you see that
as a vehicle by which we would end up with more
scientists and engineers in the boardroom because of
the capacity of universities to provide some business
training to scientists and engineers?
Mr Willetts: Yes, I do. Again, I am not going to
prescribe to universities how they construct their
courses, but you observe it in America where they
have this feature of the major and the minor. Your
chances of doing a physics degree but also doing some
business studies or some law alongside it are much
greater. One reason why we have committed ourselves
to supporting an enterprise society in every university
is because I think every undergraduate should have
the opportunity, if they wish, of some kind of
experience and engagement with business in the
course of their studies.
Q315 Chair: The Government have drawn
extensively in the past on the views of James Dyson.
He made a very interesting series of comments last
week that I am sure you are familiar with. Do you
subscribe to his views about the need to give greater
support to engineering students in universities? If so,
how are you going to do it?
Mr Willetts: We are of course all great admirers of
what he has achieved. Incidentally, his company’s
commitment to R and D is excellent. When it comes
to higher education policy, he seemed to be afraid that
our excellent new higher education regime would put
people off from studying engineering. Of course
students don’t pay up front, and the evidence is that
the information we have been releasing on
employment outcomes from particular courses at
particular universities means that applications to do
STEM subjects, if anything, are doing
disproportionately well. We always need to do better,
but there was a fear that people would be put off from
STEM subjects as a result of higher fees. The
evidence does not suggest that fear has come to pass.
Q316 Chair: So you don’t subscribe to his view that
we should subsidise engineering places.
Mr Willetts: As nobody has to pay up front to do
engineering and you only pay back if you are earning
more than £21,000 a year—
Q317 Chair: So you don’t subscribe to it.
Mr Willetts: No; I don’t agree with him on that point.
Q318 Stephen Mosley: We have had some positive
feedback about the Patent Box. Last week we had Tim
Crocker from the SME Innovation Alliance, who told
us that patents were only valuable to small companies
if they went on to sell that company to someone else.
His reasoning was that, if a small company holds a
patent that gets breached by someone else, it is
prohibitively expensive for them to defend that patent.
I think he went as far as to say that it was almost
not worth that company having the patent. Do you
subscribe to that, and what do you think can be done
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to give greater protection to small innovators and
small companies?
Mr Willetts: That is a concern of small businesses and
it is a long-standing concern that I recognise. I don’t
know whether there is a particular link to the Patent
Box. The most conspicuous effect is the GSK decision
on investment back in the UK, but, again, the
Committee may have suggestions. I am not aware of
any specific proposal for further helping companies or
protecting their IP. If the Committee has any proposal
in that area, I would happily consider it.
Q319 Stephen Mosley: One thing that was suggested
last week was that apparently a number of European
countries have criminal sanctions for people who
knowingly breach patents. The suggestion was that
you could introduce punitive damages. Would they
have any benefits?
Mr Willetts: There has been some improvement in the
Patents County Court. In terms of companies getting
protection through law, we have tried to lower the
costs for them of protecting their patents through the
legal system. We have also tried to help provide
alternatives to court action, including hearings before
the IPO tribunal or using the IPO’s mediation and
patent opinion services.
I could not talk about punitive damages. That is where
the Justice Department is in the lead about what kind
of penalties there should be. If the Committee has
proposals on that, we will obviously draw them to the
attention of the Justice Department. We have
responsibilities for IPO and we have tried to make
patent protection, so far as it is our departmental
responsibility, a bit easier.
Q320 Chair: Minister, we have covered a lot of
ground today. I don’t know if you have any closing
thoughts that you would like to leave us with. This is
a very complex area where there are strongly held
divergent views about where the solutions lie. What
would your magic trick be?
Mr Willetts: I look forward to the Committee’s report.
My final observation would be that we have, in
Research Councils and the science budget, a very
effective upstream research activity. In the TSB we
have the body that does the next stage. Some countries
have a different model. In America it is the National
Science Foundation and the National Institutes of
Health, which of themselves go closer to market. I
don’t think we need to copy the American model. We
have our own structure, which we have inherited, and
we don’t want to change it.
The interesting example is the MRC/TSB link in the
Biomedical Catalyst. If there are ways within funding
constraints and if there are some other areas where we
can similarly link up some Research Council funding
and some TSB funding in a particular area, I see the
Biomedical Catalyst as a potential precedent. As I
said, it can’t be applied uniformly in every single
sector, but if there are some other particular sectors
where that model could be applied I would be very
interested to see them.
Chair: Minister, thank you very much for your
attendance this morning.
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Introduction
1. The Government recognises that knowledge and innovation are the keys to growth in a developed
economy. Government stressed the importance of the UK’s knowledge base, and the opportunities it provides
for innovation, in the recently published Innovation and Research Strategy for Growth.1
2. The commercialisation of research is economically important, as it is one of the activities that drives
innovation in the economy. Evidence shows that innovative companies, defined as those that have introduced
a new product or process, grow nearly twice as quickly in terms of both employment and turnover as non-
innovators.2
3. The Government recognises that to succeed in the global innovation economy we must maximise all of
the benefits from research. Economic and social impact of publicly funded research is delivered through a
range of mechanisms rather than a single channel. These mechanisms include:
— delivering highly skilled people to the labour market;
— developing new businesses;
— improving the performance of existing businesses;
— improving public policy and public services; and
— attracting foreign direct investment in R&D from global businesses.
Examples of these mechanisms can be found at Appendix A.
4. The commercialisation of research is a complex area. Government plays an important role in investing in
a range of mechanisms to stimulate both the supply and demand side—through incentivising both the research
base and business to work together to drive innovation.
5. There has been much discussion about spin out companies and the intellectual property generated by the
commercialisation of research, but these activities represent only a small part of university-business relations.
The external income generated by Higher Education Institutions (HEIs) from engagement with business and
community is at an unprecedented level, having more than doubled in real terms since 2001 to £3 billion. The
majority of this income is generated by collaborative and contract research, consultancy, and the provision of
professional training, which are the main routes by which knowledge generated by the research base is
commercialised. Income from licensing and sales of shares in spin-outs accounts for only around 2–4% of total
income per annum.3
6. The Government recognises that the provision of funding for research is UK-wide. We will work closely
on these matters with the devolved administrations, who offer similar support for the commercialisation of
research in other parts of the UK. The UK Government’s key partners in this area—Research Councils UK
(RCUK) and the Technology Strategy Board (TSB)—will each be submitting a separate memorandum to the
Committee, as will the Higher Education Funding Council for England (HEFCE).
7. Professor Sir Tim Wilson is undertaking a review for Government of university-business collaboration.
The Committee may wish to consider his recommendations, which are expected to be published before Easter.
Question 1—What are the difficulties of funding the commercialisation of research, and how can they be
overcome?
8. The ability to support the translation of scientific research into new products and services depends on the
capability of the public and private sector research base and innovation system. This system needs to support
a range of processes, that bring together specific knowledge, skills, technical resources and financial capital, to
solve specific problems or exploit opportunities at different stages of the innovation cycle. There is a strong
case for the public sector investing to incentivise and drive innovation. The evidence suggests that this delivers
a significant return to the taxpayer (see response to Question 4) in terms of both supporting economic growth
and employment creation, and through other benefits such as increasing demand for higher levels skills of the
improved environmental efficiency of products and processes. However, there are a range of market failures in
relation to innovation, and public sector investments play an important role in mitigating these.
9. Commercialising research requires investment in scientific research, proof of concept and proof of market
activities, investment in R&D or in establishing spin-out companies, support for demonstration activities to
prove technologies work, and investment in design and other areas that help develop and refine products and
services for the market. Support for all of these activities is necessary for successful technology
1 Innovation and Research Strategy for Growth, Department for Business, Innovation and Skills, 2011.
www.bis.gov.uk/policies/innovation/innovating-for-growth
2 Innovation Index data, the National Endowment for Science, Technology and the Arts (NESTA).
3 Higher Education Business & Community Interaction Survey www.hefce.ac.uk/econsoc/buscom/hebci/
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commercialisation; while necessary, research strength alone is insufficient. If an innovation system is unable
to do this, and is not adequately integrated, then it poses a significant barrier to innovation.
10. There are a number of established market failures in relation to innovation, relating to the ability to
access funding, identifying potential collaborators and in the provision of information. These have an impact
on the level of investment companies are prepared to make in R&D, or other forms of funding such as venture
capital, that supports technology commercialisation. The market failures arise from the inherent risks that
technologies will not work, or work less well than anticipated, and the financial risks associated with long term
and complicated technology development projects. This is a particular problem in the UK, where Business
Expenditure on R&D (BERD) is 1.1% of GDP. This is well below the Organisation for Economic Co-operation
and Development (OECD) average of 1.63%.4 Early stage technology enterprises are particularly seen as
vulnerable to capital scarcity, and find it difficult to raise equity debt or other forms of finance.5
11. There is also the difficulty that innovators have in appropriating the economic return from their research
and innovation, due to the spillover benefits that occur through, for example, the movement of workers or the
use of technologies in new areas of application. Economic research into this area indicates that whilst the
private return on investment in R&D is likely to be 20–30%, the social rate of return is likely to be 50–100%.6
Whilst this creates a strong incentive for public investment into science and R&D, it acts as a disincentive to
private sector investment, particularly at the earlier stages of technology development, sometimes identified as
Technology Readiness Levels 1–4.7
12. Other obstacles that have been identified in the area of innovation include difficulties in accessing
specialist skills and knowledge required in connection with innovation, which individual companies do not
possess internally, or access to specialist technical facilities or services, the costs of which are too high for
most individual businesses to bear. There is also an established market failure in the area of information
provision, and the ability of innovators to identify sources of knowledge across the public and private sectors
that can support innovative projects.
13. Both the existence of these market failures, and the positive spillovers generated by innovation activities,
provide a strong rationale for Government intervention. The Department of Business, Innovation and Skills
(BIS) supports a range of programmes, both directly but also through organisations that it funds and sponsors,
that seek to address such market failures. These include:
— Support for R&D: Government provides support for companies investing in R&D through the
R&D Tax Credit. In total, over £1 billion of support was provided through the Small and Large
Companies schemes in 2009–10. In the 2011 Budget, the Chancellor of the Exchequer
announced that the level of the Small Firms R&D Tax Credit would be increased to 200% in
April 2011 and to 225% in April 2012. Direct grant funding for innovation projects, including
collaborative projects undertaken between businesses and universities is provided through the
TSB, which invests over £150 million per annum in a portfolio of Collaborative R&D projects,
many of which involve universities, and SME-focused programmes such as the Knowledge
Transfer Partnerships (KTPs), which place a graduate or postgraduate student in a business to
undertake an innovation-related project.
— Proof of concept/market funding: The TSB provides support for proof of concept and proof of
market activities within businesses and universities through the Smart Awards (previously Grant
for R&D). Companies can also seek support for the development of prototypes through this
programme. The TSB manages the Small Business Research Initiative (SBRI), which enables
technology-based SMEs to compete for contracts to develop innovative solutions to public
sector challenges, which has helped to support the commercialisation of new technologies in
sectors such as healthcare, defence and electronics.
4 OECD comparative data on levels of R&D investment, 2008. It is important to note that international comparisons are
complicated by different historical, structural and industrial factors across countries. When accounting for the UK’s sectoral
mix, BERD as a proportion of GDP is more in line with countries such as France and Germany.
5
“The Financing of Technology-Based Small Firms”, Bank of England, 1996; D J and B Tether, “New technology-based firms
in the European Union: an Introduction”, Research Policy 26, 1998; “Risk Capital: A Key to Job Creation in the European
Union”, European Commission, 1998; “Innovation market failures and state aid: developing criteria”, Oxera report for the
European Commission, 2005.
6 Z Griliches, “The Search for R&D Spillovers”, Scandinavian Journal of Economics 94, 1992; M Nadiri, “Innovations and
Technological Spillovers”, NBER Working Paper, 1993.
7 Technology Readiness Levels were developed by US Government agencies for use in defence and aerospace programmes but
have subsequently been more widely applied. They are used to determine the distance of a particular technology from the
market. They operate across a scale of 1–9, with 1 being technologies which are still the subject of fundamental scientific
research, and 9 representing technologies which are capable of being manufactured and then used in functioning products.
Technology Readiness Levels 1–4 primarily involve research in laboratories; levels 5–9 involve testing the underpinning
technologies in a relevant environment, prototyping and the development of associated manufacturing technologies.
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— Support for business investment: Government invests in a number of programmes that support
venture capital investment, notably the Enterprise Capital Funds programme, which seeks to
support early stage investments. The Government provides funding through the UK Innovation
Investment Fund which invests in a range of venture capital funds providing investment to
businesses in all sectors and from early stage to later stage investments. Tax incentives such as
the Enterprise Investment Scheme and Venture Capital Trusts provide incentives for investors
to provide equity finance for individual companies or to invest in venture capital funds.
— Demonstration support: Support for the demonstration of new technologies at scale, to prove
these work in operating environments is a key stage in the innovation process, helping to create
a market for new technologies. The TSB has supported a number of demonstrators, often linked
to its Innovation Platforms—programmes of activity which seek to bring together all those with
an interest in the development of technologies in a particular area, including academia,
companies, customers and regulators. To date, demonstrators have been supported in the areas
of low carbon vehicles, digital technologies and sustainable construction technologies. £25
million was also allocated in the Autumn Statement to support large scale demonstrators in
technologies.
— Information provision: Support for the Knowledge Transfer Networks (KTNs), which link those
interested in a particular technology area or sector across business and academia, enabling the
exchange of information and the development of new contacts. The TSB also manages the _
connect platform, which hosts the KTNs, and provides an online networking resource for
business (http://connect.innovateuk.org).
14. Another key challenge is demonstrating the market opportunity for new technology, and the potential
customer base both in the UK and internationally. A number of Government interventions are designed to
address this gap and help universities and businesses to prove the technology concept and prove market
applications. These measures include HEFCE’s Higher Education Innovation Funding (HEIF) for universities
and support from Smart Awards, which help businesses to bridge the funding gap and provide customers and
investors with reassurance of the commercial application of the technology. The SBRI also has an important
role in pulling new technology through into the market place and demonstrating to other potential customers
the commercial viability of the technology.
15. Encouraging the application and commercialisation of research and knowledge generated in the UK
research base is one of a number of key strategic priorities for Science and Research funding and policy. These
strategic objectives also include incentivising economic impact from research and supporting the leveraging of
research funding from business and charities. HEFCE and the Research Councils have developed a broad range
of mechanisms, programmes and incentives to deliver these objectives, some of which are set out in the
remainder of this memorandum. Further details of these measures and examples will be provided in separate
memoranda from HEFCE and RCUK.
16. Research and Innovation Campuses such as those at Daresbury, Harwell, Norwich and Babraham,
provide thriving environments for businesses, industry, universities and researchers. They enable innovation,
deliver impact from Science and Research investment, and act as magnets for investment. For example, 71%
(or 41 companies in total) of the companies in the Innovation Centre at Daresbury experienced a growth in
sales over the previous financial year, compared to only 30% of the small business population as a whole.8
17. Campuses support the creation and growth of businesses in life sciences and biomedical research, energy,
security, climate and the environment. In recognition of this, the Prime Minister announced in August 2011
that the campuses at Harwell and Daresbury would be within new Enterprise Zones. The Zones benefit from
over £150 million in tax breaks over four years, new superfast broadband, lower levels of planning control and
the potential to use enhanced capital allowances.
18. Public Sector Research Establishments (PSREs) are a diverse collection of public bodies carrying out
research. This research supports a wide range of Government objectives, including informing Government
policy making, statutory and regulatory functions and providing a national strategic resource in key areas of
scientific research. Many of these bodies are involved in commercialising research.
The European Union (EU) State Aids Framework
19. In delivering support for innovation and technology development in business, the UK Government is
required to work within the European Union (EU) State Aids Framework, which aims to limit market-distorting
subsidies given to companies. The State Aids framework also enables the EU to meet its international
commitments on subsidies in the World Trade Organisation (WTO). Funding for business R&D projects is
considered an allowable State Aid, and support can be provided subject to certain levels (calculated as a % of
total project costs). Support is allowed for four categories of innovation activity: fundamental research;
industrial research; experimental development; and technical feasibility studies. The definitions of these
8
“STFC Research Performance and Economic Impact Report”, 2011.
www.stfc.ac.uk/resources/pdf/stfcimpactreport2011.pdf
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activities used by the European Commission are those developed by the OECD, and are contained in the
Frascati Manual.9
20. The State Aids Framework aims to ensure that public funds are targeted on identified market failures in
the area of innovation. Therefore, higher levels of support are allowed for fundamental research (100% funding)
than R&D in businesses (50% for large companies, up to 70% for SMEs), and lower levels of funding for
experimental development (25% in large companies, up to 45% in SMEs), which includes later stage innovation
activities such as demonstration. The UK Government recognises the importance of the State Aids Framework
in ensuring fair European and international markets for products and services, and is committing to providing
support for innovation in business within this framework of rules. However, the Government believes that in
some areas improvements are needed to ensure that these enable effective support to be delivered to business,
particularly in the area of support for demonstration activities. The Government will be making proposals for
change as part of the ongoing consultation on the State Aids Framework for R&D and Innovation being run
by the European Commission.
Question 2—Are there specific science and engineering sectors where it is particularly difficult to
commercialise research? Are there common difficulties and common solutions across sectors?
21. Most of the market failures that exist in research and innovation are generic, and these affect companies
in all technology-based sectors. The difficulties in accessing finance and other resources, and market failures
relating to the provision of information, tend to be related to company size rather than sector. Most of the
available economic research has identified that SMEs face particular problems.10 However a report produced
by Oxera identified that the sector in which a company is active is a crucial variable in innovation market
failures.11 The report found that companies in technology-based sectors that depended on innovation needed
to invest a higher proportion of their resources in innovation. Because of this, any market failure in the area
of innovation would be magnified in these sectors.
22. Whilst these market failures affect all technology-based sectors, there is some evidence to suggest that
sectors are affected to a different extent. Sectors which are capital intensive and have long horizons for product
development, such as the life sciences (particularly those SMEs developing new medicines) and low carbon
energy where many R&D activities are further from market, are particularly affected by market failures. These
relate to access to finance, particularly early stage finance, and difficulties in appropriating the value of their
investments. This reduces their attractiveness to potential investors. A report by HM Treasury, Bridging the
Finance Gap, suggested that the difficulty in raising equity finance varied by region, sector, round of funding
and stage of development.12 Other evidence suggests that for technically complex investments, such as clean
energy or life sciences, the equity gap identified by Bridging the Finance Gap of £250,000–£2 million could
be higher, at £10–£15 million.
23. It is also possible that other factors play a part in reducing the level of innovation and the
commercialisation of research that takes place in particular sectors. In some sectors, the existence of long
supply chains, comprising companies of varying innovation capability can have an impact. Sectors characterised
by large numbers of SMEs (particularly micro-businesses) such as construction, also struggle to adopt new
innovations on a large scale. Skill levels in sectors, and the range of disciplines from which staff are recruited
may also play a role. The regulatory framework in sectors such as the utilities may also play a part. Companies
in the price-regulated parts of these sectors, including the main water supply and electricity transportation
companies, are required to have their pricing policies and levels of investment in different activities for pricing
periods approved by the relevant regulator. This can limit the resources available for investment in innovation,
and create uncertainty about longer term investment frameworks, although this is frequently balanced by other
regulatory incentives for companies to innovate.
Question 3—What, if any, examples are there of UK-based research having to be transferred outside the UK
for commercialisation? Why did this occur?
24. This question rests on a model of innovation that is only partially relevant. The assumption here is that
innovation consists of an act of research-based discovery, followed by a separate process of commercialisation
which is separately financed. Commercialisation of this type is only one of the multiple forms of innovation,
and this type of finance is therefore part of a much wider financial picture. Most innovation takes place in
established firms, and is financed via retained earnings. Relatively little innovation follows a linear pathway
from research and R&D to commercialisation. BIS would be keen to study well-documented cases of a clearly
British discovery that then became the basis of commercial activity elsewhere because of financing difficulties,
but at present has no evidence that this has happened on a significant scale.
9 An agreed taxonomy for classifying public investment in research and innovation, to enable effective international data gathering
and comparison. These definitions form the basis of WTO
and EU rules on subsidies.
10
“The Financing of Technology-Based Small Firms”, Bank of England, 1996; D J and B Tether, “New technology-based firms
in the European Union: an Introduction”, 1998; “Risk Capital: A Key to Job Creation in the European Union”, European
Commission, 1998.
11
“Innovation market failures and state aid: developing criteria”, Oxera report for the European Commission, 2005.
12 Bridging the Finance Gap: next steps in improving access to growth capital for small businesses, HM Treasury, 2003.
www.hm-treasury.gov.uk/d/small_business_452.pdf
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25. Even where we have clear innovation-relevant research results, the economic benefits do not necessarily
have to accrue from commercialisation of a new product. On the one hand, there can be patenting strategies
that seek licence income. On the other hand, researchers can make knowledge freely available to companies
and then derive income from consultancy, advice, and contract research (this is currently the strategy of at least
one major UK university).
26. The main analytical problem around the commercialisation of research is that innovation frequently
involves collaboration, often across borders. Innovation usually consists of the creation of new product concepts
that are then developed via design, engineering and testing processes. These often run into problems that
require further research in order to be resolved. Often such R&D is done outside the innovating firm—whether
in, for example, universities, consulting firms or Public Research Organisations (PROs). These can be located
outside the borders of the UK. By the same token, UK universities can do research for foreign firms. UK
universities, for example, have undertaken significant work for the German car industry.
The UK imports technology as well as exporting it
27. Both science and innovation involve cross-border collaboration. In 2011, 46% of all scientific papers
with a UK author were produced with at least one foreign author involved.13 Among innovating firms, 27%
have formal collaboration agreements with foreign partners.14 Although the UK performs well in both
scientific research and high tech R&D, it is important to remember that our efforts are only a small component
of a global effort, and that most technologies in use in the UK are imported to some extent. The boundaries
between UK and foreign research and innovation are therefore blurred. BIS is aware of evidence that firms
have moved from the UK to the Boston area in search of funding, and would be keen to examine further case
studies. However, at present BIS has seen no systematic evidence that might suggest whether this is more of a
problem for the UK than other countries. In addition, there is increasing international competition for
innovation-related resources, driven by the increasing globalisation of business. Investment capital and skilled
workers are increasingly internationally mobile, and there are global markets for technology-based products
and services. The exchange of people and ideas between countries (often within companies), and the movement
of people between different companies in different locations, means that knowledge, skills and technologies
are being transferred more quickly than before. These are examples of the positive spillover benefits from
innovation.
Question 4—What evidence is there that Government and Technology Strategy Board initiatives to date have
improved the commercialisation of research?
28. At the macroeconomic level, there is significant evidence that public sector investment in science, R&D
and other innovation activities has a positive economic impact. Research suggests that an increase of 1% in
public sector R&D achieves a multi-factor productivity increase of 0.17%, which is greater than the equivalent
increase of 0.13% achieved by a 1% increase in business investment in R&D.15
29. There is also strong evidence that demonstrates the innovation support programmes run by the TSB, and
other innovation supporting bodies such as the Design Council, have had a significant impact in driving
innovation, and in providing a significant return on public investment. A summary of the results of recent
evaluations of these programmes is set out below.
30. A joint evaluation of the R&D Tax Credit by BIS and HM Revenue and Customs found that the Credit
was important at different stages of a business’s life cycle. The repayable tax credit for SMEs was found to be
particularly important for new innovative companies, helping them with cash flow and securing external
investment. The evaluation also found that the Tax Credit enabled R&D projects to happen sooner and that
more risky research and development projects were able to take place.
31. The Collaborative R&D (CR&D) programme provides funding to enable business and research
communities to work together on R&D projects from which successful new products, processes and services
can emerge. It funds activities in both large and small companies, and is used to support the largest scale R&
D projects, such as those in the aerospace sector. It is a particularly effective mechanism for supporting
innovation projects in existing of new supply chains, strengthening links between large companies and SMEs.
Since it was established in 2007 the TSB has funded over 1,300 projects through this process, amounting to
around £550 million of grant funding to date which is matched by business. Over £150 million will be invested
in 2011–12. Evaluation of this programme showed that for each £1 of CR&D grant, there will be an increase
in gross value added (GVA) of £6.71.16
13 International Comparative Performance of the UK Research Base, Elsevier for BIS, 2011.
www.bis.gov.uk/assets/biscore/science/docs/i/11-p123-international-comparative-performance-uk-research-base-2011.pdf
14 UK Innovation Survey, BIS, 2011.
15 OECD data.
16
“Evaluation of the Collaborative Research and Development Programmes”, PACEC for the TSB, 2011.
www.innovateuk.org/_assets/pdf/publications/pacec_evaluation_of_crandd_report.pdf
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32. Smart (previously Grant for R&D), is a long running programme to help correct the recognised market
failures around private finance for high-risk and potentially high-reward technologically innovative projects
carried out by SMEs. An independent evaluation of the programme in 2001 found that 94% of these companies
could not have pursued their objectives without Smart.17 The evaluation also showed that, in spite of the risky
nature of some of these ventures, some 70% of the projects supported resulted in new or improved products
and processes reaching the market place. A further impact evaluation of the programme in 2009 highlighted
that 70% of businesses supported had since increased their R&D expenditure or activity, and that 78% had
used their participation in the programme to help open up new markets.18 The average net additional increase
in GVA was £95,000 per recipient firm, and the average net increase in employment was 2.1 FTE per firm.
Overall, the evaluation indicated that the programme generated a return of £9 for every £1 of public money
invested.
33. KTPs stimulate innovation by facilitating the transfer of knowledge and the spread of technical and
business skills. Around 1000 live projects per annum are undertaken by high calibre, recently qualified people
under the joint supervision of personnel from business and the research base. For every £1 million of
Government spend in 2009–10 the average benefits to the company amounted to a £3.53 million annual increase
in profit before tax, £1.42 million investment in plant and machinery, with 34 new jobs created and 374
company staff trained as a direct result of the KTP.19
34. Encouraging the application and commercialisation of research and knowledge generated in the UK
research base is one of a number of key strategic priorities for Science and Research funding and policy. In
January 2012 a series of reports were published on the impact of Research Council funding. They included a
report from RCUK and individual reports from the seven Research Councils. Each report details how research
has created wealth, improved society, provided skilled individuals and promoted health and well being.20
35. The impact of Research Council funding is recognised in industry. In 2005 the Medical Research Council
(MRC) received over US$200 million, from US pharmaceutical company Abbott in recognition of the
techniques invented in the MRC Laboratory of Molecular Biology in Cambridge and the Scripps Research
Institute in California, and used to develop the first blockbuster therapeutic monoclonal antibody, HUMIRA®.
The MRC has a strong track record in commercialising the outputs from its research; licensing income to the
MRC reached £61.69 million in 2010–11. This brings the total cash generated from MRC intellectual property
generated since 1998 to more than £550 million. A significant source of this income has been MRC patents on
key technologies used to produce therapeutic monoclonal antibodies. In October 2011, the Engineering and
Physical Sciences Research Council (EPSRC) received a Partner of Choice award from the world’s largest
consumer products company, Procter and Gamble.21
36. Working with the TSB, RCUK leverages wider research funding. RCUK spent £165 million between
April 2008 and March 2011 on complementary and collaborative activities with the TSB. These included:
— the Low Carbon Vehicle programme that has supported 440 company and academia
partnerships; and
— a project based on nano-scale technologies to develop the next generation of solar energy
panels.22
37. The Innovate for Universities programme delivered by the Design Council is helping improve the
commercialisation of research. An independent evaluation by Ekosgen of the 2009–10 programme, found that
the design mentoring received by the participating university technology transfer offices had helped improve
commercialisation by: reducing the risks associated with a technology; making new concepts viable and
appealing and hence more marketable and attractive to potential investors through visualisation and prototypes;
and identifying new markets or products for a technology. For example, Nottingham University subsequently
secured funding of £250,000 to conduct more proof of concept work for one of its projects.
Question 5—What impact will the Government’s innovation, research and growth strategies have on bridging
the valley of death?
38. The Government has demonstrated its strong commitment to the UK knowledge base by protecting
Science and Research programme funding with a flat-cash, ring-fenced settlement of £4.6 billion per annum
over the Spending Review period for 2011–15. Since the £1.9 billion the Government allocated for capital in
the 2010 Spending Review, the Government has announced a further £495 million of capital investment in
Science and Research.
17
“Evaluation of Smart”, PACEC, 2001.
18
“Grant for Research & Development and Smart Final Report”, DIUS/LDA, 2009.
http://webarchive.nationalarchives.gov.uk/+/http://www.bis.gov.uk/files/file52026.pdf
19
“Knowledge Transfer Partnerships Annual Report 2009/10”, TSB, 2010.
www.ktponline.org.uk/assets/Resources-page/KTPAnnualReport09–10.pdf
20
“Research Councils UK, Impact Report 2011”, 2012.
www.rcuk.ac.uk/Publications/reports/Pages/RCUKImpactReport2011.aspx
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“Research Performance and Economic Impact Report 2010/2011”, EPSRC, 2012.
www.epsrc.ac.uk/newsevents/news/2012/Pages/economicimpactreport.aspx
22
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39. The Autumn Statement and the subsequent publication of the Innovation and Research Strategy for
Growth and the Strategy for UK Life Sciences23 confirm the Government’s commitment to accelerate the
commercialisation of emerging technologies.
40. The Strategy for UK Life Sciences announced a £310 million investment to support the discovery,
development and commercialisation of research. Of this, £180 million will be used to fund an initiative that
will target the “valley of death” where investment is currently seen as too risky for many private investors,
who, due to the high early attrition rate of programmes and the long lead times to commercial returns, want
proof of efficacy in high cost clinical studies before making substantial investment decisions. Over the next
three years this joint MRC/TSB Biomedical Catalyst Fund will nurture innovative technologies from the
academic or commercial sector through to commercialisation of products or technology platforms in order to
attract private equity The fund will build on existing MRC programmes for academia and provide new funding
of £90 million through the TSB for support for SMEs, delivering growth to the Life Sciences sector and
providing support to both academically- and commercially-led R&D and development to speed up the delivery
of the benefits of science to patients.
Supporting business
41. The TSB is the Government’s prime channel of support for business-led technology innovation. The
TSB provides a range of products aimed at improving the commercialisation of R&D, with proven impacts.
These support a range of activities in the innovation cycle and include the Smart Awards, SBRI, CR&D, KTNs,
KTPs and the Catapult centres. The Innovation and Research Strategy for Growth commits to continue these
programmes and provided additional funding to support small business innovation.
42. Government has committed to extend the TSB’s Launchpad programme which aims to help strengthen
existing clusters of companies. This programme provides funding to small business to develop new products
and services and, at the same time, help these companies leverage in private sector finance. The initial
competition focussed on Tech City was successful in attracting over 200 high quality proposals, with over 80%
coming from new, small or early stage companies. The TSB supported 18 projects with funding of just over
£1.75 million.
43. The TSB is also in the process of establishing an elite network of Catapult centres. The first centres have
been announced in the areas of high value manufacturing, cell therapy, offshore renewable energy, satellite
applications and the connected digital economy. These centres will play an important role in helping the
translation and commercialisation of research for the benefit of business.
44. Clusters—geographic concentrations of interconnected businesses, knowledge base organisations and
suppliers—can play an important role in reducing risks associated with developing and commercialising new
and emerging technologies, and supporting higher adoption and diffusion. Government has committed to
remove barriers to the emergence of new clusters and the growth of existing clusters. RCUK, working with
others, will establish a principles-based framework for treatment and submission of multi-institutional funding
bids to allow consortia to tackle large-scale and ground-breaking new research beyond the capabilities of
single institutions.
45. Local Enterprise Partnerships (LEPs) have the potential to influence partnership working between all
players in a local economy, and many already have HEI representation on their boards. As LEPs develop their
strategies at the heart of local democracies, it is expected that they will play a more robust role in promoting
economic growth including bringing together business and universities to commercialise R&D.
46. To further support collaboration between SMEs and external knowledge providers across the public and
private sectors, Government will introduce a new Innovation Voucher programme in 2012–13. The Voucher
programme will initially focus on geographical areas and sectors of low economic growth, and will look to
support small businesses who have not previously engaged with the UK’s knowledge base or lack the in-house
expertise or research facilities to develop ideas into new products and services.
47. R&D tax credits support business expenditure on research and development activities. Government has
recently announced a number of reforms to the scheme, including:
— increasing the rate of relief available for SMEs to 200% from April 2011, and to 225% from
April 2012; and
— the introduction in April 2013 of an “above the line” R&D tax credit which will provide greater
visibility and greater certainty for large company investors.
48. Turning an initial patent or concept into a marketable product requires a range of complementary
activities, including further R&D activity either on the intellectual property itself or the processes required to
manufacture or deliver the product or service. The R&D tax credits scheme provides further support during
this phase, where the work is seeking to resolve scientific or technological uncertainty.
23 Strategy for UK Life Sciences, BIS, 2011.
www.bis.gov.uk/assets/biscore/innovation/docs/s/11–1429-strategy-for-uk-life-sciences
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Importance of the knowledge base
49. Strong universities and the wider knowledge base drive UK competitiveness in the global economy,
through underpinning technology-based sectors and enhancing our health, quality of life and creative output.
They train the skilled researchers and technologists who work in knowledge-driven sectors.
50. Government recognises the importance of the research base, which includes HEIs, Research Council
Institutes, PSREs, and Research and Innovation Campuses, in assisting companies to commercialise ideas.
51. Research Councils support activities which encourage researchers to work with business. These include
support for collaborative research, collaborative training, the exchange of researchers between academia and
business, and in some cases proof of concept funding. Research Councils are working with nearly 3000
businesses in sectors ranging from broadcasting to biotechnology and engineering to insurance. Research
Councils also work closely with a number of strategic partners to deliver impacts from research.
52. RCUK is committed to developing strategic partnerships to ensure that the potential impact which exists
in the research base through previous investments is tailored appropriately to meet user needs, and future
evidence can be generated collaboratively. A number of sectors have been selected as the focus for current
strategic engagement through a coordinated cross-council approach. These include pharmaceuticals, the creative
economy, water and energy.
53. Of vital importance is the support that the UK provides for fundamental, or “blue skies” curiosity-driven
research, which attracts leading researchers to work here, and allows the combination of ideas from different
research fields. Research Councils will continue to fund both responsive, curiosity-driven research proposals,
and research initiatives into specific areas. This funding will continue to be complemented through the UK
Higher Education funding bodies, which will provide universities with flexible, quality related research funding.
54. HEFCE research funding also includes an element to support research with business (amounting to £64
million per annum) allocated by reference to the collaborative research income generated from business.
55. HEIF, provided by HEFCE, enables HEIs in England to maintain and develop capacity to work with
business and other users, including:
— strengthening technology transfer offices and providing proof of concept funding to help with
commercialisation of intellectual property outputs (including through spin-outs, licensing);
— support for business development function to help increase interactions with business (such as
collaborative research, consultancy, continuing professional development training); and
— enterprise education for students and support for starting a business.
HEIF is being maintained at £150 million per annum for 2011–15, and is being reformed to increase
the rewards for universities that are most effective in business engagement.
56. Similar support is offered by Higher Education Funding Bodies in other parts of the UK.
57. Through the Higher Education Funding Councils and Research Councils, Government has developed
further incentives to recognise and reward HEIs and researchers for the broad range of economic, social and
cultural impact derived from their research. A major exercise is undertaken every few years to assess the
research performance of all UK HEIs. The Research Excellence Framework (REF), which replaces the earlier
Research Assessment Exercise (RAE), will complete and report at the end of 2014. REF 2014 will not only
assess research excellence but will also include, for the first time, an assessment of the impact that excellent
research has made on the economy and society. “Impact” will account for 20% of REF 2014.
58. Research Councils now require researchers submitting grant applications to include a proposed “Pathway
to Impact”.24 This encourages researchers to consider from the very beginning the potential “pathways to
impact” and those who may be interested in the outcome of their research. It will help speed up these impacts
and ensure researchers think about the value of their research to the economy and society.
The international dimension
59. Innovation and research are now increasingly international endeavours as most innovations originate
from multiple countries. Businesses looking to commercialise new ideas or technologies can also benefit from
international partners’ ability to provide access to wider markets. High growth economies’ strong, long-term
growth makes them of increasing importance to UK businesses looking for new markets.
60. The Innovation and Research Strategy for Growth announced a range of measures to support international
collaboration for UK businesses including:
— UK Trade & Investment (UKTI), the Science and Innovation Network (SIN) and the network
of IP attachés will focus particular support on helping innovative UK businesses take advantage
of commercial opportunities and build successful international collaborations in innovation
hotspots.
24 www.rcuk.ac.uk/kei/impacts/Pages/home.aspx
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— The Catapult centres will all have a focus on international engagement, varying according to
where the best opportunities exist.
— UKTI will create a collaborative online platform, enabling innovative companies and service
providers to support one another.
61. BIS will review the system of support available to UK participants in Horizon 2020 proposals. Under
the “Leadership in Enabling Industrial Technologies” pillar of the Commission’s proposed Horizon 2020
programme, support will be available for the deployment of the outputs of research projects by European
industry. Such support will play a key role in aiding the commercialisation of research, thereby strengthening
Europe’s productivity and innovation capacity and ensuring Europe has an advanced, sustainable and
competitive economy, global leadership in hi-tech application sectors and the ability to develop effective
solutions for societal challenges. The Government recognises its role in ensuring that UK companies are well-
placed to benefit from these opportunities by putting in place a support-system that is fit for purpose.
62. International collaboration is also important to the UK’s research base. The quality of the UK research
base attracts companies from around the world. Companies such as Ford, Pfizer, Airbus, Nokia and Syngenta
have all chosen the UK for large scale R&D investment. The RCUK International Strategy outlines how the
Research Councils can grasp new opportunities and build on the UK’s already impressive international reach.25
Building strategic links with the institutions and companies in the emerging economies such as the BRIIC
countries will be vital if the UK is to succeed in the global economy, and international collaboration in Science
and Research has a key role to play in this.
Question 6—Should the UK seek to encourage more private equity investment (including venture capital and
angel investment) into science and engineering sectors and if so, how can this be achieved?
63. Government is committed to making the UK the best place in Europe to finance and grow a business.
Despite the turbulence in global financial markets the Government believes that unlocking private sector
investment remains the key to enabling private sector led growth. Evidence from NESTA shows that about 6%
of innovative, high growth companies created 50% of new jobs.26 Government is committed to enabling
innovative, high growth businesses, including the science and engineering sectors to access more diverse
sources of finance.
64. Business Angels have an important role in supporting early stage innovative companies, not only with
small amounts of equity investment, but also in providing mentoring support and networking opportunities. In
recognition of the importance of Business Angels the Government has reformed the Enterprise Investment
Scheme (EIS) and Venture Capital Trust (VCT) tax reliefs. These changes include increasing the rate of income
tax relief for the EIS to 30% from April 2011 and doubling the investor limits to £1 million per annum from
April 2012. The EIS, which is not sector specific, supported £611 million of investment in 2009–10 including
£125 million in high tech companies (which include instrument engineering, some chemicals, R&D, and
computer consultancy among others).
65. The risks involved in investing in the newest, early stage companies are recognised by Government,
which has introduced the Seed Enterprise Investment Scheme (SEIS) providing a 50% rate of income tax relief
for individuals who invest in qualifying seed companies. To kick start the scheme the Government is providing
a Capital Gains Tax Exemption on any gains realised in 2012–13 that are invested through SEIS in the
same year.
66. Government also recognises the importance of improved access to equity investment across the English
regions. Working with Capital for Enterprise Limited and Business Angels networks the Government has
committed £50 million through the Regional Growth Fund to a Business Angel Co-Investment Fund which
will support Business Angel investment across England.
67. We know from the USA that governments can play an important role in unlocking private sector
investment for early stage, innovative companies. Apple, AOL, Hewlett Packard and Intel all received early
stage equity investment from Federal Government backed venture capital programmes. Our own Government
backed venture capital scheme is the Enterprise Capital Fund (ECF) programme which invests up to £2 million
in a range of early stage, high growth businesses including a number in science and engineering sectors. The
ECF programme specifically encourages the creation of venture funds through providing a mechanism whereby
private investors can benefit from a greater share in the profits of those funds. This helps to level the playing
field between equity gap investment and the returns that might be had from alternative asset classes.
68. The ECF programme has to date supported 10 professionally managed funds, which together have
invested £124.6 million in 114 companies. The funds have a commercial focus, but a clear target to invest
within the equity gap. Funds often collaborate with Business Angels and other early stage investors, and around
60% of investments to date are in firms at seed or early stage.
69. In the last spending review, the Government committed a further £200 million to creating new ECFs,
which will extend their reach. Proposals for ECFs can come from teams focusing on any industry sector,
25
“Our Vision for International Collaboration”, RCUK.
www.rcuk.ac.uk/documents/publications/international.pdf
26
“The Vital 6%”, NESTA, 2009. www.nesta.org.uk/events/assets/features/the_vital_6_per_cent
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including from teams working with universities and other research and technology institutions to commercialise
and invest in early stage and technology-based ventures.
70. Government is also continuing to support the UK Innovation Investment Fund (UKIIF), one of Europe’s
largest technology Fund of Funds. Working with Hermes GPE and the EIF, the UKIIF targets investment in
advanced manufacturing, clean technology, digital, and the life sciences sectors by investing up to £330 million
in a range of specialist technology funds.
71. Venture capital markets are increasingly global with a third of investment into UK venture capital coming
from overseas including the USA and Asia. Europe continues to under perform compared to US markets,
investing four times less in venture capital. The UK Government has led European proposals to create a Pan
EU Fund of Funds of the size and scale of successful US Technology Funds. We welcome proposals in the
forthcoming Horizon 2020 Framework Programme to place greater emphasis on the financing of innovative,
high growth companies across Europe including the creation of Pan EU Innovation Fund of Funds funded
through a reprioritisation of existing EU budgets through the EIF and national operators.
72. Government will also strengthen links between the UK and US venture capital sectors. Following
President Obama’s State Visit to the UK in May 2011 the UK and US Governments have announced that they
will bring together UK and US fund managers to enable strategic partnerships to be developed, and to showcase
and secure investment for some of the UK’s leading innovative companies.
73. The TSB is looking at how it can create greater links between the support it provides and the private
equity community. Companies supported through the SBRI programme for instance tend to attract private
equity interest as government funding helps to de-risk the technology and there is also the prospect of a
government contract. The Launchpad programme provides 50% of the funding to the company. The TSB then
creates the opportunity for these companies to meet the private equity community to gain the other 50% of
the funding.
74. UKTI’s strategy, Britain Open for Business, states that it will work to attract venture capital investment
from overseas through developing strategic relationships with key venture capital decision makers across the
world, making intensive use of their networks to stimulate interest.27 This new package will aim to attract
significant new investment for high growth and innovative SMEs, and bring new venture capital operations to
the UK.
75. Not all technology businesses require large amounts of capital and it is relatively common for start ups
in the creative and digital sector to use their own finance or that of friends and family to fund their enterprise.
This helps to gauge the business potential and avoids diluting the ownership of the business too early. Through
the Business Link website (www.businesslink.gov.uk) and the “No Nonsense Guide to Finance for Innovative
and High Growth Companies”, the Government wants to ensure that innovative businesses have access to the
information they need to make appropriate funding decisions.
76. As well as proving the viability of technology, investors will want to ensure that the potential market
opportunities and the customer base, both domestically and internationally, are fully understood. A number of
Government programmes help to address “investment readiness” and ensure that business owners fully
understand what investors are seeking including the potential rates of return on investment.
Question 7—What other types of investment or support should the Government develop?
77. As well as addressing supply side measures to support the commercialisation of technologies,
Government believes that there are other measures that can support innovative, high growth companies. These
include public procurement, prizes and business programmes.
Procurement
78. The scale of Government’s purchasing power means that the public sector can be a lead customer for
innovative products and services. Through engaging with the supply chain, the public sector can identify
opportunities to incentivise the development of new products and services, and use the scale of the public sector
market to accelerate the commercialisation of innovation where this represents value for money, benefitting the
wider economy.
79. The House of Lords Science and Technology Select Committee report on “Public procurement as a tool
to stimulate innovation”28 recognised innovation procurement as a vehicle to help “…stimulate British industry
to generate new products and ideas that will, in turn, lead to economic growth, often based on the translation
of scientific research into commercial products and services”. Innovation procurement initiatives reduce risk,
guarantee sales, encourage market entry, provide early testing ground and manufacturing experience, create
demand and make latent demand manifest, and diffuse technology.
27 Britain Open for Business: Growth through International Trade and Investment, UKTI, 2011.
www.ukti.gov.uk/uktihome/aboutukti/aimsobjectives/corporatestrategy.html
28
“Public procurement as a tool to stimulate innovation”, 2011.
www.publications.parliament.uk/pa/ld201012/ldselect/ldsctech/148/14802.htm
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80. In its response, Government set out how its ambitious and radical programme of procurement reform
will help foster innovative solutions, through reducing bureaucracy in the procurement process making public
procurement more attractive to smaller and more innovative suppliers, and greater use of outcome-based
specifications allowing the market to come forward with solutions. The commitments made by Francis Maude
on 21 November 2011 around procurement and growth will require Government to undertake greater pre-
market engagement before starting the formal procurement process.29 This will encourage more innovative
ideas from the market which will shape future specifications.
81. The SBRI programme operated by the TSB encourages, and provides a mechanism for, the development
of innovative solutions to public service needs. The SBRI provides innovative solutions to public sector
challenges, new business opportunities for innovative companies and a route to market for new ideas, thereby
accelerating technology commercialisation.
82. The recently published NHS strategy, Innovation, Health and Wealth, announced that the Department of
Health would double its investment in the SBRI programme to develop innovative solutions to healthcare
challenges, encourage greater competition in procurement of services, and drive growth in the UK SME
sector.30
Innovation inducement prizes
83. Governments and businesses are increasingly recognising the potential of innovation inducement prizes
as being complementary to other ways of supporting innovation. Prizes can encourage wider collaboration
across public and private sector organisations, communities and consumers in response to a clearly identified
challenge or opportunity. A well designed prize will aim to solve a multi-disciplinary problem that is not the
subject of existing research grant programmes or challenges, and can bring together different types of
knowledge and other resources to solve problems. Prizes can be particularly effective in targeting “neglected”
areas where innovation is needed, but might not otherwise take place.
84. The Innovation and Research Strategy for Growth announced that Government would work with NESTA
to establish a Centre of Expertise to run, design and facilitate inducement prizes. Government and NESTA will
co-finance a new fund to run future inducement prizes. Government will also contribute £250,000 per annum
towards the fund and will seek to leverage interest and investment from the public and private sectors and
philanthropic organisations.
Supporting business
85. In addition to the direct innovation support to business provided by the TSB, the Government enables
innovative businesses to access external finance through a basket of other measures. These include access to
finance information on the Business Link website and the production of a “No Nonsense Guide to Finance for
Innovative and High Growth Companies” and the “Fit for Finance Programme”.
86. Government has also launched “Business Coaching for Growth” to help 10,000 SMEs a year overcome
the barriers they face in achieving high growth potential. The programme will include help to commercially
exploit innovation, build a culture of innovation within the businesses and identify and protect intellectual
property. There will be strong links between the Intellectual Property Office, the TSB and the Design Council.
Appendix A
ECONOMIC AND SOCIAL IMPACT OF RESEARCH
The following examples demonstrate how economic and social impact of research is delivered through a
range of mechanisms.
Delivering highly skilled people to the labour market
— There were 20,080 new PhDs and 162,365 Masters graduates from UK HEIs in 2010–11.31
— A recent survey of doctoral graduates showed that over 90% felt that their PhD enabled them to be
innovative in the workplace.32
29 www.cabinetoffice.gov.uk/news/radical-package-unveiled-support-business-and-promote-growth
30 Innovation, Health and Wealth: Accelerating Adoption and Diffusion in the NHS, Department of Health, 2011.
31 Higher Education Statistics Agency (HESA) Student Record. These figures cover graduates of all domiciles from full-time and
part-time courses. PhD graduates from UK HEIs increased by 13.8% between 2008–09 and 2010–11. Masters qualifiers increased
by 31.7% over the same period.
32
“What Do Researchers Do? Doctoral graduate destinations and impact three years on”, Vitae, 2010.
www.vitae.ac.uk/researchers/1272–290131/What-do-researchers-do-Doctoral-graduate-destinations-and-impact-three-years-
on.html
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— David Lathbury, former Head of Process Chemistry at AstraZeneca’s Charnwood site, has looked at the
value the pharmaceutical industry gains from PhD training: “PhD students produced by our higher
education sector create far more monetary wealth than that associated with a particular project funded in
their university department”.33
Developing new businesses
— Between 2003 and 2011, 40 university spin outs were floated on the stock exchange with an IPO value of
£1.79 billion; and 25 university spin out companies were acquired by other business for a total value in
excess of £3 billion.34
— The software company Autonomy, based on research from Cambridge University, was a FTSE100
company before being acquired in 2011 by US firm Hewlett Packard for £7 billion.
Improving the performance of existing business
— Rolls Royce has a long-established network of Technology Centres in universities in the UK and
elsewhere.
— Lloyd’s Register is developing a £100 million Maritime Centre of Excellence on the campus of
Southampton University.
Improving public policy and public services
— The Natural Environment Research Council (NERC) gathered vital data from the Icelandic volcano which
grounded flights across Northern Europe in 2010, enabling flight restrictions to be lifted in airports across
Britain, saving money and bringing thousands of stranded tourists home.
— Researchers at the MRC Lifecourse Epidemiology Unit in Southampton developed a computer-based
algorithm, FRAX, to assess the fracture risk of patients, giving a 10-year probability of fracture. FRAX
is in use worldwide. The economic implications are significant—musculoskeletal disorders cause
discomfort for approximately 10 million people in the UK. This public health issue has associated costs
estimated to be in the region of £40 billion.
— Professor Theo Farrell, an Economic and Social Research Council (ESRC)/Arts and Humanities Research
Council (AHRC) Fellow, undertook an assessment of the British Army’s performance in Operation
Moshtarak, a 2010 offensive to clear the Taliban from central Helmand Province in southern Afghanistan.
The resulting classified report was briefed to Army chiefs, and has informed doctrine development and
pre-deployment training for troops going to Afghanistan.35
Attracting Foreign Direct Investment in R&D from global businesses
— 450 R&D projects were attracted to the UK in 2006–7 and 2007–08.36
— Tata Motors, which owns Jaguar Land Rover, has invested over £85 million in collaborative research with
the Warwick Manufacturing Group.
— Eisai is one of the world’s top 20 pharmaceutical companies and defines its corporate mission as enhancing
patient value by meeting unmet medical needs. As part of its global development strategy, the Japanese
company is to develop a £75 million facility on the Hatfield Business Park. The investment will ultimately
employ more than 500 people—including some 300 new roles in R&D and manufacturing.
January 2012
Written evidence submitted by Royal Aeronautical Society
(1) What are the difficulties of funding the commercialisation of research, and how can they be overcome?
1. The reduction in the level of government funding in the defence aerospace sector is having a significant
impact on the commercialisation of civilian technology. Defence based R&D has traditionally driven forward
technologies that are often seen as being too high risk or too early a stage for civilian companies prudently to
consider backing. Once defence funding has taken the technology to a level where the risk associated with
further development has been reduced or the technology has been demonstrated, civilian companies are then
more willing to back further development and subsequent commercialisation.
2. For example, the use of composite materials in structural applications in aircraft was led by early
development of composite design and manufacturing technology in military aircraft and missiles. This
experience increased civilian industry’s confidence in the technology and facilitated its further development for
use in civilian aircraft such as the Airbus A380, A350 and the Boeing 787.
33
“Pioneering Skills to Build Britain’s Future”, EPSRC
www.epsrc.ac.uk/SiteCollectionDocuments/Publications/corporate/SkillsHLP.pdf
34 Data from PraxisUnico.
35
“ESRC Research Performance and Economic Impact Report 2010–11”, ESRC, 2012.
www.esrc.ac.uk/_images/Research-performace-impact-10–11_tcm8–19067.pdf
36 Data from UKTI.
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3. The key issue is not actually one of funding defence R&D per se (although the resources allocated to
fundamental research have declined over the past decade).The problem is actually more to do with the
substantial customer capital investment involved in buying new equipment which, in turn serves to stimulate
the market. The 10 year equipment programme is now fully committed to existing programmes. As a result,
with few new programmes expected there will be few new market opportunities over the next couple of
decades. As a result, industry is unlikely to invest on a speculative basis in R&D. Equally, the UK’s stated
policy of buying leading-edge technology “off-the-shelf” on the global market also militates against either
public or private investment in core technologies. In short, this prospect underlines the need for another iteration
of the Defence Industrial and Technological Strategy which industry could use as a guide to future
investment decisions.
4. The reduction in funding for defence related technology will reduce British activity in riskier technology
which will not only reduce the overall rate of innovation, but will also imply that the UK potentially could miss
out on novel cutting edge technology, which may undermine future commercialisation of “disruptive” products.
5. The Space sector differs in several respects from aerospace generally and the context for commercialisation
of R&D is very different. The space industry and agencies in Europe use a system of Technology Readiness
Levels (TRL) to characterise the maturity of a technology and its readiness for commercialisation and/or
operational use. Items at TRL 1 to 3 are at the research stage while items at TRL 7 or 8 are ready to be applied.
The “valley of death” in this case refers to the long-standing difficulty to move technology from TRL 3 to
TRL 7.
6. To help address the space valley of death, the UK participates in many of the technology programmes of
the European Space Agency (ESA). A new five year plan for ESA will be agreed by Member governments
later this year and will include measures intended to help address the valley of death. A refocused General
Support Technology Programme (GSTP) would help technology and products to reach the highest TRL by
matching technologies needing in-orbit demonstration with the cheapest and fastest flight opportunity available.
Flight demonstration is a powerful means of bridging the gap between low TRL and the maturity required for
adoption on missions.
7. More generally, one of the key features of ESA’s technology support is that activities at higher TRL levels
that have commercial applications are co-funded with the private sector. At the blue skies end of the TRL scale
the work is usually fully funded by ESA; but from about TRL level 5 or 6, ESA requires participating
companies to provide much of the funding. The level of private sector funding ranges from 50% at about TRL
5 or 6, rising to beyond 70% for demonstration missions at TRL 7 or 8. The requirement for private sector co-
funding ensures that activities at TRL 6 and above are efficiently commercialised. One of the weaknesses of
the scheme is that there is no intermediate step between 100% ESA funding at about TRL 3 and 50% at about
TRL 6, making it difficult to bring promising TRL 3 or 4 technologies to maturity.
8. The UK Space Agency has set in place a number of national initiatives in the past year that complement
the ESA programmes. A national space technology programme was announced in 2011, which includes support
for In-orbit demonstration. More recently the TSB announced the creation of a Satellite Applications Catapult
initiative that will focus on bringing technology to the maturity needed for commercialisation. The Catapult
should provide a market pull that complements the technology-push of the national space technology
programme and is explicitly targeted at bridging two valleys of death characteristic of the space sector—the
first in bringing technology to maturity for space and ground infrastructure, the second in commercially
exploiting that infrastructure. The national programmes will also enable the UK to influence the ESA
programmes from a position of knowledge and strength, thereby enhancing the value for money the UK obtains
from both its ESA subscription and its national programme.
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The challenge – twin valleys of death
9. In the case of SMEs, companies face a number of particular problems of commercialising R&D. For an
SME whose product sales are dependent on long term evaluation and qualification controlled by regulation,
raising finance is difficult. Banks need to see regular income to service debt and R&D tends to be variable,
often grant assisted with quarterly payments in arrears. Similarly, Angel Funding tends to be in very small
amounts which although helps cash flow, is rarely sufficient to take major innovation into commercialisation;
and Venture Capital wants a business plan with a three to five year payback where new aerospace ventures
often have a far longer timescale.
10. Government backed bank lending for SMEs is considered by banks on the same merits as they would a
conventional loan and the cost of these loans is also high, added to which the Government asks for a 2% risk
payment. Banks are reluctant to use this system as the Government is very slow to cover losses.
11. A possible solution to these problems would be to establish a government Venture Capitalist such as the
original 3i with a remit to invest in UK companies. This body should commit funds for a longer period than
commercial venture capitalists. In bypassing commercial funds SMEs would have an alternative route to fund
R&D and its commercialisation. This should create a real incentive for commercial lenders/investors to get
involved.
12. In times of austerity, other countries are also having to scrutinise public spending and may cut R&D
budgets. As many UK companies, certainly those in the aerospace sector, have a global presence and companies
all over the world are looking for technical answers to similar challenges, there is significant opportunity for
cross-border collaboration to develop and commercialise technology. The European Framework Programme is
an example of how cross-border funding schemes can work.
(2) Are there specific science and engineering sectors where it is particularly difficult to commercialise
research? Are there common difficulties and common solutions across sectors?
13. All high value manufacturing activities are heavily and appropriately regulated for the safety of workers
and end users. Hence there is a need to test and verify materials, manufacturing processes and end products
extensively before release to market. Testing is especially critical in proving space technologies and products
that have to operate in an extremely stringent environment. Testing takes both time and money and difficult to
fund when the potential is recognised but hurdles such as a limited supply chain obstruct near term use.
14. In many cases the challenge of breaking into sector specific “islands of excellence” is a major barrier to
commercialisation. As a result, the silo effect can mean that high value innovation in one sector does not
transfer readily across to another. The continued difficulties faced by SME engaging with mainly OEM led
research centres create further problems. For example, TISICS, a titanium composite technology, has
applications in aerospace, space, oil and gas, defence, and marine power. Civil aerospace is well placed to act
as a “first user” to develop the technology for future products as other sectors tend to need proven technology
before considering it for use in their products.
15. This process could be better supported and technological diffusion encouraged by strategic long term
funding for such enabling technology. This would cover development and testing and could be run through the
TSB. This would have to be set against a five to 10 year plan where funds are agreed in advance and released
against milestones. For example, in the case of Graphene a £50 million investment could bring this product to
market. Industry support would be encouraged and banks and venture capitalists might be more willing to lend
money if they could see a structured plan backed with government grant funding.
Science and Technology Committee: Evidence Ev 109
(3) What, if any, examples are there of UK based research having to be transferred outside the UK for
commercialisation? Why did this occur?
16. A320 wing work has been transferred from UK to China and Korea by Airbus. If the US buys Hawk
trainers, the development R&D will shift to USA. Carbon fibre was developed at the former RAE, but there is
no longer production in the UK, leading to the importation of several billion pounds of fibre a year.
17. From the 1990s onwards there have also been relatively few major projects to encourage in new
technologies. The UK has not developed a new military or civil aircraft since the 1970s and does not participate
in large scale space programmes. Major defence programmes are now collaborative, and in the case of the F-
35 led by the US and subject to strict technology transfer controls. This could undermine national capabilities
in key areas.
18. Given the cost of developing new technology some loss of overall capability is inevitable and is often
the price of collaboration and a globalised manufacturing system, it is essential that the UK is able to keep in
touch with a cross-section of critical technologies and, in particular, systems integration skills; hence the
important of supporting enabling technology and technology demonstration.
19. These and other examples have been largely caused by the absence of a strategic policy to support the
underpinning technologies required for production. The Aerospace Innovation and Growth Team Report some
eight years ago established a technology plan for the sector that has led to some important public and private
investment in key technologies, particular composite material fabrication. This process should be repeated
regularly for aerospace and extended to other high technology manufacturing sectors. This strategic view of
aerospace technology needs is maintained in the National Aerospace Technology Strategy and updated by the
Aerospace, Aviation and Defence KTN of the TSB.
20. In the absence of new defence programmes, the funding of technology demonstration has special
significance in keeping design and development teams in being. This also plays a key role generally in reducing
the risk of aerospace programmes and thus aiding the commercialisation of new technology and combinations
of technology implied by the development of a complex aerospace system. Before the massive increase in
development costs, technology development often took the form of prototype development that replicated some
of the fundamental characteristics of the targeted technology. However, in many traditional system development
methodologies, costly prototypes are not always necessary or appropriate. Technology demonstrations can
provide a variety of benefits throughout the systems development life cycle, rather than at a single time for a
single purpose.
(4) What evidence is there that Government and Technology Strategy Board initiatives to date have improved
the commercialisation of research?
21. The collaborative R&D programmes run by the TSB are seen by industry as a key mechanism to increase
the Technology Readiness Level (TRL) of those technologies identified as crucial for future products. They
also provide a mechanism for supply chain development, with consortia coming together to deliver the
programmes. They are viewed by SMEs as an important way to make contact with, and to develop working
relationships with OEMs. This is vital to ensure that the innovation created by SMEs is seen and
commercialised by OEMs.
22. The TSB programme was developed from cross-sector companies of all sizes and demonstrated that the
alliance of OEM and SME companies in a close knit community can cross the valley of death. Members of a
consortium collaborate to commercialise their research.
23. In aerospace, the “Integrated Wing” and “Next Generation Composite Wing” are examples of important
TSB funded programmes leading to the development of UK technologies that have been fully commercialised.
The fact that both Airbus and Bombardier continue to produce wings in the UK, now largely made from
composite material, is testament to the long term strategic development of aerospace technology facilitated by
the National Aerospace Technology Strategy run by the TSB.
24. The Knowledge Transfer Networks run by the TSB also play an important role in the commercialisation
of research.
They:
— Help make companies aware of funding and other assistance that may help them increase the
TRL of the technology.
— Use their understanding of the technology requirements of different industries to encourage
consortia bidding for R&D funding.
— Provide networking opportunities to help companies with innovative technologies to meet
partners or customers who may have a need for the technology and therefore can help
commercialise it.
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— The Aerospace, Aviation and Defence KTN is also the guardian of the National Aerospace
Technology Strategy. This long-term strategy helps to ensure that the technologies required by
the UK aerospace industry are identified and developed in a timely manner for
commercialisation. This strategy is vital to ensure that the UK stays at the forefront of global
technology development retaining both know-how and high-value employment in the UK.
25. Overall, the TSB has been very beneficial to the aerospace sector. For example, TISICS helped British
companies to access major potential customers either as partners or because companies had experience of
working in TSB projects such as the Integrated Wing Project. This led directly to light weight Landing Gear
concepts, which UKTI was able to promote to a Japanese customer. Similarly, following a TSB feasibility
study for space, TISICS was able to engage with ESA in Holland and to make contact with Astrium France.
Government support for Space is bringing a lot more opportunities for TISICS generally to engage with the
European space industry. A TSB feasibility study has also enabled TISICS to work with Alstom in the UK
and Switzerland to develop a new higher efficiency turbine blade for power generation.
26. The composites “Grand challenge” competition demonstrated that a fragmented industry can be brought
together to work on new manufacturing methods. The Grand Challenge fostered strong relationships across the
groups of businesses large and small, who by working together have proven importance of open innovation in
a focussed and coordinated approach.
27. TSB funding is extremely useful to SMEs; companies can bid for large or small projects with a reasonable
expectation of winning. This contrasts with bidding for EU framework 7 funding, which is often too complex,
expensive and slow.
28. In the space sector, the government’s decision to fund a national space technology programme and a
Satellite Applications CATAPULT Centre, and to participate in the relevant ESA programmes.
(5) What impact will the Government’s innovation, research and growth strategies have on bridging the
valley of death?
29. The Valley of Death problem is difficult to address. TSB funding should only aim to get technologies to
Technology Readiness Level (TRL) 6. Companies should then invest to take technology to higher TRL levels
and on to full commercialisation. However, under the current austerity conditions companies are finding it
difficult to finance such development. The Government thus needs to work with banks and venture capitalists
to help provide financial packages that can help both SMEs and large companies to take technology beyond
TRL 6 and through to commercialisation.
30. In the aerospace sector, the UK Government has the “Repayable Launch Investment” (RPI) system which
typically provides up to a third of the launch costs for a new project, repaid from sales and subject to a long
term levy. This has facilitated the commercialisation of extremely large programmes such as Airbus wing and
Rolls-Royce engines. RPI has generated a healthy return to the UK taxpayer. RPI has tended to benefit mainly
the larger aerospace companies. RPI rules make it difficult for smaller equipment companies to qualify for
assistance. The future of RPI in its present form may also be affected by the WTO, which has challenged such
systems as a breach of its subsidy code.
31. In the space sector, the Government’s long standing participation in the technology and applications
programmes of the European Space Agency have been crucial in giving Britain a successful and growing
space industry.
February 2012
Written evidence submitted by Dr Richard Worswick
Summary
1. Although attitudes towards the commercialisation of research have changed markedly over the last two
decades, and the UK’s performance in high-technology manufacturing and knowledge-intensive services has
improved, the main obstacles to successful innovation remain cultural, such as the status (and pay) of scientists
and engineers (as opposed to that of those in, for example, the financial sector) and recognition of
entrepreneurship as well as academic achievement. It is widely recognised that the UK has to do more to
encourage young people to study and pursue training in science and engineering if we are to be competitive in
world markets.
2. There are many notable successes among UK science-based companies, and measures introduced by the
previous Labour and present Coalition Government—tax credits, changes to public procurement, support to
universities and companies (eg through the Technology Strategy Board), financial investment in venture capital
funds, etc.—have undoubtedly improved the environment for the commercialisation of science and technology,
particularly in smaller companies. However, much more needs to be done to improve links between public
sector bodies (such as the NHS) and science-based companies, and to build on initiatives to encourage the
commercial application of scientific discoveries.
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3. Supporting high technology companies, though vital to our longer term prosperity, will not provide a
quick fix to the UK’s economic woes. With some notable exceptions, new technologies take time to develop
and exploit. Emphasis on short term gains is not conducive to building new businesses.
4. Understandably, new governments and new ministers love to announce new initiatives, doing away with
some schemes and bodies and creating others. In my view, changing the organisational structure around support
for science and technology serves more to confuse than to improve. Better rapidly to build on the structures
we have and provide continuity of support.
Biographical Note
1. I have spent most of my career in the management and commercialisation of science and technology and
I have worked in both the private and public sectors. When the Laboratory of the Government Chemist Agency,
of which I was chief executive, was put up for sale in the mid-1990s, I formed a company (LGC) which was
successful in its bid to buy the agency from the DTI. During the decade following privatisation, I developed
LGC into an international company providing analytical and diagnostic services and products to a wide range
of private and public sector customers and with laboratories and offices throughout Europe, in India and in the
US. I was fortunate that the decade from 1996 was an excellent time to build a new business—low inflation,
steady interest rates, plentiful investment and loan finance, an expanding UK science budget, strong government
support for innovation, etc. Obviously, the external economic environment has changed, but there are still
fantastic opportunities to build new businesses. After retiring from LGC I was appointed part-time chairman
in 2009 of Cobalt Light Systems Ltd, a company which had been formed to exploit a scientific discovery made
at the Rutherford Appleton Laboratory (STFC).
2. This submission is essentially a case study of Cobalt Light Systems which may have relevance to the
House of Commons Select Committee on Science and Technology’s consideration of how to improve the
commercialisation of government-funded research.
The Story of Cobalt Light Systems Ltd
Scientific research and spotting an opportunity
3. In the late 1990s Dr Pavel Matousek was conducting research using the Central Laser Facilities at the
Rutherford Appleton Laboratory (RAL) into the interaction of powerful lasers with materials. He discovered a
way of obtaining a Raman spectrum from the bulk of some materials. (Raman spectra are produced by the
inelastic scattering of light from molecules and can provide a unique “fingerprint” which identifies the material).
Previous to his work, Raman spectra could generally only be obtained from the surface layers of materials, but
Dr Matousek developed ways of obtaining spectra from beneath the surface of some materials. Although the
work began using very powerful laser facilities, it became apparent that the same techniques (in particular
“Spatially Offset Raman Spectroscopy”—SORS) could be used with less powerful lasers.
4. Fortunately, the Science and Facilities Research Council (STFC) had set up a unit, now STFC Innovations
Ltd, to advise on the exploitation of intellectual property arising from work at the research council. The unit
advised on patent applications (8 applications have been filed) and provided some funding to investigate
potential applications of the technique.
5. Three applications were identified:
— Biomedical: cancer and bone disease diagnosis.
— Pharmaceutical: process control.
— Security: screening of opaque bottles (eg for drugs or liquid explosives).
6. From around 2004 small amounts of “proof of concept” funding (totalling around £25K) were provided
by STFC for different applications of the novel technology and this led to a patent application for SORS. In
2005 NESTA and Rainbow Seed Fund (who were to become investors) agreed to provide some more “proof
of concept” funding (around £50K) and in 2006 a further £100k was provided by STFC to hire a development
scientist and to fund patent applications.
Forming the company and raising capital
7. The task of developing a business plan and raising initial capital for the putative company (then called
LiteThru) fell to the staff of STFC Innovations Ltd led by Dr Tim Bestwick, who had joined in 2003, having
previously been involved in high technology and start-up companies. Approximately £700K was raised from
the initial shareholders—Oxford Technology Enterprise Capital Fund (independently managed, but two thirds
funded by Capital for Enterprise (BIS)), Rainbow Seed Fund (a government-funded enterprise), NESTA and
some private individuals. STFC’s intellectual property was made over to the company in exchange for a
shareholding, and the company moved from temporary accommodation in RAL to a recently completed
building for start-up companies adjacent to RAL on the Harwell site. Association with STFC was particularly
important at the outset in establishing the company’s credibility.
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8. Darren Andrews, who had been STFC’s IP officer, transferred to the new company and a partner form
Oxford Technology Management, David Denny, devoted much of his time to the company. Subsequently an
experienced operational director and an applications scientist were recruited. I was appointed chairman in 2009
and a few months later Dr Paul Loeffen was appointed CEO. (Paul had had experience of start-up companies
having led Oxford Diffraction Ltd, previously part of Oxford Instruments.)
9. The initial focus was on developing an instrument for pharmaceutical quality control. (The instrument can
analyse the content of tablets or capsules inside blister packs at the rate of one per second.) The first sale of
an instrument was made in December 2010. The company also sold several customised systems for research
and security applications and was successful in an application for a grant of £100K from SEEDA to develop
a hand-held probe for the system.
10. Following on from these early sales, we applied to HSBC for a £400K loan under the enterprise loan
guarantee scheme to fund working capital. Although 75% of the loan was guaranteed by the government,
HSBC insisted that three directors provide warranties for the remaining 25%. It seemed extraordinary that the
company was having to pay premium interest rates when the bank had covered its risks completely. Moreover,
HSBC required that the loan should be released in two tranches. The first tranche of £200K was released as
agreed but the second of £200K, which was to have been released on achieving agreed milestones, was initially
refused. Additional hurdles had to be jumped before the bank’s agreement was honoured.
Products and markets
11. From the outset several applications were foreseen for the novel Raman spectroscopy techniques.
However, early in the company’s development the decision was made to focus initially on the market for
pharmaceutical quality assurance. Feedback from potential users had been positive and the pharmaceutical
industry was obviously a sophisticated customer with experience in the purchase of novel instruments.
12. Of other markets we investigated it became apparent that SORS might be a powerful technique for
identifying liquids inside plastic, glass or cardboard containers. Initial discussions with airport operators and
the security services elicited positive responses and in 2010 the Home Office (taking the lead on behalf of
several government departments in the CONTEST strategy) awarded a contract to Cobalt Light Systems to
develop a prototype liquid scanner for use specifically at airports. (A grant under the Knowledge Transfer
Partnership scheme in collaboration with Hull University to investigate chemometric aspects of Raman spectra
was of limited value, mainly because of the lack of commitment by the university.) However, the overall
development programme has been remarkably successful and a scanner (Insight100) based on the prototype
developed under the government contract was approved by the European Civil Aviation Conference (ECAC)
(the body which oversees international agreements on airport safety and security) in December 2011. ECAC
approval opens the door to significant markets for Insight100 if the regulations relating to taking liquids on
board aircraft are changed, as expected, in 2013. In September 2011 we were informed that an application for
a grant from TSB for £181K (45% of the costs of developing a prototype model of the liquid scanner more
suitable for large scale production) had been successful. We have been disappointed by the administrative
delays within TSB. Formal documentation (required before work can begin) has taken over four months to
emerge from TSB’s bureaucracy, which has been deeply frustrating.
13. Using the hand-held probe developed with support from SEEDA, another product has recently been
launched. RapID is an instrument which can check the analytical content of bulk chemicals in plastic or paper
sacks which are delivered to pharmaceutical works. (Analysing material through outer containers avoids the
current procedure of cutting bags open and taking samples for analysis in a laboratory.) We have already sold
one RapID system and we believe there is a substantial potential market for this product.
14. The position today is that the Cobalt Light Systems has 16 employees and has products for sale in two
markets—pharmaceutical quality assurance and liquid security inspection. A customised system has been
supplied for medical research but it will be some time before the results of such research translate into a
significant new market opportunity. The company is currently raising further funds from investors in order to
support rapid expansion.
Ingredients for success
15. It is too early to trumpet Cobalt Light Systems’s success; although the technical risks are much reduced,
there are still significant uncertainties relating to market uptake, timing and size of the opportunity. However,
the company would not have reached its current position without some key ingredients:
— The inventor scientist was willing to contribute to the new company but to entrust the
exploitation of his ideas to others.
— STFC’s support has been exemplary. STFC Innovations Ltd, established by the research council,
is a small but highly professional and experienced unit. Their understanding (and initial funding)
of patents provided vital protection for the company’s IP, and the incubator building unit
adjacent to the Rutherford Appleton Laboratory has provided excellent facilities for an early-
stage company. The proximity to national facilities has given Cobalt Light Systems credibility
in building relations with potential customers.
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— The investors have been knowledgeable and supportive.
— The early appointment of both the operations director and CEO were crucial. Both joined with
experience that was considerably more than would be usual in a start-up company and were
willing to work for modest salaries (while receiving share options which could provide rewards
in the longer term).
— R&D tax credits provided a vital source of funds for work essential to ensure products were
sufficiently developed to attract customer funding.
— A grant from SEEDA contributed to an important technical development. A contract from the
Home Office enabled the development of a prototype instrument.
— The relationship with our bank has been good. However, obtaining loan finance was not
straightforward. Despite government guarantees under the Enterprise Finance Guarantee (EFG)
scheme (the company met the ELG eligibility criteria), additional guarantees were required
which reduced the attractiveness of the scheme.
16. There are some parallels with my experience at LGC, where new services were continuously being
developed based on emerging technologies. A constant frustration was that the time horizons of investors and
financial institutions were shorter than those of entrepreneurs trying to build new businesses. I was often struck
by the fact that government departments in Germany and Japan, for example, were prepared to envisage much
longer timescales in their relations with industry. The growth of LGC’s German operations was supported
strongly by regional governments which provided significant capital grants, for example in relation to the
company’s investment there. Government support to Cobalt Light Systems has been generous (and essential)
but ending regional support and centralising funding through the Technology Strategy Board, while probably
a sensible move, removed continuity. Small companies find it difficult to steer their way through constantly
changing government initiatives.
Conclusions
17. The science on which Cobalt Light Systems’s products are based stems from research carried out by
STFC. The research council played a pivotal role in helping spin this technology out and forming a company
to exploit it. Units such as STFC Innovations Ltd play an essential part in bridging the gap between government
research and commercial enterprises.
18. Whether directly or indirectly, Cobalt Light Systems has received significant financial support from the
government. Without such support, the company would not have got off the ground. In general, government
initiatives have been well targeted and well run, and the independent management of investment funds has led
to a more knowledgeable and professional approach than would have been likely had the funds been managed
by central government. Our lead investor is an Enterprise Capital Fund, where the tax regime enhances returns
on highly risky technology investments. Early-stage funding of technology companies needs investors who are
able to understand technology and are cognisant of the risks. R&D tax credits have been a particularly useful
source of funds with minimal bureaucracy. Cobalt Light Systems’s experience of important TSB support has
been soured by administrative inefficiencies.
19. Incentives to individual investors through the Enterprise Investment Scheme are very attractive. Business
angels get a very good deal. However, it is regrettable that those employed by a company and who wish to
invest in “their” company cannot take advantage of the EIS scheme.
20. While some technology businesses, particularly software businesses, can grow very rapidly, companies
set up to exploit advances in chemical or physical sciences often take a long time to get going. Funding
development programmes over an extended period presents a challenge. The UK’s preoccupation with quick
wins is not conducive to building a business over the longer term.
21. Attitudes in the UK towards the commercialisation of research in universities and government
laboratories have changed substantially over recent years. Fostering and accelerating this cultural change
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requires consistent leadership, sustained funding of the science base, and continuing encouragement of
entrepreneurship.
February 2012
Written evidence submitted by David Connell
INNOVATION MYTHS AND LEAD CUSTOMERS: GAME CHANGING POLICIES TO IMPROVE THE
COMMERCIALISATION OF RESEARCH
1. Background
1.1 This submission, and the specific, costed policy proposals it contains, are based on:
— My 25 years experience in the technology and venture capital sectors, including as cofounder
and for many year Chief Executive of TTP Ventures, a Cambridge based VC fund backed by
Siemens, Boeing and financial institutions and specialising in early stage science and technology
based companies.
— An extensive series of research programmes on the exploitation of academic research, the
characteristics and funding models of Cambridge’s most successful S&T companies and
overseas innovation policy models. Much of this is in collaboration with colleagues at the
Centre for Business Research/UK Innovation Policy Research Centre at the University of
Cambridge.
— Lessons learned from leading a six year campaign to get US style procurement based innovation
policies adopted in the UK and EU and advising the UK Government on the introduction of
the resulting Small Business Research Initiative.
Supporting publications are supplied with this submission and referenced in the text.
2. Innovation Myths
2.1 There have been for many years’ three implicit assumptions underpinning the approach to UK innovation
policy of successive UK governments:
(i) That academic research is the key source of innovation for new businesses.
(ii) That venture capital is the key source of funding for new businesses.
(iii) That multi-partner collaborative R&D programmes, involving industry and universities
represent the best government mechanism for funding innovative R&D in companies.
2.2 As the UK’s most successful hi-tech cluster, Cambridge is an excellent “laboratory” in which to examine
UK innovation policy. However, detailed research on the start-up strategies of its most successful companies
suggests that all of these assumptions are in fact myths.37
Myth 1: Role of Academic Research
2.3 Over the last 30 years there have been few really successful new Cambridge companies built on
university research in the physical sciences and engineering. All of Cambridge’s four largest S&T companies:
Arm, Domino Printing Sciences, CSR plc (Cambridge Silicon Radio) and Autonomy (the “big four”) are spin
outs from existing firms and based on technology developed, and start-up teams built, within their parent
companies. And whilst the parent companies were in each case founded by entrepreneurial Cambridge
University alumni in their 20s, it was the challenge of solving customer problems in a business environment
which in every case provided the stimulus for innovation. Only in the case of Autonomy, was the parent,
Neurodynamics, established to capitalise on founder, Mike Lynch’s research at Cambridge University.
2.4 The most successful Cambridge University spin outs of the last fifteen years—Abcam and Solexa, are
both essentially “Research Tools” companies whose products and services were developed to meet the needs
of other scientists. Though both companies are still much smaller than the “big four”, this category of company
represents the “low hanging fruit” in terms of commercialising the science base and more could be done to
capitalise on this opportunity.38
2.5 Besides being intuitively attractive, the myth surrounding university spin-outs has been perpetuated as a
result of premature celebration by government and media of high profile, VC-backed spin-outs when they are
still at a pre-revenue stage, together with a tendency to incorrectly ascribe university research origins to
successful Cambridge companies such as Arm and CSR.
37 See Connell, D and Probert, J (2010), Exploding the Myths of UK Innovation Policy: How ‘Soft Companies’ and R&D Contracts
for Customers Drive the Growth of the Hi-Tech Economy, Research Commissioned on Behalf of the East of England Science
and Industry Council by the East of England Development Agency. CBR, University of Cambridge.
38 This argument is developed further in “Scientists are Customers too; How the SBRI can Help Research Councils Drive Economic
Growth”, David Connell, NESTA, March 2010.
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2.6 There is no doubt that policies could be put in place to improve the commercialisation of academic
science. However, the reality is that at Cambridge, just as at MIT, it is entrepreneurial university alumni rather
than research results which play the key role in building successful new S&T companies.39 This distinction
is important as it has profound implications for policy.
2.7 In fact the most successful source of new product companies in Cambridge is the sub-cluster of
technology “consultancies”, whose business entails developing technology and products for other companies,
mainly overseas based multinationals, on a fee basis. Besides employing some 1,200 people directly, over the
last 40 years the four largest firms have created more jobs in “sponsored”40 product spin outs than the entire
university.41 These are based on intellectual property developed within the parent, usually as a bi-product of
funded projects for external clients. Surprisingly, the consultancies also make very little use of research results
developed by university academics in their core businesses.
2.8 The role of demanding customer contracts as a stimulus to innovation is also evident in the US. For
example, though it was venture capital backed, Intel’s first single chip processor, and the basis of its subsequent
success, was a side project developed under a paid contract for a Japanese calculator firm. The Federal
Government has played a similar role in relation to many other technologies.
2.9 The role of academic research in creating successful new life sciences companies is less clear and there
are prima facie reasons to believe that academic science can play a greater role in this sector than in
engineering, physics and materials based start-ups. Cambridge Antibody Technology, the UK’s most successful
biotech start up to date, was based on research by Sir Greg Winter at the MRC Laboratory of Molecular
Biology. CAT was acquired by Astra-Zeneca in 2006.
2.10 Nevertheless, no Cambridge biotech company has ever employed more than a few hundred people.
Indeed a league table published in 2007 of the 100 largest global biotech companies by revenue includes only
three UK firms.42 The largest, Acambis, ranked 46 with 285 employees and revenues of $57 million, was
acquires by Sanofi-Aventis in 2008. Given the emphasis placed on the biotechnology industry as a jobs
generator by recent governments, this is deeply disquieting. Though the Government’s Strategy for UK Life
Sciences, announced in November 2011, contains some important new initiatives, the detail of these is still
unclear and the overwhelming focus continues to be on strengthening research in universities and the NHS.
Myth 2: Role of Venture Capital
2.11 The second assumption, that venture capital is the key source of finance is also a myth. The dominant
source of early stage funding for the most successful firms in Cambridge, measured in terms of sustained
profitability and number of employees, is customer funding, especially through R&D contracts.43 Venture
capital tends to come in later or not at all. This “Soft Start Up” strategy is common in technology companies
everywhere. It contrasts with the better known “Hard Start-Up” strategy in which the development of standard
products starts immediately, financed by venture capital, and revenues and profitability can be delayed for
many years. Other examples of soft start-ups include Research in Motion (RIM, maker of the Blackberry),
Microsoft, Logica and Wolfson Microelectronics, Scotland’s most successful new technology firm. Vodafone
was a spin out from Racal, a classic soft start-up.
2.12 The soft start up model has many benefits, including enabling new entrepreneurs to learn their
management skills on the job, before moving to a higher growth model, and gain a better understanding of
their technology and potential markets before committing to developing a proprietary product. This reduces
business risk.
2.13 Venture capital is predominantly about building new product lines for other companies to acquire. In
the UK the acquirer will usually be a corporation based overseas, leading to dispersal of the entrepreneurial
team and truncation of further employment growth in the UK. Soft start-up strategies make it easier for the
entrepreneurial team to remain in control of a company’s destiny and pursue a strategy with much greater
economic impact over the long term.
2.14 This does not mean that the UK does not need a strong venture capital sector; for businesses needing
to grow fast against competitors it is essential. However, venture capital cannot alone do the job of investing
in high risk, long lead time technologies that policy makers currently expect of it. The problem is underlined
by the rates of financial return, currently averaging around zero% per annum over the life of UK VC funds.
Average returns in science and technology orientated UK VC funds have for 20 years been too far below that
39 Two thirds of entrepreneurial MIT alumni attribute the ideas for their new enterprises to industry work experience and only
10% to research. Entrepreneurial Impact: The Role of MIT, Edward B Roberts and Charles Eesley, MIT Sloan School of
Management; publ. Kauffman Foundation.
40 The term “sponsored” implies that the parent retained a shareholding in the spin out and actively supported its formation. Many
other jobs have been created in start-ups created by ex employees without the parent firm’s involvement.
41 The largest firms are TTP Group plc (The Technology Partnership), Cambridge Consultants, PA Technology and Sagentia plc;
see Myths…, op cit.
42 Top 100 Biotechnology Companies, MedAdNews, June 2007.
43 Myths…, op cit.
Ev 116 Science and Technology Committee: Evidence
of other asset classes to make them attractive to pension funds and other investors in private equity funds.44
There is no reason to believe that co-investment in VC funds by government, the current policy, will change
this position significantly. To build a viable UK venture capital industry, complementary policies are needed
that will help create more VC-ready firms and make them more likely to succeed. These are discussed below.
Myth 3: Role of Collaborative R&D
2.15 The third implicit assumption, that funding multi-partner R&D collaborations involving industry and
universities is the best way for government to fund innovative R&D projects in companies is also flawed,
particularly as regards SMEs. This is the overwhelmingly dominant approach to R&D funding used by both
the Technology Strategy Board and European Commission.
2.16 Start-ups and SMEs do not find the collaborative grant model attractive45. It does not support the
single-minded championship needed to build new businesses and projects tend to be too far from market for
small firms to participate. As they usually require matched funding, collaborative projects are inappropriate for
the majority of start ups and SMEs which do not have venture capital or significant cash reserves. Firms need
to be able to choose their partners, sub contractors and consultants freely, and to change them if things do not
work out. A “collaboration” that ticks the boxes in the application form just to get the money can end up being
a distraction.
2.17 Fully funded R&D contracts with lead customers, the commercial mechanism which drives the soft
start-up model, are much more appropriate. The SBRI scheme, based on the successful US Small Business
Innovation Research (SBIR) programme, mirrors the private sector process that has helped make the Cambridge
Cluster successful, as it funds the development of technologies and products the public sector itself needs,
either as customer or specifier.46 It also enables companies to keep the IP generated so they can go on to build
product businesses. Collaboration with a university is in both cases at the option of the SME, not an artificial
requirement which must be met just to get funding.
3. Challenges of Commercialising Academic R&D
3.1 In recent years, a good deal of emphasis has been placed on trying to modify the university model to
make it easier to spin out companies. Alongside the strengthening of university technology transfer offices,
academics have been strongly encouraged to work more closely with companies in the research they undertake.
However, EPSRC funded research carried out by the author, Dr Andrea Mina and Professor Alan Hughes47
has shown that there are major challenges in trying to accelerate commercialisation in a conventional university
research settings:
(i) Most externally funded research projects in universities are undertaken by teams staffed by PhD
students and post-docs who tend to move on quickly. As a result it is very hard to retain
competence in depth or build the core technology team required to create a spin out business.
This is exacerbated by the dominance of short term grants and employment contracts.
(ii) The time that must be devoted to writing publications, teaching, supervisions and giving papers
at academic conferences means that R&D during a pre-venture stage can only be advanced in
fits and starts.
(iii) IP is often not managed throughout a project. Past leakages of various kinds and competitor
positions may only become apparent when commercialisation is being considered. The problem
is particularly acute for the long lead time technologies which typify much academic research
as there may be an accumulation of IP over successive projects involving many different
individuals and corporate partners.
(iv) The pressure on academics to collaborate with industry, coupled with changes in personnel,
means that exploitation rights are not always properly thought through or managed over the
long term. Poorly negotiated agreements with industrial sponsors can restrict the potential for
later spin-offs or licensing deals.
(v) It is very difficult to accelerate the pace of R&D prior to the stage when a technology becomes
ripe for exploitation. As a result any competitive advantage can be eroded at this critical stage.
(vi) Universities are not normally equipped with the expertise or resources to take technologies to
the demonstrator stage required to attract investment or customer interest.
3.2 It is difficult to see how these issues could be addressed within a conventional UK university research
setting.
44 See British Venture Capital Association and European Venture Capital Association investor return statistics. There is a range of
returns around the average, but asset allocations by pension funds and other institutional investors are made largely on the basis
of average returns.
45 Myths, op cit.
46 Secrets, op cit.
47 The Role of TICs in Rejuvenating British Industry; Submission to House of Commons Committee on Science and Technology
Enquiry on Technology Innovation Centres Submission to House of Lords Enquiry on Technology Innovation Centres, December
2010 David Connell, Professor Alan Hughes and Dr Andrea Mina, Centre for Business Research, Judge Business School,
University of Cambridge.
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3.3 The challenge for innovation policy is compounded in the UK because in many areas of technology the
natural industry collaborators are foreign companies with little inclination to commercialise in the UK. Start-
ups must therefore play a disproportionate role if there is to be significant economic benefit to the UK.
4. The Commercialisation Process and Industry Differences
4.1 The process by which academic research is converted into businesses and jobs is unpredictable and non-
linear, but it can usefully be divided into the three phases shown below.
 
RESEARCH
UNIVERSITIES; CORPORATE RESEARCH
EXPLORATORY  DEVELOPMENT
TESTING DIFFERENT APPLICATIONS
MANUFACTUING SCALE UP AND YIELD
IMPROVEMENT
SCALABLE COMMERCIAL
DEVELOPMENT 
HARD COMPANY MODEL
REQUIRES COMMERCIAL ENVIRONMENT AND DISCIPLINES
BACKABLE BY VENTURE CAPITAL ALONE
POLICY GAP
4.2 The initial, Research Phase is typically carried out in universities, and sometimes in government funded
laboratories and the laboratories of some large corporations. It typically concludes with the discovery of a new
material, phenomenon, device, process, algorithm or methodology and a laboratory proof of principle
demonstration.
4.3 The final Commercial Development Phase encompasses the work of completing the development of
commercial products and bringing them to market. This is the domain of companies—particularly start-ups,
together with new ventures within existing companies.
4.4 New companies are usually in competition with others addressing the same customer need, and the size
and homogeneity of the US market means that companies based there can grow revenues much more quickly
than UK firms. This enables them to spend more on R&D and marketing as markets mature, and to make
acquisitions earlier to consolidate their position. The time taken to make the first sale is a critical factor in how
successful a firm is ultimately, as this makes it easier to make every subsequent sale, as well as to attract
investment. Policies to encourage lead customers therefore have an important role to play in reducing the width
of the “valley of death”.
4.5 In between the Research and Commercial Development phases is the process of Exploratory
Development, during which potential applications of the research are conceived, demonstrated, turned into
prototype products and trialled with lead customers.
4.6 In the case of software and some information technology hardware this process can be quite short as
there is minimal technical risk. Facebook, Google and Cisco, formed by undergraduates, doctoral students and
university computer services managers respectively, illustrate this. In each case successful, large scale product
demonstrators, involving real, university users, were produced in just a few months. The venture capital backing
that enabled the businesses to be scaled rapidly followed later.
4.7 However, in the case of the physical and biological sciences, the exploratory development phase can
take years or decades. The most important opportunities are generally based on new technology “platforms”,
with multiple commercial applications. To define and evaluate them involves working with a range of potential
users, in an exploratory manner, progressively focusing on those that look most promising. Blind alleys are
common. Lead customers, prepared to pay for initial feasibility studies and the development and trialling of
new technologies and products again play a crucial role.
4.8 Work to scale up production, improve quality and incorporate the complementary technologies needed
to create a commercially viable product or process often takes place in parallel. Dependence on advances in
other technologies means that progress takes place in fits and starts. This can take many years and be spread
across continents. Only in very few cases, mainly pharmaceuticals, is the “inventor” able to secure sufficiently
strong patent protection to ensure significant royalties at the end of this process. In most cases an accumulation
of IP and know-how takes place over many years as the process progresses, with many parties involved. In the
case of liquid crystal displays, in which UK academics played an important early role, the lead in developing
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the technology passed to RCA Corporation in the US and later to Sharp in Japan, before LCDs appeared in
consumer products.48
4.9 Large corporations are increasingly hungry for new business opportunities and operate open innovation
strategies with a global reach. Intermediate research laboratories like the Fraunhofer Institutes in Germany,
ITRI in Taiwan and SRI in the US are constantly searching for academic research findings to help build their
own internal, more mission orientated, long term R&D programmes.49 This process makes it inevitable that
research undertaken in UK universities will mainly be exploited by overseas organisations. And the longer the
lead time involved the greater the chances that this will be the case.
4.10 To increase the probability of the UK drawing an adequate return from its investment in academic
research, where it has an outstanding record, it must be more effective at points in the innovation process
which are closer to market.
5. The Policy Challenge and Lessons from Other Countries
5.1 The critical Exploratory Development Phase must be undertaken, not in a university, but in a mission
orientated R&D environment, working to commercial standards and with strong management of IP and
commercialisation rights. The challenge for policy makers is that the risks and timescales associated with this
phase are too great for venture capital backing.
5.2 Two successful policy responses to this dilemma are practised in other countries.
Procurement Based Innovation Policies
5.3 The first is for public sector agencies to fund the development of demonstrators as lead customers, based
on their own requirements for innovative technologies as users or specifiers. This enables start-ups and other
innovative companies to operate more easily during the exploratory development phase.
5.4 US support for R&D in companies is largely based on this model, using pre-commercial procurement
contracts to provide significant funding. Contracts cover 100% of project costs and enable the contractor to
retain any intellectual property. This enables start-ups and other SMEs to operate more easily during the
exploratory development phase. Key programmes are the Small Business Innovation Research Programme
($2.5 billion per annum) and DARPA ($3 billion). The total is considerably more than this, with probably
$5–8m going to SMEs directly each year.50
5.5 SBIR projects are phased to manage risk and concentrate funding on the best projects. DARPA projects
are also strongly milestone driven. This, and the fact that projects are funded by informed customers, helps
reduce the risks associated with trying to “back winners”.
5.6 The UK Small Business Research Initiative mirrors closely the US SBIR programme and has proved
highly successful since it was launched in 2009. However, it is still only worth around £20m per annum
and it has proved difficult for the Technology Strategy Board to persuade spending departments to increase
funding levels.
Intermediate Research Laboratories
5.7 The second approach is to construct R&D institutions specifically designed to conduct the kind of
mission orientated work needed during the exploratory development phase. These are typically not-for-profit
organisations funded through a mixture of public and private sector R&D contracts, sometimes with some core
government funding. Examples include the 60 German Fraunhofer Institutes, ITRI in Taiwan and a diverse
range of US organisations, including Battelle and SRI International, originally the Stanford Research
Institute.51 SRI’s most recent spin-out is Siri, which sells the voice control software used in the Apple
iPhone4S. Like SRI’s other more successful spin outs, Nuance and Intuitive Surgical, its technology was
developed on the back of a large DARPA project.
5.8 To be successful Intermediate Research Laboratories need contracts from informed lead customers, just
as early stage private sector R&D companies do.
5.9 The Cambridge technology consultancies operate in a very similar way to the Fraunhofer Institutes on
which the Technology Strategy Board’s new “Catapult Centres” are based, but with two differences. First, the
Cambridge consultancies have had little or no government funding or development contracts and have therefore
operated closer to market; and second, they have been much more successful in generating jobs in product
spin-out companies. Government innovation policy has much to learn from these businesses.
48 Sharpe, S, A Cosh and D Connell, (2009), Funding Breakthrough Technology: Final Report to the CIKC; CBR, University of
Cambridge, Cambridge.
49 Mina, A, Connell, D and Hughes, A (2009), Models of Technology Development in Intermediate Research Organisations, CBR
Working Paper No. 396, Centre for Business Research, University of Cambridge: Cambridge.
50 Further federal R&D funding flows to small US companies as subcontractors to larger firms. “Secrets” of the World’s Largest
Seed Capital Fund: How the United States Government Uses its Small Business Innovation Research (SBIR) Programme and
Procurement Budgets to Support Small Technology Firms; David Connell, Centre for Business Research, University of
Cambridge, July 2006.
51 Models of Technology Development in Intermediate Research Organisations, op cit.
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6. Policy Proposals
Lead Customer Programmes
6.1 The most important thing Government can do to improve the effectiveness with which the science base
is exploited is to increase the number and value of public and private sector lead customer contracts available
to innovative companies. This includes early stage technical feasibility and design studies, as well as
demonstrator and prototype development, and β site testing by users. This could be achieved by:
(i) Increasing the UK SBRI programme in steps from around £20 million per annum currently to
£250 million per annum. This is a sum broadly equivalent to the US SBIR programme given
the relative sizes of the two economies. All major government departments and agencies should
be asked to participate, including the Research Councils through a Research Tools
programme.52 The Technology Strategy Board should be funded to provide half of the funding
for each competition, with Departments funding the remainder and owning the topics.
(ii) Adding an equivalent sized budget for larger scale demonstration projects (above the £1 million
SBIR Phase 2 ceiling).
(iii) Establishing a similar programme to encourage more private sector organisations to act as lead
customers for new technologies developed by SMEs. This could be achieved within EU State
Aid Regulations by adapting the TSB’s multi-partner collaborative R&D grant mechanism to
fund bilateral partnerships between SME suppliers and large company customers. SME support
levels (ie the percentage of total project costs funded) should be at EC norms rather than the
less generous levels normal for TSB programmes. Further details of this proposal are available
on request. After piloting this programme, the aim should be to increase funding projects to
£100 million a year.
(iv) Encouraging the European Council and European Commission to include a significant “pre-
commercial procurement”53 element within Horizon 2020, the successor to the FP7 R&D
programme which is currently being developed by the Commission. To match the scale of the
US SBIR, the author has called for the EC to commit €1 billion per annum to match fund
national SBIR programmes on a 50:50 basis.54
6.2 Lead customer programmes would help move policy from a technology push to a more demand pull
model. It would provide funding for the exploratory development stage and, by accelerating first customer
purchases, reduce the width of the “valley of death”. By helping firms adopt a “softer” start up model it would
enable firms to remain independent for longer, thereby increasing their economic impact in the UK. It would
also improve the flow of “VC ready” firms for those that need venture capital investment, thereby increasing
average financial returns and attracting more investors into UK VC funds.
Catapult Centres
6.3 The creation of Catapult Centres is an important and necessary initiative for technologies with very long
lead times. This programme should draw lessons from the Cambridge technology consultancies, whose
experience in other areas of technology offers a valuable role model. The first Centre—in High Value
Manufacturing—is really a partnership spread over seven existing locations, most of which are university
based. To realise the potential of the Catapult programme, it is important that Centres are based on a single
site and managed outside the university system. Capital and annual operating budgets are still unclear and need
to be studied carefully to ensure the success of the programme is not compromised by underfunding.
6.4 Public sector R&D organisations easily become sleepy, so the aim should be for each to be privatised
after 10–15 years, so that new Centres focused on emerging areas of technology can be created.
Universities
6.5 Excellent research universities are a vital part of any innovation cluster, but the most important way of
exploiting that research is through their alumni, not the research results per se. The excessive pressure on
university researchers to collaborate with industry and spin out new ventures has created unrealistic
expectations and may even, in some cases, have been counter-productive. The focus must now switch to
complementary policies to create demand pull through lead customers, private sector companies and
intermediate R&D institutes. For those academics that do have technologies they believe could form the basis
of an immediate spin out, a competitive grant scheme should be put in place to enable them to employ
technologists from industry for one to two years to develop the proposition during a pre-venture stage.55
52 Proposals for a Research Tools SBRI are discussed in: Scientists are Customers Too, op cit.
53 Pre Commercial Procurement is the European Commission term for this kind of government activity.
54 Speech to member state economy ministers at the European Competiveness Council Meeting, Budapest, 13 April 2011.
55 Eight-19, a photovoltaic spin out from the Cambridge Cavendish Laboratory, was made possible by a scheme of this kind,
funded by the Carbon Trust. It emanates from one of a number of technical projects being tracked over a six year period by
CBR under the EPSRC funded Cambridge IKC.
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How these Policies could be funded
6.6 Given the pressure on Government finances, the funding for these programmes could come partly from
improving the cost effectiveness of the UK R&D tax credit programme.
6.7 Since its introduction in 2000 this has increased government funding for R&D in firms generally by
around 600%, dwarfing other policies.56 Three quarters of this money goes to large companies. This increase
in R&D funding has been strongly welcomed by the business community, but there are many question marks
over whether it represents the best way of using the money. R&D tax credits work by returning a percentage
of a firm’s total expenditure on R&D many months later, thereby increasing its profitability. There is no reason
to believe that most firms will do anything other than spread the extra cash received across their full range of
expense items, from marketing to dividends. R&D tax credits are therefore best seen as providing a subsidy to
firms that do R&D rather than an incentive for them to do more.
6.8 Although there is no requirement for firms to increase their R&D, it seems likely that the scheme has
encouraged R&D to be reported which firms did not previously treat as such, aided by eligibility extensions
by HMRC. For example, the 2009 R&D Scoreboard published by BIS indicated that three of the top 25
companies by R&D expenditure were UK banks (Royal Bank of Scotland, HSBC and Barclays, up 25%, 30%
and 13% on the year respectively) with a total recorded R&D expenditure of £1.4 billion. HSBC and RBS
were ranked 6th and 7th respectively, just above Rolls Royce and BAe Systems. A forth company, Tesco,
reported R&D expenditure of £192 million, an increase of 50% on the previous year. In 2005 none of these
four companies reported sufficient R&D (ie more than £1 million) to be included in the top 750 UK R&
D spenders.
6.9 For most established firms the majority of their R&D expenditure goes on incremental product and
process developments with relatively little risk. As such it represents part of the cost of staying in business.
Policies that focused government support for R&D on higher risk projects, particularly in firms spending a
high proportion of turnover on R&D, would appear to offer greater additionality and better value for money.
Conflicts Declaration
I am a Director of TTP Capital Partners Ltd and a minor shareholder in a number of medium and small
science and technology companies including TTP Group plc, TAP Biosystems, Knowledge Solutions (UK)
Ltd, ZBD Displays Ltd, TeraView Ltd and Argenta Therapeutics.
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Written evidence submitted by The University of Manchester
Background on the University
The University of Manchester, a member of the Russell Group, is the largest single site university in the
UK. It has 22 academic schools and hundreds of specialist research groups undertaking pioneering multi-
disciplinary teaching and research of worldwide significance.
According to the results of the 2008 Research Assessment Exercise, the University is one of the country’s
major research universities, rated third in the UK in terms of “research power”. The University had an annual
income of £808 million in 2010–11.
The University has an excellent track record of successful and beneficial relationships with business and
industry. Partnerships with and work on behalf of business and industry are central to the University’s mission.
The encouragement of enterprise is a critical part of the University’s culture. Commercialisation of our
intellectual property is consequently a fundamental part of our activity. This activity is managed by The
University of Manchester I3 Ltd (UMI3)—the University’s wholly owned Innovation Group.
The University has a substantial track record of exploiting novel and innovative research findings through
commercialisation of intellectual property. It currently has a portfolio of some 50 spin-out companies, and in
the last four years has successfully licensed over 100 inventions to commercial parties. A number of UMIP
spin out companies have achieved success securing an exit and capital return to UoM. Examples include:
Nanoco, a company listed on AIM with a current market value of c £125 million; NeuTech Pharma a spin out
sold to Novartis for over £300 million in 2006; and the molecular fungal diagnostic company Myconosticia
sold to Cambridge-based Lab21 in 2011. A number of our ventures have also attracted significant venture
capital funding, going on to launch products and generate revenues. Examples include the software optimisation
company Transitive and healthcare technology spin-out Phagenesis.
We have set out below our responses to the specific questions which you have raised.
56 This refers to funding from generally available programmes and policies and excludes expenditure through departmental
procurements or launch aid for aerospace projects, for example.
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1. What are the difficulties of funding the commercialisation of research, and how can they be overcome?
The main difficulties are that:
— Licensing proposals are typically not of interest to business angels and venture capitalists and
so “risk and development capital” is not available for these projects. They can be overcome by
special funding schemes in association with corporates but often even they are not interested in
seeing these projects at an early stage.
— Spin-out propositions suffer from a lack of significant capital at the early stages where, generally
speaking (and as with licence projects), only technology transfer offices understand the nature
and scale of the potential and would be prepared to invest.
Data shows that UK venture investment, especially into early stage projects, does not have a
good track record of (or is not perceived to be able to) generating better returns than other
investment opportunities with shorter time horizons and arguably lower risk. It is therefore
likely that it will remain difficult to secure this funding from the market in competition with
other investment opportunities. The exception is the US style entrepreneur with deep domain
knowledge which again is a scarce resource in the UK. An increase in the scale of venture
activity would beneficially allow the kind of specialisation which would increase in turn the
depth of domain knowledge.
In the absence of a fully functional market solution, much technology transfer funding therefore
comes from quasi government funding. The question then is why the government should fund
projects the private sector shies away from and the answer lies in capitalising on significant
amounts already spent on the science base where relatively small amounts in relation to research
spend could catalyse the massive research expenditure.
The original University Challenge Fund (UCF) was a very good vehicle for early stage spin-out
funding, especially pathfinder and proof-of-principle funding, as noted by the Praxis-UNICO
submission to this Inquiry. Another substantial funding initiative of this nature, having two
significant components to it: pathfinder and then follow-on funding capability would be
welcome and do a lot to bridge the gap. However, to deal with the issue properly, the size of
each successfully awarded UCF would need to be in excess of the previous Scheme (this
University’s UCF was originally £6 million to lever some £400 million of research expenditure,
ie 1.5%).
— Use of HEIF monies for licensing and spin-out proof-of-principle has been useful, as have been
grants from the Gatsby Foundation and the Research Council’s various follow-on schemes.
HEIF is critical to this field’s success.
— The arrival of the Science or Translational Funding Awards, such as the Wellcome Seeding
Drug Discovery Programme, have been very important and filled a gap, especially because they
are significant awards (c £500K-£millions). Whilst these have mostly been in the bioscience
field, they are beginning to be available in other fields such as engineering and physical sciences
and we believe that these large scale translation schemes should be supported and increased.
— The North West Venture Capital and Loan Scheme is a part of the landscape of funding though,
due to the nature of some of its EU funding, there are output expectations (time, nature) placed
upon the managers of these funds which often do not sit well with the longer-term nature and
types/scale outcomes of research commercialisation spin-outs, which may act as artificial
barriers/brakes on the decision making about such propositions.
2. Are there specific science and engineering sectors where it is particularly difficult to commercialise
research? Are there common difficulties and common solutions across sectors?
There are particular challenges associated with many environmental technologies, in that the scale-up
engineering costs, from laboratory to pilot scale and then to initial prototypes are significant (eg. wave power,
wind power) and where business angels, seed investors find that the dilution effect on their investment, and
the time to market, along with the associated market, legislative and engineering risks deter them from entry.
In addition, drug discovery and some other medical/life science IP remains a big challenge to commercialise
because of the scale of funding required and the time from inception to market.
3. What, if any, examples are there of UK-based research having to be transferred outside the UK for
commercialisation? Why did this occur?
There are a number of well-known examples. These are listed in the Praxis-UNICO submission.
In particular, as a general observation, overseas investors and firms appear to have more substantial funds
and appetites for acquisition. This means that the UK university system, its early stage investors and the
taxpayers do much of the “heavy lifting” but that, in many cases, overseas organisations derive many of the
benefits. Greater leverage for the UK could be achieved by providing more capital to follow-on early
investments so that the chances of them surviving in the UK or being partnered with a UK firm are increased.
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A particular concern is that IP holding companies in certain jurisdictions (for example Switzerland and
Luxembourg) can benefit from lower tax rates, causing in some cases an exodus from the UK.
A general point is that the UK industry base is not well equipped to support physical sciences research,
especially in fields such as electronics, and hence it is not surprising that foreign companies are able to
capitalise on UK university research.
4. What evidence is there that Government and Technology Strategy Board initiatives to date have improved
the commercialisation of research?
Initiatives such as “Catapult” are in the early stages but the goal of stimulating innovation by bringing
together universities and industry in this way are an important part of the IP commercialisation landscape and
will do much to bridge the gap for certain types of technology developments and obviously helps by introducing
the “demand pull” dimension. The new “Feasibility Studies for Technology-Inspired Innovation” Scheme is
also very welcome and would be relevant to spin-outs from universities also.
More established schemes, such as Knowledge Transfer Partnerships and “SMART” are ones which the
University has found especially helpful and relevant to research commercialisation.
5. What impact will the Government’s innovation, research and growth strategies have on bridging the valley
of death?
We have some discomfort with the phrase “valley of death” which implies that it is only necessary to get
through this particular stage. In fact successful innovation is an interactive process in which commercialisation
plans have to be effective in all stages and sometimes simultaneously. It is particularly important for many
developments to secure the interest and commitment of potential customers even at an early stage. This not
only gives investments more credibility, it also provides the innovator with invaluable feedback on the path
to commercial products. An integrated strategy for commercialisation needs to include support for demand
side measures.
However, if we turn to financial pressure points, though details of the Fund have yet to be released, the
recent launch of a BioScience Fund will be an important stimulus to an expensive field of IP commercialisation.
The Policy statements from Ministers indicating that they are taking a variety of approaches to increase
investments for applied research—to complement the venture capital approach to invention-led
commercialisation—is the “right” way to see technology transfer since it is much broader than licensing and
spinning out companies. The impact is difficult to comment upon at this stage: this will be easier to assess
once the statements and ideas have been translated to specific actions/schemes.
6. Should the UK seek to encourage more private equity investment (including venture capital and angel
investment) into science and engineering sectors and if so, how can this be achieved?
There is a distinction between “private equity” and “venture funding” and “angel investments”. It is
confusing and not helpful, to the university technology transfer scene, to see it as one. The track record of
private equity in venture funding is variable, with 3i, as an ex public fund, closing its venture fund recently.
Universities should be encouraged to engage directly with angels and venture capital and supported in their
attempts to do so. The University has been able to address this to a fair degree by “sponsoring” a dedicated
(£32 million) seed fund (The UMIP Premier Fund) which is funded by institutional investors and managed by
a venture capital firm, MTI Partners, which brings relevant direct links to the capital markets onto the local
campus and thus allows MTI to invest the time and resource in order to gain a deep understanding of the deal-
flow and the nature of the work (as opposed to a “remote” assessment on a project-by-project basis). We
believe that the University’s Premier Fund” has proved to be a good model, but there are others too, such as
Imperial Innovations (stock market listing) and the IP Group (relationships with a number of universities). A
new and larger University Challenge Fund Scheme would enable universities to create a good foundation upon
which to build and/or develop new approaches as well as enable connection to these existing investment
vehicles.
7. What other types of investment or support should the Government develop?
There should be special, dedicated schemes and funds to assist the development of universities’ licensing
business, since most market money (and many of the previous Government Schemes) is really only likely to
be relevant for “breakthrough” technologies via spin-out companies.
Key components to success are the entrepreneurs and venture capitalists and corporate venturers who can
act as mentors, sales people, and managers/directors for the spin-outs (and licence projects). The University
has embraced the contribution of such individuals, through its Innovation Centre/Incubator complex. Much
more should be done to include this dimension into the “more formal” professional management approach to
technology transfer, eg. support for mentoring programmes, master classes, networking events, seminars,
investment pitches/dragons’ dens.
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We draw attention also to the demand side policies mentioned above, including use of public procurement
and encouraging private buyers to adopt certain types of innovation.
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Written evidence submitted by UK Deans of Science
Background
1. UK Deans of Science (UKDS) is a national body that seeks to represent the individuals, usually formally
designated as Deans, who are responsible for science in HEIs across the UK and who generally hold the
budgets for science including any research budgets. Its primary aim is to ensure the health of the science base
through the promotion of science and scientists and of scientific research and science teaching in the UK.57
2. This response has been prepared by circulating the terms of reference of the inquiry to all our members,
producing a draft response before discussing and finalising it at a meeting of the Executive Committee. The
comments are mainly restricted to the challenges of commercialising research that originates in universities,
while recognising that the vast majority of commercialisation occurs in industry.
What are the difficulties of funding the commercialisation of research, and how can they be overcome?
3. Commercialisation is driven by entrepreneurs, not by Government nor, except in a relatively few cases,
by universities. Commercialisation of university research is highly dependent on there being sufficient,
sustainable funding for high quality basic and applied research to be carried out. Within the great deal of world
class research that is carried out only a small proportion of a university’s research portfolio is likely to provide
commercial opportunity. Amongst this, the great majority of projects will be at Technology Readiness Level
(TRL) 1–3, barely at proof of concept level, when they emerge from university studies. Funding directed at
developing prototypes through to pilot systems (TRL 4–7/8) is needed to promote good ideas into commercial
ventures. This would best be supplied in the form of staged funding and/or other incentives to encourage either
UK companies to work with TRL3 material and develop this in concert with the inventors and others to
commercial prototypes, or to encourage inventors and others to develop the opportunity themselves, to form
new companies and take on potentially high risk, market opportunities if no existing company is interested.
4. There is often a propensity to try to retain the commercialisation of research within a university or to
offer relatively unattractive licensing terms for work which is only at TRL-1 or TRL-2. UK universities have
created a significant number of new companies but these tend to be fairly small and underderveloped and need
investment and the involvement of professional management to take them forward and to generate significant
revenues. This process takes time as well as money and talent, making such ventures high risk. The general
economic situation, the lack of investment funding and the increased aversion to risk by investors, all increase
the width and depth of the valley of death, so many otherwise viable propositions will either be stalled or lost
completely unless action is taken.
5. In addition to the financial risks and the challenges of finding commercial partners there is a question as
to how far a university should extend its traditional role of teaching and research to encompass commercial
activities that others are better placed to do. Thus many reports have suggested that universities and public
research bodies should regard the IP they create as supporting wider societal and economic benefit rather than
expecting commercialisation to deliver a significant income stream.58
6. In summary, actions that could be taken to support commercialisation of university research include:
— a proof-of-concept fund to bridge the gap between concept and commercialisation. Such funding
would also help de-risk projects. Consideration should be given by Government to co-invest in
such schemes alongside established investors. There should be clear recognition that this is high
risk funding. Application procedures should be simple and not require full business plans or
submission of detailed monthly accounts, etc. for such early stage development, though a
steering panel should be appointed to supervise the project;
— continuation of more progressive IP policies with “easy access” to HEI IPR as a key mechanism
to encourage early stage uptake and commercialisation of university IP;
— review and rationalisation of support networks. In 2009, one of our members, using information
published by Scottish Enterprise, found that there were more legal advisers advising biotech
startups than there were actual startups;
— universities creating further mechanisms to facilitate research commercialization;
— Governments and the devolved administrations in Northern Ireland and Wales increasing their
support for commercialisation of research, for example by funding of joint university/industry
research programmes, with the companies funding a fixed percentage of the full research and
development costs in return for the right to exploit the results of the programme;
57 www.deansofscience.ac.uk
58 See, for example, Intellectual Property and Research Benefits, Wellings 2008, The Race to the Top, Sainsbury, 2007.
Ev 124 Science and Technology Committee: Evidence
— new local, national and international initiatives to enable universities to identify and engage
with end-users and commercial mentors and non-executive directors who can advise and work
with senior academics to bring IP to commercialisation. Such individuals have been located by
some universities creating groups of suitable contacts, for example through University business
angel clubs and Managing Director network clubs as well as using specialist head hunters;
— consideration as to whether aspects of the Australian Commonwealth Scientific and Industrial
Research Organisation (CSIRO) might be introduced into the UK; and
— further initiatives to encourage secondments to university departments.
7. Above all it Government must recognise the impossibility of predicting future needs of the applications
of science and fund basic science accordingly. In life sciences there are times when the concept of a commercial
proposal is very clear but the technique to deliver it is not available or not fully developed; conversely, there
are cases of a major breakthrough in development of a technique, not specifically designed to answer just one
problem, but having very wide applicability (eg DNA sequencing, polymerase chain reaction). Difficulties may
also occur when an invention is effectively complete. For example, in the development of an oral vaccine
where there can be a lack of platforms in the UK to complete trials to bring the ideas to the market.
8. Whatever initiatives may be taken, it is essential that they enable the taking of major risks to commercialise
inventions while protecting the financial health of a university.
Are there specific science and engineering sectors where it is particularly difficult to commercialise research?
Are there common difficulties and common solutions across sectors?
9. Inclusion of this question suggests that the Committee recognises that different areas have varying
potential for commercialisation. While “traditional” science and technology areas have been the source of
some considerable success in terms of commercialisation (for example, ICT, life sciences, chemistry, physics,
engineering, etc) the most successful commercial outcomes measured in terms of revenue returns to the
university can originate from less likely areas and from work at the intersection of several disciplines.
10. There are few areas where it could be said to be “easy” to find backing to commercialise research
outcomes. These tend to be in disciplines such as web-based or software development where a product is
almost ready for delivery and the market opportunity is fairly obvious. Areas in which there is a major challenge
to find sufficient funds for commercialisation include sophisticated engineered products and systems, novel
materials, new therapies and medical technologies, biotech, pharma and, perhaps particularly, in new clean
technologies where the financial return is often unproven and any developments have substantial lead-times to
market making them unattractive investments to any but the largest companies. However, in counter-argument
to this, some very large companies are the most resistant to very novel ideas, wishing instead to buy up
successful companies or near to market inventions.
11. Although being critical to the support of the world class research base in other disciplines, mathematics
has the potential for perhaps the wide and deepest “valley of death”. Most cryptography and cyber security
relies on mathematics developed many decades (and sometimes centuries ago). While it impossible for
government to plan so far ahead, the discipline must be kept vibrant and viable through appropriate funding
and supported where appropriate to commercialise its outputs, with Information Security being an example of
the usefulness of mathematics that needs to be nurtured.
12. At least some of the solutions to the difficulties mentioned here have been described in the response to
the first question above. However, setting up regular broad-based UK “technology exhibitions” as a focus for
R&D organisations and companies could bear fruit across different sectors, where an aggregation of technology
and information can be brought together to generate new product opportunities.
What, if any, examples are there of UK-based research having to be transferred outside the UK for
commercialisation? Why did this occur?
13. Generally transfers can occur either directly from the research laboratory, or when a small company is
bought out or invested in by overseas parties. This is normal and natural. However, if UK companies and
investors could be encouraged to take a longer-term attitude to opportunities (as they do in Germany and
Scandinavian countries) we might succeed further with more home-grown commercialisation.
14. In other cases the specific nature of the work may give rise to overseas investment as illustrated by the
following examples. There are other (often confidential) examples where the research that has been contracted
by an overseas company has been commercialised outside the UK by that company.
— Many thousands of sites worldwide exhibit contamination of soil, groundwater and surface
water by hazardous industrial chemicals. These chemicals, such as fuels and solvents, pose a
serious and long-term threat to soils and water quality. With funding from Scottish Enterprise’s
Proof of Concept programme, researchers at the University of Edinburgh developed novel
remediation technology for the removal of hazardous subsurface contamination. When no UK
licensing partner could be established, the technology was eventually licensed to a Canadian
company and is under-going successful trials in the USA.
Science and Technology Committee: Evidence Ev 125
— One of the greatest commercial successes in Lancaster University was the development of a
novel technique for the irrigation of high value fruiting crops. The technique reduces the amount
of irrigation water applied, maintains crop yields and increases fruit quality leading to a
significant increase in wine quality. As a result, the impact of the technique, now widely
adopted, is measured in £Ms. While there has been subsequent investment within the UK to
develop the technique domestically, a clear market demand overseas (in Australia) drove rapid
commercialisation. Critical to this commercialisation was the existence of the Commonwealth
Scientific Industry Research Organisation (CSIRO), established to ensure rapid
commercialisation and impact of national science programmes into all areas of the Australian
economy, more often than not, in close partnership with major national industry sectors (such
as the wine industry). We may draw a passing parallel with this organisation and the network
of Catapult Centres being established by the TSB in the UK, although the Australian investment
in CSIRO is significantly higher.
What evidence is there that Government and Technology Strategy Board initiatives to date have improved the
commercialisation of research?
15. Our members have commented favourably on a number of national initiatives including HEIF, KTPs,
Innovation Vouchers and SMART awards, the Scottish Enterprise Proof of Concept programme and the TSB
funding calls that have all contributed to, and improved, commercialisation and knowledge exchange.
16. External evaluations of the KTP programme indicate that funding that increases dedicated human
capacity to commercialise research and has significant (additional) impacts in terms of new product and service
development and employment, much more so than the simple supply of financial grants to carry out
commercialisation. Interventions which continue to focus on the training and development of dedicated R& D
staff in SMEs should continue to be supported as a priority. However, there are some disadvantages to
universities in KTPs as the university supplies much of the expertise, it may be mentioned in a patent, but not
share in the profit accruing from successful projects.
17. The excellent industry-led funding calls from the Technology Strategy Board are generally at the very
applied end of the research spectrum rather than directed to commercialisation. It is possible that a similar
approach aimed at facilitating commercialisation of research following from TSB collaborative R&D projects
would be helpful.
18. We believe that useful lessons may be to be learnt from the Scottish Enterprise Proof of Concept
programme, which has led to several successful new company formations in key technology areas. Such
funding can encourage significant private investment in a project. Unfortunately in spite of beginning as a
programme with a light touch, increasing regulation means that the programme is now less well regarded.
19. Although there are several positive statements to be made about TSB and other initiatives, national
statistics continue to indicate that the UK lags seriously behind its international competitors in the proportion
of GDP that is devoted to research and development. What is even more disturbing is the rate at which
emerging economies are increasing their investment in science (the BRIICS). The TSB might better perform
more matchmaking between R&D providers and UK businesses. The Catapult Centres may encourage this, but
the opportunity should be available for any TRL3–7 development project to bid for TSB funding.
What impact will the Government’s innovation, research and growth strategies have on bridging the valley of
death?
20. These strategies are unlikely to have a significant effect without the Government agreeing some
quantitative measure of success. We noted with deep concern that it decided to drop even the limited target of
the previous Government of the (very low) figure of 2.5% of GDP being spent on research and development.
It has also decided to stop funding the excellent R&D Investment Scoreboard so will have almost no robust
way of judging the success or failure of any of its policies. Unfortunately it would seem that the more
government money is made available, the more potential equity investors withdraw and demand that even more
risk be eliminated before they invest their money. It could be better to stimulate investments through further
demand side action through fiscal changes rather than seeking to address the delivery side.
21. However, some actions can have a beneficial effect for example:
— initiatives such as SBRI, improved R&D Tax Credits and increased tax incentives for private
investment in very small companies can provide pragmatic help in bridging the valley of death.
These encourage sustainable “organic growth” of young companies, in which, in the current
environment it would be very unrealistic to expect significant bank or venture capital funding;
— policy incentives driving closer collaboration and sharing of services in universities offers
significant opportunity for HEIs more effectively to collaborate, combine and commercialise
the outcomes from research;
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— leverage of TSB funding with European Regional Development funding which should aim to
ensure these regionally funds are more closely aligned to technology commercialisation, rather
than low-level business support; and
— the UK- China (and other) science programmes should attract more UK and international
venture capital and increase collaboration between companies and UK (and Chinese
universities) as well as gaining easier access to certain export markets.
22. There is much support for SMEs, though it needs to be channelled to those companies that have real
potential for growth. The high tech, high growth companies may have the potential to punch above their weight
and lead to notable wealth and job creation, but they probably only exist in a very few sectors such as IT and
medical technology. Many other SMEs are low tech and are unlikely to achieve significant growth in the near
future or contribute to the UK’s strategy to become a high technology, high value-added economy. In contrast,
support mechanisms for universities to work with large companies, who may be better placed in some cases to
commercialise research, do not seem to be available.
23. It is too early in the lifetime of Catapults to evaluate their usefulness in research commercialisation but
hopefully this will happen in the limited number of sectors where they have/are being established.
Should the UK seek to encourage more private equity investment (including venture capital and angel
investment) into science and engineering sectors and if so, how can this be achieved?
24. Categorically, yes.
25. One of the major issues is the scattered nature of intellectual property across the university sector. Any
policy that encourages connectivity across universities to pool their IPR offer whether nationally or locally
would make it easier for venture capitalists and business angels to understand the range of opportunity
available.
What other types of investment or support should the Government develop?
26. Further support could include:
— more incentivising of universities to develop their contacts with alumni, perhaps through a fund
similar to the matched funding that was set up by to encourage philanthropic donations;
— focussing on increasing the intake of high quality graduates into the SME sector; and
— more short-term posts based in industry, specifically to support university-industry
collaborations on a regional basis.
27. Above all, where SMEs exist that have the potential to deliver high technology, high value added
scientific manufacturing and R&D it is essential that they are enabled to operate in science parks, preferably
near universities, or where this is not possible, exist within networked clusters that may also include connections
with large companies.
February 2012
Written evidence submitted by SME Innovation Alliance
1. The Select Committee’s questions lie at the core of concerns of the membership of the SMEIA (see below
for a brief history of the SMEIA and affiliations and interests of the author).
2. We can report the consistently expressed opinion of the membership, however it is a frustration of all
concerned that factual data is in very short supply, we believe this absence almost certainly lies at the root of
the UK’s inability to improve its performance significantly in this sphere. There is a further frustration that the
SMEIA and precursor bodies have been engaged with government at a high level over the last 20 years, and
there are things which we “know” because they were disclosed to us in discussions bound by the Chatham
House rule, which we therefore cannot attribute.
3. The “Valley of Death” is now a recognisable term, but it is really only the most extreme manifestation of
a far more widespread and deep rooted problem. Mixing metaphors, the UK science and engineering industry
is now suffering the “perfect storm” in which very many factors interact, nearly all of them negatively and in
a very complex fashion. The SMEIA committee have spent enormous effort trying to separate cause and effect,
and to work back to any more fundamental root cause, and we do now feel that we have a considerably better
understanding, even though that understanding is far from complete. This analysis does however suggest that
many of the matters which exercise debate with and within government, particularly with DBIS and the TSB,
are still dealing with the surface symptoms, and are very far from tacking the deeper roots. Much of this
document is therefore concerned with setting this context.
4. The SMEIA membership are small companies (mainly very small) in the high technology area, and the
representatives on our committee and at our meetings are the senior officers of these companies, most of whom
will travel widely, will normally do business internationally, and often interact with universities both here and
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abroad. We are therefore very aware of the ways that our competitor nations deal with similar problems: there
is very considerable frustration at the comparisons that we make. We see that the UK could do so much better.
5. We conclude that the most fundamental root problem is simply that we are not culturally a technological
nation. The media make some excellent science programmes, but consistently they “dumb down” the science.
Senior BBC presenters feel no embarrassment in admitting ignorance (and incompetence) in science and
practical matters. Bizarrely the BBC has rebranded the word “Technology” to mean only what we would
call ICT.
6. We have a “generalist” civil service, and so our members and other industrialists have highly asymmetric
conversations with senior officials. They believe that they do not need to understand the detail of what we are
saying, and that they can make important decisions on “technical advice”. We disagree and believe that the
lack of scientific and industrial expertise within the machinery of government, which should stay within
departments and build departmental knowledge, is a severe impediment to UK policy formation, and again is
in contrast to practice in our more industrially successful competitor nations.
7. This national attitude is certainly recognised in schools, which struggle to get sufficient pupils to take
science subjects, and teachers to teach them.
8. This also extends to lack of understanding within government of industrial structures and organisations.
Both industry and the unions have been screaming out for better technician training, whereas until very recently
governments expanded the universities. In our more successful competitor nations the very high skilled
technician is a very well rewarded, high status individual. It is not better or worse than an academically based
career, but it is certainly different, and it would appear that this difference of function that is really not
understood. Whilst UK employers in the engineering sector struggle to get academic engineers and scientists
of adequate quality, they struggle far more to get technicians, on whom the output of saleable, revenue
generating products largely depends.
9. HMG over many decades completely lost the plot on manufacturing. Despite a very public reversal of
policy by the coalition government, there appears still to be little understanding of manufacture, with reversion
to the old understanding lurking in the background. In the 1980s and 1990s it was true that the low wage
economies had a massive advantage, simply because everything was so labour intensive. But with automation
the playing field is almost level. Current policy is to concentrate on automated manufacture of high added
value goods, whereas high technology automation of low added value, high volume (and high shipping cost?)
commodity goods is equally possible, and may be far more effective in balance of payments improvement.
Manufacture appears now to be a separate agenda item from the “knowledge economy”, whereas it should be
seen as the prime means of exploitation of that knowledge (they are two sides of the same coin).
10. After the national attitudinal problem, the next most basic is probably the structure of our economic
system. We own our houses and rent our factories is a pretty reasonable summary of the UK, and is in stark
contrast to Germany. This is now getting right to the heart of the problem that the committee is investigating.
The UK has high house because there has been no other sensible place to put the fruits of our earnings. If we
want to finance businesses to generate wealth, then the banks have to have deposits, and savers have to get a
healthy return on their cash, but savings interest is treated as “unearned income” and taxed. So there is little
point HMT bemoaning the UK’s low savings ratio: they are in command and their policies have caused it to
be so.
11. This cuts the other way: because we rent our factories, most businesses have relatively low capital assets
on their balance sheet to use as collateral for borrowing. Structurally, small UK businesses are in a far worse
position to take risks. Because we rent both our premises, and often our means of production (machinery),
companies do not generally build asset value over time. Again a lot of this is the result of long term government
(lack of) policy. A study of any industrial estate will show a high rental vacancy rate and very little freehold
property. HMRC policy gives far higher allowances against corporation tax for rental and lease, and by
comparison almost penalises ownership.
12. The banks are now in sharp focus, and anecdotally there are currently many horror stories of loan
facilities being withdrawn. However the banks are being asked by HMG to do something that they should not.
“Normal” banking is not about the bank taking a risk with depositors’ money, but of providing cash against
underlying assets, so that a company can realise some of its asset value as working or risk capital. As above,
our small companies do not have those collateral assets.
13. Something we have urged HMG to research is the actual current means of funding small companies.
Typically a business owner will have a massive overdraft, and in the last 20 years will also be a heavy user of
credit cards. The reason is very simple: the credit card companies do not seek personal guarantees, nor the
very onerous standard bank debenture agreement which will have a clause such as “the bank may at any time
at its sole discretion and without any other cause seek a winding up order for the company”.: we believe that
this is a major barrier to borrowing in the UK, and ought to be illegal. We would expect that HMG would
discover that a large chunk of the current personal debt is in fact disguised small business borrowing.
14. A final structural element of the UK small business environment has been the progressively increasing
influence, and actual effect, of all the vested interest groups. Each of the statements below looks, and is, a
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statement of the obvious, but is also an explanation as to why the UK environment for businesses is so complex.
We have submitted opinions in Reference (2) cited below to DBIS, in summary;
(a) We have very complex tax law, largely drawn up by consultation between HMRC and the
accountancy profession.
(b) UK commercial legal practice is disputational, every commercial agreement is written afresh,
whereas some of our competitors enjoy standardised contracts.
(c) The patent system does not work for SMEs, see Reference 1.
(d) Our technical regulatory bodies now work almost entirely in the private sector, but administer
the access to legally required compliance (= legalised printing of money).
(e) Our financial institutions are all focused on capital gain, short term aims, and export profit from
clients to themselves.
(f) The public sector “business” support organisations achieve very little good for business.
(g) The universities now do appear to have the ear of government in an entirely disproportionate
way, and almost all recent policy appears to have been determined by what the universities
advise about “their” spin-out technology businesses, and does not align very closely at all with
the advice that would have been given by the massively larger body of truly commercial
technology businesses. SMEIA is aware that university based networks have been collecting
data for submission to this call for evidence: this appears benign, but the questionnaire approach
reflects the preconceived views and will thus inevitably skew the evidence.
15. A final and perhaps most important structural element of the UK business scene is that we have very
few, long established medium sized industrial companies, we are missing the equivalent of the German
“Mittlestand”. We also have relatively few big independent companies, whereas we are well populated with
huge multinationals. This gives us a very discontinuous supply chain, the UK’s very large number of small
companies struggle to sell their products to bigger companies, and the same applies to their technology, there
is generally very little “pull” (demand) up the supply chain in the non-bio sectors.
16. It is in this general business context that the particular questions of the “Valley of Death” must be
considered.
17. The general scenario is of a company with some germ of a new idea. Mainly the SMEIA member
companies have the R&D capability in-house and so some early proving can be done out of “own funds”. It
is then normally possible to apply for grant funding (from the SMART and other TSB funds). There are two
problems with this process:
(a) There can be considerable delays (this has got better).
(b) Most funding schemes are “matched funding” (say 60%) and the problem is in finding the
other 40%.
18. Generally these problems can be overcome, perhaps by a “Friends and Family” funding round to meet
the matched funding requirement. A considerably better alternative is “procurement” funding, at 100+% of
cost, as is very successfully operated by MOD/CDE.
19. This process generally leads to something that is effective “proof of concept” and which is patentable.
Whilst the patent system is considered dysfunctional, if future funding needs to be raised, patents must be
applied for, and a cost base starts to be established.
20. The lack of supply chain “pull” and continuity means that exploitation by partnering with a bigger
organisation is less common than perhaps it should be.
21. This is the edge of the “Valley of Death”. It is recognised that total funds available “in the market” do
not meet demand, but this is not quantified: HMG have no estimate of the need. It is however easily calculable
by analysis of the figures from the www.pwcmoneytree.com website which lists US funding deals. By suitable
scaling we could have a reasonable estimate of our shortfall: it is a massive number.
22. Access (ie contact with) to funding sources is now far better through investment networks, but the
mismatch between need and available funds mean that investors can cherry pick. Generally the “network”
angel investors will have the same attitudes as the VC community, which is in short term capital gain, whereas
HNW individual investors operating privately, and PE houses, might have slightly longer term.
23. Very good projects can get funding, but often on conditions that the company feels are too onerous. The
investor’s requirement for capital gains will mean a high “burn rate” of funds, normally seeking more funds in
one or more subsequent rounds, with an “exit” for the funds by selling the company on, these days
predominantly by a trade sale. The effectiveness of this method of company development is questionable, and
very variable between scientific sectors.
24. It appears to work well in the medical, pharma and biotech sectors, where a lot of the initial R&D work
is done in universities, and where the nature of the technology is readily transferrable, with the big pharma
and medical companies encouraging this business method.
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25. Anecdotally it seems that HMG has adopted this as the “standard model” upon which technology policy
is based, whereas it is in fact only applicable in bio based sciences.
26. VCs are prepared to take a loss and abandon a project, and this means that the technology will be lost,
and this constitutes continual attrition of the industrial technology base that the UK could have had.
27. The VC funding model is also a systematic means to export UK technology. The vast majority of funds
come from overseas. If a company has three funding rounds, and if 80% of funds are non-UK, then
mathematically the chances of control remaining in the UK after three rounds is 0.8%!
28. Attendance at any investment network meeting will show that bio-science start-up companies aim to
give investors an “exit” by a sale to the large multi-nationals for sums in the region £20–£50 million. This is
sufficient for a return to the investors and kudos to the R&D teams, but it is selling UK technology short,
precisely why the big companies in these sectors are so willing to buy.
29. The alternative for a company with an idea is not to take this funding, and in general such companies
will continue, but will not grow, and will not manage to make much money from their technology (DTI did
say it had figures from the 1990s to support this).
Recommendations
30. The first is that there are no quick fixes. There are a list of things which our members will consistently
say should be done, and a few things which should not be done, but the overriding and consistent message is
that this is a structural rather than a particular problem, and it will only be fixed if the underlying problems
described above are dealt with properly and systematically.
Research Needed
31. In pursuing this policy the first thing that is necessary is for DBIS and HMT establish and publish some
background facts, including:
(a) What annual sum of risk investment money is needed for the UK match our competitor nations
in the commercialisation of technology?
(b) What is the shortfall of working capital in the industrial sector, and how are business actually
funded now?
(c) What is the rate of export of UK technology through the VC funding?
(d) Investigation of the effects and distortions of all the vested interest groups in the UK
(e) What proportion of genuine innovation happens in each of the SME, large corporate and
university sectors?
(f) A thorough revisiting of the patent system as it effects the SME sector, something the recent
Hargreaves review promised but did not do (SMEIA has these promises by email)
32. The Dos
(a) Set up a national industrial bank or banks, or mutual banks, to bring competition into general
commercial finance, to the general bank lending sector.
(b) Set up new institutions (see CrowdCube.com) that can be effective to bring the general public’s
and mutual funds to play in the risk finance sector.
(c) Pull the TSB back from playing at “Dragon’s Den”, themed competitions, timed “calls” and
get them to stick to funding projects quickly and simply on pure merit.
33. The Don’ts
(a) Expand the “business support” networks: they are a distraction and simply cost money.
(b) Allow publicly funded institutions any role in “picking winners” or strategic planning of
funding themes.
(c) Use any panels of the “Great and Good” to judge or select winners: such panels will always
pick the well presented, apparently “safe”, project and miss the exciting and good.
Author and Affiliations
The author of this report is Tim Crocker, on behalf of the SME Innovation Alliance (www.smeia.org).
SMEIA was formed about two years ago to represent the views of small high technology companies, working
across all sectors. It had its origins in part in the two remaining SMART clubs set up in the early 1990s by
DTI for the winners of the SMART awards. Member companies will typically be multiple award winners
(SMART, GRD, TSB, CDE, FP7) and the principals will most commonly have a strong scientific or R&D
background prior to setting up their own companies. Tim Crocker (www.scimar.co.uk) is a physicist and
electronics engineer, with 38 years in the electronics industry, five of them as a government scientist, with
academic work in deep sea sonar. He has a large patent portfolio, is CEO of his own company, has been
founder of seven other high tech companies, and is currently a director of four of them. His is the lead
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researcher on motors and electronic drive components within the SAFEDRIVE FP7 project which is developing
hybrid vehicle technology. He has other recent technical and commercial interests in wind turbines and LED
lighting.
Reference Material (obtainable from the SMEIA website)
1. The Economic Failure of the Patent System, by John Mitchell.
2. Joint submission of SMEIA and the East of England SMART Club to the Willetts R.I. review, by Martin
Lawrence and Tim Crocker.
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Written evidence submitted by The Aerospace, Aviation & Defence Knowledge Transfer Network
(AAD KTN)
Background to AAD KTN
AAD KTN is a single overarching network for the Aerospace, Aviation and Defence sectors spanning
Government, Industry and Academia with the principal aim of promoting and enabling innovation in the UK.59
The AAD KTN is funded by the Technology Strategy Board (TSB) and has around 3000 members. Aerospace,
Aviation and Defence as combined sectors employ close to 500,000 people through some 9,000 organisations
in the UK. Aerospace continues to be a UK success story being first in Europe and second only to the USA in
terms of turnover;60 Aviation contributes some £8.8 billion to the UK economy;61 Defence industries’ success
lie in their ability to export leading edge technology valued on average at £5 billion per year.62 The growth
of global air traffic over the past 50 years has been substantial and forecasts indicate that it will continue at
some 5% per annum.
The majority of the KTN activity takes place through 13 National Technical Committees (NTCs) and by
having the custodianship of the National Aerospace Technology Strategy (NATS).63 The NTCs are forums
facilitated by the AAD KTN which are focused around key technology themes with experts from industry,
academia and government with a remit to advise on future R&T priorities that should be invested in. The
National Aerospace Technology Strategy represents the UK national aerospace technology plan developed
and delivered by a multi-stakeholder forum comprising of industry and university representatives, alongside
government departments and agencies.
Since 1 March 2011, the KTN’s remit extended into aviation related activities and now has six priority
themes:
— National Aerospace Technology Strategy.
— Autonomous Systems.
— Aviation and the Natural Environment.
— Maintenance Repair and Overhaul (MRO).
— Passengers and Security.
— Introduction of Biofuels to the airport infrastructure.
The KTN is also host to two pan-KTN programmes working across Space and Defence communities. In
Space the KTN is the custodian of the National Space Technology Strategy (NSTS) and in Defence the KTN
is catalysing Science and Technology connectivity between the MoD and non-defence communities. These
programmes attract a further membership of around 3,000.
The AAD KTN’s response the questions posed by the Science and Technology Committee is as follows:
1. What are the difficulties of funding the commercialisation of research, and how can they be overcome?
1.1 From the various interactions with our membership the KTN believe the funding landscape within the
UK has become complicated to navigate with a vast portfolio of initiatives. Ranging from the SME focused
assistance through to the recently re-badged SMART scheme now delivered by the TSB to the Regional Growth
Fund, aimed at generating employment, operated by the Department for Business, Innovation and Skills. The
KTN can spend much time assisting organisations, large and small, in understanding this landscape explaining
how all the support mechanisms fit together. There is a need for the landscape to be presented to the SME, the
entrepreneur in such a way that it is able to articulate its need and identify the mechanism to assist them
more easily.
59 www.aeroktn.co.uk
60 UK Aerospace Industry Survey 2010.
61 What is the contribution of Aviation to the UK Economy, Oxera Report, 2009.
62 UK Aerospace Industry Survey 2010.
63 https://connect.innovateuk.org/web/national-aerospace-technology-strategy-nats/overview
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1.2 The success of the UK aerospace industry depends on the ability to deploy world-class technology,
which requires long-term investment in research and technology. Aerospace is also a safety critical and highly
regulated industry. It typically follows a technology development cycle constrained by regulation and
certification. New technology can take up to 15 years to progress from basic science to product application.
This can therefore result in long payback period for investments made in technology development which can
be a challenge for the supply chain, even the larger companies.
1.3 If there is a need for both government and industry to demonstrate impact as a result of joint working
through SMART, SBRI, KTP or other such mechanisms then it would be advantageous for the metrics across
the innovation landscape, Research Councils to the Technology Strategy Board to the Regional Growth Fund
to be better aligned. For instance, Research Councils metrics could cover demonstration of KTP or Feasibility
Study follow through; KTP could demonstrate Collaborative R&D follow through as a measure of success. If
metrics are to be used to demonstrate impact, then it is the KTN’s belief that the metrics could and should be
used to drive the right innovative behaviour across all sectors.
2. Are there specific science and engineering sectors where it is particularly difficult to commercialise
research? Are there common difficulties and common solutions across sectors?
2.1 Aerospace/aviation, nuclear, space and marine are highly regulated thereby represent sectors where it is
harder to commercialise research due to the additional hurdles that exist. The latest aircraft are increasingly
complex “systems of systems” and their often large size poses technological challenges in their own right.
Development work is spread not only across the initial R&D process, but also into the vehicle’s operational
phase, since aircraft and their systems are modified and updated during their operational life, which may be
several decades long. The aerospace industry is very conservative in terms of exploitation of innovation because
of the certification requirements. New entrants to the aerospace market can find it difficult as they have to
demonstrate the appropriate “worthiness” and must be prepared have a long term plan. Some of these issues
reside in the also fragmented and complex regulation landscape of aerospace, there are currently multiple
bodies and organisations that are involved in regulation, but there is no overarching approach.
2.2 The space community upstream is also heavily regulated with even longer timescales of delivering
technology through to completion and yet it is recognised that the value of the downstream space sector is
significant. For the UK to truly take its 10% of the forecasted £400 billion Global Space market over the next
18 years as stated in the Space Innovation and Growth Strategy then there is a need to balance short term
investments with long term investments to secure the UK’s access to satellite based data.
3. What, if any, examples are there of UK-based research having to be transferred outside the UK for
commercialisation? Why did this occur?
3.1 Other “traditional” aerospace nations and increasingly the emerging aerospace economies support
research and development activities of their aerospace sector. In an increasingly global industry with countries
keen to develop their aerospace industries, companies have a broad choice of country in which they locate
their facilities. This remains a potential threat to the UK that aerospace manufacturing will move overseas. All
the major aerospace companies have started this process and initially the activities moved offshore tended to
be the ones that will benefit from cheap labour rates. The danger is that as the overseas economies become
more technically sophisticated, a mass move of R&D activities will look increasingly attractive. The decision
to move offshore is not a straightforward one and for aerospace this can be influenced by other factors such as
the need to access a particular market (such as the US or Asia) or a skills base.
3.2 The UK was not in a position to secure the carbon composite wing skins for the latest Airbus aircraft
A350XWB due in part to the long term investments of other “Airbus” nations (Spain and Germany) in
composite capability. The UK has responded to the challenges and opportunities of composites with several
significant investments including the National Composites Centre based in Bristol, now part of the High Value
Manufacturing Catapult. The Catapult centre has the potential to become an extremely valuable initiative for
advanced manufacturing sectors such as aerospace as they represent a longer term plan of Government and
industry collaboration.
3.3 Rolls Royce continues to make investments in the UK, but has made significant investments, including
R&D facilities, in Singapore, Germany and the US. In Singapore, a large number of companies have clustered
around the Seletar Aerospace Park where for instance Rolls-Royce have based a Trent aero engine assembly
and test facility, a wide chord fan blade manufacturing facility as well as a regional training centre and
Advanced Technology Centre, an integral part of the Rolls-Royce global network for technology research.
4. What evidence is there that Government and Technology Strategy Board initiatives to date have improved
the commercialisation of research?
4.1 The Catapults centres have the potential to be a valuable initiative. The High Value Manufacturing
(HVM) Catapult represents an opportunity where UK government investment can assist industry by providing
access world leading manufacturing capability, both in terms of equipment and academic knowledge. In effect,
the HVM Catapult assists those companies wishing to de-risk manufacturing technologies and processes to such
a state where they feel confident in the business case to make the necessary investments in capital equipment.
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4.2 The TSB’s Collaborative R&D funds collaborative projects which not only support industry to industry
activity but also academic to business research activity. In certain cases where the academic content of a project
is of a high standard, the Research Councils are in many cases able to support the academic content. The
collaborative working relationship between the TSB and the Research Councils will be essential in assisting
the process of transferring scientific research into industry.
4.3 EPSRC, a major focal point for the aerospace sector, are increasingly looking to ensure the investments
in scientific research are aligned to the interests of industry and will look for academia to confirm the impact
of any proposal. However, it must be recognised by all parties that industry focused research has to be balanced
with the need to allow academia the opportunity to look at blue sky research. A positive move to support
commercialisation of scientific expertise EPSRC has supported portfolio of Centres for Innovative Manufacture
to allow industry access academic research capability at the low technology readiness levels.
4.4 The role of NATS and NSTS is to articulate an agreed set of priorities for the UK aerospace and space
sectors to preserve and expand its position in the global aerospace industry.
5. What impact will the Government’s innovation, research and growth strategies have on bridging the valley
of death?
5.1 The UK government has committed to maintain the science and research budget at £4.6 billion per
annum and so able to continue to support a wide range of sectors covering the seven research council remits.
However, at approximately £300 million per annum, the TSB are not in a position to assist UK industry transfer
research from such a wide spectrum into more commercialised products. The competition for TSB investments
is fierce, and whilst competition is advantageous, leads to strong and focused businesses, the very high levels
of over-subscription are indicative that should the TSB budgets be increased then more R&D would be de-
risked here in the UK thus creating greater opportunities for commercialisation of innovation.
6. Should the UK seek to encourage more private equity investment (including venture capital and angel
investment) into science and engineering sectors and if so, how can this be achieved?
6.1 The KTN believes that the UK needs to encourage more private equity investment but recognises there
is a potential mismatch in expectation as aerospace suffers from long term payback whilst the private equity
community look for short term return on their investment. However, once secured on an aerospace platform,
there is the likelihood of the commercialised product generating a long term income flow. An opportunity
could exist to bring the private and industry close together. If information was published on the successful
recipients of UK government grants, this could highlight to the private equity community potential opportunities
in the future. There might also be an opportunity due to the over-subscription of grant applicants for those not
successful in obtaining grant but deemed to be worthy of support by the assessment process to be flagged up
the private equity community.
7. What other types of investment or support should the Government develop?
7.1 In addition to national governments’ support for research, the EU supports research at the European
level. Companies pursue their national competitiveness through national programmes but get extra value in
wider collaborations at the European level. A strong national capability, supported through a national
programme puts the companies in a good position to win a significant part in European projects. This “leverage”
function should not be underestimated in value to the UK.
7.2 There are some resources to assist UK supply chains in accessing/navigating the EU landscape. However
a greater level of resource to assist this process would ensure that UK businesses could increase access and
share of the EU funds. The Innovation and Research Strategy has identified further staff resources for the TSB
to help leverage EU funding however a TSB presence permanently in the EU with a resourced, knowledgeable
team whose sole purpose was to represent, inform and connect would improve the UK’s draw down of EU
funding.
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Written evidence submitted by the Wellcome Trust
Key Points
— The valley of death is not merely a funding gap. While funding is important, it is equally important to
provide access to the right skills, support and infrastructure to facilitate research commercialisation.
— Commercialisation is particularly challenging in the life sciences sector, due to the long time frames,
significant capital requirements, and the higher regulatory barriers associated with products intended
for use in humans. However, these difficulties have also allowed innovative models to emerge,
such as “open innovation” models of drug discovery that enable collaboration between industry
and academia.
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— At a national level there is value in a diversity of approaches to commercialisation, incorporating a
mix of “science-push” and “business-pull” models.
Introduction
1. We welcome the opportunity to contribute to this inquiry. Effective and timely translation of research will
enable the UK to capitalise on its track record of excellent basic science to deliver health and wealth benefits.
2. Through our technology transfer division, the Wellcome Trust makes a range of investments designed to
bridge the gap between fundamental research and commercial application. The process of developing a research
discovery into a commercial product can be enormously complex and expensive, and has traditionally been
seen as the role of the private sector. However, public and charitable funders can seed the process by providing
a small amount of funding at an early stage to work up the proposition and share the early stage risk.
3. We provide five major types of funding:
— Translation Awards: a response-mode mechanism for applied R&D projects that address an
unmet need in healthcare and have a realistic expectation that the innovation will be developed
further by the market. The awards are open to UK-based academic researchers and companies
and can address almost any area of healthcare.
— Strategic Translation Awards: allow the Trust to invite applications for applied R&D projects
that align with our strategic priorities. Compared with the Translation Awards, the Trust is
more proactively engaged in project management, working alongside the institution or company
involved. The awards are open to UK and international applicants.
— Seeding Drug Discovery: a dedicated programme to facilitate early-stage small-molecule drug
discovery. The awards help applicants with a potential drug target or new chemistry embark on
a programme of compound discovery and/or lead optimisation. The goal is for funded projects
to progress to a stage where there is sufficient evidence to make the project results, intellectual
property and outcomes attractive to follow-on developers/investors who may be from the
commercial or not-for- profit sectors.
— Health Innovation Challenge Fund (HICF): a parallel funding partnership between the
Wellcome Trust and the Department of Health to stimulate the creation of innovative healthcare
products, technologies and interventions, and facilitate their development for the benefit of
patients in the NHS and beyond.
— R&D for Affordable Healthcare in India: supports translational research projects that will
deliver safe and effective healthcare products for India—and potentially other markets—at
affordable costs.
4. We have also developed a number of one-off translation initiatives and partnerships, including:
— Hilleman Laboratories—a joint venture with Merck, based in India, to focus on developing
affordable vaccines for diseases that commonly affect low-income countries.
— Stevenage Biosciences Catalyst—a £38 million partnership between the Wellcome Trust, UK
government, GlaxoSmithKline (GSK), the East of England Development Agency and the
Technology Strategy Board, to develop a bioscience park adjacent to GSK’s R&D facilities in
Stevenage, Hertfordshire. It will provide small biotech and life sciences companies with access
to the expertise, networks and scientific facilities traditionally associated with multinational
pharmaceutical companies.
— Centres of Excellence in Medical Engineering—in partnership with the Engineering and
Physical Sciences Research Council, we have funded four UK centres that provide an
environment for mathematics, physical science, engineering and medical research to come
together, to encourage exploratory research and its translation into specific product
developments of benefit to healthcare.
5. To date our technology transfer division has committed over £304 million to translational projects across
80 institutions and in excess of 50 companies. On aggregate, over £532 million has been generated in third-
party finance for these projects, which are seeking to develop a range of innovations including new drugs and
vaccines; enabling technologies; medical devices and diagnostic tools.
6. Funders of research commercialisation activities must carefully monitor and evaluate the success of their
programmes, and be prepared to adjust their strategic approach accordingly. The Trust has evolved its
technology transfer strategy over time, developing targeted schemes such as Seeding Drug Discovery and the
HICF to address specific identified gaps, while maintaining the more responsive Translation Awards scheme.
This gives us the flexibility to support a range of commercialisation models and opportunities. We have also
found it very valuable to partner with other organisations, particularly commercial partners who can provide
specific expertise in technology development to complement our experience in funding basic science. While
commercial partners may bring funding to the table, they also make valuable “in kind” contributions that
enable access to specialised expertise, equipment and other resources.
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Consultation Questions
Q1. What are the difficulties of funding the commercialisation of research, and how can they be overcome?
7. Commercialisation of a research discovery will involve a range of activities, which can be grouped under
two general categories:
— Technical proof-of-concept studies (including clinical studies) that demonstrate that a promising
technology or compound arising from basic research can be effective in a real world setting.
— Work to develop the technology into a commercially attractive proposition—developing a
business case, identifying potential customers and markets for the product, conducting market
research, manufacturing and testing prototypes etc.
8. Commercialisation will be most effective if these two types of activities are allowed to co-evolve.
Historically, one of the difficulties of funding the commercialisation of research has been the tendency of
public and charitable funders to focus primarily on the former activity, with the expectation that the private
sector will step in to fund the latter. In many cases this is not realistic, as potential private sector partners
are unlikely to want to invest in a technology until they can determine whether it represents an attractive
business opportunity.
9. While more needs to be done to develop, and assist researchers to access, appropriate funding streams for
early stage commercialisation, it is important to recognise that bridging this gap is not merely a matter of
funding. It is equally a matter of the research team having access to the right skills, support and infrastructure
to enable them to develop a promising research project into a fully-fledged commercial opportunity. Research
funders are increasingly recognising this, and attempting to integrate the necessary support as part of technology
transfer funding. For example, within the Trust’s technology transfer schemes we provide academic applicants
with a range of mechanisms such as project steering groups, advisory committees, and supporting consultancy
costs for troubleshooting or project management.
10. Despite this, the scarcity of individuals with the skills to bridge the research-business divide remains a
major barrier. Such skills are usually gained from working in large R&D-intensive firms. Given the UK’s
relatively low levels of business R&D investment, and the trend for large firms to move their R&D offshore,
it is likely that access to skills, rather than funding, will remain the most significant barrier to improving the
UK’s track record in commercialising the world-class science conducted here.
11. It is extremely difficult even for established businesses to value research concepts and their potential
return on investment at an early-stage. This is particularly so in the life sciences. A new technology may
provide, for example, diagnostic information in real time, but how much a customer will be prepared to pay
for the extra speed of information will not be known until late in the product development process. In drug
discovery, return on investment estimates typically are not used until phase 2 human trials, which is usually
after £10–15m of investment has already been risked.
Q2. Are there specific science and engineering sectors where it is particularly difficult to commercialise
research? Are there common difficulties and common solutions across sectors?
12. The difficulties of commercialising research in the life sciences are well recognised. Where products are
intended for use in humans, there is a need for comprehensive testing in a clinical environment—a lengthy and
expensive process which often requires input from multiple regulatory authorities. The fast pace of technology
development in some areas (for example mobile health technologies) means that a technology can be out-of-
date by the time this process is completed. Products used in humans also tend to have complex and specialised
manufacturing requirements. Transforming a promising research discovery into a viable product may take
10–15 years, with significant and sustained capital investment required over that period. Such opportunities are
seldom attractive to venture capital and angel investors, who typically look for a return in five to seven years.
13. From an investment perspective there is also the issue of risk. It is often observed that UK and European
venture capitalists are more risk averse than their US counterparts. Life sciences investments are seen as high
risk by investors due to the technical uncertainties and the significant regulatory hurdles that must be overcome.
A good example of this is the recent European Court of Justice decision that products derived from human
embryonic stem cells cannot be patented—while in theory there are other mechanisms to protect the associated
intellectual property, in practice investors are unlikely to invest in the development of such technologies within
Europe unless there is much greater certainty that a successful product will result. As a result, it is likely that
the public sector will need to take on a greater share of the early stage risk for the development of these types
of technologies.
14. There are a range of interventions that have the potential to assist research commercialisation in the life
sciences. Some of these are specific to the life sciences, and some are more broadly applicable across sectors.
15. With regard to life sciences-specific solutions, possible areas of action include:
— Improving funding for clinical research, particularly research that addresses unmet clinical
needs or enables clinical experts to engage with research at an earlier stage of the
development process.
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— Streamlining regulatory processes, securing the necessary regulatory approvals can add
significant time and cost to the commercialisation process. While it is important to retain robust
regulatory safeguards for products that are intended for use in humans, the recent Academy of
Medical Sciences (AMS) review suggested that the process for getting clinical studies underway
in the UK is particularly slow and complex. The UK’s share of global patient recruitment into
clinical trials fell from 6% to 2–3% between 2000 and 2006, while the share of the core EU
Member States fell less dramatically from 21% to 14% during this period.64 While we have
seen significant progress from the Government in implementing the recommendations of the
AMS review, there are a number of areas where more could be done—for example, in
streamlining the process for researchers to seek NHS R&D permissions.
— Creating the right infrastructure by deploying electronic patient records to support research
within an appropriate governance framework, reducing costs by sharing services (eg laboratory
services, testing facilities) and data. For example, in the drug discovery area the UK has
considerable expertise in identifying potential drug targets, but needs to improve access to
screening facilities, such as chemical libraries, which are normally based in industry.
16. More general solutions include:
— Improving tax incentives for R&D. In general the UK has a favourable tax environment for
business R&D, particularly given the recent introduction of the patent box. However, the tax
system does not always encourage the collaboration and interaction between research and
business which is critical to effective commercialisation. This is particularly the case with co-
located facilities. A zero rating for new charitable buildings can only be retained if the building
is used 95% for non-business charitable purposes. In the case of the new Francis Crick Institute,
this will restrict the ability to conduct on-site technology transfer and commercialisation
activities.
— Improving links between research organisations and business through exchange of staff; sharing
of resources and expertise.
— Developing more flexible intellectual property structures to enable academia and industry to
work together on the early stages of commercial development.
17. The drug discovery sector provides a good case study of both the challenges of research
commercialisation and the way models of commercialisation are evolving to address it. The current commercial
model for bringing new drugs to the market is becoming unsustainable, with increasing costs (the cost of taking
a new drug to the market is now estimated to be over £1 billion), fewer drug targets, and lower returns from
new drugs which do make it onto the market. These challenges have increasingly led the pharmaceutical
industry to explore “open innovation” models which allow new drug targets to be identified and validated in
partnership between academia and industry. While the number of academic drug discovery units based within
universities is growing, a workshop hosted by the Wellcome Trust in June 2010 identified a number of barriers
to the expansion of this approach, including: a shortage of the appropriate technical skills (for example in
target identification and validation) and entrepreneurial skills amongst academic researchers; the need to
develop appropriate systems to store and share data; and the need to facilitate research in IP-free environments.
Q3. What, if any, examples are there of UK-based research having to be transferred outside the UK for
commercialisation? Why did this occur?
18. Funders of technology transfer activities can adopt a range of strategic approaches. Where basic science
funders invest in technology transfer activities, they tend to adopt a “science push” approach that begins with
an opportunity arising from basic science and seeks to develop the project to a stage where appropriate business
partners can be attracted (or a new spin-out business created). This contrasts with “business pull” approaches
where a funder works with businesses to identify research opportunities and problems and harness scientific
knowledge and expertise to solve them. Both approaches have merit, and at a national level there is a value in
a diversity of approaches. However, it is important to recognise that a science push approach will not
necessarily prioritise research opportunities on the basis that they can be commercialised within the UK. A
technology transfer funder with an explicit mandate to deliver economic benefit to the UK will need to identify
potential UK-based partners at an earlier stage in the commercialisation process, and take this into account in
decision-making about which projects to invest in.
19. The majority of the successful research commercialisation processes the Wellcome Trust has been
involved in have involved the transfer of intellectual property to foreign partners. The main reason for this has
been the need for significant follow on funding, and the lack of appropriate funding sources and commercial
partners within the UK. As a charitable funder with a global focus, we focus on projects that are likely to
deliver a tangible benefit to human or animal health—our technology transfer programmes do not explicitly
aim to deliver an economic benefit to the UK. However, we are certainly aware of cases where opportunities
for economic co-benefits have been missed.
64 Kinapse (2008). Commercial clinical research in the UK: report for the Ministerial Industry Strategy Group Clinical Research
Working Group. www.ukcrc.org/index.aspx?o=2873
Ev 136 Science and Technology Committee: Evidence
20. Examples of research and technology transfer activities we have funded that have resulted in overseas
licenced deals include:
— CardioDigital, a spinout company from Napier University, Edinburgh, was established in 2001
to develop tools for monitoring patients to help doctors make better informed clinical decisions.
The Wellcome Trust provided funding in 2002 and 2006 to support CardioDigital to develop
its software analysis techniques to be applied in a clinical context and to prepare the resulting
technologies for the market. This funding enabled the company to develop software to adapt
existing pulse oximeter monitoring devices to assess respiration rates. In 2008, the US
healthcare provider Covidien acquired the technology and will shortly announce that the product
is now being made available in Europe with a limited market release following regulatory
approval. This technology allows doctors to detect early warning signs of patients’ breathing
problems and provide more effective treatment.
— The Wellcome Trust provided career support to Professor David Wraith at the University of
Bristol from 1989. In 2002 he established a biotechnology company, Apitope, to develop
targeted therapies to suppress the inflammatory responses causing autoimmune conditions. With
funding from a Wellcome Trust Translation Award, Apitope developed a peptide therapeutic
(ATX-MS-1467) for the treatment of multiple sclerosis. An initial clinical study was completed
in 2008, and the following year Apitope announced a licensing agreement with Swiss-based
Merck Serono to develop and commercialise ATX-MS-1467. Merck Serono has now taken
responsibility for all development activities from the beginning of phase II clinical trials, and
is providing funding for Apitope to continue research into other therapeutic peptides for the
treatment of multiple sclerosis. Apitope has also raised €10 million from European funders,
including LRM, Vesalius Biocapital, Vinnoff and Hasselt University.
Q4. What evidence is there that Government and Technology Strategy Board initiatives to date have
improved the commercialisation of research?
21. The business-led focus of the Technology Strategy Board (TSB) brings a different perspective to the
research commercialisation process from other funders, such as Research Councils and charities. As discussed
above, it is helpful to have a diversity of approaches to research commercialisation. It will be important to
ensure that the outcomes of TSB funding are monitored and evaluated over time to ensure that the most
appropriate mechanisms are being used.
Q5. What impact will the Government’s innovation, research and growth strategies have on bridging the
valley of death?
22. The Government is increasingly acknowledging the need to take a strategic approach to life sciences
innovation which seeks to coordinate action across the research, education and health sectors and address
finance and regulatory barriers to innovation. This approach was articulated in the Strategy for UK Life
Sciences, Sir David Nicholson’s review of the adoption and uptake of innovation in the NHS, and the
Innovation and Research Strategy for Growth. The Wellcome Trust contributed to the development of these
strategies and we appreciated the consultative process adopted by the Government. We are also optimistic that
the announcements will have a positive impact on innovation in the life sciences.
23. The new £180 million Biomedical Catalyst Fund is intended to directly address the valley of death, with
a focus on enabling collaboration and on providing a “seamless set of support and funding options”. The
success of this fund in achieving its objectives for growth of the UK life sciences sector will depend on its
ability to achieve strong engagement and buy-in from the business sector, as well as from researchers.
Companies will need to be engaged in the early decision-making to identify projects and technologies which
best align with the strategic priorities of UK-based businesses. If this is not achieved it is likely that the
Catalyst Fund will repeat the experience of other technology transfer funds where many projects rely on
international partners for commercialisation. Similar arguments can be made in relation to the Catapult Centres
(Technology and Innovation Centres), which are a positive evolution but need to be run in close partnership
with industry in order to succeed.
24. A number of the actions from the recent Government strategies seek to develop an innovation culture in
the NHS, for example through promoting the use of patient data for research, investing in workforce training
and building on research centres of excellence to increase collaborations between industry, academia and
clinicians. These actions will also assist in bridging the valley of death as they will create incentives for private
companies to invest in R&D in the UK and to partner with the NHS to ensure that discoveries arising from
publicly-funded research are able to benefit UK patients. The forthcoming NHS Procurement Strategy (expected
1 March) will also assist the NHS to send stronger and clearer demand signals and improve pull through of
locally-generated innovations into the NHS.
25. The Government needs to think carefully about the messages it sends about the role of universities in
the commercialisation and knowledge transfer process. In his speech on 5 January David Willetts announced
the Government’s ambition for university knowledge exchange income from external sources to grow by 10%
over the next three years. Such a target will encourage universities to see their interactions with businesses
within a context of short-term revenue generation, rather than sharing knowledge for longer-term public benefit.
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It may dissuade them from seeking out local partnerships that will create jobs and see intellectual property
retained within the UK, if greater profit can be made from licencing technology internationally. Universities
should be recognised for the broader value they add to the economy, for example through tacit knowledge and
the provision of skilled graduates, rather than just the external revenue they generate.
Q6. Should the UK seek to encourage more private equity investment (including venture capital and angel
investment) into science and engineering sectors and if so, how can this be achieved?
26. It is likely that venture capital and angel investment will remain difficult to attract in the life sciences as
angel or venture investors are typically looking for a return in five to seven years. Most life sciences projects
are seen as too risky and unlikely to deliver return within this timeframe. If the UK is serious about encouraging
venture capital investment in the sciences it will need to develop a range of measures that both reduce the risk
(for example through funding more of the business development in the public sector) and increase the potential
pay-off (for example through tax incentives) of such investment.
Q7. What other types of investment or support should the Government develop?
27. The Government has the opportunity to look at higher education policy signals to enable research assets
to be nurtured and developed in the protected environment of a university. The lack of funding mechanisms to
do this within higher education, and the expectations that are placed on universities to generate external revenue
(paragraph 25 refers) mean that universities are forced to look for external funding too early.
28. Technology transfer funders could consider developing more of a portfolio approach to investment. At
the moment they tend to focus on developing single products or technologies, often conceived, developed and
evaluated in isolation. As a result, the know-how and learning experience is not shared and often lost. Indeed,
as the number of major industrial R&D sites in the UK declines, centres of technological and applied scientific
excellence, such as the Clerk Maxwell centre, could help provide the necessary skills and experience to help
sustain an innovation culture and be a source of product concepts.
March 2012
Written evidence submitted by The Higher Education Funding Council for England
Declaration of Interest
1. The Higher Education Funding Council for England (HEFCE) was established by the Further and Higher
Education Act 1992 as a non-departmental public body operating with a high degree of autonomy within a
policy and funding context set by the Government. The Council’s main function is to administer grant provided
by the Secretary of State for Education and Skills. We provide independent advice to the Secretary of State on
the funding needs and development of higher education including relations between HE and the economy and
society. We currently provide £150 million per annum in HE Innovation Fund which supports a broad range
of knowledge exchange activities between universities and colleges and the wider world, which result in
economic and social benefit to the UK. Further information about the role, policies and funding allocations of
the HEFCE can be found on our web-site.65
HEFCE Role and Policy in Knowledge Exchange
2. HEFCE plays a part in the Government’s innovation eco-system as an higher education (HE) institutional
funder. Since the 1990s, the Council has developed policies to support universities and HE colleges to
contribute further to the economy and society. This has been through providing a stream of funding for
“knowledge exchange” (KE)—the range of inter-actions between universities and businesses, public services
and the wider community that lead to economic and social impact. These inter-actions are described and
measured in the HE Business and Community Inter-action (HE-BCI) survey.66
3. Our support for KE is provided through HE Innovation Funding (HEIF), which is now an entirely formula
allocation to universities, based on performance measures from HE-BCI, standing at £150 million per annum
over the period 2011–15. We expect universities to use their HEIF allocations most effectively to achieve
impact, developing and enhancing their own strategic approaches to KE.
4. Research commercialisation through technology transfer is a component of KE. However, KE is much
wider, reflecting the variety of roles that universities play in the innovation eco-system, including:
(a) research exploitation such as contract and collaborative research;
(b) knowledge based facilities and equipment;
(c) knowledge diffusion and networking;
(d) development of human capital;
(e) entrepreneurship;
65 www.hefce.ac.uk
66 www.hefce.ac.uk/econsoc/buscom/hebci/
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(f) community engagement; and
(g) and the contribution of HE to the competitiveness of places.
All these contributions support the development of knowledge and entrepreneurial skills for innovation, but
also help to increase the innovation capabilities and absorptive capacity of firms, places and this nation.
5. A 2004 paper from US/Europe67 defined the different models for exploitation:
— The historic Open Science model whereby academics published findings and industry had sole
responsibility for commercialisation based on scanning literature.
— The Licence model, adopted in the United States following the Bayh Dole Act of the 1980s,
whereby universities took greater responsibility to licence intellectual property (IP) from
federally funded research to industry.
— The Innovation model, prevalent in Europe, whereby universities play a much greater and richer
variety of roles, as described above as knowledge exchange.
6. Academic experts of innovation have criticised Open Science and Licence models (the “linear” models)
on grounds that these will lead to under-utilisation of research ideas because of: failures to transfer and absorb
“tacit” knowledge; and their inappropriate focus on supply not demand influences (market pull). This has led to
policies that bring universities into close engagement with business, and which spur two-way communication.
7. The 2004 paper also notes that the USA benefits from a great number of technological businesses. If
European countries do not adopt innovation models, it is likely that new technologies will gravitate anyway to
the USA. Hence a challenge for the UK is develop new technologies, but also to make these “sticky” (to ensure
some benefits accrue to this country). Even the USA has become more interested in wider KE and the
“stickiness” issue (such as in clustering policy) in recent years.68
8. For all the reasons above, HEFCE supports and incentivises universities to have regard to IP, but to take
strategic decisions on the best modes of KE to deploy. Universities are diverse; different universities are best
placed to make very different contributions to the innovation eco-system.
Trends69
9. Overall KE performance in England has improved in the last 20 years; total KE income has increased
from just under £2 billion in 2003–04 to £3 billion in the last year of the HE-BCI survey, 2009–10.
10. Income from IP licensing is a very small part of total KE income. IP income from licensing stands
presently at around £58 million and has increased by around 85% since 2003–04. There are two main modes
of commercialisation of IP, licensing IP to an existing business, or the spinning out of a new company. World
good practice generally favours licensing. (Indeed many in universities believe that good practice is to engage
closely with business and agree to licence IP to the company at the outset, with the university benefitting in
ways that fit its mission, such as through contributions to research funding. In such cases, there is then no IP
that needs to be handled by the university either in licensing or spin-outs arrangements.) Universities house
many academic entrepreneurs and provide environments to develop the entrepreneurs of the future. However,
they are not primarily commercial bodies, but public good organisations that wish to work with and support
industry for wider public benefit. It is therefore more time and resource efficient, and consistent with the
university role, to license IP to an established wealth creator. However, sometimes a new technology may be
so innovative that it does not have an obvious client, and hence a university is then acting appropriately in the
public good to spin out the technology itself (and often the spin-out will be acquired by an established wealth
creator along the line).
11. We share data with the USA70—and publish a US-UK commercialisation comparison within the HE-
BCI Survey. Unsurprisingly, given the USA’s large scale of technologically based businesses, the USA leads
on licensing—with licensing income being 3.7% of total research income, compared with UK at 1.3%.
However, UK leads on spinning out new companies, generating one new spin-off per £23 million of research
income compared to £56 million per company in the US.
12. In isolation, neither patents nor spin-outs are good measures of performance. Patents are an input to
commercialisation; licensing income provides a better view of impact (the value placed by the company related
to likely results). Spin-outs should be judged in terms of their longevity, and that they build in terms of
wealth and jobs. We collect more detailed information on spin-out performance in HEBCI including longevity,
employment, turnover and level of external investment. At the beginning of the century there seemed to be an
over-emphasis here in producing new companies with a relatively high number being formed but many
remaining effectively dormant. As KE practice became embedded, the number of new companies being formed
67
“Models of, and Missions for, Transfer Offices from Public Research Organizations”, by Gilles Capart and Jon Sandelin at
http://otl.stanford.edu/documents/JSMissionsModelsPaper-1.pdf
68 See for example US National Academies (2010) “Managing University IP in the Public Interest”, which reviews Bayh Dole,
and recommends amongst other things that USA adopt a broader KE not TT model.
69 Data is drawn from the UK HE-BCI Survey, developed by HEFCE and now run by HESA. Overall HE KE performance captured
in HEBCI reflects a number of drivers, not just HEFCE funding for KE, but overall policies of Government and the range of
innovation and research funders. HEFCE works closely with other funders, such as TSB and RCUK, in developing
complementary policies on KE, including analysis of HEIF strategies.
70 Through the US Tech Transfer professional body AUTM.
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reduced year on year while the number surviving for three or more years rose consistently, suggesting that
HEIs were being more strategic in their commercialisation decisions.
13. We also collect data on methods of commercialisation in HE-BCI, such as the use of specialist third
parties. A number of these (usually experts in IP law) have developed in recent years and have links with
specific HEIs or departments. The exact relationships vary and the details may be kept confidential for
commercial reasons. At the lower end of engagement the third-party may simply have paid a fee to have first
refusal over any IP originating in the HEI or department Other examples are where all IP generated is
automatically assigned to, protected and exploited by the third party. In these examples it is very difficult to
gauge the efficiency and effectiveness of interactions given the limited data available (it’s likely of course that
one conclusion is that more IP is being exploited than we know about).
14. International experience is that IP management is very costly; most universities that have large-scale
commercialisation capability will spend considerable sums on IP management and protection. Spending in UK
universities on the protection of IP has increased from £13 million to nearly £30 million since 2003–04 (but it
is worth noting that while both MIT and Stanford receive higher levels of income from IP than any UK HEI
they spend even more in proportional terms on protection).71 However, only a few patents usually generate
much revenue and some of these will go off-patent shortly after the significant returns begin to flow given the
long timescales and low success rates associated with IP commercialisation. This is therefore a risky area and
very careful judgement is needed on the scale of IP activity that is worthwhile in any particular university. We
believe judgement and experience in universities in this country has improved considerably in recent years.
We give some examples of innovations and good practices below. In many cases though, sound judgement
may be to do less not more on IP management and protection. We note that even in the USA universities
struggle to cover costs; and leading edge performers there who do make a profit still need to use their
considerable alumni income to smooth revenues and costs.
University Approaches
15. We ask for strategies from universities periodically, linked to HEIF,72 which describe overall policies
and procedures adopted for KE, including commercialisation. Strategies submitted to us last year for 2011–15
HEIF are presently being compiled into an overview report by PACEC researchers, which will be published in
Spring 2012.73
16. Our general impression from strategies is that there is a considerable dynamism in KE in the HE sector.
Universities are driving hard to work with businesses toward economic growth. As well as incentives from KE
funding, universities are driven to work with business to improve employability opportunities for new students,
as well as to further their effectiveness in deriving research impact. Universities are also very concerned by
cost, given overall uncertainties in the fiscal and public funding environment. Universities are restructuring and
keeping a close eye to most effective and efficient KE approaches.
17. In terms of commercialisation narrowly, we see three major trends:
(a) Universities are innovating in new ways to exploit IP. This includes exploring and adopting
“open innovation” models of collaboration with business and “easy access” approaches to IP
(where costs or legal arrangements for handling IP are kept low and simple, often as part of a
wider strategic relationship between the university and businesses). The University of Bristol
and Kings College London are examples of institutions exploring easy access approaches.
(b) Access to proof of concept funding and other support for commercialisation varies across the
sector. Even when the economy was in recession, some universities were positive about gaining
necessary funding. This is not always just about the university’s IP expertise, as much as the
industrial sector for commercialisation or even institutional brand and connections. Any
university Tech Transfer Office (TTO) worth its salt would like more proof of concept funding
to improve its results, but it is not necessarily a present constraint. Surrey University said to us
in its HEIF 2011–15 strategy: “the University of Surrey does not believe that lack of Venture
Capital or Business Angel support is proving to be a bottleneck for Surrey based start up
companies. HEIF 4 funding has helped provide an active entrepreneur and investment
community around the University which will be developed further during HEIF [2011–15]…
most of the remaining bottlenecks are due to issues beyond HEFCE and BIS control, such as
the macroeconomic situation and seismic shifts in global industry”.
(c) Universities are being inventive to cut costs and increase efficiency in commercialisation. As
well as commercial suppliers, some universities are very active in extending their capability to
provide services to other universities, in the UK and overseas (an example here is Oxford
University’s commercialisation vehicle, ISIS innovations). Some universities are being highly
prudent in reviewing the cost-effectiveness of IP activity and scaling back if appropriate. For
example, Aston University said to us in its HEIF 2011–15 strategy: Following the departure of
the Head of IP.., the [University] did not recruit a successor but has trialled outsourcing most
71 http://web.mit.edu/tlo/www/about/office_statistics.html and http://otl.stanford.edu/index.html
72 See HEIF 4 examples of strategies linked to www.hefce.ac.uk/econsoc/buscom/heif/heif.asp.
73 We and PACEC would be happy to make overview results and strategies available to the Committee.
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of its IP management through using ISIS. This trial has both demonstrated the cost-effectiveness
and the wider experience base gained through outsourcing these activities, and Aston will be
formally tendering for this service early during the new HEIF programme. Like many
universities, Aston grew its patent portfolio rapidly over recent years with a resultant increase
in patent costs. Following internal analysis, and an external review by ISIS, we shall be
reducing the size of the portfolio, setting more rigorous criteria for patenting in future and with
a greater focus on those patents which have a clear route to commercialisation. Cranfield has
a similarly successful relationship with Imperial Innovations.
International Working
18. Universities, naturally, and increasingly, work in global research networks, and contribute to the solution
of global challenges. Their commercialisation work is not therefore solely focussed in the UK, though
universities obviously are highly committed to contributing to this country’s prosperity.
19. We undoubtedly do see evidence that universities work with overseas companies, and that some UK
invented IP is likely then to end up overseas, where this is the only way forward to develop the research.74
However, much R&D in this country is funded from overseas; and many UK companies strong in R&D now
operate globally. The considerations of how research commercialisation can bring benefit to the UK are very
complex then, given globalisation of both research/universities and R&D based companies. We suspect
international knowledge protectionism will not work, so the challenge for all countries is to increase their
ability to capture a range of domestic benefits from commercialisation processes operating globally—the
“stickiness” challenge.
Tech Transfer Offices
20. It is worth making a comment here on the nature of TTOs.
21. HEIF (along with many other sources) supports the overall KE infrastructure in a university, which
includes: KE strategy and leadership in the institution; academic development in KE practice; and professional
KE infrastructure.
22. Around a half of HEIF funding 2011–15 is being used by universities for professional infrastructure,
with the residual for strategy and leadership and academic development. Around a half of infrastructure funding
supports the research commercialisation agenda (including IP but also collaborative and contract research),
with the residual for other KE aspects described in paragraph 3.
23. While many universities may incorporate an exploitation corporate vehicle, the vast majority do not have
staff established in a TTO with a sole purpose to exploit IP, but instead have capacity, centrally or across
faculties, to support a range of KE/impact activities (and most universities will also have various forms of KE
infrastructure-sharing collaborations). In only one university—as far as we are aware—is the exploitation
company not wholly owned by the university (Imperial Innovations).
24. There are a diversity of views on the balance between academic and TTO roles and responsibilities (and
of inventors and institutions) in commercialisation. However, from our experience of working with other
developed economies (including commissioning a number expert studies on US practices), professional Tech
Transfer capability is seen as essential to effective process around the globe. The very thorough US review on
this topic in Footnote 194 is well worth studying on all these matters.
25. At HEFCE, we respect the autonomy and professionalism of senior university managers to make
judgements on when and how they set up Tech Transfer arrangements. Tech Transfer capacity is smaller and
less expensive in the UK than the USA, and costs are less. This may reflect that our universities lack ambition—
or that with less overall funding (including the substantial alumni and philanthropic contributions in USA), our
universities are sensibly prudent.
Funding for the Development and Exploitation of New Technologies
26. The Committee’s enquiry is primarily focussed on the funding arrangements for early stage development
and adoption and commercialisation of technologies. HEFCE is not itself directly involved in these matters
(though universities can use HEIF for proof of concept if that is their priority); no doubt universities and their
KE professional associations will comment on their experiences.
27. A word of caution though—we do not think that financing issues particularly relate to university
commercialisation. The vast majority of new technologies in the world that become commercially adopted will
be devised and developed in the business world, by entrepreneurs, technology consultants, large and small
businesses and in supply chains (albeit, we believe, infused and informed by university ideas and human capital
74 As an example, Imperial College said to us in its HEIF strategy: “Given the economic environment, it is now more important
for the College to develop geographic diversity within its portfolio of industrial partnerships. Between 2008–09 and 2009–10,
our research income from non-EU industrial sources increased by over 18% (£9.7 million to £11.5 million) at a time when our
funding from industry generally decreased. Building on this success, we will extend our corporate partnership support by
investing in a pilot international scheme with a view to furthering our understanding of the international market. Initially
targeting the North American region.”
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development). To illustrate this, we estimate that only 19% of patent application filings from UK were from
the universities here.75
28. What is important in determining what is worth commercialising is the market (together with factors
like leadership and management, as well as finance). Universities have changed their character significantly in
recent decades, in the UK and globally, to play a greater part working with business and developing the next
set of entrepreneurs. Universities are therefore undoubtedly in the market for financing commercialisation, but
we believe the issues raised by the Committee are more generic to commercialisation activity conducted
everywhere, including, but not limited to, university activity.
February 2012
Joint written evidence submitted by Science Policy Research Unit, University of Sussex and Exeter
Business School
1. Dr Paul Nightingale is Deputy Director of SPRU, the Science Policy Research Unit at the University of
Sussex, where he leads a research group on innovation policy. Prof. Cowling is Professor of Entrepreneurship
at Exeter Business School, where he heads a research group on SME financing. Drs Coad and Siepel are
researchers at SPRU working on the financing and management of innovative firms. This submission draws
heavily on research funded by the ESRC, NESTA, BIS and TSB as part of the IRC distributed projects scheme,
as well as research funded by BIS, the BVCA, NESTA, the EPSRC, ESRC and EU through the FINNOV
project.76 None of the team have any financial interest in any organisation mentioned.
2. We welcome this opportunity to contribute to this call for evidence on this important topic. Before we
address the questions we would like provide a small amount of background and context.
3. Care must be taken when considering the “Valley of Death” as it is partly an artefact of thinking about
firm growth without taking into account the extremely high failure rates of new firms. Roughly 50% of new
firms will exit the market (fail) within their first three years. Sustained growth is atypical as growth patterns
follow a random walk. As a result, we should expect to see “dips” in performance and funding after firms
initial start up honeymoon. The resulting market exits allow lower productivity firms to be displaced by higher
productivity firms in the economy, creating economic growth in a way that is more important than the growth
of new entrants. Government policy that extends the life of poor quality firms can therefore have a damaging
impact on the economy and should be avoided. Researchers are often very sceptical that there is a major
problem with access to finance outside of a few particular areas. In general, most firms, get most of the funding
they seek, most of the time. However, it is an open question whether the small percentage of firms that have
trouble raising money overlap with the small percentage of firms that drive economic growth and employment.
We believe they do.
4. The contribution of average SMEs and entrepreneurs to commercialisation and the economy more
generally is often significantly over estimated in public policy discussions. It is true that entrepreneurs are
significantly more happy, and new firms make a significant contribution to job creation in their first year of
existence. However, it is not clear that they contribute significantly to innovation, the commercialisation of
research, or economic growth. Research by Thomas Astebro suggests that of entrepreneurs seeking to
commercialise innovations, only 7% successfully reach the market, and their average financial return is -7%.
Nor is it clear that having more entrepreneurs would be beneficial to the UK economy. Market entry rates are
extremely high in the UK, and EU, at about 20% a year, and this level of market entry may well be excessive.
It may be damaging if poor quality firms drive up factor prices, dilute managerial talent, confuse investors and
make it more difficult for higher quality firms to grow. The key public policy issue is encouraging higher
quality entrepreneurs and SMEs to grow, not increasing the quantity of new entrants having to cross the Valley
of Death.
5. There is already significant support for SMEs and their activities to commercialise research in the UK.
David Storey estimates that the UK taxpayer spends some £7 billion a year on SME support. This is more than
is spent on the Universities or the Police force. We are unconvinced that all of this spending is valuable and
think much of it could be spent more effectively. Using a significant amount of it to give SMEs a National
Insurance holiday if they employed new staff until the economy recovers, for example, might be a useful
stimulus policy.
6. These levels of spending, which are found internationally, suggest SME financing is an area subject to
considerable “rent seeking” where special interest groups lobby governments for anti-competitive support,
potentially at considerable social cost.
7. Much thinking about the commercialisation of research adopts an inappropriate and misleading “linear
model of innovation” in which university research generates innovations, that are then transferred and
commercialised. Only 3% of the economy is in high tech manufacturing that draws on research in this way, so
even major improvements are unlikely to have a significant impact.
75 Using HE-BCI data and data on patents from Elsevier International Comparative Performance of the UK Research Base 2011
(report for BIS).
76 In particular the ESRC-TSB-NESTA-BIS grant RES-598–25–0054 and EPSRC grant EP/ E037208/1.
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8. It is more appropriate to think of research as generating talent rather than technology. Universities might
be usefully thought of as factories for producing human capital. Research provides training in people who then
move from academia into firms where they generate innovations. Sometimes firms generating innovations have
technical problems that require them to seek university support, but the main locus of innovation is in firms,
not universities. The UK’s problem with the commercialisation of research compared to the US should therefore
be seen in the context of lower public investment in research (1.3% v 2.6% GDP), which leads to lower
technical skill levels in industry, which makes it harder to generate innovations in firms. Firms with poorer
quality innovations then find it harder to raise money, but the difficulties of fund raising are a consequence
rather than a cause of poor performance. Providing money without addressing quality may therefore have
limited impact.77
9. The UK is extremely rare in having government departments, such as BIS, prepared to subject its (SME)
policy to independent criticism. This is highly commendable.
1. What are the difficulties of funding the commercialisation of research, and how can they be overcome?
10. It is well recognised that there are major difficulties in funding the commercialisation of research in the
UK and elsewhere and that market failures of many kinds mean investors do not get all the benefits of
investment, which can lead to suboptimal levels of investment. This is because of uncertainties, spill overs
(where benefits cannot be captured), moral hazards and information asymmetries (where investors do not fully
understand their investments and need to depend on trust), and because innovators often lack collateral for
loans. We have found evidence this constrains growth.
11. Moreover, it is extremely difficult to make money from early stage investment. Even professional VC
funds find it very difficult. Often the problem is not lack of money, but lack of skilled investors and lack of
high quality firms worth investing in.
12. Given the difficulties of making commercial returns from innovation, governments have historically
played a key role in funding innovation.78 In the US there is significantly more support for innovation than
in the UK, which has a more market based approach.
13. The UK has a number of policy tools to address this problem. R&D tax credits which are very expensive
and of unsure value. The “Patent Box” which is extremely expensive, badly designed and unlikely to generate
additional spending. Equity support schemes (hybrid funds), which were very poor, but are now often effective
and cheap. EIS and VCT support, which are expensive and of unclear value. University Technology Transfer
policies, which are expensive and of limited value. SBIR schemes could be extended but we are sceptical of
their value. SMART type schemes and other grants have value. A key policy tool is to increase competition in
the UK (and EU), especially among large firms to drive innovation in the wider economy and encourage
corporate venturing.
2. Are there specific science and engineering sectors where it is particularly difficult to commercialise
research? Are there common difficulties and common solutions across sectors?
14. Biotechnology seems to have particular problems. Comparative research on the extent of funding
problems between sectors is lacking in the UK and more generally. Sectors requiring long term, uncertain
investments may have a general problem. Sectors where commercialisation requires the substantial levels of
investment generated by Stock Markets may also have a problem in the UK, given the lack of interest of the
markets in the UK in technology (in part caused by poor returns compared to sectors such as mining).
3. What, if any, examples are there of UK-based research having to be transferred outside the UK for
commercialisation? Why did this occur?
15. It is unclear that this is a major problem. We did not find much evidence of firms migrating in our
research. See also Michael Hopkins submission.
16. The UK benefits substantially from the international trade in technology, and protectionist measures
might be very costly. Policy in this area should consider the benefits of trade as well as any costs.
17. There is limited peer reviewed research evidence that this is a major problem. Threats by firms to leave
the UK unless they achieve some policy aim have become more common in recent years. For example, Hedge
funds threatening to move to Switzerland or New York or Private Equity Funds threatening to move to Ireland.
We are unaware of any PE funds that have gone to Dublin recently, and note that Hedge funds in New York
are threatening to move to London. These threats may be raising public attention about something that is
not really a problem. Any problem that does exist could be easily dealt with by effective EU action on
tax avoidance.
77 Nightingale et al (2009) From Funding Gaps to Thin Markets, BVCA-NESTA.
78 Mazzucato, M (2010) The Entrepreneurial State, DEMOS. FINNOV 3rd Policy Brief (2012) available at www.finnov-fp7.eu/
publications
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18. A much more important issue is the transfer of high value added commercialisation activity from larger
firms following acquisition, and the problem the UK faces in international UK firms, particularly in the
biopharmaceutical industry, moving R&D to the USA. This occurs because US science is better supported.
4. What evidence is there that Government and Technology Strategy Board initiatives to date have improved
the commercialisation of research?
19. We are unaware of any evaluations of the TSB. The PACEC report cannot be easily accessed. An
evaluation would be valuable. An evaluation of the cost effectiveness of the KTPs would be extremely valuable
given their costs and basis in a discredited linear model of innovation.
20. Evaluations of science parks suggest they are ineffective.
21. Evaluations of equity support schemes suggest the earliest schemes were extremely ineffective (ie
RVCFs), but that UK policy makers learnt very quickly and more recent funds are very well designed and
produce positive impacts.
22. The recent House of Lords S&T Committee report on procurement did not find evidence that procurement
was being as effective as it might be.
23. In general, evaluations of this kind are difficult and there are few of them. There are many schemes were
an evaluation should be undertaken, such as tax credits, KTPs etc.
5. What impact will the Government’s innovation, research and growth strategies have on bridging the valley
of death?
24. It is too early to assess the impact of many recent changes. Some general aims are probably too vague
to evaluate. We find evidence that older policies, especially equity support for hybrid VC funds, are having a
positive impact.
25. The protection of research funding in the current economic climate is a major and under-appreciated
achievement by BIS.
26. Given the economic situation the Government has limited policy options. The resulting Strategy
document is thoughtful, well informed and shows a sophisticated understanding of the economic problems it
is addressing.
27. Despite our overall positive assessment, we have a number of concerns.
(a) The document still retains an implicit discredited linear model in many places.
(b) There is too much focus on universities and not enough on firms, where the real problem lies.
(c) The value of the SBRI scheme is unclear and the costs do not seem to be fully appreciated.
There seems to be considerably more support for this scheme in the UK than the evidence
would merit.
28. The policy document seems to be informed by arguments that the UK lacks intermediate institutions to
support innovation. We remain unconvinced by this, and suggestions that Fraunhofer type organisations can be
transplanted from one nation to another. Nor is it clear that new institutions will always have a positive impact.
29. The final design of the Catapult centres remains unclear, but they seem to be based on a linear model
that sees technology transfer as the problem. This reflects a pattern in EU policy whereby, when attempts to
improve innovation by increasing technology transfer efforts fail, more money is devoted to technology transfer.
Our suggestion is the framing of the policy might be incorrect. The real problem the UK faces is in the lack
of innovation (and investment in innovation) in industry. There is also a secondary problem highlighted above
related to the lack of spending on research compared to our competitors. There is not a problem of quality in
University research in the UK, nor in engagement between industry and universities, which is probably higher
than the US, nor in Universities generating firms, which again is probably higher than in the US (although we
have major concerns about the quality of the firms that are generated). If UK firms lack the ability to innovate
then technology transfer policies are like pushing a piece of string.
30. Outside of a few areas (biotech, etc) universities are poor places to generate technology. Universities
lack understanding of markets and customer demands. Academics often lack the skills to run and grow firms.
The successful US innovation model involves substantial investment in research in universities, and then very
substantial investment in commercialisation in firms. In the EU we spend much less on research in universities,
and then attempt to encourage universities to commercialise technology either in firms (that find it hard to raise
money because the technology is too early stage), or transfer it to firms that have fewer technical skills and
less investment in innovation. Germany has a slightly more effective model that provides large amounts of
public support through core funding for technology development institutions embedded within networks of
innovative firms. We consider the US model superior.
31. There do seem to be potential problems with a lack of joined up government. For example, taxation
policy and innovation policy can sometimes clash. The IR35 legislation, which addresses a real and important
tax avoidance problem, can have the unintended consequence of forcing large firms to take on innovative
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individuals and SMEs as employees. There can be a mismatch between the focus of some departments on long
run economic growth and the focus on others on short term returns.
6. Should the UK seek to encourage more private equity investment (including venture capital and angel
investment) into science and engineering sectors and if so, how can this be achieved?
32. Policy towards private equity and VC in Europe is often confused because the two very distinct kinds
of funding mechanisms are often conflated. Private Equity (PE) investing involves the refinancing and
restructuring of existing assets (rather than creating new asset) such as management buy-outs, buy-ins and
other later stage development finance. VC is the provision of equity and substantial managerial support to early
stage (mainly technology) firms that are developed for subsequent trade sale or IPO. The considerable confusion
between VC and PE has allowed PE associations to refer to themselves as VC when lobbying for favourable
tax treatment. The effectiveness of this lobbying has made PE investment very profitable, which has attracted
VC investors and institutional investors away from early stage investing.
33. Policy making would be improved if VC and PE were considered distinct as is done in the US.
34. It is not clear PE investment is beneficial in the long run to STEM firms. Some PE investments add
value by turning around failing firms, while others asset strip. Given PE investments are often targeted at
failing firms, evaluating the impact of PE (which may be positive overall), is almost impossible.
35. VC funds struggle to make money from early stage investment. However, a small number of funds do
succeed, particularly in the USA where the VC industry and high tech sectors receive considerable government
support. These funds have had a huge impact on the US economy. In the UK VC funds are struggling to raise
funds. Well designed and well targeted equity support schemes, of the kind developed by BIS, can have a very
beneficial impact on the economy at a reasonable price.
36. We believe the value of support for VC funds should be understood in a broad sense, and go beyond the
financial returns from the investment (which is likely to be low given the difficulty of making commercial
returns from investment in early stage technology firms). It should include the additional taxation that is
generated by new firms growing and employing skilled staff.
37. Regional VC funds perform very poorly and should not be supported.
38. Angel investors are playing an important role in funding early stage innovation. Professional angel
networks are becoming more sophisticated and are moving into areas of investing that were previously
undertaken by VC funds. Making money from early stage investment is not easy, and Gordon Murray has
highlighted the moral question of whether the Government should encourage unprofessional investors to invest
in areas where professional investors find it very hard to make money. Equity support schemes of the kind
used by BIS are effective at supporting business angel networks.
39. In all areas of equity investment policy it is important to recognise that the problems the UK faces are
not necessarily on the supply side (ie lack of money). The key problem may well be a lack of good firms
worth investing in.
7. What other types of investment or support should the Government develop?
40. As well as expanding the range of options, the Government might also consider ending poorly performing
policies (after evaluation) and diverting the funds they consume elsewhere. The patent box scheme and various
technology transfer schemes would be obvious options to explore.
41. There are a range of options that the government may wish to consider:
(a) Industry supported (co-funded) grants for academic research.
(b) Grants for early stage technology development outside universities.
(c) Support to improve the capabilities of Angel Networks and the VC industry
(d) Larger, industry-sector focused hybrid funds ie a co-funded VC fund devoted to the specific
problems facing the biotech or green tech sectors.
(e) Support for pan European, rather than just national, hybrid funds, which would allow more
scale and specialisation.
(f) Loan support schemes targeted at firms seeking funds to invest in commercialisation.
(g) Changes to EU State Aid rules that constrain support for innovative firms. EU level VC funds
or EU level funds-of-funds that invest in VC funds or Angel networks help to get around this
problem. There is widespread recognition that these rules hinder European innovation and
attempts to have the rules either clarified or modified is likely to find considerable support
in Brussels.
42. In designing these schemes it is often important to consider how funding and human resource problems
interact. This makes managerial skills and the skills of investors in supporting firms extremely important. When
firms receive finance to support them through the Valley of Death, they often expand their workforces which
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makes them more difficult to manage. Similarly firms that expand often require new forms of financing.
Funding problems are therefore not only financial problems and should not be considered in isolation.
February 2012
Written evidence submitted by PraxisUnico
Background on PraxisUnico
PraxisUnico makes this submission as a key representative body of the UK’s research and development and
technology transfer profession. PraxisUnico was formed in 2009 from two separate organisations—Praxis
(committed to training for technology transfer officers in universities and research centres) and Unico which
was a membership organisation including universities and PSREs (Public Sector Research Establishments).
PraxisUnico has over 2,600 members from 108 universities and research organisations and 48 commercial
concerns, patent agents and intellectual property lawyers are associate members. PraxisUnico holds an annual
conference and has delivered professional training to around 2,500 individuals from 40 countries. PraxisUnico
makes this submission having consulted its board and members.
Although originally focused solely on “technology transfer” (commercial deals involving intellectual
property generated by universities), PraxisUnico members are engaged across the whole range of knowledge
exchange activities, promoting the transfer of knowledge in all its forms across the boundaries of universities
and into society.
Response Summary
Our draft response reflects the following themes:
— Difficulties are multi-dimensional but we welcome the Government’s commitment to exploring
ways in which they can be overcome.
— In PraxisUnico’s view, the University Challenge Fund scheme is one of the best examples of a
public sector scheme that addressed many of the difficulties in the present environment.
— PraxisUnico would like the commitment shown to the bioscience sectors to be diversified into
engineering and the physical sciences if the UK is to re-shape its industrial base.
— Although too early to address the TSB’s impact, there is no doubt that its initiatives are
providing a much needed stimulus to technology development. Recent changes are likely to
have a positive impact as they will foster development across the “valley of death” with closer
working relationships to the university sector. PraxisUnico believes that the UK must have an
innovation agency but it must take risks to work with new emerging businesses.
— Despite positive signs that the Government’s innovation, research and growth strategies will
have an impact on the bridging the “valley of death” we are concerned that none of the recent
announcements have specifically addressed the issue that a major stimulus is required to
systematically re-shape the technology and corporate venturing market in the UK.
— The UK must seek to encourage private equity investment into science and engineering sectors.
— Investment funds that help to develop the outcomes of research are required that stimulate and
avoid fragmentation. PraxisUnico believes that the University Challenge Fund scheme can
provide an investment stimulus which can be deployed effectively in a multi-dimensional way.
1. What are the difficulties of funding the commercialisation of research, and how can they be overcome?
Difficulties
The difficulties are multi-dimensional, and in simple terms there is no way to make it easy. The number of
scientific ideas which get successfully into market will always be a small fraction of the total of ideas which
are thought to have commercial possibilities. It is not possible at the first steps of commercialising an idea to
predict the outcome; insufficient is known. We first need to tolerate failure. Secondly, we need to communicate
and celebrate success. What cannot be tolerated is lack of effort and a failure to invest in our country’s future.
The second difficulty is already being addressed. The introduction of Impact to the Research Excellence
Framework has commenced the process of alignment between university research metrics and university
success in both fundamental science and research moving to application in the market. A culture change is
underway but it will take time to become fully embedded and this needs to be achieved alongside maintaining
the UK’s global position in basic science and engineering. PraxisUnico believes the solution offered below
presents a further stimulus which would hasten this culture change.
The third difficulty is financial. In 2010 the British Venture Capital Association recorded VC investment as
4% of all VC and Private Equity investment at £313 million out of a total of £8.2 billion benefitting only 397
companies; of this VC investment, £10 million was in seed capital and £46 million in start-up. As a
consequence of the high rate of failure and the nature of venture capital in the UK it is a significant challenge
to secure investment in new technologies. At the same time the in-house research capacity of many companies
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is being reduced as they commit to open innovation. In many countries it is now clear that public funding
is required to de-risk technologies (see the Entrepreneurial State—Demos Working Paper for international
comparisons).(1) Research by the Russell Group of universities (published in 2010) has demonstrated that this
is a long process, quoting an average of nine years from invention to a commercial deal (from the study of
>120 case studies). Funds expended on translational research have increased in recent years but given the time
from the emergence of a potentially commercial research finding to application can easily be more than seven
years and can often be in excess of 15 years, it is simply too early to judge any particular scheme (but see
fragmentation below). We cannot however wait to evaluate recent schemes, if part of the jigsaw is missing we
must act now.
The fourth difficulty relates to fragmentation. Each Research Council, the European Commission and each
of the major charities are committed to seeing the fruits of their funded research into application, and this is
to be welcomed. However, this fails to recognise the nature of research. Very rarely is research in any research
team funded by a single source. The commercial outcome emerges from groups with diverse funding sources,
and increasingly from inter-disciplinary and multi-institutional teams. Each funding source has different rules
which, in turn, increase the complexity of moving forward into the commercial domain. This is further
exacerbated as it is also very rare that a single research idea will succeed without adding other technologies.
Collaboration across the research community not just in research but in commercialisation will become
increasingly critical.
The fifth difficulty relates to the absorptive capacity of the UK industrial base. There are two sub-components
to this difficulty. First, overall business investment in R and D (of 1.15% of GDP for UK in 2008)(2) is very
low by OECD comparison. Secondly, where we do have strengths the trends to globalisation are significant
and few business R and D decisions are made in the UK from the perspective of benefit to UK—we would
contend that this significant international dimension to UK BERD, whilst a strength in one way is a massive
weakness in another. UK researchers looking for commercial partners will therefore increasingly turn to
overseas partners with the consequent flow of benefits outside the UK, unless further action is taken.
The sixth difficulty relates to the shape of the UK industrial base which is dominated by large and small
companies, but with few medium-sized businesses (CBI Future Champions report, October 2011).(3) This
absence of medium-sized companies in part means that the businesses which could gain substantially from
new technologies are few in number by comparison to other developed economies.
The seventh difficulty has also been addressed in recent years and this relates to UK Technology Transfer
Offices in universities and public sector research establishments. PraxisUnico has now trained over 2,500
professionals in the UK research base over the past 10 years. However, staff churn means that this is a continual
process. Income to universities from industrial R and D is now £900 million per annum and income from
intellectual property has been rising year on year. However, to evaluate outcome by examining income to
higher education is the wrong perspective; the correct approach is to start considering the return to companies
from acquiring university technologies. One possible metric is to look at the capital value of companies as they
go through IPO or trade sale. Since 2003 the valuation of university spin-out companies which have come to
market or trade sale is well in excess of £13 billion (many trade sales are private and undisclosed). These
figures are derived from 50 companies (see appendix insert list) and there are a further 1,400 spin-out
companies trading which will continue to feed this pipeline. Opinions on the role of spin-out companies in the
economy vary but given the absorptive capacity of the UK industrial base (see above) spin-out companies over
the next 10 years could make a significant cumulative contribution to the re-shaping of the UK economy when
combined with other actions addressing the overall venturing environment.
The final difficulty is “short-termism”. What is required is a sustained solution, delivered over sufficient
time to assist in the re-shaping of the UK economy. Many public sector interventions are hampered in achieving
a major impact as a consequence of being short lived interventions with limited cumulative gain. This “short-
termism” was true of the original UCSF as well as for other sub-national interventions through regional or
European funding.
Solutions
Some of the solutions are not easy in the present environment but the future growth of the UK economy
and its re-shaping will require public investment combined with public sector interventions to stimulate changes
in the private sector environment. We must reinforce successes, address fragmentation, stimulate collaboration
and invest in our research bases’ capacity to support commercialisation.
In PraxisUnico’s view one of the best examples of a public sector scheme which addressed all of the points
made in the previous paragraph was the University Challenge Fund. This scheme was relatively short lived but
its successes are still being celebrated. £65m was invested in a series of experimental funds across the UK run
and managed, for the most, by, or on behalf of, consortia of universities. This scheme assisted the development
of Imperial Innovations, the development of seed funds in universities, supported the creation of SET squared
and enticed the emergence of private sector investment in university companies, as well fostering collaboration
between major universities. Over a period of nine years to 2009 these funds leveraged seven times their public
sector investment from the private sector to £433 millio. By any measure this scheme was a success. It
promoted the development of technology transfer, it built on the strength of the university sector and fostered
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collaboration. PraxisUnico has campaigned on numerous occasions for this scheme to be reinvigorated and we
believe that the time is right, and much of the original infrastructure is still in place. The scheme should be
rekindled, new bids invited and the scheme broadened to support technologies capable of being de-risked for
development by existing companies as well as supporting new company development. Unlike the previous
versions of the Scheme the successful funds should be “open for business” to all universities, thus ensuring
that high quality technology arising in an institution with low volumes of activity would not be deprived of
access to investment funds. The scheme should have a 10 year duration in order to provide a major foundation
and to build time for traditional VC funds to emerge from the private sector as the deal flow will then be
fully established.
The scheme would not be competitive to the MRC DPFS scheme or the new Biocatalyst Fund but would be
one of the mechanisms which could provide support for their implementation. The original University
Challenge Fund was co-funded by the Wellcome Trust, The Gatsby Foundation and the Government and a
multiple sponsor scheme could re-purpose individual funds held by different public agencies for early stage
follow-on into a single coherent investment based solution delivered through universities covering the proof of
concept, seed and first round funding environment stage.
Whilst the original University Challenge Fund was a useful part of the funding environment a softer money
alternative, where innovation can remain an internal project run by the research team for longer, feels more
appropriate in some cases. Therefore a basket of funding options to drive projects to commercialisation is
required rather than relying on just one route. In early stage development “fragmentation” of support routes
can be seen as being more of a positive than a negative.
2. Are there specific science and engineering sectors where it is particularly difficult to commercialise
research? Are there common difficulties and common solutions across sectors?
There are no easy sectors. The technologies emerging from the research base are the foundation for new
industries and will always be challenging. The bioscience sector has the benefit of major corporate R and D in
the UK, as does large scale mechanical engineering thus providing considerable commercial insights for the
research community. However, even in the bioscience sector the challenges are substantial as the entire business
models are changing from traditional drug discovery to personalised medicine, with new models arising from
genetics and cellular therapies—the UK must foster the new and not simply sustain the strengths it has which
may well be under threat from major disruptions (who could have foreseen the demise of Kodak, for example).
A review of BERD statistics by sector demonstrates the challenges faced if the future of the UK rests on
building the past. There are huge opportunities in renewable energy and major opportunities in construction
and by simply reinforcing the importance of manufacturing to the UK. PraxisUnico would make one plea; the
commitment shown to the bioscience sector needs to be diversified into engineering and the physical sciences
if the UK is to re-shape its industrial base.
3. What, if any, examples are there of UK-based research having to be transferred outside the UK for
commercialisation? Why did this occur?
One of the most long standing examples relates to magnetic resonance imaging. The original patent portfolio
emerged from three universities in the UK (Oxford, Nottingham and Aberdeen) over more than 20 years
generated only royalty income to the UK of circa £300 million in total for an industry generating hardware
sales in excess of $2.5 billion per annum for licensees in Japan, US, Korea and Germany. One of the primary
inventors sought to gain investment in the UK, unsuccessfully. The importance of these decisions is huge as it
is not merely the loss of the major manufacturer but the subsequent supply chain development and investment
in further investment in innovation which, in turn, assists the re-shaping of a country’s economy. More recently
(Jan 2012) the sale of Inhibitex Inc developed in the US (check) to Bristol-Myers Squibb for $2.5 billion
relates predominantly to technology developed at Cardiff University. The company migrated to the US early
in its development as a significant early stage, higher risk investment could only be secured in the US.
Founded in 1996 by graduate student Mike Lynch and utilising a unique combination of technologies borne
out of research at Cambridge University, Autonomy has experienced a meteoric rise. The company was bought
by HP in August 2011 for £7.1 billion, producing a several hundred million dollar fortune for Mike Lynch.
Autonomy is a global leader in infrastructure software for the enterprise that helps organisations to derive
meaning and value from their information, as well as to mitigate the risks associated with those same assets.
Campath® (alemtuzumab) is a monoclonal antibody treatment for B-cell chronic lymphocytic leukaemia.
Based on a monoclonal antibody, Campath-1 discovered in the Cambridge University Department of Pathology
by Herman Waldmann and colleagues, the treatment was improved by Greg Winter and others at the MRC
Laboratory of Molecular Biology in Cambridge, using a process that became known as “humanisation”, to
create Campath-1H. The initial commercial development was undertaken by the Wellcome Foundation, under
licence from the British Technology Group, but after £50m investment, Wellcome dropped the project, it was
licensed by BTG to LeukoSite in the USA. LeukoSite merged with Millenium Inc. who then sold the rights to
ILEX, later acquired by Genzyme, who now produce and market the drug. Wellcome was a British company
(now part of GSK); the others are all American.
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Helen Lee developed diagnostics technology primarily for diseases in developing world countries at the
University of Cambridge and was seeking financial support to start up a company at the turn of the century. It
was not possible for Helen to identify readily accessible funding in the UK and she turned to the USA when
setting up her company “Diagnostics for the Real World”. She managed to secure funding from NIH through
the SBIR scheme and set up her company in California in 2002. Helen is a supporter of SBIR which has three
calls a year and has very clear rules and guidelines for engagement. She received nine rounds of SBIR funding.
The company currently has 15 employees in California and its first two products are on the market and licensed
through Thermo Fisher.
4. What evidence is there that Government and Technology Strategy Board initiatives to date have improved
the commercialisation of research?
It is probably too early to address the TSB’s impact, but there is no doubt that they are providing a much
needed stimulus to technology development. Recent changes to TSB funding schemes are likely to have a
positive impact as they will foster development across the “valley of death” with closer working relationships
to the university sector. In a recent TSB study it found that outcomes from its programmes were enhanced by
university involvement. PraxisUnico believes that the UK must have an Innovation agency. There are examples
where TSB funding has been used to pump-prime spin-out companies; for example, in the field of tissue
engineering at Cardiff University and it would have been difficult (very early stage) to get this off the ground
without the TSB funding. The challenges for the TSB are first, to avoid a naive separation between market-
pull and technology-push. Increasingly, new markets will emerge through a dynamic environment bringing
together technology push, market-pull alongside science-pull and entirely new market creation. Secondly, the
TSB must champion the linkages for companies they support into the venture funding communities both
corporate and private funds. Thirdly, the TSB must take risks and work with new emerging businesses and not
confine action to well established industrial partners.
5. What impact will the Government’s innovation, research and growth strategies have on bridging the valley
of death?
There are positive signs both in recent policy statements and speeches by Ministers and it is too early to say
two years into an electoral term. The announcements relating to TSB, Bioscience Investment and NHS
Innovation are all welcomed. We are concerned however, that none of these have specifically addressed the
topic of this investigation which requires a major stimulus to bring together all of the investments in
translational research, with those in the TSB into a new economic policy which has at its heart a systematic
re-shaping of the technology and corporate venturing market in the UK.
We also feel the commercial imperatives of a venture capital fund and the need to form a limited company
and associated management team do not seem to fit easily with the early stage innovations with long lead time
to market. By the time that a business case and project team have been put together, that is getting close to
where the investment community can understand a project and invest in it. That’s where the challenge funds
are really operating, and by then we’re climbing out of the valley. If a university spends on patent protection,
then it should be able to deploy some associated concept development money.
6. Should the UK seek to encourage more private equity investment (including venture capital and angel
investment) into science and engineering sectors and if so, how can this be achieved?
Yes, absolutely. Models such as Fusion IP, IP Group and Imperial Innovations have helped bridge the gap
between City investors and universities. Relationships such as these also bring a professional, business-like
culture into universities, helping to embed entrepreneurial culture. The further stimulus provided by a major
university challenge fund scheme as suggested above can build on these early successes, fostering university
collaboration, creation of critical mass and support the re-shaping the UK economy.
In addition there exist solutions such as Alumni Angel networks, the sale of “first look” options, specific
fundraising/sponsored research or the establishment of a proprietary fund by universities.
7. What other types of investment or support should the Government develop?
There are many different calls on funds and the simple answer is that all investment funds that help develop
the outcomes of the research are required. These vary from the costs of IP protection (there seems to be a real
lack of funding for this activity, budgets are required), undertaking effective market research, bringing in
design and engineering expertise earlier into the process, professional advice/advisors and lawyers, investment
readiness, expansion of technology transfer training for young researchers, proof of concept funding,
entrepreneurs in residence etc. But the answer is to stimulate these areas and avoid fragmentation by initiatives
which tackle only one component at a time, which seems to be the present policy dynamic. PraxisUnico
believes that the University Challenge Scheme proposed in this submission has the further beauty of providing
an investment stimulus which can be deployed effectively in a multi-dimensional way with a clear focus on
commercial goals without narrowly defining an inappropriate target for an intervention.
Across all sectors we are concerned about the early stage problems, where nobody really knows if something
is worth supporting. Best for the possible means to be fragmented in this case, because then perhaps someone
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will pick something up as worth doing. Also it’s very difficult to apply systems and measures to events or
timeframes at this stage. We recognise that support at this level.
Declaration of Interests
Dr Douglas Robertson is directly involved in the operations of university research commercialisation
functions.
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APPENDIX 1
UNIVERSITY SPIN-OUTS AND ACQUISITIONS SINCE 2003
(as extracted from PraxisUnico publication The Review, June 2011)
2003 2006 2010 Biotec Laboratories
Wolfson Micro Lipoxen Ilika APT
Syntopix Tissue Regenix Inforsense
2004 ParOS BioAnaLab
ARK Therapeutics Renovo 2011 Orthomemetics
OHM Oxford Catalysts Microsaic Systems Reactivelab
Vectura Avacta Apatech
Summit Imperial Innovations MET
Synairgen ValiRx Acquisitions Im-Sense
Ceres Power Kudos Pharma Exosect (Bee Health
IDMos 2007 NeuTech Division)
Microemissive Displays Epistem Cambridge Antibody Artemis Intelligent Power
Andor Modern Water Technology Biovex
Cambridge Display Tracsis Domantis Lab901
Technology e-Therapeutics Solexa Chameleon Biosurfaces
Oxford Advanced Arrow Therapeutics
2005 Surfaces Group Daniolabs
FusionIP Plasso Technology Pending Acquisitions
Proximagen 2008 MTEM Astex Therapeutics
Provexis Scancell Cambridge Display
Stem Cell Sciences Technology
Oxonica 2009 Meridio
ReNeuron Nanoco Group CamFPD
NeuroDiscovery OMD
GETECH SIW
SPI Lasers Transitive
Celoxica Thiakis
Toumaz Phototherapeutics
Written evidence submitted by the Confederation of British Industry (CBI)
Summary
— De-risking the innovation process and giving business the confidence to invest in new ideas and
concepts is a key element of translating ground-breaking research into new technologies and markets.
— The “valley of death” in research commercialisation needs to be approached from both sides: helping
to give an extra push to take ideas from research closer to where commercial decisions can be taken
more easily, and helping to create a demand-side pull to bring ideas through to market.
— Reform of public procurement to seek out and encourage innovative new ideas could transform the
pull side of demand in a wide range of markets. Businesses will invest to pull through ideas where
there is a clear commercial proposition. Certainty in regulation will also help generate confidence
to invest.
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— As a central part of government’s efforts on the push-side, the Technology Strategy Board needs to
ensure its efforts align closely with the needs of industry. It must develop sufficient focus to create
a critical mass of activity and use its position in the innovation ecosystem to help link up research
with development with public procurement and other new market opportunities.
Introduction
1. The CBI welcomes the opportunity to submit evidence to the Committee’s inquiry. The CBI is the UK’s
leading business organisation, speaking for some 240,000 businesses that together employ around a third of
the private sector workforce.
2. The difficulty of translating research into commercial application is an established issue and one that has
no simple solution. There is a “valley of death” where choices have to be made about which research ideas
should be taken further and which should be dropped. During early stage research the overall investment made
by a company may be significant, but each individual project will probably represent a small fraction of the
whole, so while the likelihood of failure may be high, the financial risk if a project fails is minimised.
Developing a research idea into a fully-fledged commercial offering invariably requires a different scale of
investment—perhaps even orders of magnitude more investment—and while the risk of failure may be rather
lower, the financial consequences of failure on each project are now much higher. The result is that businesses
will naturally tend towards developing research ideas that they have higher confidence about. But even here,
finite financial resources may mean that good ideas are either left behind or may not be developed fast enough
or extensively enough to become a commercial success.
3. The valley of death problem is thus about managing risk and confidence and providing businesses with a
degree of competitive advantage in order to invest in new ideas.
4. From the business perspective, there are two approaches to minimising risk and building confidence that
will help to bridge, or at least flatten out, the valley of death. The first is to look at factors from the commercial
side that will make it easier to pull ideas through. The second is to consider factors that help to push ideas that
bit further from the initial research phases to help make commercialisation decisions easier.
5. Government has a role to play on both the push and pull side of the equation, although the focus in the
UK has, until recently, been primarily on the very earliest stages of research push. Development of the
Technology Strategy Board has seen public intervention in the UK move more effort into the valley of death,
although the extent of funding available means this cannot be a panacea. Similarly, government has started to
talk about using its public procurement buying power as a demand-side pull driver for innovation, but progress
has been limited. These issues are discussed below.
Demand-side Pull
6. Public procurement is one of the most important levers available to government for influencing and
directing investment from the demand-side. Even in today’s necessarily constrained fiscal environment, the
government purchases around £¼ trillion per year of goods and services. This is in comparison to the roughly
£11 billion per year invested in all aspects of research and innovation (including university funding, defence
R&D and the R&D tax credit).
7. Securing a public procurement contract can provide the stimulus needed for businesses to invest in
developing research ideas and technologies further, helping to bring them through the valley of death. It can
also help companies secure new lines of funding and can provide the platform for potential sales to other
governments, which in turn can stimulate further investment. But to be effective, public procurement needs to
be open to innovative ideas.
8. We have welcomed the establishment and relaunch of the Small Business Research Initiative (SBRI) by
the Technology Strategy Board, which seeks to support the development of innovative ideas from smaller
companies into procurement, but the scale of this scheme is too limited. Even when the different scales of our
economies are corrected for, the US invests around six times as much in its equivalent programme as the UK
does. Clearly, SBRI’s primary focus remains SMEs and early stage businesses although competitions remain
open to all companies.
9. The economic situation provides a unique opportunity to make more effective use of the procurement
budget in order to achieve greater efficiency and long-term savings. The government must become more
intelligent as a customer, with decisions being taken on achieving whole life value, not just on short term cost
savings. Without breaking any EU procurement rules, the government can also seek other advantages through
procurement such as capability development.
10. The CBI has put forward these steps to government as part of the ongoing reform of public procurement
needed in the UK:
— Streamline the process—ensuring contractors are clear on their requirements before inviting bids and
reduce administrative burdens on suppliers.
— Incentivise commercial officials to run quick and efficient procurements through increased
transparency of timescales and reward those who run successful projects.
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— Signal the forward pipeline of projects so that businesses can plan ahead with confidence—in
particular in areas of long-term infrastructure investment.
— Focus on wider outcomes rather than the procurement process, giving providers the freedom to
design service packages, holding them to account by making payment dependent on outcomes.
— Take whole-life costs into account, ensuring decisions are based on long-term value for money.
— Foster innovation by ensuring procurers demand innovative solutions to drive product and service
development from suppliers.
— Place greater emphasis on wider economic value such as job creation and future investment into
developing industrial capability and capacity.
11. The government can also create demand-side pull by establishing or freeing up markets—although
appropriate limitations will need to be considered too. Currently, we are looking to an efficient 4G auction that
will provide the stimulus to bring forward development in the next stages of telecoms infrastructures and digital
content. There are also opportunities in housing, low carbon and other markets where targets and incentives
can be used to pull through investment or through promoting open innovation in sectors where the UK is able
to build competitive advantage.
12. In any area where government regulates activity, it needs to act intelligently when working with business
to create an environment that encourages innovation and helps drive new technologies and create new markets.
This can only be achieved through consistency and clear two-way communication with industry around what
is expected.
13. Providing certainty for companies through voluntary codes, standards and, where necessary, regulation
can act as a real driver of investment confidence, helping to bring forward the commercialisation of innovative
ideas. Government needs to:
— Inform businesses of future planned changes in the regulatory environment, allowing time to plan
and comply with new rules.
— Provide a degree of flexibility in how regulations can be met.
— Provide clarity in requirements and ensure new rules are not open to misinterpretation.
— Ensure poor regulations are dealt with effectively and that additional burdens or conflicts are not
placed on business by overlapping or multiple layers of regulation.
Push Factors
14. The Technology Strategy Board (TSB) is clearly at the centre of government’s efforts to help push or
accelerate the development of new technologies and it has now become an established part of the UK’s
innovation ecosystem.
15. The TSB operates across mid-tier technology readiness levels, where development costs rise and where
risk moves substantially from universities and research labs to business. We welcome the TSB’s efforts, but
also recognise it is trying to do a lot with only limited resources: it’s annual funding is around £317 million
per year, compared to c £4 billion per year for the Science Budget. There is an ongoing need to ensure TSB’s
efforts create a critical mass of activity and that they are not diluted by trying to do everything.
16. In our input to the recent Research and Innovation Strategy discussions, we identified a number of areas
where TSB could improve to keep its focus on the technology acceleration through to commercialisation
mission:
— Provide greater transparency around the amount of funding available for specific programmes year
by year so that businesses can plan ahead.
— Take a more proactive stance on linking R&D investments through to commercialisation—in
particular seeking to support the creation of UK value chains and linking investments in research
through to public procurement of goods and services (ie not just procurement of R&D through the
SBRI scheme).
— Undertake a review of priorities with business to ensure that critical mass of activity is being
supported, rather than spreading available funds too thinly. This needs to be end-to-end so that early
stage funding for basic research by the Research Councils can follow-on with Technology Strategy
Board support for development of the most promising areas that business wants to develop.
— Build stronger links with technology road mapping activities (such as those undertaken by sector
bodies and the government’s own innovation and growth teams) to ensure priorities identified can
be supported effectively at the right time
— Ensure adequate resources are available for demonstration and proof of concept activities and provide
supporting links through to other government funds such as the Regional Growth Fund, Business
Growth Fund and Green Investment Bank where appropriate.
— Ensure Catapult centres (previously TICs) are run by and for business, that they do not replicate nor
displace activity from existing centres of excellence in UK universities and the RTO sector, they
map effectively with business priorities and that their business model is appropriate.
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— Improve links with small and mid-sized companies to increase the effectiveness of knowledge
exchange—work through Knowledge Transfer Networks, RTOs, Catapults as they are developed and
through supply chains of businesses already engaged with the Technology Strategy Board.
17. Greater realism is needed towards the timescales of TSB competitions. Often these are too short and do
not allow enough time for businesses to develop detailed and informed proposals. This can limit the chances
of an application meeting the necessary criteria for success.
18. The government, through the TSB and other routes, also needs to help businesses access European
research, development and innovation funding. The new Horizon 2020 programme appears to have addressed
many of the concerns of business over bureaucracy and relevance associated with previous rounds of the
Framework Programme and we are particularly interested in the focus now being placed on technology
demonstration. While proposals for Horizon 2020 are still being worked-through, this appears to shift the focus
exactly to the ‘valley of death’ area of interest to business. The challenge now is to win over hearts and minds
in the business community to re-engage with this effort at European level.
February 2012
Written evidence submitted by Comments from the National Physical Laboratory (NPL)
1. Summary of Key Points
— Government laboratories such as NPL can be a bridge between academia and industry and are well
placed to support the commercialisation of research. Specifically NPL, managed by Serco under
a government-owned, contractor-operated (GoCo) arrangement since 1995, has a track record for
undertaking the commercialisation of research through effective academic and business partnerships
and application of private sector best practice.
— Government can encourage the commercialisation of research by supporting R&D to de-risk
technology and using fiscal measures to increase the return on research exploitation investments.
— The instruments of the Technology Strategy Board make a significant contribution to de-risking
technology, both through supporting collaborative R&D and through networking.
— Early adopter customers help to commercialise research, and there are opportunities for government
to increase its role as an early adopter through procurement through the SBRI.
— Involving the private sector in the operation of Public Sector Research Establishments can lead to
innovative approaches to bridging the “valley of death”.
— We are part of the intermediate sector and would welcome an opportunity to give further oral
evidence to the Committee of the importance and role of the intermediate sector in the UK
innovation ecosystem.
2. About NPL
The National Physical Laboratory (NPL) is a leading UK research establishment with an annual turnover of
£70 million and a staff of 600. It is the largest science asset directly owned by BIS and occupies a unique
position as the UK’s National Measurement Institute (NMI) sitting at the intersection between scientific
discovery and real-world application. In 1995 DTI (now BIS) established NPL as a GoCo, Government-owned
Contractor-operated, national science and technology laboratory and since that time it has been operated by
Serco. The involvement of the private sector in the management of NPL has greatly enhanced its ability to
commercialise research—see para 9, Q7.
NPL undertakes work for government and its agencies and for business. Its expertise and original research
underpin quality of life, innovation and competitiveness for UK citizens and business:
— NPL provides companies with access to world-leading technical expertise and scientific
facilities, assuring the confidence required to realise competitive advantage from the use of new
materials, techniques and technologies.
— NPL develops and maintains the nation’s top-level measurement standards, supporting an
infrastructure of traceable measurement throughout the UK and the world, to ensure accuracy
and consistency.
An important aspect of NPL’s work is the exchange of knowledge with business, government and academia
which it carries out through a Knowledge Services Division of over 30. This team:
— Supports the dissemination of knowledge from NPL’s R&D programmes; economists at BIS
estimated a return on government investment of 50:1 for NPL R&D programmes.
— Oversees the exploitation of NPL’s intellectual property; for example spinning out Argento
Diagnostics Ltd as an SME now working with UK Sport to develop a Point of Care testing
technology to support UK’s high performance sports groups.
— Manages large parts of two Knowledge Transfer Networks for the Technology Strategy Board.
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— Supports academia to exploit their research for example through a Research Council funded
Knowledge Transfer Account at Surrey University.
3. Q1: What are the difficulties of funding the commercialisation of research, and how can they be overcome?
The first step in the commercialisation of research is the identification of any intellectual property generated
by it, and then the assessment as to whether this has potential commercial value. Those carrying out research
do not always appreciate the commercial value of some of the innovations created by their work. This requires
different skills and methods which have been developed at NPL, such as procedures to capture IP and, where
appropriate, investment of Proof of Concept funds to test the commercial potential and carry out early-stage
development. As important as the potential value of the innovation itself is the leadership to support its
exploitation and whether the technology has reached a sufficient maturity for commercialisation.
Developing technology for commercialisation usually requires taking risks and making large investments.
The challenge is to match the return on investment with the size of the risks taken. This can usually only be
achieved through a staged process where the level of risk is reduced as the requirement for investment rises.
Success requires:
— Entrepreneurial drive sustained over a number of years through the stages that lead to
successfully spanning the valley of death.
— Knowledge of how to use the staged process necessary to cross the valley of death.
— Recognition of the need for and access to a range of specialist skills complementing those of
the innovator.
— Market-pull for the product, ie right product at the right time for the right market sector.
— Ready access to a wide range of finance, such as Proof of Concept funds, grants, loans and
equity investment.
Difficulties arise in commercialising research when:
— The market, eg investments provided by Angel Funds and Venture Capital, is unable or
unwilling to invest because the risks to generate a return are still too high
— The right knowledge and skills are not assembled for successful commercialisation.
Government can increase the commercialisation of research by catalysing the interactions necessary to
overcome these barriers to success, and where the “valley of death” is too wide for the market to bridge, can
provide financial support, for example through funding for translational research to prepare new technologies
for commercialisation.
4. Q2: Are there specific science and engineering sectors where it is particularly difficult to commercialise
research? Are there common difficulties and common solutions across sectors?
For many sectors the difficulties of commercialisation of research are common because they are subject to
similar risks. However for some sectors there are additional risks to commercialisation:
— Where the sector is highly regulated, eg the pharmaceutical sector. Meeting regulatory
requirements is costly and lengthens the time to market.
— Innovative, disruptive technology, such as new sensors, may offer clear technical advantages
over existing technology and be used in new applications with potentially enormous commercial
advantages. However, if based on an entirely new principles, it will require significant
investment to de-risk and demonstrate reliability if the market is going to adopt the technology,
especially in critical application areas such as healthcare, aerospace, energy, and safety. To
develop a robust technology and prove reliability, technology innovators from SMEs,
Universities and RTOs need to access and understand the end users in these critical application
areas; to access other technology areas such as materials and electronics; and to access supply
chain partners for design, manufacturing, and testing & validation. Our experience of running
technology networks is that networking is a very effective way of brokering the right
connections and bringing together development teams across the value chain to develop and
prove disruptive technologies. Further, our experience of working as part of these value chains
using NPL scientific and metrology expertise has proved that measurement, testing and
validation are critical in the acceptance of new technologies and methods in the uptake and
commercialisation of disruptive technologies.
— Where an innovation aims to replace a well-established mature technology, eg parts of the
sensors and instrumentation sector. Innovative products are initially likely to be produced in
small numbers at a higher cost so that although delivering greater value through their novelty,
they find it difficult to compete in the market because they are seen as of lower value for money
when compared with much lower cost mass produced products.
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5. Q3: What, if any, examples are there of UK-based research having to be transferred outside the UK for
commercialisation? Why did this occur?
NPL does not have specific examples of UK-based research transferring outside the UK for
commercialisation. However, we are aware of an example of an international company that chose to maintain
part of its R&D support facility in the UK. Agilent Technologies is a leading international instrumentation
company that has decided to keep some of its laboratories at Winnersh in the UK in part at least because of
the close working partnership with NPL and UK accredited laboratories, and the excellence of the services
they provide. As evidence for this we attach in an appendix an extract from a letter NPL received from a
General Manager of Agilent Technologies (UK) Ltd a couple of years ago.
6. Q4: What evidence is there that the Government and Technology Strategy Board initiatives to date have
improved the commercialisation of research?
NPL is often asked by UK businesses to partner in collaborative R&D projects funded through the
Technology Programme of the Technology Strategy Board; we are currently partners in over 50 such projects.
The fact that business seeks NPL out as a partner provides clear evidence that the research carried out by NPL,
funded by BIS through the programmes of the National Measurement System, is valued by those tasked with
commercialising research. Through our work with these business partners we also are very aware of both how
important these collaborative projects can be in de-risking the exploitation of research and of the impact they
make on innovating products and processes. However, we are constrained by commercial confidentiality from
providing specifics for current or recently completed projects.
We can also provide evidence of the support provided by the Knowledge Transfer Networks for the
commercialisation of research. During the 5 years NPL managed the Sensors and Instrumentation KTN it
helped companies leverage £97M to de-risk technology to prepare it for commercialisation. The KTN also has
much anecdotal evidence of how the networking it has facilitated has helped bridge the valley of death by
bringing together potential customers and innovators. For example an entrepreneur set up a new business as
the direct result of Rolls Royce asking to be its first customer at a KTN event. Contacts are gold-dust to start-
up businesses.
More recently, we welcome the Government’s commitment to “Catapults” (formerly Technology Innovation
Centres) managed by the TSB. However, it is important that these centres should be business-led and
complement existing centres of excellence (often Research and Technology Organisations).
Our experience of developing the Technology Innovation Fund at NPL is that a relatively small value of
support, that is well targeted, can provide disproportionate benefit to companies, especially SMEs. We can
provide examples. We encourage the Technology Strategy Board to continue to develop a diverse range of
funding mechanisms to support innovative companies which reflects the diversity of needs of these companies,
from the company size, sector, complexity of development projects and number of collaborators.
7. Q5: What impact will the Government’s innovation, research and growth strategies have on bridging the
valley of death?
We highlight the following as aspects of the Government’s recently published “Innovation and Research
Strategy for Growth” that will help bridge the valley of death:
— Government can help the commercialisation of research by tipping the balance between risk
and return on investment. This can be by funding the de-risking of new technology through
instruments like Innovation Vouchers, the SMART programme and collaborative R&D
supported by the Technology Programme.
— It also helps increase the return on investment through appropriate fiscal measures like R&D
tax credits.
— SMEs want customers even more than investment. Government procurement supports
commercialisation of research for example through the SBRI scheme.
The Strategy also highlights the role of the intermediate sector, including NPL, as an important part of the
UK’s innovation infrastructure in the following extracts:
— Our [The UK] excellence in teaching and research is underpinned by institutions with a global
reputation, such as the British Standards Institution, the UK Accreditation Service, the National
Physical Laboratory and the Intellectual Property Office.
— The government will also continue to invest in translational research at Public Sector Research
Establishments, such as the National Physical Laboratory, which support business to develop
innovative products and services.
— The UK Innovation ecosystem also embraces Innovation infrastructure organisations, including
the National Measurement Office, National Physical Laboratory, British Standards Institution
and UK Accreditation Service.
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— Research and Technology Organisations (RTOs) are positioned between academia and business
users of technology. They are a range of companies and organisations whose activities bridge
gaps in the process of converting research outcomes into innovation and new technologies for
use. Examples include … the National Physical Laboratory providing knowledge-based services
to support the application of science and technology through better measurement. This
intermediate sector is an important part of the innovation system, and is estimated to contribute
£3 billion annually to UK GDP, and support over 60,000 jobs.
— The National Measurement Office, National Physical Laboratory and British Standards
Institution will work with international measurement and standards bodies and committees to
promote the UK’s strengths in measurement and standards and to the UK businesses associated
with them.
In conclusion it states:
— We believe that the intermediate sector is an under-used asset. It provides technical advice in
many sectors, including agri-food and water where we are seeking to encourage higher levels
of investment in innovation. We will work with RTOs to develop a strategy for using their
experience and expertise as part of the innovation ecosystem.
The Strategy clearly recognises the importance of the intermediate sector to the innovation ecosystem and
that it is an under-used asset. We would welcome an invitation to give further oral evidence on the vital role
of the intermediate sector to your Committee. The key points are illustrated in the following diagram which
shows the position of NPL as a member of the intermediate sector between academia and business. The diagram
uses Technology Readiness Levels (TRLs)79 to map out the journey from scientific discovery to industrial
exploitation. The intermediate sector carries out translational research developing technology from TRL 1 to 3
in academia to TRL 7 to 9 in the applied research laboratories of business.
Academia NPL Business
TRLs
NPL’s Academic Collaboration
• Assurance and confidence
• Enhance science excellence
• Technology Push =>NPL as route to impact
NPL’s Industry Collaboration
• Assurance and confidence
• Accessible knowledge and facilities
• MarketPull => NPL supporting innovation
Our work covers the entire TRL spectrum focusing on applied science
NPL as a National Science & Technology Laboratory
1      2       3       4        5       6      7        8       9
As a government laboratory NPL along with its innovation infrastructure partners of National Measurement
Office, British Standards Institution and UK Accreditation Service supports the commercialisation of research
all the way from product concept to trading.
79 TRLs were originally developed by NASA to describe the maturity of a technology from initial principles (TRL1) to actual
system demonstrated through successful operation (TRL9).
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However, whilst the strategy recognises the importance of Public Sector Research Establishments (PSREs)
like NPL for translational research, it does not include any recommendations to enhance their role. Our
experience is that involving the private sector in the operation of PSREs significantly increases their ability to
provide translational research services to help business, both large and small, to bridge the valley of death.
(See responses to Questions 8 and 9).
We have clear evidence of the value of the support NPL can give innovating business. In an independent
survey of 1,000 UK businesses, a benefit of £700M in additional profitability was identified for a single year,
dependent upon accessing measurement services to support product and process innovation.
8. Q6: Should the UK seek to encourage more private equity investment (including venture capital and angel
investment) into science and engineering sectors and if so, how can this be achieved?
Our experience is that involving the private sector in the operation of PSREs like NPL leads to innovative
solutions for the exploitation of their intellectual property. We give as an example the exploitation of a
technology for Point of Care diagnosis by NPL:
— The new science on which the technology depends came out of a government research
programme at NPL.
— Serco used an internally funded Strategic Research Programme for a Proof of Concept project
for the technology.
— The success of this project led to the establishment of a company Argento Diagnostics to exploit
the technology.
— Serco then provided management expertise and a loan of £2 million to Argento Diagnostics to
develop a prototype.
— Argento Diagnostics was spun out of NPL as a limited company.
— Good progress is now being made to fully commercialise the technology in its first application
for UK high performance sports groups.
9. Q7: What other types of investment or support should the Government develop?
It is our experience that involving the private sector in the operation of PSREs significantly enhances the
commercialisation of their research. If we take NPL as an example:
— Tripled its revenue from the commercialisation of its research since 2004 (now approaching
£25 million per annum).
— Established regional hubs in partnership with academia and industry to serve the needs of local
industry (eg laboratory at the University of Huddersfield).
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— Provided financial (£2 million) support and management expertise to exploit NPL intellectual
property through the spin out of a bio-diagnostic company.
— Supported the exploitation of intellectual property through the establishment of a Proof of
Concept fund for NPL IP.
— Invested £40 million in the last 10 years in scientific capital assets at NPL.
— Worked with many research partners, currently over 300 in the UK and abroad, and interacted
with nearly 2,000 SMEs.
— Brokered £100 million of funding for the de-risking of technology (£1M pa of which is provided
by Serco itself through the NPL Technology Innovation Fund).
— NPL has developed partnerships with major businesses in the UK, eg Rolls Royce and BP, to
help them innovate to continue to compete internationally.
However, such commercialisation is not at the expense of the science with NPL’s peer reviewed publications
and citations more than doubling since 2004.
Public Sector Research Establishments (PSREs) like NPL maintain significant scientific and technological
capability to fulfil their core government function, in the case of NPL to provide the UK national measurement
system infrastructure. NPL makes spare capacity on this capability available to business and government
customers through R&D services at commercial rates. NPL often receives inquiries from SMEs with a need to
de-risk a technology through the application of our specialist facilities and knowledge which they cannot to
afford to access, putting the commercialisation of their research at risk.
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APPENDIX
EXTRACT FROM LETTER FROM AGILENT TECHNOLOGIES (UK) LTD TO NPL
As you known, we made some significant changes to our European services business a couple of year ago.
The main theme of that change was to centralise many of our service deliverables such as calibration and
repair. With increasing complexity of our instruments and consequent increasing cost to maintain them, we had
to get a better utilisation of our equipment ands achieve a higher productivity. Due to its proximity to two of
our main factories and excellent logistics, we selected the Agilent site in Böblingen, southern Germany, as our
main European service operation.
At the same time as we made this decision, we also realised that we had to maintain and improve our high
frequency and accredited work. Although, it might have been more obvious to set this up in Böblingen, we
took the decision to expand our operation in Winnersh, UK to deliver this European wide service. One of the
main reasons that we made this decision was due to the close working relationship that we have developed
over many years with NPL and UKAS.
As you known, we have now completed a significant investment in our UK labs—both in terms of the
infrastructure and people. We are delivering an excellent service from this operation and it is, today, one of the
highest performance labs in Agilent. The services that we deliver from Winnersh are for customers both in
Europe and countries beyond. I am certain that without the guideance and consulting that we have had from
you and your colleagues in NPL, we would not have achieved that. In particular, the help that you gave us in
the last year to establish the IPIMMS and 50GHz Noise Source systems was invaluable. These are unique
services that were only made possible through the close cooperation of NPL, UKAS and Agilent engineers.
Written evidence submitted by ADS
About ADS
ADS is the trade organisation advancing the UK Aerospace, Defence, Security and Space industries.
Farnborough International Limited (FIL), which runs the Farnborough International Airshow, is a wholly-
owned subsidiary. ADS has offices in England, Scotland, Northern Ireland, France, the Middle East and India.
ADS comprises over 900 member companies within the industries it represents, of which over 850 are small
and medium enterprises (SMEs). Together with its regional partners, ADS represents over 2,600 companies
across the UK supply chain.
ADS also supports SC21, Sustainable Aviation, Defence Industries Council, RISC, Defence Matters and
hosts the Aerospace & Defence Knowledge Transfer Network.
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Background
Investment in Science and Research today will ensure that the UK maintains its cutting edge capabilities in
the Aerospace, Defence, Security and Space industries in the decades beyond.
— Investment in Science and Research has made the UK the largest Aerospace sector in Europe
and the second largest in the world after the USA. (17% market share), and worth over
£23 billion. to the UK, of which £16 billion. (70%) is exported world-wide. The sector directly
employs nearly 100,000 people in the UK, and supports a workforce of around 360,000. Total
R&D in 2010 amounted to £1.7 billion, more than 7% of annual turnover.
— The Defence Industry employs 314,000 people in the UK—directly and through the supply
chain. The industry is highly skilled, with 59 percent of workers holding a university degree or
equivalent. The industry invests 8% of annual sales revenue in research and development—
amongst the highest in industrial sectors.
— Around 450 companies within the membership of ADS are engaged in growing Security,
resilience and policing markets, at home and overseas, for which there are many interfaces with
UK Government, the police service, the other emergency services and operators of the Critical
National Infrastructure (CNI). Security-related SMEs maintain a heavy focus on upper tier
technologies and comprise 93% of the ADS membership. A recent survey completed by ADS
found that its members generated around £2 billion worth of business in the UK security market
during 2010.
— The UK Space industry recorded a total turnover of over £7.5 billion. in 2008–09. This
represented a real growth of 8% since 2007–08—the UK sector expects to grow 10% each year.
The sector is strong in areas such as satellite communications and satellite navigation, and well
placed to capitalise on new emerging services derived from Earth Observation, Cyber Security,
Cubesats, and Broadband Services. The global market is anticipated to continue to grow at a
robust rate of 5% on average in the next decade.
1. What are the difficulties of funding the commercialisation of research, and how can they be overcome?
1.1 The long technology development cycle within the four industries ADS represents means they have a
necessity for a balanced portfolio of Research and Development (R&D) at all times. The development of
technologies is iterative and achieved by evolution rather than a series of separate discoveries, so research
continuity and funding stability are essential.
1.2 Research in defence is falling. The UK Government spend on Research and Development is less than
half the level it was fifteen years ago. This, coupled with a loss in funding from agencies, like RDAs has
created a sense of uncertainty within industry and does not incentivise the private sector to continue its own
investments. Industry welcomes the Government’s decision to halt this decline and sustain investment in
Science and Technology at a minimum of 1.2% of the defence budget, announced in the “National Security
through Technology” White Paper. The Government must now work to reverse this trend to prevent our position
in the export markets weakening.
1.3 ADS members are already successfully engaging with some excellent Technology and Innovation
Centres, recently launched as Catapult Centres. The concern here is that while future new centres are
considered, high-performing existing ones need to be supported. A comprehensive mapping of what the UK
has already is necessary and ADS does not believe this has been done.
1.3.1 Industry welcomes the Catapult Centres and ADS believes that industry involvement with them
from an early stage, is essential. From inception, Catapults must work with large businesses
(who often have the best understanding of market demand) to pull through the best research to
meet their needs.
1.3.2 Over 850 of ADS’s members are SMEs, some of which are highly innovative, and funding for
the commercialisation of their research is vital. A barrier that often disincentivises industrial
participation, disproportionately affecting smaller companies is the overly bureaucratic
processes, particularly in applying for funding. Catapults should play both a direct and indirect
role in supporting the UK in assessing European R&D support.
1.4 The Centre for Defence Enterprise (CDE) has proved effective at bringing in new ideas and providing
them with seed corn funding, but there is little evidence so far of exploitation into products. Efforts should be
made to achieve downstream exploitation by bringing in companies that may provide exploitation funding at
an early stage in the process.
1.4.1 Award of CDE funds to an SME should include a commitment to pitch the idea to Primes and
CDE should be measured on its ability to stimulate ideas which then become attractive to
industry to fund.
1.4.2 Trade bodies could be encouraged to work with CDE on engaging with companies in receipt
of CDE support to see whether they can help companies develop beyond the seedcorn phase
and attract development funding. ADS has discussed the idea in principle with banks of bringing
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together with industry expertise to help provide potential lenders with better assessment of the
risks and thereby facilitate exploitation; ADS would welcome further discussion on this aspect.
2. Are there specific science and engineering sectors where it is particularly difficult to commercialise
research? Are there common difficulties and common solutions across sectors?
2.1 In the export-led Defence sector, Government has to decide whether the UK is simply going to buy from
the global market or whether it can and should stimulate an industrial base to generate the required
technological capabilities. The Catapult programme should ensure that key strategic capabilities remain
indigenous in the UK and the MOD now needs to clearly define its priorities so that necessary future R&D
can be understood. Only this will give Industry the confidence to invest. Joint planning for the technology
development between Government and Industry is the best way forward to ensure investment is complementary
and not duplicative and delivers the confidence needed to both sides. ADS looks forward to the publication of
the MOD’s 10 year equipment plan later this year.
2.2 In the Aerospace sector, the long term returns from R&D make it an unattractive capital market
investment and so Government intervention is key. The failure of the capital market is exacerbated by
international market skewing, where other nations including France, Germany and the USA, are specifically
backing their Aerospace Industries with R&D support. Such nations have recognised the growing market and
the long term economic benefits of a strong national Aerospace Industry. Future market predictions estimate a
£352 billion return between now and 2029 for the UK if it maintains its 17% global aerospace market share.
2.3 Some of the most successful advanced manufacturing technology programmes that have delivered
innovation and growth through the supply chain have been regionally supported. With the demise of the RDAs
and no assurance that funding for their innovation activities is to be retained, there is risk that these value-add
innovative projects will evaporate. ADS has led a federation of Regional Trade Alliances to deliver a range of
technology development and exploitation projects at the regional and local supply chain level, through a
programme vying for Regional Growth Fund support. The ENTASC will be a nationally supported, regionally
delivered programme, which will embed a variety of high value and advance engineering technological
capabilities into SMEs, enabling them to achieve growth in sectors such as aerospace, defence, automotive
and energy.
3. What if any, examples are there of UK-based research having to be transferred outside the UK for
commercialisation? Why did this occur?
3.1 There has been an erosion of the Aerodynamics research capability in the UK. Unlike in France and
Germany, whose Aerospace research centres conduct industry-relevant research to the benefit of industry but
at little or no cost to those companies, the UK is reliant on Universities and Research and Technology
Organisations (RTOs), working separately with no overall coordination. These Centres influence EU research
priorities within the Framework Programme (FP7) and draw down funding once it becomes available—all to
the benefit of their national Aerospace industries. The French and German aforementioned centres have
therefore been able to build their respective countries’ Aerodynamics capability, making them much more
attractive to global business. There is a genuine risk that future wing design and therefore manufacture, will
move to these nations for future generation aircraft.
3.2 ADS is working through the Aerospace Growth Partnership (AGP) process to define an Aerodynamics
centre for the UK. Having a stronger European voice will enable the UK to act as a beacon for large scale
European Technology Demonstrators as well as European Research Infrastructure and enable UK industry to
capitalise on the globalised market as is already happening in France and Germany.
4. What evidence is there that Government and Technology Strategy Board initiatives to date have improved
the commercialisation of research?
4.1. ADS is concerned that the Technology Strategy Board model is becoming increasingly unfit for the
Industries we represent, in particular Aerospace. ADS welcomes the Government’s recognition of the need to
develop the entire Innovation Ecosystem; however this may be undermined by discrepancies in funding levels.
Whereas Research Councils receive £3.5 billion per year, the TSB only receives £500 million: £300 million in
direct funding and £200 million funding for Catapults. The value placed on knowledge creation therefore is
greatly welcomed however this should not be to the detriment of knowledge exploitation, a critical part of the
process that the TSB should provide.
4.2. Technology Demonstrators are an effective route to maturing and exploiting R&D, enabling the
thousands of discrete parts of the supply to come together in order to integrate and demonstrate these
technologies at the systems level. They allow a fair and transparent partnership with mutual benefits for all
concerned; SMEs develop their technologies quicker, gain exposure through showcasing their capabilities and
assimilate invaluable knowledge of the sector; systems integrators are able to integrate those into products that
meet market demand; and critical mass is formed through a truly multidisciplinary approach.
4.2.1 ADS therefore welcomes the £25m investment in Technology Demonstrators announced in the
Government’s Autumn Statement 2011 however looks to the Government for future clarification
on which Industries will be set to gain from this investment.
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5. What impact will the Government’s innovation, research and growth strategies have on bridging the valley
of death?
5.1 ADS welcomes Govt commitment to ring fence Science investment but is concerned about the impact
on our industries of what constitutes a 5–6% cut in real terms over the CSR period. This is in stark contrast to
the US where the Administration is seeking an annual budget for the National Science Foundation in 2012 that
is 13% higher in cash terms that the 2010 figure. This is compared to the UK science budget which will be
6.7% lower in cash terms in 2012–13 compared with 2010–11
5.1.1 Science investment needs to be supported as part of the wider innovation climate, whereby base
research can be efficiently brought to exploitation. This is best done by aligning research with
national strategies such as NATS (National Aerospace Technology Strategy), which has been a
successful partnership between Government, Industry and Academia, transitioning research into
technology demonstrators and through to products that bring economic growth, exports and
sustains jobs in the UK.
5.2 Similarly, ADS welcomes the Catapults launched to date and looks forward to engaging with further
centres as they emerge.
5.2.1 Some very hard decisions will need to be taken to ensure that Catapults are supported at a
critical mass, so that they are effective. Spreading investment too thinly is not going to create
any critical mass of activity, and the activity will fail.
5.2.2 Strong coordination will be needed to ensure that Catapults not only avoid duplicating work
that is going on elsewhere, but also influence those research and innovations streams to ensure
maximum pull through and therefore business and economic impact. A governance structure
which allows this nature of interaction needs to be established. Catapults cannot become
independent commercial operations and must link in with other parts of the innovation system.
5.2.3 ADS strongly endorses that the Centres need to evolve to financially sustainable business
models. However, the TSB should recognise that some Government money will always be
necessary to make Catapults successful. Attempts to make them financially sustainable within
too short a time window will encourage them to focus on the types of activities that are going
to generate short term income, rather than on delivering long term targets.
5.2.4 Catapults need to operate flexibly and innovatively so that SMEs can engage at any point in
the process. Large companies will sign up from the inception of a 10 year programme, SMEs
will not. This flexibility of approach will enable supply chain companies in particular to
diversify into multiple sectors; the main effect of spill-over is at the lower end of the supply
chain, where technology advances and process improvements filter down and are available for
use in the range of sectors beyond those in which they were developed.
5.3 The Government has recognised the need to develop the Innovation Ecosystem as a whole rather than a
set of separate interventions and, in the Aviation sector, Industry is working with the Government through the
Aerospace Growth Partnership to identify not just the sector’s technology and innovation needs but broader
requirements too.
6. Should the UK seek to encourage more private equity investment (including venture capital and angel
investment) into science and engineering sectors and if so, how can this be achieved?
6.1 ADS believes that at a time of financial constraint, it is all the more important for investment in research
to be focussed on the right areas and effectively pulled through. One of the features of the advanced engineering
sectors ADS represents is the very strong interaction between public and private investment. Industrial R&D
is made possible and multiplied by public funding research and innovation. Cuts in public funding for research
gives the private-sector less confidence also to invest which will ultimately hurt UK economic growth, exports
and jobs.
6.2 Catapults will play an important role in fostering international technology partnerships and will be
increasingly prevalent in paving the way for exports. In order to attract additional funding and de-risk some of
the investments that others make, the Centres need central core funding from Government and have long-term
financial stability.
6.3 ADS would suggest that Government consult with the private equity sector to gain a deeper
understanding of the incentives that would encourage investment in the science and engineering sector, however
at the outset, it is likely that tax breaks for such investments and reduced capital gains tax on returns should
be considered as a first step.
6.4 Critically, the Government must work to help businesses, particularly SMEs access European R&D
funding. The new Horizon 2020 programme addresses many bureaucracy and relevance issues but businesses
have become increasingly disenfranchised throughout FP7 and previous Frameworks until now. Government
has a role to play in reversing this trend and providing the necessary support for businesses to exploit European
funding as it becomes available.
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7. What other types of investment or support should the Government develop?
7.1 The sectors that ADS represents are primarily affected by the changes in the Engineering and Physical
Sciences Research Council (EPSRC) budget. To ensure the future success of its sectors, ADS believes that
spending on Science and Research has to increase in the long-term. Despite financial pressures, the long-term
nature of research necessitates a growth plan that spans multiple parliaments. The current freeze is in effect a
real-term cut at a time when Science spending plans of similarly developed countries are rising.
7.2 ADS is also concerned that with the existing degree of uncertainty and real-term cuts, it will be difficult
to attract students to Science, Technology, Engineering and Mathematics (STEM) subjects. This could play out
as a vicious circle which erodes the science base—making the UK a much less attractive place to invest for
global businesses.
7.3 ADS recommends that Government consider funding for long-term, large collaborative Centres. This
would be an efficient way of using resources. A good example is the Advanced Simulation Research Centre
(ASRC) in the South West that brings together industry and academia around strategically important,
exploitation driven, multidisciplinary research, that benefits multiple sectors eg rail, marine, aerospace, wind
energy in the case of ASRC.
7.4 Through a range of regional and national programmes and investments, such as the Autonomous Systems
Technology Related Airborne Evaluation & Assessment (ASTRAEA) in the aerospace sector and Systems
Engineering for Autonomous Systems Defence Technology Centre (SEAS DTC) in the defence environment,
the UK has a global lead in terms of technical capability in developing and deploying autonomous systems.
Pockets and clusters of excellence exist, comprising the knowledge and skills to both develop and exploit these
technologies. A business-focussed Catapult in this area will enable a coordinated approach to investment in
innovation. Moreover, an Unmanned Air Systems (UAS) Catapult will ensure that promising research is
transitioned through the “valley of death” to realise its wealth-creating potential.
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Written evidence submitted by the Russell Group
Summary
— The Russell Group is pleased to contribute evidence to the S&T Committee’s inquiry. Russell Group
universities are partners of choice for thousands of leading businesses in the UK and internationally.
The UK’s world-leading institutions play a crucial role in stimulating economic growth, by engaging
closely with business, enhancing skills and competitiveness, and generating major new products and
world-beating spin-out companies.
— There are significant problems in the UK’s funding pipeline to take a research idea through to a final
product or service, including problems in accessing “proof of concept” funds and sufficient venture
capital (particularly compared to the US). It remains a significant challenge in the UK to secure
investment in new technologies.
— Government initiatives should aim to address the issues in the funding pipeline, in order to increase
the commercialisation of research. However, funds should not be diverted from basic research—this
would be counter-productive. Additional tax incentives, building on the past strengths of the
University Challenge fund, and strengthened support for the role of incubators would all be very
beneficial to take research from conception to commercialisation.
— To address the UK’s needs for accelerating technology and innovation, there is real value in building
on the strengths, competitive advantage and capacity of the UK’s existing research base. In straitened
times, it is important that Government funding continues to support research-intensive universities
in their innovation and knowledge transfer/exchange activities.
1. What are the difficulties of funding the commercialisation of research, and how can they be overcome?
1.1 Russell Group universities are partners of choice for thousands of leading businesses in the UK and
internationally. According to a recent survey by the UK Innovation Research Centre, academics at Russell
Group institutions are particularly likely to have taken out a patent, licensed their research to a company or
formed a spin-out than academics at other UK institutions. Data from HEFCE’s Higher Education Business
and Community Interaction survey showed that in 2009–10:
(a) Representing just 12% of institutions included in Russell Group universities between them
received 68% of all university contract research income from commercial businesses and
charities.
(b) 81% of universities with contract research with commercial businesses worth over £5 million
were Russell Group universities.
(c) Russell Group universities accounted for 61% of all intellectual property income generated by
UK universities and for over half of all spin out company turnover.
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1.2 The Russell Group has recently established a new initiative to drive forward collaboration with
companies and enhance innovation. A new high-level working group on innovation will engage with leading
industrialists and business leaders to realise maximum benefit for the UK economy from the world-leading
research activities of Russell Group universities.
1.3 Collaboration and exchanging knowledge and skills with business is a core part of the missions of
Russell Group universities. Russell Group universities are supporting businesses in developing and
commercialising new technologies in a variety of ways, including:
(a) Technology exploitation via technology transfer offices, or often via dedicated technology
transfer companies. For example, Imperial Innovations invested over £14 million in 20
companies in 2008–09, and external investment in its portfolio of companies was £41 million
in 2008–09, rising to £75 million in 2009–10.
(b) Provision of various kinds of incubation facilities for new companies, along with investment
and knowledge transfer/exchange support. An example is the University of Warwick, which has
a “virtual tenancies” programme that allows emerging companies to access the support and
facilities at Warwick’s science park without having to physically relocate.
(c) Incentives to access research expertise. Most Russell Group universities have knowledge
transfer/exchange secondment programmes in place. In addition, the Universities of Liverpool,
Warwick, Birmingham, Nottingham, Glasgow and Newcastle have awarded local businesses
thousands of pounds worth of “innovation vouchers”, enabling small companies to access
research expertise through consultancy or collaborative projects.
(d) In collaboration with industry and the Technology Strategy Board (TSB) Russell Group
universities have sponsored the two main advanced manufacturing research facilities in the
UK (the University of Sheffield at the Advanced Manufacturing Park and the Universities of
Birmingham and Nottingham at the Manufacturing Technology Centre).
1.4 The Higher Education Innovation Fund (HEIF) in England and Northern Ireland, and the Knowledge
Transfer Grant and Horizon Fund in Scotland, are major public funding sources underpinning the highly
successful knowledge transfer/exchange activities undertaken by Russell Group universities. These funds are
an essential component of the UK’s innovation system, enabling institutions to share high quality innovation
with businesses, diffusing knowledge into the economy and creating economic benefit for the nation. Many
universities in England use HEIF funding to support Proof of Concept funding, and such small scale funding
is critical, before seed and further capital becomes available.
1.5 The Government’s recent changes to the allocation of HEIF will help to ensure Russell Group universities
in England build on successful existing initiatives, and fulfil their potential in knowledge transfer/exchange
activities. Although a cap remains on the amount of HEIF funding available to any single institution—
restricting the ability of research-intensive universities to receive funding in proportion to the full scale or
excellence of their knowledge base—the Government’s changes to the allocation of HEIF are positive moves
in the right direction. At a time of constrained resource, it is essential to target the investment through HEIF
on those universities best able to translate world-class research and knowledge into economic benefit to the UK.
1.6 Universities still face considerable barriers in transforming ideas into social and economic impact due to
the risks perceived by the private sector regarding investing in new developments. A report by the Russell
Group shows that groundbreaking research conducted in Russell Group universities has resulted in far-reaching
impacts, but successful commercialisation requires sustained long-term investment, often over many years or
even decades.80 There are significant problems in the UK’s funding pipeline to take a research idea through
to a final product or service, including problems in accessing “proof of concept” funds and sufficient venture
capital (particularly compared to the US). It remains a significant challenge in the UK to secure investment in
new technologies.
1.7 Government initiatives should aim to address the issues in the funding pipeline, in order to increase the
commercialisation of research. However, funds should not be diverted from basic research—this would be
counter-productive. Instead, key areas the Government should consider include:
(a) Resources should be focused where there is most competitive advantage to be gained from
integrating research, teaching and translation. To address the UK’s needs for accelerating
technology and innovation, there is real value in building on the strengths, competitive
advantage and capacity of the UK’s existing research base. In straitened times, it is important
that Government funding continues to support research-intensive universities in their innovation
and knowledge transfer/exchange activities. Investments should complement rather than
compete with the current capabilities of the UK’s research base, and be considered on a national
(rather than regional) scale.
(b) The Government should consider further reforms to the tax regime which would particularly
encourage more investment in early stage high-tech companies. Changes in tax should make
a clear distinction between technology-based businesses, distinct from other small or early
stage ventures.
80 Russell Group The economic impact of research conducted in Russell Group universities (2010)
www.russellgroup.ac.uk/russell-group-latest-news/121–2010/4134-economic-impact-of-research-at-russell-group-universities/
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(c) The Government should build on the past strengths and lessons learned of the University
Challenge Fund. This scheme was instrumental in promoting collaboration across institutions,
attracting private sector investment in university companies, and developing seed funds in
universities. For example, the scheme assisted the development of Imperial Innovations.
(d) Early stage ventures could be supported further, for example through rebates in corporation tax,
allowing them to roll-over losses from one year to the next.
2. Are there specific science and engineering sectors where it is particularly difficult to commercialise
research? Are there common difficulties and common solutions across sectors?
2.1 The biosciences sector and large-scale advanced engineering in the UK benefit from major corporate R&
D activities. However, even within these sectors, business models are rapidly changing with companies such
as Pfizer closing sites in the UK. It is difficult to generalise across sectors, and the UK must not only sustain
sectors which are currently strong, but also foster sectors where the UK shows promise. The £180 million
“Catalyst” fund, targeted at the biomedical sector, is a welcome boost to our universities’ efforts to attract
outside investment. However, it is important that the UK’s cutting-edge research is supported from
conceptualisation to commercialisation in a range of other fields of research, with direct potential and
opportunity for competitive global businesses.
3. What, if any, examples are there of UK-based research having to be transferred outside the UK for
commercialisation? Why did this occur?
3.1 The knowledge exchange activity at the UK’s leading institutions is often compared to the US’s top
institutions, such as Stanford and MIT. While some have criticised the under-performance of UK universities
on licensing income with respect to the US, research shows that this could be attributed to the time lags in
achieving significant financial return from licensing, and the fact that US technology transfer operations have
been established for much longer, and have had more time to build a licensing portfolio. In addition, when
individual institutions are compared between the UK and US, on their ratio of income generated from
intellectual property to research expenditure, the analysis shows that the top UK universities operate on similar
levels to US universities such as Stanford, MIT, Harvard, Cornell and the University of Pennsylvania.
3.2 It should also be noted that some Russell Group universities release some of their IP to companies for
free to maximise the impact of research. The University of Glasgow, King’s College London and the University
of Bristol are leading the Easy Access Innovation Partnership, a collaborative project to promote new ways of
sharing intellectual property with industry through increasing engagement between universities and industry.
The University of Edinburgh has developed a licensing system to allow industry easy access to two packages
of university IP. This system complements the ut.com website that allows industry access to all technologies
available from Scotland’s key research universities.
3.3 Spinout companies in the UK tend to be acquired by companies outside the UK at a relatively early
stage. For example, a company originating from technology developed at Cardiff University moved to the US
early on in its development, due to lack of funding in the UK. Similarly, a company spun out of the University
of Bristol was acquired by a Belgian company due to lack of sources of capital in the UK. In addition, there
are examples at the University of Birmingham where commercialisation needed to take place overseas, as UK
businesses were not sufficiently interested in the technology.
3.4 The fundamental weakness contributing to the movement of commercialisation of research to outside
the UK is the lack of willingness of UK businesses to invest in early stage innovations (absorptive capacity).
Overall business investment in R&D in the UK (1.15% of GDP in 2008) is very low by comparison to the rest
of OECD countries. The best route across the Valley of Death is for UK businesses to be willing customers of
innovation, taking on risks with the potential for significant downstream benefits. However, the change needed
can only be achieved through the Government creating an improved environment for innovation by
strengthening tax and other incentives for companies investing in innovation, and by becoming an innovation-
focussed customer in its own right. Without action, the UK’s top researchers will continue to turn to commercial
partners overseas, leading to a loss of financial benefits to the UK economy.
4. What evidence is there that Government and Technology Strategy Board initiatives to date have improved
the commercialisation of research?
4.1 As noted in question one, HEIF and University Challenge Funds have made a real and positive difference
to commercialisation, knowledge transfer activities and seed funding within universities. Schemes such as the
Technology Strategy Board’s Knowledge Transfer Partnership (KTP) programme are also important in
developing partnerships to transfer research outcomes into the market. Adopting a planned and systematic
approach to communicating the benefits of KTPs to companies and academics is essential to increasing the
number of KTPs. For example, the number of KTPs at Cardiff has increased from five to 26 over the past
three years.
4.2 We welcome recent changes to TSB funding schemes which will develop closer working relationships
with universities. Members of the Russell Group collaborate enthusiastically with the TSB because they
recognise the TSB’s strength in assisting to translate outstanding fundamental science into marketable products
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and process improvements. There are examples where TSB funding has been essential in funding university
spin out companies. We would emphasise that TSB funding should complement, rather than compete with, the
current capabilities of the UK’s research base, and be considered on a national (rather than regional) scale.
Also, funding for the TSB and other initiatives to increase the commercialisation of research should not be
diverted from basic research—this would be counter-productive.
4.3 The Government will need to consider and monitor how the new Catapult centres fit within the existing
research environment. To achieve maximum impact the new centres should be closely linked to the world-
class research base within the country’s leading universities. Decisions for the location of these centres should
be based on proven academic expertise and industrial capability. Existing successful centres are often closely
associated with, or even embedded within, universities which have a critical mass of excellent research and
teaching, and a proven track record of translation.
4.4 The High Value Manufacturing Catapult Centre (involving Bristol, Sheffield, Birmingham, Manchester,
Nottingham, Warwick with Loughborough and Strathclyde) is acting to bring employees of established
companies (potential customers), early stage companies and academics together in an environment where co-
creation and co-location engenders the acceleration of technology adoption—this can be viewed as a an
embodiment of open innovation. This is well exemplified in the National Composites Centre, hosted by the
University of Bristol.
5. What impact will the Government’s innovation, research and growth strategies have on bridging the valley
of death?
5.1 We welcome the Government placing research and innovation at the heart of its growth strategy, and the
recent innovation and research strategy. However, we consider it is very difficult to predict the outcome on
bridging the valley of death. As outlined in questions one to three, we would urge the Government to go further
in addressing the problems in the funding pipeline taking research from conception to commercialisation, and
to introduce funds similar to the “Catalyst” fund for other sectors.
6. Should the UK seek to encourage more private equity investment (including venture capital and angel
investment) into science and engineering sectors and if so, how can this be achieved?
6.1 Yes. Relationships between investors and universities are highly productive, resulting in much learning
on both sides of different working cultures, and models such as Fusion IP, IP Group and Imperial Innovations
have helped bridge the gap between City investors and universities. The role of informed angel investors,
where expertise is perhaps more critical that investment capital, is well documented in the US and they are
increasingly playing a more prominent role in the UK.
7. What other types of investment or support should the Government develop?
7.1 As outlined in question one, we would welcome the Government developing initiatives that address the
entirety of the funding pipeline, from conception to commercialisation. Costs include IP protection, undertaking
effective market research, and investment readiness. We would encourage the Government to develop initiatives
that look at the funding pipeline as a whole, rather than developing initiatives that only address one part of the
pipeline at a time without consideration to other parts. Regional Venture Capital funds and Enterprise Capital
Funds have been very valuable, in many cases these are co-invest funds with Government funding or interest
matched against private capital.
7.2 The role of Incubators as ideal places to support, nurture and accelerate the fragile early stage companies
should be supported. This is exemplified by the family of SET squared Business Acceleration Centres (at
Southampton, Bristol, Bath, Exeter and Surrey). This model offers a proven route that ensure ideas “fail fast”
with a controlled closure, or are accelerated in a highly supportive yet totally commercial environment.
7.3 Government tax measures are valuable in supporting early stage companies across the Valley of Death.
The Enterprise Investment Scheme is important, and its extension into SEIS is helpful, as are R&D tax credits,
although take up at early stages can be low. The Government may wish to consider how R&D tax credits could
be both better promoted and simplified.
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Written evidence submitted by Engineering the Future
This report has been developed in collaboration by the following institutions:
— The Royal Academy of Engineering.
— The Institution of Chemical Engineers.
— The Institution of Engineering and Technology.
— EngineeringUK.
Engineering the Future is a broad alliance of engineering institutions and bodies which represent the UK’s
450,000 professional engineers.
We provide independent expert advice and promote understanding of the contribution that engineering makes
to the economy, society and to the development and delivery of national policy.
Introduction
A growing recognition exists within government, industry and the media that the UK needs to “rebalance”
its economy, moving the emphasis towards capturing value from wealth-creating products and services and
away from “financial engineering”. Recent government policies and announcements explicitly recognise the
need for economic recovery based on high-value, high-technology manufacturing. Ensuring that the UK
industrial system is able to capture value from products and services based on high-value and high-technology
manufacturing requires constant innovation and commercialisation of new products, services and business
processes to maintain a competitive advantage.
Innovation is not a simple linear process—it requires feedback from the market and timely investment at
critical points of development. The “valley of death” is used to describe that period in the development of a
product or service when a significant increase in investment is required, making the risk of failure much more
likely to outweigh any potential future return. It can occur in a wholly commercial organisation as well as in
the context of commercialising university research and new, nascent, technologies.
The “valley of death” is not necessarily an intrinsically bad thing. One of the things it does is act as a filter,
taking out poorly conceived propositions. Any change in policy to support the commercialisation of products,
services and processes must be wary of artificially prolonging the lifetime of those weaker ideas.
The problem with the strict economic approach to the investment process is that strategic priorities can be
overlooked. Processes to overcome the “valley of death” must be employed where products and services are
strategically fundamental to a business or provide sovereign capability to the UK. Without a long term approach
to maintain capability via the implementation of innovation into product development can and has resulted in
a leading position in a business sector being lost. The key is to identify those technologies where bridging the
“valley of death” is essential and those where a “fast follower approach” is sufficient. The role of the TSB to
provide a focus for long term capability investment is vital.
1. What are the difficulties of funding the commercialisation of research, and how can they be overcome?
1.1 New and established companies are still having difficulties in accessing working capital from banks on
appropriate terms. Overly stringent restrictions have remained in place despite much political comment.
Government should be using its position as the main shareholder in largely taxpayer-owned banks to enforce
a change in behaviour and increase lending to companies. The Business Growth Fund (BGF) is a new venture
where the government has formed a consortium of banks that are providing cash supported by government
guarantees. The target is to support rapid growth of selected SMEs in the annual revenue range £10 million to
£100 million. However, this is a new scheme and we await take-up and outcomes. The BGF consortium model
could possibly be extended to earlier innovation phases and including venture capital and private equity houses
alongside banks. The government has put into place measures such as the Enterprise Investment Schemes (EIS)
to support the commercialisation of research. EIS helps smaller high-risk companies and established SMEs
find funding by stimulating investment via tax-incentives. It is important for government to continue to
proactively publicise the scheme to ensure that the SME community is aware of it. Government should also
ensure that, in line with its approach to reducing bureaucracy, that schemes for SMEs are not overly
bureaucratic or burdensome which could then create a disincentive to engagement.
1.2 Capital is available from UK venture capital funds and private equity, but is usually short-term in nature.
Short-term thinking also means investors start looking for the exit route from a spin-out company at the time
of creation, and do not think about growing it into a large organisation. This has dissuaded investors from
supporting innovative research, which often takes much longer to return a profit. Another reason for this
attitude among investors is a lack of understanding of engineering propositions, and the timeframes needed to
develop and establish these types of businesses.
1.3 A closer relationship between universities and business should be developed to increase the amount of
successfully commercialised research. Open innovation, “combining internal and external ideas as well as
internal and external paths to market to advance the development of new technologies”,81 is encouraging
81 www.openinnovation.eu/open-innovation/
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collaboration between universities and industry. Catapult Centres and Local Enterprise Partnerships will play
an important role here. They can effectively reduce investment capital requirements for companies entering
certain markets by offering open access prototyping, scale-up and demonstration facilities. Catapults will also
form a hub for useful multi-company and university consortium activity. Government should continue to show
support for carefully chosen growth sectors where a comparative international advantage exists. This has been
done in the recently published Strategy for UK Life Sciences. These interventions show long term support for
these areas from government and give confidence to investors. Professional engineering organisations will also
continue to act as a conduit between business and academia, bringing parties together through events, projects,
awards and funding.
1.4 The management of companies spun out from universities is also a challenge when commercialising
research. Different universities operate different technology transfer models. Universities new to
commercialising research can tend to believe that ownership of the IP is vital. They encourage academics to
form as many companies as they can, in which the university holds equity and owns IP. Companies set up in
this environment can sometimes be ill-conceived and poorly managed. Universities with more experience may
come to recognise that ownership of IP is not as important as value gained through exploitation. Where a
company owns the initial IP, and the university is one of the shareholders, the company is free to act as it
wishes guided by commercial principle. Allowing organisations independent of universities to bid to run spin-
out companies could also reduce the fail-rate.
1.5 Both in the UK and in Europe, there is a political perception that innovation and rebalancing of the
economy will be driven by the private sector with a significant contribution from SMEs, which may be
somewhat optimistic. Larger established companies are the traction engine that pulls through smaller companies
in their supply network. They should be equally encouraged and supported to commercialise research, both in
their own right and in concert with SMEs and their own supply network companies.
2. Are there specific science and engineering sectors where it is particularly difficult to commercialise
research? Are there common difficulties and common solutions across sectors?
2.1 The globalised nature of business now means that the choice of where to develop and manufacture
products is strategically and commercially very important. For example, in the past, the UK had a strong
electronics manufacturing base, but this has now largely shifted to the Far East, where the costs, skills and
fiscal regimes are more attractive. The tax havens and investment grants offered by countries such as Singapore
have also exerted a powerful pull on the pharmaceutical industry. In this context, UK companies need to be
strategic in their decisions and ensure they remain in control of value of production, even if the products are
manufactured elsewhere.
2.2 The quality of the supply network in the UK can hinder the commercialisation of research in some
sectors. For example, the chemical process industry and chemical engineering have a highly fragmented supply
network, in many cases international in nature, and with a multitude of products, processes, roadmaps and
innovation processes. These characteristics make it very difficult to implement innovative supply networks.
Another example is batteries, fuel cells and hydrogen storage products, which cannot be manufactured in the
UK as there are few, if any companies able to operate to scale up production of materials. Inevitably the
exploitation at scale must be done elsewhere.
2.3 In sharp contrast to this are the automotive and aerospace industries where dominant OEMs actively
encourage innovative supply networks to form, because they know that a quality supply network is a
comparative advantage for the business. The innovations in the automotive industry are offering something of
a renaissance opportunity for the UK where the legacy in automotive and involvement in motorsport has
established a skills base.
2.4 A lack of understanding by investors of the technologies and regulatory environment can also be a
hindrance to the commercialisation of research in some sectors. Large scale process applications tend to need
plenty of capital investment and often require stringent regulatory constraints and approvals to be satisfied. In
this environment, it is hard to envisage a succession of small start-ups. Rather than trying to secure start-up
funding, smaller companies in sectors like this could approach larger companies and offer to licence their IP
to them.
3. What, if any, examples are there of UK-based research having to be transferred outside the UK for
commercialisation? Why did this occur?
3.1 Many instances exist of UK-based research having been transferred outside the UK for
commercialisation. Factors may include: favourable tax regimes, better funding opportunities, less government
bureaucracy or availability of a skilled workforce. However, a critical issue is where the value of production
is captured, which may not devolve to the country or region where products are made. For example, ARM
designs and licenses out intellectual property (IP) rather than manufacturing and selling chips. It is an extremely
profitable and rapidly growing business with profit before tax for 2011 up 37% on the profit forecast to
£230 million.
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3.2 An example of a company choosing to manufacture abroad that will be well known to the committee is
Plastic Logic.82 When considering manufacturing bases, three sites were shortlisted, Dresden, Singapore and
New York State, and judged on:
— access to local grant support and prospects for low operating costs;
— speed of the process from outline agreement to site hand-over; AND
— access to a skilled workforce.
3.3 Dresden was the winner, because it had an excellent skills base and there was clear support for
manufacturing through the German network of Fraunhofer Institutes. Although there is access to both these
advantages in the UK, planning and construction timescales in the UK are not competitive, particularly in the
more economically successful parts of the country.
3.4 Other companies that have previously tried to base manufacturing in the UK have moved manufacture
abroad. Cambridge-based charity Raspberry Pi had to revise their plans to manufacture their low-cost computers
in the UK mainly due to prohibitive taxation.83 The organisation blamed a lack of UK competitiveness as
well as HM Revenue and Customs for their decision to manufacture in Taiwan and China.
3.5 Further anecdotal examples of companies commercialising abroad exist. Ilika is a materials discovery
business using technology developed at the University of Southampton from EPSRC funding. No adequate UK
suppliers could be found to scale up the novel hydrogen storage materials and so it is being done in the US.
Another reason for commercialising abroad was that no UK end user for the material existed.
3.6 To ensure the value of production stays within the UK, the government should develop an integrated
strategy which differentiates it from other economic centres. A joined up approach includes the following
elements: a strong research base, a skilled and flexible workforce, an effectively integrated supply network
culture, supportive and stable government policy, a tax regime proven to encourage innovation and its
commercialisation and a supported R&D infrastructure from the new Catapult network, other TSB initiatives
and greater collaboration between universities and business.
4. What evidence is there that Government and Technology Strategy Board initiatives to date have improved
the commercialisation of research?
4.1 This is a question that the committee should pursue in more depth with the Secretary of State and the
TSB itself.
4.2 The Engineering the Future partners are supportive of the TSB. Commercialisation of products and
services is a long-term endeavour. As an organisation, TSB has been in existence for four years, the Small
Business Research Initiative (SBRI) started in 2001 and the first Catapult centres have only just been created.
In relation to schemes such as SBRI, there have been examples in other countries notably the Small Business
Innovation Research (SBIR) scheme in the US, where there has been considerable success in supporting SME
growth through public procurement.84 The TSB, SBRI and Catapult centres should be given more time and
resource to embed themselves properly into the specific technology areas they have decided to support and
develop their delivery practices before a full evaluation of their impact can take place.
5. What impact will the Government’s innovation, research and growth strategies have on bridging the valley
of death?
5.1 Among the developed European nations, the UK is unusual in that it has not historically supported
“intermediate institutes” of any significance and certainly not on the scale of the Fraunhofer Institutes
(Germany), TNO (Netherlands) or VTT (Finland). Instead, the UK placed greater emphasis on university
research with mixed results for the nation’s innovation performance. The creation of the TSB Catapult centres,
following the announcement of a £200 million innovation programme in 2010, was a welcome development.
The TSB could also coordinate a strategic programme to support and strengthen the supply networks.
5.2 At the SME end of the scale, innovation vouchers aim to encourage small firms to experience a low
cost, low risk taster of working with a university or an R&D organisation. The scheme now operates nationally
and a further tranche is expected in 2012. This scheme should be carefully monitored and, if successful,
maintained and expanded.
5.3 Annual reporting of R&D expenditure should be encouraged. It is regrettable that BIS chose to withdraw
funding from the well respected and widely used R&D Scoreboard in 2010. As a measurement of innovation,
knowing the amounts of funding is of limited use, but without the Scoreboard there is no way of comparing
R&D spend across the full range of industry sectors.
82 www.publications.parliament.uk/pa/cm200809/cmselect/cmdius/50/50i.pdf
83 www.zdnet.co.uk/news/emerging-tech/2012/01/11/raspberry-pi-enters-production-but-not-in-uk-40094792/
84 www.nesta.org.uk/publications/reports/assets/features/buying_power
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6. Should the UK seek to encourage more private equity investment (including venture capital and angel
investment) into science and engineering sectors and if so, how can this be achieved?
6.1 The UK should be encouraging more private equity investment. The key to achieving this is to make the
UK an attractive area to invest in. Countries such as the USA, Germany, Switzerland, France, Singapore and
China have a much clearer and better defined landscape that is understood by business. The UK is not clear
on what the strategy is to support the rebalanced economy. A much sharper, distinctive and consistent narrative
needs to be developed to highlight our innovative, entrepreneurial and commercial spirit grounded on excellent
science and engineering.
6.2 Existing government strategies (such as the new BIS Innovation and Research Strategy) point broadly
in the right direction, but often lack sufficient resources behind them to make a real impact. Government can
improve this by continuing to support and increasing the funding behind the work of the TSB and the work
they do. Schemes such as the Enterprise Investment Scheme should be more widely advertised in order to
further stimulate “Active Angels”. The government could also consider launching an Innovation fund, as
described in our answer to question 1.
6.3 A high level of technology ignorance exists within some sectors of the funding market. The engineering
profession has been working to bridge this gap and should be supported in continuing to do this. For example,
The Royal Academy of Engineering provides:
— Engineering Enterprise fellowships, enabling researchers to spend 12 months commercialising
their research with the help of business mentors and access to business angels.
— ERA Foundation Entrepreneurs’ Award, established to identify entrepreneurial researchers,
working in UK universities, in the field of electro-technology, who are at an early stage in
their career.
6.4 Regulators also have a role to play in some sectors. They should examine the need for capability
development and retention beyond the requirements of their license and authorisation conditions. This would
encourage further investment from outside sources.
7. What other types of investment or support should the Government develop?
7.1 There can be no innovation and growth without the skills base to drive it. With this in mind the
government should:
— maintain investment in engineering undergraduate education;
— take steps to encourage companies to invest in training (such as tax breaks on training costs);
— facilitate easier take up of visa rules for STEM academia and those who bring both learning
and experience (such as chartered professionals including chartered engineers);
— continue to reduce bureaucracy around apprenticeships; and
— provide loans for postgraduate study.
7.2 Universities and industry should be encouraged to cooperate. Incentives to encourage individual
academics and universities to undertake high quality industry outreach, both on a national and international
level, as well as academic research could be created through the REF scheme. The Wilson Review of university-
business collaboration may provide further guidance on this. Universities should also be encouraged to
cooperate rather than compete with each other, both within the UK and internationally. The recent
announcement to exempt universities from VAT on shared services is a strong signal of support from
government in this area.
7.3 Government can also encourage innovation further in the UK by:
— acting as a smart customer, driving innovation through procurement;
— strengthening UKTI’s capability in engineering and science;
— negotiating trade agreements that include collaboration and innovation; and
— creating a regulatory environment that can encourage innovation.
7.4 Companies should be encouraged to base their R&D activities within the UK. Putting into place tax and
funding policies that have been successfully shown to support R&D activities within companies would
encourage this. The NESTA supported study Innovation: what works? may provide some guidance in this area.
Additional benefits to companies beyond R&D tax credits should also be examined where re-investment is
towards UK infrastructure and academia. Bodies offering funding for R&D should have simple, transparent
and fast response administrative processes for grant applications. Grant funding and tax relief facilities should
also be continuously available, with no artificial deadlines for applications. Multinational companies
headquartered in the UK should also be allowed to offer secure career paths to top talent from overseas.
7.5 Government should also continue to support the work of the engineering professional bodies to promote
engineering within the UK. These bodies work to bring people from industry and academia together and also
by recognising companies and individuals that have contributed to innovation in the UK by means of award
schemes. They also provide funding for researchers keen to commercialise research. Initiatives which raise the
Science and Technology Committee: Evidence Ev 169
profile of engineering within the UK, such as the Queen Elizabeth Prize for Engineering, Tomorrow’s
Engineers, The Big Bang Fair and I’m an Engineer, get me out of here! should also continue to be supported.
February 2012
Written evidence from the Technology Strategy Board
Introduction
1. The Technology Strategy Board is a business-led organisation with a leadership role to stimulate
technology development and innovation for the benefit of UK business in the areas which offer the greatest
potential for boosting UK growth. The organisation operates across Government and advises on polices which
relate to technology, innovation and knowledge transfer. The Technology Strategy Board is the UK innovation
agency and acts as the prime channel through which the Government incentivises business-led technology
innovation.
2. The Technology Strategy Board was established in July 2007 and has invested more than £1 billion to
date, the majority of the funding being matched by business. It has directly supported around 4,000 companies
and works with nearly every University in the UK as well as many further education organisations.
3. The route from idea to new product or service is neither straightforward nor always linear, requiring lots
of different interactions. In our strategy for the period 2011–15, “Concept to Commercialisation”,85 we set
out the role of the Technology Strategy Board in providing financial stimulus to support R&D and innovation
as well as the importance of connecting the innovation landscape. This involves supporting interaction between
the science base and business at earlier stages of research & development as well as between business and
private sector investors at the later stages of commercialisation.
4. Our partnership with Research Councils UK (RCUK) enables the Research Councils to take advantage of
the business-led expertise of the Technology Strategy Board in catalysing innovation in focussed priority areas;
and enables the Technology Strategy Board to capitalise on the Research Councils’ role in funding and
influencing excellent research and knowledge transfer—so that both are more effective in strengthening the
knowledge-based economy and attracting inward investment.
5. The commercialisation of research and the support of innovation across the economy are vital to deliver
future products and services and to generate economic growth. The Technology Strategy Board welcomes
the Committee’s inquiry and we make the following points in response to the specific questions raised by
the Committee.
Question 1—What are the difficulties of funding the commercialisation of research, and how can they be
overcome?
6. Looking firstly at funding the commercialisation of research by public sector organisations, bodies such
as the Technology Strategy Board operate against a set of rules which underpin the types of support which can
be provided. This includes the need to demonstrate market failure and additionality and to operate within
European State aid rules.
7. Market failure, as set out in the Treasury Green Book,86 refers to “where the market has not and cannot
of itself be expected to deliver an efficient outcome”. We therefore need to ensure that the projects we are
supporting address the additionality criteria and we are not supporting projects which the private sector should
support. European State aid rules govern how far we can help a business take a product through to
commercialisation. The rules generally allow the funding of R&D and innovation projects up to the
development and demonstration of prototypes but not beyond, although there is greater flexibility for early
stage SMEs.
8. Looking at the question from the perspective of a business, it is usually the case the closer the research
gets towards commercialisation the higher the costs tend to be and accessing the necessary funding and skills
becomes more of an issue. The development and demonstration phases tend to be the phases where there is
the highest level of risk and also the highest cost.
9. The deployment of wave and tidal devices or the need to undertake clinical trials for the introduction of
a new medical product are two examples where moving from research towards commercialisation is a huge
step. The level of funding needed can be significant and even if the required performance can be achieved,
doing so at the necessary price point can be a major hurdle. In some cases this can be made more difficult if
regulatory or environmental compliance is lengthy and costly in the home market or overseas.
10. To overcome these issues, we are looking at ways of better joining up with other parts of the innovation
system to help businesses move innovative projects closer to commercialisation more easily. This includes
developing better connections with the private equity community who can fund projects through to
85 www.innovateuk.org/_assets/0511/technology_strategy_board_concept_to_commercialisation.pdf
86 www.hm-treasury.gov.uk/d/green_book_complete.pdf
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commercialisation as well as working with experts in areas such as design, IP protection, legal and corporate
finance advice, business coaching and mentoring providers, incubators and accelerators.
11. The European Commission is currently undertaking a consultation on the “Review of the EU state aid
rules for research, development and innovation”.87 We will be providing input to that review looking at how
the rules can be improved to enable us to provide better support to business, particularly towards
commercialisation.
12. One of the key issues of bridging the gap between research and commercialisation is scaling up and
demonstrating technology. One of the advantages delivered by our programmes, and where we have achieved
some of our biggest successes to date, is the ability to demonstrate at scale. We have supported large scale
demonstrators such as the Retrofit fit for the Future programme with 87 dwellings in the UK being used to
assess the potential of new approaches to reducing the environmental impact of the current housing stock. The
Low Carbon Vehicles Innovation Platform demonstration programme trailed 340 low carbon vehicles on the
roads in the UK helping to test and validate the technology and to understand the user issues. The Innovation
Platform is expected to continue for up to 10 years, and co-ordinates the UK’s low carbon vehicle activity
from initial strategic research through collaborative research and development, leading to the production of
demonstration vehicles and the strengthening of supply chains. The long term nature of the programme, agreed
with all stateholders, is important in developing the long term vision and for engaging with business who want
a consistent approach.
13. We are also in the process of implementing the DALLAS programme which is currently being developed
to test out assisted living technologies with approximately 50,000 users across the UK. Only by undertaking
these trials, too expensive for any one company to do on its own, will business be able understand how
technologies and systems work in practice which can then feed into their development pathways.
14. The Technology Strategy Board has an annual budget of approximately £330 million per annum to
support R&D and innovation activities across the economy. With the three demonstrator programmes mentioned
costing over £20m each there is a limit to how many we can run, which is why the Government in the Autumn
statement provided an additional £25 million to deliver another demonstrator. There are opportunities to do
more.
15. To further support the UK’s capability to commercialise research, we are currently putting in place a
network of Catapult centres. As well as the core support the centres provide, we expect them to have a much
larger impact on the overall innovation system in the UK and a greater impact on supporting the
commercialisation of research. The Technology Strategy Board, RCUK and the Funding Councils are
developing a joint strategy to encourage collaboration between the research base and Catapults to maximise
the benefit to the UK’s innovation landscape.
Question 2—Are there specific science and engineering sectors where it is particularly difficult to
commercialise research? Are there common difficulties and common solutions across sectors?
16. The Technology Strategy Board works across the economy and has a good view of the problems faced
by different sectors. Examples include the high costs for the development, deployment, testing and validation
in the energy sector such as for wave and tidal devices or the long timescales it often takes to move research
to commercial product in the life sciences and healthcare sectors as well as regulatory environment in which
companies must operate.
17. Distruptive technologies can be particularly difficult to commercialise and we have developed an
Emerging Technologies and Industries strategy88 exactly for this scenario. The strategy has four themes: invest
in demonstrators, generate critical mass, create a nationally co-ordinated programme and nurture capability.
18. The difficulties however tend to relate less to specific areas of science and engineering and more to a
set of generic issues. The journey of moving a concept through to commercialisation is often complex, requiring
many different steps and interactions. There are a number of problems and challenges which we consider
impede this journey, in particular:
— Business investment is too low and too late—The immaturity of technology leads to uncertainty
about time to market, development costs and commercial viability. Small businesses in
particular lack the capital to invest and are seen as higher risk investments by capital providers.
Investment in new and emerging markets is delayed because total market size and rate of
development is uncertain. Many businesses will wait until the market development is clearer
and are likely to miss valuable opportunities.
— Innovation disrupts value chains and business models—New technologies, and technologies
newly applied to existing markets, can disrupt existing relationships and value chains. Bringing
new technologies to market requires discussions and relationship building with multiple
players—public (standards, regulation) and private (suppliers, competition). This requires time,
effort, knowledge of players in new technologies and the ability to bring parties together which
is generally beyond the capabilities of individual businesses, particularly SMEs.
87 http://ec.europa.eu/competition/consultations/2012_stateaid_rdi/
88 www.innovateuk.org/_assets/pdf/corporate-publications/tsb_emergingtechnologiesstrategy.pdf
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— Longer term trends not visible to all players—Longer term opportunities can emerge from
emerging technologies, new uses of existing technologies, cross over applications from one
sector to another, new challenges for society, or new government policies. These are not always
visible to all players.
— Innovation infrastructure complex and inefficient—The public (and private) innovation system
is complex, fragmented and often difficult to navigate. Information and knowledge does not
flow optimally through the system.
— Government does not make best use of its levers—Government action in areas of procurement,
regulation, standardisation and fiscal incentives shapes markets, but not always in a way that
benefits UK business the most.
19. In supporting the commercialisation of research, there are some issues although not directly linked to
the difficulties of funding, which do have an impact on the ability to commercialise the research. There are
issues such as making the first connection and bringing business, particularly SMEs, together with academia.
There are often differences between business and academia in the language used and also in expectations in
terms of timescales and the value of intellectual property. These issues largely come down to a lack of
understanding from both sides as to how each other operate.
20. It is important to help the business and academic communities forge closer and better relationships where
the translation of research happens more naturally. The initial engagement can be achieved through tools such
as innovation vouchers or support such as that provided by the Knowledge Transfer Networks where there is
the capability to put a company in touch with the best academic to meet their needs, which might not necessarily
be the closest. The relationship can then be taken forward through different routes such as collaborative R&D
projects which provide a focus for the relationship. The Technology Strategy Board’s connect platform also
provides a novel way for business and universities to network, collaborate and share knowledge online.
21. The network of Catapult centres will add a new dimension to the support being provided, giving
companies access to the equipment, facilities and expert knowledge in the centres which would otherwise be
unaffordable or unattainable for small companies.
Question 3—What, if any, examples are there of UK-based research having to be transferred outside the UK
for commercialisation? Why did this occur?
22. Academia and business operate on a global basis and value chains are increasingly global in nature and
so it is likely the value from UK research will not all be generated in the UK. Universities are increasingly
seeking private funding from overseas to support spin-outs and with large companies manufacturing in many
locations, the commercilisation of research overseas may be the manifestation of a healthy global manufacturing
presence. Other factors include the need to compenstate for only having a small domestic market by developing
new products and services where they are most likely to be exploited and a difficult regulatory environment
making it easier and more efficient to obtain approvals and access markets overseas.
23. There is evidence of early stage companies that have moved their focus to the US in order to access the
necessary funding for comercialisation and scale-up, such as from the US venture capital sector and the US
Government through the SBIR programme. For example, a UK academic spin-out became a US registered
company so that it was able to access support through the SBIR programme in order to get the funding needed
to move the business forward. A condition of SBIR is that the company must be registered and have a US
base. Although that particular company has a growing footprint in the UK, such a move away from the UK
could well lead to a greater shift to the US overtime.
24. It is necessary to accept that we are in a global market and so can expect some offshore ownership. The
issue is how to get non-UK companies to spend and anchor their R&D money in the UK, including through
centres of expertise such as the Catapults and by creating a favourable investment environment.
Question 4—What evidence is there that Government and Technology Strategy Board initiatives to date have
improved the commercialisation of research?
25. There are a number of studies conducted over the last 3 years showing the impact of the initiatives
supported by the Technology Strategy Board, in particular Collaborative R&D,89 Knowledge Transfer
Networks,90 Knowledge Transfer Partnerships 91and an early assessment of SBRI.92 The economic evidence
of impact of our programmes shows in the region of a 10 to 1 return on investment with an indication that our
more recent “demand led” approach is delivering higher returns. The evidence shows that 83% of the projects
supported will deliver products or services likely to reach the market and that the majority of businesses would
not have invested in the project without government support. Other impacts demonstrated include collaborative
R&D projects delivering on average an additional net 33 jobs per project and softer impacts such as enhanced
image and reputation and skills for the businesses involved.
89 www.innovateuk.org/_assets/pdf/publications/pacec_evaluation_of_crandd_report.pdf
90 www.innovateuk.org/content/press-release/knowledge-transfer-networks-reviewed.ashx
91 www.innovateuk.org/_assets/pdf/corporate-publications/ktp%20strategic%20review%20feb%202010.pdf
92 www.nesta.org.uk/publications/reports/assets/features/buying_power
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26. The evaluations of individual schemes do not however demonstrate the impact of the Technology Strategy
Board overall such as the role we play in the innovation system and the value we add through our convening
power, bringing communites of people together from different backgrounds to move an area forward. A review
of the Technology Strategy Board will be carrried out during 2012.
Question 5—What impact will the Government’s innovation, research and growth strategies have on bridging
the valley of death?
27. Taking into consideration the time lags in the system, the true impact of the Government’s strategies in
these areas may not be known for some time. We do however feel that the Government’s strategies provide a
framework and contain all the elements necessary to help reduce the impact of the “valley of death”. The next
stage is very much the co-ordination of all the different activities, both public and private, to ensure the sum
is more than the individual parts.
28. The Government provides a wide range of support including investment in the knowledge base, advice
and guidance, funding to support R&D and innovation projects (grants, contracts, equity investment through
funds of funds), through to infrastructure and centres. To help address the valley of death the various forms of
support need to be used collectively and in a way that efficiently and effectively moves an idea from concept
to commercialisation.
29. There is one vital ingrediant necessary to underpin this approach which is continuity, both of funding
and commitment, over the long-term.
Question 6—Should the UK seek to encourage more private equity investment (including venture capital and
angel investment) into science and engineering sectors and if so, how can this be achieved?
30. The simple answer to the question is yes. It is important to create an environment which encourages
such investment to happen. The Enterprise Investment Scheme, Seed Enterprise Investment Scheme and
Venture Capital Trust tax reliefs are examples of where the Government has put in place support which helps
to encourage such investment and are viewed positively by business and at the same time felt to be under
publicised. There is also potential to attract more foreign investment into the UK.
31. As well as creating the environment, a potential way of addressing the “valley of death” is to create
better linkages between the support provided by the public and private sectors. The Technology Strategy Board
support of R&D and innovation projects provides a way of de-risking the technology, therefore making it more
attractive to potential investors. Each project funded will have been selected from a wider number of
applications and been subjected to a technical and financial assessment. By the end of the project, in most
instances, the technology will be closer to market making it more attractive to potential investors.
32. We are currently looking at ways of providing greater visibility of the businesses and projects we support
as well as making the best connections to the private investor community, including working with organisations
such as Capital for Enterprise. We are looking at the potential to use an online database of projects seeking
support as well as creating opportunities where companies needing finance can meet with or pitch to those
looking to invest. This approach was trialled recently as part of the Tech City Launchpad competition.
Companies successful in obtaining a grant of 50% from the Technology Strategy Board were given up to 12
months to obtain the other 50%. To help them obtain the funding, companies were brought together with
potential private investors and provided with access to other business support, such as organisations providing
“investment readiness” training and business coaching and mentoring.
33. There should certainly be an encouragement of more private equity investment into science and
engineering. The soultion rests with creating the right environment and the need for greater communication
and visibility, creating the linkages between those seeking finance and those looking to invest.
Question 7—What other types of investment or support should the Government develop?
34. It is our view that Government does not necessarily need to introduce new types of support, but ensure
the greater use, co-ordination and alignment of existing support. Our strategy “Concept to Commercialiation”
as well as the Government’s “Innovation and Research Strategy” both set out plans for the greater co-ordination
of publically funded support, together with building the links to sources of private funding.
35. There is the opportunity to do more to support the commercialisation of research by government acting
more as a lead customer, supporting innovative ideas which address policy challenges faced by government
departments and the wider public sector. The combination of a potential government contract and the use of a
mechanism such as SBRI can help to rapidly move research towards commercialisation. The first customer can
be the lifeblood of a new company and so a contract from Government to support R&D such as through SBRI
has the potential to have an enormous impact. Our experience of the projects we have supported through SBRI
is that they are particularly attractive to the private finance community.
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36. A good example is Eykona Technologies, a company spun out of University of Oxford in 2007, which
is developing a wound measurement device. The company won funding through SBRI in October 2010 and
since then has raised £2.4 million of private funding and grown from 4 to 14 employees.93
37. Schemes such as Smart can help companies access funding of between £25k and £250k, often the level
of funding needed to get an idea off the ground but difficult to access from private sources such as institutional
investors and banks. There is huge demand for funding through Smart and at present only the best of the best
projects are funded.
38. The Catapult centres are a new edition to the innovation landscape and will once established will play
an effective role in helping with the translation and commercialisation of research. The Innovation and Research
Strategy announced that the Technology Strategy Board would be responsible for delivering innovation
vouchers and again they have a role to play helping to create the initial engagement between SMEs and
academic institutions. There are also other models which are showing promise such as the Easy Access IP
model developed by the University of Glasgow.
39. The new Business Coaching for Growth programme will be important in ensuring that high-growth
SMEs (including those that seek to take research-led business ideas to commercialisation) have access to
support in developing their commercial capabilities and connecting with private sector sources of early-stage
funding. We will work actively with the BCG providers to signpost this service to appropriate companies.
40. The Technology Strategy Board and the Research Councils are working closely together developing joint
strategies and co-ordinating and aligning activities in a number of areas. An example is the recently announced
Biomedical Catalyst Fund, a joint activity between the Technology Strategy Board and the MRC aiming to
help the commercialisation of MRC funded research. Another example is the Innovation and Knowledge
Centres (IKCs) which are centres of excellence with five years’ funding to accelerate and promote business
exploitation and to build critical mass in an emerging research and technology field. Their key feature is a
shared space and entrepreneurial environment, in which researchers, potential customers and skilled
professionals from both academia and business can work side by side to scope applications, business models
and routes to market. To date, six IKCs have been supported.94
41. The key activity across all of the areas is joining up the support and making it simple and easy to access.
There is the potential for more co-ordinated strategic programmes between the Research Councils and the
Technology Strategy Board to ensure continuity of support across the innovation system. There is the potential
to do more through schemes such as SBRI and Smart and to ensure new activities such as the Catapult Centres
and Innovation Vouchers form part of the overall support system.
Conclusion
42. The valley of death is not something unique to the UK and is an issue countries globally are trying to
overcome. The need however to move ideas more rapidly to commercial products and services is vital to
generate economic growth. More needs to be done in a more joined up manner to make the UK a truly
attractive investment proposition in terms of fiscal measures, skills, labour flexibility, supportive regulatory
environment and facility to navigate.
43. We need to create a favourable environment in the UK which supports investment and makes the UK
an attractive proposition for overseas investors and companies looking to fund and locate their R&D here. The
Government could act more as a lead customer and ensure that approvals processes, which can be lengthy and
costly, do not unduly impede a companies progress. There needs to be a higher level of co-ordination of the
existing support that is available to help businesses and to more effectively create the links between the support
provided by the public sector and the private investment community.
44. Long-term continuity of funding and commitment are vital. A lot of the basic ingredients are in place or
in progress. Co-ordination of effort is now what is needed.
Case studies of projects supported by the Technology Strategy Board can be found at—
http://www.innovateuk.org/publications/case-studies.ashx
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93 Video cases studies—www.innovateuk.org/content/case-study/sbri/nhs-east-of-england-healthcare-competitions.ashx
94 www.epsrc.ac.uk/funding/grants/business/schemes/Pages/ikcs.aspx
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Written evidence submitted by Research Councils UK
Key Points
Research is a vital component in the UK innovation landscape, as highlighted within the Innovation and
Research Strategy for Growth economics paper.95 Research Councils are instrumental in shaping the research
landscape to play a leading role in the innovation ecosystem—through the research we fund; the infrastructure,
both nationally and globally, we support; the talents we develop and help prosper; as well as the partnerships
with business and government that we forge on behalf of UK research; the Research Councils nurture
innovation and the broad contributions of research to the growth and wellbeing of the UK.
Research Councils UK consider that there is no single point of failure—or “Valley of Death”—that affects
the whole innovation system, but sector by sector there are a number of different aspects where there can be
insufficient progress towards impact. Commercialisation problems are often sector specific and therefore there
is no single solution. In order to ensure that the innovation ecosystem is highly effective it is important to
address the full range of factors including funding, regulation and cohesion of different sectors working across
actual or perceived boundaries.
One of the key challenges identified by the Research Councils for commercialising research ideas is the time
required to take research forward to the point of commercial output. This can vary widely and is often over a
long timescale, with significant consequences for securing commercial funding and interest. Commercialisation
of a research idea or innovation also carries considerable scientific and technical risk and the less developed
the idea, the greater the risk. At a time when the economic climate is challenging, the risk appetite across all
sectors of business may be expected to be reduced, with the consequence that engagement with, and investment
in, early stage ideas will be more challenging. In various sectors, the challenges of time, investment and
risk can combine to create serious “valleys”. We believe public intervention from the Research Councils—in
coordination with others—to support the timely de-risking of scientific96 and technical breakthroughs, and to
aid commercialisation of research outcomes, can result in substantially greater impact. In addition, our support
can enable the leverage and deployment of further funding from both the public and private sector.
1. Research Councils UK (RCUK) is the strategic partnership set up to champion the research supported by
the seven UK Research Councils. RCUK was established in 2002 to enable the Councils to work together more
effectively to enhance the overall impact and effectiveness of their research, training and innovation activities,
contributing to the delivery of the Government’s objectives for science and innovation.97
2. This evidence is submitted by RCUK on behalf of all the Research Councils and represents their
independent views. It does not include, or necessarily reflect the views of the Knowledge and Innovation Group
in the Department for Business, Innovation and Skills (BIS).
The Research Councils’ Role in the Innovation System
3. The commercialisation and exploitation of the UK’s world leading research is critical for enabling
innovation, contributing to the growth of the economy and tackling societal challenges.
4. The Research Councils believe the inquiry is considering commercialisation as the process by which the
outcomes of research activity are brought to the market place through the development of new or improved
products, processes, services or technologies. The innovation process is non-linear and complex, as explained
for example in the BIS Innovation and Research Strategy December 2011. The term “valley of death” can be
a useful way of looking at issues of commercialisation in some sectors, for example, we consider the Catalyst
fund98 to be an effective solution in the biomedical area. However, this approach is not necessarily appropriate
for all sectors, and in some sectors the concept of a “valley of death” can be misleading through its implication
of a linear journey. Other sectors have different complexities and challenges which require appropriately
tailored solutions.
5. Whilst the commercialisation of outcomes is an important mechanism through which research delivers
benefit and impact, there are a wide variety of other ways through which research can deliver benefit to society
and the economy. A broad range of knowledge and support models are necessary. A critical aspect of this is
the role of highly skilled people as carriers of knowledge and tacit information, and as the potential recipients
and interpreters of new knowledge, providing critical absorptive capacity in business.
6. The Research Councils have several different roles in supporting the UK’s innovation landscape. First of
all we provide leadership in funding world-leading research that has the potential to lead to innovative products,
processes, services or technologies. We also provide a number of interventions to develop research outcomes
95 Innovation and Research Strategy for Growth Economics Paper (No. 15)
www.bis.gov.uk/assets/biscore/innovation/docs/e/11–1386-economics-innovation-and-research-strategy-for-growth.pdf
96 Adhering to the BIS definition of science “encompassing research and practice in the physical, biological, engineering,
mathematical, health and medical, natural and social disciplines, and research in the arts and humanities”.
97 www.rcuk.ac.uk
98 www.mrc.ac.uk/Newspublications/News/MRC008394
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into economic and societal impact. Some of these interventions are outlined below (see Appendix 1 for further
information on the Research Councils interventions). The Research Councils:
6.1 Fund collaborative research and knowledge exchange which provides opportunities for the co-
production, application, exploitation and commercialisation of research between business and
academia. To achieve this we usually fund the higher education sector directly to support
collaborative research projects.
6.2 Provide flexible finance to allow the outcomes of research to be developed towards wider
benefits within the higher education sector including supporting the very early stage of turning
research outputs into a commercial proposition. This funding helps take an idea to the stage at
which the potential for commercialization is more clearly defined, enabling the possibility of
securing further funding to progress.
6.3 Support initiatives and opportunities for early commercial development of research produced
by research staff working in their institutes, for example through the Rainbow Seed Fund,99
MRC-T,100 and STFC Innovations Ltd.101
6.4 Train the next generation of researchers and innovative people through investment in doctoral
training. This is an extremely important route for the provision of highly skilled people into
business. Indeed, 56% of doctoral graduates, three years after graduating, are employed outside
of higher education.102 The Research Councils training portfolio also includes major
collaboration with business for example through CASE studentships103 and Industrial
Doctorate Centres.104
6.5 Maintain a broad, deep and direct relationship with the business sector and work in partnership
with major UK and global companies to support relevant pre-competitive research. We work in
partnership with business at all levels from business members on our Councils, strategic
partnerships with sectors or individual companies, to facilitating relationships with business at
the individual project level. The Research Councils portfolio includes collaboration with over
2,500 companies including many small and medium sized enterprises (SMEs).
6.6 Build connectivity in the innovation ecosystem by working with innovation and knowledge
infrastructure partners including the Technology Strategy Board,105 Funding Councils, and the
Design Council, and key Government departments including the Department of Business
Innovation and Skills (BIS), Ministry of Defence (MOD), Defra and the Department of
Health (DH).
6.7 Promote a culture within the research base where commercialisation can thrive and commercial
research outcomes are recognised and rewarded appropriately. The Research Councils are
working closely with other key stakeholders such as the Higher Education Funding Council for
England (HEFCE)106 and the other Higher Education funding bodies to achieve culture change
within the research base; key drivers include Pathways to Impact, the Research Excellence
Framework (REF) and Higher Education and Innovation Funding (HEIF). For example,
Pathways to Impact was implemented in 2009 within the application and assessment process
for Research Council funding. This policy encourages researchers to explore pathways for
realising the impact of their research, including where appropriate, pathways towards
commercial application early in the research process.
6.8 Operate or fund innovation-led campuse,s107 centres, institutes and facilities, which create a
critical mass of facilities, equipment, skills, and innovation-led research and provide a platform
for businesses, universities and the research base to undertake collaborative projects. These
investments make a key contribution to the UK innovation system in a global context, ensuring
that our research contributes to UK economic growth, national security and societal well-being.
Research Council operated campuses, centres, institutes and facilities are complementary to the
Catapult Centres that are being established by the Technology Strategy Board.
6.9 Include within our portfolio research into innovation and commercialisation. Our research
centres in these areas have been encouraged to input independent and expert advice into this
inquiry.
99 www.stfc.ac.uk/Funding+and+Grants/1192.aspx
100 www.mrctechnology.org/
101 www.stfcinnovations.co.uk/
102 www.vitae.ac.uk/policy-practice/291901/What-do-researchers-do-Doctoral-graduate-destinations-and-
impact-three-years-on-2010.html
103 www.rcuk.ac.uk/kei/ktportal/Pages/DoctoralStudentships.aspx
104 Industrial Doctorate Centres: www.epsrc.ac.uk/funding/students/centres/Pages/indd.aspx
105 In the 2007 Comprehensive Spending Review RCUK set a target of committing a minimum of £120 million in collaborative
and complementary activities with the Technology Strategy Board, between April 2008 and March 2011. The target was exceeded
by 27%, collectively reaching over £165 million.
106 Joint RCUK/HEFCE statement on impact: www.rcuk.ac.uk/kei/maximising/Pages/Impactstatement.aspx
107 Examples include: Babraham, Cambridge; Daresbury, Cheshire; Harwell, Oxfordshire and NRP, Norwich.
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7. Further information is available on the knowledge exchange and impact section of the RCUK website.108
This includes the RCUK impact strategy, Pathways to Impact, and the Knowledge Transfer Portal which is a
gateway to further information on Research Councils support for knowledge exchange.
Commercialisation of Research: Key Challenges
Q1. What are the key difficulties of funding the commercialisation of research and how can they be
overcome?
8. RCUK note that the “valley of death” is helpful in understanding and responding to the challenges of
commercialisation within some sectors, but consider that there is no single “valley of death” within the overall
innovation system. In addition there are also a number of areas where there is insufficient connectivity109
which hinders the commercialisation of research.
9. RCUK recognise that there are a number of challenges associated with the commercialisation of research
across the entire innovation spectrum which relate to funding. These include:
9.1 Duration to market: the time needed to take forward a research idea to the point of commercial
output can vary widely and can take decades to be realised. This can have significant
consequences for securing commercial funding and interest. This represents challenges for the
commercialisation of research which require solutions from all parts of the innovation system.
The long time to market from initial research ideas can problematic for companies funded by
short term VC investment. Pelamis Wave Power Ltd, now 14 years old, is one of the world’s
leading wave energy developers. The company, a start-up from the University of Edinburgh,
has been funded by venture capital. However, short term VC funding was not well suited to
this complex engineering challenge. For example, the need to demonstrate progress and
achievable revenue to secure continued VC funding led to a move to an array of machines
sooner than was optimal for the overall wave energy device development110. In a different
sector, Beneforté super broccoli, which has potential health benefits for people with
cardiovascular disease and cancer, was introduced in a UK supermarket in October 2011—
27 years after the first research was undertaken.111 The development of the product involved
fundamental research, specialist commercial and legal expertise, product development and
extensive marketing, every step of which required funding and commitment.
9.2 Risk: commercialisation of a research idea carries considerable risk and the less developed the
idea, the greater the risk. This will reduce the take up of early stage ideas by the commercial
sector and at a time when the economic climate is challenging, the risk appetite across all
sectors of business could be expected to be further reduced. To mitigate this element Research
Councils, working with partners like the Technology Strategy Board, provide direct support to
bridge this gap in terms of follow-on funding for proof of technical and market concepts, and
also specialist support for emerging technologies through Innovation and Knowledge Centres.
The current MRC translational funds, and the future Catalyst fund also tackle this gap in the
biomedical area. The Rainbow Seed Fund (RSF), which is collaboratively managed by three
Research Councils and other research partners, also acts as a catalyst by investing directly in
early stage companies. Commercial sector investment can also be facilitated through seed cord
VC funding, and specialist sector bodies like MRCT. The Rainbow fund has encouraged over
£100 million worth of private equity investment and the development of a number of different
spin-out companies; new companies facilitated by MRCT have won similar amounts of
private investment.
9.3 Management of intellectual assets: For the research that we support, we make it a condition of
funding that the research organisation will make every reasonable effort to ensure that the
intellectual assets obtained in the course of the research, whether protected by intellectual
property rights or not, are used to the benefit of society and the economy. Identifying and
managing intellectual property can be central to delivering commercial benefit from research
outcomes in certain sectors such as pharmaceuticals, chemicals, personal care products,
aerospace and defence and energy technologies. We welcome the novel approaches some
research organisations are adopting; for example Easy Access IP.112 We encourage other
organisations to consider innovative and appropriate ways of managing intellectual assets
including recognising circumstances where free access might be the most effective approach to
ensure that potential economic and societal benefits can be realised by beneficiaries. There are
still considerable challenges in managing IP in a European and global context. We welcome
the Hargreaves review as making a key contribution to this.
108 RCUK Knowledge Exchange and Impact www.rcuk.ac.uk/kei/Pages/home.aspx
109 Connectivity relates to the richness of the network of connections, via formal or informal relationships, partnerships, agreements,
etc that exist between the different agents (individuals, companies, universities, etc) in the innovation landscape.
110 (Energy Research Partnership, October 2011).
111 www.bbsrc.ac.uk/news/health/2011/111123-f-super-broccoli.aspx
112 www.gla.ac.uk/news/headline_181588_en.html
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10. RCUK also recognises the issues outlined below in addition to funding are important:
10.1 Culture: The Research Councils are working with other key stakeholders to achieve culture
change within the research base and ensure that the academic community has the time, interest
and expertise to ensure that the outputs from their research are taken forward and
commercialised if appropriate. A 2010 study for ESRC and EPSRC found that industrial
engagement is common and increasing among UK academics working in engineering and
physical sciences.113 We expect this culture change to be reflected within institutions’
recognition and reward policies to ensure that this culture change is supported.
10.2 Absorptive Capacity. Many commercial innovations will involve researchers working with
existing businesses. Therefore, business will need absorptive capacity to work with researchers.
Research Councils help to contribute to the solution through the training of PhD and post-
doctoral researchers and by facilitating movement of highly skilled people at all career stages
between the research base and business and other users.
10.3 Research Environment. Key to increasing the speed and likelihood of research
commercialisation is to create an environment which brings researchers and business together
to meet informally and to work alongside each other in multidisciplinary teams. This creates a
suite of effective knowledge transfer activities that deliver impact and could include: longer
term collaborative research, shorter term problem solving projects and expert staff available to
aid commercialisation. An example of this in action is through the Innovation and Knowledge
Centres114 which are supported by the Research Councils and the Technology Strategy Board
to accelerate business exploitation of emerging research.115
Q2. Are there specific science and engineering sectors where it is particularly difficult to commercialise
research? Are there common difficulties and common solutions across sectors?
11. The Research Councils fund research into policy, regulation and new business models all of which are
essential for a successful innovation system. As noted above there are various challenges associated with the
commercialisation of research, and the impact on sectors varies considerably from sector to sector; therefore a
common solution is not to be expected and different mechanisms are needed in different circumstances. Any
interventions for improving the commercialisation of research must be sensitive to both the context of research
and business sectors.
Q3. What, if any, examples are there of UK-based research having to be transferred outside the UK for
commercialisation? Why did this occur?
12. Research and business both operate in a global innovation system. The UK has a particularly high level
of R&D funding from overseas116 and many of our largest active R&D businesses are global companies. We
should expect UK research to sometimes be transferred outside of the UK for commercialisation and for UK
business to draw on research from overseas.
Q4. What evidence is there that Government and Technology Strategy Board initiatives to date have
improved the commercialisation of research?
13. Public intervention from the Research Councils and others to support the commercialisation of research
outcomes contributes to reducing the risk and enable the leverage and deployment of further funding, including
from the private sector. Appendix 1 provides examples of RCUK interventions and Appendix 2 provides RCUK
examples to illustrate the breadth and diversity of potential commercial applications of Research Council
funded research. There is evidence that follow-on funding helps researchers to bridge the funding gap between
traditional research grants and commercial funding by supporting the very early stage of turning research
outputs into commercial proposition. This is achieved by support to develop the commercial potential of a
concept and establish both commercial feasibility and scientific/technical merit through a mix of technical and
business development activities.
14. A 2009 external evaluation of the EPSRC follow-on fund reports that 78% of projects led to further
commercialisation activity. An investigation of the economic impact of 32 case studies arising from EPSRC
Innovative Manufacturing Research Centres (about 10 % of the total IMRC investment) showed that this work
had generated £70 million of additional sales for industrial partners, £43 million of licensing fees, cost-savings
of at least £17 million to the public sector and £10 million to the private sector, and 20 new technologies and
products were brought to market.117 From MRC’s translational schemes, there is good evidence that early
stage, shorter term (<two year) investments have helped commercialisation; assessments of outcomes from the
portfolios of longer-term projects (three years) will be made later.
113 The Republic of Engagement. Exploring UK Academic Attitudes to Collaborating with Industry and Entrepreneurship. AIM
Research and UK-IRC for ESRC and EPSRC 2010.
114 www.epsrc.ac.uk/funding/grants/business/schemes/Pages/ikcs.aspx
115 www.epsrc.ac.uk/funding/grants/business/schemes/Pages/ikcs.aspx
116 The UK R&D Landscape: Enhancing Value Task Force (February 2011, CIHE, UK-IRC).
117 Economic Impact of the Innovative Manufacturing Research Centres, DTZ report for EPSRC 2011.
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15. The Research Councils work together with the Technology Strategy Board to ensure that there are
initiatives and opportunities to improve the commercialisation of research, for example through Knowledge
Transfer Networks, Knowledge Transfer Partnerships, Innovation and Knowledge Centres, Innovation
Platforms and Collaborative R&D funding. By working strategically with the Technology Strategy Board we
are improving the journey towards commercialisation in key areas, for example, the development of the
Catapult Centres118 and co-funding the Biomedical Catalyst Fund. The RCUK Economic Impact Report
2011119 outlines the close working relationship between RCUK and the Technology Strategy Board, and the
various impacts we have achieved together.
16. Research Councils and the Technology Strategy Board have complimentary but distinct roles within the
innovation system. The Technology Strategy Board has key strategic areas of focus120 where there are well
evidenced technology and innovation opportunities for UK wealth creation. Research Councils fund a much
broader research base, and aim to provide flexible support to help commercialise developments from research
as they emerge, working with the Technology Strategy Board and other partners when appropriate.
Q5. What impact will the Government’s innovation, research and growth strategies have on bridging the
valley of death?
17. RCUK welcomes the Government’s innovation, research and growth strategies. The Innovation and
Research Strategy121 clearly sets out the Government’s approach to boosting investment in innovation and
enabling UK success in the global economy. We welcome the clear intent of the strategy to achieve closer
working in the innovation system, for example, through support for Innovation Vouchers, Venture Capital
investment finance, emerging technology areas with the Technology Strategy Board. The critical role of
research and the ecosystem approach highlighted within the Innovation and Research Strategy for growth
economics paper is also particularly important.
18. To stimulate long-term growth, further investment is important but tailored solutions for specific sectors
will be required. For example, RCUK welcomes the £180 million Catalyst fund to help the next generation of
British medical breakthroughs.122
Q6. Should the UK seek to encourage more private equity investment (including venture capital and angel
investment) into science and engineering sectors and if so, how can this be achieved?
19. Both venture capital funding and investment by existing companies played an important role in
commercialisation of our portfolio. Venture capital funding appears to be relatively healthy and strong in sheer
volume in the UK compared with many other countries; the UK saw large venture capital investments in
2008123 (0.2% of GDP) although this market is directed towards European as well as UK businesses. It is
important to look at the potential for further investment from large global business as well as venture capital
and angel investment.
20. The Government has a role to play in promoting greater awareness of UK investment opportunities in
the international capital markets by marketing UK innovation capabilities. However, as mentioned in paragraph
9.1 the long time to market from initial research ideas can problematic for companies funded by short term
VC investment.
Q7. What other types of investment or support should the Government develop?
RCUK makes the following recommendations to help improve the commercialisation of research:
21. The Government and the research community need to build on the progress already made in developing
the environment and culture within the research base that encourages the exploration of impact from research
and in which commercial research outcomes are recognised and rewarded.
22. The Government should continue to invest in and promote the UK’s research base. The UK’s research
base is a vital component of the UK’s innovation landscape and makes an important contribution to economic
growth through our research outputs.
23. The Government should continue to encourage innovative and appropriate ways of managing intellectual
assets—to ensure that potential economic and societal benefits can be realised by beneficiaries. RCUK support
the Hargreaves Review in making a contribution to this.
24. The government should maintain its current focus on the innovation system and on addressing issues of
connectivity, funding, timescales and scientific risk within sectors. Sectors vary considerably, therefore a
common solution is not to be expected; different mechanisms are needed in different circumstances and any
118 www.innovateuk.org/deliveringinnovation/catapults.ashx
119 www.rcuk.ac.uk/Documents/publications/RCUK%20Impact%20report%202011.pdf
120 www.innovateuk.org/ourstrategy.ashx
121 www.bis.gov.uk/assets/biscore/innovation/docs/i/11–1387-innovation-and-research-strategy-for-growth.pdf
122 www.mrc.ac.uk/Newspublications/News/MRC008394
123 Innovation and Research Strategy for Growth Economics Paper (No 15)
www.bis.gov.uk/assets/biscore/innovation/docs/e/11–1386-economics-innovation-and-research-strategy-for-
growth.pdf
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interventions for improving the commercialisation of research must be sensitive and tailored to both the context
of research and business sectors.
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APPENDIX 1
RESEARCH COUNCIL INTERVENTIONS FOR THE COMMERCIALISATION OF RESEARCH
BBSRC National Research and Innovation Campuses provide strategic funding for 8 institutes based at 6
separate and distinctive campuses across the UK.
www.bbsrc.ac.uk/organisation/research-innovation-campuses/campuses-index.aspx
The Science and Innovation Campuses at Daresbury, Cheshire and Harwell, Oxfordshire are creating a
critical mass of facilities, skills and business, in synergy with the universities and research base.
www.stfc.ac.uk/3574.aspx
STFC operates several world-class research facilities in the UK; industry makes use of these facilities to
develop their products and processes, often working collaboratively with university researchers and STFC
facilities staff.
www.stfc.ac.uk/3574.aspx
STFC Innovations Ltd (SIL), a wholly owned technology transfer company, SIL was set up in 2002 and its
role is to support STFC in identifying and brokering deals to exploit and manage our IP rights, including
gathering revenue through spinouts and licensing agreements.
www.stfcinnovations.co.uk/
The Innovation Technology Access Centres (ITAC) are unique, fully equipped space for innovation, research
and development providing flexible access to offices, laboratory space, clean rooms, workshops, “hot-labs” and
high specification scientific equipment. The facilities are designed to suit start-up companies, SMEs and also
research & development teams from established companies. I-TACs are based on the Daresbury Science and
Innovation Campus and Harwell Oxford. www.itac.stfc.ac.uk/
The Rainbow Seed Fund (RSF) was launched in May 2002 and comprises a partnership of publicly funded
research laboratories with funding of £10 million provided by the Department of Business, Innovation and
Skills. The Rainbow Seed Fund provides investment to support the early stages of commercialisation of
technology and services from its partners.
www.stfc.ac.uk/Funding+and+Grants/1192.aspx.
Biomedical Catalyst Fund will deliver growth to the UK life sciences sector through supporting and driving
the development of innovation life sciences products and services. Support will be available to both
academically and commercially-led research and development. This is a joint programme between MRC and
TSB and builds on MRC Translational Funding.
www.mrc.ac.uk/Newspublications/News/MRC008394
MRC Translational Funding—following the Cooksey Review, MRC provides extensive grant support for
developing medical discoveries into new treatments, diagnostics and devices, on a larger scale than general
Follow-on Funding (see below). Grants to HEIs or HEI/business collaborations can help take important medical
discoveries into early-phase clinical trials if needed, as well as providing smaller awards that add enough
knowledge to ensure commercial investment follows.
MRC Technology—was formed in January 2000 and is the technology transfer agent for the Medical Research
Council’s intramural researchers employed in MRC Units and Institutes and has a string track record in
translating cutting edge scientific discoveries into commercial products.
www.mrctechnology.org/about/how-we-work
Follow-on Funding provides financial support at the very early stage of turning research outputs into a
commercial proposition. This funding helps take the idea to the stage at which the route to commercialisation
is clearand it is possible to secure further funding to progress, , for example, through a spin-out (seed or venture
finance) or licensing opportunity.
www.rcuk.ac.uk/kei/ktportal/Pages/Followon.aspx
Collaborative Training Schemes—enables researchers to develop the relevant skills to undertake excellent
research, work effectively in business (and/or the government or other important sectors), and exploit the
outcomes of their research. Training opportunities include vocational courses, collaborative studentship projects
between academia and industry, and training in entrepreneurship.
http://www.rcuk.ac.uk/kei/ktportal/Pages/home.aspx
Support for Enterprise includes a range of activities and opportunities to allow researchers to develop their
entrepreneurial skills and to access business advice while commercialising their existing research, initiatives
include enterprise fellowships, Young Entrepreneurs Scheme (YES).
www.rcuk.ac.uk/kei/ktportal/Pages/home.aspx
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People and Information Exchange—All Research Councils encourage increased levels of university-business
interaction; support the exchange of researchers between academia and industry, and stimulate partnerships
between business and researchers. This includes support for brokering and networking activities, fellowship/
secondment schemes that enable researchers to work in a commercial environment, and support for Knowledge
Transfer Partnerships.
www.rcuk.ac.uk/kei/ktportal/Pages/home.aspx
Collaborative Research: The Research Councils fund collaborative research which is academic research
undertaken in partnership with other research organisations, with business, with government and/or with the
third sector (eg charities). Collaborative research can take a number of forms, from a basic grant between two
partners, through to a complex multi-partner research programme.
www.rcuk.ac.uk/kei/ktportal/Pages/home.aspx
Knowledge Transfer Accounts (KTA) provide flexible funding for institutions to make sure the research we
fund is fully exploited. KTAs utilise a wide variety of approaches, including workshops, seed funding, training
and development in KE skills, and people exchange, including funding Knowledge Transfer Partnerships
(KTPs).
www.epsrc.ac.uk/funding/grants/business/schemes/Pages/knowledgetransferaccounts.aspx
Knowledge Transfer Secondments (KTS) are focussed on ensuring the research we support is fully exploited,
but are focussed on the secondment and exchange of people between academe and users. KTS also utilise
KTPs as a way of delivering people exchange.
www.epsrc.ac.uk/funding/grants/business/schemes/Pages/knowledgetransfersecondments.aspx
Innovation and Knowledge Centres (IKCs) (now in partnership with the Technology Strategy Board) are
centres of excellence to accelerate and promote business exploitation of emerging research and technology.
Their key feature is a shared space and entrepreneurial environment.
www.epsrc.ac.uk/funding/grants/business/schemes/Pages/ikcs.aspx
Centres for Innovative Manufacturing aim to maximise the impact of innovative research for the UK,
supporting existing industries, and opening up new industries and markets in growth areas.
www.epsrc.ac.uk/funding/centres/innovativemanufacturing/Pages/default.aspx
APPENDIX 2
RCUK EXAMPLES OF SUCCESSFUL COMMERCIALISATION
Conformetrix: Dr Almond’s unique technology, to determine the dynamic 3D shapes of drug molecules, is
the culmination of a large body of work produced during a BBSRC David Phillips Fellowship. Within the
space of three years, Dr Almond’s research has gone from laboratory concept to the edge of commercial reality,
which promises to have a substantial contribution to drug discovery and, ultimately, patient health. His research
group’s discovery of the flexible 3D molecular shape of hyaluronan quickly led to a UK patent and the all-
important “proof of concept” that their new methodology could be generalised to any small flexible molecules,
such as antibiotics and hormones With the support of two Follow on Fund awards and a BBSRC/RSE Enterprise
Fellowship, Dr Almond has made rapid progress towards commercialisation and, with his colleague Dr Charles
Blundell, formed the spin out company Conformetrix to exploit the technology. They went on to raise seed
funding from Aquarius Equity Partners.
Beneforte Broccoli “super broccoli” was launched onto selected UK supermarket shelves in October 2011,
and represented more than two decades of work by a collaboration between two BBSRC-supported research
world-class institutes and a specialist technology transfer company, part-owned by BBSRC.
www.bbsrc.ac.uk/news/health/2011/111123-f-super-broccoli.aspx
Eight19 Ltd is a solar energy company, spun out of the Cambridge Integrated Knowledge Centre (one of the
EPSRC IKCs) that builds on the development of clean technology to enable a new generation of low-cost,
flexible plastic solar cells that have the potential to dramatically reduce the manufacturing cost and increase
the throughput of solar technology. The IKC funding enabled fundamental science to be transformed into a
sustainable manufacturing process and a strong team to be built. This de-risked the investment in a commodity
market (unattractive to VC funding) which, together with support from the Carbon Trust catalysed further
significant inward-investment from the specialty chemicals company Rhodia. Eight19’s current product, IndiGo,
is an affordable pay-as-you-go source of solar electricity to provide electrical lighting and phone charging for
communities that are not connected to power grids. It’s much cheaper than kerosene, the most common source
of lighting, and far cleaner and safer. IndiGo has already changed the lives of several hundred Kenyan families
and over the next two months 4,000 solar units will be distributed in Kenya, Malawi and Zambia. Eight19’s
work won the Rushlight Solar award124 in February 2012 and is also endorsed by Solar Aid.125
NERC has recently spun out an international geological consultancy from the British Geological Survey, BGS
International, which is based on the skills and experience of a small team from BGS identifying new
opportunities for surveying, especially in African countries funded by those countries or the World Bank. As
124 www.rushlightawards.co.uk/
125 http://solar-aid.org/
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a result, the company can access multimillion dollar contracts from the World Bank and African countries.
This is a knowledge-based consultancy bringing funding from overseas sources into the UK. It requires a
different approach to commercialisation than that which is based on IP. Whilst the data available from the BGS
is free to access, significant value can be achieved for house builders, mining companies, oil and gas and other
industries through providing specific added-value products eg high value data and information products from
geological data and knowledge. This brings significant income to the UK and BGS and is a more
straightforward route to market than is possible with IP-based commercialisation.
Next generation solar energy harvesting projects will improve quality of life and generate economic benefit:
EPSRC and the Technology Strategy Board launched a joint £7 million investment through a staged approach
in 2010 to transfer world class knowledge from universities into business led early stage projects to research
the use of nanoscale technologies. The technology focus was to develop and scale up the next generation of
solar energy harvesting. The purpose of the investment was to connect UK based supply chains and position
industry as a dominant force in next generation solar energy harvesting for worldwide markets and as a cost
effective course to the UK renewables energy mix for 2020/50. Building on the success of this competition,
EPSRC and the Technology Strategy Board have teamed up to deliver a joint £9 million investment in nano-
enabled healthcare diagnostics and targeted delivery of therapeutics in November 2011.
www.rcuk.ac.uk/Documents/publications/RCUK%20Impact%20report%202011.pdf
BAS has recently licensed some innovative tracking technology to a UK SME This licence deal was facilitated
by the TSB’s Electronics, Sensors, and Photonics KTN, who helped run a wide-ranging and transparent bidding
process for the right to manufacture and sell the technology. This collaboration allowed BAS to fairly licence
a technology which had been developed using public money, retain accountability to the taxpayer and bring in
money from a private company to continue to support UK science.
www.antarctica.ac.uk/about_bas/news/news_story.php?id=1648
Through STFC Innovations Limited, the STFC’s wholly owned technology transfer office, the STFC has
launched 15 spin-out companies since creation in 2002. These companies last year employed 88 people in the
high-technology jobs in the UK. Examples of STFC Innovation’s success include:
Cobalt Light Systems, which develops equipment for non-invasive analysis of materials. They offer unique
and proprietary analysis systems with applications in many market areas. Cobalt’s technology can rapidly and
accurately measure chemical composition without touching or changing the sample. This ability allows the
content of bottles, pills, containers to be determined without damaging the products which makes them
especially well suited to pharmaceutical assay, pharmaceutical lot release and QC and fine chemicals analysis
and identification.
www.cobaltlight.com/
CellaEnergy was the winner of the 2011 Shell Sprinboard Award and makes safe, low-cost hydrogen storage
materials which could produce a viable and practical alternative to fossil fuels. Cella’s materials use nano-
structuring to safely encapsulate hydrogen at ambient temperatures and pressures. This sidesteps the
requirement for an expensive hydrogen infrastructure. Cella has A round funding from an established UK
chemical company. http://www.cellaenergy.com/
Heptares Therapeutics (formed in 2007). Heptares Therapeutics is a drug discovery company focused on
novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable
targets. The Company has developed a unique, transformational and proprietary technology for making purified,
stabilised and functional GPCRs (known as StaRs™, Stabilised Receptors), overcoming a major limiting factor
to the development of new drugs targeting this group. It is an MRC Technology spin out based on MRC
intellectual property from MRC LMB and NIMR. The company received seed funding from the venture capital
firm MVM Life Sciences Partners LLP of some £2.2 million. In 2009, it raised a further £21 million
($30 million) of equity finance in a successful Series A private round from three blue-chip international venture
capital firms. Clarus Ventures led the syndicate, which includes the founding investor, MVM Life Science
Partners, and the Novartis Option Fund. It has reached substantial commercial deals with Novartis, Takeda
Pharmaceuticals, Shire, and AstraZeneca.
www.heptares.com
Bicycle Therapeutics: Formed in 2009 Combes the most desirable features of small molecules and biologics,
to create highly specific and highly stable peptide drugs. It is an MRC Technology spin out, based on the
research of Sir Greg Winter, at MRC LMB. The company announced a collaboration with Pepscan Therapuetics
(Netherlands) in November 2009 to use its constrained peptide technology for the development of new
therapeutics. In 2010 Bicycle Therapeutics signed a License agreement with the Ecole Polytechnique Federale
de Lausanne (EPFL) in Lausanne, Switzerland and secured additional seed funding from SR One, the
independent corporate venture fund of GlaxoSmithKline, and SV Life Sciences.
www.bicycletherapeutics.com
Activiomics Ltd: Formed in 2010 provides a mass spectrometry based phosphoproteomics service to industry
and has in house programs for biomarker discovery and validation. The company’s scientific founders are Dr
Pedro Cutillas and Professor Bart Vanhaesebroeck from QMUL. Professor Vanhaesebroeck is a world leading
expert in PI3K signalling (a major disease target in oncology and inflammatory diseases) and has MRC funding.
Dr Cutillas is an expert in quantitative mass spectrometry and conceived the technology that is the basis of
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Activiomics. In 2010 Activiomics secured agreements with UCB and GSK to apply its technology to identify
new drug targets. In 2011 Activiomics secured investment from the IP group Plc.
www.activiomics.com
Oxford Nanopore Technologies: Formed in 2005 to develop a disruptive, proprietary technology platform for
the label-free analysis of single molecules. The company was founded by Professor Hagan Bayley, who is
currently Professor of Chemical Biology at the University of Oxford, in partnership with IP Group Plc.
Professor Bayley is MRC funded and the company supports a number of postdoctoral workers in Professor
Bayley’s laboratory. Until May 2008, the company was named Oxford NanoLabs Ltd. In 2011 the Company
announced it had raised a further £25 million from issuing shares to existing investors, the latest in six rounds
of funding that has raised a total of £75 million. The funding will be used to develop the company’s technology
for nanopore DNA sequencing, protein analysis and solid-state nanopore research.
www.nanoporetech.com
Novacem, company developing a new carbon-negative cement, spun out of Imperial College London. EPSRC
funding has played a key role in developing both the cement itself and the manufacturing process via a PhD
studentship, Follow-On Fund award (with the London Development Agency) and latterly two industrial
research grants jointly with the TSB. The cement absorbs CO2 from the atmosphere during manufacture.126
Novacem is still in the development stage but has partnerships with the biggest cement companies in the world
(including Laing O’Rourke, Lafarge and Rio Tinto)127 and believes that within 20 years, 25% of the world’s
cement needs could be based on Novacem technology. It currently employs over a dozen people, has a
prototype plant that can produce five tonnes per annum and is developing a facility that can produce 200 tonnes
per annum. Likely demand means that, in time, Novacem will have to licence its technology for manufacture
all over the world. In 2012 Novacem is on the Global Cleantech 100 for the second year running. It was a
World Economic Forum Technology Pioneer for 2011 and featured on MIT Technology Review’s list of the
10 most important emerging technologies for 2010. It was also a Wall Street Journal Technology Innovation
winner and a Bloomberg New Energy Pioneer for 2010.
Energy efficient lighting—with long-term EPSRC sponsorship, the teams of Professor Sir Colin Humphreys
(Cambridge University) and Professor Philip Dawson (Manchester University) have been developing gallium
nitride (GaN) for use in light emitting diodes (LEDs) suitable for solid-state lighting (savings of $20 billion
for US/£3 billion for UK p.a. predicted)128 and other applications. The groups have collaborated with businesses
across the lighting industry and its supply chain.129 For example, SMEs like Forge Europa have grown by over
100% in a three year period and PhotonStarLED, founded in 2007, is enjoying phenomenal growth,130 from 5
employees three years ago to around 90 now. Professor Humphreys’ research group has helped AIXTRON to
achieve sales of over £800 million in 2010 alone via collaboration on systems for growing GaN-based LEDs
and a new division of Plymouth based Plessey will utilise the Cambridge Group’s technology to grow GaN on
silicon, rather than costly sapphire, in a bid to drastically reduce the cost of making LEDs for lighting in offices
and homes.
Written evidence submitted by Rolls-Royce
Introduction
Rolls-Royce welcomes the opportunity to submit evidence to the Committee’s inquiry. As one of the leading
engineering and high-technology manufacturing companies in the UK, we have significant experience in pulling
through innovative new technology into high value products and services. This experience has taught us that
to pull through technology and to compete effectively in a global industry requires partnerships with our
suppliers, academia and government.
“The Valley of Death”
NASA introduced the concept of Technology Readiness Levels (TRL), which became a lingua franca across
many of the sectors and industries Rolls-Royce is involved in. TRL describes the progression of technology
from the bright idea (TRL1) through scientific investigation (TRL2–3) to laboratory scale testing (TRL4), large
scale rig testing (TRL5), full scale system demonstration (TRL6), flight or in service test (TRL7), product
development and prototyping (TRL8) to mature product in service (TRL9). The scale is useful, and in Rolls-
Royce R&T programmes go through a rigorous gate review as they pass from one TRL to the next. The
programme cannot continue to the next (usually more expensive) level without a successful pass at the previous
level. In most of the sectors Rolls-Royce is involved in, this progression takes many years. For a novel material,
the journey from laboratory formulation to flying engine component can take 20 years.
126
−0.11 tonnes of CO2 is produced manufacturing one tonne of Novacem cement—compared with 0.8 tonnes for one tonne of
Portland cement.
127 www.smithsonianmag.com/science-nature/Building-a-Better-World-With-Green-Cement.html?c=y&page=1
128 US DoE Report 2010 “Energy Savings Potential of Solid-State Lighting in General Illumination. Applications 2010–30”.
129 UK Parliamentary Office of Science and Technology, POST Note 351, Lighting Technology, January 2010.
130 Its award winning colour tuneable LED product ChromaWhite has recently been nominated as part of Vince Cable’s Made by
Britain project.
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The valley of death can be expressed in TRL terms. It normally reflects the difficulty of getting a new
technology through TRLs 4 to 7. In this area the investment required is high, but the certainty of success
remains low. In many of the sectors Rolls-Royce operates in, the valley of death is deepened and widened by
the long timescales referred to above and the safety-critical nature of many of the applications. As we look
around the world, we see that bridging the valley of death in sectors we operate in almost always requires
some degree of Government intervention, or partnership. Companies and countries that do not offer such
mechanisms can be at a severe competitive disadvantage.
Manufacturing Capability Readiness Level (MCRL)
A focus on technology readiness alone is not sufficient to bring a technology to market. In parallel, a
manufacturing process must be developed and matured so that the product can be manufactured economically,
in volume and with consistent quality. In order to put some structure into this process, Rolls-Royce has
developed a set of Manufacturing Capability Readiness Levels (MCRLs), also on a nine-point scale. MCRL
1–4 represent the conception and assessment of the manufacturing technology. MCRL 5 and 6 are the critical
“pre-production” phase, where expensive full-scale equipment and processes must be used, but ahead of product
launch, or factory investment. MCRL 7, 8 and 9 implements the process on the shop floor and confirms volume
production with assured quality. Again, there is a valley of death around MCRL 4 to 6, where investment is
high, but there is no certainty that the product will be launched, or that the proposed process will be successful.
TRL and MCRL must be managed together. Letting MCRL get too far ahead means wasted investment if
the technology is not eventually proven. Letting TRL get too far ahead means delayed entry to the market, or
worse, launch of a product with low quality and unduly high cost.
The Rolls-Royce Research Model
Rolls-Royce develops its technologies through close collaboration with Universities through its University
Technology Centres (of which there are 19 in the UK across 14 Universities). A consequence of this approach
is that the Universities must be prepared to take the technology to higher TRLs (3–4) before it is brought into
the Company for large-scale rig testing and demonstration. We have found our UTCs willing to do this and
the Universities willing to invest in the larger scale facilities required.
A second leg of the model addresses MCRL. Again, working with Universities in partnership with other
Companies, we have created a series of Advanced Manufacturing Research Centres, jointly termed AxRCs,
where full-scale development and maturation of manufacturing processes for novel products, or using novel
manufacturing technologies, can be achieved before bringing the capabilty to the shop floor.
1. What are the difficulties of funding the commercialisation of research, and how can they be overcome?
1.1 The prime difficulty is to provide the correct funding profile so that as certainty of the technology
increases (TRL), the investment can be ramped up. High investment too early brings a risk of wasting money.
Inadequate investment though the critical TRL 4–7 levels and the technology will never emerge from the valley
of death.
1.2 In sectors with long technology maturation timescales, such as those in which Rolls-Royce operates,
normal investment mechanisms are inadequate to provide this financial support. The risk/reward profile is not
one that most financial investors would accept.
1.3 Continuity of funding over long periods of time is essential. It cannot be turned on and off due to
external pressures.
1.4 A company will attract shareholders who understand this process and are not in the game for quick
returns, but are willing to see their investment in a technologically-based company grow as technology levels
in products are increased.
1.5 In most of the sectors Rolls-Royce operates in there is a need for and evidence of Government support
as technology is brought to market. Where this support is inadequate, or not available, there is a risk of severe
competitive disadvantage.
1.5.1 Rolls-Royce invested over £900 million in R&D in 2011. Only half of this from shareholder
funds, the remainder from Governments and external partners.
1.5.2 In the UK, support from the MoD for defence-related R&D within the Company has fallen
significantly over the past 20 years. In 2011 it was less than 20% (in real terms) of the
investment in 1990. In the USA, defence-related R&D support remains strong, despite recent
cut-backs.
1.6. The TSB has developed efficient mechanisms for supporting collaborative research. Their funding, at
just over £300 million per annum is, however, inadequate for the task in hand.
1.6.1 The Government is spending over £3.5 billion on low TRL research, and cannot hope to
adequately capture the benefits from this investment when spending so little on support through
the valley of death.
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1.6.2 A recent TSB call for manufacturing technology was oversubscribed 20 times, despite having
£24 million available, showing the appetite in the UK for technology pull-through.
1.6.3 An area for improvement in the TSB mechanism is that it relies on a series of technology-
focused calls. We understand the need to focus resources, but recommend improving the long
term visibility of subject areas to improve planning and industrial alignment.
1.7 One novel funding mechanism and model in the UK was the formation the Energy Technologies Institute
(ETI) and is a consortium of six industrial partners (up to 10 are envisaged). Each company pledges up to
£5 million each year, with this sum being matched by Government. The Government’s investment is managed
by the TSB. Over the 10 year life of the programme up to £1 billion can be invested in maturing promising
energy-related technologies.
1.7.1 One great advantage of the ETI model is that because the funding is “pre-geared” grants up to
100% can be provided to promising projects without tripping over EC funding rules. The model
has proved very successful and responsive.
1.7.2 One example is the ReDAPT (Reliable Data Acquisition Platform For Tidal) project which is
allowing Rolls-Royce with its research partners to build and deploy a full-size tidal-stream
turbine of the Orkneys.
1.7.3 The same model might be applied to other focused technology maturation areas. We would
suggest consideration be given to technology institutes in (for example) nuclear technology,
advanced electrical machines, cyber defence and mass transportation.
1.8. The AxRCs have had no single, consistent funding source or model. They have been pieced together
with support from the RDAs, TSB, EPSRC and their industrial partners/subscribers. The RDAs have been
particularly useful in providing underpinning capital investment for machine-tools and infrastructure.
1.8.1 The high value manufacturing Catapult (see 1.9), may bring some stability and long-term
assurance to the funding for infrastructure and under-pinning capability growth and expansion.
1.9 The recent launch by the Government of Catapults (Technology Innovation Centres) is welcomed. This
model envisages a funding stream coming one third from an underpinning, long-term Government grant, one
third from industrial members and one third through the collaborative bidding by the Catapult and its industrial
partners being successful in other funding competitions, creating an overall 50/50 public private funding model.
1.9.1 The first Catapult is focused on high value manufacturing. It provides the underpinning support
(especially capital and infrastructure investment) for a network of seven advanced
manufacturing centres around the UK.
1.10 The abolition of the RDAs has removed an important source of localised funding for innovation and
technology pull-through. The RDAs were particularly useful in being able to support the capital elements of
R&D programmes, but often found it difficult to provide revenue support. Combining industrial partner money,
TSB funding, research council money and RDA support in individual programmes was complex, but proved
to be successful.
1.10.1 Under the National Aerospace Technology Strategy, the aerospace industry developed a
relatively efficient mechanism for coordinating all of this.
1.10.2 The Rolls-Royce led Environmentally Friendly Engine programme (EFE) is a £125 million
programme which enjoyed support from four RDAs, the TSB and industrial partners. It was
able to equip a test-bed in Bristol and enable several builds of a full-scale, Trent engine core
to prove novel combustion and high-temperature component technologies which will reduce
the impact of aviation on the environment.
1.10.3 On a smaller scale, the relocation of the QinetiQ light piston tunnel for turbine blade
aerodynamic testing from their site in Farnborough was achieved with support from SEEDA,
Oxford University, Rolls-Royce and the TSB. This has provided Oxford University with a vital
facility for TRL4–5 work.
1.10.4 Whilst we are not advocating the re-establishment of RDAs, a mechanism for fast-access to
funding for capital-intensive R&D would help maintain key capabilities in the UK.
1.11 Our overseas competitors benefit significantly from access to rigs and facilities in National research
centres which are funded and maintained at the state-of-the art out of the public purse (eg NASA in the USA,
DLR in Germany, ONERA in France). In the UK, such facilities have largely been privatised. It is no surprise
then that many of these facilities have been, or are being closed as they cannot be maintained as a commercial
operation, or else face under-investment so that they become uncompetitive. Such facilities are essential to take
technology through the TRLs 4, 5 and 6. Below are some examples:
1.11.1 The UK no long has an engine altitude test facility
1.11.2 The Noise Research Centre in QinetiQ is under repeated threat of closure.
1.11.3 The Aircraft Research Association in Bedford finds it difficult to raise the level of investment
needed to modernise its facilities.
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1.12 In the EC Framework 7 programme a new instrument was introduced, specifically focused on large-
scale technology demonstration, the JTI (Joint Technology Initiative). In aerospace, a JTI called Clean Sky
was formed. It has €1.6 billion available, with half of this coming from industry, and half from the EC.
1.12.1 The JTI is managed by its twelve founding industrial members, of which Rolls-Royce is one.
75% of the programme budget goes directly to these prime industrial members and their
associates, with the remaining 25% being released through open calls managed by the
industrial consortium.
1.12.2 The programme is committed for seven years, giving long term stability, but allowing flexibility
to change shape and direction of the programmes as market needs and technology developments
might dictate.
1.12.3 A similar mechanism at a National level in the UK should be considered.
1.13 The EPSRC is an essential part of the technology maturation pipeline. With its increased focus on
“impact” of research and ability to co-fund university research activities with the TSB, or in direct partnership
with companies, it provides a significant stimulus to taking technology through TRL 3 and 4. Improved focus
on EPSRC funded Centres for Innovative Manufacturing (CIM’s) is welcomed, however, we would recommend
better alignment to the AxRC’s and the development of a requirement led framework based on a gap analysis
rather than open bidding process.
2. Are there specific science and engineering sectors where it is particularly difficult to commercialise
research? Are there common difficulties and common solutions across sectors?
2.1 The valley of death gets deeper and wider as the timescales for technology maturation in a particular
sector increase. In fast-moving consumer electronics, technology can be brought to market relatively quickly
and normal investment mechanisms can apply. In sectors like aerospace, with stringent safety requirements and
the need for rigorous, large-scale, system-level demonstration; or pharmaceuticals, with its need for lengthy
clinical trials, the investment and return horizons do not favour conventional funding mechanisms.
2.2 Venture capitalists will normally be looking for a return in three to five years. They will tend to find
aerospace and energy technologies unattractive for such investment.
2.3 The most extreme investment return sector for Rolls-Royce is nuclear where it is not unusual for a new
technology or design to take 30 years to make it into service. This sector has always seen the need for
significant Government intervention.
2.4 Each sector is different. One common theme is the increasing use of computer simulation, rather than
physical testing, to reduce the cost and time-to-market across most sectors. Access to major computational
infrastructure by Companies as well as Universities is essential. (see 5.4)
2.4.1 We welcome the increased investment in e-infrastructure in the Government’s “Innovation and
Research Strategy for Growth”. However, unless companies have adequate access to this at
affordable rates, it will not drive the innovation required.
3. What, if any, examples are there of UK-based research having to be transferred outside the UK for
commercialisation? Why did this occur?
3.1 Rolls-Royce has recently transferred the centre of gravity of its solid-oxide fuel-cell development to
Ohio, USA because of the significant opportunities for Department of Environment investment.
3.2 Compressor and fan aerodynamic and noise testing facilities have been consolidated in Brandenburg,
Germany because of the support and funding mechanisms available.
3.3 Outdoor noise-testing of large engines has been transferred to Stennis, Mississippi because of noise
regulation and planning difficulties in the UK.
4. What evidence is there that Government and Technology Strategy Board initiatives to date have improved
the commercialisation of research?
4.1 The Rolls-Royce led Environmentally Friendly Engine programme (EFE) is a £125 million programme
which enjoyed support from four RDAs, the TSB and industrial partners. It is able to equip a test-bed in Bristol
and enable several builds of a full-scale Trent engine core to prove novel combustion and high-temperature
component technologies which will reduce the impact of aviation on the environment.
4.2 The ETI REDAPT project is allowing Rolls-Royce, with its research partners, to build and deploy a full-
size tidal-stream turbine off the Orkneys.
4.3 There are numerous examples from the TSB part-funded Advanced Manufacturing Research Centre in
Rotherham where novel manufacturing technology has already helped bring significant reductions in the cost of
our products, thus ensuring our continued competiveness in our very price-conscious, high technology markets.
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4.4 A good example is the Advanced Simulation Research Centre (ASRC) in the South West that brings
together industry and academia around advanced simulation using high power computing. It benefits multiple
sectors including rail, marine, aerospace and wind energy.
4.5 Significant programmes in a number of the AxRCs have been conducted or are in progress that are key
to the investments in new Rolls-Royce UK factories , eg Advanced Blade Casting Facility—Rotherham, Civil
Nuclear Facility—Rotherham and UK Disc Production Facility—Washington, Tyne & Wear.
5. What impact will the Government’s innovation, research and growth strategies have on bridging the valley
of death?
5.1 The Government’s publication “Innovation and Research Strategy for Growth” December 2011 sets out
the latest policy in this area and this document is referred to below.
5.2 Science investment needs to be supported as part of the wider innovation infrastructure, whereby research
results can be efficiently brought to market. This is best done by aligning research with national strategies
such as NATS (National Aerospace Technology Strategy), which has been a successful partnership between
Government, Industry and Academia, transitioning research into technology demonstrators and through to
products that bring economic growth, exports and sustains jobs in the UK.
5.3 The proposal from Government for more Catapults is welcomed. This model envisages a funding stream
coming one third from an underpinning, long-term Government grant, one third from industrial members and
one third through the collaborative bids by the Catapult and its industrial partners being successful in other
funding competitions.
5.3.1 The first Catapult is focused on high-value-added manufacturing. It provides the underpinning
support (especially capital and infrastructure investment) for a network of seven advanced
manufacturing centres around the UK. However, there is concern that the funding model is now
shifting away from capability growth and towards capability maintenance. We strongly believe
this shift towards revenue-based funding will reduce ambition and stifle growth.
5.3.2 Offshore Renewable Energy is another area where a Catapult has recently been announced and
is well matched to the UK capabilities and resources.
5.3.3 The Catapults have, as part of their inspiration, the German Fraunhofer institutes. However, we
must not be under any delusion that we are going to emulate this system. Total direct funding
for Catapults at £200m over the next five years, even when geared by the third/third/third
model, pales into insignificance when compared to the €1.6 billion annual turnover of the
Fraunhofer network.
5.4 We welcome the Government’s increased investment in e-infrastructure of £158 million.
5.4.1 Companies must have adequate access to this at affordable rates, or it will not drive the
innovation required.
5.4.2 Even this funding will not put the UK in the world top 20 in supercomputing.
5.5 The return of “Smart” grants for SMEs is welcomed.
5.5.1 The document, however, perpetuates the myth that all/most innovation originates from SMEs.
Large companies have a significant role to play in innovation in the UK. Very few SMEs and
inventors have a direct route to market. Their technology must be integrated and proven as part
of a bigger system (normally provided by a large company) before it can be taken to market.
5.5.2 Large-scale technology demonstrators enable elements of the supply chain, including SMEs and
universities, to come together in order to integrate and demonstrate technologies at the systems
level. They allow fair, transparent and mutual partnership; SMEs develop their technologies
quicker, gain exposure through showcasing their capabilities and assimilate invaluable
knowledge; systems integrators are able to integrate those into products that meet market
demand.
5.5.3 US Small Business Innovation Grants recognise this and allow the SME to use part of the grant
with a larger company for system-level verification.
5.6 The Government policy document pledges £25 million for “large-scale demonstration” without any
further explanation as to its application.
5.6.1 From our experience, large scale demonstrator programmes require funding a scale of which is
greater than this amount of funding. The already-mentioned EFE technology demonstrator will
cost around £125 million, for a single demonstrator.
5.7 The Universities receive too little attention in the policy document given that they are a key part of
the UK’s innovation landscape. Close working between Rolls-Royce and its UTCs is essential to delivering
proven technology.
5.7.1 We await with interest the report BIS commissioned from Sir Tim Wilson on University/
Industry interaction which should recommend the policy context to redress the balance.
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5.8 The role of the EPSRC in funding research and partnering with industry to focus on impact of research
is also understated.
5.8.1 The Strategy seems almost apologetic about the EPSRC’s recent statements on “Shaping
Capabilities”. The focus on research with real impact and areas UK industry has the proven
capability to exploit and access to growing global markets in order to contribute to growth is
essential. This is particularly true against a budget which is decreasing in real terms despite
bold statements on ring-fencing science and engineering.
5.9 Proposals in the document for increasingly “Open Data” must be implemented with great care. If such
proposals help all companies access the mass of data in the public domain more effectively and free up
Government-owned data for easier access, they are to be welcomed. However, if they make it easier for our
overseas competitors to access and exploit the research base in the UK, especially those elements where UK
companies, like our own, have made a significant contributions, then, far from promoting growth in the UK,
they could be severely damaging our competiveness.
5.10 The EU “Horizon 2020” (Framework 8) proposal will go to the Council of Minsters for approval this
year. The document promises full engagement of UK business in the programme, which is welcomed. We
need, before then, to endorse the significantly-increased budget and ensure that the topic areas chosen for
research funding reflects those where the UK industrial base has a proven track-record to develop and exploit.
5.10.1 The perpetuation of the new JTI mechanisms in the Horizon 2020, especially the Clean Sky
programme, is seen as essential for encouraging collaborative research at TRL 5, 6 and 7.
5.11 The document lists the selection of three key emerging technologies: “synthetic biology, energy efficient
computing and energy harvesting”, seems narrow and idiosyncratic. No explanation is provided as to why these
three were selected. Nor is it obvious they meet the test of a UK industrial base well-positioned for exploitation.
6. Should the UK seek to encourage more private equity investment (including venture capital and angel
investment) into science and engineering sectors and if so, how can this be achieved?
6.1 Cuts in public funding for research give the private-sector less confidence to invest its own money, or
drive it to consider such investment overseas, where Government’s support and incentives for such investment
are stronger. This will ultimately hurt UK economic growth, exports and jobs.
6.2 If mechanisms can be found to encourage private equity investment in science and technology with
longer term gestation periods, then this will be welcomed. A radical view of the necessary tax incentives will
be required, along with a stimulus package to initiate private investment.
7. What other types of investment or support should the Government develop?
7.1 The Government should consider whether a funding mechanism and governance structure like the Clean
Sky JTI might be applicable at a national level for sectors where there is a strong UK supply chain to benefit.
7.2 Government should consider whether the successful ETI model and governance structure could be
extended to other sectors beyond sustainable energy.
7.3 Government should take an urgent and radical view of the UK nuclear power generation industrial sector
to consider how to create wealth from investment in the next generation of reactor technology and associated
fuel cycle. This has the opportunity to stimulate both a significant export industry and more rapidly meet
climate change targets. We welcome the announcement that the Government will publish a long-term strategy
and R&D roadmap for civil nuclear.
7.4 Government should look to stop the further decline in S&T funding in the MoD. Among major developed
nations with significant defence industries, the UK alone considers its defence S&T to be simply a cost rather
than a national wealth creation opportunity. We believe that this area deserves significant review.
7.5 Government should ensure that the capital support for collaborative research programmes, previously
provided by the RDAs is replaced by some other mechanism.
7.5.1 The Catapults are doing this within their individual scopes, but a broader mechanism, possibly
through TSB need to be supported.
7.6 Government needs to support test equipment and test infrastructure (eg wind tunnels) which are vital to
UK business, but which are unable to be operated and invested in to keep them at the state-of-the-art status
purely on a commercial basis.
7.6.1 Our competitors enjoy access to such facilities embedded within publicly funded National
research centres.
7.7 Tax credits need to be converted in to a real cash benefits to assist those less-profitable companies that
cannot directly benefit from the tax credit in the near term.
February 2012
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Written evidence submitted by Dr. Andy Richards, Biotech Entrepreneur and Business Angel
Dr Andy Richards is a serial Biotechnology entrepreneur and business angel. He is currently Chairman of
Altacor, Novacta, Abcodia and Ixico and is a director of Arecor, Summit Corp plc, PsychologyOn-line, Cancer
Research Technology (commercial arm of CR-UK) and Babraham Bioscience Technology.
Dr Richards spent his early career with ICI (now AstraZeneca) and with PA Technology. He was a founder
of Chiroscience and an executive director through to the sale to Celltech in 1999. Since that time he has
invested in and helped to found more than 20 UK based biotechnology and healthcare companies including
Chiroscience, Arakis, Vectura, Geneservice, Biowisdom and Cambridge Biotechnology Ltd.
He is a council member of the Biotechnology and Biological Sciences Research Council (BBSRC), a Trustee
of the British Science Association, a founder member of the Cambridge Angels, and an advisor to both Vectura
plc, and several Venture Capital Funds.
This submission is being made by Dr Richards in his personal capacity as a business angel and investor and
is not a submission made by any of the companies of which he is an investor or a director or the organisations
that he is associated with.
Background to Response
1. This submission is made, based on experience as an active angel investor, a founder and board member
of both public and private SMEs and an advisor to both technology transfer organisations and venture capital
funds. This experience is mostly in the life sciences and healthcare arena.
2. The financing environment for the commercialisation of science and technology projects and the financing
of science and technology start-ups is constantly changing. It has been termed “the financing continuum” but
is rarely a continuum and at any one time there are gaps making it difficult to finance certain sorts of companies,
businesses models or technologies. It is assumed that these gaps are the subject of the “valley of death” enquiry.
The funding environment is not as negative as is often portrayed and recent announcements of a series of new
life-science funds targeting the UK are consistent with a healthier outlook.
1. What are the difficulties of funding the commercialisation of research and how can they be overcome?
3. The strong research base in the UK, combined with a more vibrant and active community interested in
the commercialisation of science and technology has resulted in an increasing number of commercialisable
projects, technologies and companies. This community is made up of entrepreneurs interested in science and
technology, academics who are becoming more entrepreneurial, industrial scientists who are leaving large
companies as those companies either downsize or move to an open innovation model and an increasingly
professional set of technology transfer organisations. Whilst there are more and diverse sources of financing
than are generally recognised, this level of commercialisable opportunity still results in a supply and demand
problem such that many promising projects and companies are finance limited.
4. It is important to recognise that by no means all technology capable of being commercialised is spun out
from the academic base. In my experience an increasing number (probably the majority) of UK quality
investible opportunities are being initiated by entrepreneurs with a specific business in mind who then seek out
appropriate intellectual property/technology from industry or academia, and very often from international
sources. This is an important and positive development; as such entities when founded by experienced
entrepreneurs have a higher success rate.
5. The financing environment has changed significantly from a traditional business school view of a seed
financing followed by Series A, B & C venture capital financings followed by a likely IPO. If this model ever
dominated it has now broken down for certain and companies/ventures are rarely set up with a view to
following this financing path. In addition there is a much greater diversity of sources of private financing than
are recognised. Classic venture capital only accounts for a proportion (almost certainly a minority) of
investment. Important sources of investment now include corporate venture capital (CVCs) angel and high net
worth individual investment, publicly quoted investment companies (eg Imperial innovations and IP Group
etc.). Data on this breadth of investment sources are rarely collated effectively and this alongside a fashion by
venture capital for stealth investments means that the statistics of private and venture investment levels in
science and technology companies are significantly under estimated.
6. On the public markets (LSE and AIM) investment levels are easier to track and whilst there are some
successful UK quoted companies (eg Shire, BTG, Abcam, and Vectura), many of the UKs more promising
companies have been acquired and the appetite for investment in new home grown ventures (IPOs) has not
been sustained. This is an important discontinuity in the financing continuum and is one reason why when
companies reach a certain stage they are either sold or migrate to eg The US instead of raising further growth
capital from the UK markets.
7. As the old sequential model of finance broke down, entrepreneurs and active early stage investors evolved
financing models that were appropriate for the new financing environment. This has resulted in a whole series
of resilient capital efficient often virtual companies or businesses based on “soft start” financing and early
revenues rather than intensive venture investment in R&D.
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8. There are now several somewhat disconnected investor ecosystems A), angel and small funds investing
in capital efficient businesses aimed at early revenues B), larger venture funds backing businesses often created
in stealth mode aimed at early trade sales whilst avoiding multiple financings and C), public market investors
funding companies which when successful get acquired without replenishment from new IPOs. The lack of
communication and transfer between these investor silos is a barrier to growth.
2. Are there specific science and engineering sectors where it is particularly difficult to commercialise
research. Are there common difficulties and common solutions across these sectors?
9. A number of technology areas typified by medical technologies and therapeutics, but including others as
well have characteristics that make gaining sufficient investment a challenge when the financing environment
is unfavourable, these have all or some of the follow characteristics:
— High technical risk and uncertainty eg drug discovery or therapeutic development.
— The need for a strong intellectual property position (both established patents to protect, as well
as access to patents to gain “freedom to operate”).
— A heavily regulated value chain eg medical.
— High development costs or technical proof of principle that occurs late in development.
— When there is no early potential of revenues particularly where the value chain is dominated
by a small number of big customers eg energy, pharmaceuticals or healthcare systems.
— A proposition that requires global market access to achieve a return on investment.
10. Alongside new medicines and medical technologies in other areas where higher financing levels are
critical for commercialisation include novel materials, new forms of energy generation etc.
11. Gaining investment for new ventures can be particularly difficult when there is no established financing
community in that sector or where interested investors are diffuse and are poorly connected. Such sectors in
the UK include novel foods and agricultural biotechnology and certain aspects of bioenergy. These more
challenging ecosystems are hampered further when there is a lack of entrepreneurs with experience of that
sector.
3. What if any examples are there of a UK based research having to be transferred outside the UK for
commercialisation? Why did this occur?
12. There are numerous examples of where UK based research has been transferred outside the UK for
commercialisation. Good examples would be the Solexa DNA sequencing technology which was migrated to
the US and then commercialised by Illumina. Antibody success stories which originated in the UK provide
further examples. Leading antibody products originated in the UK which were all commercialised by non UK
corporates include Humira now the world’s leading selling drug marketed by Abbot; Campath launched by
Genzyme (now Sanofi) and Cimzia commercialised by UCB. In addition, the leading early UK companies in
antibodies Celltech and Cambridge Antibody technology (CAT), whilst having successfully achieved IPO’s on
LSE were both acquired by larger pharmaceutical companies before products could be launched.
13. It is typical in sectors with long development cycles, such as in new medicines, for technologies or
products to be passed through multiple companies before they reach the market. (Campath is an excellent
example). Products or technologies (or in many cases companies) are acquired by or licensed to a succession
of companies with a greater access to finance and a greater market presence. At times the London stock markets
(LSE and AIM) have been less supportive of aggressive growth propositions than the US Nasdaq (and some
other European exchanges) thereby restricting the growth and financing options for UK companies.
Consequently companies have often been sold early in the UK.
14. This passing on from one company to the next in the value chain until a product reaches the market is
typical. Each transaction in itself can be seen as a commercialisation event even through a product has not
reached the market. This should not always be looked on in a negative light providing that capital, technology,
expertise and people are recycled back in to the sector. The antibody example is again useful here where the
next generation of antibody companies Domantis (already sold to GSK) Pangenetics (already sold to Abbot),
Kymab, Bicycle and Crescendo, all having been spawned in one way or another from the earlier successes/
ventures.
15. In addition to financing barriers, the other main reason for transferring research outside of the UK for
commercialisation is to access more receptive large markets. In the medical world the uptake of innovative
products in the UK is both low and late and hence the UK market is a relatively unattractive place to initiate
marketing and commercialisation of a new product.
4. What evidence is there that government and technology strategy board initiatives to date have improved
the commercialisation of research?
16. Continued strong support by government for the science base is a key aspect that must be maintained.
The strength of the science base in providing skilled scientists, scientifically literate entrepreneurs and
technologies to be commercialised are at the heart of the opportunity. In the medical and therapeutic fields
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ensuring that this extends into an innovative culture of translation with the NHS is a challenge but a prize
worth fighting for.
17. Government driven incentives such as R&D tax credits have had a sustained impact and the recent
introduction of “patent box” incentives should be significant. Refinements to both of these would be welcome.
18. Mechanisms to encourage and support private investment such as the EIS scheme have provided an
important stimulus particularly to the angel community and this has helped the start-up phases of businesses
as well as the growth phases of those with relatively capital efficient business models. Further refinements to
EIS, such as the recently announced Seed Enterprise Investment Scheme, and moves to ensure that EIS is
targeted towards real growth companies and not “investment schemes” that just exploit the tax benefits are
also welcome.
19. The TSB (Technology Strategy Board) is an important body set up to engage with applied technology
and commercialisation. The existence of such an organisation is very positive, however, its strong established
links to the engineering community has often made it seem less orientated towards the life sciences where its
criteria of “close to market” innovation is often less appropriate for life sciences. In this latter area it may be
useful to consider innovations that are “close to commercialisation” where commercialisation is some form
of transaction.
20. In relation to the TSB’s SBRI scheme in the medical field, this should also be re-evaluated given the
challenges of innovation within the NHS.
21. It is too early to say whether Catapult Centres are being effectively implemented and the Biomedical
Catalyst fund will be a key test for both the TSB and MRC.
5. What impact will the Government’s innovation and growth strategies have on bridging the valley of death?
22. The Government has established a series of promising initiatives that should maintain positive momentum
in the growth of innovation particularly in the life science sector.
23. Government initiatives to encourage funding and investment are particularly important and should be
used to leverage other sources of investment from either inside the UK or from venture investors outside of
the UK. The Biomedical Catalyst fund will have a key role in achieving this and it is hoped an effective
process can be established between the TSB and MRC to ensure that the fund works for quality fast growing
companies at the time when they need it, and without too much bureaucracy.
24. Government initiatives to encourage more innovation within the NHS and early uptake of innovations
within the NHS could make a very significant difference to both time to market in the UK and the invest
ability of UK R&D initiatives pushing forward with the “early access key” is therefore very important.
6. Should the UK seek to encourage more private equity investment including venture capital and angel
investment into Science and engineering sector and if so how can this be achieved?
25. The UK Government should be strongly encouraged to seek more private equity investment into UK
science and technology ventures, and whilst there is funding available the UK sector is still “innovation rich
and funding poor” with too many of our quality ventures being constrained by limited financing. In addition,
uncertainty in the financing environment encourages cautious behaviour amongst entrepreneurs and company
directors who build smaller, more virtual, capital constrained companies and exit these by trade sale at any
earlier stage. A more vibrant financing continuum with fewer gaps would encourage the growth of bigger more
sustainable technology companies.
26. In encouraging more private investment from within the UK it is important not to just focus on traditional
venture capital funds and to ensure that a diversity of financing sources is available and stimulated. This
should include angel financing through enhancements to the EIS scheme and mechanisms to support “soft
start” companies.
27. Private investment into the UK from funds outside the UK is also be encouraged and here there is an
important role for UKTI to target potential investors and provide them with a compelling story along with
clear case examples of how investment in the UK can provide superior returns. Specific investor classes should
be targeted and in the first instance corporate venture capital funds (CVCs) who are already dominating the
early stage life science investment environment and internationalising US VC funds that have started searching
out investments in Europe should be an initial priority.
7. What other types of investment support should the covenant develop?
28. The relative lack of enthusiasm from public market investors for home grown UK science and technology
based growth companies is a challenge that needs careful evaluation. A situation where high quality companies
once more consider an IPO as a viable route alongside a potential trade sale exit would be a healthy
development.
April 2012
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Written evidence submitted by Dr D J Tapolczay CEO, MRC Technology
MRC Technology (www.mrctechnology.org) is a technology transfer company responsible for adding
commercial value to cutting edge scientific discoveries through strategic patent protection, creative licensing
of intellectual property (IP), partnered research or further scientific development.
As well as offering technology transfer services to the UK’s Medical Research Council the Company has
recently broadened its activity to include helping other charitable and academic organisations (such as AICR)
with IP management and commercial development of healthcare-related science, thus bringing valuable income
back to the organisations to help fund further research.
Questions Provided by the Committee
1. What are the difficulties of funding the commercialisation of research, and how can they be overcome?
There are numerous difficulties associated with funding the commercialisation of research. Some of the
hardest questions that must be addressed first are what research is worth commercialising and what are the
benefits or what is the return on investment that would make funding of the commercialisation worthwhile?
The answers to these are frequently dependent on the type or mechanism of funding to be used. Venture Capital
or angel funding is clearly looking for a straightforward financial return on the investment whereas state
funding or funding from charitable sources will be predominantly interested in societal benefits such as job
creation or benefit to the population or sectors of the population. In order to be successful in securing the
necessary funding it is critical to address the specifics of the return on investment and make sure that they are
appropriate to the source of the funds.
Some very exciting basic research may not have a clear or obvious path to commercialisation or the return
on investment proposition may not be clear. In these cases there is often a need for an “act of faith” investment
in carrying out a clearly defined small programme of work to evaluate the “feasibility” of commercialisation.
This type of funding is extremely difficult to find in the UK. Unless there is access to this type of funding
some of the most exciting commercial opportunities may fail to be exploited in the UK. One example of this
type of funding is the MRC Technology development gap fund (funded by the MRC but managed by MRC
Technology Ltd) which funds very early stage commercial validation of MRC funded research programmes.
This and the MRC development pathway funding scheme DPFS are already proving very successful in the
biomedical field. However the scale of the funding is still limited and can only fund a fraction of the science
worthy of exploring the potential for commercialisation. With more funding available more could be done!
It is also important to recognise that commercialisation of research is a process that has a sequence of events
associated with it and that these events all need to be adequately funded for success to be achieved. Each step
along the pathway is like a link in a chain and unless the whole chain is intact the process will not complete
and commercialisation will not be achieved and indeed money may well be wasted!
2. Are there specific science and engineering sectors where it is particularly difficult to commercialise
research? Are there common difficulties and common solutions across sectors?
Life sciences or health care have specific difficulties associated with commercialisation. Firstly in the drug
molecule space the costs of commercialisation are significant! These may include the capital costs associated
with access to the necessary equipment and the labour costs of a highly skilled workforce. Secondly there is
the time to commercial return. Most venture funds function on a five year cycle time to return yet the time for
return in the pharmaceutical space is frequently much greater than eight years. As a consequence, securing
venture capital has become increasingly difficult for life science companies in the last five years. There are
notable exceptions such as Heptares, Bicycle Therapeutics (both MRC spin outs facilitated by MRC
Technology) and Convergence (spun out of GSK) but the point is that these are “notable exceptions”!
However, I believe that the current economic situation in the UK provides a possible solution to this.
There are now plenty of redundant pharmaceutical research facilities in the UK that could be exploited for
translational research!
There are also a large number of highly skilled and highly trained scientists recently displaced from large
pharmaceutical companies with the necessary knowledge and ability to take on the challenges of translating
the output of basic research activities in the UK and even those from other nations. This opportunity, created
by the current economic circumstances in the large pharmaceutical corporations, could see Britain become the
innovation and translation centre for the world if a suitable mechanism for funding these activities can be
found! Britain has a long and very distinguished history of innovation in this area. A survey by BIS reported
that 20% of all prescription medicines on sale throughout the world can trace their origins to the UK. This is
despite the fact that UK spend on pharmaceutical R and D is 1/16th that of the USA!
I believe that a generic single “fix” across all sectors will be very difficult to achieve. In fact it may be so
generic that it will be difficult for each sector to see how to make it benefit. The principle of funding for
translational research available to all sectors is fine but individual sectors should have funding systems tailored
to their specific needs. A good example of this is the recent creation of the MRC/TSB Biomedical Catalyst for
life sciences. Similarly the announcement by the Wellcome Trust of the creation of a new Venture Capital fund
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is good news. It is important to remember that the creation of a fund is not the “fix” in itself. How the fund
operates and its ability to select what warrants funding and on what basis (of return) will determine the degree
of success achieved. There are many examples of Venture Capital funds that despite having substantial funds
have failed to make an adequate return on their investments in biotech and lifesciences.
3. What, if any, examples are there of UK-based research having to be transferred outside the UK for
commercialisation? Why did this occur?
I have personal experience of where this has happened. It may not all be totally negative but I question
whether better economic return could have been achieved in the UK by continued exploitation in the UK. I
was personally involved in the creation and development of two companies in the UK. Cambridge Discovery
Chemistry and Cambridge Material Science were start ups in the UK that became successful profitable SME
businesses in Cambridge. In July of 2000 both of these companies were acquired by Millennium Pharmaceutical
Inc, a Massachusetts based biopharmaceutical company. Post the acquisition, both of these UK companies were
closed and the knowledge base transferred to the US with the loss of 130 UK jobs.
MRC Technology also provides several good examples of where UK innovation can lead to economic return
in the UK but where the availability of suitable funding and a greater appetite to risk could see much more
substantial economic gain. MRC Technology incubates early stage research using both MRC and MRC
Technology financial resources and MRC Technology physical resources (namely industry trained scientists
employed by MRC Technology). In the pharmaceutical and Biopharmaceutical area, these early stage assets
are taken through to early pre-clinical stage before being partnered with major pharmaceutical companies. Two
such examples are the monoclonal antibody products Tysabri and Actemra. The MRC Technology income from
these two products totaled approx £22 million in the 2011–12 financial year. This income is derived from a
small % royalty that was negotiated by MRC Technology at the point of licensing. Had MRC Technology had
the access to suitable UK funding to develop these products to clinical phase 2, the revenue stream from a deal
for such Phase 2 assets would have been potentially three to six times higher. Both of these assets were licensed
to US and European companies.
4. What evidence is there that Government and Technology Strategy Board initiatives to date have improved
the commercialisation of research?
The MRC funding of MRC Technology activities provides substantial evidence of improved
commercialisation of research through both the creation of new companies and hence employment in this sector
in the UK (eg Celltech, Cambridge Antibody Technology, Domantis, Heptares and Bicycle Therapeutics), the
commercialisation of new technologies (phage display and cdr grafting for antibodies) and new therapeutic
products (eg Herceptin, Humira, Avastin, Actemra, Tysabri and Benlysta). This has generated more than £550
million in income in the UK.
MRC Technology has a triage system for analysing all new opportunities for translating basic research
towards commercialisation and there are more projects that pass the triage than MRC Technology can fund
using its own resources. MRC Technology are currently exploring links to other UK charities in order to
identify additional sources of funding in order to take more of these projects forwards.
5. What impact will the Government’s innovation, research and growth strategies have on bridging the valley
of death?
In some respects it is too early to tell. Undoubtedly the injection of cash into translational activities will
show measurable results but the more difficult question will be were these the best possible results? By this I
mean look at the life science VC community as an example. Many large funds have made investments in life
sciences but not all are successful; indeed some has ceased investment in this sector or at least decreased it
whereas others such as Abingworth have been disproportionately successful. The creation of new funds
especially from the public sector is difficult enough in the current economic circumstances but it therefore
becomes even more important that they are appropriately applied!
6. Should the UK seek to encourage more private equity investment (including venture capital and angel
investment) into science and engineering sectors and if so, how can this be achieved?
Yes without doubt this will help provide opportunities for additional exploitation of basic research here in
the UK. It should be remembered however that VC funding is notnecessarily applicable across all areas of
translation in the life sciences. The time to return on investment in the VC community means that VC funds
are increasingly targeting later stage investments in life sciences. This means there is an increasing need for
“bridging” funding to cover the gap between basic research grant funding and the later stage VC investment.
Also VC investment is primarily interested in straight financial return to the fund investors, not necessarily in
other societal returns such as job creation or even patient benefit in areas where there is unmet medical need
but small patient populations.
The corporate venture companies of the major pharmaceutical companies are a good and, in my view, in the
UK “under invested” group. The government could approach the corporate ventures arms of the major
multinationals looking to get them to apply more of their funds here in the UK.
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In my view it has for some time been true that there is an increasing need for public private partnership
funding of translational activities. The public funding is there to look for the “societal” returns on the
investments made and the private funding to maximise financial return. In this way both parties can minimise
risk of exposure in a particular investment, and in doing so increase the number of opportunities funded.
7. What other types of investment or support should the Government develop?
The government has always been active in facilitating investment in the UK from foreign investment funds
and companies. This has been very successful in many sectors. I think that there is still more to be one in the
life sciences sector. As I mentioned earlier, the current situation in the UK with site closures and job losses
provides a tantalising opportunity to see the UK become a global leader of translational innovation in
healthcare. A new business model exists to exploit this opportunity and bring foreign investment to the UK. It
should be used for the benfit of the UK before other nations see the opportunity!
April 2012
Written evidence submitted by GlaxoSmithKline (GSK)
1. Introduction to GlaxoSmithKline (GSK)
GSK is one of the world’s leading research-based pharmaceutical and healthcare companies, developing and
supplying medicines to improve patients’ quality of life. We employ over 96,000 people in over 100 countries.
Our products cover a wide range of healthcare areas: prescription medicines, vaccines, rare diseases,
dermatology, and consumer healthcare, and we produce medicines that treat six major disease areas—asthma,
virus control, infections, mental health, diabetes and digestive conditions. In addition, we are a leader in
dermatology and we are developing new treatments for cancer and rare diseases.
GSK is the largest pharmaceutical company by value in the UK, is British-owned, and is headquartered in
the UK, employing more than 14,700 people. We are the largest private sector funder of R&D in the UK,
spending £1.8 billion in the UK in 2010; over 40% of our global R&D expenditure.
2. The Changing Pharmaceutical R&D Model
The pharma business model is changing—declining R&D productivity, patent expiries, increasing regulatory
demands and increasing demands from payers, a shift to new technologies such as biologicals that will require
new skill sets (in both R&D and manufacturing) and new technologies; this is coupled with downward price
pressures, but also external opportunities, such as the ever-increasing rate of technological innovation.
This has a range of implications:
— Need to boost innovation and spread risk resulting in increasing importance of collaborations
with external partners, both in industry and in academia, to access the best science and develop
differentiated medicines which patients need.
— Need to find cost-savings across the business, which is driving increased efficiency in R&D,
manufacturing, and in our commercial operations.
— Need to demonstrate value of our products to payers as well as healthcare professionals, and
ensure that payers understand the need to balance delivering value for money in health systems
with the need to value and reward medical innovation.
These developments place increasing emphasis on the importance of an effective and efficient life sciences
ecosystem in the UK—from early discovery research, through clinical trials, manufacturing and commercial
use once licensed—where industry flourishes, patient outcomes improve and the economy thrives.
The UK has historically been a strong environment for GSK—a world-class science base, skilled workers,
a national health service that provided an opportunity for first global launches of new medicines, a strong IP
framework, and an established and trusted relationship with Government.
In recent years other countries, such as Singapore and Ireland, have attracted a significant share of investment
by companies such as GSK; the UK Patent Box will make a significant contribution to ensuring the UK can
continue to compete to maintain and grow its share of global life sciences investment. Furthermore, the Growth
Review commitment to decrease clinical trial times will have a positive impact on patient numbers recruited
into clinical trials, once changes are implemented.
However, the global environment for medicines is extremely challenging and the industry is shrinking; it is
likely that in 10 years, the landscape will look very different with fewer players. Part of this is the natural
evolution of the industry as a response to an environment that has changed significantly; 10 years ago any
medicine with regulatory approval was available to patients.
There is a still a need for new medicines for many diseases that have no treatments or where treatments
could bring patient benefits. There is a wealth of good science around the globe. With 11,000 people in GSK
R&D, we still only represent <1% of science and we know we cannot come up with all the good ideas.
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Academia and biotechs are increasing their partnerships with larger pharmaceutical companies (and vice versa).
Biopharmaceuticals will represent the largest type of new medicines in future.
3. How GSK has Changed its R&D Model
GSK is changing our R&D model, making it more agile, focussing our efforts in areas where the patient
need is greatest and science is more fertile. This will improve our productivity and our return on investment.
We have re-personalised R&D—created an entrepreneurial environment in drug discovery, pursuing the best
scientific opportunities whether internal or external. We are focused on furthering our R&D efforts through
externalisation in pursuit of the best science. We take a long-term, customer-driven approach to building
external alliances.
We have been leading the industry in forming progressive new alliances and collaborations with biotechs
and academia to further the best science that can help us deliver new medicines to patients. We are building
our biopharmaceuticals s investment and research and seeking to continue investing in this area to diversify
the platforms we can use to make medicines. We have made fundamental changes to how we allocated our
R&D expenditure, directing it to our late stage pipeline; reducing cost and risk through externalising parts of
our early-stage discovery; dismantling infrastructure; and terminating development in areas with low financial
and scientific return.
Internally we have created Discovery Performance Units (DPUs) which are groups of between 5–70
empowered scientists, with each group focusing on one particular disease or pathway, or platform technology
and responsible for driving discovery and development of potential new medicines through to early stage
clinical trials (up to completion of Phase IIa). Externally, over the past 10 years, GSK has signed more late
stage collaborations than anyone else in the industry, and about 70% of them are still active today. In fact, a
large portion of our current late stage pipeline comes from these collaborations.
4. The Development of Open Innovation within GSK R&D
GSK has been active in assessing the potential of pursuing an open innovation strategy to help speed up R&
D for diseases of the developing world (DDW). This includes being more flexible with our intellectual property
and providing access to our know-how and resources, and sharing our data with the research community. At
our DDW—focussed R&D facility in Spain (Tres Cantos) GSK has been developing an “Open-lab” concept.
The open lab has space for visiting scientists from universities, not-for-profit partnerships and other research
institutes to come to the site, work on projects with us, learn from our expertise and share our world-class
facilities.
GSK’s Academic DPU/Discovery Partnership in Academia initiative provides an opportunity for world-class
academic researchers to work very closely with GSK. For example, GSK outlines assets available for
collaborative partnerships with the academic group proposing innovative ideas for evaluation of their
therapeutic potential or academic groups with disease and biology (target) understanding work jointly with
GSK to discover new medicines, with both partners providing their key areas of expertise.
The Stevenage Bioscience Catalyst (SBC) is being developed as the first UK bioscience open innovation
campus. The campus will create a unique bioscience community providing small biotech and life sciences
companies and start-ups with access to the expertise, networks and scientific facilities traditionally associated
with multinational pharmaceutical companies.
GSK and Wellcome Trust are founders of SBC and the phase I development opened for business in February
2012 with the completion of an incubator and accelerator building. Phase I construction was funded by GSK,
EEDA, BIS, TSB, and the Wellcome Trust.
5. GSK Views on the Availability of Funding for Bioscience Companies in the UK
Funding at the early stages can either be through VCs (independent or corporate VCs) but is more often
through Angel funding or the provision of grants from, eg, the Wellcome Trust or the MRC. GSK notes that
VCs tend to be very selective in choosing the early companies they invest in but securing investment from a
VC (independent or Corporate) usually means that the biotech will have a stronger support system and be
better able to access the knowledge it needs to grow and to then be able to secure Series A and future follow-
on funding. GSK understands fully the desire of VCs to focus on companies with excellent science and strong,
experienced leadership.
GSK considers that funding by Business Angels and through grants can be positive. However, we suggest
that early stage bioscience companies need to be encouraged to access good advice about how they structure
these early financings with a view to what will be needed to raise further capital as the company develops.
Otherwise they can often fail to secure follow-on funding and Angel/grant funding alone is insufficient to
support anything other than very early stage companies.
GSK’s Corporate Venture group SR One invests globally in emerging life science companies that are
pursuing innovative science which will significantly impact medical care. SR One has a team of investment
professionals, located in the US and Europe, with experience spanning basic science, industry and the market.
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SR One takes an active role in its portfolio companies and works with management teams and fellow venture
investors to create significant value. SR One’s current portfolio includes approximately 30 private and public
companies and since its founding in 1985, the fund has invested over $600m in the biotech space. SR One’s
expanded remit also focuses on maximizing the value of GSK technological innovation to establish new
businesses and revenue opportunities across a range of industries.
In the UK, SR One has a lot of experience in seeing proposals for follow-on funding from companies that
were created with Angel/grant funding where the companies have not progressed their assets or technology
sufficiently to secure follow-on funding and has thus declined to invest. Many such companies seen by SR One
were considered un-fundable for a number of reasons including the credibility or experience of management, an
overly complicated company structure, an inflated valuation or expectation of value by founder investors or
management, poor asset differentiation, a business model not well enough constructed, or the fact that the
company had been in existence for some time with little progress to date. While there is undoubtedly a lot of
great science in the UK, a number of elements need to come together to make a fundable company. This is
one reason, along with the limited number of early stage VC investors with which to syndicate deals (see
below), why investing the £50m GSK has committed to spend on UK biotechs will remain a challenge for
SR One.
GSK is not in a good position to quantitatively assess the amount of funding available to the sector, but
there is no doubt that there are now less VCs operating in the biotech space; the players investing in early
stage opportunities have reduced from around 12 to 4–5 in the last few years. This is due to a number of
issues, primarily the 2002–08 financial crises and the pressure on financing generally. There has though been
some recent good news with new investors emerging including the Wellcome Trusts Sigma Fund, CRT’s
Pioneer Fund and the TSB/MRC’s Biomedical Catalyst Fund.
However, our experience is that money follows great science, coupled with experienced leadership. SR One
will invest based on the science, the heritage of the leadership in the company and the ability to pull together
a syndicate of experienced investors. Experienced leaderships where the UK tends to fall short compared, for
example, to the talent pool available in US biotech hubs such as Boston and San Francisco as there are still
only a limited number of experienced biotech entrepreneurs in the UK.
It is worth remembering that the end customer of most biotechs is the pharmaceutical industry; a few
companies do make it and grow into successful stand-alone companies but most are purchased or partner with
pharma to develop and commercialise assets thus understanding how to make this model succeed is critical.
6. What would a Successful UK Life Sciences Sector Look Like?
The UK would be a true life sciences ecosystem, with trusted and collaborative partnerships between and
within industry, specialist life science investors, academia and the NHS that turn cutting-edge ideas into
commercial products that are used by the NHS, delivering patient benefit and contributing to UK economic
growth. In particular, it would have:
— A culture within academia and within the NHS that proactively seeks engagement with industry
and understands the contribution that collaboration with industry can bring to advance research,
improve patient outcomes, and drive growth in the economy.
— A strong cohort of entrepreneurial academics driving forward the translation of excellent science
into clinical benefit, supporting a vibrant SME sector that is able to secure sustained funding.
— A vibrant advanced manufacturing sector in life sciences, able to forge well-funded public-
private partnerships to develop new technology that can then be deployed in the UK swiftly
with minimal regulatory delay.
— A pricing and reimbursement environment for medicines which ensures that the NHS’s need to
deliver value to the taxpayer also considers the significant economic impact of the life sciences
sector and the UK’s potential to impact the global profitability of the sector.
— An NHS environment which embraces new technology and medicines more rapidly than other
European countries, providing benefits to patients, to research and to the growth of UK-based
companies.
April 2012
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Written evidence submitted by Matthew Bullock
Starting a technology business without venture capital funding has been a familiar challenge in the
Cambridge area since 1960s, but the Phenomenon there was and is still largely not funded by venture capital,
although the periodic availability of venture capital is welcomed as additional funding for growth.
It would thus be wrong to regard the technology pathway as blocked at the outset because of a lack of
venture capital funding. It is always the “first best” solution for companies if it can be raised, but the number
of companies that get venture capital will always be a small minority, and too little time is spent examining
the “second best” option adopted by the great majority, and whether there are steps that could be taken to
improve that.
In my experience, venture capital more commonly comes in at the later stages of a company’s development,
building on a market and product position that has been developed more gradually along the alternative route,
and then kicks the company’s growth trajectory onto a higher plane.
What is the alternative route and how does it come about? How is it financed? And what could policy do to
improve it?
I christened this route the “Soft Company Model” in 1984, to distinguish it from the “Hard Company Model”
that I saw had come to be favoured by US venture capitalists after around 40 years of predominantly soft
company growth in the US.
The soft company model grows out of the nature of most technology sales: these predominantly involve the
delivery of an intermediate industrial component or system to a large lead client—corporate, institutional or
governmental; there are very few technology companies that sell to consumers, at least in the early stages. The
sale is usually, therefore, based on an R&D or technical equipment contract for delivery over a period with
agreed milestones, often with stage payments. It is not a sale from a catalogue, with simple payment on delivery.
The product is frequently quite specific to that lead client’s needs and is based on the founding technologist’s
understanding of how to apply a broad corpus of technical expertise to a client’s particular problem. This
problem solving of specific issues often starts off as a consultancy service, or offering a testing or design
service. The company may then build a one-off system that embodies their design skills. This can then transition
to a more routinised delivery of their service, before the company reaches the point where it feels sufficiently
confident from its own experience to launch a discreet product with defined features that will address most of
the demand from its clients.
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How quickly this happens depends in part on the evolution of the technology. Most initial science in a new
area is quite inchoate; a lot of initial work goes into measurement and other instrumentation as the problems
get more defined. In these circumstances there is a risk in rushing to “reify” issues and solutions too early; the
smarter move is to place a series of lower risk bets around solving particular problems with the developing
technology, than to bet that Product X is the solution to all current problems in the field.
This gradual product “Hardening Process” can take a long time to achieve: in TAP Biosystems it took us
several years before we and the market were ready for standard products; in other technologies a clearly defined
product need may emerge over two to three years. Hardening may also be paced by the internal development
of the company: in TAP’s case a great many internal changes were necessary to alter our processes appropriately
after we decided to manufacture standard products, following years of designing and building customised
systems.
This progressive approach also sits more comfortably with the development of the scientific entrepreneur’s
own personal skills. In my experience scientists can become better than average business people once they
have applied themselves to it, but it takes time and experience to learn, even for quick learners like them, and
the risks of building “softly” are much more manageable than plunging into a “hard start”.
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Typical cash flow profile for a Hard Company start-up
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The financial risks are quite different: assuming the research costs have been incubated elsewhere, the first
costs will be the salaries and overheads of development work, plus such equipment as is needed for this; in a
“hard company” start up there will then be expenditure on manufacturing equipment and staffing, distribution
and sales staff, and marketing expenditure to launch the product; on top of this will be stock/work in progress
and debtors, maybe partially offset by trade creditors. The rule IBM adopted for a new product launch was
1:3:10: 1 to stabilise the product; 3 to get it manufactured; and 10 for marketing. That would not be untypical
for a novel piece of equipment; it would be substantially greater for a novel pharmaceutical product, because
of the clinical testing required. And for a start up, all that has to be incurred with an untested management team,
no certainty of customers or sales at the end, and losses increasing each month until the launch is successful.
Cumulative
Cash Flow
Quarterly Cash
Flow
Peak funding requirement ~£100,000
500
Cash Flow (£)
Typical cash flow for a Soft Company start-up
0
-200
Research and Development Overheads
Soft Marketing
1                         2                        3                        4                          5     Years
For a “soft company”, the development costs are the same, but the manufacturing costs are lower and the
marketing and working capital costs are much lower; the processes are more familiar to the management team;
crucially, the costs are primarily incurred against a certain sale to a credit-worthy client; and, depending on the
contract terms, the company can be making monthly profits and getting stage payments as it reaches the
agreed milestones.
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Typical cash flow profile for the Hardening Process
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Moreover, soft companies are usually quite profitable from the outset and, once they have a better feel for
the market, they can use their profits to invest in the internal development of a hard product idea, with which
to kick up their subsequent growth rate; in my experience the resilience of the soft company model meant that
several attempts at hard product launches could be tried without wrecking the business; and often it was at the
successful launch of such an internally incubated hard product that venture capital could be brought in.
As a result, while the first company’s business plan has to be financed by equity, the second, soft company
is usually financeable by a bank with a closely monitored, secured working capital facility from early on in its
life, and with personal equity and/or a government loan guarantee scheme, even from start up. This was how
Barclays was able to support the growth of Cambridge companies well before the availability of venture capital
in the late 1980s—as indeed the Bank of Boston and Bank of America had done in Boston and California in
their pre-venture capital days.
What policy changes would make this Soft Company Model easier to start and succeed?
An important point to make is that the development of technology products and equipment on contract—
what the great, soft majority of smaller technology companies do—does not appear anywhere in the R&D
statistics: the activity does not conform to the Frascati definition used by BIS/ONS to measure R&D activity;
for the small supplier the activity is recorded as sales; and in their large customer’s accounts it may appear as
capital expenditure or revenue expense. The Frascati definition requires the activity to be speculative, without
a firm sale in prospect—ie to be crossing the Valley of Death.
Since no one measures soft company activity, there are no tax allowances or other incentives for it.
The first suggestion would be to develop a method of measuring the activity.
The second suggestion would be to encourage the growth of the market for technology procurement from
small companies by larger companies, research institutions and government departments: development contracts
in my experience are much more commonly available from US corporations as a way for them to develop
access to new technologies than in the UK—so-called “open innovation”; in particular, British government
procurement has long operated a closed innovation system for procuring technology in defence and has shown
remarkable unwillingness until recently to consider using its procurement capability in an open way to seed
new technology or policy areas—no doubt because the civil servants fear being arraigned before the Public
Accounts Committee for wasteful expenditures. Contrast this with the very effective open procurement
activities of such agencies as DARPA, ARPA and ONR in the US, which have been used as a conscious
stimulus to advanced technological and economic growth since the 1940s. The Maddock Report made a similar
suggestion in the UK in the 1970’s. More active funding of SBRI contracts in government departments,
agencies and the Research Councils would be a first step in this direction.
A further suggestion is to revive the pre-production prototype financing scheme that was once offered by
the DTI. This was available to large UK companies that placed prototype development contracts with small
technology suppliers to cover the cost of experimental pieces of equipment. Adapting the TSB’s multi-partner
collaboration R&D mechanism to fund bilateral partnerships between small technology suppliers and large
companies would help the latter to move towards more open technology procurement models.
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Lastly, a word in the ears of some of the banks to get back to doing more of this sort of lending would
be useful.
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Written evidence submitted by Dr Peter Dean
When I was a reader in Biochemistry in Liverpool University (1968–1984), I was fairly certain that none of
my colleagues knew the meaning of innovation. Scientists were supposed to study science not invent, patent
and take inventions into the marketplace. I had a modest sized research group working on three main areas;
steroid hormones, squalene cyclases, affinity chromatography. My main criticism of the system of control of
Intellectual Property at Liverpool is that there was none. Research discoveries were reported on an ad hoc
basis to a senior administrator. He and his committee would decide what if anything to do with an invention.
The innovation process was foreign and I suspect somewhat distasteful to the academics in my department if
not throughout academe. For example, one of my colleagues (Dr Duncan Troup) and I invented the
“Backfriend” orthopaedic support. We funded the start of a company (Medesign) ourselves without any support
from the University.
My biochemical research resulted in my being asked to consult for a number of commercial companies
(Genentech, GD Searle, Amicon, HM Government and Ayerst Harrison & McKenna amongst others). As a
result of discussions with the latter company in Montreal, I was asked to research ideas for a possible test to
monitor diabetics for glycated haemoglobin. The proposal was that if I could discover such a test then the
company would protect any discovery by applying for patents at their expense and we would decide about
innovation if and when the invention was filed. After about three months, I discovered that immobilised
boronate bound glycosylated haemoglobin and showed (with Professor Sir Alistair Bellingham) that diabetic
patients could be very rapidly and more accurately assessed using my procedure than the electrophoretic
methods used at the time. Indeed we showed that one of my students (Sarojani Angal) was not diabetic but
beta-thalassaemic (Alistair had observed “fast” haemoglobin in her blood which was easily confused with
diabetes). The patents were filed with more than 9 months to run before completion. In other words there
would have been plenty of time to find another sponsor (eg BTG). The company informed me that their
research objectives had changed and they were happy for me to take over the patents as inventor. I approached
the University development officer and was told very firmly that it was my invention and they were not
interested in pursuing or supporting the patent. Bear in mind that a UK patent filing could easily cost £20,000
per year for foreign filing costs at the time (about the size of my salary as a reader). I then approached Amicon
for whom I had been doing some consultancy and they agreed to take on the product. Without any help from
the University towards the negotiations, I agreed to sell the patent to the Americans for a token sum with the
understanding that they paid my laboratory 5% of sales and 40% if the company was taken over. Two years
later, W.R.Grace acquired Amicon and vigorously defended the US patent (the Americans failed to file outside
the USA). Whilst my lab and I did accrue some reward from US sales, we had absolutely nothing from
worldwide sales although the method was very widely exploited and still is the basis for the HbA1c method,
what irks is the complete failure of the establishment to recognise a major worldwide contribution to diabetic
health and no academic recognition was offered from fellow academics for 20 years of invention and
innovation. There was a stigma attached to commercialisation which caused me to leave the University system.
Towards the end of my stay in Liverpool, I was invited to help develop a new company (P & S Biochemicals)
which attracted a number of awards including the Prince of Wales Innovation Awards and The Mersyside
Entreprise Award. Despite all the attention from the media, I do not feel the University ever really understood
the objectives of the company which was to create a manufacturing base for making tools for genetic engineers.
When the Finnish Sugar Company offered to fund a personal chair for me with a large research grant to
continue my work, the Vice Chancellor and his pro-vice (a Prof Harris) decided that 40% of the grant must be
given to the University without discussion. Since this would have compromised the research and since I also
was not that impressed by the change in title, I immediately applied to work elsewhere. This I regard as an
excellent example of why the University could not innovate even if you paid them to do so. I understand that
nowadays venture capitalists offer “development” funds to some universities with the proviso that they get full
commercial rights. This cannot be the best way. Attempts in the past such as BTG, 3i and AGC have failed to
live up to expectations and have left academic inventions devoid of innovation.
Another innovation failure at Liverpool was my experience with steroid hormones. My group and I made
many antibodies to steroid hormones over the years I was at Liverpool. We were the first to construct assays
for oestriol, oestradiol, cortisol, and many others. The University failed to set up a system to protect or
commercialise these discoveries and all innovation was conducted single handedly.
I left the University in disgust (1984) to start Agricultural Genetics in Cambridge. We had an ideal
opportunity to create an innovation laboratory which failed to materialise and led me to form Cambio three
years later. Soon after, Professor (now Sir) Martin Evans brought the design of the UK’s first PCR machine to
me and whilst the University did not stand in our way, the technical assistance we received was rather out of
date and unimaginative so that we went to a local electronics firm to develop the machine rather than stay
“in house”.
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In 1992, Cambio was approached by Professor Malcolm Fergusson-Smith then Professor of Pathology at
Cambridge, with a novel series of chromosome paints. We successfully commercialised these worldwide and
were happily paying the laboratory in the region of £200,000 per year being a large proportion of sales of the
product. The University technology transfer group (CUTS) decided to get involved in order to force an increase
in the contribution made to the University. Their approach to negotiation caused Cambio to withdraw
completely from the market, losing both sides considerable amounts of money. The Professor failed to keep
the laboratory going as a result. The technology transfer officer was trained as a broker in the City and
unfortunately did not understand negotiation is a two way process.
One general point worth mentioning is our British patent system. We have to complete a patent within 12
months of filing. In the USA, Japan and Canada to name but three, there is an extended grace period which
allows inventors to talk about their inventions without compromising the patent which is some cases is three
years retrospectively. Hence a UK filing from these countries can be significantly ahead of competitive
inventions from the UK system.
Another point is that UK universities are very slow to innovate because the academic way is to explore
every possibility, discuss the pros and cons ad libitum whereas the commercial need and method is to make
decisions quickly even if the process has flaws.
British inventors lose out because the patent process is not clearly understood, because there is no clear way
to innovate processes or products (the classic example is the failure to patent monoclonal antibodies). There is
a dearth of good patent lawyers whereas in the USA there are probably too many. The perfect innovation team
might include: The inventor, someone experienced in reducing inventions to practice, a good lawyer who has
worked in the area, a lateral thinker who can get outside the box, a designer and marketing expert to bring the
idea towards the final goal Pamela Ramsden’s book on top teams spells out the perfect group. AGC was
classically unbalanced with 1500 AFRC scientists feeding all their inventiveness into one small office—no
wonder it failed.
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Written evidence submitted by Katie Potts, Herald Investment Management Ltd
1. What are the difficulties of funding the commercialisation of research, and how can they be overcome?
From Herald’s perspective the UK is one of the most attractive markets in which to invest, with a strong
regulatory framework, and low valuations particularly relative to bonds in spite of having to fund the cost of
the welfare state, and relatively high salaries. There is also a reasonably high level of innovation and
entrepreneurial spirit in the UK, particularly compared to Continental Europe, if not Israel and the US. There
seems to be a greater sense of inferiority that overseas markets have greater attractions than is justified from
the micro perspective of investing globally in smaller TMT stocks. We are proud that we have made long term
returns, without Government subsidies, well ahead of all the wider indices in early stage investments.
Nevertheless, we have been on the defensive, as we ourselves have directly been victims of the pension funds
selling Herald shares, and they have gradually been replaced by private investors, who are regrettably less
stable. Furthermore we have had to defend our overweight position in the UK to certain investors in Herald’s
funds in spite of the evident solid long term returns.
It has been our stock in trade at Herald to provide early stage (ie pre-profits) capital, mainly at IPO and
follow on secondary offerings in the quoted market through Herald Investment Trust plc. Historically we have
co-invested with other investors, and taken stakes up to 10% of the issued share capital. In the current
environment IPOs are unattractive for two reasons (a)There are insufficient co-investors to raise the needed
capital (b)There are too many cheap stocks in the secondary market (which we want to protect against
predators), which have less risk. Furthermore, at Herald’s venture meetings I have repeatedly said “I can’t get
my mind round investing £2 million in a pre revenue company on a valuation of £10 million, when I can buy
companies in the quoted market that are already profitable and growing on similar valuations.”
It is only with healthy secondary market valuations that IPOs are attractive, and thereby justifies the risk of
venture investing early stage. There is a disincentive to attempt to commercialise research if follow-on funding
is uncertain or expensive.
(i) Shortage of capital
Equity Shortage
There is much media discussion about the difficulties small companies have in raising bank debt. Bank debt
has never been available for early stage technology companies, and furthermore it is an inappropriate form of
funding for companies pre profits. The current environment shows an absence of equity. This is reflected in
the virtually closed market for quoted IPOs since 2007, and a similarly meagre venture pool. Unfortunately
the bubble of IPOs when the TMT sector was too fashionable, led to poor returns, which has led investors to
perceive the sector as risky. AIM had a similar but less pronounced bubble and bust. There has also been a
shortage of major successes in the UK versus the US. This has led US investors to have greater confidence
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and therefore US technology companies have had a lower cost of capital. However, even in the US the number
of US IPOs in the last decade is 80% lower than in the1980s or 1990s, with investors in US IPOs having
equally inadequate returns. It is frustrating to have watched the bubble of investor interest into emerging Asia,
even from UK based investors. As global investors we find the lack of established regulation, and the lack of
IP in markets such as China a pretty unattractive investment proposition, and despair to see limited UK
resources going there, and not to lower risk propositions in the UK. In Continental Europe there are very few
emerging technology companies, and closed public equity markets.
Why the shortage of equity investment in the UK?
However, there is an even greater issue, which has led to the shortage of equity. It is the evaporation of
pension fund and insurance company asset allocation into UK equities, and an even greater reduction in the
exposure to smaller companies. These institutions were professional long-term stable investors, with good
corporate governance skills who controlled executive remuneration etc. It is a tragic and devastating unintended
consequence of the abolition of ACT relief, combined with the rising liabilities for defined benefit pension
schemes as life expectancy has grown, and investment returns have diminished. The accounting requirement
to disclose these liabilities with valuation methodologies which discourages equity investing has been the final
death knell, which has led to the disappearance of institutional investors on the registers of our investee
companies. In addition, historically fund flows into UK equities were to some extent guaranteed as pension
trustees had positive cash inflows, and believed that sterling liabilities should be matched by predominantly
sterling assets. It was also in their members’ interests to have a strong UK economy, so there should be an
allocation to small companies which will provide growth to the economy, and there is strong historical evidence
that small companies over the long term do outperform large companies: For example the Numis Smaller
Companies Index (previously HGSC Index) has returned 404.8%% over since 31/12/1994, versus 255.3% for
the FTSE 100. On an even longer term basis over the 57 years from the start of 1955 to the end of 2011 the
Numis Smaller Companies Index, representing the bottom 10% of UK companies by market capitalisation, has
generated a total return of around £3 million for each £1,000 originally invested (dividends reinvested), while
the overall market (FTSE All-Share) has given a total return of approximately £0.6 million for each £1,000
originally invested. The return from smaller companies over this period has therefore been five times greater
than the market overall. Annualised returns over this period are 15.1% for the NSCI, and 11.9% for the All-
Share. This does not feature in Trustees’ consideration today, and allocation seems determined by actuaries
and accountants and not fund managers, and the pressure for consistent short term returns. Furthermore, defined
contribution schemes means that companies care less about maximizing performance, and more about
minimizing risk. It seems to me to be a frightening mistake which we shall come to rue.
I stress I am more despondent about the funding environment for UK technology companies than at any
stage in my career, which now spans nearly thirty years, and believe there is a bigger problem than realised.
(I am despondent as a taxpayer. As an investor having some money when others don’t has its attractions, but
at times I fear we have a watering can in a desert!).
To me the obvious simple solution is to require pension funds, in order to maintain their existing favourable
tax treatment, to allocate at least say 1–2% of total assets to equity investment in small private and public UK
companies. This could be extended to European small companies if EU rules require. The definition of small
company should be £0 million to c£500 million in valuation, and care needs to be taken in defining UK—eg
% of employees. In practice this investment should phased over a reasonable time period. This would allow
professional investors to make commercial judgments and investments at no cost to the taxpayer.
As a matter of urgency Government needs to encourage greater equity ownership, especially by long-term
high-quality investors such as pension funds.
(ii) Shortage of commercial management
It is evident that the cluster of successful companies in northern and southern California, to take the most
extreme example, has occurred because there has been a succession of fast growing companies, which has
taught a succession of management teams about how to scale a business. There is no such UK training ground.
It is depressing how few first generation businesses have become large companies in the UK compared to the
US. A radical suggestion would be to make private investors pay income tax rates on realised gains on assets
that are held for less than three years, and lower the CGT rate from 28% on assets held for longer than 10
years and/or at least index the book cost in line with inflation. (NB At current rates of inflation CGT rates of
28% are in real terms higher than income tax for long term investments.) In addition pensions could be charged
a gains tax on profits realized within five years. This would encourage longer term ownership, and help develop
a generation of management that can scale a business.
In 2002 we were approached by the Russell Group to consider managing a fund to invest in technology
transfer out of university laboratories. We were flattered to be considered, and undertook an extensive process
to consider the viability of such funds. This included meetings with successful universities overseas (Colombia,
Harvard, Massachusetts Institute of Technology, New York and Stanford in the United States and Technion in
Israel. Our conclusion was that money alone could not solve the problem. Commercial management was
equally necessary. Academics can underestimate the skills associated with developing, producing, marketing
and selling. We also observed how effectively Columbia, for example, had commercialized IP through royalties.
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It is an obvious way to reduce the business risk if you can leverage an existing corporate structure and sales
force to launch a new product. However, it is a challenge in the UK because there is a shortage of large
companies who could be incentivized to commercialise products. We were impressed by the commercial
approach at Technion which is reflected in a remarkably successful technology sector in Israel in relation to
the size of the economy. In contrast the UK universities seemed far less commercially aware or astute. I suspect
that efforts made over the last few years mean that UK universities have improved. Overall, regrettably we
came to the conclusion that we, at Herald, had inadequate resources to take on the challenge.
(iii) Shortage of skills for the development and marketing phase
Every day we meet companies who complain about the difficulty of recruiting qualified UK schooled staff.
Often we hear that immigrant labour is better qualified with a better work ethic, and overseas offices are often
opened for skills not just cost (eg Poland and India). From the micro perspective of a TMT fund manager the
education policy has been daft in not offering more places, and incentivizing students, to study disciplines
where there are skill shortages. Maybe statistics published for employment rates a year after graduation for
each course from each University should be more proactively analysed and published, and places be expanded
where there are high recruitment rates, and reduced or closed where there are poor employment rates. In
addition there is a shortage of large UK companies to undertake graduate training. For example GEC/Marconi
was a great training ground, but no more.
In a knowledge world there is a mismatch between rising remuneration where there are skill shortages, and
simultaneously rising unemployment. There is a similar disconnect in the corporate world where cash rich
companies cannot invest cash to grow. Innovation is not a function of money but ideas. Small companies can
be more innovative and productive than large ones, but they are cash limited. It is an investment challenge to
invest in ideas, where no reliable discounted cash flow projection can be modelled. Economists are disappointed
by subdued capital expenditure, but in the knowledge based TMT sector in which we invest R&D is more
relevant than capital expenditure. Manufacturing for so many volume products is now in the Far East, with
lower cost labour.
There is no shortage of creativity and IP generation in the UK. It has been said that the indisciplined UK
culture, whilst bad for productivity, has been good for stimulating creativity.
2. Are there specific science and engineering sectors where it is particularly difficult to commercialise
research? Are there common difficulties and common solutions across sectors?
Technology offering solutions to a large addressable market are more commercially viable, albeit certain
niches can be less competitive. Clearly products where there is a long development and design-in cycle require
more capital, and hence makes capital less available.
3. What, if any, examples are there of UK-based research having to be transferred outside the UK for
commercialisation? Why did this occur?
We have been frustrated by the plethora of takeovers in the quoted market, at valuations that might have
constituted a premium to the stock market valuation, but were disappointing in terms of invested capital, and
our expectations. In particular it is frustrating to have invested at a risky pre profit, and sometimes pre revenue
early stage, and to have seen the company through to cash flow profitability only to see the less risky upside
taken, generally, by US corporate and private equity houses. The UK financial sector has very limited expertise
in the technology sector, and is particularly poor at ascribing value to progress other than profitability.
4. What evidence is there that Government and Technology Strategy Board initiatives to date have improved
the commercialisation of research?
From my perspective invisible. I have been in the technology investment industry since the mid 1980s. If
initiatives have been helpful they have been more than offset by the evaporation of capital looking to invest in
early stage and smaller companies equity.
5. What impact will the Government’s innovation, research and growth strategies have on bridging the valley
of death?
From my perspective the Government would see better returns from nurturing 50 -100 man companies who
have a greater chance of doubling and doubling again. Too much resource has been focused early stage only
for them to gobbled up by overseas buyers.
6. Should the UK seek to encourage more private equity investment (including venture capital and angel
investment) into science and engineering sectors and if so, how can this be achieved?
Private equity in City parlance relates to leveraged buyouts of established companies with positive EBITDA
(cash flow), whereas venture capital is providing capital to start-ups and early stage companies that have not
reached profitability. Now that pension funds are taxed on dividends, but not interest there is a fiscal incentive
for companies to own corporate debt rather than equity. This combined with low nominal interest rates, and
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low public equity valuations has been a stimulus to private equity. There is zero need for Government to
encourage private equity. On the whole they have short term time horizons. Cynically the parallel is a property
developer who covers up the cracks, and sells on at a profit. Long term ownership like that of home ownership,
is more desirable for businesses. In fact there is a case for making interest costs a non tax deductible expense
to level the playing field with equity ownership. The short term shock to leveraged sectors such as property
and private equity would be too traumatic, and have knock on negative effects on the fragile banks, but maybe
tax deductibililty could be removed on all but loans secured on tangible assets. In contrast the Government
must encourage venture investing, which is vital for the emergence of new businesses, added value job creation
and exports.
The outside world has a tendency to see the City as homogeneous in attitudes and practices. Within the
financial sector there are very evident divergences. We our long term in our approach we endeavour to invest
in companies that will be making sustainably higher profits on a five to ten year view, and are supportive to
that end. We cynically view so many short term investors as psychologists ie they endeavour to work out what
other people will pay more for tomorrow than they do today.
Building successful businesses takes time. Pension funds and insurance companies have appropriate long
term funds and professional managers. Angel investing is difficult and expensive to attract, and does not have
sufficient depth for follow on funding.
At Herald we have managed two venture partnerships. After twelve years the IRR on the first fund (on
unsubsidised investment) was a modest 3.6% per annum. This fund was launched in September 1999, and the
return does exceed the total return on the UK equity market over that time frame, and according to BVCA
data makes the fund respectably top decile. However, frankly, it has been an inadequate return on effort, and
insufficient to get investors enthused about reinvesting. Idealistically I know that the economy needs venture
investment, and I feel that we are well placed with our skill set and knowledge of the global sector through
the quoted markets to be relatively proficient, and have useful experience. However, experience makes me
realize that it takes many years to establish a sustainable business, and many of the stresses have been
associated with inadequate capital, and the struggle to raise follow on funding. My judgment is that this makes
it too risky to embark on early stage investing without sufficiently deep pockets to see an investment through
to profitability, because external follow on funding may either not be available, or too expensive in terms of
dilution. Equally it is uneconomic to have committed capital idle for up to 10 years when the final round might
be needed. If the health of the market improved as described previously with better funded smaller quoted
companies market, then this problem would be addressed. Candidly I would be unable to raise a fund of
sufficient scale without this improvement. Idealistically I should like to raise a further fund, but selfishly I do
not want the distraction or the stress, and cannot honestly present a case to potential investors with the same
belief that I have in the potential performance of our quoted funds.
7. What other types of investment or support should the Government develop?
At Herald we have considered raising a VCT but have resisted the temptation. Why? The market is limited
in scale, and the tax subsidy is devoured by the cumbersome expensive structure, and the high cost of marketing
to retail investors. Furthermore, the time horizon is short, the availability of capital for follow on funding
uncertain, and the size restrictions too dangerous. Hence my preference for encouraging the deeper pockets of
pension funds who have long term money to fund the follow on investment required. In addition it would
make investing more appealing to angels if they have knowledge that there would be a competitive market for
follow on funding at higher prices. In other words I think existing VCT and EIS incentives would be more
attractive, and yield a better return for the tax payer if the follow on market improved.
23 April 2012
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Written evidence submitted by Dr Trevor Francis, Technical Director, Byotrol Technology Ltd
THE PERSPECTIVE OF A SCIENCE-BASED SME
Experience of Financial Funding
Context
— Byotrol plc. is a biosciences technology SME with a market cap of ca. £10 million.
— The company originally started in 2001 as a spin out from a paint company and initially used family
money to fund initial set up.
— It has developed a patented anti-microbial technology based upon a combination of commercially
available biocides and a polymer that gives a long lasting protection when applied to surfaces (hard
surface or skin). The technology has applications that spread from Food and Healthcare and to
household and personal consumer products.
— The company has an Industrial Division and a Consumer Products Division (50/50 JV). The
Industrial Division sells both to distributors and to service providers, while the Consumer Division
is licensing the technology to fmcgs and retail manufacturers for use in consumer products.
— The plc. company has raised over £15 million from AIM in five separate funding rounds.
1. What are the general challenges of science based SME’s for obtaining funding?
— Science based technology is expensive (laboratory, equipment, scientists, IP, materials etc.) so there
is always a need to secure significant funds to keep afloat (cf software companies which generally
have a much lower requirement for funds).
— As a generalisation, most “scientific inventors” are creative people with new thoughts on how to
develop their innovations. As a result of not achieving sufficient funds, the risk is that many of these
new ideas get lost, or if patented will pass into the public domain.
— Once investment has been received, there is a heavy outlay simply to stay still and yet most
companies want to grow and invest in additional research streams. So there is never enough to
cover what could develop from such science-based start-ups without radically finding new sources
of investment.
— The process of raising funds itself is very time demanding and stressful.
— Many companies have suffered due to going too early to the City without properly managing
expectations, resulting in having to meet the expectations of the City for short term sales revenue,
— There is often an added pressure in the funding “pitch” to be too optimistic and to make the company
prospects seem very attractive, which subsequently leads to harder targets to fulfill.
— Frequently SME’s report of being offered more money than they were asking for, which can create
a “rich” feeling and not appreciating the need to use the money wisely.
2. Disadvantages of seeking VC or Business Angel money
— Quite often, early stage start-ups have nowhere else to go to get seed money.
— VC’s are primarily focused on ROI and if a tech company has no assets (not manufacturing) but is
knowledge based then providing funding is of less interest.
— IP isn’t heavily valued within VC’s, while for the company it is often a sizable cost.
— VC’s will generally take a significant share of the business and leave the “entrepreneur” with only a
small share of the cake. This creates subsequent problems with the founder having “less ownership”
of the business that might otherwise be the case. In fact most founders end up with no more than
5% of the company they founded, leading to desire to exit at some stage.
— Getting a realistic funding of the potential of the company is difficult for the entrepreneur and can
leave the founder with the feeling of being squeezed in terms of own value.
— VC assessors have really no expertise in assessing the technology and when joining a Board of a
company have no understanding of what the opportunities might be—so discussions with the founder
and management are frequently difficult with differences of opinion on strategy and longer-term
activities.
— VC’s tend to provide money in stage-gates that means that the company is frequently chasing for
the previous payment, and having to manage additional cash flow dips.
3. Perspectives of becoming AIM listed
— AIM tends to be only for companies with a market cap of £10 million so isn’t an option for early
stage companies, who need alternative sources of seed money, business angels etc.
— AIM tends to be more speculative than VC’s and having no track record doesn’t put AIM off.
— AIM tends not to get involved in running of the business and leaves the management to get on with
leadership decisions.
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— Potentially works well but requires the CEO/FD to have a good knowledge of the process otherwise
setting of sales revenue targets can lead to “ short termism”.
— Being a plc. adds gravitas as a company and especially in discussions re licenses and allows the use
of “share options’ to incentivize employees.
— General process with NOMAD’s provides good financial discipline, but disadvantage of AIM tends
to be overall cost with annual fees, NOMAD’s and NED’s and corporate lawyers.
— RNS communications can materially affect share price, so need careful management.
4. What else can companies do for increased funding?
— Various range of R & D funds are available from TSB and these generally are working well.
Innovation vouchers may be useful to embryonic companies for early stage studies, but creating next
stage funding through extending the voucher schemes for larger sums of money and prior to getting
into TSB calls would be helpful.
— Byotrol was able to benefit from regional Development Agency Exceptional award that has been
really helpful for R & D development including skills and capabilities.
— Our company has just made a European fund application and our perception of these is that the
scope allows for bigger awards. This has a disadvantage for UK plc. in that that it encourages cross
European working with the risk of technology moving out of the UK.
— Making grant applications is time and resource demanding and requires the company to decide
strategically that they present a source of “extra money” and worth doing.
— R & D tax credits offer another source of financial support but for Byotrol they are just being
reviewed due to lack of clarity whether the Regional Exceptional award represented “state aid”.
5. How can the Funding process be improved?
(1) Build Scientific skills of Investment Houses
(a) There is a clear perception amongst SME’s that the investment world really understands neither
science nor the complexities of scientific companies and wants to value scientific companies as for
any other. This leads to poor evaluations and little understanding of the challenges, but also the
longer term opportunities open to science and technology companies.
(b) One solution would be to encourage Professional Investors of VC’s and Investment Houses that have
the skills and technical capability to invest in technology companies.
(c) Additionally, it would be beneficial to require VC’s and NOMAD’s to carry out technical due
diligence on companies that are seeking investment, rather than just financial due diligence.
(d) This would also require the VC’s and IH’s to work with the management of the company to build a
sensible business plan and to take a long term view, not only short term financial goals.
(e) Equally the technical due diligence should include gaining an assessment of the value of the IP that
is held within the company.
(f) This would allow the Investors to also build in longer term non-financial targets that focus on the “
enablers” rather than just financial results.
6. (2) Building a longer term ownership of the company
(a) If UK plc. wants for founders to retain ownership their companies as they grow and not sell on to
overseas investors, they need to allow founders to retain a much higher percentage of the original
company after funding. One way could be to establish a cap on the amount that VC’s and IH’s can
own of a company.
(b) This would however potentially limit the amount that companies could raise in investment.
(c) Helping the owner/founder to get a better long term evaluation of the company to try and get closer
to its true worth could potentially help with the total amount that is raised without breaking the
investment cap.
7. (3) Training for listing and investment
(a) As mentioned above, most companies that go for floatation have little knowledge of the challenges
that they will face in the process.
(b) This can result in under-valuation of the long-term value of the company, selling too much value of
their company and setting over optimistic targets etc.
(c) One solution would be to require CEO’s and FD’s of SME’s who are seeking funding for the first
time to go on a training course that develops their knowledge of the process, including setting
sensible goals for the company and the need to “manage expectations” of the investors.
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(d) Another part of the training should be to get CEO’s to look at different business models for how he
will commercialize it’s invention. Few companies take the time to think through what business model
will be most appropriate to maximize the value of the technology and it’s value.
8. (4) Management of companies
(a) As previously stated, starting and running science based companies (non IT) is intrinsically
expensive, so access to finance is always going to be needed.
(b) What VC’s and IH’s require is for each company to have it’s own CEO, it’s own Finance Director
and it’s own accountancy function which are both costly and assume that the company founder has
the skills to carry out some of these functions.
(c) It is however also questionable whether within the UK there exist sufficient number of quality
individuals who understand the challenges of running scientific companies and the interaction with
Investment Houses.
(d) One alternative would be to encourage experienced and highly capable individuals to work part time
across a number of companies with the right level of incentivisation, thus providing their knowledge
and skills to a few non-competitive companies. This could potentially reduce the cost for individual
companies and allow the founders to focus on what they do best.
Other than improving the funding Process what else can the UK Government do to improve the
Commercialization of UK Innovation?
9. (1) Change the Culture relating to the view that Innovation only happens in large companies working with
universities
— Innovation can happen anywhere, mostly driven by serendipity!
— Innovation means the commercialization of an idea and in many ways small companies are much
faster in doing that than large companies.
— In spite of the contribution SME’s make to the UK GDP, much of the UK cultural belief is that
Innovation works best with UK Universities working with large companies. In many ways this denies
the sector that is most in need of access to University and academic support and that can make the
most impact to UK growth—SME’s
— The biggest difficulty is that many universities don’t know how to work with small companies and
is related to how universities are structured while small companies are often unclear, un-strategic
and short of money for big research programmes. Creating demand for universities to meet and
discuss with small companies their needs should be considered.
— In the NW, the Knowledge Centre for Materials Chemistry (Chemicals NW funded) has played a
very helpful role in interfacing the needs of small tech companies with university support. This
model should be copied elsewhere.
10. (2) Give companies, especially SME’s greater knowledge of university patents
— Intellectual Property that has been generated in UK universities is valuable in its own right and
should be protected.
— However after a period of time the university can decide that it no longer wants to financially support
that patent and let the patent subside. For that to happen means that it the knowledge inside the
patent and discovery is passed into the public domain where anyone can access it.
— Universities should be encouraged before that happens to make companies aware that the patent
exists and seek a new owner, preferably to one that will benefit from the patent and continue to
maintain it.
— A searchable database that companies (including SME’s) can access of all current patents within UK
universities would help this process.
— Should no company wish to take up the patent, then the UK Government should consider acquiring
the patent as it still represents something of potential value, that has already had investment from
the UK taxpayer.
11. (3) Give companies, especially SME’s greater knowledge of funding from other sources
— SME’s are very small companies that are always short of resources, both people and money.
— With more access to funding, SME’s can set up additional Research projects that are beneficial to
both the SME and UKplc.
— Creating a searchable database, that compiles all the funding that is available, across the UK by
category would be very helpful.
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12. (4) Create environments that foster innovation
— Byotrol has been helped in its commercial activities by being located at the Daresbury Science and
Innovation Campus.
— There, the site management has done much to encourage networking between tenants, make
connections with leaders of other organisations and create opportunities and support for small
companies in a range of commercial areas such as marketing.
— The site is proactive in looking to provide new laboratory facilities and previous equipment that at
one stage was destined for disposal has been made available at low cost to its SME tenants.
13. (5) Build the recognition for scientific entrepreneurs in Britain
— Using Dyson and others as examples, there is a need to shift the general public recognition of the
role that science and technology plays in Britain’s future. In many other countries, science and
engineering are given a higher status that results in students seeking studies in the natural sciences
and engineering.
14. (6) Focus more on commercialization activities
— There is a risk that the main focus is on spending money on research and this will equals commercial
success. In our experience there is insufficient attention paid to taking the technology to market and
the skills needed to do it successfully.
— This requires having access to key decision makers for procurement of the technology, a challenge
in itself.
— So where Public sector is a potential customer, make it easier to sell innovation to it. For example
the NHS, which is one of our potential customers is unbelievably difficult to have our technology
accepted.
Please note that in providing this opinion paper, the author knows of no conflict of interest.
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Written evidence submitted by The Shelford Group
Introduction
1. The Shelford Group represents the Chief Executives of England’s leading Academic Medical Centres
(AMC’s) or Large Teaching Hospitals.
The 10 members collectively employ over 83,000 people with a turnover of £7,279 million. The institutions
that make up the Shelford Group are of strategic significance to NHS care, the pharmaceutical industry and
the wider UK economy.
2. Members
University Hospitals Birmingham Oxford University Hospitals
Cambridge University Hospitals Sheffield Teaching Hospitals
Central Manchester University Hospitals Newcastle upon Tyne Hospitals
Guy’s and St Thomas’ University College Hospitals
Imperial College Healthcare King’s College Hospital
Background
3. For several decades the UK has excelled and benefitted from its status as a global leader in the life
sciences industry. The Shelford Group believes that there is great potential to secure this position for the
future—especially if opportunities for joint working between industry, academic institutions and the National
Health Service can be properly developed.
4. The Shelford Group welcomed the publication of the Government’s Life Science Strategy and the
Innovation, Health and Wealth—Accelerating Adoption and Diffusion in the NHS reports, both published in
December 2011.
5. The Life Sciences Strategy, with the confirmation of a £180 million catalyst fund to help commercialise
new medical treatments, is also welcome; though it is a small amount relative to the scale of developing any
medicine.. The Innovation, Health and Wealth report makes clear the importance of recognising the £4 trillion
a year value of the international healthcare market and emphasises that “the NHS must do more to exploit the
commercial value of its knowledge, information, ideas and people.”131
131 Innovation, Health and Wealth—Accelerating Adoption and Diffusion in the NHS, Page 27, December 2012.
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Transfer of Clinical Research and Commercialisation Abroad
6. There has been a dramatic decline in clinical trials in the UK, from 6% of the global total in 2000, to
only 1.4% in 2010. Emerging economies are increasingly competitive with developed countries as places for
multinational companies to establish their medical research facilities, commission and exploit research.132
7. Local experience shows that a significant proportion of high value licences are made with overseas
companies. There appears to be a better appetite for funding life sciences risks in the EU and the United States
of America than in the UK. This is in part linked to the end point when the products enter the market—where
other healthcare markets are more ready to welcome innovation and the potential benefits obtained, rather than
the difficulties of reimbursement.
The Technology Strategy Board
8. The Technology and Strategy Board (TSB) could be ideally placed to assist with commercialisation in the
medical arena with large pharmaceutical and bio-tech firms, and also with instrument and device partners.
Along these lines it has recently developed a stratified medicine programme in collaboration with the
Association of the British Pharmaceutical Industry and the Medical Research Council. This requires industrial
partnerships and is an interesting and welcome innovation.
9. However, historically the TSB, although used to the element of risk in the translation and
commercialisation of research, is less experienced in dealing with medical academia and the National Health
Service.
10. The nature of medical and health sectors means that there are a greater number of variables which can
affect the course, speed and ultimate outcome of research. Research can be dependent upon regulatory
approvals (with their unspecified timelines) and success in recruiting the number of patients required to further
develop emerging clinical research.
11. As such, TSB Funding application and management requirements are less suitable for the exploitation
of medical research and have demanding time-lines that are quite unrealistic for clinical trials. In addition, the
requirements for lengthy quarterly reports and approvals for minor deviation from spending targets and
timelines, severely limits the value of the TSB for commercialisation in the sector.
12. However, with their experience of other sectors and developing partnerships, the TSB could be very
useful in commercialisation. But this does require recognition that commercialisation of medical and health
research requires a more tailored approach, a more realistic and flexible approach to timeframes and a simplified
application and monitoring process and acceptance of metrics that better fit clinical/medical research.
Joint Working across Government; Industry; Academia and the NHS
13. Implementing the recommendations of both reports will require departments such as the Department for
Business, Innovation and Skills, the Department for Health and the Cabinet Office to work closely across their
respective portfolios.
14. Government departments can also assist in bringing together the joint capabilities or clusters of
internationally leading trusts, universities and industry. Concentrating on joint efforts helps provide sufficient
density of patients, facilities and investigations for industry to examine rare patients and diseases.
15. One example of this would be the Global Medical Excellence Cluster (GMEC) which provides a
precedent in bringing together leading universities, companies and NHS Trusts into a globally competitive base
for biomedical research to attract inward investment.
16. Another model of collaboration is The Experimental Medicine Hub between King’s College London,
Guy’s and St Thomas’, King’s College Hospital and South London and Maudsley NHS Foundation Trusts and
a biopharmaceutical services company Quintiles. This collaboration provides a critical mass of research activity
in one location. And the National Institute for Health Research (NIHR) Transnational research partnerships,
that include a number of Shelford group members, which have been set up to facilitate, collaborative work
with industry to accelerate the commercialisation of Intellectual Property.
17. The value of the research needs to be better recognised and one opportunity is during the appraisals of
NHS Trusts. As occurs in universities outputs such as approved patents, industry collaborations and commercial
activities should be seen as achievements during review.
18. Also, unlike many universities, the NHS does not have the structure to capture the value of investment
in Intellectual Property. Currently the NHS invests more than £1 billion each year into primary research, but
as an organisation it lacks an agreed structure to capture the value of that investment in Intellectual Property.
132 This has been highlighted recently by the closure of facilities such as the Pfizer Research and Development site in Kent.
Elsewhere significant investments, such as by GSK in China, are becoming more common. China now has a large facility for
Clinical Trial of an Investigational Medicinal Products (CTIMP).
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Enhanced Tariffs for Academic Medical Centres to Protect Fundamental Infrastructure for
the UK’s Medical Science Industry
19. Academic Medical Centres (AMCs) and large teaching hospitals within the NHS provide the fundamental
infrastructure for the UK’s medical science industry. As leading tertiary centres they provide state of the art
training and education opportunities for the UK’s clinicians. However, the current NHS funding system is
putting these leading research establishments increasingly at a disadvantage.
20. Case-mix funding systems, such as that used in the NHS, operate through allocating funding via payment
systems, where a price per unit of activity is paid for service outputs provided by health services. However,
these policies and rules do not adequately take complexity of care into account, and therefore the leading
hospitals specialising in these more expensive treatments are consistently under-funded.133 In addition, the
overheads associated with the delivery of clinical research are not taken into account in NHS funding. In time
this will seriously impact the ability of the pharmaceutical industry, AMCs and large teaching hospitals to
maintain their existing level of research and development in the UK, with long reaching implications for
employment, exports and the economy.
21. The Shelford Group believes that a full review of NHS funding systems, to consider these issues, is
required with a view to bringing funding in line with international best practice.
February 2012
133 The Dutch Government recognised a similar shortfall affecting its AMCs created an “intensity payment” allocation (equivalent
to an enhanced tariff).
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